<SEC-DOCUMENT>0001387131-19-008469.txt : 20191108
<SEC-HEADER>0001387131-19-008469.hdr.sgml : 20191108
<ACCEPTANCE-DATETIME>20191108161722
ACCESSION NUMBER:		0001387131-19-008469
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20190930
FILED AS OF DATE:		20191108
DATE AS OF CHANGE:		20191108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		191204276

	BUSINESS ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431
		BUSINESS PHONE:		561-961-1900

	MAIL ADDRESS:	
		STREET 1:		951 YAMATO ROAD, SUITE 220
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33431

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>txmd-10q_093019.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:txmd="http://therapeuticsmd.com/20190930">
<head>
     <title></title>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_021_US%2DGAAP%2D2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_txmd_therapeuticsmd.com_20190930 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20190101_20190930 -->
<!-- Field: Set; Name: xdx; ID: xdx_054_edei%2D%2DEntityCentralIndexKey_0000025743 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DDocumentFiscalPeriodFocus_Q3 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DDocumentFiscalYearFocus_2019 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_073_XDX_P%2D%2D\Clients\TherapeuticsMD\2019\q19%2D03220__10%2DQ\merged.xdx -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<!-- Field: Set; Name: xdx; ID: xdx_065_EUR_0_iso4217%2D%2DEUR -->
<!-- Field: Set; Name: xdx; ID: xdx_064_SQFT_0_utr%2D%2Dsqft -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Tranches_0_Tranch -->
<body>
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityCentralIndexKey">0000025743</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:DocumentFiscalPeriodFocus">Q3</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:DocumentFiscalYearFocus">2019</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0036" name="dei:EntityFilerCategory">Large Accelerated Filer</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2018-12-31" id="xdx2ixbrl0079" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2018-12-31" id="xdx2ixbrl0112" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2019-09-30" id="xdx2ixbrl0123" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2018-12-31" id="xdx2ixbrl0124" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-07-012019-09-30" id="xdx2ixbrl0210" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-07-012018-09-30" id="xdx2ixbrl0211" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0213" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-07-012019-09-30" id="xdx2ixbrl0235" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2018-07-012018-09-30" id="xdx2ixbrl0236" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0237" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0238" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0268" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0272" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0274" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0277" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0278" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0290" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0318" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0346" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0350" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0352" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0355" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0356" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0366" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0368" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0371" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0372" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0384" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" id="xdx2ixbrl0393" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0417" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0426" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0461" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:LicenseExpendituresIncurredButNotYetPaid" contextRef="From2018-01-012018-09-30" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" id="xdx2ixbrl0640" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">P13Y3M</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" id="xdx2ixbrl0651" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">P10Y9M</ix:nonNumeric>
    <ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" id="xdx2ixbrl0654" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="txmd:AccruedIntellectualLicenseFee" contextRef="AsOf2018-12-31" id="xdx2ixbrl0743" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2018-12-31" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonFraction name="us-gaap:AccruedRentCurrent" contextRef="AsOf2019-09-30" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0881" name="txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife">P2Y73D</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_WarrantsMember" id="xdx2ixbrl0906" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P146D</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0960" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P5Y343DT2H24M</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl0979" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">P6Y18DT6H</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0987" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">P4Y292D</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0995" name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">P9Y21DT21H36M</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" id="xdx2ixbrl1007" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y146D</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockUnitsRSUMember" id="xdx2ixbrl1015" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">P2Y73D</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="txmd-20190930.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2019-01-01to2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_ProductMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-012018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-02">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-02</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-08-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_custom_PrescriptionVitaminsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_custom_ImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_BijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUSPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignPatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignPatentsBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticPatentsNonApprovedBijuvaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUSPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUSUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUSDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignUtilityPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignDesignPatentsImvexxyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUSPatentsTopicalCreamMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsTopicalCreamMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_ForeignUtilityPatentTransdermalPatchMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUtilityPatentOperaMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUtilityPatentDLimoneneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentDLimoneneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_DomesticUtilityPatentTx009HRMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentOneMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-30</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-04</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-04</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-08-04</xbrli:startDate>
        <xbrli:endDate>2019-08-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoThreeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-04-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-04-30</xbrli:startDate>
        <xbrli:endDate>2018-05-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-232019-04-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-23</xbrli:startDate>
        <xbrli:endDate>2019-04-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_MidCapAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_TrancheOneMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_FinancingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CreditAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:CreditAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-28</xbrli:startDate>
        <xbrli:endDate>2018-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-08-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-08-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-052018-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-05</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-08-05</xbrli:startDate>
        <xbrli:endDate>2018-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_WarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_WarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-09-30_custom_OutsideConsultant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_WarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_Plan2019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-12</xbrli:startDate>
        <xbrli:endDate>2018-12-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-29</xbrli:startDate>
        <xbrli:endDate>2019-07-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_RestrictedStockUnitsRSUMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-07-012019-09-30_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-07-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-012018-09-30_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-09-30_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_srt_AffiliatedEntityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_ThreeCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:ThreeCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-01</xbrli:startDate>
        <xbrli:endDate>2019-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-292013-07-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-07-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-10-01">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-10-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-23</xbrli:startDate>
        <xbrli:endDate>2019-10-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-10-24</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-282018-08-01_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-28</xbrli:startDate>
        <xbrli:endDate>2018-08-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-10-232019-10-29_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-10-23</xbrli:startDate>
        <xbrli:endDate>2019-10-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="EUR">
      <xbrli:measure>iso4217:EUR</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="SQFT">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Tranches">
      <xbrli:measure>txmd:Tranch</xbrli:measure>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<!-- Edge Version : 2.0 -->



<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>UNITED STATES</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 14pt Times New Roman, Times, Serif"><b>SECURITIES AND EXCHANGE COMMISSION</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 12pt Times New Roman, Times, Serif"><b>WASHINGTON, D.C. 20549</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 16pt Times New Roman, Times, Serif"><b>FORM <span id="xdx_900_edei--DocumentType_c20190101__20190930_zovsUXQlehWk"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">(Mark One)</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--DocumentQuarterlyReport_c20190101__20190930_zaX7QVkEKDh8"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span></span></td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT</b></span>
                </p>
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>OF 1934</b></span>
                </p>
            </td>
        </tr>
    </table>
    <p style="margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin-bottom: 0; margin-left: 0.5in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">For the quarterly period ended <span id="xdx_906_edei--DocumentPeriodEndDate_c20190101__20190930_z2Q2IaQ5we6j"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">September 30, 2019</ix:nonNumeric></span></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">or</span></b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif">
        <tr style="vertical-align: top; text-align: justify">
            <td style="width: 0in"></td>
            <td style="width: 0.5in; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--DocumentTransitionReport_c20190101__20190930_zmkPLWxuOINc"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport">&#x2610;</ix:nonNumeric></span></span>
            </td>
            <td style="text-align: justify">
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT </b></span>
                </p>
                <p style="margin-bottom: 0; margin-top: 0">
                    <span style="font: 12pt Times New Roman, Times, Serif"><b>OF 1934</b></span>
                </p>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">For the transition period from________ to ___________</span>
    </p>
    <p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Commission File No. <b><span style="text-decoration: underline"><span id="xdx_909_edei--EntityFileNumber_c20190101__20190930_zi5fQTb7x5H9"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityFileNumber">001-00100</ix:nonNumeric></span></span></b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 18pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline"><span id="xdx_900_edei--EntityRegistrantName_c20190101__20190930_z97n8sYMbQoh"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityRegistrantName">THERAPEUTICSMD, INC.</ix:nonNumeric></span></span></b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">(Exact Name of Registrant as Specified in Its Charter)</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="width: 22%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityIncorporationStateCountryCode_c20190101__20190930_zjUqFCbiQ8zb"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 22%; text-align: center">&#160;</td>
            <td style="width: 18%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 11%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90E_edei--EntityTaxIdentificationNumber_c20190101__20190930_zq5xybnT4cM4"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityTaxIdentificationNumber">87-0233535</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 19%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(State or Other Jurisdiction of Incorporation or Organization)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer Identification No.)</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: top; text-align: left">
            <td style="border-bottom: Black 1pt solid; width: 60%; text-align: center">                 <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20190101__20190930_zwUKwFjFZLI2"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityAddressAddressLine1">951 Yamato Road</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressAddressLine2_c20190101__20190930_zRIk2ryo01k3"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityAddressAddressLine2">Suite 220</ix:nonNumeric></span>, <span id="xdx_909_edei--EntityAddressCityOrTown_c20190101__20190930_zYjB7PoBO4sj"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityAddressCityOrTown">Boca Raton</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressStateOrProvince_c20190101__20190930_zA4YORZhpHh3"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityAddressStateOrProvince">FL</ix:nonNumeric></span> </b></span>
            </td>
            <td style="width: 18%; text-align: center">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 4%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressPostalZipCode_c20190101__20190930_zEGwxKvKuROd"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityAddressPostalZipCode">33431</ix:nonNumeric></span></b></span>
            </td>
            <td style="width: 18%; text-align: center">&#160;</td>
        </tr>
        <tr style="vertical-align: top; text-align: left">
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices)</span>
            </td>
            <td colspan="3" style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--CityAreaCode_c20190101__20190930_zyzgkCHusEG5"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:CityAreaCode">561</ix:nonNumeric></span>-<span id="xdx_90C_edei--LocalPhoneNumber_c20190101__20190930_zGihqOdFKUoj"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:LocalPhoneNumber">961-1900</ix:nonNumeric></span></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#x2019;s telephone number, including area code)</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">N/A</span></b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">(Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report)</span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Securities registered pursuant to Section 12(b) of the Act:</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-top: Black 1pt solid; width: 40%; text-align: center"><b>Title
    of Each Class</b></td>
    <td style="border: Black 1pt solid; width: 15%; text-align: center"><b>Trading Symbol</b></td>
    <td style="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid; width: 45%; text-align: center"><b>Name
    of Each Exchange on Which Registered</b></td></tr>
<tr style="vertical-align: top">
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><span id="xdx_901_edei--Security12bTitle_c20190101__20190930_z4Z3tGAGKxW8"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td>
    <td style="border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span id="xdx_907_edei--TradingSymbol_c20190101__20190930_zChd2ttRdhwc"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:TradingSymbol">TXMD</ix:nonNumeric></span></td>
    <td style="border-bottom: Black 1pt solid; border-right: Black 1pt solid; text-align: center"><span id="xdx_908_edei--SecurityExchangeName_c20190101__20190930_zFSo9YnpUFd3"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr>
</table>

    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <span id="xdx_905_edei--EntityCurrentReportingStatus_c20190101__20190930_zmTdARYoiuHa"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span> &#9746; No &#x2610;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xA7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <span id="xdx_900_edei--EntityInteractiveDataCurrent_c20190101__20190930_zv8hT8tGqjw2"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#x2612; No &#x2610;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer,&#x201D; &#x201C;smaller reporting company&#x201D; and &#x201C;emerging growth company&#x201D; in Rule 12b-2 of the Exchange Act (Check one):</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 30%"><span id="xdx_90A_edei--EntityFilerCategory_c20190101__20190930_zibEu63UkpEg"><span style="-sec-ix-hidden: xdx2ixbrl0036">Large accelerated filer</span></span> &#9746;</td>
    <td style="width: 20%">&#160;</td>
    <td style="width: 30%">Accelerated filer &#x2610;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>Non-accelerated filer &#x2610;</td>
    <td>&#160;</td>
    <td>Smaller reporting company<span id="xdx_902_edei--EntitySmallBusiness_c20190101__20190930_zskfPZpPNg83"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness"> &#x2610;</ix:nonNumeric></span></td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Emerging growth company <span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20190101__20190930_z50Jep4DUF35"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany">&#x2610;</ix:nonNumeric></span></td></tr>
</table>

    <p style="margin: 0pt 0; text-indent: 5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#x2610; <span id="xdx_902_edei--EntityShellCompany_c20190101__20190930_zcjq24BTQtqi"><ix:nonNumeric contextRef="From2019-01-01to2019-09-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span> &#9746;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">         <span style="font: 10pt Times New Roman, Times, Serif">The
    number of shares outstanding of the registrant&#x2019;s common stock, par value $0.001 per share, as of November 4, 2019 was <span id="xdx_905_edei--EntityCommonStockSharesOutstanding_iI_c20191104_zWFmsQMGcuEj"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2019-11-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">271,177,076</ix:nonFraction></span>.    <br /> </span>     </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span>
    </p>
    <!-- Field: Page; Sequence: 1-->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b>&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>INDEX</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 10%; white-space: nowrap">&#160;</td>
            <td style="width: 82%; white-space: nowrap">&#160;</td>
            <td style="border-bottom: Black 1pt solid; width: 8%; text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">Page</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td colspan="2" style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#part1">PART I - FINANCIAL INFORMATION</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap">3</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><a href="#item1">Item. 1</a></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><a href="#item1">Financial Statements</a></span>
            </td>
            <td style="text-align: center; white-space: nowrap">3</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="font-size: 10pt">                 <span style="font-family: Times New Roman, Times, Serif"><a href="#txmd10qa001">Consolidated
            Balance Sheets as of  September 30, 2019 (Unaudited) and December 31, 2018</a></span>             </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">3</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="font-size: 10pt">                 <span style="font-family: Times New Roman, Times, Serif"><a href="#txmd10qa002">Consolidated
            Statements of Operations for the Three and Nine  Months Ended  September 30, 2019 (Unaudited) and 2018 (Unaudited)</a></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">4</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="font-size: 10pt">                 <span style="font-family: Times New Roman, Times, Serif"><a href="#txmd10qa003">Consolidated
            Statements of Stockholders&#x2019; Equity for the Three and  Nine Months Ended September  30, 2019 (Unaudited) and 2018
            (Unaudited)</a></span>             </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">5</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="font-size: 10pt">                 <span style="font-family: Times New Roman, Times, Serif"><a href="#txmd10qa004">Consolidated
            Statements of Cash Flows for the Nine  Months Ended  September 30, 2019 (Unaudited) and 2018 (Unaudited)</a></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">6</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><a href="#txmd10qa005">Notes to Unaudited Consolidated Financial Statements</a></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">7</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr>
            <td style="padding-left: 0.25in; vertical-align: top; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa006">Item 2.</a></b></span>
            </td>
            <td style="vertical-align: bottom; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa006">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</a></b></span>
            </td>
            <td style="vertical-align: bottom; text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">28</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa007">Item 3.</a></b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa007">Quantitative and Qualitative Disclosures about Market Risk</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">44</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa008">Item 4.</a></b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa008">Controls and Procedures</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">44</span></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td colspan="2" style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa009">Part II - OTHER INFORMATION</a></b></span>
            </td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa010">Item 1.</a></b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa010">Legal Proceedings</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">45</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa011">Item 1A.</a></b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa011">Risk Factors</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">45</span>
            </td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa012">Item 6.</a></b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><a href="#txmd10qa012">Exhibits</a></b></span>
            </td>
            <td style="text-align: center; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif">46</span>
            </td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->2<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td colspan="2" style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><span id="part1"></span>PART I - FINANCIAL INFORMATION</b></span>
            </td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 10%; white-space: nowrap">&#160;</td>
            <td style="width: 82%; white-space: nowrap">&#160;</td>
            <td style="width: 8%; white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b><span id="item1"></span>Item. 1</b></span>
            </td>
            <td style="white-space: nowrap; font-size: 10pt">
                <span style="font-family: Times New Roman, Times, Serif"><b>Financial Statements</b></span>
            </td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.25in; white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
            <td style="white-space: nowrap">&#160;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa001"></span>CONSOLIDATED BALANCE SHEETS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" id="xdx_305_111_pp0p0_zadIi3iwPD43" summary="xdx: Statement - CONSOLIDATED BALANCE SHEETS" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_497_20190930_zmHCUhlDUCM8" style="border-bottom: Black 1pt solid; text-align: center"><b>September
            30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_498_20181231_zWL1VfHBVVH4" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td colspan="2" style="text-align: center">(Unaudited)</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
        </tr>
        <tr id="xdx_409_eus-gaap--AssetsAbstract_iB_zFSSth1MF7Yh" style="vertical-align: bottom">
            <td colspan="8" style="text-align: center">ASSETS</td>
            <td style="text-align: center">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--AssetsCurrentAbstract_i01B_zubUVBHJNnle" style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Current Assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--Cash_i02I_maCzn16_zApzGl8SRtna" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 68%; text-indent: -0.125in">Cash</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">155,330,050</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 13%; text-align: right"><ix:nonFraction name="us-gaap:Cash" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,613,077</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzn16_z9GmCwv5gBTk" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accounts receivable, net of allowance for doubtful accounts&#160;of $<span id="xdx_907_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20190930_zmN9XAzFq7R9" title="allowance for doubtful accounts"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">691,699</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--AllowanceForDoubtfulAccountsReceivable_iI_c20181231_z6B2ubMl3ukh"><ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivable" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">596,602</ix:nonFraction></span>, respectively</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,323,614</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,063,821</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_409_eus-gaap--InventoryNet_i02I_maCzn16_z8FT8Tf5GVIa" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Inventory</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,532,844</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,267,670</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_401_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzn16_zdNaFiOseTZ3" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Other current assets</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,578,260</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,834,693</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_401_eus-gaap--AssetsCurrent_i02TI_mtCzn16_zGKmHX6rEnR9" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total current assets</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">191,764,768</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186,779,261</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="color: red; font: bold 9pt Sans-Serif">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentNet_i02I_zi10dKp2fph1" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: left; text-indent: -0.125in">Fixed assets, net</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,338,346</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">472,683</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--OtherAssetsAbstract_i01B_zfT1teutunVf" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Other Assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="color: red; font: bold 9pt Sans-Serif">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_ecustom--LicenseRights_i02I_maANzku5_zvDX9rY0aJL4" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">License rights, net</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">39,984,002</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:LicenseRights" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i02I_maANzku5_zqWwfKZiU5R1" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Intangible assets, net</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,942,151</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,092,679</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
                <tr id="xdx_40D_eus-gaap--OperatingLeaseRightOfUseAsset_i02I_maANzku5_zOoW2stb55Jg" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Right of use asset</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,459,635</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0079">&#8212;</span></td>
            <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--OtherAssetsNoncurrent_i02I_maANzku5_zloDg293QDud" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in; padding-bottom: 1pt">Other assets</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td>
            <td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">473,009</ix:nonFraction></td>
            <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td>
            <td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">639,301</ix:nonFraction></td>
            <td style="text-align: left; padding-bottom: 1pt">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--AssetsNoncurrent_i02TI_mtANzku5_z96PQWD77ra7" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total other assets</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,858,797</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,731,980</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_403_eus-gaap--Assets_i02I_zAI5vAMdOKOd" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in">Total assets</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">249,961,911</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">211,983,924</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_zhvtfcToU8M9" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td colspan="8" style="text-align: center">&#160;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</td>
            <td style="text-align: center">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LiabilitiesCurrentAbstract_i01B_z9xTwhtUKN4c" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Current Liabilities:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--AccountsPayableCurrent_i02I_maCzz6y_zIAWL6TzA9x2" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accounts payable</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,133,506</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,743,841</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_401_eus-gaap--OtherLiabilitiesCurrent_i02I_maCzz6y_zJhTlM2oyP9c" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Other current liabilities</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,196,032</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,334,948</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_eus-gaap--LiabilitiesCurrent_i02TI_mtCzz6y_maCzfFZ_maLz5tU_z2D98HJo1npk" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total current liabilities</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,329,538</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,078,789</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_eus-gaap--LongTermDebtNoncurrentAbstract_i01B_zAHkY3AuGQj" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Long-Term Liabilities:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--LongTermDebtNoncurrent_i02I_maLz5tU_zhru8OiU2Z09" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Long-term debt</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,361,169</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,381,014</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40B_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maLz5tU_zf3As8qF5nZ6" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Operating lease liability</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,500,133</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0112">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_403_eus-gaap--Liabilities_i02TI_maLASEzGhz_mtLz5tU_zdSbzlcDvHdf" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total liabilities</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,190,840</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">114,459,803</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40D_eus-gaap--CommitmentsAndContingencies_i02I_zYkFvk6ZGB2i" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Commitments and Contingencies - See Note 15</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_401_eus-gaap--StockholdersEquityAbstract_i01B_zeBHJNmhH2E5" style="background-color: White; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Stockholders&#x2019; Equity:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40B_eus-gaap--PreferredStockValue_i02I_maCzk1u_maSEz6Tk_zWuBRKYT2IG9" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Preferred stock - par value $<span id="xdx_902_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20181231_zmLB9vw75XQe"><span id="xdx_90C_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20190930_zrbU5wxXEBql"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_903_eus-gaap--PreferredStockSharesAuthorized_iI_c20181231_zDgXHms2eEHd"><span id="xdx_90B_eus-gaap--PreferredStockSharesAuthorized_iI_c20190930_zFzi4IQiYzqg"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_900_eus-gaap--PreferredStockSharesIssued_iI_do_c20181231_zH5rP9iDE4b3"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_do_c20190930_zWUsZzGmahve"><span id="xdx_90C_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20190930_z1DE8eusoBJa"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20181231_zdJAq3P8w5G6"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2018-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2019-09-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2019-09-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2018-12-31" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0123">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0124">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40D_eus-gaap--CommonStockValue_i02I_maSEzNqL_zewHR1ZC1rgl" style="background-color: White; vertical-align: bottom">
    <td style="padding-left: 0.25in; text-indent: -0.125in">Common stock - par value $<span id="xdx_905_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20181231_zSznOiWZmU7l"><span id="xdx_908_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pii_c20190930_zHpooUPWoZm6"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span>; <span id="xdx_90F_eus-gaap--CommonStockSharesAuthorized_iI_c20181231_zl8Fx36S6uTc"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_c20190930_znQGJE2FrMS1"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">350,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized:<br />
<span id="xdx_901_eus-gaap--CommonStockSharesIssued_iI_c20190930_zbxI3V4OisBg"><span id="xdx_90A_eus-gaap--CommonStockSharesOutstanding_iI_c20190930_zhxTWr3sR6K6"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,277,076</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_iI_c20181231_zy7l4LBW1yBl"><span id="xdx_90C_eus-gaap--CommonStockSharesOutstanding_iI_c20181231_zuYsbvWyP30d"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">240,462,439</ix:nonFraction></ix:nonFraction></span></span> issued and outstanding, respectively</td>
    <td>&#160;<br />
&#160;</td>
    <td style="text-align: left">&#160;<br />
&#160;</td>
    <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,277</ix:nonFraction></td>
    <td style="text-align: left">&#160;<br />
&#160;</td>
    <td>&#160;<br />
&#160;</td>
    <td style="text-align: left">&#160;<br />
&#160;</td>
    <td style="text-align: right">&#160;<br />
<ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,463</ix:nonFraction></td>
    <td style="text-align: left">&#160;<br />
&#160;</td>
</tr>
<tr id="xdx_404_eus-gaap--AdditionalPaidInCapitalCommonStock_i02I_maSEzNqL_zXNhU0ruItk8" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Additional paid-in capital</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,515,559</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapitalCommonStock" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">616,559,938</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_409_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maSEzNqL_zJighggnBbNc" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Accumulated deficit</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">645,985,765</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--StockholdersEquity_i02TI_mtSEzNqL_maLASEzGhz_zAsMgroayTo" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.375in; text-align: left; text-indent: -0.125in">Total stockholders&#x2019;
            (deficit) equity</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,228,929</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,524,121</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_401_eus-gaap--LiabilitiesAndStockholdersEquity_i02TI_mtLASEzGhz_zlx9sJu2q5G" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.5in; text-align: left; text-indent: -0.125in">Total liabilities and stockholders&#x2019; equity</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">249,961,911</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">211,983,924</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->3<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa002"></span>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" id="xdx_307_113_pp0p0_zpjDxmk36iw1" summary="xdx: Statement - CONSOLIDATED STATEMENT OF OPERATIONS" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_492_20190701__20190930_zTUf7EfkcRy4">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_495_20180701__20180930_zgqFPiXPIeF7">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_493_20190101__20190930_zqRjI1PtgGEh">&#160;</td><td>&#160;</td>
    <td colspan="3" id="xdx_49F_20180101__20180930_znXwsDSy52Gf">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="6" style="text-align: center"><b>Three Months Ended</b></td>
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="6" style="text-align: center"><b>Nine</b>  <b>Months Ended</b></td>
            <td><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30,</b></td>
            <td><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>


<tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>

<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 43%; text-align: left">Product revenue, net</td><td style="width: 3%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zu1pr9TzWqFj" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,213,341</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zWZH7mPRB9yh" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,473,535</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zqGBjST2LYKb" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,238,857</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__us-gaap--ProductMember_zNTuKrvpidRl" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-09-30_us-gaap_ProductMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,009,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zbPAhBv0Vy6c" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_d0_c20180701__20180930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z93KNg9RE1Jh" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zNuByPc7YQqg" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_d0_c20180701__20180930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zpvdRBPIasdc" style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="USD">&#8212;</ix:nonFraction>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maGPzXMZ_maGPz3fN_z5h0XRXP70qc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;&#160;&#160;&#160;Total revenue, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,719,741</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,473,535</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,745,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,009,937</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--CostOfGoodsAndServicesSold_msGPzXMZ_msGPz3fN_z4e9lilUNe73" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Cost of goods sold</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,444,308</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">699,118</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,455,995</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,786,902</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--GrossProfit_iT_maOILzYhJ_mtGPz3fN_z8ytAPtAC2Da" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Gross profit</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,275,433</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,774,417</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,289,262</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,223,035</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingExpensesAbstract_iB_zy4jsbvWL7Sk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--SellingGeneralAndAdministrativeExpense_i01_maCz4dY_zbB12HQhDGO4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Sales, general, and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,126,986</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,354,072</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,378,519</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,578,079</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_maCz4dY_zLdIBzxRju89" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,077,738</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,708,271</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,359,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,545,948</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--DepreciationAndAmortization_i01_maCz4dY_zPYt5OCDAlo" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation and amortization</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">141,959</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,321</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">363,956</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">198,545</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--OperatingExpenses_i01T_mtCz4dY_msOILzYhJ_z1r4EdZBK5U7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">&#160;&#160;&#160;&#160;&#160;Total operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,346,683</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,135,664</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">137,102,463</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">101,322,572</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--OperatingIncomeLoss_i01_mtOILzYhJ_maILFCOzfov_zAfsYdfKoyQd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">27,071,250</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">34,361,247</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">106,813,201</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">92,099,537</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01_maNIEzeq0_msIEzWOq_maNIEzAHV_zNvJq19fNEA4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Loss on extinguishment of debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0210">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0211">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0213">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--OtherNonoperatingIncome_i01_maCzHgF_maNIEzeq0_msIEzWOq_maNIEzAHV_zLeECgSAQws5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Miscellaneous income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">703,662</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">809,022</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,878,980</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNonoperatingIncome" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,457,817</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--InterestExpense_i01N_di_msNIEzAHV_zt4qF7OTv7F2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Interest expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,599,005</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,053,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,717,632</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,584,459</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr id="xdx_403_eus-gaap--NonoperatingIncomeExpense_i01T_mtNIEzAHV_maILFCOzfov_zsgr8PGy50ud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">&#160;&#160;&#160;&#160;&#160;Total other expense</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,895,343</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,244,055</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">19,896,284</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,126,642</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_maNILzeie_mtILFCOzfov_zpgsPkSkn6U8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss before income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">35,605,302</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">93,226,179</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--IncomeTaxExpenseBenefit_msNILzeie_zHb2AFZ0Ayog" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1pt">Provision for income taxes</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0235">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0236">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0237">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0238">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_mtCz177_mtNILzeie_zK7fQJPqWTJk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">35,605,302</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">93,226,179</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--EarningsPerShareAbstract_iB_zn7t07HhrtK4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss per share, basic and diluted:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--EarningsPerShareBasicAndDiluted_pp2i_zneCIbIVI1G9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="2" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="2" sign="-" unitRef="USDPShares">0.16</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="2" sign="-" unitRef="USDPShares">0.53</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="2" sign="-" unitRef="USDPShares">0.42</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_zgFWBPThtJik" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Weighted average
    number of common shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,261,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">228,107,240</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,163,994</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">220,466,673</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>


    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->4<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa003"></span>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</b></p>

<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>Nine Months Ended September 30,
2019 and 2018</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" id="xdx_308_114_pp0p0_zXQZmSW4e2Vg" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="2" style="text-align: center"><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zMOntv0P1nZ1" style="text-align: center"><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zPtZR88LR4h8" style="text-align: center"><b>Additional</b></td>
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="2" id="xdx_4BD_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zHhKGkf1kZZ7"><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td><b>&#160;</b></td>
            <td colspan="2" id="xdx_4B4_zpIMRupUf6Ub"><b>&#160;</b></td>
            <td><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Common Stock</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="text-align: center"><b>Paid in</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="text-align: center"><b>Accumulated</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Shares</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Capital</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Deficit</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Total</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
            <td>&#160;</td>
            <td colspan="2">&#160;</td>
            <td>&#160;</td>
        </tr>
        <tr id="xdx_431_c20180101__20180331_eus-gaap--StockholdersEquity_iS_z9UQyR0lKasi" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="width: 25%; font-weight: bold">Balance, December 31, 2017</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_983_eus-gaap--CommonStockSharesOutstanding_iS_c20180101__20180331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zx8bizksvOY3" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">216,429,642</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,430</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">516,351,405</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">386,659,120</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">129,908,715</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
                <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zm2osjM2Gne9" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td>Shares issued for exercise of options, net</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20180331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zif5zjDQTLSk" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">154,632</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">154</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,902</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0268">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">44,056</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zOk3rVhHOU7h" style="background-color: White; vertical-align: bottom">
            <td style="text-align: left">Share-based compensation</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0272">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,751,358</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0274">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,751,358</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--NetIncomeLoss_zQ6fHRxhNyil" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: left">Net loss</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0277">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0278">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">24,401,829</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">24,401,829</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_433_c20180401__20180630_eus-gaap--StockholdersEquity_iS_zX6FpXet0ud8" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="font-weight: bold">Balance, March 31, 2018</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_988_eus-gaap--CommonStockSharesOutstanding_iE_c20180101__20180331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zyKqwzbTq0e" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">216,584,274</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,584</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">518,146,665</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">411,060,949</ix:nonFraction></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,302,300</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zD4zxJEbbm2h" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td>Shares issued for exercise of options, net</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180401__20180630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z10I31PKtP91" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">249,785</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,084,689</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0290">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,084,939</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zGru3rCmXfrb" style="background-color: White; vertical-align: bottom">
            <td style="text-align: left">Share-based compensation</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,377,082</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,377,082</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_409_eus-gaap--NetIncomeLoss_zy7VcM6oSYY" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: left">Net loss</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">33,219,048</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-04-012018-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">33,219,048</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_43D_c20180701__20180930_eus-gaap--StockholdersEquity_iS_zOvMY6a5KNVf" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 2pt; font-weight: bold">Balance, June 30, 2018</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td id="xdx_985_eus-gaap--CommonStockSharesOutstanding_iE_c20180401__20180630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeJrAs3VTIAk" style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">216,834,059</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left"></td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">216,834</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left"></td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">521,608,436</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">444,279,997</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left"></td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,545,273</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
                                <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td></tr>
        <tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_znvt6MlMTsYe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Shares issued for exercise of options, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180701__20180930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFyIIiAhvac2" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,052,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,053</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">106,265</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">107,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
        <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zuNRkF1sj8P8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Shares issued in offering, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180701__20180930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zzYQhq1icOnh" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">18,578,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,578</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,889,219</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0318">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,907,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zU2YwEC0S3ii" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,260,195</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,260,195</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--NetIncomeLoss_zWptbqnQISe4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">35,605,302</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">35,605,302</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_43D_c20181001__20181231_eus-gaap--StockholdersEquity_iS_zIj0K98u4kM4" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2018</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--CommonStockSharesOutstanding_iE_c20180701__20180930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHAH2xyCD6mj" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">236,464,789</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">236,465</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">613,864,115</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">479,885,299</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,215,281</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td></tr>
<tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_431_c20190101__20190331_eus-gaap--StockholdersEquity_iS_zf29E6f2hogg" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="font-weight: bold">Balance, December 31, 2018</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98A_eus-gaap--CommonStockSharesOutstanding_iS_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zbprdbSMjdB4" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">240,462,439</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,463</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">616,559,938</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">519,276,280</ix:nonFraction></td>
            <td style="text-align: left">)</td>
            <td style="color: red">&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">97,524,121</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
                <tr style="background-color: White; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--StockIssuedDuringPeriodValueOther_zbTpHrf7lAqg" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="text-align: left">Shares issued for exercise of options and warrants, net</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesOther_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zgxfjgOfXYw8" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">759,401</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">759</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,348</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0346">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueOther" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,107</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zCmVOJ1zI812" style="background-color: White; vertical-align: bottom">
            <td style="text-align: left">Share-based compensation</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0350">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,575,369</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0352">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,575,369</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--NetIncomeLoss_zjYA1wdAPXWe" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: left">Net loss</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0355">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0356">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-012019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">39,506,375</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: White; vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_43F_c20190401__20190630_eus-gaap--StockholdersEquity_iS_ztNbJscEmTj8" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="font-weight: bold">Balance, March 31, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_988_eus-gaap--CommonStockSharesOutstanding_iE_c20190101__20190331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0VRJXOq5phh" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,221,840</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,222</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">619,234,655</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">558,782,655</ix:nonFraction></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-03-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">60,693,222</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
                <tr style="background-color: White; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zlkIs6YGasfh" style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="text-align: left">Share-based compensation</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0366">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,637,264</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0368">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,637,264</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40A_eus-gaap--NetIncomeLoss_zwL8g2pAbAZ9" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: left">Net loss</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0371">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0372">&#8212;</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">55,236,517</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-04-012019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">55,236,517</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td>&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_43A_c20190701__20190930_eus-gaap--StockholdersEquity_iS_za2V9ijyg6j2" style="background-color: White; vertical-align: bottom">
            <td style="padding-bottom: 2pt; font-weight: bold">Balance, June 30, 2019</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td id="xdx_985_eus-gaap--CommonStockSharesOutstanding_iE_c20190401__20190630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCVsA7frNOz2" style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,221,840</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">$</td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,222</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">$</td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">621,871,919</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">$</td>
            <td style="padding-bottom: 2pt; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">614,019,172</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">$</td>
            <td style="padding-bottom: 2pt; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,093,969</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: rgb(204,238,255); vertical-align: bottom">
            <td style="padding-bottom: 2pt; font-weight: bold">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zzvVtpQwTUWg" style="vertical-align: bottom; background-color: White">
    <td>Shares issued for exercise of options, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190701__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0BslyD5kzph" style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">55,236</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,494</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0384">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,549</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zH8Ta8KekwS1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,635,146</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,635,146</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--NetIncomeLoss_z6UMHg2KRreb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt">Net loss</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0393">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">31,966,593</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_433_c20190701__20190930_eus-gaap--StockholdersEquity_iE_z9D64VfxwRWc" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 2.5pt">Balance, September 30, 2019</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--CommonStockSharesOutstanding_iE_c20190701__20190930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z0bHMWJwpPKf" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">241,277,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,277</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,515,559</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">645,985,765</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">21,228,929</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
</table>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">The accompanying footnotes are an integral part of these consolidated financial statements.</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->5<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa004"></span>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 5.4pt; text-align: center">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b></b></p>

<table cellpadding="0" cellspacing="0" id="xdx_303_122_pp0p0_zYDD3a6PcHLd" summary="xdx: Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;&#160;&#160;&#160;&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_494_20190101__20190930_zlv4gDieAaJ4" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_492_20180101__20180930_zJaxpybgYuA8" style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="7" style="text-align: center"><b>Nine Months Ended</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td colspan="3" style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="3" style="font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-weight: bold">CASH FLOWS FROM OPERATING ACTIVITIES</td>
    <td colspan="3">&#160;</td><td>&#160;</td>
    <td colspan="3">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--NetIncomeLoss_maCPBUIznfy_z59FSFR0cahg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif; width: 68%">Net loss</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">126,709,485</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">93,226,179</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">&#160;&#160;&#160;&#160;&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_iB_zX8gFpZrO32i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Adjustments to reconcile net loss to net cash used in&#160;operating activities:</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40D_eus-gaap--Depreciation_i01_maCPBUIznfy_zbBhpPS7ogm5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Depreciation of fixed assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">223,750</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">121,423</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--AmortizationOfIntangibleAssets_i01_maCPBUIznfy_zr8QI9sVPH77" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization of intangible assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">140,206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">77,123</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--OtherNoncashExpense_i01_maCPBUIznfy_zT0MJzs8yOkc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Write off of patent and trademark cost</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherNoncashExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">78,864</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0417">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_404_ecustom--NoncashOperatingLeaseExpense_i01_maCPBUIznfy_zziNRdbC5C1e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Non-cash operating lease expense</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:NoncashOperatingLeaseExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">711,836</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ProvisionForDoubtfulAccounts_i01_maCPBUIznfy_zvRnpuK9h8B7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Provision for doubtful accounts</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">95,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">231,475</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_406_eus-gaap--GainsLossesOnExtinguishmentOfDebt_i01N_di_msCPBUIznfy_z0mRi8Haqqda" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Loss on extinguishment of debt</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0426">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--ShareBasedCompensation_i01_maCPBUIznfy_zGXd6kw0qeF5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Share-based compensation</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,859,357</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,388,635</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--OtherAmortizationOfDeferredCharges_i01_maCPBUIznfy_zgatcw8Fx18g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization
    of intellectual property license fee</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,998</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--AmortizationOfFinancingCosts_i01_maCPBUIznfy_z3r199LkOqCh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Amortization of deferred financing fees</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">582,829</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">149,909</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_iB_zLu0StwKpDV5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.5in; font-family: Times New Roman, Times, Serif">Changes in operating assets and liabilities:</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--IncreaseDecreaseInAccountsReceivable_i01N_di_msCPBUIznfy_zZaN3rRcg2He" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Accounts receivable</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,354,890</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,705,325</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_407_eus-gaap--IncreaseDecreaseInInventories_i01N_di_msCPBUIznfy_zGpZrBOdRapa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Inventory</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,265,174</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">892,863</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40D_eus-gaap--IncreaseDecreaseInOtherCurrentAssets_i01N_di_mscashflow_msCPBUIznfy_zlJyGBUA19Va" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Other current assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,128,515</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentAssets" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">1,233,482</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40A_eus-gaap--IncreaseDecreaseInAccountsPayable_i01_maCPBUIznfy_zkSyrqJtLndl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif">Accounts payable</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,389,665</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,284,493</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_402_eus-gaap--IncreaseDecreaseInOtherCurrentLiabilities_i01_maCPBUIznfy_z6GgfutOspv1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.625in; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt">Accrued expenses and other liabilities</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,402,511</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">&#160;</td><td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherCurrentLiabilities" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,670,986</ix:nonFraction></td><td style="text-align: left; padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCPBUIznfy_maCCERCzqpD_zVkNcTrsyKm" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in; font-family: Times New Roman, Times, Serif">Net cash used in operating activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">114,900,319</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">78,666,841</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_408_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zF7XqbCbJAOl" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_ecustom--PaymentsToAcquireIntellectualPropertyLicense_i01N_di_msNCPBUzwlS_zNQSk0kPLe6b" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Payment for intellectual property license</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0461">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="txmd:PaymentsToAcquireIntellectualPropertyLicense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_40F_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCz5jv_msNCPBUzw4q_msNCPBUzwlS_zJgx0nyllGA7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Patent costs</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,068,542</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">748,906</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_402_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCz5jv_msNCPBUzw4q_msNCPBUzwlS_z8qc8EDc157k" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Purchase of fixed assets</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,089,413</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">66,295</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_406_eus-gaap--IncreaseDecreaseInRestrictedCash_i01N_di_msCz5jv_msNCPBUzw4q_msNCPBUzwlS_zEtsUrEET4m3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Payment of security deposit</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,420</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInRestrictedCash" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,485</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtNCPBUzwlS_maCCERCzqpD_zgMSZ5Bfsbp2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash used in investing activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,178,375</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">20,826,686</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zb5DPbkpnawh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_407_eus-gaap--ProceedsFromOtherDebt_i01_maNCPBUzXbh_zD84R2j4IYIc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from  Financing Agreement</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromOtherDebt" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_401_eus-gaap--ProceedsFromStockOptionsExercised_i01_maNCPBUzXbh_zK1oe4weyZN" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from exercise of options and warrants</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,656</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,236,313</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_maNCPBUzXbh_zpTSbRMjjIqj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from sale of common stock, net of costs</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,907,797</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--ProceedsFromIssuanceOfOtherLongTermDebt_i01_maNCPBUzXbh_zMj7803iBKeh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Proceeds from Credit Agreement</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40C_eus-gaap--PaymentsOfFinancingCosts_i01N_di_msNCPBUzXbh_zM22bRTwkvxe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Payment of deferred financing fees</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,652,270</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,786,918</ix:nonFraction></td><td style="text-align: left">)</td></tr>
<tr id="xdx_409_eus-gaap--RepaymentsOfOtherLongTermDebt_i01N_di_msNCPBUzXbh_zerD9eB1uzUg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in; font-family: Times New Roman, Times, Serif">Repayment of Credit Agreement</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfOtherLongTermDebt" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">81,660,719</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span>&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_405_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtNCPBUzXbh_maCCERCzqpD_z69g9ardtS05" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Net cash provided by financing activities</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">111,795,667</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">162,357,192</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_iT_mtCCERCzqpD_zCaebITcUNEd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">(Decrease) increase in cash</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,283,027</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">62,863,665</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iS_zpAuxasFLKvj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1pt; padding-left: 10pt">Cash, beginning of period</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">161,613,077</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2017-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">127,135,628</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iE_zo8975jRDJm9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Cash, end of period</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">155,330,050</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="AsOf2018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">189,999,293</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: center">Supplemental disclosure of cash flow information</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_400_eus-gaap--InterestPaid_zB0OPeo0IEWi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Interest paid</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,446,792</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="us-gaap:InterestPaid" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,759,316</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 0"><b>Non-cash investing activity</b></td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center; padding-bottom: 2.5pt; padding-left: 0">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
<tr id="xdx_408_ecustom--LicenseExpendituresIncurredButNotYetPaid_zJj395nQkfA3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 10pt">Amount accrued for intellectual property license</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid"><ix:nonFraction name="txmd:LicenseExpendituresIncurredButNotYetPaid" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="text-align: left; border-bottom: Black 1pt solid">$</td><td style="text-align: right; border-bottom: Black 1pt solid"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span>&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
</table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p>


    <p style="margin-bottom: 0; margin-top: 0; text-align: center">&#160;</p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
    accompanying footnotes are an integral part of these consolidated financial statements.</span></p>
    <p style="margin-bottom: 0; margin-top: 0; text-align: center">&#160;</p>
    <!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->6<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt">
        <p style="margin: 0pt">&#160;</p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa005"></span>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:NatureOfOperations"><p id="xdx_800_eus-gaap--NatureOfOperations_zowNzJ6U04ue" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 1 &#x2013; THE COMPANY</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">TherapeuticsMD, Inc., a Nevada corporation,
    or TherapeuticsMD or the Company, has <span id="xdx_909_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20190930_znCImS6ahGld"><ix:nonFraction name="txmd:NumberOfSubsidiaries" contextRef="AsOf2019-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three
    </ix:nonFraction></span>wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
    corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
    otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our
    company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D; TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>&#160;and BIJUVA<sup>&#174;</sup> are registered trademarks of our company and ANNOVERA<sup>&#8482;</sup> is a licensed trademark of our company.</p>



<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Nature of Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&#8217;s healthcare company focused
on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#8217;s
healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD,
we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that
enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled,
long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD&#174;
and BocaGreenMD&#174; brands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With our SYMBODA&#8482; technology,
we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of
bio-identical hormones through a variety of dosage forms and administration routes. Our commercialization plan allows us to
efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products. During
2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our
FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain
associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we
launched our FDA-approved product BIJUVA, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus, which was approved by the FDA on October 28, 2018. In October 2019, we began a
test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal
system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was
approved by the FDA on August 10, 2018. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On
July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the
Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we
entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an
exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive
license and supply agreement, or the License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and
IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory.</p>

    </ix:nonNumeric><p id="xdx_81B_zzKjd0eDnQZa" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 7; Options: NewSection; Value: 7 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock"><p id="xdx_803_ecustom--BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_zMhcMYXC0EOc" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim consolidated
financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the
audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December
31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated
balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying
unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete
financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting
of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the
interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period
in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">In August 2018, the Financial
Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure
requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies
some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project,
which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly
communicate the most important information to users of the financial statements. The new guidance is effective for all entities
for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to
early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating
the effect of this guidance on our disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07 to
simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to
employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees
in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50.
The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods
within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not
been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard
did not have a material effect on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued
ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses
on their income statements in a manner similar to current accounting. The guidance also eliminates current real
estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the
accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual
periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new
leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for
transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the
alternative transition method allowed for under ASU 2018-11 and we recorded a $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pii_dm_c20190102_zM6IIzq6G3xf"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-01-02" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">3.8</ix:nonFraction>
million</span>  right of use asset and a $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pii_dm_c20190102_z89xzluQxGR2"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-01-02" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">4.1</ix:nonFraction>
million </span> liability related to adoption of this standard. In addition, upon commencement of additional lease space
in the third quarter of 2019 (as disclosed in Note 15) we recorded an additional  $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zFgr8m2nMBHd"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-08-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">7.4</ix:nonFraction>
million</span> right of use asset and an additional $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zs16srcNqZn4"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-08-31" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">7.2</ix:nonFraction>
million</span> liability related to our new lease space. Comparative financial information was not adjusted and will continue
to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did
not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired
leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical
expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate
lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard
resulted in increased disclosure requirements in our quarterly and annual filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">Other recent accounting pronouncements
issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC
did not, and are not expected to, have a material effect on our results of operations or financial position.</p>

    </ix:nonNumeric><p id="xdx_815_zhJGuc8a7Qi4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 8 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zs8Vy2lmjPK4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzgriDLIUlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Fair Value of Financial Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of September 30, 2019 (as
disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification,
or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 1in; text-align: justify"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unadjusted quoted prices in active markets for identical assets or liabilities;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unobservable inputs for the asset or liability.</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2019 and 2018, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets or
long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the company&#8217;s
impairment test on an annual basis.</p>

    </ix:nonNumeric><p id="xdx_854_zo3oEjfEs0g" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zDF1c5buzsl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations due under normal
trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for
doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing
economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off
delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when
received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does
not accurately reflect bad debts, adjustments to these reserves may be required.</p>

</ix:nonNumeric><p id="xdx_85C_zz08qjZ5B6nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>



    <ix:exclude><!-- Field: Page; Sequence: 9 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_230_zCsz0lfOSEfd" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_23F_z3jyVPhMaQGb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_23D_zheajL5RyTog" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_231_zoJ92XXzrfv7" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"></span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zUS9yHUzpj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Revenue Recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC 606 on January 1, 2018 using
the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is
considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance
that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of
our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are
considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary
upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control
of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to
receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue
recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be
entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with
the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, our products
consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third
quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the
third quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and
retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors,
which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail
pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat
shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we
satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to
be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s
ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts,
we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We
disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or
services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transaction price of a contract is the
amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration
to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative
assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated
with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain
event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the
future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in
the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable prescription
products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product
returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be
returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers.
For our newly launched products, for which the right of return exists but for which we currently do not have history of product
returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory
remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated
balance sheet.</p>

<ix:exclude><p id="xdx_238_zJAGrX39mbDg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>


<ix:exclude><!-- Field: Page; Sequence: 10 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_232_z88UqeBse5dj" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<ix:exclude><p id="xdx_23A_zUeJKVfQfZtl" style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p></ix:exclude>

<ix:exclude><p id="xdx_231_zrh7pdlh4h8d" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>

<ix:exclude><p id="xdx_23F_zy04wKSPJqF5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL
STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We offer various rebate and discount programs
in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance
for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at
the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates
and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate
chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience.
Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our
customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues
at the time the revenues are recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of commercial launches for
our FDA-approved prescription products, we introduce a co-pay assistance program where eligible enrolled patients, out of
pocket cost is reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in
line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We
consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction
price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated
based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance
paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any
time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our
prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a
result, we constrain revenue recognized for our prescription products to an amount that will not result in a
significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription
products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related
to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated
co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate
any constraint each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable up-front fees
that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data or technology is delivered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:DisaggregationOfRevenueTableTextBlock"><p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Three Months <br />Ended September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Nine Months <br />Ended September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,550,330</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,261,459</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,309,174</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-09-30_custom_PrescriptionVitaminsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,797,861</ix:nonFraction></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,772,354</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,076</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,904,744</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-09-30_custom_ImvexxyMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">212,076</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">490,705</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_BijuvaMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,987</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">399,952</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">399,952</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,506,400</ix:nonFraction></span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,719,741</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,473,535</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,745,257</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,009,937</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</ix:nonNumeric><p id="xdx_8AF_zOXgLiMXZZF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


    </ix:nonNumeric><p id="xdx_851_zZ4tGTJsR7Ka" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>



<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:CostOfSalesPolicyTextBlock"><p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zY3xkSL9zzw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Cost of Sales&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Cost of sales includes the cost of
inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. Certain
license agreements require the payment of royalties based on the sale of future products. Such royalties are recorded as a
component of cost of sales. Additionally, the&#160;amortization of license&#160;fees or milestone payments related to
licensed products are classified as components of cost of sales to the extent such payments become due in the future.</p>

</ix:nonNumeric><p id="xdx_85F_zyE5LzD267Nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
    <ix:exclude><p id="xdx_23B_z2PTwCa7agw6" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 11 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_230_z0ojkbV03AG7" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_231_zo86sdtu2UFi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_230_zzXna8GRt2vd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_23C_zMAry9WuqVS1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ttCnOrRyR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Share-Based Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options.
Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option
using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have
no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective
judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates.
The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions,
our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based
compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation
expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for
forfeitures when they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, we adopted ASU 2018-07
which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

    </ix:nonNumeric><p id="xdx_85A_zHBHVAziZYij" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zH5JRMQSacq9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&#38;D,
expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their
clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity
expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting
expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and
investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make
payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense
nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has
been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO
expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the
completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.</p>

    </ix:nonNumeric><p id="xdx_85B_zGkKZQMLVu8b" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGdDrHDqi1a4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Segment Reporting</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single management team that reports to the President of our company. We do not operate separate lines of business with respect
to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales
are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>

</ix:nonNumeric><p id="xdx_853_zfPbqggqPpWi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    </ix:nonNumeric><p id="xdx_814_zdxDxSTUgKs9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 12 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_237_zaIOp675z5L6" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p id="xdx_239_zLExnnmyimAd" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_z7F4ior80dE" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 4 &#x2013; INVENTORY</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zAswskwBVkSe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49C_20190930_zM0dt3gzECm9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20181231_zTdogbT3oo4d" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maINz2Fg_zjcVWlMql0t2" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Finished product</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,011,192</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,908,958</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz2Fg_zCD9rjFup0P9" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Work in process</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,005,575</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">339,312</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz2Fg_zI2NxnPuA5f7" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Raw material</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,516,077</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterialsAndSupplies" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,400</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_mtINz2Fg_z5Z9mF4uMIt9" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,532,844</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,267,670</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A0_zFgQLRpRYzM3" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

</ix:nonNumeric><p id="xdx_819_z3ov2KkgWSt4" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:OtherCurrentAssetsTextBlock"><p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_zESUyHuAmxX4" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 5 &#x2013; OTHER CURRENT ASSETS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zgT8WEKmKcYf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current assets consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20190930_z5lFsdxdiy6h" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49B_20181231_zqoOZTX38e02" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzWNe_z03udn5Zcvz5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Prepaid sales and marketing costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,313,192</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="txmd:PrepaidSalesAndMarketingCostsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,148,789</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzWNe_zKF6ZFEUcpnc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Deferred financing fees (Note 9)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">550,757</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredFinanceCostsCurrentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,898,074</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzWNe_zEu94eEnCyRd" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Prepaid insurance</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,542,008</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">790,465</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzWNe_zt6BMaq8zV2k" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other prepaid costs</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,172,303</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,997,365</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzWNe_zIBTXHrUL8Xg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,578,260</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,834,693</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A5_zX2pXPGsf8Sa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

</ix:nonNumeric><p id="xdx_819_zMv06oXft5Kb" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zymnE1GYXyh1" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 6 &#x2013; FIXED ASSETS, NET</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcUFkzdYbJ8l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Fixed assets, net consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September</b>  <b>30, <br />2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Accounting system</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPuW8gNhfigf"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,096</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBQTwKu5NDS8"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">301,096</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Equipment</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKxvlZ4OsLs7"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,371,390</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zedjHDHH1z3f"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_EquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">490,576</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Furniture and fixtures</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRHfmaqz8eue"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,294,241</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxPPECpfGlQj"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">116,542</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Computer hardware</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zy9v8zzBD225"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,211</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zINZNj8PrU57"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">80,211</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Leasehold improvements</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwF24goIlzf6"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">68,788</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6bhwtAy5Nn"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">37,888</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930_zRv4nr0Xjkgl"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,115,726</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231_z2f4fZOthu39"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,026,313</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Accumulated depreciation</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20190930_zGl7iKfBxxva"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">777,380</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20181231_zBUbMCBfqcaj"><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">553,630</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20190930_zYJbMIldt7cj"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,338,346</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20181231_z6vkyVW9hikf"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">472,683</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A7_zhu1GBB3i4Mc" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Depreciation expense for the three months ended
September 30, 2019 and 2018 was $<span id="xdx_90B_eus-gaap--Depreciation_c20190701__20190930_zrirdn6ufr2j"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">90,700</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--Depreciation_c20180701__20180930_zbbsakzAFXRh"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,221</ix:nonFraction></span>, respectively, and $<span id="xdx_902_eus-gaap--Depreciation_c20190101__20190930_zDktTGWTHR9i"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">223,750</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--Depreciation_c20180101__20180930_zlCmbV1Sy2A8"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">121,423</ix:nonFraction></span> for the nine months ended September
30, 2019 and 2018, respectively.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

</ix:nonNumeric><p id="xdx_814_zWe16Um4UXfd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 13 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_23C_zMby3WxTImte" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p id="xdx_230_zhcyoFVfJLNh" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock"><p id="xdx_809_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zUGf6R4dvZ5k" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 7 &#x2013; INTANGIBLE ASSETS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="txmd:ScheduleOfIntangibleAssetsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zF2pG48UUutj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible
    assets as of  September 30, 2019 and December 31, 2018:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br />Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br />Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHT4kcSu00h4"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,138,308</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfGFHL86MePe"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">421,694</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zjdehtxU1VZ9"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,716,614</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxexs92WpqWl"><span style="-sec-ix-hidden: xdx2ixbrl0640">13.25 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patent (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zecx6GTDwx55"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,937,691</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zyr7z5nVMYtb"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,937,691</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--IndefiniteLivedTrademarks_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zrVf8dqjdmQ3"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,846</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zGkffbfhIFqd"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">287,846</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20190930_z0pNSTmUTR7l"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,363,845</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930_zPaKAwZSUr06"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">421,694</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_902_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20190930_zE2rT6V2zNge"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,942,151</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="14" style="text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br />Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br />Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">OPERA<sup>&#xAE;</sup> software patent</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zH8PtIeI4Yu1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,951</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zlWYTVlSdoy7"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,484</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zhNgaqL1IuJ5"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,467</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zfomTckYUkHf"><span style="-sec-ix-hidden: xdx2ixbrl0651">10.75 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Development costs of corporate website</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zPFT8hiW06a9"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">91,743</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zeGvdBObtG81"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">91,743</ix:nonFraction></span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_z0VUomajPbY2"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z0rhyjQ4RQr8"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,234,129</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4pIuwCw1lQa"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">282,485</ix:nonFraction></span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaymSAUbGVT5"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,951,644</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zRlkL68D776a"><ix:nonNumeric contextRef="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">14</ix:nonNumeric></span> years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zRu92iHsrlo3"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,855,279</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zlXVUgqxn2Id"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,855,279</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z4YwYthUGCE3"><ix:nonFraction name="us-gaap:IndefiniteLivedTrademarks" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,289</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zv60HoAHnCZk"><ix:nonFraction name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">264,289</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_zg4kASQUQK9c"><ix:nonFraction name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,477,391</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231_zYJpcxmeA1gi"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">384,712</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_903_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zJnQ5BGJ8R23"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,092,679</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A9_zKlXrzk73vTi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We capitalize external costs,
    consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize
    the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of
    approximately <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcxFu8f3xYy7"><ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">20</ix:nonNumeric></span> years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized
    patent costs at that time. Trademarks are perpetual and are not amortized. During the  nine months ended  September 30, 2019,
    we     wrote off $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20190930_zO4zzKp2gqA7"><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">78,864</ix:nonFraction></span>
    in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.</p>
    <ix:exclude><p id="xdx_236_zd7ZXOJ0V4Hd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 14 -->
    <div id="xdx_23D_z6RbnpauYAa1" style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_230_zh0ErtH5lgUl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_237_zPp2zJJPLzGg" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_238_z9kZXHsEc78" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of  September 30, 2019, we had <span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zMV96WVwqBkd"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUSPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">26</ix:nonFraction></span>
    issued domestic, or U.S., patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zy5qZxrzt4Ge" title="Number of issued patents"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignPatentsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">28</ix:nonFraction></span>
    issued foreign patents, including: </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_pii_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_z8qfltyCATu4"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticPatentsBijuvaMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">12</ix:nonFraction></span> domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zjdDjw9dWhB6"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignPatentsBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">six</ix:nonFraction></span> foreign patents that relate to BIJUVA as well as <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_z4P5ToYu9xPl"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticPatentsNonApprovedBijuvaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zTbMhinwjrg1"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUSPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Five</ix:nonFraction></span> domestic patents (<span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zcdUdW1K7ehf"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUSUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> utility and <span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zOfhXCHGy0vg"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUSDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span> design) and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zFWiHHvOLaU4"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignPatentsImvexxyMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">13</ix:nonFraction></span> foreign patents (<span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zknycpPqXsr5"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignUtilityPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span> utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z9VjnyiAQjzc"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignDesignPatentsImvexxyMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">ten</ix:nonFraction></span> design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zoHdGdPLtO7"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUSPatentsTopicalCreamMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zHMvCZ8shUN6"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zNuk6TOMOVLe"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_ForeignUtilityPatentTransdermalPatchMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">five</ix:nonFraction></span> foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Europe, Mexico, and South Africa;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_ziuOF0i3T0Ji"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentOperaMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentDLimoneneMember_zwEEMWSOa8Wa"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentDLimoneneMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">One</ix:nonFraction></span> domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036; and</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#x25CF;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zgILgfro8lkc"><ix:nonFraction name="txmd:NumberOfIssuedPatents" contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentTx009HRMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">Two</ix:nonFraction></span> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</p>


    <ix:exclude><p id="xdx_23E_zJlec4qVRLIk" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 15 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23D_z6PVtZVrJtid" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_239_zyLrrUcklgyj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_23C_z6vq3qIXkJKg" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_231_zC8A7l5X53He" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Amortization expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930_zMNDtbUkzAB6"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">51,259</ix:nonFraction>
</span>and $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20180701__20180930_zx62xv28P7Jd"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">31,100</ix:nonFraction></span> for the three months ended September 30, 2019 and 2018, respectively, and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930_zlKbrsgfu9Hl"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">140,206</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20180930_zT82fUYIIuta"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,123</ix:nonFraction></span> for the nine
months ended September 30, 2019 and 2018, respectively. </p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"><p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAci4sN9jYqf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20190930_zThwUBK0S9ml"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,259</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2020</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20190930_zUjJVCXk7WT8"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,035</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2021</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20190930_zgQfK1pgKl12"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,035</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2022</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20190930_zC6w2B1yBR7j"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,035</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2023</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20190930_zTOwKhv8PJre"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">205,035</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A3_zrdPQqZP9AGa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with the Population Council</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 30, 2018, we entered into the Council License Agreement to
commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full
commercial launch in the first quarter of 2020.</p>



<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Under the terms of the Council
    License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_900_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zdEopnBw5039"><ix:nonFraction name="txmd:MilestonePaymentUponFDAApproval" contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>
    within 30 days following approval by the FDA of the new drug application, or NDA, for ANNOVERA. The first commercial batch
    of     ANNOVERA         was     released     during the     third quarter of 2019 and we are required to pay the
    Population     Council     $<span id="xdx_907_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4aqI3Gp9oY2"><ix:nonFraction name="txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch" contextRef="AsOf2019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span> as a result of the commercial batch release. Both milestone payments of $<span id="xdx_90C_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zJisBxrnrfj8"><ix:nonFraction name="us-gaap:FinitelivedIntangibleAssetsAcquired1" contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>
    were recorded as  finite-lived intangible asset in the consolidated balance sheet as of September 30, 2019. We     started
    amortizing the intangible asset in  the third quarter of 2019 once ANNOVERA became commercially available for use. The cost
    is     amortized     over     the     remaining useful life over which an intangible asset will contribute directly or
    indirectly to     our cash     flows.     During     both the three and nine months ended September 30, 2019, we recorded
    $<span id="xdx_908_eus-gaap--OtherAmortizationOfDeferredCharges_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zxgyFE9a4CWc"><span id="xdx_902_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z1LXOHwdFNU5"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherAmortizationOfDeferredCharges" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,998</ix:nonFraction></ix:nonFraction></span></span>
    in amortization expense related to the license fee     which was recorded as a component of cost of
    sales.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The Population Council is also
eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for
marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to  $<span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember__custom--RoyaltyTierAxis__custom--StepBasedRoyaltyPaymentOneMember__srt--RangeAxis__srt--MaximumMember_ztQwC0HJUrof"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentOneMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_904_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zVFqGfPOp1V4"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">5</ix:nonFraction></span>%
of net sales; (ii) for annual net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zRjIN2F1tYPf"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>
and less than or equal to $<span id="xdx_90B_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zp8hnq8MjsR"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_90F_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zzm6ms4ydZK3"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">10</ix:nonFraction></span>%
of such net sales; and (iii) for net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z16mp6wmofGb"><ix:nonFraction name="txmd:NetSalesAmountPerStepbasedRoyalty" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,000,000</ix:nonFraction></span>,
a royalty of <span id="xdx_901_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zr2gy2T8UbS9"><ix:nonFraction name="txmd:RoyaltyPercent" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">15</ix:nonFraction></span>%
of such net sales. The annual royalty rate will be reduced to <span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zh7ru0AV8nTi"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">50</ix:nonFraction></span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will
be     reduced to <span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zw5UuV3ddgpg"><ix:nonFraction name="txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">20</ix:nonFraction></span>%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed  $<span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zpjdnchgCzA3"><ix:nonFraction name="txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid" contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Council
License Agreement. We and the Population Council have agreed to form a joint product committee responsible for overseeing
activities under the Council License Agreement. We will be responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the
one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. The Council
License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal
contraceptive systems in development by the Population Council.</p>

<ix:exclude><p id="xdx_235_zkW5lRQbMqif" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 16 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_234_zRY9FrKtdQkl" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_230_zJfxbEt6DKv8" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_23C_zwXbpbyqwQld" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_239_zughl8hNbYqk" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We assess our intangible assets for impairment
if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or
changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated
undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash
flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset
and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining
useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would
indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining
useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining
useful life.</p>


<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with Knight Therapeutics Inc.</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 30, 2018, we entered into a license
and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us
a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and
Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either
party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified
time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement,
Knight entered into a subscription agreement with us, pursuant to which Knight purchased  <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zuRaBA4CGKlj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,921,568</ix:nonFraction></span> shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_znvoxappvw2k"><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>, for proceeds of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_uUSD_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zpFM1wNNrC1a"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>, on August 6, 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with Theramex</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR <span id="xdx_90C_ecustom--CashUpfrontPaymentReceived_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zcXjUxf5vXja"><ix:nonFraction name="txmd:CashUpfrontPaymentReceived" contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">14</ix:nonFraction> </span>million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the License Agreement, we provided Theramex the
regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other
applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee,
which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and
benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive
additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_901_ecustom--RegulatoryMilestoneAdditionalPayment_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zz9bQKJRfMme"><ix:nonFraction name="txmd:RegulatoryMilestoneAdditionalPayment" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">2</ix:nonFraction> </span>million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and
(ii) up to an aggregate of EUR <span id="xdx_908_ecustom--SalesMilestonePaymentsInTranches_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_znvl9LeAbaif"><ix:nonFraction name="txmd:SalesMilestonePaymentsInTranches" contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">27.5</ix:nonFraction></span>
million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR <span id="xdx_904_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zrf9gehw4FDh"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">25</ix:nonFraction> </span>million
to EUR <span id="xdx_906_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zlCKA6MO19Zg"><ix:nonFraction name="txmd:AnnualNetSalesMilestone" contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="EUR">100</ix:nonFraction> </span>million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    </ix:nonNumeric><p id="xdx_81A_zsDe1osAbC83" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 17 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_233_zecWrXVIZJll" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p id="xdx_23E_zalkE0CH7Ped" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zKU8DQ7vNe2j" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 8 &#x2013; OTHER CURRENT LIABILITIES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock"><p id="xdx_89D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zHT0ZkweaNyb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current liabilities consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49E_20190930_z1xiew4yGEf9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_496_20181231_zwgr1Gv7Yx4i" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_403_eus-gaap--AccruedSalariesCurrent_iI_maOLCzFFK_zQBchktIR34g" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; width: 50%; text-align: justify; text-indent: -0.125in">Accrued payroll, bonuses and commission costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,536,358</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,854,002</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
<tr id="xdx_400_ecustom--AccruedIntellectualLicenseFee_iI_maOLCzFFK_zbTF9nuIxlf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued intellectual license fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="txmd:AccruedIntellectualLicenseFee" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzFFK_zvwBizl1yWcj" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for coupons and returns</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,079,005</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:SalesDiscountsReturnsAndAllowancesGoods1" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,294,120</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzFFK_z2n8nuuRe9Mf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued sales and marketing costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,560,257</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedMarketingCostsCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,288,028</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--AccruedVacationCurrent_iI_maOLCzFFK_zp1m4PVFG1P4" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued compensated absences</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,551,042</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,178,110</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzFFK_zyS87ucdA3Q8" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for wholesale distributor fees</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,375,894</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AllowanceForWholesaleDistributorFeesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">792,891</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzFFK_zm9mIQ4XU8Ke" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued legal and accounting expense</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">469,446</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">385,824</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopment_iI_maOLCzFFK_zNWXwppcCpWf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued research and development</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,226,160</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AccruedResearchAndDevelopment" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">388,675</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzFFK_zQT2vGFHlBFg" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,242,290</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_eus-gaap--AccruedRentCurrent_iI_maOLCzFFK_zINtVwuf6UUg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rent</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRentCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">365,155</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedRebates_iI_maOLCzFFK_zXduvJzfogJ9" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rebates</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,543,456</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="txmd:AccruedRebates" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">412,570</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzFFK_zD1HVBJRBcP6" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Other accrued expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">612,124</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">375,573</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzFFK_z82CcnQ6IA11" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">43,196,032</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:OtherLiabilitiesCurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,334,948</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8AD_zWRKTMXGmG38" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

</ix:nonNumeric><p id="xdx_81D_zJR6aYbMUFg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b></b></p>


<!-- Field: Page; Sequence: 18 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 12pt Arial, Helvetica, Sans-Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL
STATEMENTS</b></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:LongTermDebtTextBlock"><p id="xdx_800_eus-gaap--LongTermDebtTextBlock_zdGgh6tvQ3Kh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 9 &#x2013; DEBT</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2019, we entered into a Financing
    Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent,
    various lenders from time to time party thereto, and certain of the Company&#8217;s subsidiaries party thereto from time to
    time as guarantors, which provides us with a $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zUb2QC61vNT9"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">300,000,000</ix:nonFraction></span> first lien secured term loan credit facility, or the Facility. The
    Facility provides for availability to us in three tranches: (i) $<span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_z5yhTnbQyXJa"><ix:nonFraction name="us-gaap:ProceedsFromLinesOfCredit" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span> was drawn upon entering into the Financing Agreement;
    (ii) $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zXWdeo4W1wy5"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span> will be available to us upon the designation of our ANNOVERA product as a new category of birth control by
    the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zqS7FM6o0EG5"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>
    will be available to us upon our achieving $<span id="xdx_901_ecustom--RevenueRequirementToDrawOnTermLoan_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zAXiKjGcRLkj"><ix:nonFraction name="txmd:RevenueRequirementToDrawOnTermLoan" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,000,000</ix:nonFraction></span> in net revenues, as defined in the Financing Agreement, from our IMVEXXY,
    BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent.
    Borrowings under the Facility accrue interest at either (i) <span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zICa8SIqMjFl"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">3-month LIBOR</ix:nonNumeric></span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJDoA3NI2lxh"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.75</ix:nonFraction></span>%, subject to a LIBOR floor of <span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z6OHd3kwZDy9"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.70</ix:nonFraction></span>% or
    (ii) the <span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zJGqH9ymcwL9"><ix:nonNumeric contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">prime rate</ix:nonNumeric></span> plus <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zwZPcyTMB8Qc"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">6.75</ix:nonFraction></span>%, subject to a prime rate floor of <span id="xdx_909_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zlGPWPBelbk6"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.2</ix:nonFraction></span>% as selected by us. Interest on amounts borrowed under
    the Facility will be payable quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_900_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zqHAO5bOIhW6"><ix:nonFraction name="txmd:NumberOfInstallmentPayments" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span> equal quarterly
    installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings
    under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i)
    <span id="xdx_90B_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9XkKYONZ6Zk"><ix:nonFraction name="txmd:PrepaymentFeeForFirstTwoYearsFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">30.0</ix:nonFraction></span>% for the first two years following the initial funding date of the applicable borrowing, (ii) <span id="xdx_907_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zdW1hUCH8g93"><ix:nonFraction name="txmd:PrepaymentFeeThirdYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% for the third year
    following the initial funding date of the applicable borrowing, (iii) <span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zYnRxXvIpj4g"><ix:nonFraction name="txmd:PrepaymentFeeFourthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">3.0</ix:nonFraction></span>% for the fourth year following the initial funding
    date of the applicable borrowing and (iv) <span id="xdx_90D_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3kQEd2XbCj3"><ix:nonFraction name="txmd:PrepaymentFeeFifthYearFundingPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.0</ix:nonFraction></span>% for the fifth year following the initial funding date of the applicable borrowing
    but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the
    lenders, a facility fee equal to <span id="xdx_909_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zwOFIdSBJqMi"><ix:nonFraction name="txmd:FacilityFeePaidPercent" contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.5</ix:nonFraction></span>% of the initial amount borrowed and will be required to pay such a facility fee in connection
    with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an
    annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments,
    restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are
    required to (i) maintain a minimum unrestricted cash balance of $<span id="xdx_904_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zHvuzfaTSxxi"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,000,000</ix:nonFraction></span>, which will increase to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_z1eMhj5FoEXa"><ix:nonFraction name="txmd:MinimumCashBalanceRequirementUnderCreditAgreement" contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">60,000,000</ix:nonFraction></span> if we draw
    either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable
    to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020.
    The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary
    for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an
    event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing
    Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement.
    The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted
    liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after-acquired
    assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our
    future direct and indirect subsidiaries, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2018, we entered into a Credit and
Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the
additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement
provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zliFhCtFd7j5"><ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span>, or the Term Loan. Under the terms
of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_909_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uTranches_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zp4qL7gV5o3l"><ix:nonFraction name="txmd:NumberOfTranchesUnderTermLoanFacility" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Tranches">three</ix:nonFraction></span> separate tranches, with each tranche to be made available
to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate
equal to the sum of (i) <span id="xdx_901_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zQEuiyFE6Cwk"><ix:nonNumeric contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember" name="us-gaap:DebtInstrumentDescriptionOfVariableRateBasis">one-month LIBOR</ix:nonNumeric></span> (subject to a LIBOR floor of <span id="xdx_906_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z9QUX4BDIIMd"><ix:nonFraction name="txmd:LiborFloorRate" contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.50</ix:nonFraction></span>%) plus (ii) <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zIzBNZt0SsFd"><ix:nonFraction name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">7.75</ix:nonFraction></span>% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_904_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zLTRnyXdkh4g"><ix:nonFraction name="txmd:RepaymentOfDebtWithNewCreditFacility" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">81,661,000</ix:nonFraction></span>
was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of <span id="xdx_90A_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424_zAQHBCcaAHGk"><ix:nonFraction name="txmd:PrepaymentFeePercentage" contextRef="From2019-04-232019-04-24" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4</ix:nonFraction></span>%, a repayment fee of <span id="xdx_90A_ecustom--RepaymentFeePercentage_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_ziXmQE8FbiSk"><ix:nonFraction name="txmd:RepaymentFeePercentage" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">4</ix:nonFraction></span>% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit
Agreement, we recorded $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zY5uklUD2Bcl"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,057,632</ix:nonFraction></span> in loss on extinguishment of debt in the accompanying unaudited consolidated financial statements.
Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the nine months
ending September 30, 2019 related to the Credit Agreement was $<span id="xdx_901_eus-gaap--InterestExpenseDebt_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBO6TnW43oJ5"><ix:nonFraction name="us-gaap:InterestExpenseDebt" contextRef="From2019-01-012019-09-30_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,816,747</ix:nonFraction></span>. During the nine months ended September 30, 2019, and
prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z8w78dm3QLJk"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-09-30_custom_MidCapAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">120,146</ix:nonFraction></span> of deferred financing fees as interest expense in the accompanying
unaudited consolidated financial statements.</p>

<ix:exclude><p id="xdx_238_zsjhw5JtHAmd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p></ix:exclude>

    <ix:exclude><!-- Field: Page; Sequence: 19 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_235_zojiwKs4nOKh" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_238_zJbWGWmaJ6P2" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_231_z5X27ghfxbZg" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_230_zXSohxdupGE2" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of September 30, 2019, we had
    $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zmXXipafmeEg"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">200,000,000</ix:nonFraction></span>
    in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
    unaudited consolidated financial statements. We incurred $<span id="xdx_901_eus-gaap--PaymentsOfFinancingCosts_c20190101__20190930_z11mGaBanh4a"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,652,270</ix:nonFraction></span>
    in deferred financing fees related to the Financing Agreement.     Deferred financing fees related to the entire Financing
    Agreement have been allocated pro rata between the funded and unfunded     portions of each tranche. Allocated deferred
    financing fees related to Tranche 1 of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190930_zNU5p2P7KhJ1"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,101,513</ix:nonFraction></span>
    have been reflected as a debt     discount and are accreted to interest expense using the effective interest method. Deferred
    financing fees associated with     unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones
    have been met. As of September 30,     2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in
    other current assets in the accompanying     consolidated financial statements. During the three and nine months ended
    September 30, 2019, we amortized $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_c20190701__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zztLAoHxCQP5"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-07-012019-09-30_custom_TrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,949</ix:nonFraction></span>
    and $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zaJ9vsMFTHGe"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="From2019-01-012019-09-30_custom_TrancheOneMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">462,683</ix:nonFraction></span>,
    respectively, of deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated
    financial statements.     Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears.
    Interest expense for the three and nine months ended September 30, 2019 was $<span id="xdx_900_eus-gaap--InterestExpenseBorrowings_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zvR1wRq01M3f"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,333,056</ix:nonFraction></span>
    and $<span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zAZw34Z0j7pe"><ix:nonFraction name="us-gaap:InterestExpenseBorrowings" contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,318,056</ix:nonFraction></span>,
    respectively. The overall effective interest     rate under the Financing Agreement was approximately <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_c20190930_zdXK3sHJsMQi"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">11</ix:nonFraction></span>%
    as of September 30, 2019.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span></span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zdbjB65BooBl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;As
of  September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br />2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br />2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Financing Agreement</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zLAtaomMsoWl"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2019-09-30_custom_FinancingAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000,000</ix:nonFraction></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">&#8212;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Credit Agreement</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zerwox7m3Tek"><ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" contextRef="AsOf2018-12-31_custom_CreditAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">75,000,000</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Debt discount and financing fees</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20190930_zDle5W3cHaC"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,638,831</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20181231_z91shXXUtoF2"><ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,618,986</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL LONG-TERM DEBT</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--LongTermDebtNoncurrent_iI_c20190930_z5GQliQ99n25"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">194,361,169</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_c20181231_znb2rDrzaIvk"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2018-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">73,381,014</ix:nonFraction></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A6_zOEvQirJXnF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</ix:nonNumeric><p id="xdx_817_zabZ3wBa4q85" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 20 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_231_zg2dxtarvoQi" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p id="xdx_237_z8OqTXJs6vrg" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zbXpKliL0H3a" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
    10 &#x2013; NET LOSS PER SHARE</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We calculate earnings per share, or EPS, in
accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted.
We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock,
outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding
plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our
Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted EPS because
their effect would have been antidilutive due to the net loss reported by us.<span></span></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWarCx3JZYAg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three and  Nine months ended</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 30%; text-align: justify">Stock options</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOYTmjrLe0t6"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJrVAKWWCSlc"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">24,849,984</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zge6deMEgupj"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrrfOQAYp4bk"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-07-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">24,837,349</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Warrants</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzo6au7jLMJl"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXMIaNe9C2D3"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-07-012019-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,832,571</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQ6UEgPMZx3"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMQohizb05J"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-07-012018-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-09-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">3,007,571</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Restricted stock awards</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4coHhgm7APk"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0fGdSduEef6"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-07-012019-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">1,240,000</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpHXTVFnBHi7"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAcuMHRwC7M2"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-07-012018-09-30_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-09-30_us-gaap_RestrictedStockMember" format="ixt:zerodash" decimals="0" scale="0" unitRef="Shares">&#8212;</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930_zRk9YdjIQD27"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930_z5VUxV5e6f1f"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">27,922,555</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930_zjSqvqZLtHL8"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930_zdrT0GLApXQ6"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">27,844,920</ix:nonFraction></ix:nonFraction></span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A5_z8L2y6L6fDZa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

</ix:nonNumeric><p id="xdx_818_zXQfvjotkuri" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs3ZJAYk7w7i" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred Stock</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At  September 30, 2019, we had <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20190930_zFYiirVeCzil"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></span>
    shares of preferred stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20190930_zDt5xLPzJTLl"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span>
    per share, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common Stock</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At  September 30, 2019, we had <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20190930_ziDok71XeBAl"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350,000,000</ix:nonFraction> </span>shares
    of Common Stock authorized for issuance, of which <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20190930_zargAC1LU7o8"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20190930_zrNdXVze2qQ2"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">241,277,076</ix:nonFraction></ix:nonFraction></span></span>
    shares of Common Stock were issued and outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During the Three and Nine Months
Ended September 30, 2019</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the three months ended September 30,
2019, certain individuals exercised stock options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20190701__20190930_zJUfJORn5Tx6"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">55,236</ix:nonFraction></span>  shares of Common Stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190701__20190930_zC8RXIjxh6cf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,549</ix:nonFraction></span> in cash. During the nine
months ended September 30, 2019, certain individuals exercised stock options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930_zbMDX7EsnWol"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">331,619</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20190930_zDNYOWqYezTe"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">108,656</ix:nonFraction></span> in cash. Also, during the same period, stock options to purchase <span id="xdx_906_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20190930_zd9sfAbvvH05"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,097</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein <span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20190930_zkWxwKjSwESd"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,834</ix:nonFraction></span> shares of Common Stock were issued.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During the Three and Nine Months
Ended September 30, 2018</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2018, certain individuals exercised stock options to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180701__20180930_zM3Z0XU79EDd"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,052,300</ix:nonFraction></span> shares of Common Stock for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180701__20180930_zLnvjtbWk4z8"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,318</ix:nonFraction></span> in cash. During the
nine months ended September 30, 2018, certain individuals exercised stock options to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20180930_zGmNdsAgIoyf"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,446,876</ix:nonFraction></span> shares of Common Stock
for $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20180930_zkEy4oiUdphb"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,236,313</ix:nonFraction></span> in cash. Also, during the nine months ended September 30, 2018, stock options to purchase <span id="xdx_908_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20180930_zvWmEtndmXkc"><ix:nonFraction name="txmd:NumberOfStockOptionsExercisedInCashlessExercise" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> shares of Common
Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_90B_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20180930_zAxNw5hUUWY7"><ix:nonFraction name="txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,841</ix:nonFraction></span> shares of Common Stock were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2018, we entered into an
underwriting agreement with Goldman Sachs &#38; Co. LLC, as representative of the underwriters, relating to an underwritten
public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRAyHGwaTnOj"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">12,745,098</ix:nonFraction></span>
shares of our Common Stock at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20180801_zR3nP3CWo06c"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2018-08-01" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.10</ix:nonFraction></span>
per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zHkRZHv9eKK9"><ix:nonNumeric contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt-sec:durday" name="txmd:PeriodExercisableUnderwritersOption">30</ix:nonNumeric></span> days,
to purchase up to <span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zoFFUgInk1Kk"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,911,764</ix:nonFraction></span>
additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds from
the offering, including the exercise of the option to purchase additional shares, were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180805__20180806_ze683lWjlzc7"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2018-08-052018-08-06" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,908,000</ix:nonFraction></span>,
after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In
connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight
purchased $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXEcnarx6TEi"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,000,000</ix:nonFraction></span>
of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock on August 6,
2018.</p>

    <ix:exclude><p id="xdx_23E_zVeGLR0a9P35" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 21 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_236_zudUsodiseOi" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_233_z5W1c3SCb8Xe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_235_zxNl3OnccrUl" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_237_zBx6CaNtw8z4" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of  September 30, 2019, we had
    warrants outstanding to purchase an aggregate of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_c20190930_zhEn3S8s7EO7"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,832,571</ix:nonFraction></span>
    shares of Common Stock with a weighted-average contractual remaining life of approximately <span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_c20190101__20190930_z9ik3ScS5mxb"><span style="-sec-ix-hidden: xdx2ixbrl0881">2.2
    years</span></span>, and exercise prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z1huLMDtVZy3"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-30_custom_WarrantsMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.24</ix:nonFraction></span>
    to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zDL9culEKwC8"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-30_custom_WarrantsMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.20</ix:nonFraction></span>
    per share, resulting in a weighted average exercise price of $<span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_c20190101__20190930_z5pnRBhFW3fb"><ix:nonFraction name="txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.62</ix:nonFraction></span>
    per share.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to
    determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number
    of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2019, we granted warrants to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zurnvHwd7nG8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">75,000</ix:nonFraction>
    </span>shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvXzbPTO7jNa"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.63</ix:nonFraction></span>.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z46SCijEdjxk"><ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">5
    years</ix:nonNumeric></span>; volatility of <span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMOS2WUC2lia"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">60.8</ix:nonFraction></span>%;
    risk free rate of <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zPEXATfZlAE5"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">2.52</ix:nonFraction></span>%;
    and dividend yield of <span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ziGrNJcskqX"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0</ix:nonFraction></span>%.
    The grant date fair value of the warrants was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zN5TCM3mEkf3"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.00</ix:nonFraction>
    </span>per share. The warrants are vesting ratably over a <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zuaXz5DfZRqk"><ix:nonNumeric contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12
    month </ix:nonNumeric></span>period and have an expiration date of February 12, 2024. During the nine months ended September 30, 2018, we
    granted warrants to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z1WM5rXAF84"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">175,000</ix:nonFraction>
    </span>shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z5kXncaapQI9"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.16</ix:nonFraction></span>.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    <span id="xdx_903_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmyr7B2zqr5l"><ix:nonNumeric contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">5
    years</ix:nonNumeric></span>; volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmCkIPCu4sm8"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">62.1</ix:nonFraction></span>%;
    risk free rate of <span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zEwqfvsNz0ii"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">2.36</ix:nonFraction></span>%;
    and dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zV7xpkvTpTmg"><ix:nonFraction name="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0</ix:nonFraction></span>%.
    The grant date fair value of the warrants was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zoKk1K3FCr2d"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.79</ix:nonFraction>
    </span>per share. The warrants vest ratably over a <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zjjDzZbXZ328"><ix:nonNumeric contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">12
    month </ix:nonNumeric></span>period and have an expiration date of March 15, 2023. During the three months ended September 30, 2019 and 2018,
    we recorded $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zd2AhydHsA63"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-07-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,418</ix:nonFraction>
    </span>and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zeXbsmf4CiV4"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-07-012018-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">150,977</ix:nonFraction></span>,
    respectively, and during the nine months ended September 30, 2019 and 2018, we recorded $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zds0ppTmdsw1"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2019-01-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">198,306</ix:nonFraction>
    </span>and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zR8JQpsHKJXc"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2018-01-012018-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">407,292</ix:nonFraction></span>,
    respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants.
    As of September 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants
    was approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zVS1ElagjrLi"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">83,000</ix:nonFraction></span>,
    which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zUiDDld9hpZ2"><span style="-sec-ix-hidden: xdx2ixbrl0906">0.4
    years</span></span>.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30,
2019, warrants to purchase  <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHLrhYc10rh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2019-01-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,250,000</ix:nonFraction></span> shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions,
wherein  <span id="xdx_903_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zGtOfVnkIIZe"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2019-01-012019-09-30_custom_WarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">471,184</ix:nonFraction></span> shares of Common Stock were issued. During the nine months ended September 30, 2018, <span id="xdx_90E_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfuvSuSYti4d"><ix:nonFraction name="txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants" contextRef="From2018-01-012018-09-30_custom_WarrantsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">no</ix:nonFraction></span> warrants were exercised.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options to Purchase Common Stock </span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2009, we adopted the 2009 Long
    Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
    consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
    providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
    consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
    units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
    as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
    on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
    exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
    September 30, 2019, there were non-qualified stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z084QCI0OcH9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,028,509</ix:nonFraction></span>
    shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.</p>
    <ix:exclude><p id="xdx_23D_zj7Sgyk0VoUg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 22 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23B_zxaKIMq1Oabb" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_23F_zNfPYsin6f4f" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_23D_zPtw6grnKxt5" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_237_zJXnIKpZ9UTc" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"> In 2012, we adopted the 2012 Stock
    Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve
    as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
    advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights,
    restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
    in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each
    option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested
    and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date
    is generally ten years from the date the option is issued. As of September 30, 2019, there were non-qualified stock options
    to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zEdFpQOY1fQa"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,316,474</ix:nonFraction></span>
    shares of Common Stock outstanding and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCJZpEGc0iH7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></span>
    restricted stock awards under the 2012 Plan. Effective upon our adoption of the  2019 Plan,
    no future awards may be made under the 2012 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On June 20, 2019, we adopted the
    2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
    consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock
    appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash
    awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of
    directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
    after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if
    any. The expiration date is generally ten years from the date the option is issued. As of September 30, 2019, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930_zcxt7nlgS7Gg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,779,632</ix:nonFraction></span>
    shares of Common Stock available  for issuance thereunder, consisting of (i) <span id="xdx_900_ecustom--PlanAwardsNumberOfNewShares_iI_c20190930_zcHVE9Tn5KH4"><ix:nonFraction name="txmd:PlanAwardsNumberOfNewShares" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">11,294,999</ix:nonFraction></span>
    new shares, (ii) <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z9InMTp5NhH9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,395,333</ix:nonFraction></span>
    unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding
    &#x201C;Awards&#x201D; (as defined in the 2012 Plan), and (iii) <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z56BRzUqMncb"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">89,300</ix:nonFraction></span>
    <span style="background-color: white">unallocated shares previously available for issuance under the 2009 Plan that were
    not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options
    or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or
    otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not
    result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in
    connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those
    Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again
    be available for delivery with respect to Awards under the 2019 Plan. As of September 30, 2019, there were non-qualified
    stock options to purchase</span> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member_zzzyUoJA9mo8"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_custom_Plan2019Member" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,505,001</ix:nonFraction></span>
    shares of Common Stock outstanding and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyja3bnqdq9h"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span>
    restricted stock awards outstanding under the 2019 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. <span></span></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBj64RxovG9h" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The
assumptions used in the Black-Scholes Model for options granted during the  nine months ended  September 30, 2019 and 2018
are set forth in the table below.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: top">
            <td><b>&#160;</b></td>
            <td colspan="3" style="border-bottom: Black 1pt solid">
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>Nine months ended</b></p>
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></p>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="width: 38%"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span>
            </td>
            <td style="width: 2%; text-align: right"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztEnj6eKOIo1" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">1.83</ix:nonFraction></span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNcE7gUfeyDl" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">2.54</ix:nonFraction></span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY6csQbSvxrk" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">2.78</ix:nonFraction></span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ7wNll52r2" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">2.82</ix:nonFraction></span>%</span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Volatility</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBKnAH03VqWa" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">61.25</ix:nonFraction></span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW5gMV6ePm46" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">64.49</ix:nonFraction></span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z349HZXWPMU4" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">61.8</ix:nonFraction></span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z62HC0owMh6j" title="Volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">63.34</ix:nonFraction></span>%</span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Term (in years)</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span title="Term (in years)"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z3iipLHbbVJh"><ix:nonNumeric contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span></span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxarVQm1Gd1j"><ix:nonNumeric contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.5</ix:nonNumeric></span></span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHWgG5iMFhy"><ix:nonNumeric contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.5</ix:nonNumeric></span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zO3ML0oAWKh9"><ix:nonNumeric contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.25</ix:nonNumeric></span></span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Dividend yield</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6t5D207Slki" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTRX8BsOqGud" title="Dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="4" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span>%</span>
            </td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A6_zUoD2ZARFQZd" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:exclude><!-- Field: Page; Sequence: 23 -->
    <div id="xdx_234_zJhMPq3cPPXd" style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_236_z7cu9FKpEGci" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_236_zj4DNNiNhvw9" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_237_z164VhvJiEQh" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <ix:exclude><p id="xdx_235_zjQeXwqCofZ4" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwxpXkWpakyh" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">A
    summary of activity under the 2009,  2012 and 2019 Plans and related information follows:</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Underlying Stock Options</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted <br />Average <br />Remaining <br />Contractual <br />Life in Years</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 39%">Balance at December 31, 2018</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs3V32eqjqE8" title="Balance, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">20,872,824</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAxABV2Rww02" title="Balance, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">4.93</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX9qeCnIo42i" title="Balance, beginning" style="width: 11%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0960">5.94 years</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EpKMBVobLh" title="Balance, beginning" style="width: 11%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,239,876</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in">Granted</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzSngjQz0iC2" title="Granted"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">4,419,501</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMYc3ltrTObg"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">3.13</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in">Exercised</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTz7PTTdeK1e" title="Exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">343,716</ix:nonFraction></span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgIE1urwOXzf"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">0.32</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zon5Zys4OMge" title="Exercised"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,426,828</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in">Expired/Forfeited</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxIxwNq315De" title="Expired Forfeited"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">98,625</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4e5hGktTPj1"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">5.63</ix:nonFraction></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt">Balance at  September 30, 2019</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgBuC4KYmSw7" title="Balance, ending" style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">24,849,984</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmsrULLhSaKi" title="Balance, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">4.67</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znAcD8jplAsi" title="Balance, ending" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0979">6.05 years</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4EflkOoQvyh" title="Balance, ending" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,761,778</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Vested and Exercisable at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrfkt827YW56" title="Vested and Exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">17,601,027</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9wcx9jAGAZe" title="Vested and Exercisable"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">4.85</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dt_c20190101__20190930_zNxPz67KfwP1" title="Vested and Exercisable" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0987">4.81 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwbiAOAHChfc" title="Vested and Exercisable"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,745,527</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Unvested at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjo6frZNvAx2" title="Unvested"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="Shares">7,248,957</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhDCRxWuRz6c" title="Unvested"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="2" unitRef="USDPShares">4.22</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_pii_dt_c20190101__20190930_zdCGHXLXTN4e" title="Unvested" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">9.06 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCtVwMvrQmEj" title="Unvested"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,016,251</ix:nonFraction></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A2_zAyFDSj1qmFh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2019,
our outstanding stock options had exercise prices ranging from  $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MinimumMember_zIKC6OCqcw6a"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2019-09-30_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.19</ix:nonFraction></span>
to $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MaximumMember_z8pkrFQCNi9f"><ix:nonFraction name="txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" contextRef="AsOf2019-09-30_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">8.92</ix:nonFraction></span>
per share. The weighted average grant date fair value per share of options granted was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930_zaLpT0qHUF6e"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.84</ix:nonFraction></span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930_zj44DzaWsxx7"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.27</ix:nonFraction></span>
during the nine months ended September 30, 2019 and 2018, respectively. Share-based compensation expense for
options recognized in our results of operations for the three months ended September 30, 2019 and 2018 ($<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930_zAZWRMss6SD5"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,194,667</ix:nonFraction></span>
and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20180701__20180930_zmYXcgmeQJM"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,109,218</ix:nonFraction></span>,
respectively)  and for the nine months ended September 30, 2019 and 2018 ($<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930_zI3suye304c5"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,568,736</ix:nonFraction></span>
and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20180930_znBu4p2Pse9c"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,981,343</ix:nonFraction></span>,
respectively) is based on vested awards. At September 30, 2019, total unrecognized estimated compensation expense related to
unvested options granted prior to that date was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20190930_z0gpzIhwTbe8"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,468,000</ix:nonFraction></span> which may be adjusted for future changes in
forfeitures. This cost is expected to be recognized over a weighted-average period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv80CJ3wG3ff"><span style="-sec-ix-hidden: xdx2ixbrl1007">2.4 years</span></span>. No tax benefit was realized
due to a continued pattern of operating losses.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock awards granted under our 2009,
2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock.
Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably
over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 13, 2018, we granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK9m5YUnOWm5"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,040,000</ix:nonFraction></span>
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5FyY4NUCrGh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.06</ix:nonFraction></span>
per unit. On July 30, 2019, we granted <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpBzKDfdNFIh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span>
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value was
$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zunBbgO17NGj"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.18</ix:nonFraction></span>
per unit. During the three and nine months ended September 30, 2019, we recorded $<span id="xdx_90D_eus-gaap--RestrictedStockExpense_c20190701__20190930_z6zPla3PyFB1"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">384,061</ix:nonFraction></span>
and $<span id="xdx_903_eus-gaap--RestrictedStockExpense_c20190101__20190930_z3VLgpLjCcb5"><ix:nonFraction name="us-gaap:RestrictedStockExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,080,738</ix:nonFraction></span>, respectively, in
share-based compensation expense related to restricted stock units. At September 30, 2019, total unrecognized estimated
compensation expense related to unvested restricted stock units was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20190930_zcL9lwCGZUZi"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,505,000</ix:nonFraction></span>,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR7fVr6H4ceb"><span style="-sec-ix-hidden: xdx2ixbrl1015">2.2
years</span></span>. At September 30, 2019, we had <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930_zPGdpZY9VZXl"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,240,000</ix:nonFraction></span>
restricted stock awards outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cash-Settled Stock Appreciation Rights (SARs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2018, we issued cash-settled SARs
to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30,
2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled
SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant
price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over
the grant price is paid in cash and not in Common Stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

    <ix:exclude><p id="xdx_236_z5IUxlxoqkFi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 24 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_239_z5vVPUgEaJ24" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_239_zhgXRGbA0yna" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_233_zb6CUeMoHyA8" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_232_zaG60yvr8zij" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Cash settled SARs were recorded in our consolidated
balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes
valuation model. In accordance with ASC Topic 718, &#8220;Stock Compensation,&#8221; the fair value of each SAR award was recalculated
at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested.
At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded
liability was reversed and no cash payment was made.</p>
    </ix:nonNumeric><p id="xdx_811_zw2CN5GIc0bd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zLZMvvRx8HFf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 12 &#x2013; INCOME TAXES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the nine months ended September
30, 2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior
years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is &#34;more likely
than not&#34; that some component or all of the benefits of deferred tax assets will not be realized. As of September 30, 2019,
we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income
taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    </ix:nonNumeric><p id="xdx_817_z8Wk4p6IGb7l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z9lBeo3fc59e" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 13 &#x2013; RELATED PARTIES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the three months ended September 30, 2019 and 2018,  we were billed by Catalent approximately $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z5ZbCHddDQCj"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-07-012019-09-30_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,196,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180701__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zBOQJnvfxA5f" title="Amount billed"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2018-07-012018-09-30_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">830,000</ix:nonFraction></span>, respectively,
for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.
During the nine months ended September 30, 2019 and 2018, we were billed by Catalent approximately $<span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zbqgsDGIuhij"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2019-01-012019-09-30_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,118,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zsGGVNSFHjZ1"><ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" contextRef="From2018-01-012018-09-30_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,774,000</ix:nonFraction></span>, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of September 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $<span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z0aHDfBmz2Xi"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2019-09-30_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">425,000</ix:nonFraction></span> and $<span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zCm29zDWXhca"><ix:nonFraction name="us-gaap:AccountsPayableRelatedPartiesCurrent" contextRef="AsOf2018-12-31_srt_AffiliatedEntityMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,000</ix:nonFraction></span>, respectively.</p>
    </ix:nonNumeric><p id="xdx_81D_zdFGVgyNrYPi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:ConcentrationRiskDisclosureTextBlock"><p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zGhipIvhCcZf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 14 &#x2013; BUSINESS CONCENTRATIONS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We purchase our prescription
    products from several suppliers with approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zJOO7dqE9r2c" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">36</ix:nonFraction></span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z10Khkqoi0cj"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">28</ix:nonFraction></span>%,
    and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zSAfmDABDcB2"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">26</ix:nonFraction></span>%
    of our purchases supplied by <span id="xdx_901_ecustom--NumberOfVendors_dc_uPure_c20190101__20190930_zD8mSqSvTHzi" title="Number of vendors - suppliers"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2019-01-01to2019-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">three</ix:nonFraction></span>
    vendors each, respectively, during the nine months ended September 30, 2019. Approximately <span title="Number of vendors - suppliers"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2bG5jRNZPqj"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">100</ix:nonFraction></span></span>%
    of our products were manufactured by  <span id="xdx_90B_ecustom--NumberOfVendors_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zU5zOInSbSh9" title="Number of vendors - suppliers"><ix:nonFraction name="txmd:NumberOfVendors" contextRef="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">one</ix:nonFraction></span>
    vendor related to each of IMVEXXY
and prenatal vitamins during the nine months ended September 30, 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our prescription prenatal
    vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
    generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
    September 30, 2019, <span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcbxkREYLq0h"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span>
    customers each generated more than <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeIcHfUSk864" title="Concentration risk"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
    of our total prescription revenues. During the nine months ended September 30, 2018,  <span id="xdx_904_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zp4ZEpTALvCh" title="Number of customers - revenue"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span>
    customers each generated more than <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUKn9O2RkR63"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">10</ix:nonFraction></span>%
    of our total prescription revenues. Prescription revenue generated from the <span id="xdx_90D_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX18O6ouVBDj"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span>
    customers combined accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember_zGN3tQi0UoVd"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_ThreeCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">68</ix:nonFraction></span>%
    of our prescription revenue for the nine months ended September 30, 2019, and prescription revenue generated from the  <span id="xdx_907_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znBjqGIh6T91"><ix:nonFraction name="txmd:NumberOfCustomers" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">four</ix:nonFraction></span>
    customers combined accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zbTlgbKrTkW5"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">71</ix:nonFraction></span>%
    of our prescription revenue for the nine months ended September 30, 2018.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30,
2019, PI Services accounted for approximately $<span id="xdx_901_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zv0WckalJ6g5"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,935,000</ix:nonFraction></span> of our prescription revenue, Pillpack, Inc. accounted for approximately
$<span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zqu4stv5lTEl"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,397,000</ix:nonFraction></span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zFoOtj3urO81"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,226,000</ix:nonFraction></span> of our prescription revenue and
Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zNpuvcB7IJY5"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,863,000</ix:nonFraction></span> of our prescription revenue. During the nine months ended September 30,
2018, PI Services accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zsCm87i31OMl"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,559,000</ix:nonFraction></span> of our prescription revenue, Pillpack, Inc. accounted for approximately
$<span id="xdx_908_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zZkrb1oUo9Kl"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,057,000</ix:nonFraction></span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_904_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zKa65h6uYBD2"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,834,000</ix:nonFraction></span> of our prescription revenue and
Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zq0VyYCaUdhg"><ix:nonFraction name="us-gaap:Revenues" contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,399,000</ix:nonFraction></span> of our prescription revenue.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    </ix:nonNumeric><p id="xdx_813_zX19AXDR3Mch" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 25 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_23E_zuHXPW66SJxl" style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_231_z3DDWmjoTR85" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
    <p id="xdx_238_zBDW6KPv4W0g" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zt7pYfi40Gx9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 15 &#x2013; COMMITMENTS AND CONTINGENCIES</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC 842 effective January 1, 2019.
Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used
to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have
commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease
liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at
cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease
incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present
value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease
because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based
on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect
at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion
of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease
liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial
lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We lease administrative office space
    in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided
    for a <span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dt_c20130629__20130701_zXWLNbBEhyCd"><ix:nonNumeric contextRef="From2013-06-292013-07-01" format="ixt-sec:durwordsen" name="txmd:CapitalLeaseObligationsTerm">63 month</ix:nonNumeric></span> term. On
    February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the
    same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the
    same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
    1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an
    agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum
    to such lease. This addendum is effective beginning November 1, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_908_ecustom--NetRentableAreaLease_iI_uSQFT_c20181001_z2xtmJDClHXf"><ix:nonFraction name="txmd:NetRentableAreaLease" contextRef="AsOf2018-10-01" format="ixt:numdotdecimal" decimals="INF" unitRef="SQFT">56,212</ix:nonFraction></span> rentable square feet, or the full premises, of which lease on <span id="xdx_908_ecustom--RentedAreaLease_iI_uSQFT_c20181001_zAu0BnRUfJL5"><ix:nonFraction name="txmd:RentedAreaLease" contextRef="AsOf2018-10-01" format="ixt:numdotdecimal" decimals="INF" unitRef="SQFT">7,561</ix:nonFraction></span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_909_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSQFT_c20181001_zEIYwbIZzzqa"><ix:nonFraction name="txmd:AdditionalAreaOfLeaseOccupied" contextRef="AsOf2018-10-01" format="ixt:numdotdecimal" decimals="INF" unitRef="SQFT">48,651</ix:nonFraction></span> square feet commenced in August 2019, or the full
premises commencement date. The lease will expire <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20190930_zxwXhiRgdfkg"><ix:nonNumeric contextRef="AsOf2019-09-30" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseTermOfContract">11</ix:nonNumeric></span> years after full premises commencement date, unless terminated earlier in
accordance with the terms of the lease. We have the option to extend the term of the lease for <span id="xdx_906_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20190930_zxAN8GnjQKV6"><ix:nonFraction name="txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber" contextRef="From2019-01-01to2019-09-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Pure">two</ix:nonFraction></span> additional consecutive periods
of <span id="xdx_90C_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20190930_zAB5OHfC6tc1"><ix:nonNumeric contextRef="AsOf2019-09-30" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1">5</ix:nonNumeric></span> years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be
exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating
costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors
to lease additional <span id="xdx_906_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSQFT_c20190930_zkteCQtw3eLe"><ix:nonFraction name="txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" unitRef="SQFT">6,536</ix:nonFraction></span> square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.</p>
    <ix:exclude><p id="xdx_23B_zd0NjWzQOQug" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><!-- Field: Page; Sequence: 26 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td id="xdx_232_zWclry5M9vsi" style="width: 33%">&#160;</td><td id="xdx_00A" style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>
    <ix:exclude><p id="xdx_239_z4YI4u0ze7e9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p></ix:exclude>
    <ix:exclude><p id="xdx_23D_zrjLenouQCNc" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p></ix:exclude>
    <ix:exclude><p id="xdx_23C_z7pIDWwG9pr8" style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_zYiFlHN7nJS1" summary="xdx: Disclosure - Supplemental lease information (Details)" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information  <br />
at September 30,
            2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Right-of-use asset</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20190930_ze72r3SrGogd" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,459,635</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Short-term operating lease liability (included in Other current liabilities)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20190930_z7rpaP1P99r" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,242,290</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">Long-term operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20190930_zOVkoE6yvSrg" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,500,133</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td>Weighted average remaining term</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20190930_zKJ121cxsyt3"><ix:nonNumeric contextRef="AsOf2019-09-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">9</ix:nonNumeric></span> Years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Weighted average discount rate</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20190930_znuDhfIpmbua" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.25</ix:nonFraction></td>
            <td style="text-align: left">%</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental cash flow information <br />for  nine months
            ended September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_982_eus-gaap--OperatingLeasePayments_c20190101__20190930_zLWiTbrLwsS9" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">849,440</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20190930_zeOWIvNo2GZ2" style="text-align: right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">11,171,471</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table></ix:nonNumeric>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqAsztLw02Nd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease
    liabilities recorded on the balance sheet:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left"></td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_493_20190930_zRCcJ7ZiCOd6" style="text-align: right"></td>
            <td style="text-align: left">&#160;</td>
        </tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: left"><b>Years Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzviC_zvmluQVXekw4" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 2%; text-align: left">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">314,670</ix:nonFraction></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzviC_z5W1ORnPZWP4" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2020</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,566,617</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzviC_zqlbVbfakOD5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2021</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,198,541</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzviC_zi09GQCrlCVc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2022</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,262,302</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzviC_zVZQYJZM1UYe" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2023</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,293,859</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzviC_zqenOG7RntNe" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">9,363,136</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzviC_maOLLzDJI_zXyLb0F2X4eg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span>
            </td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,999,125</ix:nonFraction></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityImputedInterestAmount_iNI_di_msOLLzFSB_msOLLzDJI_zaePQXH7GRA2" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<ix:nonFraction name="txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,256,702</ix:nonFraction></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzDJI_zLzePcvvgFx9" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span>
            </td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,742,423</ix:nonFraction></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    </ix:nonNumeric><p id="xdx_8A9_z6oWlmWoyIbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"> During the three and nine  months
    ended September 30, 2019, operating lease expense related to our real estate leases was approximately $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zn3CMh36la1a" title="Operating lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-07-012019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">458,000</ix:nonFraction></span>
    and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20190101__20190930_zSeePHiSmW3e"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2019-01-01to2019-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,062,000</ix:nonFraction></span>, respectively, and
    variable lease expense was insignificant for the three and nine months ended September 30, 2019. Rent expense totaled $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20180701__20180930_zzuHt0mauBd4"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2018-07-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">257,000</ix:nonFraction></span>
    and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20180101__20180930_z4rn8gJT0G6f"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2018-01-012018-09-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">772,000</ix:nonFraction></span> during the three and
    nine months ended September 30, 2018, respectively.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Intellectual Property Licenses </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have license agreements with third parties
that provide for minimum royalty, license, and exclusivity payments to be paid by us for access to certain technologies. In addition,
we pay royalties as a percent of revenue as described in Note 7, Intangible Assets, to these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Purchase commitments</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a manufacturing and supply agreement
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent <span id="xdx_900_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20190930_z9J48PRHhMyl"><ix:nonFraction name="txmd:SignificantSupplyCommitmentPercentagePayable" contextRef="AsOf2019-09-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and the
sum of all purchases of our products from Catalent during the contract year.&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    </ix:nonNumeric><p id="xdx_81A_zMUDpX3RNCe5" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<ix:nonNumeric contextRef="From2019-01-01to2019-09-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zjWsXK4Vjrsc" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters,
relating to an underwritten public offering of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zuTda8ha01Nc"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">26,000,000</ix:nonFraction></span> shares of our Common Stock at a public offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zdMpApxnu2Ti"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.75</ix:nonFraction></span> per share.
We granted the underwriters an option, exercisable for a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zv1tZUXL8Mb2"><ix:nonNumeric contextRef="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt-sec:durday" name="txmd:PeriodExercisableUnderwritersOption">30</ix:nonNumeric></span> days, to purchase up to <span id="xdx_900_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zjLEa2Iqock2"><ix:nonFraction name="txmd:UnderwritersOptionGrantedInPeriodShares" contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,900,000</ix:nonFraction></span> additional shares of Common
Stock, which was exercised in full. The net proceeds from the offering were approximately $<span id="xdx_90F_ecustom--ProceedsFromIssuancePublicOffering_dm_c20191023__20191029__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zgWWyCK7Sm62"><ix:nonFraction name="txmd:ProceedsFromIssuancePublicOffering" contextRef="From2019-10-232019-10-29_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember" format="ixt:numdotdecimal" decimals="0" scale="6" unitRef="USD">77.0</ix:nonFraction> million</span>, after deducting the underwriting
discount and offering expenses payable by us. The offering closed on October 29, 2019.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</ix:nonNumeric><p id="xdx_812_zFfplNLR8Cnf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <!-- Field: Page; Sequence: 27 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 33%">&#160;</td><td style="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td><td style="width: 33%; text-align: right">&#160;</td></tr></table></div>
    <div style="page-break-before: always; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="width: 100%"><tr><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa006"></span>Item 2. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><span style="text-decoration: underline">General</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our unaudited consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission, or the SEC, on February 27, 2019, or our Annual Report, including the audited financial statements and notes included therein. The reported results will not necessarily reflect future results of operations or financial condition.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In addition, this Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. These statements are often characterized by terminology such as &#8220;believes,&#8221; &#8220;hopes,&#8221; &#8220;may,&#8221; &#8220;anticipates,&#8221; &#8220;should,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;will,&#8221; &#8220;expects,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;positioned,&#8221; &#8220;strategy&#8221; and similar expressions and are based on assumptions and assessments made in light of management&#x2019;s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are made as of the date of this Quarterly Report on Form 10-Q and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled &#8220;Risk Factors&#8221; in our Annual Report, and include the following: our ability to maintain or increase sales of our approved products; our ability to develop and commercialize IMVEXXY, BIJUVA, ANNOVERA and our hormone therapy drug candidates and obtain additional financing necessary therefor; our commercialization, marketing and manufacturing capabilities and strategy for our approved products; the size of markets and the potential market opportunity for which our products are approved and our ability to penetrate such markets; the rate and degree of market acceptance of our products; the willingness of healthcare providers to prescribe and patients to use our products; our ability to obtain additional financing when needed; our competitive position and the success of competing products that are or become available for the indications that we are pursuing; our intellectual property position; whether we will be able to comply with the covenants and conditions under our term loan facility, including the conditions to draw additional tranches thereunder; the length, cost and uncertain results of our clinical trials, the potential of adverse side effects or other safety risks that could adversely affect the commercialization of our current or future approved products; our reliance on third parties to conduct our clinical trials, research and development and manufacturing; the ability of our licensees to commercialize and distribute IMVEXXY and BIJUVA; the availability of reimbursement from government authorities and health insurance companies for our products; the impact of product liability lawsuits; and the influence of extensive and costly government regulation.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Throughout this Quarterly Report on Form 10-Q, the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;TherapeuticsMD,&#8221; or &#8220;our company&#8221; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">This Quarterly
Report on Form 10-Q includes our trademarks, trade names and service marks, such as vitaMedMD<sup>&#174;</sup>,
BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>, BIJUVA<sup>&#174;&#160;</sup>and ANNOVERA<sup>&#8482;</sup> which are
protected under applicable intellectual property laws and are the property of, or licensed to, our company. This Quarterly
Report on Form 10-Q also contains trademarks, trade names and service marks of other companies, which are the property of
their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this quarterly
report may appear without the &#174;, &#8482; or SM symbols, but such references are not intended to indicate, in any way,
that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to
these trademarks, trade names and service marks. We do not intend our use or display of other parties&#x2019; trademarks,
trade names or service marks to imply, and such use or display should not be construed to imply, a relationship with, or
endorsement or sponsorship of us by, these other parties.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div>
    <div style="page-break-before: always; margin-top: 6pt">&#160;</div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><span style="text-decoration: underline">Overview</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We are a women&#x2019;s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#x2019;s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD<sup>&#174;</sup> and BocaGreenMD<sup>&#174;</sup> brands.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">With our
SYMBODA&#8482; technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable
delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our commercialization plan
allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved
products. During 2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from
predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we
launched our FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia
(vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April
2019, we launched our FDA-approved product BIJUVA, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus, which was approved by the FDA on October 28, 2018. In October 2019, we began a
&#8220;test and learn&#8221; market introduction phase of launch for our licensed FDA-approved product ANNOVERA (segesterone
acetate and ethinyl estradiol vaginal system), the first and only long-lasting, patient-controlled, procedure-free,
reversible prescription contraceptive option for women, which was approved by the
FDA on August 10, 2018. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On July 30, 2018, we
entered into an exclusive license agreement, or the Population Council License Agreement, with the Population Council, Inc.,
or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we entered into a license and
supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive license and supply
agreement, or the License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and IMVEXXY outside of
the U.S., excluding Canada and Israel, or the Territory.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our common stock, par value $0.001 per share, or the Common Stock, is traded on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC, or the Nasdaq, under the symbol &#8220;TXMD.&#8221; We maintain websites at <span style="text-decoration: underline">www.therapeuticsmd.com </span>as well as various product websites. The information contained on our websites or that can be accessed through our websites does not constitute part of this Quarterly Report on Form 10-Q.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>IMVEXXY</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On May 30, 2018, we announced that the FDA had approved the 4-&#956;g and 10-&#956;g doses of IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. The 4-&#956;g formulation of IMVEXXY represents the lowest FDA-approved dose of vaginal estradiol available.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On July 9, 2018, we launched IMVEXXY 10-&#956;g with our early experience program to a targeted sample of healthcare providers, or HCPs, throughout the U.S. The national launch of the 10-&#956;g dose of IMVEXXY began in August 2018, and the 4-&#956;g dose of IMVEXXY launched on September 13, 2018. Since FDA approval of our NDA for IMVEXXY, we have been focused on executing our launch plan. The key objectives of our launch plan include: (i) providing broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of IMVEXXY amongst HCPs, (iii) designing and deploying our customer facing model, and (iv) developing our internal capabilities (for example, in the areas of finance, human resources, medical affairs, information technology, data analytics, pharmacovigilance capacity and compliance) to support our commercial-stage company. We have made progress in each of these key strategic areas:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Commercial Access:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Both the 4-&#956;g and 10-&#956;g doses of IMVEXXY are broadly available in major pharmacy chains in the U.S., as well as with our BIO-IGNITE&#8482; partners, via our third-party logistics and our distribution partners.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">We
have obtained the majority of commercial payer coverage and continue to seek unrestricted coverage from the remaining
commercial insurance plans that we have not yet contracted with to provide affordable access for patients.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Through
September 30, 2019, we achieved unrestricted coverage with eight of the top ten commercial payers of VVA products by commercial payer lives and we
continue to sign new agreements with payers to cover IMVEXXY.&#160; In addition, as of September 30, 2019, two of the top six Medicare Part D payers of VVA products were adjudicating IMVEXXY, with additional decisions for
other Medicare Part D payers expected during the fourth quarter of 2019.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Beginning
at launch, we instituted a patient education and affordability program that allows all eligible patients who enroll to
receive IMVEXXY at a reasonable cost. When a product is not covered, the patient is responsible to pay the full price for the
medication, which can significantly limit a patient&#x2019;s ability to pay and subsequent utilization of the product. Prior
to October 1, 2019, enrolled patients did not pay more than $35 for a prescription of IMVEXXY. Starting October 1, 2019,
enrolled patients pay as little as $35 for a prescription of IMVEXXY with commercial insurance coverage and pay as little as
$50 for a prescription of IMVEXXY without commercial insurance coverage.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">We have designed initiatives to drive starter pack volume and target competitors using clinical data, which are expected to begin in the first quarter of 2020. We have also begun a distribution optimization process that we expect will result in improvement over current distribution costs by the third quarter of 2020, including improved  fees and new retail partnerships.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Brand Awareness and Adoption:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">In addition to our focus on direct selling from our sales organization, we have executed a branded multichannel awareness campaign for HCPs leveraging digital, non-personal promotion and journal advertising and have already reached most of the active writing HCPs within the VVA category with IMVEXXY branded messages. The focus of our interactions with HCPs included: (i) introducing IMVEXXY and highlighting the unmet medical need that IMVEXXY can fulfill for many women, (ii) increasing awareness of the clinical data and patient features of IMVEXXY, and (iii) familiarizing HCPs with our patient support services for IMVEXXY. As of September 30, 2019, approximately 15,600 HCPs had sent an IMVEXXY prescription to a pharmacy for at least one patient.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Patient Awareness, Affordability and Adherence Programs:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">We believe the patient affordability and adherence programs that we created and piloted around our prescription prenatal vitamin business have the potential to improve patient compliance for IMVEXXY, compared to other products in the VVA category. We launched our patient affordability and adherence program for IMVEXXY to help patients manage out-of-pocket costs and improve education regarding VVA and IMVEXXY with the goal of increasing patient adherence and compliance for an improved treatment experience.&#160; As of September 30, 2019, approximately 92% of our total IMVEXXY fills have utilized the patient savings programs. We launched print, social, point of care and digital direct-to-consumer marketing for IMVEXXY in the third quarter of 2019. As of September 30, 2019, we had approximately 95,300 patients who have received at least one paid IMVEXXY prescription filled at a pharmacy.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Customer Model:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">As
of September 30, 2019, we had a sales force that covers approximately 200 territories throughout the U.S. Within these
territories there are approximately 40,000 HCPs that represent the majority of the volume of FDA-approved prescriptions for
these product categories. The sales representatives target a subset of these specific HCPs based on product and messaging
objectives for a particular quarter. Our sales force is deploying a hybrid sales model that combines an internal sales
leadership team with a fully dedicated contract sales force to call on our customer universe. Additionally, we have an
internal sales team that covers areas of the U.S. where key HCPs are located but where we do not have defined territories and
we have launched our Key Account Managers (KAMs) to engage with our BIO-IGNITE partners. <span style="text-transform: uppercase">Bio-Ignite</span>
is a program focused on supporting the synergistic relationships between community pharmacies and HCPs so that offering
BIJUVA and IMVEXXY as appropriate treatment alternatives is economically practical for the pharmacy.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Infrastructure:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">We continue to expand our internal capabilities to support the continued launch of IMVEXXY. We have launched KAMs to support our BIO-IGNITE partners and continue to build our internal capabilities to support both organizations, including compliance professionals and programs and key data support systems that provide real-time data for the sales force and KAMs.<span style="color: black"> Our KAMs have national coverage and target over 1,900 community pharmacies that have a focus on compounded bio-identical hormones and the over 2,000 additional HCPs that are affiliated with these pharmacies.&#160;The KAM role is a dual role in delivering a trade message at the pharmacy level and a commercial message at the HCP level.&#160;</span></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Regulatory:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">As part of the FDA&#x2019;s approval of IMVEXXY, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a low-dose vaginal estrogen unopposed by a progestogen. The FDA has also asked the sponsors of other vaginal estrogen products to also participate in the observational study. In connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. The development of this method is underway, and we do not believe that the costs will be material. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#x2019;s specifications, which we submitted to FDA, fully completing this request. &#160;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>BIJUVA</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On October 28, 2018, the FDA approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms, or VMS (commonly known as hot flashes or flushes), due to menopause in women with a uterus. The estrogen and progesterone in BIJUVA have the same chemical and molecular structure as the hormones that are naturally produced in a woman&#x2019;s body. Following meetings with the FDA, we plan to submit a New Drug Application (NDA) efficacy supplement for the 0.5/100 mg dose of BIJUVA to the FDA in the fourth quarter of 2019 for review and potential approval using existing data from our Phase 3 REPLENISH trial for BIJUVA, for which we announced results in December 2016, together with additional information and analyses. We do not anticipate that the FDA will require any new clinical trials in connection with our submission of the NDA efficacy supplement. If accepted for review by the FDA, we expect that the NDA efficacy supplement will be reviewed, under current Prescription Drug User Fee Act timeline goals, within ten months of receipt by the FDA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We launched BIJUVA on April 17, 2019 with a similar model to IMVEXXY. The key objectives of our launch plan include: (i) broad commercial access at the retail level and with commercial payers, (ii) increasing awareness and appreciation of the clinical and patient features of BIJUVA amongst HCPs, (iii) expanding and leveraging our existing customer facing model, and (iv) leverage our internal capabilities (for example, in the areas of finance, human resources, information technology, data analytics and compliance) to support the launch of BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our initial focus has been on key OB/GYN targets, particularly those that already adopted IMVEXXY, to deliver the core clinical messages as well as provide information on our patient affordability and adherence programs. In support of BIJUVA, our field force expanded to approximately 200 territories in April 2019. In addition, we will continue to deploy our BIO-IGNITE program with a fuller expansion towards the end of 2019 into 2020 when we have achieved coverage for the majority of commercial insurance plans that is beyond the six month payer block.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We launched our patient
affordability and adherence program for BIJUVA, similar to IMVEXXY, to help patients manage out-of-pocket costs and improve patient
education with the goal of increasing patient adherence and compliance for an improved treatment experience. As of September 30,
2019, approximately 88% of our total BIJUVA fills have utilized the patient savings programs. Prior to October 1, 2019, enrolled
patients did not pay more than $35 for a prescription of BIJUVA. Starting October 1, 2019, enrolled patients pay as little as
$35 for a prescription of BIJUVA with commercial insurance coverage and pay as little as $50 for a prescription of BIJUVA without
commercial insurance coverage. As of September 30, 2019, we have approximately 9,100 patients who have received at least one paid
BIJUVA prescription filled at a pharmacy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe that
the successful launch of IMVEXXY allows us to leverage existing contracts with our third-party logistics partner and our
distribution partners. We anticipate similar timing regarding commercial payer coverage as we experienced with IMVEXXY as
many commercial payers employ &#8220;new-to-market blocks&#8221; for newly launched brands while they make their decision on
coverage. However, our ability to leverage existing payer contracts by amending to include BIJUVA, along with our recent
experience with the payers may simplify and accelerate the process. Through September 30, 2019, we achieved unrestricted
coverage with five of the top ten commercial payers of VMS products by commercial payer lives and we continue to sign
new agreements with payers to cover BIJUVA. Although Medicare is a small percentage of the VMS market, as of September 30,
2019, two of the top six Medicare Part D payers of VMS products was adjudicating BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">With the approval of BIJUVA, the FDA required a post-approval commitment to further develop and validate our in-vitro dissolution method to show how BIJUVA is released from the capsule in an in-vitro setting for quality control assessments. The development of this method and validation were completed and submitted to the FDA as required in our approval.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b>ANNOVERA</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On July 30,
2018, we entered into an exclusive license agreement with the Population Council to commercialize in the U.S. ANNOVERA
(segesterone acetate and ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible
prescription contraceptive that can prevent pregnancy for up to a full year, which was approved by the FDA on August 10,
2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">ANNOVERA was classified by the FDA as a &#8220;new chemical entity,&#8221; or NCE, and thus has five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. ANNOVERA is a one-year ring-shaped contraceptive vaginal system, or CVS. ANNOVERA, which is made with a silicone elastomer, contains segesterone acetate, a 19-nor progesterone derivative also known as Nestorone<sup>&#174;</sup>, or NES, and ethinyl estradiol, or EE. EE is an approved active ingredient in many marketed hormonal contraceptive products. Segesterone acetate, a new chemical entity, is a potent progestin. Segestrone acetate also does not bind to the androgen or estrogen receptors and has no glucocorticoid effects at contraceptive doses.&#160;&#160; NES has been evaluated in 51 clinical studies across these delivery systems with more than 26,794 cycles of exposure.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">ANNOVERA can be inserted and removed by the woman herself without the aid of a healthcare provider and, unlike oral contraceptives, or OCs, ANNOVERA does not require daily administration to obtain the contraceptive effect. After 21 days of use, the woman removes ANNOVERA for seven days, thereby providing a regular bleeding pattern (i.e., withdrawal/scheduled bleeding). The same CVS is then re-inserted for additional 21/7-days in/out, for up to a total of 13 cycles (one year). ANNOVERA releases daily vaginal doses of both active ingredients (NES and EE). The claimed release rate of 150 &#956;g/day NES and 13/day &#956;g EE is supported by the calculated average release rate from an ex vivo analysis of ANNOVERA used for 13 cycles and is also supported by data from 13 cycles of in vitro release.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We launched
ANNOVERA in the third quarter of 2019 with limited sales and a full-scale launch expected in the first quarter of 2020. In
October 2019, we began a &#8220;test and learn&#8221; market introduction phase of launch for ANNOVERA, with 36 of
our existing sales representatives currently promoting ANNOVERA in addition to our other products, and our 23 regional
sales managers and 12 compounding KAMs introducing ANNOVERA to top targeted healthcare practitioners outside of these
36 territories.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We believe that the strong initial commercial net revenue per unit of ANNOVERA and rapid commercial insurance adoption provide us with an opportunity to deploy additional financial resources to maximize ANNOVERA&#x2019;s consumer-focused commercialization strategy and leverage the ability of doctor/patient choice of contraceptive to override insurance company formularies when a generic equivalent has not been established.&#160; As part of this strategy, we are pursuing distribution opportunities for ANNOVERA with multiple direct-to-consumer contraceptive platforms that are both low cost to TXMD and offer an attractive return to the platforms.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We continue to
dialogue with the FDA regarding the potential inclusion of ANNOVERA as a new class of contraception for women in the
FDA&#x2019;s Birth Control Guide, which would require private health plans to cover ANNOVERA with no patient out-of-pocket
costs as part of the Affordable Care Act. Eight states require insurance coverage of prescription contraception with co-pay
regardless of inclusion in the FDA&#x2019;s Birth Control Guide and 11 states, plus Washington D.C., require coverage of
prescription contraception with no co-pay regardless of inclusion in the FDA&#x2019;s Birth Control Guide. We believe that a
recent reorganization of the FDA&#x2019;s Division of Bone Reproductive and Urologic Products (DBRUP) may delay a decision
regarding the inclusion of ANNOVERA as a new class of contraception for women in the FDA&#x2019;s Birth Control Guide beyond
the fourth quarter of this year, which could affect our ability to borrow an additional tranche of $50 million under our
financing agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the
Administrative Agent. Given the strong initial commercial net revenue per unit of ANNOVERA and rapid commercial insurance
adoption during our &#8220;test and learn&#8221; market introduction phase of launch, as well as the potential for the
FDA&#8217;s decision regarding the inclusion of ANNOVERA as a new class of contraception to come after the fourth quarter of
this year, we have begun discussions with the Administrative Agent about revising the draw trigger for this $50
million tranche in order to take into account the positive ANNOVERA launch trends that we are experiencing. The
Administrative Agent has informed us that it is open to considering a revision to the terms and timing of this draw trigger,
although there is no assurance that we and the Administrative Agent will agree on any such revisions.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160; </p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 33; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As part of the approval of ANNOVERA, the FDA has required a post-approval observational study be performed to measure the risk of venous thromboembolism.&#160; A draft protocol submission for the study was submitted to the FDA in August 2019. We have agreed to perform and pay the costs and expenses associated with this post-approval study, provided that if the costs and expenses associated with such post-approval study exceed $20 million, half of such excess will offset against royalties or other payments owed by us to the Population Council under the Population Council License Agreement. Given the observational nature of the study, we do not believe that the costs of the study will be material on an annual basis.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of September 30,
2019, we had 28 issued foreign patents and 26 issued domestic or, U.S., patents, which included 12 domestic utility patents that
relate to BIJUVA, three domestic patents that relate to estradiol and progesterone product candidates, five domestic patents that
relate to IMVEXXY, which establish an important intellectual property foundation for IMVEXXY, one domestic utility patent that
relates to a pipeline transdermal patch technology, one domestic utility patent that relates to our topical-cream candidates,
one domestic utility patent that relates to a product candidate containing d-limonene, one domestic utility patent that relates
to our OPERA&#174; information technology platform that we wrote off in the second quarter of 2019, and two domestic utility patents
that relate to TX-009HR, our progesterone and estradiol drug candidate.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Research and Development Expenses</i></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">A portion of our operating expenses to date have been incurred in research and development activities.&#160; Research and development expenses relate primarily to the discovery and development of our drug candidates.&#160; Our business model is dependent upon our company continuing to conduct research and development.&#160; Our research and development expenses consist primarily of expenses incurred under agreements with contract research organizations, or CROs, and consultants that conduct our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and costs associated with other research activities and regulatory approvals. Other research and development costs listed below consist of costs incurred with respect to drug candidates that have not received Investigational New Drug application approval from the FDA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The following table indicates our research and development expense by project for the periods indicated:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<div style="margin-left: auto; margin-right: auto">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />September 30,</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid">&#160;</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">2019</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">2018</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">2019</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">2018</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 40%">TX 001-HR (BIJUVA)</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 12%">454</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,017</td><td style="text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 12%">2,869</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">8,432</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">TX 004-HR(IMVEXXY)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">527</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">764</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,869</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,922</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">396</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other research and development</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,701</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">2,927</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,513</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,192</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2pt">Total</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">4,078</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">6,708</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">15,360</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">20,546</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Research and development expenditures will continue to be incurred as we develop our drug pipeline, continue stability testing and validation on our drugs, develop and validate secondary manufacturers, prepare regulatory submissions and work with regulatory authorities on existing submissions.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 34; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The costs of clinical trials may vary significantly over the life of a project owing to a variety of factors. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties. Research and development expenditures for the drug candidates will continue after the trial completes for on-going stability and laboratory testing, regulatory submission and response work. For a discussion of the nature of efforts, steps and costs necessary to complete these projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b><span style="text-decoration: underline">Results of Operations</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Three months ended September 30, 2019 compared with three months ended September 30, 2018</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Change</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 55%">Product revenue, net</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 12%">8,213</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,474</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,739</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,444</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">699</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">745</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">49,347</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">37,136</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">12,211</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 10pt">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,072</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(34,361</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,289</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(4,895</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,244</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,651</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2pt">Net loss</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(31,967</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(35,605</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(3,638</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Revenues and Cost of Goods Sold</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Product revenue
is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns. Product
revenue for the three months ended September 30, 2019 increased approximately $4,739,000, or 136%, to approximately
$8,213,000, compared with approximately $3,474,000 for the three months ended September 30, 2018.&#160; Product revenue
increased primarily due to an increase in sales of approximately $4,560,000 of IMVEXXY in the current period, partially
offset by a decrease in prenatal vitamin sales of approximately $711,000. Product revenue for the three months ended
September 30, 2019 also included sales of BIJUVA of approximately $490,000 and sales of ANNOVERA of approximately $400,000.
The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as compared to the
prior year period, partially offset by increased revenue per unit. We launched IMVEXXY in the third quarter of 2018, BIJUVA
in the second quarter of 2019 and ANNOVERA in the third quarter of 2019. Since the launches, revenues related to IMVEXXY and
BIJUVA have been greatly affected by the co-pay assistance programs that we introduced to launch these products, which allows
eligible enrolled patients to access the products at a reasonable cost regardless of insurance coverage. We expect our
product revenues to improve as commercial and Medicare payer coverage increases, and plans complete the process needed to
adjudicate IMVEXXY, BIJUVA and ANNOVERA prescriptions at pharmacies. In addition to our product revenue, during the three
months ended September 30, 2019, we recognized license revenue of approximately $15,506,000 from the upfront fee, which was a
non-refundable payment, payable to us by Theramex under the terms of the License Agreement, which we recognized at the point
in time when Theramex was able to use and benefit from the license, which was when the knowledge transfer of regulatory
documents occurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Cost of goods sold increased approximately $745,000, or 107%, to approximately $1,444,000 for the three months ended September 30, 2019, compared with approximately $699,000 for the three months ended September 30, 2018.&#160; Our gross margin related to prescription products was approximately 82% and 80% for the three-month periods ended September 30, 2019 and 2018, respectively. The change in our gross margin is primarily related to the change in product mix between the two periods.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 35; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Operating Expenses</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our principal operating costs include the following items as a percentage of total operating expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 70%; text-align: justify">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">45.7</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">44.6</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Human resources related costs, including salaries, benefits and taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.4</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.9</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Operating expenses increased by approximately $12,211,000, or 33%, to approximately $49,347,000 for the three months ended September 30, 2019, from approximately $37,136,000 for the three months ended September 30, 2018 as a result of the following items:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 97%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Three Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Change</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; width: 55%">Sales and marketing, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 12%">22,547</td><td style="text-align: left; width: 1%">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,970</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Human resources related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,507</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,911</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,596</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,708</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,630</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,650</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,450</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">Other operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,115</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">3,290</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">1,825</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2pt">Total operating expenses</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">49,347</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">37,136</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">12,211</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Sales and marketing costs for the three months ended September 30, 2019 increased by approximately $5,970,000, or 36%, to approximately $22,547,000, compared with approximately $16,577,000 for the three months ended September 30, 2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of our prescription products, including costs related to outsourced sales personnel and their related expenses, physician education, advertising and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA and ANNOVERA and continue to support our growing business and commercialization of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Human resources costs, including salaries, benefits and taxes, for the three months ended September 30, 2019 increased by approximately $4,596,000, or 52%, to approximately $13,507,000, compared with approximately $8,911,000 for the three months ended September 30, 2018, primarily as a result of an increase of approximately $4,259,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our prescription products and an increase of approximately $337,000 in non-cash compensation expense included in this category related to employee stock-based compensation during 2019 as compared to 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 36; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Research and development costs for the three months ended September 30, 2019 decreased by approximately $2,630,000, or 39%, to approximately $4,078,000, compared with approximately $6,708,000 for the three months ended September 30, 2018.&#160; Research and development costs include costs related to manufacturing validation and early development trials, as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased primarily as a result of certain employees and activities that were previously classified as research and development being transferred to operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Since the project&#x2019;s inception in February 2013, we have incurred approximately $130,056,000 in research and development costs with respect to BIJUVA.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
</td>
<td style="vertical-align: top; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">&#9679;</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Since the project&#x2019;s inception in August 2014, we have incurred approximately $47,608,000 in research and development costs with respect to IMVEXXY.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Professional fees and consulting costs for the three months ended September 30, 2019 increased by approximately $2,450,000, or 148%, to approximately $4,100,000, compared with approximately $1,650,000 for the three months ended September 30, 2018, primarily as a result of increased recruiting and consulting fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">All other operating expense for the three months ended September 30, 2019 increased by approximately $1,825,000, or 55%, to approximately $5,115,000, compared with approximately $3,290,000 for the three months ended September 30, 2018, as a result of increased information technology, travel, dues and subscriptions, allowance for bad debt expense, insurance and other office expenses primarily to support commercialization of our new drugs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Operating Loss</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As a result of the foregoing, our operating loss decreased approximately $7,289,000, or 21%, to approximately $27,072,000 for the three months ended September 30, 2019, compared with approximately $34,361,000 for the three months ended September 30, 2018, primarily as a result of increased total net revenue, partially offset by an increase in total operating expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA and ANNOVERA will be successful.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Other expense, net</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="color: black">Other non-operating expense, net increased by approximately $3,651,000, or 293%, to an expense of approximately $4,895,000 for the three months ended September 30, 2019, compared with an expense of approximately $1,244,000 for the three months ended September 30, 2018, primarily as a result of loss on extinguishment of debt and increased interest expense related to our Financing Agreement.&#160; For more information regarding our Financing Agreement, see &#8220;Liquidity and Capital Resources&#8221; below.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Net Loss</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Because of the net
effects of the foregoing, net loss decreased approximately $3,638,000, or 10%, to approximately $31,967,000 for the three months
ended September 30, 2019, compared with approximately $35,605,000 for the three months ended September 30, 2018.&#160; Net loss
per share of Common Stock, basic and diluted, was ($0.13) and ($0.16) for the three months ended September 30, 2019 and 2018,
respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>
<!-- Field: Page; Sequence: 37; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i><span style="text-decoration: underline">Nine months ended September 30, 2019 compared with nine months ended September 30, 2018</span></i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Change</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%; text-align: justify; padding-bottom: 1pt">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="width: 1%; padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Product revenue, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">18,239</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,010</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">7,229</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,506</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Cost of goods sold</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,456</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,787</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,669</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">137,102</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">101,323</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">35,779</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(106,813</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(92,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(14,713</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1pt">Other expense, net</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(19,896</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(1,126</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">(18,770</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2pt">Net loss</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(126,709</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(93,226</td><td style="padding-bottom: 2pt; text-align: left">)</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">(33,483</td><td style="padding-bottom: 2pt; text-align: left">)</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Revenues and Cost of Goods Sold</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Product
revenue is recorded net of sales discounts, chargebacks, wholesaler fees, customer rebates, coupons and estimated returns.
Product revenue for the nine months ended September 30, 2019 increased approximately $7,229,000, or 66%, to
approximately $18,239,000, compared with approximately $11,010,000 for the nine months ended September 30, 2018.&#160;
Product revenue increased primarily due to an increase in sales of approximately $9,693,000 of IMVEXXY in the current period
partially offset by a decrease in prenatal vitamin sales of approximately $3,489,000. Product revenue during the nine months
ended September 30, 2019 also included sales of BIJUVA of approximately $625,000 and sales of ANNOVERA of approximately
$400,000. The revenue decrease related to our prenatal vitamins was primarily affected by lower number of units sold as
compared to the prior year period. We launched IMVEXXY in the third quarter of 2018, BIJUVA in the second quarter of 2019 and
ANNOVERA in the third quarter of 2019. Since the launches, revenues related to IMVEXXY and BIJUVA have been greatly affected
by the co-pay assistance programs that we introduced to launch these products, which allows eligible enrolled patients to
access the products at a reasonable cost regardless of insurance coverage. We expect our product revenues to improve as
commercial and Medicare payer coverage increases, and plans complete the process needed to adjudicate IMVEXXY, BIJUVA and
ANNOVERA prescriptions at pharmacies. In addition to our product revenue, during the nine months ended September 30, 2019, we
recognized license revenue of approximately $15,506,000 from the upfront fee, which was a non-refundable payment, payable to
us by Theramex under the terms of the License Agreement, which we recognized at the point in time when Theramex was able to
use and benefit from the license, which was when the knowledge transfer of regulatory documents occurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Cost of goods sold increased approximately $1,669,000, or 93%, to approximately $3,456,000 for the nine months ended September 30, 2019, compared with approximately $1,787,000 for the nine months ended September 30, 2018, primarily due to an increased number of units sold.&#160; Our gross margin for our prescription products was approximately 81% and 84% for the nine months ended September 30, 2019 and 2018, respectively.&#160; The change in our gross margin is primarily related to the change in product mix between the two periods.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Operating Expenses</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our principal operating costs include the following items as a percentage of total operating expenses.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Sales and marketing costs, excluding human resources costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">44.2</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">43.1</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Human resources related costs, including salaries, benefits and taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27.1</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5.3</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Other operating expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10.2</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8.3</td><td style="text-align: left">%</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 38; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Operating expenses increased by approximately $35,779,000, or 35%, to approximately $137,102,000 for the nine months ended September 30, 2019, from approximately $101,323,000 for the nine months ended September 30, 2018 as a result of the following items:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.25in">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">Change</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="width: 64%; text-align: justify; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="width: 1%; padding-bottom: 1pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="width: 9%; border-bottom: Black 1pt solid; text-align: right"></td><td style="width: 1%; padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Sales and marketing, excluding human resources costs</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">60,537</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">43,695</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">16,842</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Human resources related costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">37,162</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23,296</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,866</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Product research and development costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,360</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,546</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,186</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">Professional fees and consulting costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,025</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,411</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,614</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">Other operating expenses</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">14,018</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">8,375</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">5,643</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2pt; text-indent: -0.125in; padding-left: 0.125in">Total operating expenses</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">137,102</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">101,323</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td><td style="padding-bottom: 2pt">&#160;</td>
    <td style="border-bottom: Black 2pt double; text-align: left">$</td><td style="border-bottom: Black 2pt double; text-align: right">35,779</td><td style="padding-bottom: 2pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Sales and marketing costs for the nine months ended September 30, 2019 increased by approximately $16,842,000, or 39%, to approximately $60,537,000, compared with approximately $43,695,000 for the nine months ended September 30, 2018, primarily as a result of increased expenses associated with sales and marketing efforts to support launch and commercialization of our prescription products, including costs related to outsourced sales personnel and their related expenses, physician education and product samples, advertising and travel expenses related to product commercialization. We expect sales and marketing expenses to continue to increase as we continue the launch of BIJUVA and ANNOVERA, and continue to support our growing business and commercialization of our products.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Human resources costs, including salaries, benefits and taxes, for the nine months ended September 30, 2019 increased by approximately $13,866,000, or 60%, to approximately $37,162,000, compared with approximately $23,296,000 for the nine months ended September 30, 2018, as a result of an increase of approximately $12,278,000 in personnel costs in sales, marketing and regulatory areas to support commercialization of our prescription products and an increase of approximately $1,588,000 in non-cash compensation expense included in this category related to employee stock-based compensation during 2019 as compared to 2018.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Research and development costs for the nine months ended September 30, 2019 decreased by approximately $5,186,000, or 25%, to approximately $15,360,000, compared with approximately $20,546,000 for the nine months ended September 30, 2018. Research and development costs included costs related to on-going stability and laboratory testing, early development trials, as well as salaries, wages, non-cash compensation and benefits of personnel involved in research and development activities. Research and development costs decreased for the nine months ended September 30, 2019 as compared to the prior period primarily as a result of lower costs related to scale-up and manufacturing activities as well as decreased pre-clinical work to support our product pipeline. Research and development costs also decreased as a result of certain employees and activities that were previously classified as research and development being transferred to operations as they began to support commercial and launch efforts after the FDA approvals of IMVEXXY and BIJUVA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">For a discussion of the nature of efforts, steps and costs related to our research and development projects, see &#8220;Item 1. Business &#8212; Research and Development&#8221; and &#8220;Item 7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations &#8212; Research and Development Expenses&#8221; contained in our Annual Report.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 39; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Professional fees and consulting costs for the nine months ended September 30, 2019 increased by approximately $4,614,000, or 85%, to approximately $10,025,000, compared with approximately $5,411,000 for the nine months ended September 30, 2018, primarily as a result of increased recruiting and consulting fees, partially offset by lower legal fees.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">All other operating expense for the nine months ended September 30, 2019 increased by approximately $5,643,000, or 67%, to approximately $14,018,000, compared with approximately $8,375,000 for the nine months ended September 30, 2018, as a result of increased information technology, travel, allowance for bad debt expense, insurance and other office expenses primarily to support commercialization of our new drugs.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Operating Loss</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="color: black">As a result of the foregoing, our operating loss increased approximately $14,713,000, or 16%, to approximately $106,813,000 for the nine months ended September 30, 2019, compared with approximately $92,100,000 for the nine months ended September 30, 2018, primarily as a result of increased personnel costs, sales and marketing expenses to support commercialization of our prescription products, including costs related to outsourced sales personnel and their related expenses, professional fees and other operating expenses, partially offset by a decrease in research and development costs and an increase in total net revenue.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We anticipate that we will continue to have operating losses for the near future until we successfully commercialize IMVEXXY, BIJUVA, and ANNOVERA, although there is no assurance that any commercialization of IMVEXXY, BIJUVA, and ANNOVERA will be successful.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Other Expense, net</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Other
non-operating expense increased by approximately $18,770,000 to an expense of approximately $19,896,000 for the nine months
ended September 30, 2019 compared with an expense of approximately $1,126,000 for the nine months ended September 30, 2018,
primarily as a result of loss on extinguishment of debt and increased interest expense related to our <span style="color: black">Financing
Agreement.&#160; For more information regarding our Financing Agreement, see &#8220;Liquidity and Capital Resources&#8221;
below.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Net Loss</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Because of the net effects of the foregoing, net loss increased approximately $33,483,000, or 36%, to approximately $126,709,000 for the nine months ended September 30, 2019, compared with approximately $93,226,000 for the nine months ended September 30, 2018. Net loss per share of Common Stock, basic and diluted, was ($0.53) and ($0.42) for the nine months ended September 30, 2019 and 2018, respectively.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><span style="text-decoration: underline">Liquidity and Capital Resources</span></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We have funded our operations primarily through public offerings of our Common Stock and private placements of equity and debt securities. For the three years ended December 31, 2018, we received approximately $293,344,000 in net proceeds from the issuance of shares of our Common Stock. As of September 30, 2019, we had cash and cash equivalents totaling approximately $155,330,000, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 40; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our net days
sales outstanding, or net DSO, is calculated by dividing gross accounts receivable less the reserve for doubtful accounts,
chargebacks and payment discounts by the average daily net product revenues during the quarter. We also disclose gross DSO,
which includes the calculation of gross accounts receivable divided by the average daily gross product revenues to
distributors during the quarter. For the three months ended September 30, 2019, our gross DSO was 46 days compared to 77 days
for the three months ended December 31, 2018 and our net DSO was 172 days for the three months ended September 30, 2019
compared to 200 days for the three months ended December 31, 2018. Our DSO decreased primarily due to more
favorable arrangements with customers that we entered into in the second quarter of 2019. We anticipate that our DSO will
fluctuate in the future based upon a variety of factors, including longer payment terms associated with the launch of
IMVEXXY, BIJUVA and ANNOVERA and changes in the healthcare industry.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On October 29, 2019, we closed our underwritten public offering of 29,900,000 shares of our common stock at a price to the public of&#160;$2.75&#160;per share, inclusive of the underwriters&#x2019; option to purchase additional shares of common stock, which option was exercised in full.&#160;We&#160;received net proceeds from the offering of approximately&#160;$77.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by&#160;us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">On April 24, 2019, we entered into the Financing Agreement with the Administrative Agent, various lenders from time to time party thereto, and certain of the Company&#x2019;s subsidiaries party thereto from time to time as guarantors, which provided us with a $300,000,000 first lien secured term loan credit facility, or the Facility. The Facility provides for availability to us in three tranches: (i) $200,000,000 was drawn upon entering into the Financing Agreement; (ii) $50,000,000 will be available to us upon the designation of ANNOVERA as a new category of birth control by the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $50,000,000 will be available to us upon our achieving $11,000,000 in net revenues from our IMVEXXY, BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent. A portion of the initial tranche of borrowing under the Facility in the amount of approximately $81,661,000 was used to repay all amounts outstanding under our prior financing agreement with MidCap Financial Trust, or the MidCap Agreement. As a result of the termination of the MidCap Agreement, we recorded $10,057,632 in loss on extinguishment of debt in our unaudited consolidated financial statements. We believe that our existing cash and availability under the Facility will allow us to fund our operating plan through at least the next 12 months from the date of this Quarterly Report. However, if the commercialization of IMVEXXY, BIJUVA, or ANNOVERA is delayed, our existing cash and availability under the Facility, if we are able to access such funds, may be insufficient to satisfy our liquidity requirements until we are able to commercialize IMVEXXY, BIJUVA and ANNOVERA and we may not be able to access funds under the Facility. If our available cash is insufficient to satisfy our liquidity requirements, we may curtail our sales, marketing and other commercialization and pre-commercialization efforts and we may seek to sell additional equity or debt securities. Our ability to sell debt securities or obtain additional debt financing is restricted pursuant to the Financing Agreement. To the extent that we raise additional capital through the sale of equity or convertible debt securities, to the extent permitted under the Financing Agreement, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, certain of which are restricted under the Financing Agreement, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products, if permitted under the Financing Agreement. Additionally, we may have to grant licenses on terms that may not be favorable to us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 41; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">License Agreement with Theramex</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><span style="color: black">On June 6, 2019, we entered into an exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR 14 million in cash as an upfront fee on August 5, 2019. Within thirty days of signing the License Agreement, we provided Theramex the regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee, which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive additional milestone payments comprised of (i) up to an aggregate of EUR 2 million in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and (ii) up to an aggregate of EUR 27.5 million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR 25 million to EUR 100 million. We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">We need substantial amounts of cash to complete the launch and commercialization of our hormone therapy and contraceptive drugs.&#160; The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Summary of (Uses) and Sources of Cash</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid">Nine Months Ended <br />September 30,</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2019</td><td style="padding-bottom: 1pt">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid">2018</td><td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify; padding-bottom: 1pt; text-indent: -0.125in; padding-left: 0.125in">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td colspan="5" style="border-bottom: Black 1pt solid; text-align: center">(000s)</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in; width: 76%">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">$</td><td style="text-align: right; width: 9%">(114,900</td><td style="text-align: left; width: 1%">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(78,667</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(3,178</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(20,827</td><td style="text-align: left">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.125in; padding-left: 0.125in">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">111,796</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">162,357</td><td style="text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Operating Activities</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">The principal use of cash in operating activities for the nine months ended September 30, 2019 was to fund our current expenses primarily related to supporting commercialization activities for IMVEXXY, BIJUVA, and ANNOVERA, sales, marketing, scale-up and manufacturing activities and clinical development, adjusted for non-cash items. The increase of approximately $36,233,000 in cash used in operating activities for the nine months ended September 30, 2019 compared with the comparable period in the prior year was due primarily to an increase in our net loss and changes in the components of working capital, partially offset by an increase in non-cash items.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Investing Activities</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -0.5pt; text-align: justify; text-indent: 38.45pt">Investing
activities for the nine months ended September 30, 2019 decreased primarily due to a $20,000,000 payment for an
intellectual property license fee that occurred during the nine months ended September 30, 2018, partially offset by higher
spending related to patent, trademark and fixed asset costs during the nine months ended September 30, 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt -0.5pt; text-align: justify; text-indent: 38.45pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><i>Financing Activities</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5pt; text-align: justify; text-indent: 35.5pt">Financing activities represent the principal source of our cash flow. Our financing activities for the nine months ended September 30, 2019 provided net cash of approximately $111,796,000 which consisted of the net funding from our Facility of approximately $193,348,000 and exercise of options and warrants to purchase Common Stock of approximately $109,000, partially offset by the repayment of our Credit Agreement of approximately $81,661,000. Our financing activities for the nine months ended September 30, 2018 provided net cash of approximately $162,357,000, which consisted of the net funding from our Credit Agreement of approximately $71,213,000 and the exercise of options to purchase Common Stock of approximately $1,236,000 and approximately $89,908,000 in proceeds from the sale of our Common Stock.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 42; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>New Accounting Pronouncements</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In August 2018, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project, which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly communicate the most important information to users of the financial statements. The new guidance is effective for all entities for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating the effect of this guidance on our disclosures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In June 2018, the FASB issued ASU 2018-07 to simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50. The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard did not have a material effect on our consolidated financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In February 2016, the FASB issued ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses on their income statements in a manner similar to current accounting. The guidance also eliminates current real estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the accounting for sales-type and direct financing leases. The standard is effective for public business entities for annual periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the alternative transition method allowed for under ASU 2018-11 and we recorded a $3.8 million right of use asset and a $4.1 million liability related to adoption of this standard. In addition, upon commencement of additional lease space in the third quarter of 2019, we recorded an additional $7.4 million right of use asset and an additional $7.2 million liability related to our new lease space. Comparative financial information was not adjusted and will continue to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard resulted in increased disclosure requirements in our quarterly and annual filings.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC did not, and are not expected to, have a material effect on our results of operations or financial position.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 43; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->

    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;
&#160;</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa007"></span>Item 3. Quantitative and Qualitative Disclosures about Market Risk</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates.&#160; To minimize this risk, we intend to maintain an investment portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates.&#160; Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">As of April 24, 2019,
we repaid all amounts outstanding under the MidCap Agreement and became subject to market risk in connection with borrowings under
the Financing Agreement. Amounts borrowed under the Financing Agreement will accrue interest at either (i) 3-month LIBOR plus
7.75%, subject to a LIBOR floor of 2.70% or (ii) the prime rate plus 6.75%, subject to a prime rate floor of 5.20%. Considering
the total outstanding principal balance under the Financing Agreement of approximately $200,000,000 at September 30, 2019, a 1.0%
change in interest rates would result in an impact to income before income taxes of approximately $2,000,000 per year.&#160;<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa008"></span>Item 4. Controls and Procedures</b></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>

    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="text-decoration: underline">Disclosure Controls and Procedures</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported, within the time period specified in the SEC&#x2019;s rules and forms and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, in order to allow timely decisions in connection with required disclosure.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Evaluation of Disclosure Controls and Procedures</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q were effective in providing reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC&#x2019;s rules and forms and (ii) accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<!-- Field: Page; Sequence: 44; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: #000000 1pt solid">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt">&#160;</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="text-decoration: underline">Changes in Internal Controls</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">During the three months
ended September 30, 2019, there were no changes in our internal control over financial reporting that have materially affected,
or are reasonably likely to materially affect, our internal control over financial reporting.&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa009"></span>PART II - OTHER INFORMATION</b></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa010"></span>Item 1. Legal Proceedings</b></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">In August 2019, without admitting or denying the findings, we consented to an order issued by the Securities and Exchange Commission charging us with violations of Regulation FD in connection with communications during 2017 regarding TX-004HR and agreed to pay a $200,000 penalty.&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">From time to time, we are involved in litigation
and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe
would have a material effect on our business or financial condition.&#160;</p>

    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa011"></span>Item 1A. Risk Factors</b></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">There have been no material changes to the risk factors previously disclosed in our Annual Report.</p>

    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>
    <p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <!-- Field: Page; Sequence: 45; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->45<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="txmd10qa012"></span>Item 6. Exhibits</b></span>
    </p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <table border="0" cellspacing="0" cellpadding="0" style="border: Black medium none; border-collapse: collapse; width: 100%">

<tr>
<td style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; width: 10%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; border-style: none"><b>Exhibit</b></p>
</td>
    <td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; width: 25%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; border-style: none"><b>Date</b></p>
</td>
    <td style="width: 1%">&#160;</td>
<td style="border-bottom: black 1pt solid; border-top-style: none; border-right-style: none; border-left-style: none; border-image: initial; width: 63%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; padding: 0pt; border-style: none"><b>Description</b></p>
</td>
</tr>


<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex10-1.htm">10.1*+</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">September 28, 2018</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Commercial Supply Agreement by and between TherapeuticsMD, Inc. and QPharma AB.</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex10-2.htm">10.2*+</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">October 5, 2018</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Lease by and between 951 Yamato Acquisition Company, LLC and TherapeuticsMD, Inc.</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex31-1.htm">31.1*</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">November 8, 2019</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&#160;</p>
</td>
</tr>
<tr>
<td style="border-bottom-style: none; text-align: left; vertical-align: top">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: left; font: 10pt Times New Roman, Times, serif"><a href="ex31-2.htm">31.2*</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">November 8, 2019</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a)</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex32-1.htm">32.1**</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">November 8, 2019</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Section 1350 Certification of Chief Executive Officer</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><a href="ex32-2.htm">32.2**</a></p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">November 8, 2019</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Section 1350 Certification of Chief Financial Officer</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.INS*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.SCH*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Taxonomy Extension Schema Document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.CAL*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Taxonomy Extension Calculation Linkbase Document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.DEF*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Taxonomy Extension Definition Linkbase Instance Document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.LAB*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Taxonomy Extension Label Linkbase Instance Document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">101.PRE*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">XBRL Taxonomy Extension Presentation Linkbase Instance Document</p>
</td>
</tr>
<tr>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">104*</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">n/a</p>
</td>
    <td>&#160;</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">Cover Page Interactive Data File (formatted as Inline XBRL and Contained in Exhibit 101)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; float: left"><div style="font-size: 1pt; border-top: Black 1pt solid; width: 20%">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">*</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Filed herewith.</p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; width: 100%">

<tr>
<td style="vertical-align: top; width: 36pt">
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">**</p>
</td>
<td style="vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt">Furnished herewith.</p>
</td>
</tr>

<tr>
<td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">+</span></td>
<td style="vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Portions of this exhibit
have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely
cause competitive harm to the Company if publicly disclosed.</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>
    <!-- Field: Page; Sequence: 46; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->46<!-- Field: /Sequence -->
        </p>
    </div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">
        <p style="margin: 0pt"></p>
    </div>
    <!-- Field: /Page -->
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span>
    </p>
    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">
        <span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>
    </p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">DATE: November&#160; 8, 2019</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td colspan="2" style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>THERAPEUTICSMD, INC.</b></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; width: 50%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; width: 3%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; width: 47%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">By:</p>
</td>
<td style="padding: 0pt; vertical-align: top; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><i>/s/ Robert G. Finizio</i></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Robert G. Finizio</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Chief Executive Officer</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">(Principal Executive Officer)</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">By:</p>
</td>
<td style="padding: 0pt; vertical-align: top; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">/<i>s/ Daniel A. Cartwright</i></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Daniel A. Cartwright</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Chief Financial Officer</p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p>
</td>
<td style="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">(Principal Financial and Accounting Officer)</p>
</td>
</tr>

</table>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <!-- Field: Page; Sequence: 47; Value: 28 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid">
        <p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif">
            <!-- Field: Sequence; Type: Arabic; Name: PageNo-->47<!-- Field: /Sequence -->
        </p>
    </div>
    <!-- Field: /Page -->
</body>

</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex10-1.htm
<DESCRIPTION>COMMERCIAL SUPPLY AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM
TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMERCIAL
SUPPLY AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commercial
Supply Agreement (the &ldquo;<B>Agreement</B>&rdquo;) is made as of the 28th day of September, 2018, by and between
TherapeuticsMD, Inc., a Nevada corporation, with a place of business at 6800 Broken Sound Parkway NW, Third Floor, Boca
Raton, Florida 33487 (&ldquo;<B>TXMD</B>&rdquo;), and QPharma AB, a Sweden corporation, having a place of business at
Agneslundsvagen 27, Malmo, Sweden (&ldquo;<B>QPharma</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of QPharma and TXMD is sometimes referred to herein as a &ldquo;Party&rdquo; and collectively as the &ldquo;Parties&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECITALS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
is a company that develops, markets and sells pharmaceutical products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;QPharma
is a developer and contract manufacturer of a variety of pharmaceutical products and medical devices including, but not limited
to, intra-vaginal devices eluting pharmaceutical substances;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
is the exclusive licensee of the Population Council to commercialize in the United States a certain intra-vaginal ring system
eluting segesterone acetate and ethinyl estradiol;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;QPharma
is a qualified manufacturer of such intra-vaginal ring systems; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
desires to engage QPharma to manufacture and supply quantities of such intra-vaginal ring systems, and QPharma desires to manufacture
and supply such quantities of intra-vaginal ring systems, all pursuant to the terms and conditions set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW,
THEREFORE,</B> for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties
intending to be legally bound, hereby agree as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEFINITIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following terms have the following meanings in this Agreement:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Acknowledgement</B>&rdquo;
has the meaning set forth in Section 4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Affiliate(s)</B>&rdquo;
means, with respect to a referenced party, whether TXMD, QPharma or a third party, any corporation, firm, partnership or other
entity that controls, is controlled by or is under common control with such referenced party. For the purposes of this definition,
&ldquo;<B>control</B>&rdquo; means the ownership of at least 50% of the voting share capital of an entity or any other comparable
equity or ownership interest or possession of the right to control the management and policies of such entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the introductory paragraph, and includes all its Attachments and other appendices agreed to by the
parties (all of which are incorporated herein by reference) and any amendments to any of the foregoing made as provided herein
or therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>API(s)</B>&rdquo;
means the compounds segesterone acetate and ethinyl estradiol, as further described in the Specifications that either (i) have
been procured and released by TXMD and provided to QPharma or (ii) have been procured and released by QPharma, in either case
along with a certificate of analysis from the manufacturer of such compounds, as provided in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Applicable
Laws</B>&rdquo; means, with respect to TXMD, all laws, ordinances, rules and regulations of each jurisdiction in which an API
or Product is produced, marketed, distributed, used or sold; and with respect to QPharma, all laws, treaties, or ordinances, rules,
regulations, cGMP, guidances, interpretations, authorizations, judgments, directives, injunctions, or orders of any court of any
international, national, regional, local, or other governmental body, agency, authority, or court, or arbitrator, that has jurisdiction
over the location where QPharma performs services, handles or stores an API, Raw Materials or Product, and manufactures Product
under this Agreement (and applicable cGMP), including, but not limited to, the Federal Food, Drug and Cosmetic Act and Good Laboratory
Practices, in each of the foregoing cases as in effect from time-to-time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Batch</B>&rdquo;
means a defined quantity of Product that has been or is being Processed in accordance with the Specifications in a single production
run. At the date of this Agreement, the theoretical size of a commercial validated Batch is approximately [***] units of Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Components</B>&rdquo;
means the silicon ring system and other tangible elements incorporated into or packaged with the Product, but for the avoidance
of doubt, excluding APIs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>cGMP</B>&rdquo;
means current Good Manufacturing Practices promulgated by the Regulatory Authorities in the jurisdictions included in Applicable
Laws (as applicable to TXMD and QPharma, respectively). In the United States, this includes 21 C.F.R. Parts 210, 211 and 820,
as amended from time-to-time, together with pertinent guidelines and guidance documents, and in the European Union, to the extent
applicable to the manufacture, handling and storage of the Product in Sweden for shipment to, and sale in, the United States,
2003/94/EEC Directive (as supplemented by Volume 4 of EudraLex published by the European Commission), as amended, Council Directive
90/385/EEC on Active Implantable Medical Devices (AIMDD)(1990) and Council Directive 93/42/EEC on Medical Devices (MDD) (1993),
as amended, supplemented and superseded from time-to-time, together with pertinent guidelines and guidance documents then in effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Commencement
Date</B>&rdquo; means the first day of the Initial Pricing Term as established pursuant to Section 7.1, provided such date follows
approval by a Regulatory Authority of QPharma as a manufacturer of the Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Confidential
Information</B>&rdquo; has the meaning set forth in Section 10.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.11&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Contract
Year</B>&rdquo; means each consecutive twelve (12) month period beginning on the Commencement Date or anniversary thereof, as
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.12&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Defective
Product</B>&rdquo; has the meaning set forth in Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.13&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Discloser</B>&rdquo;
has the meaning set forth in Section 10.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.14&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Effective
Date</B>&rdquo; means July 26, 2018, [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.15&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Exception
Notice</B>&rdquo; has the meaning set forth in Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.16&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Facility</B>&rdquo;
means QPharma&rsquo;s facility located in Malmo, Sweden, or such other facility as agreed by the parties in writing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.17&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Initial
Pricing Term</B>&rdquo; has the meaning set forth in Section 7.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.18&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Initial
Term</B>&rdquo; means the period of time commencing as of July 26, 2018, and ending on July 26, 2024.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.19&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Index</B>&rdquo;
has the meaning set forth in Section 7.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Losses</B>&rdquo;
has the meaning set forth in Section 13.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.21&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Marks</B>&rdquo;
means trademarks, trade names, service marks, logos and symbols.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Process</B>&rdquo;
or &ldquo;<B>Processing</B>&rdquo; means the compounding, filling, manufacturing, producing, testing and packaging of APIs, TXMD-supplied
Materials, if any, and Raw Materials into Product by QPharma, and their handling, storage and delivery in accordance with the
Specifications and under the terms of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.23&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Processing
Date</B>&rdquo; means the day on which the first step of physical Processing is scheduled to occur, as identified in an Acknowledgement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.24&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Process
Know-How</B>&rdquo; means all know-how provided by or on behalf of TXMD to QPharma and know-how to the extent it relates to the
processing, manufacture, quality control, formulation, filling, finishing, testing and packaging of a Product, whether in bulk
or final form, and regardless of container, including, without limitation, analytical tests methods for in-process and final Product,
copies of manufacturing records, formulation recipes, designs and drawings, and formulae, used in the Processing for a Product
to the extent it is in the possession, or under the control, of QPharma, its Affiliates and their respective subcontractors. For
the avoidance of doubt, such Process Know-How includes the Know-How TXMD obtained from The Population Council by operation of
TXMD&rsquo;s acquisition of the Product&rsquo;s New Drug Application under the License Agreement with The Population Council dated
August 1, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.25&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Process
Know-How Transfer</B>&rdquo; means the commercially reasonable efforts of the parties undertaken pursuant to the Process Know-How
Transfer Plan to transfer copies of all Process Know-How (together with relevant books and records) and the &ldquo;Standards&rdquo;
(defined below) in QPharma&rsquo;s possession or under its control, to TXMD as set forth in greater detail in the Process Know-How
Transfer Plan. As used herein &ldquo;Standards&rdquo; means data, information, or samples of validated or QPharma manufactured
or partially manufactured Product or other indicia measured at various points during Processing, to the extent QPharma possesses
such data, information, or samples.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.26&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Process
Know-How Transfer Plan</B>&rdquo; means that plan addressing orderly Process Know-How Transfer, to be prepared in writing and
reasonably agreed to by the parties within the sixty (60) day period following notice from TXMD to QPharma of its intention to
commence Process Know-How Transfer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.27&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Product</B>&rdquo;
means a silicon-based removable intra-vaginal ring system eluting segesterone acetate and ethinyl estradiol meeting the Specifications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.28&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Product
Maintenance Services</B>&rdquo; has the meaning set forth in Section 2.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.29&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Purchase
Order</B>&rdquo; has the meaning set forth in Section 4.3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.30&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>QPharma</B>&rdquo;
has the meaning set forth in the introductory paragraph, or any successor or permitted assign. QPharma shall have the right to
cause any of its Affiliates, upon prior written notice to and approval from TXMD, to perform any of its obligations hereunder,
and TXMD upon its prior approval of the use of such an Affiliate, shall accept such performance as if it were performance by QPharma,
but QPharma shall remain jointly and severally liable for the performance by any of its Affiliates under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.31&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>QPharma
Defective Processing</B>&rdquo; has the meaning set forth in Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.32&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>QPharma
Indemnitees</B>&rdquo; has the meaning set forth in Section 13.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.33&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>&ldquo;Qualified
Person (QP)&rdquo; </B>means a company employee that fulfils the requirements as described in European Directive 2001/83(2)/EC.
These requirements include personal qualities of integrity, maturity, open-mindedness, assertiveness, sound analytical skills
and judgment as well as a level of education, combined with practical work experience within pharmaceutical development, manufacture,
or Quality Assurance. The regulations specify that no batch of medicinal product can be released for sale or supply prior to certification
by a QP that the batch is in accordance with the relevant requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.34&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Quality
Agreement</B>&rdquo; has the meaning set forth in Section <U>9.7</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.35&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Raw
Material(s)</B>&rdquo; means any and all raw materials, supplies, Components and packaging necessary to manufacture and ship Product
in accordance with the Specifications, but excluding the APIs and TXMD-supplied Materials, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.36&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Recall</B>&rdquo;
has the meaning set forth in Section 9.5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.37&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Recipient</B>&rdquo;
has the meaning set forth in Section 10.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.38&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Regulatory
Approval</B>&rdquo; means any approvals, permits, product and/or establishment licenses, registrations or authorizations, including
approvals pursuant to U.S. Investigational New Drug Applications, New Drug Applications and Abbreviated New Drug Applications,
as applicable, of any Regulatory Authorities that are necessary or advisable in connection with the development, manufacture,
testing, use, storage, exportation, importation, transport, promotion, marketing, distribution or sale of APIs or Product in the
Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.39&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Regulatory
Authority</B>&rdquo; means the international, federal, state or local governmental or regulatory bodies, agencies, departments,
bureaus, courts or other entities in the Territory that are responsible for (A) the regulation (including pricing) of any aspect
of pharmaceutical or medicinal products intended for human use including, but not limited to, their manufacture, handling and
storage, or (B) health, safety or environmental matters generally. In the United States, this includes the United States Food
and Drug Administration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.40&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Representatives</B>&rdquo;
of an entity mean such entity&rsquo;s duly-authorized officers, directors, employees, agents, accountants, attorneys or other
professional advisors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.41&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Review
Period</B>&rdquo; has the meaning set forth in Section 5.2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.42&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Risk
Mitigation Plan</B>&rdquo; has the meaning set forth in Section 16.5(B).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.43&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Specifications</B>&rdquo;
means the procedures, requirements, standards, quality control testing and other data and the scope of services as set forth in
<U>Attachment A</U>, as modified from time to time in accordance with Article 8.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.44&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Term</B>&rdquo;
has the meaning set forth in Section 16.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.45&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Term
Sheet</B>&rdquo; means that certain Binding Pricing Term Sheet for Supply of Product entered into on [***], between TherapeuticsMD
and QPharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.46&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Territory</B>&rdquo;
means the United States of America, its territories, insular possessions and commonwealths.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.47&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>TXMD</B>&rdquo;
has the meaning set forth in the introductory paragraph, or any successor or permitted assign.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.48&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>TXMD
Equipment</B>&rdquo; means the equipment listed on <U>Attachment B</U>, together with all diagrams, schematics, operator&rsquo;s
manuals, operating software and warranties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.49&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>TXMD
Indemnitees</B>&rdquo; has the meaning set forth in Section 13.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>TXMD
IP</B>&rdquo; has the meaning set forth in the Development Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.51&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>TXMD-supplied
Materials</B>&rdquo; means materials to be supplied by or on behalf of TXMD to QPharma, other than APIs, for Processing, if any.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.52&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Unit
Pricing</B>&rdquo; has the meaning set forth in Section 7.1(A).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.53&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Validation
Plan</B>&rdquo; has the meaning set forth in Section 7.7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.54&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&ldquo;<B>Vendor</B>&rdquo;
has the meaning set forth in Section 3.1(B).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROCESSING
&amp; RELATED SERVICES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
and Purchase of Product</U>. QPharma shall Process Product and deliver the same to TXMD, its Affiliates and licensees in accordance
with the Specifications, Applicable Laws and the terms and conditions of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Product
Maintenance Services</U>. TXMD will receive the following product maintenance services (the &ldquo;<B>Product Maintenance Services</B>&rdquo;):
one annual audit (as further described in Section 9.5); regulatory audits (as further described in Section 9.4); one annual Product
review (within the meaning of 21 CFR &sect; 211.180); access to document library over and above the Quality Agreement, including
additional copies of Batch paperwork or other Batch documentation; assistance in preparing Regulatory Approvals; Product document
and sample storage relating to cGMP requirements; vendor re-qualification; and maintenance, updates and storage of master batch
records and audit reports. For avoidance of doubt, the following services and items are not included in Product Maintenance Services:
technology transfer; analytical work; stability; and process rework.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Other
Related Services</U>. QPharma shall provide such Product-related services, other than Processing or Product Maintenance Services,
as agreed to in writing by the parties from time to time. Such writing shall include the scope and fees for any such services
and be appended to this Agreement. The terms and conditions of this Agreement shall govern and apply to such services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Validation
Services</U>. QPharma operates a validated Process for the production of the Product, and will continue to do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
3</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>API,
MATERIALS &amp; EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>The
APIs and Raw Materials</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
shall be responsible for establishing a source of supply of the APIs. TXMD, at its option, shall enable QPharma to place orders
for the API&rsquo;s from such source of supply. QPharma shall be responsible for inspecting and releasing adequate quantities
of the APIs and Raw Materials as necessary to meet the Firm Commitment, unless otherwise agreed to by the parties in writing.
QPharma shall not be liable for any delay in delivery of Product if (i) TXMD is unable to obtain, in a timely manner, a particular
API or (ii) QPharma is unable to obtain, in a timely manner, a particular API through its placement of orders therefor from TXMD&rsquo;s
source of supply or Raw Material necessary for Processing and (iii) QPharma placed orders for such API or Raw Material promptly
following receipt of TXMD&rsquo;s Firm Commitment. In the event that any API or Raw Material becomes subject to purchase lead
time beyond the Firm Commitment time frame, the parties will negotiate in good faith an appropriate amendment to this Agreement.
TXMD shall reimburse to QPharma its cost for the APIs. QPharma shall provide a credit to TXMD in the amount of any credit received
by QPharma from an API supplier resulting from a pricing agreement with such supplier, with such credits to be applied to the
next invoice issued thereafter to TXMD and successive invoices until fully expended. In order to facilitate the ordering and delivery
of initial supplies of APIs to QPharma, TXMD, in consultation with QPharma, may purchase supplies of APIs for delivery to QPharma.
Further, in order to facilitate the timely manufacture of Product for the Firm Commitment, QPharma shall maintain a safety stock
of APIs and Raw Materials. Such safety stock shall be in an amount mutually agreed to by the Parties. TXMD shall be responsible
for payment of the purchase price of any such APIs so ordered by it for delivery to QPharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
certain instances, TXMD may require a specific supplier, manufacturer or vendor (&ldquo;<B>Vendor</B>&rdquo;) to be used for a
Raw Material. In such an event occurring after the date of this Agreement, such Vendor will be identified in the Specifications.
If the cost of such Raw Material from any such Vendor is greater than QPharma&rsquo;s costs for the same Raw Material of equal
quality from other vendors, QPharma shall add the difference between QPharma&rsquo;s cost of such Raw Material and the Vendor&rsquo;s
cost of the Raw Material to the Unit Pricing. TXMD will be responsible for all costs associated with qualification of any Vendor
specifically required to be used upon written instruction from TXMD, which Vendor has not been previously qualified by QPharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of (i) a Specification change for any reason, (ii) obsolescence of any API or Raw Material or (iii) termination or expiration
of this Agreement, TXMD shall bear the cost of any unused API or Raw Materials (including packaging), so long as QPharma purchased
such API and Raw Materials in quantities consistent with TXMD&rsquo;s most recent Firm Commitment and the vendor&rsquo;s minimum
purchase obligations. Such APIs and Raw Material shall be the property of TXMD upon payment therefor.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Supply
of Materials</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
shall supply to QPharma for Processing, at TXMD&rsquo;s cost, all TXMD-supplied Materials set forth on <U>Attachment </U>C, if
any, in quantities sufficient to meet TXMD&rsquo;s requirements for Product. TXMD shall deliver such items and associated certificates
of analysis to the Facility no later than [***] ([***]) days before the Processing Date. TXMD&rsquo;s failure to fulfill the foregoing
obligations in this Section 3.2 shall not by itself give rise to a cause of action in QPharma or a right by it to terminate this
Agreement. However, QPharma shall not be held liable for a delayed Processing Date related to TXMD&rsquo;s own delay in delivering
TXMD supplied Materials and associated certificates to the Facility. TXMD shall be responsible at its expense for securing any
necessary DEA, export or import, similar clearances, permits or certifications required in respect of such supply. QPharma shall
use such items solely for Processing. Prior to delivery of any such items, TXMD shall provide to QPharma a copy of all associated
material safety data sheets, safe handling instructions and health and environmental information and any Regulatory certifications
or authorizations that may be required under Applicable Laws with respect thereto, and shall promptly provide any updates thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following
receipt of TXMD-supplied Materials, QPharma shall inspect, test and release such items employing such measures as are set forth
in the Specifications. QPharma will receive, handle, store and use all TXMD-supplied Materials in compliance with all Applicable
Laws and labeled storage requirements, or lacking labeled storage requirement, the written instructions of TXMD, as agreed to
by QPharma, such agreement not to be unreasonably withheld. In the event that QPharma detects a nonconformity with Specifications,
QPharma shall give TXMD prompt notice of such nonconformity. QPharma shall not be liable for any defects in TXMD-supplied Materials,
or in Product resulting from defective TXMD-supplied Materials, unless QPharma failed to properly perform the foregoing obligations.
QPharma shall follow TXMD&rsquo;s reasonable written instructions in respect of return or disposal of defective TXMD-supplied
Materials, at TXMD&rsquo;s cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
shall retain title to TXMD-supplied Materials at all times and shall bear the risk of loss thereof, except for losses to the extent
due to the negligent acts or omissions of QPharma or QPharma&rsquo;s failure to follow storage and handling requirements or mutually
agreed to written instructions of TXMD, in each case, subject to Article 14.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Artwork
and Labeling</U>. TXMD shall provide or approve, prior to the procurement of applicable Raw Materials, all artwork, advertising
and labeling information necessary for Processing, if any. Such artwork, advertising and labeling information is and shall remain
the exclusive property of TXMD, and TXMD shall be solely responsible for the content thereof. Hence, TXMD will be responsible
for the artwork and labelling information communicated to QPharma for Processing and ensure itself that the latter comply with
provided text and relevant applicable laws and regulations prevailing in the Territory. Such artwork, advertising and labeling
information or any reproduction thereof may not be used by QPharma in any manner other than performing its obligations hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TXMD
Equipment</U>. QPharma hereby acknowledges that the TXMD Equipment is the sole and exclusive property of TXMD, and is in the possession
of QPharma. During the Term, except as set forth below, QPharma shall be entitled to use the TXMD Equipment in the performance
of its obligations to TXMD pursuant to this Agreement. QPharma (i) shall mark the TXMD Equipment so as to identify it as the property
of TXMD, (ii) shall safeguard the TXMD Equipment with the same degree of care as it uses in connection with the safeguarding of
its own equipment and (iii) shall be responsible for the proper operation, maintenance and repair of the TXMD Equipment. QPharma
shall not sell, lease or lend the TXMD Equipment to any third party or relinquish possession or control of the TXMD Equipment.
QPharma shall not move the TXMD Equipment from its current location without the advance written consent of TXMD. QPharma shall
not grant a security interest in, use as collateral or otherwise encumber the TXMD Equipment in any way, or suffer the placement
of a lien or other security device upon the TXMD Equipment. Upon request of TXMD, whether at the expiration of the Term or prior
thereto, QPharma shall promptly make the TXMD Equipment ready for removal by TXMD or its designees, and shall grant access to
TXMD and its designees to QPharma facilities for the purpose of such removal. During the Term, in the event, and to the extent,
there exists capacity in the use of the TXMD Equipment in excess of its use to fulfill purchase orders of TXMD, QPharma may use
the TXMD Equipment for its intended purpose in the performance of its manufacturing obligations for The Population Council, Inc.
or its designee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Additional
Manufacturing Line</U>. In order to plan for and meet potential demand for the Product in excess of QPharma&rsquo;s current capacity,
the Parties will prepare and reasonably agree to a manufacturing capacity expansion plan within ninety (90) days of the date of
this Agreement, such plan to address the actions to be taken, the equipment to be purchased and installed, and financial responsibility
therefor, along with a timeline, headcount plan, budget and assignment of responsibilities in the implementation of a second manufacturing
line and other capacity improvements, all as set forth in such plan. For the avoidance of doubt, the Additional Manufacturing
Line will also be comprised of TXMD Equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
4</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURCHASE
ORDERS &amp; RELATED MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
Order Requirement</U>. No purchase order shall be submitted for less than [***] commercial validated [***]. Purchase orders reflecting
purchases in excess of [***] shall be submitted only in [***] Batch multiples.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Guidance</U>.
TXMD shall keep QPharma generally informed of its anticipated need for Product, including anticipated launch quantities, through
delivery of a summary report every [***] ([***]) months. The parties shall cooperate in an effort to provide for an orderly process
of purchase order submissions and deliveries of Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
Orders</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
provided in this Section 4.3(A), TXMD shall submit to QPharma a binding, non-cancelable purchase order for Product specifying
the number of Batches to be Processed, the Batch size (to the extent the Specifications permit Batches of different sizes) and
the requested delivery date for each Batch (&ldquo;<B>Purchase Order</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Promptly
following receipt of a Purchase Order, QPharma shall issue a written acknowledgement (&ldquo;<B>Acknowledgement</B>&rdquo;) that
it accepts or rejects such Purchase Order. Each acceptance Acknowledgement shall either confirm the delivery date set forth in
the Purchase Order or set forth a reasonable alternative delivery date, and shall include the Processing Date. QPharma may reject
any Purchase Order not given in accordance with this Agreement; provided, however, QPharma shall accept any Purchase Order that
meets the requirements of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a conflict between the terms of any Purchase Order or Acknowledgement and this Agreement, the terms of this Agreement
shall control. No Purchase Order, confirmation, shipping document, receipt or similar document shall amend any term set forth
in this Agreement or set forth any term inconsistent with the terms and conditions contained in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>QPharma&rsquo;s
Cancellation of Purchase Orders</U>. Notwithstanding Section 4.5, QPharma reserves the right to cancel all, or any part of, a
Purchase Order upon written notice to TXMD, and QPharma shall have no further obligations or liability with respect to such Purchase
Order, if TXMD refuses or fails to timely supply conforming TXMD-supplied Materials in accordance with Section 3.2. Any such cancellation
of Purchase Orders shall not constitute a breach of this Agreement by QPharma. QPharma shall use reasonable efforts to re-schedule
Processing reflected on such Purchase Order promptly after conforming TXMD-supplied Materials are delivered to QPharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TXMD&rsquo;s
Modification or Cancellation of Purchase Orders</U>. TXMD may modify the delivery date or quantity of Product in a Purchase Order
only by submitting a written change order to QPharma at least [***] ([***]) days in advance of the earliest Processing Date covered
by such change order. Such change order shall be effective and binding against QPharma only upon the written approval of QPharma.
QPharma shall endeavor in good faith to mitigate the costs of such change order, but TXMD shall be responsible to QPharma for
unavoidable costs, including those resulting from non-cancellable contracts entered into by QPharma in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Unplanned
Delay or Elimination of Processing</U>. QPharma shall use commercially reasonable efforts to meet the Purchase Orders, subject
to the terms and conditions of this Agreement. QPharma shall provide TXMD with as much advance notice as practicable if QPharma
determines that any Processing will be delayed or eliminated for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Observation
of Processing</U>. In addition to TXMD&rsquo;s audit right pursuant to Section 9.5, TXMD may send up to [***] ([***]) Representatives
to the Facility to observe Processing. Provided that QPharma has given TXMD adequate notice of commencement of Processing, TXMD
shall give QPharma written notice of its intention to observe processing at least [***] ([***]) days prior to the date of its
visit. The foregoing limitations shall not apply to time spent by TXMD Representatives on site at the Facility to participate
in or witness research and development activities or to witness Processing of validation Batches of Product. Such Representatives
shall abide by all QPharma safety rules and other applicable employee policies and procedures, and TXMD shall be responsible for
such compliance. TXMD shall indemnify and hold harmless QPharma for any action, omission or other activity of such Representatives
while on QPharma&rsquo;s premises. TXMD&rsquo;s Representatives who are not employees of TXMD shall be required to sign QPharma&rsquo;s
standard visitor confidentiality agreement prior to being allowed access to the Facility. QPharma shall not be required to accommodate
any observation request or activity that would violate GMP or Swedish law. TXMD acknowledges that space constraints at QPharma&rsquo;s
facilities also may limit its ability to observe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
5</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TESTING;
RELEASE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Batch
Release</U>. After QPharma completes Processing of a Batch, QPharma shall also provide TXMD or its designee with QPharma&rsquo;s
certificate of analysis, certificate of compliance and Qualified Person release for such Batch. Issuance of a certificate of analysis,
executed batch records and a certificate of compliance by QPharma constitutes release of the Batch by QPharma to TXMD. TXMD shall
be responsible for final release of Product to the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Testing;
Rejection</U>. No later than [***] days after receipt of the Batch (&ldquo;<B>Review Period</B>&rdquo;), TXMD or its designee
shall notify QPharma whether the Batch conforms to Specifications. Upon receipt of notice from TXMD that a Batch meets Specifications,
or upon failure of TXMD to respond by the end of the Review Period, the Batch shall be deemed accepted by TXMD and TXMD shall
have no right to reject such Batch other than for defects which existed at the time of delivery and were not discovered or discoverable
in the exercise of reasonable care (&ldquo;<B>Latent Defects</B>&rdquo;). For the avoidance of doubt, (i) Batches failing to meet
Specifications at the time of delivery due to Latent Defects may be rejected, if at all, only upon notice to QPharma within [***]
([***]) days following the date on which such Latent Defect was discovered or should have been discovered in the exercise of reasonable
care and (ii) in no event may TXMD reject Product after such Product&rsquo;s expiration date. If TXMD or its designee timely notifies
QPharma in writing (an &ldquo;<B>Exception Notice</B>&rdquo;) that a Batch does not conform to the Specifications or otherwise
does not meet the warranty set forth in Section 12.1(A), whether due to a Latent Defect or otherwise (&ldquo;<B>Defective Product</B>&rdquo;),
and provides a sample of the alleged Defective Product, QPharma shall conduct an appropriate investigation in its discretion to
determine whether or not it agrees with TXMD that Product is Defective Product and to determine the cause of any nonconformity.
If QPharma agrees that Product is Defective Product and determines that the cause of nonconformity is attributable to QPharma&rsquo;s
failure to perform the Processing in accordance with the Specifications (&ldquo;<B>QPharma Defective Processing</B>&rdquo;), then
Section 5.4 shall apply. For avoidance of doubt, where the cause of nonconformity cannot be determined or assigned, it shall be
deemed not QPharma Defective Processing. For the avoidance of doubt, the Processing of any Batch that does not proceed to completion
or any Batch that does not pass release testing by QPharma shall be treated as Defective Product resulting from QPharma Defective
Processing. In such case, the remedies set forth in Section 5.4 shall apply.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Discrepant
Results</U>. If the parties disagree as to whether Product is Defective Product and/or whether the cause of the nonconformity
is QPharma Defective Processing, and this is not resolved within [***] days of the Exception Notice date, the parties shall cause
a mutually acceptable independent third party to review records, test data and to perform comparative tests and/or analyses on
samples of the alleged Defective Product and its components, including TXMD-supplied Materials. The independent party&rsquo;s
results as to whether or not Product is Defective Product and the cause of any nonconformity shall be final and binding. Unless
otherwise agreed to by the parties in writing, the costs associated with such testing and review shall be borne by QPharma if
Product is Defective Product attributable to QPharma Defective Processing, and by TXMD in all other circumstances. TXMD will be
apprised in writing of all Defective Product investigations executed by QPharma on TXMD&rsquo;s materials/products, including
Product and TXMD-supplied Materials, as well as final investigation outcome and conclusion(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Defective
Processing</U>. QPharma shall, at TXMD&rsquo;s option, either (A) replace at its cost another Batch of Product (as a replacement
for any Batch of Defective Product attributable to QPharma Defective Processing) using TXMD-supplied Materials provided at QPharma&rsquo;s
cost, if any such items are required or (B) credit any payments made by TXMD for such Batch. THE OBLIGATION OF QPHARMA TO REPLACE
QPHARMA DEFECTIVE PROCESSING IN ACCORDANCE WITH THE SPECIFICATIONS OR CREDIT PAYMENTS MADE BY TXMD FOR DEFECTIVE PRODUCT ATTRIBUTABLE
TO QPHARMA DEFECTIVE PROCESSING SHALL BE TXMD&rsquo;S SOLE AND EXCLUSIVE REMEDY UNDER THIS AGREEMENT FOR DEFECTIVE PRODUCT (APART
FROM RECALL COSTS SET FORTH IN SECTION 9.6, AND IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
6</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DELIVERY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Delivery</U>.
QPharma shall deliver Product ExWorks (Incoterms 2010) at the Facility promptly following TXMD&rsquo;s approval and notification
to QPharma&rsquo;s to release the Product; provided, however, QPharma shall be responsible for loading the Product on the carrier&rsquo;s
vehicle using due care. QPharma shall segregate and store all Product until tender of delivery. Title to Product shall transfer
to TXMD upon such delivery. TXMD shall qualify at least [***] ([***]) carriers to ship Product and then designate the priority
of such qualified carriers to QPharma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Storage</U>.
Any items temporarily stored at QPharma shall be stored in compliance with requirements set forth in the Specification, or if
no such storage Specification exists for such item, QPharma shall store such items using due care taking into account the identity
of such item.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Subcontracting</U>.
QPharma may utilize third parties to provide any part of the Processing only with the prior written approval of TXMD, provided
that the foregoing will not apply to generally available goods and services or to subcontracting to QPharma Affiliates. If TXMD
approves a subcontractor, then QPharma shall enter a written agreement with such subcontractor that enables QPharma to comply
with its obligations under this Agreement and places such subcontractors under obligations of confidentiality, non-use and intellectual
property ownership no less burdensome than those set forth herein and applicable to QPharma. QPharma will oversee all services
performed by any subcontractor, and will be responsible for such services as if such services were performed by QPharma. QPharma
shall remain liable for the performance of its subcontractors under this Agreement. The use of subcontractors shall not relieve
QPharma of any responsibility under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
7</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PAYMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Fees</U>.
In consideration for QPharma performing services hereunder:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;TXMD
shall pay QPharma the unit pricing for Product set forth on Attachment D (&ldquo;<B>Unit Pricing</B>&rdquo;), which shall be in
effect for the period ending on (i) the third anniversary of delivery by QPharma of the first commercial Batch of Product to or
for TXMD; provided launch occurs on or before [***], or (ii) [***], if there is no such launch on or before [***] (the &ldquo;<B>Initial
Pricing Term</B>&rdquo;). QPharma shall sell and deliver Product in final dosage form, packaged for end user use. QPharma shall
submit an invoice to TXMD for such fees upon tender of delivery of Product as provided in Section 6.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><U>Other
Fees</U>. TXMD shall pay QPharma for all other fees and expenses of QPharma owing in accordance with the terms of this Agreement,
including pursuant to Sections 2.3 and 4.1. QPharma shall submit an invoice to TXMD for such fees as and when appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Unit
Pricing Increase</U>. After the Initial Pricing Period, the Unit Pricing may be adjusted on an annual basis, effective on each
July 1st (with the first possible price adjustment to be effective on July 1, 2021), upon [***] days&rsquo; prior written notice
from QPharma to TXMD, to reflect increases in labor, utilities and overhead and shall be in an amount equal to the change in the
Producer Price Index (the &ldquo;<B>Index</B>&rdquo;), &ldquo;Pharmaceutical Preparation Manufacturing&rdquo; (Series ID: PCU325412325412),
not seasonally adjusted, as published by the U.S. Department of Labor, Bureau of Labor Statistics. The initial base period for
comparison shall be the twelve (12) month period ending on June 30 immediately preceding the expiration of the Initial Pricing
Period. For the avoidance of doubt, if launch of the Product occurs on or after [***], but before [***], QPharma shall be entitled
to adjust Unit Pricing for the Initial Pricing Period based upon the difference in the Index on [***] and on [***], but not to
exceed [***] percent ([***]%). For the further avoidance of doubt, Unit Pricing Increases after the Initial Pricing Period shall
not exceed [***] percent ([***]%) in the aggregate for the Index. In addition, price increases (or decreases) for APIs and Raw
Materials shall be passed through at cost to TXMD and not included in the Index-based price adjustment described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.3&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
Terms</U>. All QPharma invoices shall be due [***] ([***]) days after the date of receipt of invoice. No invoice shall be issued
to TXMD for Processing until the Batch so Processed has been released pursuant to Section 5.1; provided, however, with respect
to purchase orders for the initial [***] ([***]) Batches ordered by TXMD pursuant to this Agreement (the &ldquo;<B>Initial Batches</B>&rdquo;),
QPharma shall be entitled to issue invoices to TXMD upon receipt of such purchase orders in a non-refundable pre-paid amount equal
to [***] percent ([***]%) of the price of each such purchase order. Purchase orders for the Initial Batches shall be placed only
for even numbers of Batches to be Processed. Under a given purchase order covering some or all of the Initial Batches, TXMD shall
pay for all Batches released pursuant to Section 5.1, but shall first receive a credit in the amount of the pre-payment made pursuant
to such purchase order. If more than [***] percent ([***]%) the Batches Processed pursuant to a given purchase order for the Initial
Batches fail release pursuant to Section 5.1, QPharma nevertheless shall be entitled to retain the pre-payment made in respect
of such purchase order. TXMD shall make payment in U.S. dollars, and otherwise as directed in the applicable invoice. If any payment
is not received by QPharma by its due date, then QPharma may, in addition to any other remedies available at equity or in law,
charge interest on the outstanding sum from the due date (both before and after any judgment) at [***]% per month until paid in
full (or, if less, the maximum amount permitted by Applicable Laws).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.4&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Advance
Payment</U>. Notwithstanding any other provision of this Agreement, if at any time TXMD is in arrears in paying amounts due under
this Agreement, QPharma may require payment in advance before performing any further services or making any further shipment of
Product. If TXMD shall fail, within a reasonable time, to make such payment in advance, or if TXMD shall fail to make any payment
when due, QPharma shall have the right, at its option, to suspend any further performance hereunder until such default is corrected,
without thereby releasing TXMD from its obligations under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Taxes</U>.
All taxes, duties and other amounts assessed (excluding tax based on net income and franchise taxes) on TXMD-supplied Materials,
services or Product prior to or upon provision or sale to QPharma or TXMD, as the case may be, are the responsibility of TXMD,
and TXMD shall reimburse QPharma for all such taxes, duties or other expenses paid by QPharma or such sums will be added to invoices
directed at TXMD, where applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<U>TXMD
and Third Party Expenses</U>. Except as may be expressly covered by Product Maintenance Service fees, TXMD shall be responsible
for 100% of its own and all third-party expenses associated with the development, Regulatory Approvals and commercialization of
Product, including regulatory filings and post-approval marketing studies. The preceding sentence shall not be construed in derogation
of QPharma&rsquo;s obligations pursuant to Section 9.2 herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<U>Capital
Equipment; Process Development and Validation</U>. QPharma shall develop and implement a plan for the acquisition and installation
of certain required capital equipment, and for the validation of the manufacturing process for the Product at the facilities where
it is to be Processed, pursuant to a written plan to be agreed to by the Parties within sixty (60) days following the Effective
Date (the &ldquo;<B>Validation Plan</B>&rdquo;). The Validation Plan shall set forth the obligations of QPharma with regard to
equipment procurement and installation, process and facility validation activities, and the headcount, the budget (on a not-to-exceed
basis) and the timeline for the accomplishment of such activities. Validation costs and expenses, including stability testing,
will not exceed $[***]. Capital equipment procurement and installation costs and expenses will not exceed $[***]. The elements
of the foregoing costs and expenses shall be set forth in the Validation Plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Manufacturing
and Cost Improvement.</U> Promptly following execution and delivery of this Agreement, the parties shall confer, as advisable,
to formulate and put in place a plan for continuous improvement in manufacturing after considering appropriate means by which
to increase efficiency, yield and process improvement with a view toward lowing the Unit Pricing for Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGES
TO SPECIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;All
Specifications and any changes thereto agreed to by the parties from time to time shall be in writing, dated and signed by the
parties. No change in the Specifications shall be implemented by QPharma, whether requested by TXMD or requested or required by
any Regulatory Authority, until the parties have agreed in writing to such change, the implementation date of such change, and
any increase or decrease in costs, expenses or fees associated with such change (including any change to Unit Pricing). QPharma
shall respond promptly to any request made by TXMD for a change in the Specifications, and both parties shall use commercially
reasonable, good faith efforts to agree to the terms of such change in a timely manner. As soon as possible after a request is
made for any change in Specifications, QPharma shall notify TXMD of the costs associated with such change and shall provide such
supporting documentation as TXMD may reasonably require. TXMD shall pay all costs associated with such agreed upon changes. If
there is a conflict between the terms of this Agreement and the terms of the Specifications, this Agreement shall control. QPharma
reserves the right to postpone effecting changes to the Specifications until such time as the parties agree to and execute the
required written amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
9</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RECORDS;
REGULATORY MATTERS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;<U>Recordkeeping</U>.
QPharma shall maintain complete and accurate Batch, laboratory data, reports and other technical records relating to Processing
in accordance with QPharma standard operating procedures. Such information shall be maintained for a period of at least [***]
([***]) years from the relevant finished Product expiration date or longer if required under Applicable Laws or the Quality Agreement.
QPharma will retain samples required by cGMP and such samples shall be stored at the Facility pursuant to QPharma&rsquo;s standard
operating procedures. Prior to the destruction of any such Product specific items, QPharma shall notify TXMD of the impending
destruction and provide TXMD a reasonable opportunity to receive any or all such items.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;<U>Regulatory
Compliance</U>. QPharma shall obtain and maintain, at its cost and expense, all permits and licenses with respect to general Facility
operations required by any Regulatory Authority in the jurisdiction where QPharma Processes Product and by any Regulatory Authority
in the Territory. QPharma acknowledges that the Product is a hormonal product and as such is subject to specialized regulations
relating to its manufacture. QPharma&rsquo;s Facility presently complies with such regulations and QPharma shall maintain the
Facility&rsquo;s compliance with such regulations. TXMD shall obtain and maintain, at its cost and expense, all other Regulatory
Approvals, authorizations and certificates, including those necessary for QPharma to commence Processing for the Territory. Upon
reasonable written request, TXMD shall provide QPharma with a copy of applicable Regulatory Approvals required to distribute,
market and sell Product in the Territory. If TXMD is unable to provide such information, QPharma shall have no obligation to deliver
Product to TXMD, notwithstanding anything to the contrary in this Agreement. During the Term, QPharma will assist TXMD with all
regulatory matters relating to Processing and review the Common Technical Document pertaining to the Product and make such corrections
as are necessary to accurately reflect the Product, in each case at TXMD&rsquo;s request and reasonable expense; provided, however,
QPharma shall review and correct such documents as they relate to QPharma activities at no charge to TXMD. The parties intend
and commit to cooperate to allow each party to satisfy its obligations under Applicable Laws relating to Processing under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;<U>Regulatory
Communications</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;Each
party may communicate with any governmental agency, including, but not limited to, governmental agencies responsible for granting
regulatory approval for the Products, regarding such Products if in the opinion of that party&rsquo;s counsel, such communication
is necessary to comply with the terms of this Agreement or the requirements of any Applicable Law; provided, however, that unless
in the reasonable opinion of its counsel there is a legal prohibition against doing so, such party will permit the other party
to review and take part in any communications with the applicable agency, and to receive copies of all such communications from
that agency.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;QPharma
will notify TXMD promptly if QPharma receives any warning letters from or on behalf of a governmental agency directly related
to the Product or systems utilized in Processing the Product including, without limitation, any Form FDA-483. QPharma will provide
TXMD copies of any written communication from a governmental agency relating to a TXMD Product within [***] ([***]) Swedish business
days of its receipt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;QPharma
will promptly notify TXMD upon receipt of a notice from a Regulatory Authority for an inspection of any Facility where the Processing
is being performed due to an issue related to the Product or a system used in the performance of such services, or, in the event
of an unannounced inspection, QPharma will provide such prior notice as is possible and permissible. If not prohibited by the
Regulatory Authority, TXMD will have the right to be present at the Facility and participate in and any wrap-up meeting with such
Regulatory Authority as it applies to the Product. If QPharma receives any request by a Regulatory Authority with respect to the
Product, including, but not limited to, a notice of deficiency or FDA-483 that requires a written response regarding TXMD-supplied
Materials, project, or protocol, QPharma will provide a copy to TXMD of the deficiency notice within [***] ([***]) [***] of QPharma&rsquo;s
receipt of the notice. QPharma will provide TXMD a draft of the response prior to the response being submitted to the Regulatory
Authority so as to provide TXMD with reasonable time to review and comment on the response, which comments QPharma, in good faith,
will consider incorporating into the response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;<U>Governmental
Inspections and Requests</U>. QPharma shall promptly advise TXMD if an authorized agent of any Regulatory Authority notifies QPharma
that it intends to or does visit a Facility or any other site for the purpose of reviewing the Processing or testing. Upon request,
QPharma shall provide TXMD with a copy of any report issued by such Regulatory Authority received by QPharma following such visit,
redacted as appropriate to protect any confidential information of QPharma and QPharma&rsquo;s other customers. TXMD acknowledges
that it may not direct the manner in which QPharma fulfills its obligations to permit inspection by and to communicate with Regulatory
Authorities, but such acknowledgement shall not be construed to vitiate QPharma&rsquo;s obligations to TXMD pursuant to this Agreement.
TXMD will not be required to pay costs to mitigate any deficiencies cited in a Form 483 or QPharma&rsquo;s Facility deficiencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;<U>TXMD
Facility Audits</U>. During the Term, TXMD&rsquo;s Representatives shall be granted access upon at least [***] ([***]) business
days&rsquo; prior notice, at reasonable times during regular business hours, to (A) the portion of the Facility where QPharma
performs Processing, (B) relevant personnel involved in Processing and (C) Processing records described in Section 9.2, in each
case solely for the purpose of verifying that QPharma is Processing in accordance with cGMPs, Applicable Laws, the Specifications
and the Product master Batch records. TXMD may not conduct an audit under this Section more than once during any [***]-month period;
provided, that additional unlimited inspections may be conducted by or on behalf of TXMD as deemed appropriate by TXMD in the
event there is a material quality or compliance issue concerning Product or its Processing or to measure remediation following
an audit by either TXMD or a Regulatory Authority that resulted in a finding of deficiency. TXMD&rsquo;s Quality Assurance Manager
will arrange TXMD audits with QPharma Quality Management. Audits shall be designed to minimize disruption of operations at the
Facility. TXMD&rsquo;s Representatives who are not employees of TXMD shall be required to sign QPharma&rsquo;s standard visitor
confidentiality agreement prior to being allowed access to the Facility. Such Representatives shall comply with the Facility&rsquo;s
rules and regulations which are made known in advance to TXMD. TXMD shall indemnify and hold harmless QPharma for any action or
activity of such Representatives while on QPharma&rsquo;s premises. QPharma shall not be required to accommodate any activity
that would violate GMP or Swedish law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Recall</U>.
If a Regulatory Authority orders or requires the recall of any Product supplied hereunder or if either QPharma or TXMD believes
a recall, field alert, Product withdrawal or field correction (&ldquo;<B>Recall</B>&rdquo;) may be necessary with respect to any
Product supplied under this Agreement, the party receiving the notice from the Regulatory Authority or that holds such belief
shall promptly notify the other party in writing. With respect to any Recall, QPharma shall provide all necessary cooperation
and assistance to TXMD. TXMD shall provide QPharma with an advance copy of any proposed submission to a Regulatory Authority in
respect of any Recall, and shall consider in good faith any comments from QPharma. The cost of any Recall shall be borne by TXMD,
and TXMD shall reimburse QPharma for expenses incurred in connection with any Recall, in each case except to the extent such Recall
is caused by QPharma&rsquo;s breach of its Processing obligations under this Agreement or QPharma&rsquo;s violation of Applicable
Laws, then such cost shall be borne by QPharma in proportion to QPharma&rsquo;s contribution to the cause of the Recall, limited
to an amount equal to the aggregate price for all Product subject to Recall plus the price for all Product sold to TXMD during
the [***] ([***]) [***] period prior to Recall. For purposes hereof, such QPharma cost shall be limited to reasonable, actual
and documented administrative costs incurred by TXMD for such Recall and if applicable, replacement of the Product subject to
Recall both in accordance with Article 5.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>9.7</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Quality
Agreement</U>. The parties shall negotiate in good faith and enter into a quality agreement on QPharma&rsquo;s standard template
or such other template agreed to by the parties (the &ldquo;<B>Quality Agreement</B>&rdquo;). If the parties have not entered
into a Quality Agreement by the first to occur of (i) [***] ([***]) days following the date execution by the last party signing
this Agreement or (ii) commencement of manufacturing of Product for human use, TXMD shall be entitled to terminate this Agreement
on [***] ([***]) days&rsquo; written notice to QPharma, without cost or expense; provided, however, TXMD shall reimburse QPharma
for any (i) equipment acquired by QPharma upon written authorization of TXMD and (ii) Raw Materials procured upon written authorization
by TXMD, which unused Raw Materials, at the election of TXMD, and such equipment shall become the property of TXMD upon payment
pursuant to this Section. The Quality Agreement shall in no way determine liability or financial responsibility of the parties
for the responsibilities set forth therein. In the event of a conflict between any of the provisions of this Agreement and the
Quality Agreement with respect to quality-related activities, including compliance with cGMP, the provisions of the Quality Agreement
shall govern. In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement with respect
to any commercial matters, including allocation of risk, liability and financial responsibility, the provisions of this Agreement
shall govern.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>9.8</U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Audit
of Suppliers.</U> QPharma shall be responsible for the audit of suppliers in accordance with its standard auditing plans and practices.
TXMD hereby agrees to conduct audits on behalf of QPharma of suppliers with locations in the United States, currently only [***],
and of certain contract laboratories to be agreed to by QPharma and TXMD. QPharma will reimburse to TXMD its out-of-pocket costs
in conducting such audits. TXMD is responsible for API audits. QPharma can audit other relevant suppliers, including [***] and
[***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ARTICLE
10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONFIDENTIALITY
AND NON-USE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;<U>Definition</U>.
As used in this Agreement, the term &ldquo;<B>Confidential Information</B>&rdquo; includes all information furnished by or on
behalf of QPharma or TXMD, their respective Affiliates or any of its or their respective Representatives (the &ldquo;<B>Discloser</B>&rdquo;),
to the other party (the &ldquo;<B>Recipient</B>&rdquo;), its Affiliates or any of its or their respective Representatives, whether
furnished before, on or after the date of this Agreement, and furnished in any form, including written, verbal, visual, electronic
or in any other media or manner and information acquired by observation or otherwise during any site visit at the other party&rsquo;s
facility. Confidential Information includes all proprietary technologies, know-how, trade secrets, discoveries, inventions and
any other intellectual property (whether or not patented), analyses, data, regulatory submission Information, compilations, business
or technical information, strategies, or plan, samples, and other materials prepared or possessed by either party, their respective
Affiliates, or any of its or their respective Representatives, containing or based in whole or in part on any information furnished
by the Discloser, its Affiliates or any of its or their respective Representatives. Confidential Information also includes the
existence of this Agreement and its terms. The manufacturing process parameters which are being provided to QPharma from TXMD,
the Specifications and data resulting from performance of this Agreement by QPharma shall be considered TXMD&rsquo;s Confidential
Information. Items and information for which ownership has been allocated to TXMD under the Development Agreement shall be deemed
to be the Confidential Information of TXMD under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;<U>Exclusions</U>.
Notwithstanding Section 10.1, Confidential Information does not include information that (A) is or becomes generally available
to the public or within the industry to which such information relates other than as a result of a breach of this Agreement, (B)
is already known by the Recipient at the time of disclosure as evidenced by the Recipient&rsquo;s written records created in the
ordinary course of business, (C) becomes available to the Recipient on a non-confidential basis from a source that is entitled
to disclose it on a non-confidential basis or (D) was or is independently developed by or for the Recipient without reference
to the Confidential Information of the Discloser as evidenced by the Recipient&rsquo;s contemporaneously created written records
(E) is required to be disclosed by a court or judicial or governmental authority of competent jurisdiction, and in such event,
only after the party required to disclose the other party&rsquo;s Confidential Information provides prompt written notice to that
party so as to enable that party to resist any such required disclosure and/or to obtain suitable protection regarding such required
disclosure as is described in provision 10.4 below</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><U>Mutual
Obligation</U>. The Recipient agrees that it will not use the Discloser&rsquo;s Confidential Information except in connection
with the performance of its obligations or the exercise of its rights under this Agreement, and will not disclose, without the
prior written consent of the Discloser, Confidential Information of the Discloser to any third party, except that the Recipient
may disclose the Discloser&rsquo;s Confidential Information to any of its Affiliates and its or their respective Representatives
and subcontractors for which consent has been given pursuant to Section 6.3 and who have obligations of confidentiality and non-use
at least as rigorous as those terms herein, in each case, that (A) need to know such Confidential Information for the purpose
of performing under this Agreement, (B) are advised of the contents of this Article and (C) are bound to the Recipient by obligations
of confidentiality at least as restrictive as the terms of this Article. Each party shall be responsible for any breach of this
Article by its Affiliates or any of its or their respective Representatives or any person receiving Confidential Information directly
or indirectly from or through the Recipient. The Recipient also may disclose any information to The Population Council, as may
be required by any written contract now in existence.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;<U>Permitted
Disclosure</U>. The Recipient may disclose the Discloser&rsquo;s Confidential Information to the extent required by law or regulation;
<I>provided</I>, that prior to making any such legally required disclosure, the Recipient shall give the Discloser as much prior
notice of the requirement for and contents of such disclosure as is practicable under the circumstances. Any such disclosure,
however, shall not relieve the Recipient of its obligations contained herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;<U>No
Implied License</U>. Except as expressly set forth in Section 10.1, the Recipient will obtain no right of any kind or license
under any Confidential Information of the Discloser, including any patent application or patent, by reason of this Agreement.
All Confidential Information will remain the sole property of the Discloser, subject to Article 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;&nbsp;<U>Return
of Confidential Information</U>. Upon expiration or termination of this Agreement, the Recipient will (and will cause its Affiliates
and its and their respective Representatives to) cease its use and, upon written request, within thirty (30) days either return
or destroy (and certify as to such destruction) all Confidential Information of the Discloser, including any copies thereof, except
for a single copy which may be retained for the sole purpose of ensuring compliance with its continuing obligations under this
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0px"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7&#160;&#160;&#160;&#160;&nbsp;&#160;&#160;&#160;<u>Survival</u>.
The obligations of this Article will terminate with respect to items of Confidential Information upon the entry thereof into general
knowledge in the public domain, other than due to breach of this Agreement by the Recipient thereof or by a person receiving such
Confidential Information from or through the Recipient, but in no event earlier than [***] ([***]) years from the expiration or
earlier termination of this Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8&#160;&#160;&#160;&#160;&#160;&nbsp;&#160;&#160;<u>Reverse
Engineering</u>. Unless otherwise consented to by the Discloser in writing or provided for in a separate agreement between the
parties, the Recipient will not analyze for chemical composition any samples or materials that are the Confidential Information
of Discloser, nor to allow or cause any such samples or materials that are the Confidential Information of Discloser to be released
to third parties for analysis; provided, however, (i) this Section 10.8 shall not be construed to prevent TXMD from testing Product
or items related to Product itself or through third parties, as it sees fit in its sole and absolute discretion; and (ii) this
Section 10.8 shall not be construed to prevent QPharma from analyzing for chemical composition samples or materials that are commercially
available.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
11</b><br><b>INTELLECTUAL PROPERTY</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.1&#160;&#160;&#160;&#160;&#160;&nbsp;&nbsp;&nbsp;The
parties hereby acknowledge that it is neither their intention nor the purpose of this Agreement to engage in inventive steps in
the conception, reduction to practice or development of intellectual property. Nevertheless, in the event, and to the extent,
that intellectual property is conceived, reduced to practice, developed or otherwise created by or on behalf of either or both
of the parties in connection with this Agreement, the ownership of such intellectual property, as between the parties, shall be
with TXMD with respect to such intellectual property that relates to the Product and its Processing. Otherwise ownership shall
be with QPharma.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; color: black"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.2&#160;&#160;&#160;&#160;&nbsp;&#160;&#160;&#160;<u>Transfer</u>.
Following notice given by TXMD to QPharma, QPharma will provide reasonable assistance to effect the timely and orderly transfer
of the Process Know-How, and pertinent books and records (or copies thereof, as the case may be) pursuant to the Process Know-How
Transfer Plan to TXMD pursuant to this Section 11.2 and the Process Know-How Transfer Plan whether to establish a second source
during the term of this Agreement or at or about the time of termination or expiration of this Agreement. QPharma shall only be
obligated to use its commercially reasonable efforts in the implementation of the Process Know-How Transfer Plan. QPharma will
be reimbursed at a reasonable rate for the time of its personnel for such technology transfer.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.3&#160;&#160;&#160;&#160;&#160;&nbsp;&nbsp;&#160;&#160;<u>Books
and Records</u>. Where any document, or books and records contain Process Know-How together with other information of QPharma,
its Affiliates or their respective subcontractors, or other QPharma customers, QPharma shall only be required to provide to TXMD
a copy of that portion of that document or books and records that discloses the Process Know-How that pertains to the Product.
When transferred to TXMD, such copies will be the property of TXMD. QPharma may retain the original books and records and any
documents required by Applicable Laws to be retained by QPharma, which disclose the Process Know-How. After completion of performance
of the Process Know-How Transfer Plan, before destroying any documents, or books and records which contain material disclosures
of Process Know-How that have not been previously been provided to TXMD (whether in the same form or some other form), QPharma
will notify TXMD of such intended destruction and provide TXMD with [***] ([***]) days to notify QPharma in writing whether TXMD
wishes to obtain the same to the extent it is entitled to under this Agreement, in which case QPharma will deliver the requested
document or books and records (or copies of all or a portion thereof, as the case may be) to TXMD at TXMD&#8217;s sole cost and
expense.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 19; Options: NewSection; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.4&#160;&#160;&#160;&nbsp;&nbsp;&#160;&#160;<u>TXMD
Marks</u>. QPharma will not use TXMD&#8217;s Marks without prior written authorization from TXMD. The Marks are, and will remain,
TXMD&#8217;s sole and exclusive property, and QPharma has not acquired, and will not acquire (by operation of law, this Agreement,
or otherwise), any right, title, or interest in any of TXMD&#8217;s Marks other than as explicitly provided in writing by TXMD.
Any and all goodwill and rights that arise under trademark and copyright law, and all other intellectual property rights that
arise in favor of TXMD&#8217;s Marks as a result of this Agreement or otherwise, will inure to the sole and exclusive benefit
of TXMD. Subject to the next sentence, during the Term of this Agreement, QPharma will not attack, dispute, or challenge TXMD&#8217;s
right, title, and interest in and to TXMD&#8217;s Marks or assist others in so doing. QPharma reserves the right to attack, dispute,
or challenge TXMD&#8217;s right, title, and interest in and/or to TXMD&#8217;s Marks or assist others in so doing, if QPharma
believes in good faith that TXMD&#8217;s Mark infringes a Mark owned by or licensed to QPharma or one of its Affiliates. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
12</b><br><b>REPRESENTATIONS AND WARRANTIES AND COMPLIANCE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>QPharma.</u> QPharma represents, warrants and undertakes to TXMD that:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;at
the time of delivery by QPharma as provided in Section 6.1, Product shall have been Processed in accordance with this Agreement
and with Applicable Laws and in conformance with the Specifications and shall not be adulterated, misbranded or mislabeled within
the meaning of Applicable Laws; <i>provided</i>, that QPharma shall not be liable for defects attributable to TXMD-supplied Materials
(including artwork, advertising and labeling); </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;all
personnel, employees, and agents of QPharma and its Affiliates and their respective subcontractors who perform services, are and
will continue to be qualified and to have sufficient technical expertise to perform QPharma&#8217;s obligations under this Agreement;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
has the full power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described
in this Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon QPharma;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
is not now, nor will it be, a party to any agreement, whether with The Population Council or others, which would prevent QPharma
from fulfilling its obligations under this Agreement, and that during the Term of this Agreement will not enter into any agreement
with any other party that would in any way prevent QPharma from performing its obligations under this Agreement;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 20; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.&#160;&#160;&#160;&#160;&#160;&#160;QPharma&#8217;s
Facility complies with and QPharma will maintain its compliance with the regulations for the manufacture of hormonal products;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
will maintain all records and reports as required under this Agreement, and as required to comply with Applicable Laws;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
will not in the performance of its obligations under this Agreement use those services prohibited to be provided by any person
debarred or suspended (or subject to debarment or suspension) under 21 U.S.C. &#167;335(a) or (b) or otherwise disqualified by
Applicable Law; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.&#160;&#160;&#160;&#160;&#160;&#160;(i)
QPharma is not nor has it ever been, and (ii) QPharma has not used, and will not use, the services of any person excluded, debarred,
suspended, or otherwise ineligible to participate in the Federal health care programs or in Federal procurement or non-procurement
programs, and has not used, and will not use, those services prohibited to be provided by any person listed on the HHS/OIG List
of Excluded Individuals/Entities (<u>http://www.oig.hhs.gov</u>), the GSA&#8217;s List of Parties Excluded from Federal Programs
(<u>http://www.epls.gov</u>), or the FDA Debarment List (<u>http://www.fda.gov/ora/compliance_ref/debar/default.htm</u>), as amended
or replaced from time to time, in connection with any of the services performed under this Agreement. QPharma further certifies
that it, and, to its knowledge, any other person or entity used by QPharma in performing any of the services under this Agreement,
has not been convicted of a criminal offense that falls within the ambit of 42 U.S.C. &#167;1320a-7(a). QPharma agrees to notify
TXMD promptly in the event QPharma, or any person used by QPharma in connection with this Agreement, ever becomes excluded, debarred,
suspended, or, otherwise to its knowledge, ineligible to participate in Federal health care programs or in Federal procurement
or non-procurement programs. This certification applies to QPharma and its respective officers, agents, and employees as well
as subcontractors performing on behalf of QPharma under this Agreement;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">I.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
has all necessary authority to use the QPharma technology utilized with the Product and as contemplated by this Agreement; there
are no patents owned by others related to the QPharma IP utilized with the Product that would be infringed or misused by QPharma&#8217;s
performance of the Agreement; and, to its knowledge, no trade secrets or other proprietary rights of others related to the QPharma
IP utilized with the Product that would be infringed or misused by QPharma&#8217;s performance of this Agreement; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
will not release any Batch of Product if the required certificates of conformance indicate that Product does not comply with the
Specifications; and</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">K.&#160;&#160;&#160;&#160;&#160;&#160;no
transactions or dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the
target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the
United States. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>TXMD</u>.
TXMD represents, warrants and undertakes to QPharma that:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;all
TXMD-supplied Materials shall have been produced in accordance with Applicable Laws, shall comply with all applicable specifications,
including the Specifications, shall not be adulterated, misbranded or mislabeled within the meaning of Applicable Laws, and shall
have been provided in accordance with the terms and conditions of this Agreement; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 21; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;the
content of all artwork provided to QPharma shall comply with all Applicable Laws; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;all
Product delivered to TXMD by QPharma shall be held, used and disposed of by or on behalf of the TXMD in accordance with all Applicable
Laws, and TXMD will otherwise comply with all laws, rules, regulations and guidelines applicable to TXMD&#8217;s performance under
this Agreement; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&#160;&#160;&#160;&#160;&#160;&#160;TXMD
will not release any Batch of Product if the required certificates of conformance indicate that Product does not comply with the
Specifications or if TXMD does not hold all necessary Regulatory Approvals to market and sell the Product; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">E.&#160;&#160;&#160;&#160;&#160;&#160;TXMD
has all necessary authority to use and to permit QPharma to use pursuant to this Agreement all intellectual property related to
Product or TXMD-supplied Materials (including artwork), and the Processing by QPharma of the foregoing, including any copyrights,
trademarks, trade secrets, patents, inventions and developments; to TXMD&#8217;s knowledge there are no patents owned by others
related to the TXMD IP utilized with the Product that would be infringed or misused by TXMD&#8217;s performance of the Agreement;
and, to its knowledge, no trade secrets or other proprietary rights of others related to the TXMD IP utilized with the Product
that would be infringed or misused by TXMD&#8217;s performance of this Agreement; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F.&#160;&#160;&#160;&#160;&#160;&#160;To
TXMD&#8217;s knowledge the services to be performed by QPharma under this Agreement will not violate or infringe upon any trademark,
tradename, copyright, patent, trade secret, or other intellectual property or other right held by any person or entity; provided
that TXMD makes no representation with respect to the QPharma IP; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">G.&#160;&#160;&#160;&#160;&#160;&#160;TXMD
has the full power and authority to execute and deliver this Agreement and perform its covenants, duties, and obligations described
in this Agreement, and once executed, this Agreement will be a valid, legal, and binding obligation upon TXMD; and</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">H.&#160;&#160;&#160;&#160;&#160;&#160;no
transactions or dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the
target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom, or the
United States. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Limitations</u>.
THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY
EACH PARTY TO THE OTHER PARTY, AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER,
INCLUDING ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE INCLUDING, WITHOUT LIMITATION,
ANY REPRESENTATION OR WARRANTY BY TXMD WITH REGARD TO THE TXMD EQUIPMENT, WHICH IS PROVIDED &#8220;AS IS.&#8221;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Compliance
with Anti-Corruption Laws</u>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
Party agrees that, in the performance of its obligations under this Agreement, it will not: (i) provide or promise to provide,
directly or indirectly, any unlawful contribution, gift, entertainment, or other unlawful payment to any foreign or domestic government
employee relating to political activity; (ii) take any action, directly or indirectly, that violates Foreign Corrupt Practices
Act (&#8220;FCPA&#8221;), or any other applicable anti-corruption law of any foreign jurisdiction, including, without limitation,
&#8220;use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment,
promise to pay, or authorization of the payment of any money, or offer, gift, promise to give, or authorization of the giving
of anything of value&#8221; to any &#8220;foreign official&#8221; (as is defined in the FCPA), any foreign political party or
official thereof, or any candidate for foreign political office, to influence their acts or decisions in their official capacity,
to induce them to do or omit from doing any act in violation of their lawful duty, or to secure any improper advantage in order
to assist in obtaining business, or retaining business, or directing business to any person; and (iii) make or propose to make
any bribe, payoff, influence payment, kickback, unlawful rebate, or other similar unlawful payment of any nature, including to
healthcare providers or those employed by any governmental institutions.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 22; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<U>Covenant
of QPharma</U>. QPharma hereby covenants and agrees that it shall neither directly or indirectly, on behalf of itself or a third
party, engage in or assist a third party, in developing, manufacturing or commercializing a generic product of the Product in
the Territory during the Term of this Agreement, and during the [***] ([***]) month period thereafter. [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#160;</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
13</b><br><b>INDEMNIFICATION</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification
by QPharma</u>. QPharma shall indemnify, defend and hold harmless TXMD, its Affiliates, and their respective shareholders, directors,
officers and employees (&#8220;<b>TXMD Indemnitees</b>&#8221;) from and against any and all suits, claims, losses, demands, liabilities,
damages, costs and expenses (including reasonable attorneys&#8217; fees and reasonable investigative costs) in connection with
any suit, demand or action brought by any third party (&#8220;<b>Losses</b>&#8221;) directly or indirectly arising out of or resulting
from (a) any breach of its representations, warranties or obligations set forth in this Agreement; (b) any negligence or willful
misconduct by QPharma, its Affiliates, subcontractors, employees or agents; (c) any misrepresentation made by QPharma in this
Agreement; (d) a violation of, or non-compliance with any Applicable Law by QPharma, its Affiliates, subcontractors, employees
or agents in the performance of this Agreement; (e) the infringement or alleged infringement of any trade secrets, copyrights,
trademarks, trade names, or other proprietary or contractual rights of any third party arising from QPharma&#8217;s performance
of services under this Agreement (except to the extent arising from the making or using of TXMD-supplied Materials) or (f) the
use of the TXMD Equipment on behalf of any third party, and the storage, handling and use of any items manufactured with the use
of the TXMD Equipment, in each case of clauses (a) through (e) above, except to the extent that TXMD is obligated to indemnify
any of the QPharma Indemnitees pursuant to Section 13.2 for such events.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification
by TXMD</u>. TXMD shall indemnify, defend and hold harmless QPharma, its Affiliates, and their respective shareholders, directors,
officers and employees (&#8220;<b>QPharma Indemnitees</b>&#8221;) from and against any and all Losses directly or indirectly arising
out of or resulting from (a) any promotion, distribution, sale or use of or exposure to the Product or TXMD-supplied Materials,
or APIs, other than claims by QPharma employees and contractors arising from Processing under this Agreement; (b) any negligence
or willful misconduct of TXMD, its Affiliates, subcontractors, employees or agents, (c) any breach of TXMD&#8217;s representations,
warranties or obligations set forth in this Agreement; (d) the content of TXMD&#8217;s instructions to the extent they are followed
by QPharma and violate Applicable Laws; (e) the conduct of any clinical trials by or on behalf of TXMD utilizing Product or APIs;
(f) any actual or alleged infringement or violation of any third party patent, trade secret, copyright, trademark or other proprietary
right by the use, as authorized, of intellectual property or other information provided by TXMD to QPharma, including TXMD-supplied
Material; in each case of clauses (a) through (f) above, except to the extent that QPharma is obligated to indemnify any of the
TXMD Indemnitees pursuant to Section 13.1 for such events. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 23; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Indemnification
Procedures</u>. All indemnification obligations in this Agreement are conditioned upon the indemnified party (a) promptly notifying
the indemnifying party of any claim or liability of which the indemnified party becomes aware (including a copy of any related
complaint, summons, notice or other instrument); provided, that failure to provide such notice within a reasonable period of time
shall not relieve the indemnifying party of any of its obligations hereunder except to the extent the indemnifying party is prejudiced
by such failure, (b) allowing the indemnifying party to conduct and control the defense of any such claim or liability and any
related settlement negotiations (at the indemnifying party&#8217;s expense), (C) cooperating with the indemnifying party in the
defense of any such claim or liability and any related settlement negotiations (at the indemnifying party&#8217;s expense) and
(D) not compromising or settling any claim or liability without prior written consent of the indemnifying party.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
14</b><br><b>LIMITATIONS OF LIABILITY</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.1&#160;&#160;&nbsp;&nbsp;&#160;&#160;&#160;NEITHER
PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES OR LOSS OF REVENUES,
PROFITS OR DATA ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, WHETHER IN CONTRACT OR IN TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED
OF THE POSSIBILITY OF SUCH DAMAGES.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
15</b><br><b>INSURANCE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36pt; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
so long as each Party has any indemnity obligations hereunder to the other Party, each Party shall obtain and maintain such type
and amounts of liability insurance as are normal and customary for the activities contemplated by this Agreement. Each Party shall
upon request provide the other Party with written proof of insurance. Notwithstanding the foregoing, QPharma hereby represents
and warrants to TXMD that it has and shall maintain at all times during the term of this Agreement product liability insurance,
professional negligence insurance and general commercial liability insurance in a minimum in aggregate of [***] Euros (&#8364;[***]).
QPharma shall name TXMD as an additional named insured under such policies.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 24; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
16</b><br><b>TERM AND TERMINATION</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Term</u>.
The term of this Agreement shall commence as of the Effective Date and shall expire at the end of the Initial Term; provided,
however, TXMD shall have the right to renew the Agreement thereafter for successive one-year terms upon giving at least [***]
([***]) days&#8217; written notice of such renewal prior to the expiration of the Initial Term or any annual renewal thereafter.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Termination</u>.
This Agreement may be terminated Immediately upon written notice without further action:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;By
either Party if the other Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for
or consents to the appointment of a receiver, administrative receiver, trustee or administrator, or makes an assignment for the
benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order
is not discharged within thirty (30) days, or takes any equivalent or similar action in consequence of debt in any jurisdiction;
or</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;By
TXMD upon [***] ([***]) days prior written notice to QPharma in the event TXMD ceases pursuit of Regulatory Approval for, or to
offer for sale or to sell, Product, due to material regulatory, patient health, or intellectual property issues. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">C.&#160;&#160;&#160;&#160;&#160;&#160;By
either Party due to an uncured breach of this Agreement following [***] ([***]) days&#8217; written notice, the elements of such
breach being described in such notice in reasonable detail.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D.&#160;&#160;&#160;&#160;&#160;&#160;By
TXMD for convenience upon [***] ([***]) months&#8217; written notice, or by QPharma after the first anniversary of this Agreement
upon [***] ([***]) months&#8217; written notice due to the failure of QPharma to produce Product at a profit based upon the then
existing supply projections by TXMD or for other demonstrated economic hardship. Upon notice from QPharma of the exercise of its
rights under this Section 16.2(D) to terminate the Agreement, TXMD shall have the right exercisable in the [***] ([***]) day period
following such notice to require QPharma to re-negotiate the price of Products in good faith for a period of up to [***] ([***])
days. The Parties shall not be obligated to reach agreement regarding a revised price of Products.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Effects
of Termination</u>. Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued
to the benefit of either party prior to such expiration or termination. In the event of a termination of this Agreement:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;QPharma
shall promptly return to TXMD, at TXMD&#8217;s expense and direction, any remaining inventory of Product or TXMD-supplied Materials;
<i>provided</i>, that all outstanding invoices have been paid in full; </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;TXMD
shall pay QPharma all invoiced amounts outstanding hereunder, plus, upon receipt of invoice therefor, for any (i) Product that
has been shipped pursuant to Purchase Orders but not yet invoiced, (ii) Product Processed pursuant to Purchase Orders that has
been completed but not yet shipped, and (iii) except following a termination by TXMD pursuant to Section 16.2(A) or (B), all Product
in process of being Processed pursuant to Purchase Orders (or, alternatively, TXMD may instruct QPharma to complete such work
in process, and the resulting completed Product shall be governed by clause (ii)); and </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 25; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;Except
as otherwise set forth in this Agreement, in the event that this Agreement is terminated for any reason other than by TXMD pursuant
to Section 16.2(A) or (B), TXMD shall pay QPharma for all costs and expenses incurred, and all non-cancellable commitments made,
in connection with QPharma&#8217;s performance of this Agreement, so long as such costs, expenses or commitments were made by
QPharma consistent with TXMD&#8217;s most recent ordering history, and have not otherwise been paid pursuant to Section 16.3(B).
At TXMD&#8217;s discretion, such transfer shall not be considered complete until such third party transferee has successfully
Processed and released for human use [***] ([***]) successive Batches of Product. If QPharma terminates this Agreement pursuant
to Section 16.2(D), it shall provide to TXMD reasonable person-hours as TXMD shall require, at QPharma&#8217;s then standard published
rates, to effectuate a transfer of Processing to a third party of TXMD&#8217;s choice. QPharma shall provide reasonable assistance,
as requested by TXMD, to identify third parties capable and willing to provide Processing of Product promptly.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Interruption
of Supply; Safety Stock</u>.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#160;&#160;&#160;&#160;&#160;&#160;In
the event QPharma fails to timely deliver the quantities of Product ordered that comply with the requirements of this Agreement
on [***] ([***]) consecutive occasions or on any [***] ([***]) occasions during any [***] ([***]) [***] period, TXMD shall be
entitled to cause QPharma to conduct Process Know-How Transfer along with pertinent books and records to TXMD or its designee,
pursuant to the Process Know-How Transfer Plan in order to allow the Processing of Product by a third party for TXMD, its Affiliates
and their respective licensees. QPharma will be reimbursed at a reasonable rate for the time of its personnel for such technology
transfer.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.&#160;&#160;&#160;&#160;&#160;&#160;To
mitigate the risk of TXMD going out of stock, QPharma shall maintain such safety stocks of APIs, Raw Materials, Components and
Product as would be reasonably prudent in the combination drug-device product industry under relevant circumstances, particularly
in light of those APIs, Raw Materials and Components that are procured from single sources of supply. QPharma shall use reasonable
efforts to put in place a written risk mitigation plan with the consultation of TXMD to address such issues, and shall reasonably
endeavor to secure multiple sources of supply for all critical APIs, Raw Materials and Components (the &#8220;<b>Risk Mitigation
Plan</b>&#8221;).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Survival</u>.
The rights and obligations of the parties shall continue under Articles 11 (Intellectual Property), 13 (Indemnification), 14 (Limitations
of Liability), 17 (Notice), 18 (Miscellaneous); under Articles 10 (Confidentiality and Non-Use) and 15 (Insurance), in each case
to the extent expressly stated therein; and under Sections 7.3 (Payment Terms), 7.5 (Taxes), 7.6 (TXMD and Third Party Expenses),
9.1 (Recordkeeping), 9.6 (Recall), 12.3 (Limitations on Warranties), 16.3 (Effect of Termination) and 16.4 (Survival), in each
case in accordance with their respective terms if applicable, notwithstanding expiration or termination of this Agreement. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 26; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
17</b><br><b>NOTICE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
notices and other communications hereunder shall be in writing and shall be deemed given: (A) when delivered personally or by
hand; (B) when received or refused, if sent by registered or certified mail (return receipt requested), postage prepaid; or (C)
when delivered, if sent by express courier service; in each case to the parties at the following addresses (or at such other address
for a party as shall be specified by like notice; <i>provided</i>, that notices of a change of address shall be effective only
upon receipt thereof):&#160;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; height: 192px; width: 100%; font: 10pt Times New Roman, Times, Serif">

<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 70%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
TXMD:</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TherapeuticsMD,
Inc.</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6800
Broken Sound Parkway NW, Third Floor</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boca
Raton, Florida 33487</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
President</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
a copy to:</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Department at the above address</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
QPharma:</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QPharma
AB</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Agneslundsvagen
27</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Malmo,
Sweden</font></p>
</td>
</tr>
<tr style="height: 16px; font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 30%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 80%; height: 16px; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attn:
Managing Director</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ARTICLE
18</b><br><b>MISCELLANEOUS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.1&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Entire
Agreement; Amendments</u>. This Agreement, the Quality Agreement, and the Validation Costs and Expenses; Capital Equipment Procurement
and Installation Costs and Expenses (referenced as Exhibit B to the Term Sheet) constitute the entire understanding between the
Parties, and supersede any contracts, agreements or understandings (oral or written) of the Parties, with respect to the subject
matter hereof including the Term Sheet, other than Exhibit B thereto. For the avoidance of doubt, this Agreement does not supersede
any existing generally applicable confidentiality agreement between the Parties as it relates to time periods prior to the date
hereof or to business dealings not covered by this Agreement. No term of this Agreement may be amended except upon written agreement
of both parties, unless otherwise expressly provided in this Agreement. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.2&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Captions;
Certain Conventions</u>. The captions in this Agreement are for convenience only and are not to be interpreted or construed as
a substantive part of this Agreement. Unless otherwise expressly provided herein or the context of this Agreement otherwise requires,
(A) words of any gender include each other gender, (B) words such as &#8220;herein&#8221;, &#8220;hereof&#8221;, and &#8220;hereunder&#8221;
refer to this Agreement as a whole and not merely to the particular provision in which such words appear, (C) words using the
singular shall include the plural, and vice versa, (D) the words &#8220;include(s)&#8221; and &#8220;including&#8221; shall be
deemed to be followed by the phrase &#8220;but not limited to&#8221;, &#8220;without limitation&#8221; or words of similar import,
(E) the word &#8220;or&#8221; shall be deemed to include the word &#8220;and&#8221; (e.g., &#8220;and/or&#8221;) and (F) references
to &#8220;Article,&#8221; &#8220;Section,&#8221; &#8220;subsection,&#8221; &#8220;clause&#8221; or other subdivision, or to an
Attachment or other appendix, without reference to a document are to the specified provision or Attachment of this Agreement.
This Agreement shall be construed as if it were drafted jointly by the parties.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 27; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.3&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Further
Assurances</u>. The parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental
acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.4&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No
Waiver</u>. Failure by either party to insist upon strict compliance with any term of this Agreement in any one or more instances
will not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.5&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Severability</u>.
If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining
terms of this Agreement will continue in full force and effect.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.6&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Independent
Contractors</u>. The relationship of the parties is that of independent contractors, and neither party will incur any debts or
make any commitments for the other party except to the extent expressly provided in this Agreement. Nothing in this Agreement
is intended to create or will be construed as creating between the parties the relationship of joint ventures, co-partners, employer/employee
or principal and agent. Neither party shall have any responsibility for the hiring, termination or compensation of the other party&#8217;s
employees or contractors or for any employee benefits of any such employee or contractor.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.7&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Successors
and Assigns</u>. This Agreement will be binding upon and inure to the benefit of the parties, their successors and permitted assigns.
Neither party may assign this Agreement, in whole or in part, without the prior written consent of the other party, except that
either party may, without the other party&#8217;s consent (but subject to prior written notice), assign this Agreement in its
entirety to an Affiliate or to a successor to substantially all of the business or assets of the assigning party or the assigning
party&#8217;s business unit responsible for performance under this Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.8&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>No
Third Party Beneficiaries</u>. This Agreement shall not confer any rights or remedies upon any person or entity other than the
parties named herein and their respective successors and permitted assigns.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.9&#160;&#160;&#160;&#160;&#160;&#160;&#160;<u>Governing
Law</u>. This Agreement shall be governed by and construed under the laws of England and Wales, excluding its conflicts of law
provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.10&#160;&#160;&#160;&#160;&#160;<u>Dispute
Resolution</u>. Any dispute that arises between the parties in connection with this Agreement shall first be presented to the
senior executives of the Parties for consideration and resolution. If such executives cannot reach a resolution of the dispute
within a reasonable time, then the parties may seek remedies in a court of law. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.11&#160;&#160;&#160;&#160;&#160;<u>Publicity</u>.
Neither party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated
hereby without the other party&#8217;s express prior written consent, except as required under Applicable Laws, by any governmental
agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the party
required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the
other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or
making the public disclosure.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 28; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.12&#160;&#160;&#160;&#160;&#160;<u>Right
to Dispose and Settle</u>. If QPharma requests in writing from TXMD direction with respect to disposal of any inventories of Product,
TXMD-supplied Materials, equipment, samples or other items belonging to TXMD and is unable to obtain a response from TXMD within
a reasonable time period after making reasonable efforts to do so, QPharma shall be entitled in its sole discretion to (A) dispose
of all such items and (B) set-off any and all amounts due to QPharma or any of its Affiliates from TXMD against any credits TXMD
may hold with QPharma or any of its Affiliates.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.13&#160;&#160;&#160;&#160;&#160;<u>Force
Majeure</u>. Except as to payments required under this Agreement, neither party shall be liable in damages for, nor shall this
Agreement be terminable or cancelable by reason of, any delay or default in such party&#8217;s performance hereunder if such default
or delay is caused by events beyond such party&#8217;s reasonable control, including but not limited to acts of God, law or regulation
or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction of production
facilities or materials by earthquake, fire, flood or weather, labor disturbances, epidemic or failure of suppliers, vendors,
public utilities or common carriers; <i>provided</i>, that the party seeking relief under this Section shall immediately notify
the other party of such cause(s) beyond such party&#8217;s reasonable control. The party that may invoke this Section shall use
commercially reasonable efforts to reinstate its ongoing obligations to the other party as soon as practicable. If the cause(s)
shall continue unabated for three (3) consecutive months, then both parties shall meet to discuss and negotiate in good faith
what modifications to this Agreement should result from such cause(s).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">18.14&#160;&#160;&#160;&#160;&#160;<u>Counterparts</u>.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original but all of which together
will constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall
constitute an original.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>[Signature
page follows]</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 29; Value: 19 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 36pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>IN
WITNESS WHEREOF</b>, the parties have caused their respective duly authorized Representatives to execute this Agreement effective
as of the date first written above.&#160;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 3%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 1%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 1%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 43%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 4%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 3%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 1%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 1%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 43%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td colspan="4" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QPHARMA
PHARMA AB</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="4" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THERAPEUTICSMD,
INC.</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td colspan="4" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="4" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></p>
</td>
<td colspan="3" style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
David Segerberg</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></p>
</td>
<td colspan="3" style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Dan Cartwright</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></p>
</td>
<td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Segerberg</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></p>
</td>
<td style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dan
Cartwright</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="3" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></p>
</td>
<td colspan="2" style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Managing
Director</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="2" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</font></p>
</td>
<td colspan="2" style="vertical-align: top; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 30 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>ATTACHMENT
A</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SPECIFICATIONS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<!-- Field: Page; Sequence: 31 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>ATTACHMENT
B</u></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TXMD
EQUIPMENT (as of 12/18/18)</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Purchased
Assets</b><br><b>Equipment used for production and analysis of NES/EE CVR</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; width: 24%; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
(swe)</font></p>
</td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt none; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; width: 30%; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Description
(eng)</font></p>
</td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt none; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; width: 14%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment<br>No</font></p>
</td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt none; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; width: 18%; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
step</font></p>
</td>
<td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt none; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; width: 14%; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">QPharma<br>Building</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; background-color: #C5D9F1; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="border-top: black 1pt none; border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
<td style="border-top-style: none; border-left-style: none; border-right: black 1pt solid; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0pt 5.4pt; vertical-align: bottom; "><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 32 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>ATTACHMENT
C</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TXMD-SUPPLIED
MATERIALS (as of 12/18/18)</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<!-- Field: Page; Sequence: 33 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>ATTACHMENT
D</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNIT
PRICING</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the Initial Pricing Period, QPharma shall sell Product in final dosage form, packaged for end user use, to TXMD at the prices
set forth below. [***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 49%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Purchase
Per Contract Year</u></font></p>
</td>
<td style="padding: 0pt; width: 2%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 4%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; width: 45%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Prices
Not to Exceed (low yield)</u></font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Purchase
Per Contract Year</u></font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td colspan="2" style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><u>Prices
Not to Exceed (anticipated yield)</u></font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]
&#8211; [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$[***]
per unit</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">More
than [***] units of Product</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</td>
<td style="padding: 0pt; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
be determined</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing prices include a recovery for depreciation expenses of Facility improvements made by QPharma. Recovery of these depreciation
expenses will end upon expiration of the depreciation recovery schedule. TXMD will purchase a minimum of [***] units of Product
per Contract Year.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing prices include the purchase by, and payment for, both of the Product&#8217;s APIs by QPharma. If TXMD supplies one or
both of the Product&#8217;s APIs to QPharma at no cost, or QPharma procures one or both APIs and passes the cost through to TXMD,
the foregoing prices will be adjusted downward, as reasonably agreed to by QPharma and TXMD.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font: 10pt Times New Roman, Times, Serif"></font></p>

<!-- Field: Page; Sequence: 34 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font: 10pt Times New Roman, Times, Serif">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
prices will be applied to cumulative purchased by TXMD together with its Affiliates and licensees, if any. The unit price for
which QPharma will sell Product to TXMD, its Affiliates and their licensees during the Initial Pricing Period will be as set forth
in the table above in accordance with the cumulative quantities ordered by and on behalf of such parties during each Contract
Year. Within [***] ([***]) days following (i) the end of each Contract Year or (ii) the expiration or termination of the Agreement,
as the case may be, QPharma shall determine the total quantity of Product ordered by or on behalf of TXMD, its Affiliates and
their respective licensees during the prior Contract Year (or portion of a Contract Year in the event of a termination) and issue
a credit memo or refund to TXMD, at its option, in such amount as may be necessary to true up amounts actually paid by TXMD with
the prices to which TXMD, its Affiliates and their respective licensees were entitled during such Contract Year based on their
actual cumulative orders.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TXMD
and QPharma will revisit this yield-based pricing scheme after the first commercial Batch of Product as defined in Section 7.1A.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"></p>

<!-- Field: Page; Sequence: 35 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>

    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</font></p>
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>ex10-2.htm
<DESCRIPTION>LEASE BY AND BETWEEN 951 YAMATO ACQUISITION COMPANY
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, serif"><B>Exhibit 10.2</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED.</font></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>LEASE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>BY AND BETWEEN</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>951 YAMATO ACQUISITION COMPANY, LLC</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(&#8220;Landlord&#8221;)</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>and</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>TherapeuticsMD, Inc.</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>(&#8220;Tenant&#8221;)</b></font></p>
<!-- Field: Page; Sequence: 1 -->
    <div style="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><u>TABLE OF CONTENTS</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="width: 100%; border-collapse: collapse; margin: 0px;" border="0" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt;width:4%;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
<td style="padding: 0pt;width:90%;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
<td style="padding: 0pt;width:6%;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Page</font></b></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">1.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">TERMS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">1</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">2.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">THE PREMISES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">4</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">3.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">TERM</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">5</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">4.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">CONDITION OF THE PREMISES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">5</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">5.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">MONTHLY RENT</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">6</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">6.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">TAXES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">7</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">7.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">OPERATING EXPENSES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">8</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">8.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">RECONCILIATION</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">10</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">9.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">INSURANCE</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">12</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">10.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">WAIVER OF SUBROGATION</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">13</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">11.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SECURITY DEPOSIT</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">14</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">12.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">USE</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">14</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">13.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">MAINTENANCE; SERVICES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">15</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">14.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SUBLEASE; ASSIGNMENT</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">16</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">15.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">INDEMNITY; NON-LIABILITY OF LANDLORD</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">18</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">16.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">UTILITIES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">19</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">17.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">HOLDING OVER</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">20</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">18.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">NO RENT DEDUCTION OR SET OFF</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">20</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">19.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">CASUALTY</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">20</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">20.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SUBORDINATION; ESTOPPEL LETTERS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">21</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">21.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">ALTERATIONS; RESTORATION</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">22</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">22.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">DEFAULT; REMEDIES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">24</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">23.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">LANDLORD&#x2019;S DEFAULT</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">27</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">24.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">NOTICES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">27</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">25.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">EMINENT DOMAIN</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">28</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">26.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">QUIET ENJOYMENT</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">28</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">27.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">RULES AND REGULATIONS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">28</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">28.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">ENVIRONMENTAL</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">29</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">29.</font></b></font></p>
</td>
<td style="padding: 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">INTENTIONALLY OMITTED</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">29</font></font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="border-collapse: collapse; width: 100%; margin: 0px;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt;width:4%;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">30.</font></b></font></p>
</td>
<td style="padding: 0pt;width:90%;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">BROKERS</font></b></font></p>
</td>
<td style="padding: 0pt;text-align: right;width:6%;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">29</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">31.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">MISCELLANEOUS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">30</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">32.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SOUTH FLORIDA COMMUTER SERVICE PROGRAMS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">31</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">33.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">CITY APPLICATION</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">31</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">RADON GAS</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">32</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">35.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">MOLD</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">32</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">36.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">PARKING</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">32</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">37.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SIGNAGE</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">33</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">38.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">RIGHT OF ENTRY</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">33</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">39.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">CERTAIN RIGHTS RESERVED TO LANDLORD</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">33</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">40.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">LEASE COMMENCEMENT/ACCEPTANCE OF PREMISES</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">41.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">WAIVER OF RIGHT TO JURY TRIAL</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">42.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">RECORDING</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">43.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">SUBORDINATION OF LANDLORD&#x2019;S LIEN</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">44.</font></b></font></p>
</td>
<td style="padding: 0pt 0pt 0pt 0pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">NO RELOCATION</font></b></font></p>
</td>
<td style="padding: 0pt; text-align: right;" valign="bottom">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt 0pt 6pt; text-align: right; text-indent: 0px;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">34</font></font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 3; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TERMS</font></b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">.&nbsp; Each reference in this Lease to any of the following subjects shall be construed to incorporate the data stated for that subject in this Section 1:</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="border-collapse: collapse; width: 100%; margin: 0px;" border="0" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt 5.4pt;width:35%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Effective Date:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;width:65%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">October 5, 2018</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Name of Tenant:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">TherapeuticsMD, Inc., a Nevada corporation</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notice Address of Tenant:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(a)&nbsp; Prior to possession:</font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">6800 Broken Sound Parkway NW</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">3rd Floor</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Boca Raton, Florida 33487</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">(b)&nbsp; Following the Full Premises Commencement Date:</font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">951 Yamato Road</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Suite 160</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Boca Raton, Florida 33431</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Name of Landlord:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">951 Yamato Acquisition Company, LLC</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Notice Address of Landlord:</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">with a copy to:</font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">138 Conant Street</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Beverly, MA&nbsp; 01915</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Attention:&nbsp; Director of Asset Management</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Michael C. Wilde, Esq.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">BAKER &amp; HOSTETLER LLP</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">SunTrust Center, Suite 2300</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">200 South Orange Avenue</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Orlando, Florida 32801</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Landlord&#x2019;s Remittance Address:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">951 Yamato Acquisition Company</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">P.O. Box 864885</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Orlando, FL&nbsp; 32886-4885</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Building:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">The building located at</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">951 Yamato Road, Boca Raton, Florida</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Property:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">The Building and the real property on which the Building is located and any other buildings and improvements located thereon as shown on the site plan attached hereto as <b>Exhibit A-1</b>.&nbsp; For all purposes under this Lease, the Property shall include all related site land, property, improvements, parking facilities, common areas, driveways, sidewalks and landscaping which form a part of the project located at 951 Yamato Road, Boca Raton, Florida 33431 and commonly known as 951 Yamato Road.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="border-collapse: collapse; width: 100%; margin: 0px;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt 5.4pt;text-align: left;width:35%;" valign="top">
<p style="font: 10pt Times New Roman, Times, serif; margin: 0pt; text-align: left;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Premises:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;width:65%;">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Approximately 56,212 rentable square feet of space located on the first and second floors of the south wing of the Building and comprised of: (i) Suite&nbsp;150 containing approximately 27,321 rentable square feet (&#8220;Suite&nbsp;150&#8221;), (ii) Suite&nbsp;220 containing approximately 21,330 rentable square feet (&#8220;Suite&nbsp;220&#8221;) and (iii) Suite&nbsp;160 on the first floor of the west wing containing approximately 7,561 rentable square footage (&#8220;Suite&nbsp;160&#8221;), as shown by the floor plans attached hereto as <b>Exhibit A</b>.&nbsp; The &#8220;rentable square footage&#8221; of the Premises shall be deemed to be 56,212 square feet for all purposes under this lease.&nbsp; The usable square footage of the Premises has been measured in accordance with the American National Standard Method of Measuring Floor Area in Office Buildings of the Building Owners and Managers Association International (ANSI Z65.1-2010), provided the load factor is not calculated per BOMA.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt;width:35%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Permitted Use:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;width:65%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">General office use, and no other use or purpose.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Term:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">The period of time beginning on the Suite&nbsp;160 Commencement Date and ending at 11:59 P.M. on the Expiration Date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;</font></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Suite&nbsp;160 Commencement Date:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Subject to the terms of Section 3 of the Lease, the earlier to occur of (i) October 27, 2018 or (ii) the date Tenant commences operation of its business in Suite&nbsp;160.&nbsp; Tenant shall confirm the Suite&nbsp;160 Commencement Date pursuant to the terms herein.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Full Premises Commencement Date:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Subject to the terms of Section 3 of the Lease, the Full Premises Commencement Date shall be the earlier to occur of (i) &#8220;Substantial Completion&#8221; of the &#8220;Tenant Improvements&#8221; (as said terms are defined in the Work Letter attached as <b>Exhibit F</b>) but no earlier than June 1, 2019 or (ii) the date Tenant commences operation of its business in either Suite&nbsp;150 or Suite&nbsp;220.&nbsp; Tenant shall confirm the Full Premises Commencement Date pursuant to the terms herein.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Expiration Date:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">That certain date which is the last day of the one hundred thirty second (132<sup>nd</sup>) complete calendar month following the Full Premises Commencement Date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Tenant&#x2019;s Percentage:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">[***]%, being the ratio of rentable square footage of the Premises to the total rentable square footage of the Building (currently [***] rentable square feet), provided that until the occurrence of the Full Premises Commencement Date the Tenant&#x2019;s Percentage shall be [***]% (based on Suite&nbsp;160).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="border-collapse: collapse; width: 100%; margin: 0px;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt 5.4pt;width:35%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Prepaid Rent:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;width:65%;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">$[***] (to be applied, pursuant to the terms herein), representing the amounts estimated for the first month in which rent is payable for the entire Premises (estimated to be $[***]) and the last month in which rent is payable for the entire Premises (estimated to be $[***]).&nbsp; Provided that (i) Tenant has paid all amounts due and has otherwise performed all obligations hereunder, (ii) there exists no Event of Default hereunder, and (iii) this Lease is then in full force and effect, the Landlord shall credit the remaining portion of the Prepaid Rent (after deducting the amount for the first month&#x2019;s rent) to the Rent payable for the month of January 2024, with such credit to be conditioned on (i), (ii), and (iii) above.&nbsp; In the event the conditions above are not satisfied as of December 31, 2023, the remaining portion of the Prepaid Rent shall be held and credited to the last month of the Term.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Security Deposit:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">$[***].</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Exhibits:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit A-1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Site Plan of the Building</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit A-2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Location of Parking Spaces</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit A-3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Building Lot and Shared Lot</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit A&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Premises</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit B&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Rules and Regulations</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit C&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Commencement Letter</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit D&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Additional Stipulations</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit E&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Suite&nbsp;160 Work Letter</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit F&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Landlord Work Letter</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit G&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Intentionally Deleted</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit H&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Current Lender Form SNDA</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit I&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Assumed Rent Table</font></p>
<p style="font: 10pt Times New Roman, Times, serif; margin: 3pt 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Exhibit J&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Landlord&#x2019;s Agreement</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">All of the Exhibits listed above are incorporated into and made part of this Lease.<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;</font></font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<table style="border-collapse: collapse; width: 100%;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td style="padding: 0pt 5.4pt;width:35%;">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Rent:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;width:65%;">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Base Rent and all Additional Rent, plus all applicable sales tax thereon.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Additional Rent:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">All amounts required to be paid by Tenant to Landlord pursuant to this Lease other than Base Rent, including, without limitation, Tenant&#x2019;s Percentage of Operating Expenses and Taxes.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b>Base Rent:</b></font></p>
</td>
<td style="padding: 0pt 5.4pt;" valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Base Rent is at the initial rate of $[***] per rentable square foot, plus all applicable sales tax thereon, escalating annually at the rate of [***]% on each anniversary of the Suite 160 Commencement Date (as to the Base Rent for Suite 160) and each anniversary of the Full Premises Commencement Date (as to the Base Rent for Suite 150 and Suite 220) with the Term to expire at the end of the 132<sup>nd</sup> full month from the Full Premises Commencement Date.</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the foregoing, Base Rent and Tenant&#x2019;s Percentage of Operating Expenses and Taxes for Suite&nbsp;160 (7,561 rentable square feet) shall be abated for the first [***] ([***]) [***] period of the Term commencing on the Suite&nbsp;160 Commencement Date (the &#8220;Suite&nbsp;160 Rent Abatement Period&#8221;).&nbsp; The Base Rent and Tenant&#x2019;s Percentage of Operating Expenses and Taxes for Suite&nbsp;160 due for any partial calendar month immediately following the Suite&nbsp;160 Rent Abatement Period shall be prorated based on the number of days in that month.&nbsp; Notwithstanding anything herein to the contrary, during the Suite 160 Rent Abatement Period, Tenant shall pay the Tenant&#x2019;s Percentage of electricity for Suite 160 and Tenant&#x2019;s Percentage of janitorial services for Suite 160 which is estimated to be $[***] psf, provided that Tenant&#x2019;s Percentage of electricity and janitorial services shall be subject to reconciliation based upon the actual cost of the electricity and janitorial services, but in no event shall the cost exceed $[***] per rsf for calendar year 2018.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Further, notwithstanding the foregoing, Base Rent and Tenant&#x2019;s Percentage of Operating Expenses and Taxes for the Suite 150 (27,321 rentable square feet) and Suite 220 (21,330 rentable square feet) shall be abated for the [***] ([***]) [***] period commencing on the Full Premises Commencement Date (the &#8220;Suites 150 &amp; 220 Rent Abatement Period&#8221;).&nbsp; The Base Rent and Tenant&#x2019;s Percentage of Operating Expenses and Taxes for Suites 150 &amp; 220 due for any partial calendar month immediately following the Suites 150 &amp; 220 Rent Abatement Period shall be prorated based on the number of days in that month.&nbsp; Tenant shall pay the Tenant&#x2019;s Percentage of electricity for Suite 150 and Suite 220 and Tenant&#x2019;s Percentage of janitorial services for Suite 150 and Suite 220, which shall be based on 2019 budgets, provided that Tenant&#x2019;s Percentage of electricity and janitorial services shall be subject to reconciliation based upon the actual cost of the electricity and janitorial services, but in no event shall the cost exceed $[***] per rsf for calendar year 2019.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">2.&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; THE PREMISES</font></b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">.&nbsp; Landlord leases to Tenant, and Tenant leases from Landlord, upon and subject to the terms and conditions of this Lease, the Premises together with certain rights to the Common Areas as hereinafter specified, it being acknowledged and agreed that the commencement dates for the respective suites of the Premises shall be staggered in accordance with the terms herein.&nbsp; The term &#8220;Common Areas&#8221; is defined as all areas and facilities outside the Premises and within the exterior boundary line of the Property that are designated by Landlord from time to time for the general non-exclusive use of Landlord, Tenant and the other tenants of the Building and their respective employees, suppliers, customers and invitees, including, but not&nbsp;</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">limited to, common entrances, lobbies, corridors, stairwells, public restrooms, conference rooms, elevators, parking areas, loading and unloading areas, roadways and sidewalks.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
TERM</B>.&nbsp; The Premises, or applicable portion thereof as they case may be, are leased for the Term.&nbsp; If for any reason
Landlord is unable to deliver possession of the Suite&nbsp;160 Premises to Tenant on or prior to October 7, 2018 (subject to a
day-for-day extension due to Force Majeure), in addition to any other free rent periods as provided for in this Lease, Tenant
shall receive one day of free rent for each day in the period commencing on October 7, 2018 (subject to a day-for-day extension
due to Force Majeure) and ending on the date that Landlord delivers the Suite&nbsp;160 Premises to Tenant.&nbsp; If Landlord has
not completed the Phase&nbsp;2 portion of the Landlord&#x2019;s Suite&nbsp;160 Work (as defined in <B>Exhibit&nbsp;E</B>) on or
before December 15, 2018 (subject to a day-for-day extension due to Force Majeure or Tenant Delay), in addition to any other free
rent periods as provided for in this Lease, Tenant shall receive one day of free rent for each day in the period commencing on
December 15, 2018 (subject to a day-for-day extension due to Force Majeure or Tenant Delay) and ending on the date that Landlord
completes the Phase&nbsp;2 portion of the Landlord&#x2019;s Suite&nbsp;160 Work.&nbsp; If for any reason Landlord is unable to
deliver possession of the Suite&nbsp;150 &amp; Suite&nbsp;220 portion of the Premises to Tenant on or prior to July 1, 2019 (subject
to a day-for-day extension due to (i) Force Majeure, (ii) Tenant&#x2019;s failure to fully approve of the plans for Tenant Improvements
by November 15, 2018, or (iii) Tenant Delay) in the condition required by the Work Letter, Tenant shall receive one day of free
rent for each day in the period commencing on July 1, 2019 (subject to a day-for-day extension due to (i) Force Majeure, (ii)
Tenant&#x2019;s failure to fully approve of the plans for Tenant Improvements by November 15, 2018, or (iii) Tenant Delay) and
ending on the date that Landlord delivers the Suite&nbsp;150 &amp; Suite&nbsp;220 portion of the Premises to Tenant in the condition
required by the Work Letter.</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><FONT STYLE="font-family: Times New Roman, Times, serif; font-size: 10pt">If
for any reason Landlord has not delivered the Suite 150 &amp; Suite 220 portion of the Premises to Tenant on or prior to November
30, 2019 (subject to a day-for-day extension due to (i) Force Majeure, (ii) Tenant&#x2019;s failure to fully approve of the plans
for Tenant Improvements by November&nbsp;15, 2018, or (iii) Tenant Delay) in the condition required by the Work Letter, Tenant
shall have the right to terminate this Lease by providing written notice of such termination to Landlord on or before December
10, 2019.&nbsp; Tenant shall have the option to extend the Term subject to the terms and conditions of <B>Exhibit&nbsp;D</B> attached
hereto.</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CONDITION OF THE PREMISES</B>.&nbsp; Except as expressly set forth herein and in the Work Letter, the Premises are leased in an
&#8220;as is&#8221; and &#8220;where is&#8221; condition without any warranty of suitability, habitability or fitness for use,
occupation or any particular purpose express or implied, it being agreed that Tenant has had an opportunity to examine the condition
of the Premises, that Landlord has made no representations or warranties of any kind with respect to such condition, and that
except as expressly set forth herein and in the Work Letter, Landlord has no obligation to do or approve any work or make or approve
any improvements to or with respect to the Premises to prepare the same for Tenant&#x2019;s occupancy except as expressly set
forth herein and in the Work Letter.&nbsp; Landlord shall make improvements to the Suite&nbsp;160 Premises and tender possession
of the Suite&nbsp;160 Premises in accordance with the terms of the Work Letter attached as <B>Exhibit&nbsp;E</B>.&nbsp; Landlord
shall make improvements to Suite&nbsp;150 and Suite&nbsp;220 and tender possession of Suite&nbsp;150 and Suite&nbsp;220 as described
in the Work Letter attached as <B>Exhibit&nbsp;F</B>.</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MONTHLY RENT</font></b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">.&nbsp; Subject to the rent abatement periods provided herein, commencing on the Suite&nbsp;160 Commencement Date and the Full Premises Commencement Date (respectively), Base Rent for the applicable portion of the Premises, plus applicable sales tax, shall be paid monthly in advance on or before the first day of each calendar month.&nbsp; The Base Rent shall not be adjusted or modified if the actual rentable square footage of the Premises varies from the rentable square footage set forth herein by [***]% or less.&nbsp; If the Suite&nbsp;160 Commencement Date or the Full Premises Commencement Date (respectively) shall be on any day other than the first day of a calendar month, Base Rent, plus applicable sales tax, for the partial month shall be prorated based on the number of days in that month.&nbsp; Unless otherwise provided herein, commencing on the Suite&nbsp;160 Commencement Date and the Full Premises Commencement Date (respectively), Additional Rent, plus applicable sales tax, shall also be paid monthly in advance on or before the first day of each calendar month.&nbsp; If the Suite&nbsp;160 Commencement Date or the Full Premises Commencement Date (respectively) shall be on any day other than the first day of a calendar month, Additional Rent, plus applicable sales tax, for the partial month shall be prorated based on the number of days in that month.&nbsp; Rent shall be paid to Landlord, without notice or demand, and without deduction or offset, in lawful money of the United States of America, at Landlord&#x2019;s Remittance Address as set forth in Section 1 or to such other address as Landlord may from time to time designate in writing.&nbsp; Tenant acknowledges that the late payment of Rent or other sums due hereunder shall cause Landlord to incur costs not contemplated by this Lease, the exact amount of which shall be extremely difficult to ascertain.&nbsp; Such costs include, but are not limited to, processing and accounting charges, and late charges which may be imposed on Landlord by the terms of any mortgage or trust deed covering the Property.&nbsp; Accordingly, if any installment of Rent or any other sums due from Tenant shall not be received by Landlord within [***] ([***]) days of when due, Tenant shall pay to Landlord a late charge equal to [***] percent ([***]%) of such overdue amount.&nbsp; In addition, any amount due to Landlord, if not paid within [***] ([***]) days of when due, shall bear interest from the date due until paid at the lesser of: (i) the Prime Rate (as hereinafter defined) plus [***] percent ([***]%) per annum, or (ii) the highest rate permitted by law (the &#8220;Default Rate&#8221;).&nbsp; The term &#8220;Prime Rate&#8221; shall mean the Prime Rate as published in </font><u>The Wall Street Journal</u><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"> from time to time.&nbsp; The parties agree that such late charges represent a fair and reasonable estimate of the costs Landlord shall incur by reason of late payment by Tenant.&nbsp; The acceptance of such late charges by Landlord shall in no event constitute a waiver of Tenant&#x2019;s default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies granted hereunder.&nbsp; Notwithstanding anything to the contrary in this Lease, Tenant shall pay the Prepaid Rent simultaneously with Tenant&#x2019;s execution and delivery of this Lease.&nbsp; Notwithstanding the foregoing, Landlord shall not charge Tenant interest or late charges for the first late payment in any [***] ([***]) month period provided that Tenant pays any all sums due within [***] ([***]) days of the date due, with any subsequent late payment to incur fees and interest without any additional grace period.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding anything to the contrary, at the expiration of any rent abatement period, Landlord shall apply the portion of the Prepaid Rent (as apportioned to Suite&nbsp;160 after the expiration of the Suite&nbsp;160 Rent Abatement Period and to Suites&nbsp;150 and 220 after expiration of the Suites&nbsp;150 and 220 Rent Abatement Period) applicable to the first month in which Rent is payable to Landlord, and Tenant shall not be obligated to pay Rent for that month, unless the amount of the Prepaid Rent is insufficient to cover the entire amount of the actual Rent due in which case Tenant will be obligated to pay the additional amount owed upon the same terms and at&nbsp;<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">the same time such payment would otherwise be due.&nbsp; The remaining amount of any Prepaid Rent shall be credited or applied as set forth above.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TAXES</font></b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">.&nbsp; Tenant shall pay monthly, as Additional Rent, one-twelfth (1/12) of Tenant&#x2019;s Percentage of annual Taxes based on estimates provided by Landlord from time to time and subject to reconciliation as provided in Section 8 below.&nbsp; &#8220;Taxes&#8221; means all taxes, assessments and fees levied upon the Property by any governmental entity based upon the ownership, leasing, renting or operation of the Property. &nbsp;Taxes shall not include any federal, state or local net income, capital stock, succession, transfer, replacement, gift, estate or inheritance taxes; provided, however, if at any time during the Term, a tax or excise on income is levied or assessed by any governmental entity in lieu of or as a substitute for, in whole or in part, real estate taxes or other ad valorem taxes, such tax shall constitute and be included in Taxes.&nbsp; In addition to the foregoing, Tenant shall pay Landlord, as Additional Rent, for any use, rent or sales tax, service tax, value added tax, franchise tax or any other tax on Rent however designated as well as for any taxes which are reasonably attributable to the cost or value of Tenant&#x2019;s equipment, furniture, fixtures and other personal property located in the Premises or the cost or value of any leasehold improvements made in or to the Premises by or for Tenant.&nbsp; All expenses, including attorneys&#x2019; fees and disbursements, experts&#x2019; and other witnesses&#x2019; fees, incurred in contesting the validity or amount of any Taxes or in obtaining a refund of Taxes shall be considered as part of the Taxes for the year in which the expenses are incurred.&nbsp; For property tax purposes, to the extent allowed by Law, Tenant waives all rights to protest or appeal the appraised value of the Premises, as well as the Property, and all rights to receive notices of reappraisement.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Landlord may, in Landlord&#x2019;s commercially reasonable opinion, contest the real property Taxes assessed against the Building on an annual basis and, upon Tenant&#x2019;s request, Landlord and Tenant shall meet to discuss such contest and Landlord shall share such information that Landlord may have obtained relative to any recommendation from a tax consultant.&nbsp; All costs incurred by Landlord in seeking to obtain a real property Tax reduction shall be considered an Operating Expense.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OPERATING EXPENSES</font></b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">.&nbsp; Tenant shall pay monthly, as Additional Rent, one-twelfth (1/12) of Tenant&#x2019;s Percentage of annual Operating Expenses based on commercially reasonable estimates provided by Landlord on or about each January 1 during the term of this Lease and subject to reconciliation as provided in Section 8 below.&nbsp; &#8220;Operating Expenses&#8221; means </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">and includes, but is not limited to:&nbsp; (a) all expenses paid or incurred by Landlord for ownership, maintaining, operating and repairing the Property, and all other systems and components of the Building, its parking areas, the curbs, sidewalks and plazas adjoining the same, including, but not limited to, the cost of painting, cleaning, refurbishing, re-carpeting, redecorating, gardening, planting, seeding and maintenance of landscaped areas, trash removal, drain maintenance, assessments, expenses and contributions in connection with the City of Boca Raton&#x2019;s Transportation Demand Management Programs, security guard service and Building security access, exterior maintenance of the improvements, window cleaning, janitorial service, uniforms, management fees, supplies and sundries; (b) utility expenses incurred by Landlord in furnishing utility services for the Property, including the cost of electricity, gas or other fuel, heating, lighting, air conditioning, sewer and waste water service and general surface drainage; (c) those expenses paid or incurred by Landlord for insurance, including, but not limited to, fire, extended coverage, liability, workers compensation, elevator, or any other insurance carried in good faith by Landlord and applicable to the Property; (d) the cost of rental of all supplies, tools, materials and equipment, including expenses paid or incurred by Landlord for sales or use taxes on supplies or services; (e) the cost of wages and salaries of all persons engaged in the operation, maintenance and repair of the Property, and so-called fringe benefits, including social security taxes, unemployment insurance taxes, cost for providing coverage for disability benefits, cost of any pensions, hospitalization, welfare or retirement plans, or any other similar or like expenses incurred under the provisions of any collective bargaining agreement, or any other cost of expense which Landlord pays or incurs to provide benefits for employees so engaged in the operation, maintenance and repair of the Property; (f) the charges of any independent contractor who, under contract with Landlord or its representatives, does any of the work of operating, maintaining or repairing the Property, including without limitation, the charges for services, materials and supplies furnished in connection with the operation, maintenance or repair of any part of the Building or the heating, air conditioning, ventilating, plumbing, roofing, electrical, elevator, escalators, fire detection systems (including sprinklers) and other systems of the Building; (g) depreciation of hand tools and other moveable equipment used in the repair, maintenance or operation of the Property; (h) legal, accounting, and other professional expenses incurred in connection with the operation, maintenance and management of the Property, including, but not limited to, such expenses as relate to seeking refunds of or obtaining reductions in the taxes; (i) the costs of any capital improvement or alteration, together with any financing charges incurred in connection therewith, made to the Property which is either required by a change in or enactment of any new law (or governmental regulation) after the Effective Date or intended by Landlord to reduce operating costs or expenses, it being understood that such costs shall be amortized over their useful life as reasonable determined by Landlord; and (j) the cost of any other service provided by Landlord or any cost that is elsewhere stated in this Lease to be an &#8220;Operating Expense&#8221;.&nbsp; Landlord may allocate any item of Operating Expenses among different portions or occupants of the Building or Property based on use or other considerations as determined by Landlord in Landlord&#x2019;s reasonable discretion.&nbsp; <font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">If during any calendar year, any rentable space in the Building shall be vacant or unoccupied, at Landlord&#x2019;s option, the Operating Expense for such calendar year which vary with occupancy shall be adjusted to reflect the expenses that would have been incurred if such space had been occupied.&nbsp; If any Operating Expense, though paid in one (1) year, relates to more than one (1) calendar year, at the option of the Landlord such expense may be proportionately allocated among such related calendar years.&nbsp; </font></font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the foregoing, Operating Expenses shall not include:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(i)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp; &nbsp;&nbsp;</font>Ground lease rental payments;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(ii)&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; </font>Costs incurred by Landlord for the repair of damage to the Building to the extent that Landlord is reimbursed by insurance proceeds;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(iii)&nbsp; &nbsp; &nbsp; &nbsp;</font>Costs, including permit, license and inspection costs, incurred with respect to the installation of tenant improvements made for tenants or other occupants in the Building or incurred in renovating or otherwise improving, decorating, painting or redecorating vacant space for tenants or other occupants of the Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(iv)&nbsp;&nbsp;&nbsp; &nbsp; &nbsp; </font>Marketing costs including leasing commissions, attorneys&#x2019; fees in connection with the negotiation and preparation of letters, deal memos, letters of intent, leases, subleases and/or assignments, space planning costs, and other costs and expenses incurred in connection with lease, sublease and/or assignment negotiations and transactions or the enforcement of the terms of any leases or subleases with present or prospective tenants or other occupants of the Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Expenses in connection with services or other benefits which are not offered to Tenant or for which Tenant is charged for directly but which are provided to another tenant or occupant of the Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(vi)&nbsp; &nbsp; &nbsp;&nbsp; &nbsp;</font>Overhead and profit increment paid to Landlord or to subsidiaries or affiliates of Landlord for goods and/or services in the Building to the extent the same exceeds the costs of such goods and/or services rendered by unaffiliated third parties on a competitive basis;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(vii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Interest, principal, points and fees on debts or amortization on any mortgage or mortgages or any other debt instrument encumbering the Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(viii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Landlord&#x2019;s general corporate overhead and general and administrative expenses;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(ix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Any compensation paid to clerks, attendants or other persons in commercial concessions operated by Landlord;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(x)&nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp;</font>Advertising and promotional expenditures, and costs of signs in or on the building identifying the owner of the Building or other tenants&#x2019; signs, other than directional signs,&nbsp; the building directory and maintenance of the Building&#x2019;s monument sign;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Property management fees in excess of the rates then customarily charged for building management by property managers with equal or better qualifications for buildings of like class and character;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Penalties for the late payment of any taxes (provided that Tenant is not the cause of such late payment);</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xiii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Wages, cost, and salaries associated with home office, off-site employees of Landlord and wages, cost and salaries attributable to persons above the level of &#8220;General Manager&#x0094;;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xiv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The cost of separate metering and/or tap in charges for utilities for other tenants of Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The cost of correcting defects in the design or construction of or latent defects in the Premises or the Building, including repair or replacement of any item actually paid for or completed under a warranty, except that conditions (not occasioned by construction defects) resulting from ordinary wear and tear will not be deemed defects for the purpose of this category;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xvi)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Except as specifically permitted under this Lease, the cost of any repairs, alterations, additions, changes, replacements, and other items which under generally accepted accounting principles are properly classified as capital expenditures or capital improvements;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xvii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>The cost of tools and equipment used initially in the construction, of the Building;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xviii)&nbsp;&nbsp;&nbsp; </font>The cost of removal, abatement, or treatment of asbestos or any other hazardous substance, including any amounts expended by Landlord as environmental response costs for removal, enclosure, encapsulation, clean-up, remediation or other activities regarding Landlord&#x2019;s compliance with federal, state, municipal or local hazardous waste and environmental laws, regulations or ordinances;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xix)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Charitable and political contributions of Landlord; and</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Cost and maintenance of paintings, sculptures or other art work leased and/or purchased for display at the Building.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding anything to the contrary contained in this Section 7, Tenant&#x2019;s total Operating Expense payment obligations for all Operating Expenses other than security costs, insurance premiums, utilities, uninsured costs related to weather related events (but in no event more than $[***] per year), and real property taxes shall not increase by more than [***] percent ([***]%) (on a cumulative and compounded basis) over the sum paid by Tenant in the immediately preceding full calendar year.&nbsp; In the event that the immediately preceding calendar year is not a full calendar year, the Operating Expenses shall be equitably estimated so as to approximate the cost for a full calendar year.&nbsp; Any increases in Operating Expenses not recovered by Landlord due to the foregoing limitation may be carried forward into all succeeding calendar years during the Term (on a cumulative and compounded basis) until fully recouped by Landlord.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">8.&nbsp; &nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;RECONCILIATION</font></b></font><font style="font-size: 10pt; text-indent: 72pt;">.&nbsp; Landlord shall deliver to Tenant within one hundred twenty (120) days after the expiration of each calendar year a reasonably detailed statement (the &#8220;Statement&#8221;) showing Tenant&#x2019;s Percentage of the actual Operating Expenses incurred during such year.&nbsp; Except as otherwise set forth below, Landlord&#x2019;s failure to deliver the Statement to Tenant within said period shall not constitute Landlord&#x2019;s waiver of its right to collect said amounts or otherwise prejudice Landlord&#x2019;s rights hereunder.&nbsp; If Tenant&#x2019;s payments under this Section 8 during said year exceed Tenant&#x2019;s Percentage of Operating Expenses as indicated on the Statement (the &#8220;Operating Expense Overstatement&#8221;), Landlord shall credit the amount of such overpayment against such payment of Rent next falling due, or, if the Term will expire before the overpayment is fully credited, Landlord shall pay such difference to Tenant within [***] ([***]) days of the determination of such Operating Expense Overstatement.&nbsp; If Tenant&#x2019;s payments under this Section 7 during said year were less than Tenant&#x2019;s Percentage as indicated on the Statement, Tenant shall pay to Landlord the amount of the deficiency within [***] ([***]) days after delivery by Landlord to Tenant of the Statement. Landlord and Tenant shall forthwith adjust between them by cash payment any balance determined to exist with respect to that portion of the last year of the Lease Term for which Tenant is responsible for Operating Expenses, notwithstanding that the Lease Term may have terminated before the end of such year. The obligations set forth in this subsection shall survive the expiration, or earlier termination, of this Lease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Provided Tenant is not then in default beyond applicable notice and cure periods and has paid the Operating Expenses shown on the Statement, if Tenant disputes the amount set forth in the Statement, Tenant shall have the right, at Tenant&#x2019;s sole expense, not later than [***] ([***]) days following receipt of such Statement, to cause Landlord&#x2019;s books and records with respect to the calendar year which is the subject of the Statement to be audited by a certified public accountant mutually acceptable to Landlord and Tenant); provided, however, Landlord&#x2019;s approval shall not be unreasonably withheld, and the [***] ([***]) day period shall be tolled for the period during which Landlord is determining whether to approve such certified public accountant.&nbsp; The audit shall take place at the offices of Landlord where its books and records are located at a mutually convenient time during Landlord&#x2019;s regular business hours in Palm Beach County, Florida.&nbsp;&nbsp; The accountant conducting the audit shall be compensated on an hourly basis and shall not be compensated based upon a percentage of overcharges it discovers.&nbsp; If Tenant gives Landlord notice of its intention to audit Operating Expenses, it must commence such audit within [***] ([***]) days after such notice is delivered to Landlord, and the audit must be completed within [***] ([***]) days after such notice is delivered to Landlord.&nbsp; If Tenant does not commence and complete the audit within such periods, the Statement that Tenant elected to audit shall be deemed final and binding upon Tenant and shall, as between the parties, be conclusively deemed correct. Tenant will use good faith commercially reasonable efforts to keep the results of any Operating Expense audit confidential. Upon Landlord&#x2019;s receipt of a timely objection notice from Tenant, Landlord and Tenant shall work together in good faith to resolve the discrepancy between Landlord&#x2019;s statement and Tenant&#x2019;s review.&nbsp; If Landlord and Tenant determine that Operating Expenses for the year in question are less than reported in Landlord&#x2019;s statement, Landlord shall provide Tenant with a credit against future Rent in the amount of any overpayment by Tenant.&nbsp; Likewise, if Landlord and Tenant determine that Operating Expenses for the year in question are greater than reported in Landlord&#x2019;s statement, Tenant shall forthwith pay to Landlord the amount of underpayment by Tenant.&nbsp; If after Landlord and Tenant agree on the results of any audit of Landlord&#x2019;s books and records indicates that Landlord has made an error in Landlord&#x2019;s favor for more than [***] percent ([***]%) of the amount of Operating Expenses for any calendar year, Landlord shall reimburse Tenant for Tenant&#x2019;s reasonable costs of conducting the audit up to a maximum of $[***].&nbsp; In addition, Landlord shall pay to Tenant an amount equal to such overstated amounts, which sums shall be paid within [***] ([***]) days of Tenant&#x2019;s demand therefore.&nbsp; If such payment is not received by Tenant prior to the expiration of such [***] ([***]) day period, Tenant may withold such amount from future payments of Rent until such amount is reduced to 0.00.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding any provision in this Lease to the contrary, Landlord shall not be entitled to collect any charge or expense for Operating Expenses if Landlord has not presented Tenant with a billing within [***] ([***]) years after the date such charge or expense was incurred.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INSURANCE</font></b></font><font style="font-size: 10pt;">.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant shall maintain the following insurance in force from the date upon which Tenant first enters the Premises and throughout the Term and thereafter for so long as Tenant is in occupancy of any part of the Premises: </font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT STYLE="font-family: Times New Roman, Times, serif; font-size: 10pt">Commercial
General Liability insurance with limits of at least $[***] per occurrence, $[***] general aggregate, and, if the Tenant
manufacturers or produces a product, $[***] products completed operations aggregate or such larger amounts as Landlord may
reasonably require from time to time, covering bodily injury and property damage arising out of the use of the Premises, as
well as products/completed operations, blanket contractual liability, personal injury and advertising liability;</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Worker&#x2019;s Compensation insurance as required by the state in which the Premises is located covering occupational injuries or disease to all employees of Tenant and to any contractors, subcontractors or other agents used by Tenant for work or other activities on or about the Premises.&nbsp; If such insurance is not required by the state in which the Premises is located, then, and in any event, Tenant shall maintain such insurance with Employer&#x2019;s Liability limits of at least $[***] each accident, $[***] each employee, and $[***] disease;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Business Automobile Liability insurance for all owned (Symbol 1), non-owned (Symbol 9) hired, rented and/or borrowed (Symbol 8) vehicles used by the Tenant, its employees or agents.&nbsp; Such policy shall include a combined single limit of liability of at least $[***] per claim for bodily injury and property damage;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(iv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Excess or Umbrella Liability insurance with a limit of at least $[***] providing additional limits of insurance over the primary per occurrence and aggregate limits of the Commercial General Liability (including bodily injury, property damage, products/completed operations, personal/advertising injury and blanket contractual liability); and</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Property insurance covering &#8220;all risk&#8221; of physical damage to Tenant&#x2019;s personal property.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant&#x2019;s Commercial General Liability, Property, and Excess Liability/Umbrella Liability policies shall name Landlord and Landlord&#x2019;s managing agent and any mortgagee that Landlord has provided the name of to Tenant, as Additional Insureds and the Commercial General Liability and Excess Liability/Umbrella Liability shall be primary and non-contributory insurance as to any insurance carried by the parties designated as Additional Insureds.&nbsp; All policies purchased and maintained by Tenant to satisfy the requirements in this Lease must be purchased from an insurance company with a minimum rating of &#8220;A- X&#8221; or its equivalent from one of the major rating agencies (AM Best, Moodys, Standard &amp; Poors, Fitch) that is admitted or eligible to do business in the state where the Premises is located.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant shall provide Landlord with a certificate of insurance for each policy simultaneously with the delivery of an executed counterpart of this Lease and at least </font>[***] ([***]) days prior to each renewal of such insurance.&nbsp; Such certificates of insurance shall be on an ACORD Form 25 or ISO Form 2026 or their equivalent, shall certify that such policy has been or shall be issued and that it provides the coverage and limits required above, and shall provide that the insurance shall not be canceled or materially changed unless [***] ([***]) days prior written notice shall have been given to Landlord.&nbsp; Tenant shall notify Landlord in writing at least [***] ([***]) days in advance if Tenant intends to or receives a notice that its insurance company intends to cancel or non-renew such insurance for any reason, or if the required coverage or limits are to be materially changed from the initial requirements in this Lease.&nbsp; In the event that the applicable statutory time period is less than [***] ([***]) days, then Tenant shall notify Landlord within [***]&nbsp;</font><font style="font-size: 10pt;">(</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">[***]</font><font style="font-size: 10pt;">) business days of receipt of any cancellation or non-renew notice.&nbsp; In the event that Tenant fails to obtain or maintain the insurance required above or fails to provide the Certificates of Insurance required, Landlord may, at its option, after providing Tenant with written notice and a reasonable opportunity to cure, obtain such insurance on behalf of Tenant.&nbsp; Tenant shall pay, as Additional Rent within [***] ([***]) days after Landlord&#x2019;s written demand, the reasonable cost of such insurance.&nbsp; Landlord&#x2019;s failure to obtain such coverage on behalf of Tenant shall not limit Tenant&#x2019;s liability in the event of an uncovered loss.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(D)&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Landlord shall carry or cause to be carried property insurance for full replacement cost and commercial general liability insurance in amounts and with deductibles as a reasonably prudent owner of a building similar to the Building in the geographic vicinity of the Building (&#8220;Comparable Building&#8221;) would purchase and maintain with respect to the Property.&nbsp; Tenant shall pay Tenant&#x2019;s Percentage of Landlord&#x2019;s insurance premiums (&#8220;Insurance Premiums&#8221;) during the Term of the Lease as a part of Operating Expenses.&nbsp; If Tenant does conduct any activity within or about the Premises that result in an increase to the cost of Landlord&#x2019;s insurance Tenant shall reimburse Landlord for the entire amount of such additional premiums or surcharges </font>within [***] ([***]) days after Landlord&#x2019;s written demand.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(E)&nbsp; &nbsp;&nbsp; &nbsp;&nbsp;&nbsp;</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">The limits of insurance required by this Lease, or as carried by Tenant, will not limit the liability of Tenant or relieve Tenant of any obligation hereunder, except to the extent provided for under Section 10 below (Subrogation).&nbsp; Any deductibles selected by Tenant will be the sole responsibility of Tenant.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(F)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Landlord may, at its sole discretion, change the insurance policy limits and forms which are required to be provided by Tenant; such changes will be made to conform with common insurance requirements for Comparable Buildings if commercially reasonably available.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">10.&nbsp; &nbsp; &nbsp; &nbsp; WAIVER OF SUBROGATION</font></b></font><font style="font-size: 10pt;">.&nbsp; All provisions of this Lease to the contrary notwith&#173;standing, Landlord waives any and all rights of recovery against Tenant, Tenant&#x2019;s employees, agents and contractors for or arising out of damage to, or destruction of the Building, the Premises or Landlord&#x2019;s personal property to the extent that such damage or destruction is covered by Landlord&#x2019;s insurance policies then in effect or the insurance policies Landlord is required to obtain by Section&nbsp;9 (whether or not the insurance Landlord is required to obtain by Section&nbsp;9 is then in force and effect), whichever is broader.&nbsp; Landlord&#x2019;s waiver shall not be limited by the amount of insurance then carried by Landlord.&nbsp; All provisions of this Lease to the contrary notwithstanding, Tenant waives any and all rights of recovery against Landlord, Landlord&#x2019;s employees, agents and contractors for loss or damage to the Premises and Tenant&#x2019;s personal property to the extent such liability or damage is covered by Tenant&#x2019;s insurance policies then in force or the insurance policies Tenant is required to obtain by Section&nbsp;9 (whether or not the insurance Tenant is required to obtain by Section&nbsp;9 is then in force and effect), whichever is broader.&nbsp; Tenant&#x2019;s waiver shall not be limited by the amount of insurance then carried by Tenant.&nbsp; Each party shall cause the property insurance policies it obtains in accordance with Section&nbsp;9 to provide that the insurance company waives all right of recovery by subrogation against the other party in connection with any liability or damage covered by such insurance policies.&nbsp; If necessary to effect the foregoing waivers, Landlord and Tenant hereby agree to cause an endorsement to be issued to their respective insurance policies (including any contents, fire and casualty insurance) recognizing this waiver of subrogation;&nbsp;</font><font style="font-size: 10pt;">provided, however, that failure to obtain such endorsements shall not affect the releases hereinabove given.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SECURITY DEPOSIT</font></b></font><font style="font-size: 10pt;">.&nbsp; Upon execution of this Lease, Tenant shall deposit with Landlord the amount of the Security Deposit specified in Section 1 of this Lease.&nbsp; Provided that Tenant has paid all amounts due and has otherwise performed all obligations hereunder, the Security Deposit shall be returned to Tenant without interest within [***] ([***]) days of the expiration of the Term, further provided that Landlord may deduct from the Security Deposit prior to returning it any amounts owed by Tenant to Landlord.&nbsp; If Tenant defaults under any provision of this Lease, Landlord may, but shall not be obligated to, apply all or any part of the Security Deposit to cure the default.&nbsp; In the event Landlord elects to apply the Security Deposit as provided for above, Tenant shall, within [***] ([***]) business days after Landlord&#x2019;s demand, restore the Security Deposit to the original amount.&nbsp; Landlord may, at its discretion, commingle the Security Deposit with its other funds.&nbsp; Upon any sale or other conveyance of the Building, Landlord may transfer the Security Deposit (or any amount of the Security Deposit remaining) to a successor owner, and upon such successor&#x2019;s actual receipt of the Security Deposit (or any amount of the Security Deposit remaining) Tenant agrees to look solely to the successor owner for repayment of the same.&nbsp; The Security Deposit shall not operate as a limitation on any recovery to which Landlord may be entitled.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; USE</font></b></font><font style="font-size: 10pt;">.&nbsp; The Premises shall be used for the Permitted Use and for no other purposes whatsoever.&nbsp; Tenant shall not do or permit to be done in or about the Premises, Building or Property anything which is prohibited by any ordinance, order, rule, regulation, certificate of occupancy, or other governmental requirement, now in force or which may hereafter be enacted, including, without limitation, the Americans with Disabilities Act of 1990, as amended (collectively, &#8220;Applicable Law&#8221;).&nbsp; Tenant shall comply with all Applicable Law that applies to Tenant&#x2019;s use or occupation of the Premises and common areas of the Property.&nbsp; Tenant shall use and cause all contractors, agents, employees, invitees and visitors of Tenant to use the Premises and any common area of the Property in such a manner as to prevent waste, nuisance and any disruption of other occupants.&nbsp; Tenant shall not place a load upon any floor in the Premises exceeding the floor load per square foot of area which such floor was designed to carry or which is allowed by law.&nbsp; The judgment of any court of competent jurisdiction or the admission by Tenant in any action or proceeding against Tenant, whether Landlord is a party thereto or not, that Tenant has violated any Applicable Law in the use or occupancy of the Premises, Building or Property shall be conclusive of that fact as between Landlord and Tenant.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; MAINTENANCE; SERVICES</font></b></font><font style="font-size: 10pt;">.&nbsp; Excepting only those obligations for which Landlord is expressly responsible pursuant to this section, Tenant will, throughout the Term and at its sole cost, keep and maintain the interior of the Premises and all fixtures and equipment located therein, including, without limitation, carpeting, wall-covering, doors, plumbing and other fixtures, and any alterations performed for the benefit of the Premises, clean safe and in good working order, condition and repair and make all necessary repairs and replacements thereto, including, without limitation, replacing all interior broken glass with glass of the same size and quality as that broken and maintain all systems or portions of systems exclusively serving the Premises including, without limitation, electrical, mechanical, plumbing and heating, ventilating and air conditioning systems.&nbsp; All repairs and replacements required of Tenant in connection herewith shall be of a&nbsp;</font><font style="font-size: 10pt;">quality and class at least equal to the minimum building standards established by Landlord and shall be done in a good and workmanlike manner in compliance with all applicable laws and the terms and conditions of this Lease.&nbsp; If Tenant fails to maintain the Premises in compliance with the terms hereof, Landlord shall have the right after written notice to do such acts and expend such funds at the expense of Tenant as are reasonably required and Tenant shall reimburse Landlord for the cost thereof as Additional Rent within [***] ([***]) business days after written demand. </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">&nbsp;In the event Tenant shall request that it be allowed to consume, or actually does consume electrical services in excess of that so determined by Landlord to be reasonable for office use, Landlord may require that upgraded supply facilities, panels and/or sub-meters be installed at Tenant&#x2019;s expense.&nbsp; Tenant agrees not to connect with water pipes any apparatus using water without consent of Landlord.&nbsp; Tenant shall not be permitted to install any equipment causing a floor load in excess of </font><font style="font-size: 10pt;">eighty</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"> (</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">80</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">) pounds per square foot.&nbsp; Landlord&#x2019;s may, in its reasonable discretion, grant Tenant the right to exceed the floor loading capacity stated above in certain portions of the Building.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Should Tenant require any additional service not provided by Landlord pursuant to this Lease, Landlord shall reasonably cooperate with Tenant to obtain such additional service and Tenant agrees to pay Landlord&#x2019;s charges therefor, including a reasonable administrative fee, any taxes imposed thereon, and, where appropriate, a reasonable allowance for depreciation of any systems being used to provide such service, as Additional Rent within [***] ([***]) days after Landlord&#x2019;s written demand.&nbsp; Landlord will provide afterhours HVAC upon Tenant&#x2019;s request subject to limitations due to reasonable maintenance and repair on such systems and Force Majeure.&nbsp; The current charge for after-hours HVAC usage is $[***] per hour, subject to adjustment from time to time by Landlord but not more than [***]% per year, on a cumulative and compounded basis.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">If there is a tenant in the Building that will consume electricity materially beyond that of a typical office tenant, Landlord shall equitably allocate the total cost of electricity for the Building to all tenants and shall require the tenant that is consuming electricity materially beyond that of a typical office tenant to pay an increase in its electricity costs.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">If the Premises contains supplemental HVAC equipment which is sub metered, Tenant shall be responsible to pay the cost for the same.&nbsp; During the Term, Tenant shall be solely responsible for maintaining any supplemental HVAC equipment in good condition and repair at Tenant&#x2019;s sole cost and expense, and Tenant shall reimburse Landlord for all electricity consumed by the supplemental HVAC equipment, as Additional Rent, within [***] ([***]) days after Tenant&#x2019;s receipt of Landlord&#x2019;s invoice for same.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Landlord shall maintain the roof, foundation, exterior walls, structural portions of the Building, elevators, if any, any Common Areas and electrical, plumbing, mechanical and fire protection systems (subject to systems exclusive to the Premises such as dishwashers) of the Building, the cost of which shall be included as a part of Operating Expenses, provided that Landlord shall have no obligation to make any repairs unless Landlord has first received written notice of the need for such repairs from Tenant.&nbsp; Notwithstanding the foregoing and subject to the terms herein, any damage to the Property occasioned by the negligence or willful act of Tenant or any person claiming under Tenant, or contractors, agents, employees, invitees or visitors of Tenant or any such person, shall be repaired by and at the sole expense of Tenant, except that Landlord shall have the right, at its sole option, to make such repairs and to charge Tenant for all costs and expenses incurred in connection therewith and Tenant shall pay the cost therefor as Additional Rent within&nbsp;</font><font style="font-size: 10pt;">[***] ([***]) days after Landlord&#x2019;s written demand.&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Landlord shall not be responsible to maintain any additional air conditioning equipment particular to the Premises, such as air conditioning units located in a computer room or other utility area, or for any plumbing particular to the Premises, such as a break room or restroom located within the Premises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">In addition to the foregoing, during normal hours of operation of the Building throughout the Term, Landlord shall provide: (i) reasonable quantities of electricity for the common areas; (ii) electricity for Tenant&#x2019;s normal office use; (iii) heating, ventilation and air conditioning as required in Landlord&#x2019;s reasonable judgment for the comfortable use and occupancy of the Premises during the normal hours of operation of the Building; (iv) building standard window washing and janitorial services; (v) water for drinking, cleaning and restroom purposes only, and (vi) such other services as Landlord reasonably determines are necessary or appropriate.&nbsp; The normal hours of operation of the Building shall be 8:00 a.m. to 6:00 p.m. on Monday through Friday (except holidays) and 9:00 a.m. to 1:00 p.m. on Saturday (except holidays).&nbsp; Upon Tenant&#x2019;s request, Landlord shall replace Building standard bulbs and ballasts in the Premises (to be included in Operating Expenses).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBLEASE; ASSIGNMENT</font></b></font><font style="font-size: 10pt;">.&nbsp; Tenant shall not mortgage, pledge, hypothecate or otherwise encumber its interest in this Lease without Landlord&#x2019;s consent, which will not be unreasonably withheld, conditional or delayed.&nbsp; Except in connection with a Permitted Transfer (as hereinafter defined), Tenant shall not allow the Premises to be occupied, in whole or in part, by any other party and shall neither sublet the Premises, in whole or in part, nor assign this Lease, nor amend any sublease or assignment to which Landlord has consented, without in each case obtaining the prior written consent of Landlord.&nbsp; Any sublease or assignment, or amendment to any sublease or assignment, without Landlord&#x2019;s prior written consent shall, at Landlord&#x2019;s option, be null, void and of no effect, and shall, at Landlord&#x2019;s option, constitute an Event of Default.&nbsp; Except in connection with a Permitted Transfer, the provisions of this section shall apply to a transfer, by one or more transfers, of all, or substantially all, of the business or assets of Tenant, of a majority of the stock, partnership or membership interests, or other evidences of ownership, of Tenant, and of any shares, voting rights or ownership interests of Tenant which results in a change in the identity of the entity or entities which exercise, or may exercise, effective control of Tenant as if such transfers were an assignment of this Lease.&nbsp; Tenant must request Landlord&#x2019;s consent to any assignment or sublease at least [***] ([***]) days prior to the proposed effective date of the assignment or sublease.&nbsp; At the time of its request, Tenant shall provide Landlord in writing: (a) the name and address of the proposed assignee or subtenant, (b) a complete copy of the proposed assignment or sublease, (c) reasonably satisfactory information about the nature, business, and business history of the proposed assignee or subtenant and its proposed use of the Premises, and (d) banking, financial or other credit information about the proposed assignee or subtenant sufficient to enable Landlord to determine its financial condition and operating performance.&nbsp; Concurrently with such request, Tenant shall pay to Landlord a fee of $[***] to defray Landlord&#x2019;s expenses in reviewing such request.&nbsp; Landlord shall not unreasonably withhold or delay its consent to Tenant&#x2019;s written request to sublease the Premises or assign this Lease which is made in compliance with the terms and conditions of this section.&nbsp; Without limiting the other instances in which it may be reasonable for Landlord to withhold its consent to an assignment or sublease, Landlord&#x2019;s refusal to consent to any proposed assignment or sublease shall not be unreasonable if:&nbsp; (a) the financial condition or operating performance of the proposed subtenant or assignee,&nbsp;</font><font style="font-size: 10pt;">determined in Landlord&#x2019;s reasonable discretion does not meet Landlord&#x2019;s then existing Leasing criteria, (b) Tenant is in default under any of the terms, covenants or conditions of this Lease beyond applicable notice and cure periods, (c) the proposed use of the Premises may result in increased wear and tear on the Premises or the Building, (d) the proposed subtenant or assignee is a governmental agency, (e) Landlord has comparable space available elsewhere in the Building which can accommodate the needs of the proposed subtenant or assignee or the proposed subtenant and the assignee is a prospect to whom Landlord has made a proposal for the lease of space within the Building within the prior [***] ([***]) months, (f) the proposed subtenant or assignee would cause Landlord to be in violation of any covenant or restriction contained in another lease or other agreement, or (h) Landlord&#x2019;s lender, if any, does not consent to the proposed sublease or assignment.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">No subletting or assignment shall release Tenant from Tenant&#x2019;s obligations under this Lease or alter the primary liability of Tenant to pay the Rent and to perform all other obligations to be performed by Tenant hereunder.&nbsp; Any subtenant shall, at Landlord&#x2019;s election, attorn to Landlord following any early termination of this Lease and any assignee shall be jointly and severally liable for the full performance of all of Tenant&#x2019;s obligations hereunder.&nbsp; Landlord may require, as a condition to granting Landlord&#x2019;s consent with respect to the provisions of this section, that the proposed subtenant or assignee enter into a written agreement with Landlord confirming the obligations of such subtenant or assignee under this Lease.&nbsp; If Tenant receives rent or other payments under any assignment or sublease in excess of the payments made by Tenant to Landlord under this Lease (as such amounts are adjusted on a per square foot basis if less than all of the Premises is transferred), then Tenant shall pay Landlord [***] ([***]%) of such excess after first deducing the reasonable and customary third party costs incurred by Tenant to effectuate the transfer.&nbsp; Landlord&#x2019;s consent to one assignment or sublease shall not be deemed a waiver of the requirement of Landlord&#x2019;s consent to any subsequent assignment or sublease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding anything to the contrary contained in this Section 14, provided Tenant is not in default beyond applicable notice and cure periods, Tenant may assign this Lease or sublet the Premises (or a portion thereof) in connection with any of the following without the prior written consent of Landlord (and without being required to pay any excess rents to Landlord), each a &#8220;Permitted Transfer&#8221; to an entity (each a &#8220;Permitted Transferee&#8221;) in connection with: (i) a sale of all or substantially all of Tenant&#x2019;s assets or stock to an unrelated entity, (ii) any merger, consolidation, reorganization or similar transaction, (iii) any assignment or sublease to an Affiliate, or (iv) any transfer of stock whenever Tenant is a corporation, the outstanding stock of which is listed on a recognized national stock exchange.&nbsp; The term &#8220;Affiliate&#8221; as used in this Section 14, shall mean any person or entity that is, directly or indirectly, controlled by, under common control with, or controlling, another person or entity.&nbsp; Tenant acknowledges and agrees that any such assignment or sublease shall not release Tenant from Tenant&#x2019;s obligations hereunder or alter the primary liability of Tenant to pay the Rent and other sums due Landlord hereunder and to perform all other obligations to be performed by Tenant hereunder.&nbsp; In such event, Tenant must give Landlord at least [***] ([***]) days prior written notice with respect to any such Permitted Transfer.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INDEMNITY; NON-LIABILITY OF LANDLORD</font></b></font><font style="font-size: 10pt;">.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Subject to the terms of Section 10 hereof, and except to the extent caused by the negligence or willful misconduct of an Indemnified Party, Tenant hereby agrees to indemnify, defend and hold harmless Landlord and its employees, partners, agents, members, managers, lenders and ground lessors (said persons and entities are hereinafter collectively referred to as the &#8220;Indemnified Parties&#8221;) from and against any and all liability, loss, cost, damage, claims, loss of rents, liens, judgments, penalties, fines, settlement costs, investigation costs, the reasonable cost of consultants and experts, reasonable attorneys&#x2019; fees, court costs and other legal expenses,&nbsp; insurance policy deductibles and other reasonable expenses (hereinafter collectively referred to as &#8220;Damages&#8221;) arising out of or related to an &#8220;Indemnified Matter&#8221; (as defined below).&nbsp; For purposes of this Section 15, an &#8220;Indemnified Matter&#8221; shall mean any matter for which one or more of the Indemnified Parties incurs liability or Damages if the liability or Damages are caused by (a) any negligent act or omission or willful misconduct of Tenant or its employees, agents, assignees, subtenants, licensees, contractors or invitees (all of said persons or entities are hereinafter collectively referred to as &#8220;Tenant Parties&#8221;), (b) Tenant&#x2019;s failure to perform any of its obligations under the Lease (which failure continues after the passage of any applicable notice and cure period under the Lease), (c) the use or occupancy of the Premises by Tenant or any person claiming under Tenant, and/or (d) any other matters for which Tenant has agreed to indemnify Landlord pursuant to any other provision of this Lease.&nbsp; Tenant&#x2019;s obligations hereunder shall include, but shall not be limited to, compensating the Indemnified Parties for Damages arising out of Indemnified Matters within [***] ([***]) days after written demand from an Indemnified Party plus a reasonable period of time for Tenant&#x2019;s investigation of the claim.&nbsp; Tenant shall also defend, with counsel reasonably satisfactory to the Indemnified Party, at Tenant&#x2019;s sole expense, within [***] ([***]) days after written demand from the Indemnified Party, plus a reasonable period of time for Tenant&#x2019;s investigation of the claim, any claims, action or proceeding arising out of or relating to an Indemnified Matter whether or not litigated or reduced to judgment and whether or not well founded.&nbsp; This indemnity is intended to apply to the fullest extent permitted by applicable law.&nbsp; Tenant&#x2019;s obligations under this Section shall survive the expiration or termination of this Lease unless specifically waived in writing by Landlord after said expiration or termination.&nbsp; Except in connection with liabilities, obligations, and claims pursuant to Sections 17 and 28 herein, Landlord hereby waives its right to recover consequential, special, indirect, exemplary or punitive damages (including but not limited to, lost profits) arising out of an Indemnified Matter.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Subject to the terms of Section 10, and except to the extent caused by the negligence or willful misconduct of a Tenant Indemnified Party, Landlord hereby agrees to indemnify, defend and hold harmless Tenant and its employees, affiliates and agents (said persons and entities are hereinafter collectively referred to as the &#8220;Tenant Indemnified Parties&#8221;) from and against any and all Damages that result from (i) the negligence or intentional misconduct of Landlord its employees and its authorized representatives (ii) Landlord&#x2019;s failure to perform any of its obligations under the Lease (which failure continues after the passage of any applicable notice and cure period under the Lease), and (iii) any other matters for which Landlord has agreed to indemnify Tenant pursuant to any other provision of this Lease (a &#8220;Tenant Indemnified Matter&#8221;).&nbsp; Landlord&#x2019;s obligations hereunder shall include, but shall not be limited to (a) compensating the Tenant Indemnified Parties for Damages arising out of Tenant Indemnified Matters within [***] ([***]) days after written demand from a Tenant Indemnified Party plus a reasonable period of time for Landlord&#x2019;s investigation of the claim and (b) providing a defense, with counsel reasonably satisfactory to the Tenant Indemnified Party, at Landlord&#x2019;s sole expense, within [***] ([***]) days&nbsp;</font><font style="font-size: 10pt;">after written demand from the Tenant Indemnified Party plus a reasonable period of time for Landlord&#x2019;s investigation of the claim, of any claims, action or proceeding arising out of or relating to an Tenant Indemnified Matter. This indemnity is intended to apply to the fullest extent permitted by applicable law. Landlord&#x2019;s obligations under this section shall survive the expiration or termination of this Lease unless specifically waived in writing by Tenant after said expiration or termination.&nbsp; Tenant hereby waives its right to recover consequential, special, indirect, exemplary or punitive damages (including but not limited to, lost profits) arising out of a Tenant Indemnified Matter.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UTILITIES</font></b></font><font style="font-size: 10pt;">.&nbsp; Tenant shall contract directly with public utility providers for all utilities which are separately metered to the Premises and shall pay such utility providers directly and promptly when due.&nbsp; If any utility is not separately metered to the Premises, the cost of such utility consumed on the Premises, as reasonably determined by Landlord, shall be paid by Tenant as a part of Operating Expenses.&nbsp; Tenant&#x2019;s obligation to pay for utilities provided to the Premises during the Term shall survive the expiration or earlier termination of the Lease.&nbsp; Tenant shall not utilize an alternative provider for a utility service other than the public utility provider servicing the Property unless Tenant shall first obtain the written consent of Landlord.&nbsp; Landlord shall not be liable or responsible for any loss, damage, or expense that Tenant may sustain or incur by reason of any change, failure, interruption, or defect in the supply or character of the electric energy furnished to the Premises or Building by the applicable utility provider.&nbsp; To ensure the proper functioning and protection of all utilities, Tenant agrees to abide by all reasonable regulations and requirements which Landlord may prescribe and to allow Landlord and its utility providers&#x2019; access to all electric lines, feeders, risers, and wiring within the Premises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the provisions of this Section 16, in the event the Building experiences an interruption of electrical, telephone, HVAC or water service, which in any such case prevents Tenant from utilizing the Premises (or portion thereof) to conduct its business (a &#8220;Service Failure&#8221;) which Service Failure is due to Landlord&#x2019;s actions (i.e. not as a result of the inability of Landlord to obtain the applicable utility service through no fault of Landlord (a &#8220;Controllable Service Failure&#8221;), Landlord shall commence and diligently pursue the curative action within a commercially reasonable amount of time after written notice from Tenant of a Controllable Service Failure.&nbsp; Notwithstanding the foregoing, if Tenant does not conduct business in the Premises (or portion thereof) as a result of a Controllable Service Failure, Tenant shall be entitled to an equitable abatement of Rent (in proportion to the portion of the Premises subject to the Service Failure) with respect to a Controllable Service Failure commencing with the [***] ([***]) consecutive business day after Tenant&#x2019;s notice to Landlord of the Controllable Service Failure until such time as the services are restored and/or the applicable repair is made, as the case may be.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">17.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; HOLDING OVER</font></b></font><font style="font-size: 10pt;">.&nbsp; If Tenant or any party claiming by or under Tenant remains in occupancy of the Premises or any part thereof beyond the expiration or earlier termination of this Lease, such holding over shall be without right and a tenancy at sufferance, and Tenant shall be liable to Landlord for any actual loss or damage incurred by Landlord as a result thereof, including consequential damages, provided that in the case of consequential damages Landlord has first provided Tenant with at least [***] ([***]) days prior written notice that Landlord is obligated to deliver the space to a bona fide new tenant and that Landlord&#x2019;s failure to deliver the space to such new tenant could result in consequential damages.&nbsp; In addition, for each month or any part thereof that such holding over continues, Tenant shall pay to Landlord a monthly fee for the use and occupancy of the Premises equal to [***] percent ([***]%) of the Base Rent payable for the month immediately preceding such hold over, plus all Additional Rent due hereunder and there shall be no adjustment or abatement for any partial month.&nbsp; The provisions of this section shall not be deemed to limit or exclude any of Landlord&#x2019;s rights of re-entry or any other right granted to Landlord hereunder, at law or in equity.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">18.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NO RENT DEDUCTION OR SET OFF</font></b></font><font style="font-size: 10pt;">.&nbsp; Tenant&#x2019;s covenant to pay Rent is and shall be independent of each and every other covenant of this Lease.&nbsp; Tenant agrees that any claim by Tenant against Landlord shall not be deducted from Rent nor set off against any claim for Rent in any action except as expressly permitted under this Lease.&nbsp; No payment by Tenant or receipt by Landlord of a lesser amount than the Rent herein stipulated shall be deemed to be other than on account of the earliest stipulated Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord&#x2019;s right to recover the balance of such Rent or pursue any remedy provided in this Lease or at law.&nbsp; In connection with the foregoing, Landlord shall have the absolute right in its sole discretion to apply any payment received from Tenant to any account or other payment of Tenant then not current and due or delinquent.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">19.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CASUALTY</font></b></font><font style="font-size: 10pt;">.&nbsp; If the Premises or any part thereof are damaged by fire or other casualty, Tenant shall give prompt notice thereof to Landlord.&nbsp; If the Premises or the Building are totally or partially damaged or destroyed by fire or other casualty, thereby rendering the Premises totally or partially inaccessible or unusable, Landlord shall diligently restore and repair the Premises and the Building to substantially the same condition they were in prior to such damage.&nbsp; Until the repair and restoration of the Premises is completed, Rent shall be abated for that part of the Premises that Tenant is unable to use and is not occupied while repairs are being made, based on the ratio that the amount of unusable rentable area bears to the total rentable area of the Premises.&nbsp; Landlord shall bear the costs and expenses of repairing and restoring the Premises and the Building, provided, however, that Landlord shall not be obligated to spend more than the net proceeds of insurance proceeds made available for such repair and restoration nor shall Landlord be obligated to repair or restore, or to pay for the repair or restoration of, any furnishings, equipment or personal property belonging to Tenant.&nbsp; It shall be Tenant&#x2019;s sole responsibility to repair and restore all such items.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the foregoing, (a) if there is a destruction of the Building that exceeds [***] percent ([***]%) of the replacement value of the Building from any risk, whether or not the Premises are damaged or destroyed, or (b) if Landlord reasonably believes that the repairs and restoration cannot be completed despite reasonable efforts within [***] ([***]) days after the occurrence of such damage, or (c) if Landlord reasonably believes that there shall be less than [***] ([***]) year remaining in the Term (exclusive of any extension options) upon the substantial completion of such repairs and restoration, or (d) if any mortgagee or lender fails or refuses to make sufficient insurance proceeds available for repairs and restoration, or (e) if zoning or other applicable laws or regulations do not permit such repairs and restoration, Landlord shall have the right, at its sole option, to terminate this Lease by giving written notice of termination to Tenant within [***] ([***]) days after the occurrence of such damage.&nbsp; If this Lease is terminated pursuant&nbsp;</font><font style="font-size: 10pt;">to the preceding sentence, all Rent payable hereunder shall be apportioned and paid to the date Tenant was unable to occupy and ceased operations in the Premises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">Notwithstanding the foregoing, (a) if there is a destruction of the Building that exceeds [***] percent ([***]%) of the replacement value of the Building from any risk, and Tenant&#x2019;s use of the Premises or the Common Areas are materially adversely impacted, or (b) if Landlord reasonably believes that the repairs and restoration cannot be completed despite reasonable efforts within [***] ([***]) days after the occurrence of such damage, and Tenant&#x2019;s use of the Premises or the Common Areas are materially adversely impacted, or (c) if Landlord reasonably believes that there shall be less than [***] remaining in the Term (exclusive of any extension options) upon the substantial completion of such repairs and restoration, and Tenant&#x2019;s use of the Premises or the Common Areas are materially adversely impacted, or (d) if the Premises or Common Areas are damaged or destroyed and any mortgagee or lender fails or refuses to make sufficient insurance proceeds available for repairs and restoration, or (e) if zoning or other applicable laws or regulations do not permit such repairs and restoration, then Tenant shall have the right, at its sole option, to terminate this Lease by giving written notice of termination to Landlord within [***] ([***]) days after the occurrence of such damage.&nbsp; If this Lease is terminated pursuant to the preceding sentence, all Rent payable hereunder shall be apportioned and paid to the date Tenant was unable to occupy and ceased operations in the Premises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">If neither party elects to terminate this Lease and Landlord commences to restore the Building but does not substantially complete the repair and restoration of the Building within [***] ([***]) days following the date of casualty, then Tenant may terminate this Lease upon written notice to Landlord as of the end of such [***] ([***]) day period by providing written notice to Landlord, such termination to be effective [***] ([***]) days after notice from Tenant is received by Landlord, unless Landlord substantially completes the repairs within such [***] ([***]) day period upon which the Tenant&#x2019;s termination shall be vitiated and the Lease shall continue in full force and effect.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">In the event of any damage or destruction to the Building or Premises, it shall be Tenant&#x2019;s responsibility to secure the Premises and, upon notice from Landlord, to remove forthwith, at its sole cost and expense, property belonging to Tenant or its licensees from such portion of the Premises as Landlord shall request.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">20.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBORDINATION; ESTOPPEL LETTERS</font></b></font><font style="font-size: 10pt;">.&nbsp; This Lease is expressly subject and subordinate to any current or future mortgage or mortgages placed on the Property and to all other documents executed in connection with any such mortgage.&nbsp; Tenant agrees that from time to time it shall deliver to Landlord or Landlord&#x2019;s mortgagee or designee within ten (10) business days of the date of Landlord&#x2019;s or Landlord&#x2019;s mortgagees or such other designee&#x2019;s request, a statement, in writing, certifying (i) that this Lease is unmodified and in full force and effect, if this is so, or if there have been modifications, that the Lease, as modified, is in full force and effect; (ii) the dates to which Rent and other charges have been paid; (iii) that Landlord is not in default under any provisions of this Lease or, if in default, the nature thereof in detail; and (iv) such other true statements as Landlord or Landlord&#x2019;s mortgagee or designee may reasonable require.&nbsp; Tenant&#x2019;s failure to execute and deliver such statements within the time required shall, at Landlord&#x2019;s election, be an Event of Default and shall also be conclusive upon Tenant that (a) this Lease is in&nbsp;</font><font style="font-size: 10pt;">full force and effect and has not been modified except as represented by Landlord; (b) that Landlord is not in default under any provisions of this Lease and that Tenant has no right of offset, counterclaim or deduction against Rent.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><FONT STYLE="font-family: Times New Roman, Times, serif; font-size: 10pt">Notwitstanding
the foregoing, Landlord will obtain a subordination, non-disturbance and attornment agreement in the form attached hereto as <B>Exhibit&nbsp;H
</B>(the &#8220;SNDA&#8221;) executed by Landlord and the current mortgagee, and Tenant shall execute and deliver such SNDA concurrently
with Tenant&#x2019;s execution and delivery of this Lease and until the Full Premises Commencement Date, Landlord shall obtain
a subordination/non-disturbance and attornment agreement from any future mortgagee on such mortgagee&#x2019;s standard form, subject
to Tenant&#x2019;s reasonable comments.&nbsp; After the occurrence of the Full Premises Commencement Date and upon Tenant&#x2019;s
request, Landlord agrees to use reasonable efforts to have any mortgagee of the Property enter into its usual subordination, non-disturbance
agreement with Tenant provided that Tenant is not then in default under this Lease.</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">21.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ALTERATIONS; RESTORATION</font></b></font><font style="font-size: 10pt;">.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(A)&nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant shall not make or permit to be made any alterations, additions, or improvements in or to the Premises (&#8220;Alterations&#8221;) without first obtaining the prior written consent of Landlord which consent shall not be unreasonably withheld, conditioned or delayed, provided any Alterations that may impact the structural portions of the Building or any mechanical systems shall be in Landlord&#x2019;s sole discretion.&nbsp; All Alterations (i) must comply with all applicable laws, (ii) must be compatible with the Building and its mechanical, electrical, heating, ventilating, air-conditioning and life safety systems; (iii) must not interfere with the use and occupancy of any other portion of the Building by any other tenant or their invitees; and (iv) must not affect the integrity of the structural portions of the Building. &nbsp;In addition, Landlord may impose as a condition to such consent such additional requirements as Landlord in its sole discretion deems necessary or desirable, including, without limitation:&nbsp; (a) Tenant&#x2019;s submission to Landlord, for Landlord&#x2019;s prior written approval, of all plans and specifications relating to the Alterations; (b) Landlord&#x2019;s prior written approval of the time or times when the Alterations are to be performed; (c) Landlord&#x2019;s prior written approval of the contractors and subcontractors performing work in connection with the Alterations; (d) Tenant&#x2019;s receipt of all necessary permits and approvals from all governmental authorities having jurisdiction over the Premises prior to the construction of the Alterations; (e) Tenant&#x2019;s delivery to Landlord of such bonds and insurance as Landlord customarily requires; (f) Tenant&#x2019;s payment to Landlord of a commercially reasonable fee for Landlord&#x2019;s supervision of any Alterations; (g) Tenant&#x2019;s and Tenant&#x2019;s contractor&#x2019;s compliance with such construction rules and regulations and building standards as Landlord promulgates from time to time; and (h) Tenant&#x2019;s delivery to Landlord of &#8220;as built&#8221; drawings of the Alterations in such form or medium as Landlord may reasonably require.&nbsp; All direct and indirect costs relating to any modifications, alterations or improvements of Building, whether outside or inside of the Premises, required by any governmental agency or by law as a condition or as the result of any Alteration requested or effected by Tenant shall be borne by Tenant.&nbsp; Tenant shall not permit any mechanic&#x2019;s lien or other liens to be placed upon the Premises or the Building as a result of any materials, services or labor ordered by or provided to Tenant or any of Tenant&#x2019;s agents, officers, or employees.&nbsp; Without waiving any other rights or remedies under this Lease, Landlord may bond or insure or otherwise discharge any such lien and Tenant shall reimburse Landlord for any amount&nbsp;</font></font><font style="font-size: 10pt;">paid by Landlord in connection therewith as Additional Rent </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">within [***] ([***]) days after Landlord&#x2019;s written demand</font><font style="font-size: 10pt;">.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Upon the expiration or earlier termination of the Lease, Tenant shall surrender the Premises in good working order and condition, reasonable wear and tear and damage by casualty or condemnation excepted.&nbsp; Tenant shall remove any trade fixtures, equipment, data/telecommunica&#173;tions cabling and wiring installed by or on behalf of Tenant and furniture from the Premises and Tenant shall fully repair any damage, including any structural damage, occasioned by the removal of the same.&nbsp; Notwithstanding the foregoing, Landlord may require that Tenant not remove any or all Alterations and any such Alteration or Alterations shall become a part of the realty and shall belong to Landlord without compensation, and title thereto shall pass to Landlord under this Lease as by a bill of sale.&nbsp; At the time Tenant requests approval for an Alteration, Tenant may request that Landlord also provide consent for such Alteration to remain upon expiration of the Term, with Landlord not to unreasonably withhold consent thereto, and if Landlord consents (i) to the Alteration, and (ii) for the Alteration to remain, Tenant shall not be required to remove the Alteration in accordance with the terms of the Lease upon expiration of the Term.&nbsp; At Landlord&#x2019;s election, all Alterations, trade fixtures, equipment, wire and cable, furniture, fixtures, other personal property not removed shall conclusively be deemed to have been abandoned by Tenant and may be appropriated, sold, stored, destroyed or otherwise disposed of by Landlord without notice to Tenant or to any other person and without obligation to account for them.&nbsp; Tenant shall pay Landlord all reasonable expenses incurred in connection with Landlord&#x2019;s disposition of such property, including without limitation the cost of repairing any damage to the Building or the Premises caused by removal of such property, and shall hold Landlord harmless from loss, liability, or expense arising from the claims of third parties such as Tenant&#x2019;s lenders whose loans are secured by such property.&nbsp; Tenant&#x2019;s obligations under this section shall survive the end of this Lease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">The interest of Landlord in the Premises shall not be subject in any way to any liens, including construction liens, for improvements to or other work performed in the Premises by or on behalf of Tenant.&nbsp; Tenant shall have no power or authority to create any lien or permit any lien to attach to the present estate, reversion, or other estate of Landlord in the Premises or in the Property and all mechanics, materialmen, contractors, artisans, and other parties contracting with Tenant or its representatives or privies as to the Premises or any part of the Premises are charged with notice that they must look to Tenant to secure payment of any bill for work done or material furnished or for any other purpose during the Lease term.&nbsp; These provisions are made with express reference to Section 713.10, Florida Statutes.&nbsp; Landlord and Tenant acknowledge and agree that there is no requirement under this Lease that Tenant make any alterations or improvements to the Premises.&nbsp; Tenant shall notify every contractor making improvements to the Premises that the interest of Landlord in the Premises shall not be subject to liens for improvements to or other work performed in the Premises by or on behalf of Tenant.&nbsp; In the event that a construction claim of lien is filed against the Property in connection with any work performed by or on behalf of Tenant, Tenant shall satisfy such claim, or shall transfer same to security, within </font>[***]<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"> ([***]) business days from the date that Tenant becomes aware of the same.&nbsp; In the event that Tenant fails to satisfy or transfer such claim within said [***] ([***]) business day period, Landlord may do so and thereafter charge Tenant, as Additional Rent, all costs incurred by Landlord in connection with the satisfaction or transfer of such claim, including attorneys&#x2019; fees.&nbsp; Further, Tenant agrees to&nbsp;</font></font><font style="font-size: 10pt;">indemnify, defend and save Landlord harmless from and against any damage or loss incurred by Landlord as a result of any such claim or lien.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">If so requested by Landlord, Tenant shall execute a short form or memorandum of this Lease, which may, in Landlord&#x2019;s discretion be recorded in the Public Records for the purpose or protecting Landlord&#x2019;s estate from construction claims of lien, as provided in Florida Statutes, Chapter 713.10.&nbsp; No other memorandum of this Lease, nor this Lease itself shall be recordable in the public records of any county within the State of Florida without Landlord&#x2019;s written consent and joinder, which may be arbitrarily withheld by Landlord in its sole discretion.&nbsp; In the event such short form of Memorandum of Lease is executed, Tenant shall simultaneously execute and deliver to Landlord an instrument terminating Tenant&#x2019;s interest in the real property upon which the Premises are located, which instrument may be recorded by Landlord at the expiration of the term of this Lease, or such earlier termination hereof.&nbsp; The Security Deposit paid by Tenant may be used by Landlord for the transfer of any claim of lien, as provided in this Section.&nbsp; This Section shall survive the termination of this Lease.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Notwithstanding the foregoing to the contrary, during the Term of this Lease, Tenant shall be permitted, with prior written notice to Landlord, but without Landlord&#x2019;s prior written consent, to make non-structural interior alterations to the Premises costing in the aggregate not more than <font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">[***]</font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"> Dollars ($</font>[***]<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">) in any </font>[***]<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"> (</font>[***]<font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">) month period, provided that such alterations (i) are not structural, (ii) do not affect the use or proper strengthening of any utilities, building systems, or other tenant spaces, (iii) are not visible from outside the Premises, (iv) do not include the penetration of the roof, and/or (v) do not require building permits.</font></font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">22.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; DEFAULT; REMEDIES</font></b></font><font style="font-size: 10pt;">.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">In addition to any other acts or omissions designated in this Lease as Events of Default, each of the following shall constitute an Event of Default by Tenant hereunder:&nbsp; (i) the failure to make any payment of Rent, Additional Rent or any installment thereof or to pay any other sum required to be paid by Tenant under this Lease within </font>[***] ([***]) days after written notice for Landlord that such sum is due; (ii) the use or occupancy of the Premises for any purpose other than the Permitted Use without Landlord&#x2019;s prior written consent or the conduct of any activity in the Premises which constitutes a violation of law; (iii) if the interest of Tenant or any part thereof under this Lease shall be levied on under execution or other legal process and said interest shall not have been cleared by said levy or execution within [***] ([***]) days from the date thereof; (iv) if any voluntary or involuntary petition in bankruptcy or for corporate reorganization or any similar relief shall be filed by or against Tenant or any guarantor of the Lease or if a receiver shall be appointed for Tenant or any guarantor or any of the property of Tenant or guarantor; (v) if Tenant or any guarantor of the Lease shall make an assignment for the benefit of creditors or if Tenant shall admit in writing its inability to meet Tenant&#x2019;s debts as they mature; (vi) if any insurance required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as permitted in this Lease, or mutually agreed to in writing by the parties; (vii) if Tenant shall fail to discharge or bond over any lien placed upon the Premises as a result of Tenant&#x2019;s actions in violation of this Lease; (viii) if any Letter of Credit required to be maintained by Tenant pursuant to this Lease shall be cancelled or terminated or shall expire or shall be reduced or materially changed, except, in each case, as&nbsp;</font><font style="font-size: 10pt;">permitted in this Lease, or mutually agreed to in writing by the parties; (ix) if Tenant shall abandon or vacate the Premises during the Term and otherwise fail to comply with the terms of the Lease; (x) if Tenant shall fail to execute and deliver an estoppel certificate or subordination agreement as required hereunder; or (xi) the failure to observe or perform any of the other covenants or conditions in this Lease which Tenant is required to observe and perform and which Tenant has not corrected within </font><font style="font-size: 10pt;">[***]</font><font style="font-size: 10pt;"> ([***]) days after written notice thereof to Tenant,&nbsp; provided, however, that if the nature of Tenant&#x2019;s non-performance is such that more than [***] ([***]) days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant commences such cure within said [***] ([***]) day period and thereafter diligently and continuously pursues such cure to completion.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Upon the occurrence of an Event of Default by Tenant, Landlord may, at its option, with or without notice or demand of any kind to Tenant or any other person, exercise any one or more of the following described remedies, in addition to all other rights and remedies provided at law, in equity or elsewhere herein, and such rights and remedies shall be cumulative and none shall exclude any other right allowed by law:</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Upon [***] ([***]) days written notice to Tenant, Landlord may terminate this Lease, repossess and re-let the Premises in accordance with Florida law, as the agent and for the account of Tenant upon such terms and conditions as Landlord may deem advisable or satisfactory, in which case Landlord shall be entitled to recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting.&nbsp; For the purpose of determining present value, Landlord and Tenant agree that the interest rate shall be the rate applicable to the then-current yield on obligations of the U.S. Treasury having a maturity date on or about the Expiration Date.&nbsp; Should the fair market rental value of the Premises for the balance of the Term (after deduction of all anticipated expenses of reletting) exceed the value of the Rent to be paid by Tenant for the balance of the Term, Landlord shall have no obligation to pay to or otherwise credit Tenant for any such excess amount;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, serif"><FONT STYLE="font: 10pt Times New Roman, Times, serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>Landlord may, without terminating the Lease, terminate Tenant&#x2019;s right of possession, repossess the Premises including, without limitation, removing all or any part of Tenant&#x2019;s personal property in the Premises and to place such personal property in storage or a public warehouse at the expense and risk of Tenant, and relet the same for the account of Tenant for such rent and upon such terms as shall be satisfactory to Landlord.&nbsp; For the purpose of such reletting, Landlord is authorized to decorate, repair, remodel or alter the Premises.&nbsp; Tenant shall pay to Landlord as damages a sum equal to all Rent under this Lease for the balance of the Term unless and until the Premises are relet.&nbsp; If the Premises are relet, Tenant shall be responsible for payment within [***] ([***]) days after Landlord&#x2019;s written demand of any deficiency between the Rent as relet and the Rent for the balance of this Lease, all costs and expenses of reletting, and all reasonable decoration, repairs, remodeling, alterations, additions and collection of the rent accruing therefrom.&nbsp; Tenant shall not be entitled to any rents received by Landlord in excess of the rent provided for in this Lease.&nbsp; No re-entry or taking possession of the Premises by Landlord shall be&nbsp;</FONT><FONT STYLE="font-size: 10pt">construed as an election to terminate this Lease unless a written notice of such intention be given to Tenant or unless the termination thereof be decreed by a court of competent jurisdiction.&nbsp; Notwithstanding any reletting without termination, Landlord may at any time thereafter elect to terminate this Lease for any breach, and in addition to the other remedies it may have, recover as damages (in addition to any other sums or damages for which Tenant may be liable to Landlord) a lump sum equal to the amount by which the present value of the excess Rent remaining to be paid by Tenant for the balance of the Term of the Lease exceeds the fair market rental value of the Premises, after deduction of all anticipated expenses of reletting.&nbsp; In the event Landlord repossesses the Premises as provided above, Landlord may remove all persons and property from the Premises and store any such property at the cost of Tenant, and Tenant hereby waives any and all claims against Landlord for loss, destruction and/or damage or injury which may be occasioned by any of the aforesaid acts; and</FONT></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 28; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><FONT STYLE="font-family: Times New Roman, Times, serif; font-size: 10pt">&nbsp;&nbsp;</FONT></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0pt 0pt 36.0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(iii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Landlord may, but shall not be obligated to, and without waiving or releasing Tenant from any obligations of Tenant hereunder, make any payment or perform such other act on Tenant&#x2019;s part to be made or performed as provided in this Lease.&nbsp; All sums so paid by Landlord and all necessary incidental costs shall be payable to Landlord as Additional Rent within [***] ([***]) days after Landlord&#x2019;s written demand and Tenant covenants to pay such sums.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant agrees that Landlord may file suit to recover any sums falling due under the terms of this section from time to time and that no suit or recovery of any portion due Landlord hereunder shall be any defense to any subsequent action brought for any amount not theretofore reduced to judgment in favor of Landlord.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">Tenant shall promptly pay upon notice, as Additional Rent, all reasonable costs, charges and expenses incurred by Landlord (including, without limitation, reasonable fees and out-of-pocket expenses of legal counsel, collection agents, and other third parties retained by Landlord) together with interest thereon at the rate set forth in Section 5 of this Lease, in collecting any amount due from Tenant, enforcing any obligation of Tenant hereunder, or preserving any rights or remedies of Landlord. </font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">No waiver of any provision of this Lease shall be implied by any failure of Landlord to enforce any remedy on account of the violation of such provision, even if such violation be continued or repeated subsequently, and no express waiver by Landlord shall be valid unless in writing and shall not affect any provision other than the one specified in such written waiver and that provision only for the time and in the manner specifically stated in the waiver.&nbsp; No receipt of monies by Landlord from Tenant after the termination of this Lease shall in any way alter the length of the Term or Tenant&#x2019;s right of possession hereunder or after the giving of any notice shall reinstate, continue or extend the Term or affect any notice given Tenant prior to the receipt of such monies, it being agreed that after the service of notice or the commencement of a suit or after final judgment for possession of the Premises, Landlord may receive and collect any Rent due, and the payment of Rent shall not waive or affect said notice, suit or judgment.&nbsp; Landlord shall not be required to serve Tenant with any notices or demands as a prerequisite to its exercise of any of its&nbsp;</font></font><font style="font-size: 10pt;">rights or remedies under this Lease, other than those notices and demands specifically required under this Lease.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 29; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">(F)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">In the event of a breach or threatened breach by Tenant of any of the covenants or provisions hereof, Landlord shall have the right of injunction and the right to invoke any remedy allowed at law or in equity as if re-entry, summary proceedings and other remedies were not herein provided for.&nbsp; Mention in this Lease of any particular remedy shall not preclude Landlord from any other remedy, in law or in equity.&nbsp; Tenant hereby expressly waives any and all rights of redemption granted by or under any present or future laws in the event of Tenant being evicted or dispossessed for any cause, or in the event of Landlord obtaining possession of Premises by reason of the violation by Tenant of any of the covenants and conditions of this Lease, or otherwise.</font></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;"><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">23.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">LANDLORD&#x2019;S DEFAULT</font></font></b></font><font style="font-size: 10pt;">.&nbsp; </font><font style="font-size: 10pt;">Landlord shall not be in default under this Lease unless Landlord fails to perform obligations required of Landlord within [***] ([***]) days after written notice by Tenant to Landlord and to the holder of any mortgage or deed of trust encumbering the Building whose name and address shall have theretofore been furnished to Tenant in writing, specifying wherein Landlord has failed to perform such obligation; provided, however, that if the nature of Landlord&#x2019;s obligation is such that more than [***] ([***]) days are required for its cure, then Landlord shall not be in default if Landlord commences performance within such [***] ([***]) day period and thereafter diligently pursues the same to completion. In the event Landlord shall be in default under this Lease, Tenant may exercise any rights and remedies as provided for at law or in equity.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">If Landlord fails to commence to cure any default by Landlord within the period provided in the paragraph above and if, as a result, Tenant is incapable despite commercially reasonable efforts to continue operations within the Premises, Tenant may give Landlord an additional written notice confirming that the default has not been cured and that Tenant intends to cure such default, and, if Landlord fails to cure such default within [***] ([***]) days after such notice, Tenant may take such steps within the confines of its Premises as are reasonably appropriate to cure the default and deduct the reasonable cost of such cure from the rent next coming due.&nbsp; Tenant shall have no right to perform any obligation of Landlord in lieu of Landlord to the <font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">extent</font> the same involves or may impact any base building system or any area of the Building outside of the Premises, including, without limitation, common areas or the premises of any other tenant or occupant of the Building.&nbsp; Landlord&#x2019;s liability to keep, maintain, and repair shall be limited to the cost of making such repair or accomplishing such maintenance or repair and Landlord shall in no case be liable for consequential or any indirect damages.&nbsp; The provisions of this paragraph are subject to the provisions of Section 19 Casualty, Section 25 Eminent Domain, and Section 31(G) Force Majeure.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">24.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTICES</font></b></font><font style="font-size: 10pt;">.&nbsp; All notices permitted or required hereunder shall be in writing and (i) delivered personally, (ii) sent by U.S. certified mail, postage prepaid, with return receipt requested, or (iii) sent overnight by nationally recognized overnight courier and sent to the respective parties at the Notice Addresses provided in Section 1 of this Lease.&nbsp; If sent by U.S. certified mail, such notice shall be considered received by the addressee upon receipt.&nbsp; If sent by nationally recognized overnight courier, such notice shall be considered received by the addressee upon receipt.&nbsp; Notices may be given by an agent on behalf of Landlord or Tenant.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 30; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">25.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; EMINENT DOMAIN</font></b></font><font style="font-size: 10pt;">.&nbsp; If during the Term (a) the whole of the Premises or the Building shall be taken by any governmental or other authority having powers of eminent domain or conveyed to such entity under threat of the exercise of such power or (b) any part of the Premises or the Building including parking or access to the Building shall be so taken or conveyed and as a result, the remainder of the Premises or the Building has been rendered impractical, in Landlord&#x2019;s and Tenant&#x2019;s mutual reasonable judgment, for the operation of Tenant&#x2019;s business, this Lease shall terminate on the date of the taking or conveyance, and Rent shall be apportioned to the date thereof.&nbsp; Any award for the taking of all or any part of the Premises or the Building under the power of eminent domain or any payment made under threat of the exercise of such power shall be the property of Landlord, whether such award shall be made as compensation for diminution in value of the leasehold, for good will, for the taking of the fee, as severance damages, or as damages for tenant improvements; provided, however, that Tenant shall be entitled to any separate award for loss of or damage to Tenant&#x2019;s removable personal property and for moving expenses, provided it does not reduce the amount payable to Landlord.&nbsp; In the event that this Lease is not terminated by reason of such condemnation, Landlord shall to the extent of severance damages received by Landlord in connection with such condemnation, repair any damage to the Building caused by such condemnation except to the extent that Tenant has been reimbursed therefor by the condemning authority.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">26.&nbsp; &nbsp; &nbsp;&nbsp;&nbsp; &nbsp;QUIET ENJOYMENT</font></b></font><font style="font-size: 10pt;">.&nbsp; Landlord represents and warrants that it has full right and authority to enter into this Lease and that Tenant, while paying the rental and performing its other covenants and agreements contained in this Lease, shall peaceably and quietly have, hold and enjoy the Premises for the Term without hindrance or molestation from Landlord subject to the terms and provisions of this Lease.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">27.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RULES AND REGULATIONS</font></b></font><font style="font-size: 10pt;">.&nbsp; Tenant agrees to comply with (and cause its agents, contractors, employees and invitees to comply with) the rules and regulations attached hereto as Exhibit&nbsp;B and with such reasonable modifications thereof and additions thereto as Landlord may from time to time make and deliver to Tenant in writing.&nbsp; Landlord agrees to enforce the rules and regulations uniformly against all tenants of the Property.&nbsp; Landlord shall not be liable, however, for any violation of said rules and regulations by other tenants or occupants of the Building or Property.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 31; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">28.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ENVIRONMENTAL</font></b></font><font style="font-size: 10pt;">.&nbsp; &#8220;Environmental Laws&#8221; shall mean all federal, state, including but not limited to </font><font style="font-size: 10pt;">the Florida Department of Environmental Regulation or the Florida Department of Health,</font><font style="font-size: 10pt;"> and local laws (including, without limitation, case and common law), statutes, regulations, rules, ordinances, guidance, permits, licenses, grants, orders, decrees and judgments relating to the environment, human health and safety.&nbsp; &#8220;Hazardous Substances&#8221; shall mean all explosive materials, radioactive materials, hazardous or toxic materials, wastes, chemicals or substances, petroleum, petroleum by-products and petroleum products (including, without limitation, crude oil or any fraction thereof), asbestos and asbestos-containing materials, radon, lead, polychlorinated biphenyls, mold, urea-formaldehyde, and all materials, wastes, chemicals and substances that are regulated by any Environmental Law.&nbsp; &#8220;Release&#8221; shall mean any spilling, leaking, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, or disposing of Hazardous Substances into the environment.&nbsp; Tenant shall not (i) manufacture, generate, utilize, store, handle, treat, process, or Release any Hazardous Substances at, in, under, from or on the&nbsp;</font><font style="font-size: 10pt;">Premises or Property or (ii) suffer or permit to occur any violation of Environmental Laws with respect to the Premises or Property.&nbsp; Tenant shall indemnify, defend (with counsel reasonably acceptable to Landlord and at Tenant&#x2019;s sole cost) and hold harmless Landlord and its partners, managers, members, officers, directors, employees, agents, successors, grantees, assigns and mortgagees from any and all claims, demands, liabilities, damages, expenses, fees, costs, fines, penalties, suits, proceedings, actions, causes of action and losses of any and every kind and nature, including, without limitation, diminution in value of the Property, damages for the loss or restriction on use of the rentable or usable space or of any amenity, natural resource damages, damages arising from any adverse impact on leasing space on the Premises or Property, and sums paid in settlement of claims and for attorney&#x2019;s fees, consultant&#x2019;s fees and expert&#x2019;s fees that may arise during or after the Term or any extension of the Term as a result of Tenant&#x2019;s or Tenant&#x2019;s agents, employees, contractors, assignees, subtenants, guests, invitees, or representatives introduction of any Hazard Substance to the property.&nbsp; For purposes of this section, the term &#8220;costs&#8221; includes, without limitation, costs, expenses and consultant&#x2019;s fees, expert&#x2019;s fees and attorney&#x2019;s fees incurred in connection with any investigation of site conditions or any cleanup, remedial, removal, restoration, monitoring or maintenance work.&nbsp; This covenant of indemnity shall survive the termination of this Lease.&nbsp; Notwithstanding the foregoing, the prohibition contained herein shall not apply to ordinary office products that may contain de minimis quantities of Hazardous Substances, provided such products are used in compliance with Environmental Laws; however, Tenant&#x2019;s indemnification obligations are not diminished with respect to the presence of such products.&nbsp; Tenant shall notify Landlord of any Release or threatened Release at, in, under, from, to or on the Premises or Property, promptly after Tenant become aware of the same.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 36.0pt; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">To Landlord&#x2019;s actual knowledge, as of the Effective Date, there are no Hazardous Substances in the Premises or the Building in violation of applicable law.&nbsp; Notwithstanding anything contained in this Section 28 to the contrary, Tenant shall have no obligation under this Lease arising from or related to Hazardous Substances, unless such Hazardous Substances were introduced to the Premises or the Building by Tenant or Tenant&#x2019;s agents, employees, contractors, assignees, subtenants, guests, invitees, or representatives.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">29.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INTENTIONALLY OMITTED</font></b></font><font style="font-size: 10pt;">.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="font-family: Times New Roman, Times, serif; font-size: 10pt;"><b><font style="font-size: 10pt; font-family: Times New Roman, Times, Serif;">30.&nbsp; &nbsp; &nbsp; &nbsp; BROKERS</font></b></font><font style="font-size: 10pt;">.&nbsp; Tenant and Landlord each represent and warrant to the other that neither has had any dealings or entered into any agreements with any person, entity, broker or finder in connection with the negotiation of this Lease other than NAI Merin Hunter Codman, Inc., representing the Landlord, and Butters Realty and Management, representing the Tenant (the &#8220;Disclosed Brokers&#8221;).&nbsp; No other broker, person, or entity is entitled to any commission or finder&#x2019;s fee in connection with the negotiation of this Lease, and the party against whom a claim is made agrees to indemnify, defend and hold the other harmless from and against any claims, damages, costs, expenses, attorneys&#x2019; fees or liability for compensation or charges which may be claimed by any such unnamed broker, finder or other similar party by reason of any dealings, actions or agreements of the indemnifying party.&nbsp; Landlord shall pay the Disclosed Brokers pursuant to the terms of a separate agreement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 32; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>

<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">&nbsp;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>31.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
MISCELLANEOUS</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Time is of the essence of this Lease and each
of its provisions.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;This Lease and all covenants and agreements herein
contained shall be binding upon, apply, and inure to the respective heirs, executors, successors, administrators and assigns of
all parties to this Lease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Lease contains the entire agreement of the
parties, all other and prior representations, negotiations and agreements having been merged herein and extinguished hereby.&nbsp;
No modification, waiver or amendment of this Lease or of any of its conditions or provisions shall be binding upon either party
hereto unless in writing signed by both parties.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(D)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The captions of sections and subsections of this
Lease are for convenience only and shall not be deemed to limit, construe, affect or alter the meaning of such sections or subsections.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(E)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Interpretation of this Lease shall be governed
by the laws of the state or commonwealth in which the Premises is located, without regard to conflict of laws.&nbsp; The parties
irrevocably submits to the nonexclusive jurisdiction of the courts of said state or commonwealth and agrees that all suits, actions,
claims or proceedings may be heard and determined in such courts.&nbsp; The parties waive any objection which it may have at any
time to the laying of venue of any suit, action, claim or proceeding arising out of or relating to this Lease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(F)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font>&nbsp;&nbsp;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Lease is and shall be deemed and construed
to be the joint and collective work product of Landlord and Tenant and, as such, this Lease shall not be construed against either
party, as the otherwise purported drafter of same, by any court of competent jurisdiction in order to resolve any inconsistency,
ambiguity, vagueness or conflict, if any, in the terms or provisions contained herein.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(G)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the event that either party thereto shall
be delayed or hindered in or prevented from the performance of any act required hereunder by reason of strikes, lock-outs, labor
troubles, inability to procure labor, inability to procure materials or equipment or reasonable substitutes therefore, failure
of power, fire or other casualty, restrictive government laws or regulations, judicial orders, enemy or hostile government actions,
riots, insurrection or other civil commotions, war or other reason of a like nature not the fault of the party delayed in performing
any act as required under the terms of this Lease (&#8220;Force Majeure&#8221;), then performance of such act shall be excused
for the period of delay and the period for the performance of any such act shall be extended for a period equivalent to the period
of such delay.&nbsp; Force Majeure shall not operate to excuse either party from the prompt payment of Rent or any other payments
required under the terms of this Lease.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(H)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant shall reimburse Landlord as Additional
Rent within [***] ([***]) days after Landlord&#x2019;s written demand for all reasonable out-of-pocket expenses, including without
limitation legal, engineering or other professional services or expenses incurred by Landlord in connection with any requests
by Tenant for consents or approvals hereunder.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(I)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A final determination by a court of competent
jurisdiction that any provision of this Lease is invalid shall not affect the validity of any other provision, and any provision
so determined to be invalid shall, to the extent possible, be construed to accomplish its intended effect.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(J)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If more than one person or entity shall ever
be Tenant, the liability of each such person and entity shall be joint and several.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(K)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each individual executing this Lease on behalf
of Tenant, represents and warrants that such individual is duly authorized to execute and deliver this Lease on behalf of Tenant,
that Tenant is duly authorized to enter into this Lease, and that this Lease is enforceable against Tenant in accordance with
its terms.&nbsp; Each individual executing this Lease on behalf of Landlord, represents and warrants that such individual is duly
authorized to execute and deliver this Lease on behalf of Landlord, that Landlord is duly authorized to enter into this Lease,
and that this Lease is enforceable against Landlord in accordance with its terms.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(L)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The submission of this Lease to Tenant is not
an offer to lease the Premises, or an agreement by Landlord to reserve the Premises for Tenant.&nbsp; Landlord shall not be bound
to Tenant until Tenant has duly executed and delivered an original Lease to Landlord and Landlord has duly executed and delivered
an original Lease to Tenant.&nbsp; Notwithstanding the Suite&nbsp;160 Commencement Date or Full Premises Commencement Date contemplated
in Section 1 hereof, this Lease shall take effect and be binding upon the parties hereto as of its execution and delivery.&nbsp;
</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(M)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This Lease may be executed in any number of counterparts,
and by different parties hereto on separate counterparts, each of which shall be deemed an original, but all of which together
shall constitute one and the same instrument.&nbsp; Any signature to this Lease transmitted via PDF or electronic signature shall
be deemed an original signature and be binding upon the parties hereto.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(N)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each party represents and warrants that neither
such party nor any of its members, shareholders or other equity owners, is a person or entity with whom U.S. persons or entities
are restricted from doing business under regulations of the Office of Foreign Asset Control (&#8220;OFAC&#8221;) of the Department
of the Treasury (including those named on OFAC&#x2019;s Specially Designated and Blocked Persons List) or under any statute, executive
order (including the September 24, 2001, Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit,
Threaten to Commit, or Support Terrorism), or other governmental action.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>32.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
SOUTH FLORIDA COMMUTER SERVICE PROGRAMS</b>.&nbsp; The Property participates in programs promoted by regional commuter service
and other similar organizations designed and intended to maximize the people-moving capability of the transportation system, encourage
mass transit and manage transportation demand.&nbsp; Information relating to such programs, including contact information for
the Employee Transportation Coordinator, is available at the main security desk as well as the mailroom/vending area of the Property.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>33.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
CITY APPLICATION</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(A)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Prior to Tenant&#x2019;s submission to the City of Boca Raton (the &#8220;City&#8221;) of an application (the &#8220;City Application&#8221;)
for a business tax receipt, certificate of use or any other item which requires any statement as to the use of the Premises (the
&#8220;Proposed Use&#8221;), Tenant shall deliver to Landlord a copy of the proposed City Application for Landlord&#x2019;s prior
review to ensure the Proposed Use complies with the City&#x2019;s zoning and other laws and regulations pertaining to the Premises.&nbsp;
Landlord shall have the right to require Tenant to modify, amend or adjust the City Application prior to Tenant&#x2019;s submission
of the City Application to the City.&nbsp; Landlord&#x2019;s approval of a City Application does not create any liability on the
part of Landlord and is merely being provided by Landlord to help ensure the City Application is properly submitted.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 2; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(B)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each year during the Term, Tenant shall provide
Landlord with evidence that Tenant has timely and properly renewed its business tax receipt, certificate of use or other item
relating to the Proposed Use, within [***] ([***]) days of such renewal.&nbsp; In connection with such renewal, Tenant agrees
not to modify, amend or adjust the Proposed Use in any manner.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">(C)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&#x2019;s failure to comply with the terms
and provisions of this paragraph shall be an Event of Default and Landlord shall have any and all rights and remedies set forth
in Section 22 (Default; Remedies) hereof on account of such Event of Default.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>34.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RADON GAS</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Radon is a naturally occurring
radioactive gas that, when it has accumulated in a building in sufficient quantities, may present health risks to persons who
are exposed to it over time.&nbsp; Levels of radon that exceed federal and state guidelines have been found in buildings in Florida.&nbsp;
Additional information regarding radon and radon testing may be obtained from your county public health unit.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>35.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;MOLD</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Mold is a naturally occurring
substance.&nbsp; Mold is found both indoors and outdoors.&nbsp; The presence of mold may cause property damage or health problems.&nbsp;
Tenant acknowledges that it shall be Tenant&#x2019;s responsibility to undertake necessary measures to retard and prevent mold
from accumulating within the Premises, including, but not limited to, the following: (i) maintaining appropriate climate control
within the Premises; (ii) maintaining the cleanliness of the Premises; (iii) removing visible moisture accumulations on windows,
window sills, walls, floors, ceilings and other surfaces as soon as reasonably possible; and (iv) not blocking or covering any
heating, ventilating or air conditioning ducts within the Premises.&nbsp; Tenant shall report in writing to Landlord any evidence
of mold or of a water leak or excessive moisture within the Premises, promptly after Tenant becomes aware of same.&nbsp; Should
Tenant desire a mold inspection or additional information about mold, Tenant should contact a professional in this field.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>36.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;PARKING</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;
At all times during the Term (with the allocation of such spaces to be staggered based on the Suite 160 Commencement Date and
the Full Premsies Commencement Date), Tenant shall be entitled to the non-exclusive use of 281 parking spaces in the Building&#x2019;s
parking lot or the shared lot (as shown on <b>Exhibit&nbsp;A-3</b>) (37&nbsp;spaces as of the Suite&nbsp;160 Commencement Date,
and the remaining 244&nbsp;spaces as of the Full Premises Commencement Date).&nbsp; As part of the overall parking allocation
(with the allocation of such spaces to be staggered based on the Suite 160 Commencement Date and the Full Premsies Commencement
Date) provided to Tenant herein (with the following parking to count towards Tenant&#x2019;s 281 parking spaces), Landlord shall
provide forty-eight (48) covered spaces (6&nbsp;covered spaces as of the Suite&nbsp;160 Commencement Date, and the remaining 42&nbsp;covered
spaces as of the Full Premises Commencement Date) at the locations identified on <b>Exhibit&nbsp;A-1</b>, at the initial rate
of $[***] per space, per month, with such rate to increase at the same time and at the same percentage increase as Base Rent.&nbsp;
Landlord reserves the right to control the method, manner and time of parking in all parking spaces. &nbsp;Tenant shall not use
any parking space designated by Landlord as visitor parking or as exclusive to other parties.&nbsp; Tenant shall insure that its
employees, customers, clients, guests, invitees and licensees comply with the provision of this Section 36. If Tenant uses parking
in excess of that provided for herein, and if such excess use occurs on a regular basis, and if Tenant fails, after written notice
from Landlord of any one violation, to reduce its excess use of the parking areas, then Landlord may assess a charge of [***]
Dollars ($[***]) against the Tenant for each violation, which shall be payable as Additional Rent. &nbsp;Further, Landlord reserves
the right to post a notice of violation on any offending vehicle and to tow the offending vehicle regardless of whether the vehicle
is owned by a Tenant or any other party, including any employee, customer, client, invitee or licensee of a Tenant, and to charge
the expense thereof to owner of the vehicle.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 3; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>37.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SIGNAGE</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Tenant shall be entitled to
Building standard suite entry and directory signage.&nbsp; Landlord may specify that the design of such signage be similar to,
or consistent with, the design and location of other signs identifying tenants in the Building.&nbsp; Such signage shall be subject
to all applicable laws and ordinances.&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>38.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;RIGHT OF ENTRY</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Except in the event
of an emergency, Landlord shall only have the right to enter the Premises after first providing Tenant with at least twenty-four
(24) hours prior advance notice (which may be verbal) to Tenant.&nbsp; Such entry shall only be permitted for purposes of allowing
Landlord to perform those acts required of or permitted to Landlord herein, including, without limitation, (i) the right to make
any repairs or replacements Landlord reasonably deems necessary, (ii) the right to show the Premises to prospective purchasers
and mortgagees, (iii) during the last twelve (12) months of the Term, the right to show the Premises to prospective tenants.&nbsp;
Notwithstanding anything to the contrary contained in this Lease, no entry by Landlord or its agents or representatives shall
be made into or upon the Premises without the presence of an authorized employee of Tenant, except in a bona fide emergency not
permitting prior notification to Tenant. Tenant shall make an authorized employee available at reasonable hours to allow Landlord
to exercise its right to enter the Premises in accordance with the terms of this Section 38. It is understood that entry is being
restricted because of the nature of the business of Tenant requiring special security. In addition to the foregoing, except in
the event of a bona fide emergency or a specific request to acess such secure area in connection with an inspection by a governmental
authority, and provided that an authorized employee of Tenant accompanies the party entering into the secure area during such
emergency or governmental inspection, Tenant may prohibit Landlord from entering certain secure areas of the Premises as reasonably
determined by Tenant.&nbsp; During any entry on to the Premises as permitted under this Section 38, Landlord and Landlord&#x2019;s
agents and representatives shall comply with Tenant&#x2019;s customary security procedures and shall use good faith efforts to
minimize any interference with Tenant&#x2019;s operations at the Premises.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>39.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CERTAIN RIGHTS RESERVED TO LANDLORD</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;
Landlord reserves the following rights, and the exercise of any such rights shall not be deemed to constitute an eviction or disturbance
of Tenant&#x2019;s use or possession of the Premises and shall not give rise to any claim for set-off or abatement of Rent or
any other claim provided that such rights do not adversely interfere with Tenant&#x2019;s use of and operations at the Property:
(a) to enter the Premises for the purposes of examining the same or to make repairs or alterations or to provide any service;
(b) to change the arrangement and/or locations of entrances, or passageways, doors and doorways, and corridors, windows, elevators,
stairs, parking areas and any other common areas, (c) to change the name or street address of the Building or the suite number
of the Premises; (d) to install, affix and maintain any and all signs on the exterior or interior of the Building; (e) to make
repairs, decorations, alterations, additions or improvements, whether structural or otherwise, in, about and to the Building or
common areas and for such purposes temporarily close doors, corridors and other areas of the Building and interrupt or temporarily
suspend services or use of common areas; (f) to retain at all times, and to use in appropriate instances, keys to all doors within
and into the Premises; (g) to grant to any person or to reserve unto itself the exclusive right to conduct any business or render
any service in the Building; (h) if the Premises have been permanently vacated or abandoned by Tenant, to prepare the Premises
for re-occupancy; (i) to install, use and maintain in and through the Premises pipes, conduits, wires and ducts serving the Building;
(j) to approve the weight, size and location of safes or other heavy equipment or other articles which may be located in the Premises
and to determine the time and manner in which such articles may be moved in, about or out of the Building or Premises; and (k)
to take any other action which Landlord deems reasonable in connection with the operation, maintenance, marketing or preservation
of the Premises or Building.&nbsp; The reduction or elimination of Tenant&#x2019;s light, air or view shall not affect Tenant&#x2019;s
liability under this Lease, nor shall it create any liability of Landlord to Tenant.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 4; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>40.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
LEASE COMMENCEMENT/ACCEPTANCE OF PREMISES</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;
At Landlord&#x2019;s request, Landlord and Tenant shall enter into a commencement letter agreement (the &#8220;Commencement Letter&#8221;)
in form substantially similar to that attached hereto as <b>Exhibit&nbsp;C</b> once the Suite&nbsp;160 Commencement Date has occurred
and once the Full Premises Commencement Date has occurred in accordance with the terms of <b>Exhibit&nbsp;F</b>.&nbsp; Tenant&#x2019;s
failure to execute and return the Commencement Letter, or to provide written objection to the statements contained in the Commencement
Letter, within [***] ([***]) days shall be deemed an approval by Tenant of the statements contained therein.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>41.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
WAIVER OF RIGHT TO JURY TRIAL</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; LANDLORD
AND TENANT WAIVE THEIR RESPECTIVE RIGHTS TO A TRIAL BY JURY OF ANY CLAIM, ACTION, PROCEEDING OR COUNTERCLAIM BY EITHER PARTY AGAINST
THE OTHER ON ANY MATTERS ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS LEASE, THE RELATIONSHIP OF LANDLORD AND TENANT, AND/OR
TENANT&#x2019;S USE OR OCCUPANCY OF THE PREMISES OR BUILDING (INCLUDING ANY CLAIM OF INJURY OR DAMAGE OR THE ENFORCEMENT OF ANY
REMEDY UNDER ANY CURRENT OR FUTURE LAWS, STATUTES, REGULATIONS, CODES OR ORDINANCES).</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>42.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
RECORDING</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Tenant shall not record
this Lease without the prior written consent of Landlord.&nbsp; Tenant, upon the request of Landlord, shall execute and acknowledge
a short form memorandum of this Lease for recording purposes.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>43.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
SUBORDINATION OF LANDLORD&#x2019;S LIEN</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp;
Landlord hereby agrees to subordinate (on the form of agreement attached hereto as <b>Exhibit&nbsp;J</b>) any rights to a lien
(including statutory rights) on any of Tenant&#x2019;s personal property located within the Premises to any purchase money lender.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>44.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
NO RELOCATION</b></font><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.&nbsp; Landlord waives any
right to relocate Tenant to any other space in the Building without first obtaining Tenant&#x2019;s prior written consent, which
consent may be withheld by Tenant in its sole discretion.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[signatures
on following page]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
WITNESS WHEREOF, the parties hereto have executed this Lease.&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 50%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 2%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 3%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 1%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 2%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 42%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>LANDLORD:</b></font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>&nbsp;</b></font></p>
</td>
<td colspan="4" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>TENANT:</b></font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</td>
<td colspan="4" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif">&nbsp;</td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">951
YAMATO ACQUISITION COMPANY, LLC,
a Florida limited liability company</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td colspan="4" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">TherapeuticsMD,
Inc., a Nevada corporation</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td colspan="4" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">By:
BROOKWOOD YAMATO INVESTORS, LLC,
a Delaware limited liability company, its Sole
Member</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td colspan="4" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"></font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td colspan="2" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">By:</font></p>
</td>
<td colspan="2" style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">/s/
Daniel Cartwright</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td rowspan=2 style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">By:
BROOKWOOD YAMATO CO., LLC, a Delaware
limited liability company, its Manager</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td colspan="3" style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Name:</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Daniel
Cartwright</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Its:</font></p>
</td>
<td colspan="3" style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">CFO</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 3%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Kurt M. Zernich</font></p>
</td>
<td style="padding: 0pt; width: 51%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 5%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 44%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kurt
M. Zernich</font></p>
</td>
<td style="padding: 0pt; width: 51%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>

</table>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 3%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 46%; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized
Signer</font></p>
</td>
<td style="padding: 0pt; width: 51%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></font></p>
<table border="0" cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse; margin: 0px; font: 10pt Times New Roman, Times, Serif">

<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; width: 49%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>&nbsp;</b></font></p>
</td>
<td style="padding: 0pt; width: 2%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; width: 49%; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>&nbsp;</b></font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>WITNESS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>(2
witnesses required)</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>WITNESS:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</b>(2
witnesses required)</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">/s/
Jennifer Johnson</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">/s/
John Milligan</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#1 Signature</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#1 Signature</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Jennifer
Johnson</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">John
Milligan</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#1 Print Name</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#1 Print Name</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">/s/
Nicole Reeves</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">/s/
Lisa Maxwell</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#2 Signature</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#2 Signature</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Nicole
Reeves</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</td>
<td style="padding: 0pt; border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Lisa
Maxwell</font></p>
</td>
</tr>
<tr style="font: 10pt Times New Roman, Times, Serif">
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#2 Print Name</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: top; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black">Witness
#2 Print Name</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>THE
PREMISES</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit A, Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A-1</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Site
Plan for the Building]</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->, Page 1</p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A-2</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Location
of Parking Spaces]</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->, Page 1</p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
A-3</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>[Building
Lot and Shared Lot]</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->, Page 1</p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
B</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>RULES
AND REGULATIONS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 11; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit B, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
C</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
OF COMMENCEMENT LETTER</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 12; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit C, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
D</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADDITIONAL
STIPULATIONS</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 13; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit D, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
D-1</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&#x2019;s
Exterior Building Signage</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit D, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
D-2</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&#x2019;s
Monument Signage</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit D, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
E</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SUITE&nbsp;160
WORK LETTER</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 16; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit E, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Schedule
E-1</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Space
Plan for Suite&nbsp;160 Work]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit E, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
F</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>TENANT
IMPROVEMENTS LETTER</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 18; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit F, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Schedule
F-1</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>[Suite
150 Space Plan]</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit F, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>Schedule
F-1</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><u>[Suite
220 Space Plan]</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit F, Page&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
H</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
SNDA</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 72pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 21; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit H, Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
I</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ASSUMED
RENT TABLE</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<!-- Field: Page; Sequence: 22; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit I, Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<div style="page-break-before: always; margin-top: 6pt;">
<p style="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">&nbsp;</p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>EXHIBIT
J</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b><u>LANDLORD&#x2019;S
AGREEMENT</u></b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: center"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</font></p>
<!-- Field: Page; Sequence: 23; Options: NewSection; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;">Exhibit J, Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p>
</div>
<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></p>
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>

<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"></P>

<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><b>Exhibit 31.1</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">I, Robert G. Finizio, certify that:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; margin: 0px; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(1)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; margin: 0px; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(2)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; margin: 0px; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(3)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; margin: 0px; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(4)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(a)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(b)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(c)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(d)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; margin: 0px; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(5)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(a)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(b)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 50%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.0pt; margin: 0pt 0pt 0pt 12.0pt;">November 8, 2019</p>
</td>
<TD STYLE="padding: 0pt; width: 50%; vertical-align: bottom; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><I>/s/ Robert G. Finizio</I></p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.0pt; margin: 0pt 0pt 0pt 12.0pt;">Robert G. Finizio</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.25pt; margin: 0pt 0pt 0pt 12.25pt;">Chief Executive Officer</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.25pt; margin: 0pt 0pt 0pt 12.25pt;">(Principal Executive Officer)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 1; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p>
</div>

<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 1; Value: 1 --><!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt;"><b>Exhibit 31.2</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">I, Daniel A. Cartwright, certify that:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(1)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">I have reviewed this quarterly report on Form 10-Q of TherapeuticsMD, Inc.;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(2)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(3)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(4)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(a)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(b)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(c)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(d)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(5)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 18pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; width: 18pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(a)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">(b)</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; margin: 0px">

<tr>
<TD STYLE="padding: 0pt; width: 50%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.0pt; margin: 0pt 0pt 0pt 12.0pt;">November&nbsp; 8, 2019</p>
</td>
<TD STYLE="padding: 0pt; width: 50%; vertical-align: bottom; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><I>/s/ Daniel A. Cartwright</I></p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.0pt; margin: 0pt 0pt 0pt 12.0pt;">Daniel A. Cartwright</p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<TD STYLE="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.25pt; margin: 0pt 0pt 0pt 12.25pt;">Chief Financial Officer</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: -12.25pt; margin: 0pt 0pt 0pt 12.25pt;">(Principal Financial and Accounting Officer)</p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p>
</div>

<!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html><head>
<title></title></head><body>
<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>
<p style="margin: 0pt 0pt 10pt; text-align: right;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: black"><b>Exhibit
32.1</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="color: black;">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 44.65pt; margin: 0pt;"><font style="color: black;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table style="width: 100%;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td valign="top" style="width:45pt;">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</td>
<td valign="top" style="width:55pt;">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">(1)</font></p>
</td>
<td valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table style="width: 100%;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td valign="top" style="width:45pt;">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</td>
<td valign="top" style="width:55pt;">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">(2)</font></p>
</td>
<td valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<td style="padding: 0pt; width: 60%; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">November&nbsp; 8, 2019</font></p>
</td>
<td style="padding: 0pt; width: 40%; vertical-align: bottom; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black"><i>/s/ Robert
G. Finizio</i></font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">Robert G. Finizio</font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">&nbsp;</font></p>
</td>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">Chief Executive Officer </font></p>
</td>
</tr>
<tr>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;">&nbsp;</p>
</td>
<td style="padding: 0pt; vertical-align: bottom">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">(Principal Executive Officer)</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 1; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p>
</div>

<!-- Field: /Page -->
</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<!-- Field: Rule-Page --><div align="left" style="margin-top: 3pt; margin-bottom: 3pt"><div style="font-size: 1pt; border-top: Black 2px solid; width: 100%">&nbsp;</div></div><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: left"><A HREF="txmd-10q_093019.htm">TherapeuticsMD, Inc. 10-Q</A></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right">&nbsp;</P>
<p style="margin: 0pt 0pt 10pt; text-align: right;"><b><font style="color: black;">Exhibit 32.2</font></b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin: 0pt;"><font style="color: black;">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 46.1pt; margin: 0pt;"><font style="color: black;">In connection with the quarterly report of TherapeuticsMD, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended September 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table style="width: 100%; margin: 0px;" border="0" cellspacing="0" cellpadding="0">

<tr>
<td valign="top" style="width:45pt;">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</td>
<td valign="top" style="width:55pt;">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">(1)</font></p>
</td>
<td valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<table style="width: 100%;" border="0" width="100%" cellspacing="0" cellpadding="0">

<tr>
<td valign="top" style="width:45pt;">
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</td>
<td valign="top" style="width:55pt;">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">(2)</font></p>
</td>
<td valign="top">
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="color: black;">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="border-collapse: collapse; width: 100%; width: 100%">

<tr>
<TD STYLE="padding: 0pt; width: 60%; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;">November&nbsp; 8, 2019</p>
</td>
<TD STYLE="padding: 0pt; width: 40%; vertical-align: top; border-bottom: Black 1pt solid">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><FONT STYLE="color: black"><I>/s/ Daniel A. Cartwright</I></FONT></p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">&nbsp;</font></p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">Daniel A. Cartwright</font></p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">&nbsp;</font></p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">Chief Financial Officer </font></p>
</td>
</tr>
<tr>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">&nbsp;</font></p>
</td>
<TD STYLE="padding: 0pt; vertical-align: top">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt;"><font style="color: black;">(Principal Financial and Accounting Officer)</font></p>
</td>
</tr>

</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt;"><font style="color: black;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
<!-- Field: Page; Sequence: 1; Value: 1 -->
<div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: 1pt #000000 solid;">
<p style="margin-top: 0pt; text-align: Center; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p>
</div>

<!-- Field: /Page -->
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>txmd-20190930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSa2HqbP9w5dzeelBtm99HYn6ry4qTC2vqCwhn2+WIWAI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:txmd="http://therapeuticsmd.com/20190930" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20190930">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" id="ConsolidatedStatementOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1Company" id="Note1Company">
	  <link:definition>00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" id="Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements">
	  <link:definition>00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" id="Note3SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4Inventory" id="Note4Inventory">
	  <link:definition>00000010 - Disclosure - NOTE 4 &#8211; INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" id="Note5OtherCurrentAssets">
	  <link:definition>00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" id="Note6FixedAssetsNet">
	  <link:definition>00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssets" id="Note7IntangibleAssets">
	  <link:definition>00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" id="Note8OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9Debt" id="Note9Debt">
	  <link:definition>00000015 - Disclosure - NOTE 9 &#8211; DEBT</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" id="Note10NetLossPerShare">
	  <link:definition>00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" id="Note11StockholdersEquity">
	  <link:definition>00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" id="Note12IncomeTaxes">
	  <link:definition>00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" id="Note13RelatedParties">
	  <link:definition>00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" id="Note14BusinessConcentrations">
	  <link:definition>00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" id="Note15CommitmentsAndContingencies">
	  <link:definition>00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" id="Note16SubsequentEvents">
	  <link:definition>00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" id="Note3SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" id="Note3SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" id="Note4InventoryTables">
	  <link:definition>00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" id="Note5OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" id="Note6FixedAssetsNetTables">
	  <link:definition>00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" id="Note7IntangibleAssetsTables">
	  <link:definition>00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" id="Note8OtherCurrentLiabilitiesTables">
	  <link:definition>00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtTables" id="Note9DebtTables">
	  <link:definition>00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" id="Note10NetLossPerShareTables">
	  <link:definition>00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" id="Note11StockholdersEquityTables">
	  <link:definition>00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" id="Note15CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" id="Note1CompanyDetailsNarrative">
	  <link:definition>00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" id="Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative">
	  <link:definition>00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" id="FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details">
	  <link:definition>00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" id="InventoryConsistsOfFollowingDetails">
	  <link:definition>00000037 - Disclosure - Inventory consists of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" id="OtherCurrentAssetsConsistOfFollowingDetails">
	  <link:definition>00000038 - Disclosure - Other current assets consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" id="FixedAssetsNetConsistOfFollowingDetails">
	  <link:definition>00000039 - Disclosure - Fixed assets, net consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" id="Note6FixedAssetsNetDetailsNarrative">
	  <link:definition>00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" id="FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details">
	  <link:definition>00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" id="EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails">
	  <link:definition>00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" id="Note7IntangibleAssetsDetailsNarrative">
	  <link:definition>00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" id="OtherCurrentLiabilitiesConsistOfFollowingDetails">
	  <link:definition>00000044 - Disclosure - Other current liabilities consist of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" id="AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails">
	  <link:definition>00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" id="Note9DebtDetailsNarrative">
	  <link:definition>00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" id="TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details">
	  <link:definition>00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" id="AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details">
	  <link:definition>00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" id="SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails">
	  <link:definition>00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" id="Note11StockholdersEquityDetailsNarrative">
	  <link:definition>00000050 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" id="Note13RelatedPartiesDetailsNarrative">
	  <link:definition>00000051 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" id="Note14BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000052 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" id="SupplementalLeaseInformationDetails">
	  <link:definition>00000053 - Disclosure - Supplemental lease information (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" id="FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails">
	  <link:definition>00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" id="Note15CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000055 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" id="Note16SubsequentEventsDetailsNarrative">
	  <link:definition>00000056 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20190930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
    <element id="txmd_PrescriptionVitaminsMember" name="PrescriptionVitaminsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ImvexxyMember" name="ImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BijuvaMember" name="BijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnoveraMember" name="AnnoveraMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsMember" name="DomesticUSPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsMember" name="ForeignPatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsBijuvaMember" name="DomesticPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsBijuvaMember" name="ForeignPatentsBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticPatentsNonApprovedBijuvaMember" name="DomesticPatentsNonApprovedBijuvaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsImvexxyMember" name="DomesticUSPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSUtilityPatentsImvexxyMember" name="DomesticUSUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSDesignPatentsImvexxyMember" name="DomesticUSDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignPatentsImvexxyMember" name="ForeignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentsImvexxyMember" name="ForeignUtilityPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignDesignPatentsImvexxyMember" name="ForeignDesignPatentsImvexxyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUSPatentsTopicalCreamMember" name="DomesticUSPatentsTopicalCreamMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTransdermalPatchMember" name="DomesticUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ForeignUtilityPatentTransdermalPatchMember" name="ForeignUtilityPatentTransdermalPatchMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentOperaMember" name="DomesticUtilityPatentOperaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentDLimoneneMember" name="DomesticUtilityPatentDLimoneneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DomesticUtilityPatentTx009HRMember" name="DomesticUtilityPatentTx009HRMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreement1Member" name="CouncilLicenseAgreement1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StepBasedRoyaltyPaymentOneMember" name="StepBasedRoyaltyPaymentOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep1Member" name="CouncilLicenseAgreementStep1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep2Member" name="CouncilLicenseAgreementStep2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CouncilLicenseAgreementStep3Member" name="CouncilLicenseAgreementStep3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SubscriptionAgreementKnightMember" name="SubscriptionAgreementKnightMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseAgreementTheramexMember" name="LicenseAgreementTheramexMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FinancingAgreementMember" name="FinancingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheOneMember" name="TrancheOneMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoMember" name="TrancheTwoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheThreeMember" name="TrancheThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_TrancheTwoThreeMember" name="TrancheTwoThreeMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MidCapAgreementMember" name="MidCapAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CreditAgreementMember" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementGoldmanSachsMember" name="UnderwritingAgreementGoldmanSachsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsMember" name="WarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultant2Member" name="OutsideConsultant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Plan2019Member" name="Plan2019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierTwoConcentrationRiskMember" name="SupplierTwoConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SupplierThreeConcentrationRiskMember" name="SupplierThreeConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ThreeCustomersConcentrationRiskMember" name="ThreeCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FourCustomersConcentrationRiskMember" name="FourCustomersConcentrationRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPIServicesRiskMember" name="CustomerConcentrationPIServicesRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationPillPackRiskMember" name="CustomerConcentrationPillPackRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationAmerisourceBergenRiskMember" name="CustomerConcentrationAmerisourceBergenRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationCardinalHealthRiskMember" name="CustomerConcentrationCardinalHealthRiskMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritingAgreementJPMorganChaseMember" name="UnderwritingAgreementJPMorganChaseMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseRights" name="LicenseRights" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NoncashOperatingLeaseExpense" name="NoncashOperatingLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PaymentsToAcquireIntellectualPropertyLicense" name="PaymentsToAcquireIntellectualPropertyLicense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LicenseExpendituresIncurredButNotYetPaid" name="LicenseExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" name="DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" name="BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfIntangibleAssetsTableTextBlock" name="ScheduleOfIntangibleAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" name="ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSubsidiaries" name="NumberOfSubsidiaries" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidSalesAndMarketingCostsCurrent" name="PrepaidSalesAndMarketingCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyTierAxis" name="RoyaltyTierAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_RoyaltyTierDomain" name="RoyaltyTierDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentUponFDAApproval" name="MilestonePaymentUponFDAApproval" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" name="MilestonePaymentsAfterReleaseOfFirstCommercialBatch" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetSalesAmountPerStepbasedRoyalty" name="NetSalesAmountPerStepbasedRoyalty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RoyaltyPercent" name="RoyaltyPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" name="AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" name="MaximumCostsAndExpensesForPostApprovalStudyToBePaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CashUpfrontPaymentReceived" name="CashUpfrontPaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RegulatoryMilestoneAdditionalPayment" name="RegulatoryMilestoneAdditionalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesMilestonePaymentsInTranches" name="SalesMilestonePaymentsInTranches" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AnnualNetSalesMilestone" name="AnnualNetSalesMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedIntellectualLicenseFee" name="AccruedIntellectualLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedResearchAndDevelopment" name="AccruedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedRebates" name="AccruedRebates" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DebtTrancheAxis" name="DebtTrancheAxis" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" />
    <element id="txmd_DebtTrancheDomain" name="DebtTrancheDomain" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RevenueRequirementToDrawOnTermLoan" name="RevenueRequirementToDrawOnTermLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LiborFloorRate" name="LiborFloorRate" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfInstallmentPayments" name="NumberOfInstallmentPayments" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" name="PrepaymentFeeForFirstTwoYearsFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeThirdYearFundingPercent" name="PrepaymentFeeThirdYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFourthYearFundingPercent" name="PrepaymentFeeFourthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeeFifthYearFundingPercent" name="PrepaymentFeeFifthYearFundingPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_FacilityFeePaidPercent" name="FacilityFeePaidPercent" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" name="MinimumCashBalanceRequirementUnderCreditAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfTranchesUnderTermLoanFacility" name="NumberOfTranchesUnderTermLoanFacility" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentOfDebtWithNewCreditFacility" name="RepaymentOfDebtWithNewCreditFacility" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaymentFeePercentage" name="PrepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RepaymentFeePercentage" name="RepaymentFeePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" name="NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PeriodExercisableUnderwritersOption" name="PeriodExercisableUnderwritersOption" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_UnderwritersOptionGrantedInPeriodShares" name="UnderwritersOptionGrantedInPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ProceedsFromIssuancePublicOffering" name="ProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" name="WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" name="NumberOfStockIssuedInCashlessExerciseOfWarrants" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PlanAwardsNumberOfNewShares" name="PlanAwardsNumberOfNewShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfVendors" name="NumberOfVendors" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfCustomers" name="NumberOfCustomers" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" name="LesseeOperatingLeaseLiabilityImputedInterestAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NetRentableAreaLease" name="NetRentableAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_RentedAreaLease" name="RentedAreaLease" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalAreaOfLeaseOccupied" name="AdditionalAreaOfLeaseOccupied" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" name="LesseeFinanceLeaseExistenceOfOptionToExtendNumber" nillable="true" xbrli:periodType="duration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" name="LesseeOperatingLeaseLeaseNotYetCommencedArea" nillable="true" xbrli:periodType="instant" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SignificantSupplyCommitmentPercentagePayable" name="SignificantSupplyCommitmentPercentagePayable" nillable="true" xbrli:periodType="instant" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercised" name="NumberOfStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>txmd-20190930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20190930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:href="txmd-20190930.xsd#ConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20190930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20190930.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:href="txmd-20190930.xsd#Note7IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20190930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20190930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20190930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20190930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20190930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20190930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20190930.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20190930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20190930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20190930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:href="txmd-20190930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20190930.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:href="txmd-20190930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:href="txmd-20190930.xsd#EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:href="txmd-20190930.xsd#AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20190930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20190930.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20190930.xsd#AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:href="txmd-20190930.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20190930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20190930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_txmdLicenseRights" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherLongTermDebt" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfOtherLongTermDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedIntellectualLicenseFee" xlink:label="loc_txmdAccruedIntellectualLicenseFee" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedIntellectualLicenseFee" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:title="00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:title="00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000051 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000053 - Disclosure - Supplemental lease information (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="loc_txmdLesseeOperatingLeaseLiabilityImputedInterestAmount" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeaseLiability" xlink:to="loc_txmdLesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000055 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000056 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>txmd-20190930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20190930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:href="txmd-20190930.xsd#ConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20190930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20190930.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:href="txmd-20190930.xsd#Note7IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20190930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20190930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20190930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20190930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20190930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20190930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20190930.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20190930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20190930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20190930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:href="txmd-20190930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20190930.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:href="txmd-20190930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:href="txmd-20190930.xsd#EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:href="txmd-20190930.xsd#AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20190930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20190930.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20190930.xsd#AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:href="txmd-20190930.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20190930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20190930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapDepreciationAndAmortization_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapOperatingExpenses_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapOperatingIncomeLoss_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_120" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapOtherNonoperatingIncome_120" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapInterestExpense_120" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingExpensesAbstract_120" xlink:to="loc_us-gaapNonoperatingIncomeExpense_120" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_120" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_120" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_120" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract_120" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_120" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_120" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapScheduleOfProductInformationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_190" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_130" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_140" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_140" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_140" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks_140" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_140" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_140" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_140" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="loc_txmdDomesticUSPatentsTopicalCreamMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsTopicalCreamMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentDLimoneneMember" xlink:label="loc_txmdDomesticUtilityPatentDLimoneneMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentDLimoneneMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member_220" xlink:type="arc" order="221" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember_350" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember_350" xlink:type="arc" order="351" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierAxis" xlink:label="loc_txmdRoyaltyTierAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_txmdRoyaltyTierAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmdRoyaltyTierDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdRoyaltyTierAxis" xlink:to="loc_txmdRoyaltyTierDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmdRoyaltyTierDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdRoyaltyTierAxis" xlink:to="loc_txmdRoyaltyTierDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="loc_txmdStepBasedRoyaltyPaymentOneMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdRoyaltyTierDomain" xlink:to="loc_txmdStepBasedRoyaltyPaymentOneMember_250" xlink:type="arc" order="253" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_250" xlink:type="arc" order="254" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_270" xlink:type="arc" order="272" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_txmdSubscriptionAgreementKnightMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_400" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_400" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_400" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_400" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval_400" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch_400" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1_400" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges_400" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty_400" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRoyaltyPercent_400" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_400" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_400" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid_400" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_400" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_400" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_400" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived_400" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment_400" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches_400" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone_400" xlink:type="arc" order="19" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CreditAgreementMember" xlink:label="loc_txmdCreditAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdCreditAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent_50" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheOneMember" xlink:label="loc_txmdTrancheOneMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheOneMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoThreeMember" xlink:label="loc_txmdTrancheTwoThreeMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoThreeMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_240" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit_240" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="loc_txmdRevenueRequirementToDrawOnTermLoan_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRevenueRequirementToDrawOnTermLoan_240" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis_240" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1_240" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate_240" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments_240" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent_240" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent_240" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent_240" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent_240" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent_240" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement_240" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility_240" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility_240" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage_240" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage_240" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt_240" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt_240" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_240" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount_240" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts_240" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount_240" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings_240" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_240" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_170" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:title="00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:title="00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_60" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_60" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_60" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_60" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_60" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_60" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_200" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_200" xlink:type="arc" order="201" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member_230" xlink:type="arc" order="231" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember_220" xlink:type="arc" order="222" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember_280" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember_280" xlink:type="arc" order="281" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized_320" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare_320" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_320" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_320" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_320" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_320" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_320" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_320" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_320" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_320" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_320" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption_320" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares_320" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering_320" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_320" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_320" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_320" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_320" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_320" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_320" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_320" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_320" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_320" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_320" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_320" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation_320" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_320" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_320" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_320" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants_320" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_320" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_320" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_320" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmdPlanAwardsNumberOfNewShares_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPlanAwardsNumberOfNewShares_320" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_320" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_320" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_320" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_320" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_320" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_320" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_320" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_320" xlink:type="arc" order="42" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000051 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="loc_txmdThreeCustomersConcentrationRiskMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdThreeCustomersConcentrationRiskMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="loc_txmdCustomerConcentrationPIServicesRiskMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesRiskMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember_110" xlink:type="arc" order="112" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues_180" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000053 - Disclosure - Supplemental lease information (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000055 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000056 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering_50" xlink:type="arc" order="4" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>txmd-20190930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="txmd_PrescriptionVitaminsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrescriptionVitaminsMember_lbl" xml:lang="en-US">Prescription Vitamins [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ImvexxyMember" xlink:label="txmd_ImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ImvexxyMember_lbl" xml:lang="en-US">Imvexxy</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_BijuvaMember" xlink:label="txmd_BijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BijuvaMember_lbl" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnoveraMember" xlink:label="txmd_AnnoveraMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnoveraMember_lbl" xml:lang="en-US">ANNOVERA [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple Trademarks [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Internet Domain Names [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsMember" xlink:label="txmd_DomesticUSPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsMember_lbl" xml:lang="en-US">Domestic US Patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsMember" xlink:label="txmd_ForeignPatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsMember_lbl" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="txmd_DomesticPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsBijuvaMember_lbl" xml:lang="en-US">Domestic Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="txmd_ForeignPatentsBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsBijuvaMember_lbl" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_lbl" xml:lang="en-US">Domestic Patents NonApproved BIJUVA</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="txmd_DomesticUSPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="txmd_ForeignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="txmd_ForeignDesignPatentsImvexxyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_lbl" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsTopicalCreamMember" xlink:to="txmd_DomesticUSPatentsTopicalCreamMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember_lbl" xml:lang="en-US">Domestic US Patents Topical Cream</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_lbl" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="txmd_DomesticUtilityPatentOperaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentOperaMember_lbl" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentDLimoneneMember" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentDLimoneneMember" xlink:to="txmd_DomesticUtilityPatentDLimoneneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember_lbl" xml:lang="en-US">Domestic Utility Patent DLimonene</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="txmd_DomesticUtilityPatentTx009HRMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_lbl" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="txmd_CouncilLicenseAgreement1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreement1Member_lbl" xml:lang="en-US">Council License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierAxis" xlink:label="txmd_RoyaltyTierAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyTierAxis" xlink:to="txmd_RoyaltyTierAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyTierAxis_lbl" xml:lang="en-US">Royalty Tier [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="txmd_StepBasedRoyaltyPaymentOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StepBasedRoyaltyPaymentOneMember" xlink:to="txmd_StepBasedRoyaltyPaymentOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StepBasedRoyaltyPaymentOneMember_lbl" xml:lang="en-US">Step-based Royalty Payment One [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="txmd_CouncilLicenseAgreementStep1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep1Member_lbl" xml:lang="en-US">CouncilLicenseAgreementStep1Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="txmd_CouncilLicenseAgreementStep2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep2Member_lbl" xml:lang="en-US">CouncilLicenseAgreementStep2Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="txmd_CouncilLicenseAgreementStep3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CouncilLicenseAgreementStep3Member_lbl" xml:lang="en-US">CouncilLicenseAgreementStep3Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="txmd_SubscriptionAgreementKnightMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SubscriptionAgreementKnightMember_lbl" xml:lang="en-US">Subscription Agreement Knight [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="txmd_LicenseAgreementTheramexMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseAgreementTheramexMember_lbl" xml:lang="en-US">License Agreement Theramex Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="txmd_FinancingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FinancingAgreementMember_lbl" xml:lang="en-US">Financing Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="us-gaap_CreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreditFacilityAxis_lbl" xml:lang="en-US">Credit Facility [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="us-gaap_RevolvingCreditFacilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevolvingCreditFacilityMember_lbl" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheAxis" xlink:label="txmd_DebtTrancheAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DebtTrancheAxis_lbl" xml:lang="en-US">Debt Tranche [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheOneMember" xlink:label="txmd_TrancheOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheOneMember" xlink:to="txmd_TrancheOneMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheOneMember_lbl" xml:lang="en-US">Tranche 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoMember" xlink:label="txmd_TrancheTwoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoMember_lbl" xml:lang="en-US">Tranche Two [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheThreeMember" xlink:label="txmd_TrancheThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheThreeMember_lbl" xml:lang="en-US">Tranche Three [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VariableRateAxis_lbl" xml:lang="en-US">Variable Rate [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrimeRateMember_lbl" xml:lang="en-US">Prime Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoThreeMember" xlink:label="txmd_TrancheTwoThreeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoThreeMember" xlink:to="txmd_TrancheTwoThreeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_TrancheTwoThreeMember_lbl" xml:lang="en-US">Tranche Two Three Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="us-gaap_SecuredDebtMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecuredDebtMember" xlink:to="us-gaap_SecuredDebtMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecuredDebtMember_lbl" xml:lang="en-US">Secured Debt [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MidCapAgreementMember" xlink:label="txmd_MidCapAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MidCapAgreementMember_lbl" xml:lang="en-US">Credit Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CreditAgreementMember" xlink:label="txmd_CreditAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CreditAgreementMember" xlink:to="txmd_CreditAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CreditAgreementMember_lbl" xml:lang="en-US">Credit Agreement Member</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_lbl" xml:lang="en-US">Underwriting Agreement Goldman Sachs [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsMember" xlink:label="txmd_WarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsMember_lbl" xml:lang="en-US">Warrants Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_OutsideConsultant2Member" xlink:label="txmd_OutsideConsultant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultant2Member_lbl" xml:lang="en-US">Outside Consultants Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_Plan2019Member" xlink:label="txmd_Plan2019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Plan2019Member_lbl" xml:lang="en-US">Plan 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="srt_AffiliatedEntityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliatedEntityMember" xlink:to="srt_AffiliatedEntityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliatedEntityMember_lbl" xml:lang="en-US">Affiliated Entity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="txmd_SupplierTwoConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierTwoConcentrationRiskMember_lbl" xml:lang="en-US">Supplier</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="txmd_SupplierThreeConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_SupplierThreeConcentrationRiskMember_lbl" xml:lang="en-US">Supplier</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="txmd_ThreeCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Three Customers Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="txmd_FourCustomersConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FourCustomersConcentrationRiskMember_lbl" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesRiskMember" xlink:to="txmd_CustomerConcentrationPIServicesRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember_lbl" xml:lang="en-US">Customer Concentration P I Services Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="txmd_CustomerConcentrationPillPackRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_lbl" xml:lang="en-US">PillPack - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_lbl" xml:lang="en-US">AmerisourceBergen - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_lbl" xml:lang="en-US">Cardinal Health - Major Customer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_lbl" xml:lang="en-US">Underwriting Agreement JP Morgan Chase</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts&#160;of $691,699 and $596,602, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseRights" xlink:label="txmd_LicenseRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseRights_lbl" xml:lang="en-US">License rights, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrentAbstract_lbl" xml:lang="en-US">Long-Term Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Long-term debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 15</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 shares authorized: 241,277,076 and 240,462,439 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; (deficit) equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivable_lbl" xml:lang="en-US">allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenue, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in offering, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued for exercise of options and warrants, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in&#160;operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Write off of patent and trademark cost</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="txmd_NoncashOperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US">Non-cash operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for doubtful accounts</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_2_lbl" xml:lang="en-US">Loss on extinguishment of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of intellectual property license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortization of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_lbl" xml:lang="en-US">Payment for intellectual property license</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Payment of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="us-gaap_ProceedsFromOtherDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherDebt" xlink:to="us-gaap_ProceedsFromOtherDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherDebt_lbl" xml:lang="en-US">Proceeds from Financing Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options and warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt_lbl" xml:lang="en-US">Proceeds from Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl" xml:lang="en-US">Payment of deferred financing fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_lbl" xml:lang="en-US">Repayment of Credit Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">(Decrease) increase in cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseExpendituresIncurredButNotYetPaid" xlink:label="txmd_LicenseExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseExpendituresIncurredButNotYetPaid" xlink:to="txmd_LicenseExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LicenseExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Amount accrued for intellectual property license</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">NOTE 1 &#8211; THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract_lbl" xml:lang="en-US">Note 2 Basis Of Presentation And Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_lbl" xml:lang="en-US">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 4 &#8211; INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">NOTE 5 &#8211; OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 6 &#8211; FIXED ASSETS, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 7 &#8211; INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtTextBlock_lbl" xml:lang="en-US">NOTE 9 &#8211; DEBT</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_2_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">NOTE 10 &#8211; NET LOSS PER SHARE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 12 &#8211; INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 13 &#8211; RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">NOTE 16 &#8211; SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfSalesPolicyTextBlock_lbl" xml:lang="en-US">Cost of Sales</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock_lbl" xml:lang="en-US">The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Inventory consists of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Other current assets consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Fixed assets, net consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Other current liabilities consist of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock_lbl" xml:lang="en-US">As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below.</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_lbl" xml:lang="en-US">Supplemental lease information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfSubsidiaries" xlink:label="txmd_NumberOfSubsidiaries" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSubsidiaries_lbl" xml:lang="en-US">Number of subsidiaires</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="us-gaap_ScheduleOfProductInformationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfProductInformationTable" xlink:to="us-gaap_ScheduleOfProductInformationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfProductInformationTable_lbl" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="us-gaap_ProductInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductInformationLineItems" xlink:to="us-gaap_ProductInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductInformationLineItems_lbl" xml:lang="en-US">Product Information [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsAndSupplies" xlink:to="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsAndSupplies_lbl" xml:lang="en-US">Raw material</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_lbl" xml:lang="en-US">Prepaid sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsCurrentNet_lbl" xml:lang="en-US">Deferred financing fees (Note 9)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="us-gaap_IndefiniteLivedTrademarks" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedTrademarks" xlink:to="us-gaap_IndefiniteLivedTrademarks_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedTrademarks_lbl" xml:lang="en-US">Indefinite-Lived Trademarks</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="txmd_MilestonePaymentUponFDAApproval" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentUponFDAApproval_lbl" xml:lang="en-US">Milestone payment upon FDA Approval</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_lbl" xml:lang="en-US">Milestone payments (payment after release of first commercial batch)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinitelivedIntangibleAssetsAcquired1_lbl" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAmortizationOfDeferredCharges" xlink:to="us-gaap_OtherAmortizationOfDeferredCharges_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAmortizationOfDeferredCharges_2_lbl" xml:lang="en-US">Amortization of Other Deferred Charges</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_lbl" xml:lang="en-US">Net sales amount per step-based royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyPercent" xlink:label="txmd_RoyaltyPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RoyaltyPercent_lbl" xml:lang="en-US">Royalty (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_lbl" xml:lang="en-US">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_lbl" xml:lang="en-US">maximum costs and expenses for post approval</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="txmd_CashUpfrontPaymentReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CashUpfrontPaymentReceived_lbl" xml:lang="en-US">Cash upfront payment received</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_lbl" xml:lang="en-US">Regulatory milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="txmd_SalesMilestonePaymentsInTranches" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesMilestonePaymentsInTranches_lbl" xml:lang="en-US">Sales milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualNetSalesMilestone" xlink:label="txmd_AnnualNetSalesMilestone" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AnnualNetSalesMilestone_lbl" xml:lang="en-US">Sales milestone</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedIntellectualLicenseFee" xlink:label="txmd_AccruedIntellectualLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedIntellectualLicenseFee" xlink:to="txmd_AccruedIntellectualLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedIntellectualLicenseFee_lbl" xml:lang="en-US">Accrued intellectual license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="us-gaap_AccruedMarketingCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedMarketingCostsCurrent" xlink:to="us-gaap_AccruedMarketingCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedMarketingCostsCurrent_lbl" xml:lang="en-US">Accrued sales and marketing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="txmd_AccruedResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedResearchAndDevelopment_lbl" xml:lang="en-US">Accrued research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedRebates" xlink:label="txmd_AccruedRebates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedRebates_lbl" xml:lang="en-US">Accrued rebates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentCarryingAmount_lbl" xml:lang="en-US">Long-term Debt, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebtNoncurrent_2_lbl" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RevenueRequirementToDrawOnTermLoan" xlink:to="txmd_RevenueRequirementToDrawOnTermLoan_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan_lbl" xml:lang="en-US">Revenue requirement to draw on term loan tranche</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_lbl" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_lbl" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LiborFloorRate" xlink:label="txmd_LiborFloorRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LiborFloorRate_lbl" xml:lang="en-US">LIBOR floor rate</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="txmd_NumberOfInstallmentPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfInstallmentPayments_lbl" xml:lang="en-US">Number of quarterly principal installment payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_lbl" xml:lang="en-US">Prepayment fee for first two years funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee third year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fourth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_lbl" xml:lang="en-US">Prepayment fee fifth year funding (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FacilityFeePaidPercent" xlink:label="txmd_FacilityFeePaidPercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_FacilityFeePaidPercent_lbl" xml:lang="en-US">Facility fee paid (percent)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_lbl" xml:lang="en-US">Minimum cash balance requirement under credit agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_lbl" xml:lang="en-US">[custom:NumberOfTranchesUnderTermLoanFacility-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_lbl" xml:lang="en-US">Repayment of debt with new credit facility</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeePercentage" xlink:label="txmd_PrepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaymentFeePercentage_lbl" xml:lang="en-US">Prepayment fee percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentFeePercentage" xlink:label="txmd_RepaymentFeePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RepaymentFeePercentage_lbl" xml:lang="en-US">[custom:RepaymentFeePercentage]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_3_lbl" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfFinancingCosts_2_lbl" xml:lang="en-US">Payments of Financing Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_3_lbl" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="us-gaap_InterestExpenseBorrowings" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseBorrowings" xlink:to="us-gaap_InterestExpenseBorrowings_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseBorrowings_lbl" xml:lang="en-US">Interest Expense, Borrowings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Balance, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Balance, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Balance, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Expired Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Balance, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="txmd_PeriodExercisableUnderwritersOption" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PeriodExercisableUnderwritersOption_lbl" xml:lang="en-US">[custom:PeriodExercisableUnderwritersOption]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_lbl" xml:lang="en-US">[custom:UnderwritersOptionGrantedInPeriodShares]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="txmd_ProceedsFromIssuancePublicOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ProceedsFromIssuancePublicOffering_lbl" xml:lang="en-US">Proceeds from issuance public offering</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_lbl" xml:lang="en-US">[custom:NumberOfStockIssuedInCashlessExerciseOfWarrants]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="txmd_PlanAwardsNumberOfNewShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlanAwardsNumberOfNewShares" xlink:to="txmd_PlanAwardsNumberOfNewShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PlanAwardsNumberOfNewShares_lbl" xml:lang="en-US">Plan Awards Number of New Shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_lbl" xml:lang="en-US">Range - exercise price of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted Stock or Unit Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl" xml:lang="en-US">Amount billed</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Accounts Payable, Related Parties, Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfVendors" xlink:label="txmd_NumberOfVendors" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfVendors_lbl" xml:lang="en-US">Number of vendors - suppliers</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCustomers" xlink:label="txmd_NumberOfCustomers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfCustomers_lbl" xml:lang="en-US">Number of customers - revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2019 (3 months)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:to="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Present value of lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NetRentableAreaLease" xlink:label="txmd_NetRentableAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NetRentableAreaLease_lbl" xml:lang="en-US">Net rentable area</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RentedAreaLease" xlink:label="txmd_RentedAreaLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_RentedAreaLease_lbl" xml:lang="en-US">Rented area lease</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="txmd_AdditionalAreaOfLeaseOccupied" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_lbl" xml:lang="en-US">[custom:AdditionalAreaOfLeaseOccupied-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_lbl" xml:lang="en-US">Number of options to extend lease</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseRenewalTerm1_lbl" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_lbl" xml:lang="en-US">Lease not yet commenced (area)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Operating lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_lbl" xml:lang="en-US">[custom:SignificantSupplyCommitmentPercentagePayable-0]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ImvexxyMember" xlink:to="txmd_ImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ImvexxyMember_doc" xml:lang="en-US">Information about ImvexxyTm.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsMember" xlink:to="txmd_DomesticUSPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsMember_doc" xml:lang="en-US">Domestic US Patents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsMember" xlink:to="txmd_ForeignPatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsMember_doc" xml:lang="en-US">Foreign Patents Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsBijuvaMember" xlink:to="txmd_DomesticPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsBijuvaMember_doc" xml:lang="en-US">Domestic Patents Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsBijuvaMember" xlink:to="txmd_ForeignPatentsBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsBijuvaMember_doc" xml:lang="en-US">Foreign Patents BIJUVA</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:to="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticPatentsNonApprovedBijuvaMember_doc" xml:lang="en-US">Domestic Patents NonApproved Bijuva</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsImvexxyMember" xlink:to="txmd_DomesticUSPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:to="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSDesignPatentsImvexxyMember" xlink:to="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSDesignPatentsImvexxyMember_doc" xml:lang="en-US">Domestic US Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignPatentsImvexxyMember" xlink:to="txmd_ForeignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentsImvexxyMember" xlink:to="txmd_ForeignUtilityPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Utility Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignDesignPatentsImvexxyMember" xlink:to="txmd_ForeignDesignPatentsImvexxyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignDesignPatentsImvexxyMember_doc" xml:lang="en-US">Foreign Design Patents IMVEXXY</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUSPatentsTopicalCreamMember" xlink:to="txmd_DomesticUSPatentsTopicalCreamMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUSPatentsTopicalCreamMember_doc" xml:lang="en-US">Domestic US Patents Topical Cream</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:to="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Domestic Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:to="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ForeignUtilityPatentTransdermalPatchMember_doc" xml:lang="en-US">Foreign Utility Patent Transdermal Patch</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentDLimoneneMember" xlink:to="txmd_DomesticUtilityPatentDLimoneneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentDLimoneneMember_doc" xml:lang="en-US">Domestic Utility Patent DLimonene</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentOperaMember" xlink:to="txmd_DomesticUtilityPatentOperaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentOperaMember_doc" xml:lang="en-US">Domestic Utility Patent Opera</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DomesticUtilityPatentTx009HRMember" xlink:to="txmd_DomesticUtilityPatentTx009HRMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DomesticUtilityPatentTx009HRMember_doc" xml:lang="en-US">Domestic Utility Patent TX009HR</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreement1Member" xlink:to="txmd_CouncilLicenseAgreement1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreement1Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnoveraMember" xlink:to="txmd_AnnoveraMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnoveraMember_doc" xml:lang="en-US">The drug name.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep1Member" xlink:to="txmd_CouncilLicenseAgreementStep1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep1Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyPercent" xlink:to="txmd_RoyaltyPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyPercent_doc" xml:lang="en-US">The percent of the net sales to be paid as royalty per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep2Member" xlink:to="txmd_CouncilLicenseAgreementStep2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep2Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CouncilLicenseAgreementStep3Member" xlink:to="txmd_CouncilLicenseAgreementStep3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CouncilLicenseAgreementStep3Member_doc" xml:lang="en-US">Information about agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:to="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_doc" xml:lang="en-US">The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:to="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid_doc" xml:lang="en-US">The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubscriptionAgreementKnightMember" xlink:to="txmd_SubscriptionAgreementKnightMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubscriptionAgreementKnightMember_doc" xml:lang="en-US">Subscription Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RegulatoryMilestoneAdditionalPayment" xlink:to="txmd_RegulatoryMilestoneAdditionalPayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RegulatoryMilestoneAdditionalPayment_doc" xml:lang="en-US">Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesMilestonePaymentsInTranches" xlink:to="txmd_SalesMilestonePaymentsInTranches_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesMilestonePaymentsInTranches_doc" xml:lang="en-US">Amount of sales milestone payments per licensing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedResearchAndDevelopment" xlink:to="txmd_AccruedResearchAndDevelopment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedResearchAndDevelopment_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedRebates" xlink:to="txmd_AccruedRebates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedRebates_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CreditAgreementMember" xlink:to="txmd_CreditAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CreditAgreementMember_doc" xml:lang="en-US">CreditAgreementMember</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FinancingAgreementMember" xlink:to="txmd_FinancingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FinancingAgreementMember_doc" xml:lang="en-US">Represents member of financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierTwoConcentrationRiskMember" xlink:to="txmd_SupplierTwoConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierTwoConcentrationRiskMember_doc" xml:lang="en-US">Supplier Two Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SupplierThreeConcentrationRiskMember_doc" xml:lang="en-US">Supplier Three Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ThreeCustomersConcentrationRiskMember" xlink:to="txmd_ThreeCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ThreeCustomersConcentrationRiskMember_doc" xml:lang="en-US">Three Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FourCustomersConcentrationRiskMember" xlink:to="txmd_FourCustomersConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FourCustomersConcentrationRiskMember_doc" xml:lang="en-US">Four Customers Concentration Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPillPackRiskMember" xlink:to="txmd_CustomerConcentrationPillPackRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPillPackRiskMember_doc" xml:lang="en-US">Major customers in concentration of sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:to="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationAmerisourceBergenRiskMember_doc" xml:lang="en-US">Custome rConcentration AmerisourceBergen Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:to="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationCardinalHealthRiskMember_doc" xml:lang="en-US">Customer Concentration Cardinal Health Risk Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetRentableAreaLease" xlink:to="txmd_NetRentableAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetRentableAreaLease_doc" xml:lang="en-US">Net rentable area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RentedAreaLease" xlink:to="txmd_RentedAreaLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RentedAreaLease_doc" xml:lang="en-US">Rented area as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:to="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea_doc" xml:lang="en-US">Future rented area to be occupied for administrative office space as defined in lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:to="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_doc" xml:lang="en-US">Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsMember" xlink:to="txmd_WarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsMember_doc" xml:lang="en-US">Warrants Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:to="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which warrant holders can acquire the shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultant2Member" xlink:to="txmd_OutsideConsultant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultant2Member_doc" xml:lang="en-US">A person who provides consutling services to the Company.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:to="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants_doc" xml:lang="en-US">Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PlanAwardsNumberOfNewShares" xlink:to="txmd_PlanAwardsNumberOfNewShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PlanAwardsNumberOfNewShares_doc" xml:lang="en-US">Number of new shares authorized for stock awards.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Plan2019Member" xlink:to="txmd_Plan2019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Plan2019Member_doc" xml:lang="en-US">New 2019 Plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationPIServicesRiskMember" xlink:to="txmd_CustomerConcentrationPIServicesRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationPIServicesRiskMember_doc" xml:lang="en-US">PI Services</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalAreaOfLeaseOccupied" xlink:to="txmd_AdditionalAreaOfLeaseOccupied_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalAreaOfLeaseOccupied_doc" xml:lang="en-US">Additional rented area occupied under the lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SignificantSupplyCommitmentPercentagePayable" xlink:to="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SignificantSupplyCommitmentPercentagePayable_doc" xml:lang="en-US">Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementGoldmanSachsMember" xlink:to="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementGoldmanSachsMember_doc" xml:lang="en-US">Underwriter Agrrement GoldmanSachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PeriodExercisableUnderwritersOption" xlink:to="txmd_PeriodExercisableUnderwritersOption_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PeriodExercisableUnderwritersOption_doc" xml:lang="en-US">The period the option is exercisable per agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritersOptionGrantedInPeriodShares" xlink:to="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritersOptionGrantedInPeriodShares_doc" xml:lang="en-US">The number of shares available to be purchased per underwriter's option.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheAxis" xlink:to="txmd_DebtTrancheAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheAxis_doc" xml:lang="en-US">Portions of the Credit and Security Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheOneMember" xlink:to="txmd_TrancheOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheOneMember_doc" xml:lang="en-US">Tranche of the Credit Facility Agreement to draw funds.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoMember" xlink:to="txmd_TrancheTwoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoMember_doc" xml:lang="en-US">Tranche Two as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheThreeMember" xlink:to="txmd_TrancheThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheThreeMember_doc" xml:lang="en-US">Tranche Three as defined in financing agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RevenueRequirementToDrawOnTermLoan" xlink:to="txmd_RevenueRequirementToDrawOnTermLoan_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RevenueRequirementToDrawOnTermLoan_doc" xml:lang="en-US">The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LiborFloorRate" xlink:to="txmd_LiborFloorRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LiborFloorRate_doc" xml:lang="en-US">Represents libor floor rate.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:to="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeForFirstTwoYearsFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeThirdYearFundingPercent" xlink:to="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeThirdYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFourthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFourthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeeFifthYearFundingPercent" xlink:to="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeeFifthYearFundingPercent_doc" xml:lang="en-US">The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_FacilityFeePaidPercent" xlink:to="txmd_FacilityFeePaidPercent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_FacilityFeePaidPercent_doc" xml:lang="en-US">The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:to="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MinimumCashBalanceRequirementUnderCreditAgreement_doc" xml:lang="en-US">The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_TrancheTwoThreeMember" xlink:to="txmd_TrancheTwoThreeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_TrancheTwoThreeMember_doc" xml:lang="en-US">Tranche Two Three Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfTranchesUnderTermLoanFacility" xlink:to="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfTranchesUnderTermLoanFacility_doc" xml:lang="en-US">The number of seperate tranches under terms of the Credit Agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentFeePercentage" xlink:to="txmd_RepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentFeePercentage_doc" xml:lang="en-US">The repayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MidCapAgreementMember" xlink:to="txmd_MidCapAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MidCapAgreementMember_doc" xml:lang="en-US">Represents member of Mid Cap agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:to="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber_doc" xml:lang="en-US">Number of options to extend lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentUponFDAApproval" xlink:to="txmd_MilestonePaymentUponFDAApproval_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentUponFDAApproval_doc" xml:lang="en-US">The amount of milestone payments upon FDA approval.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:to="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_doc" xml:lang="en-US">The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_BijuvaMember" xlink:to="txmd_BijuvaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_BijuvaMember_doc" xml:lang="en-US">BIJUVA [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheDomain" xlink:label="txmd_DebtTrancheDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DebtTrancheDomain" xlink:to="txmd_DebtTrancheDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DebtTrancheDomain_doc" xml:lang="en-US">DebtTrancheDomain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:to="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_doc" xml:lang="en-US">The amount of computed imputed interest for operating lease liability.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseRights" xlink:to="txmd_LicenseRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseRights_doc" xml:lang="en-US">The amount of license rights.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:to="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch_doc" xml:lang="en-US">The amount of milestone payments payable after release of first commercial batch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NetSalesAmountPerStepbasedRoyalty" xlink:to="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NetSalesAmountPerStepbasedRoyalty_doc" xml:lang="en-US">The net sales amount as defined in license agreement for step-based royalty payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NoncashOperatingLeaseExpense" xlink:to="txmd_NoncashOperatingLeaseExpense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NoncashOperatingLeaseExpense_doc" xml:lang="en-US">Amount of expense related to operating lease costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfInstallmentPayments" xlink:to="txmd_NumberOfInstallmentPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfInstallmentPayments_doc" xml:lang="en-US">Number of principal installment payments under credit and security agreement.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="txmd_NumberOfStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:to="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidSalesAndMarketingCostsCurrent_doc" xml:lang="en-US">It refers to the amount of prepaid sales and marketing costs incurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrescriptionVitaminsMember" xlink:to="txmd_PrescriptionVitaminsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrescriptionVitaminsMember_doc" xml:lang="en-US">Information about Prescription Vitamins.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RepaymentOfDebtWithNewCreditFacility" xlink:to="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RepaymentOfDebtWithNewCreditFacility_doc" xml:lang="en-US">Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyTierAxis" xlink:to="txmd_RoyaltyTierAxis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyTierAxis_doc" xml:lang="en-US">Royalty Tier of step-based royalty payment.</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierDomain" xlink:label="txmd_RoyaltyTierDomain" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_RoyaltyTierDomain" xlink:to="txmd_RoyaltyTierDomain_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_RoyaltyTierDomain_doc" xml:lang="en-US">Royalty Tier Domain</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:to="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfIntangibleAssetsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of intangible assets, which may be broken down by major class.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_doc" xml:lang="en-US">Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire unvested shares reserved for issuance.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StepBasedRoyaltyPaymentOneMember" xlink:to="txmd_StepBasedRoyaltyPaymentOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StepBasedRoyaltyPaymentOneMember_doc" xml:lang="en-US">The step-based royalty payment information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_doc" xml:lang="en-US">The cash outlow for payments to acquir intellectual property license.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfVendors" xlink:to="txmd_NumberOfVendors_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfVendors_doc" xml:lang="en-US">Number of vendors.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfCustomers" xlink:to="txmd_NumberOfCustomers_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfCustomers_doc" xml:lang="en-US">Number of customers.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseAgreementTheramexMember" xlink:to="txmd_LicenseAgreementTheramexMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseAgreementTheramexMember_doc" xml:lang="en-US">License Agreement Theramex Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AnnualNetSalesMilestone" xlink:to="txmd_AnnualNetSalesMilestone_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AnnualNetSalesMilestone_doc" xml:lang="en-US">Annual net sale milestones in the Territory per license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedIntellectualLicenseFee" xlink:to="txmd_AccruedIntellectualLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedIntellectualLicenseFee_doc" xml:lang="en-US">Amount of expenses incurred but not yet paid for intellectual license fee, due within one year or the normal operating cycle, if longer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CashUpfrontPaymentReceived" xlink:to="txmd_CashUpfrontPaymentReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CashUpfrontPaymentReceived_doc" xml:lang="en-US">The cash inflow from license agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaymentFeePercentage" xlink:to="txmd_PrepaymentFeePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaymentFeePercentage_doc" xml:lang="en-US">The prepayment fee, expressed as a percentage of the tranche funding being repaid,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSubsidiaries" xlink:to="txmd_NumberOfSubsidiaries_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfSubsidiaries_doc" xml:lang="en-US">Number of subsidiaires for period reported.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:to="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_doc" xml:lang="en-US">Disclosure of supplementary lease and cash flow information.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_UnderwritingAgreementJPMorganChaseMember" xlink:to="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_UnderwritingAgreementJPMorganChaseMember_doc" xml:lang="en-US">Underwriting Agreement JP Morgan Chase Member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ProceedsFromIssuancePublicOffering" xlink:to="txmd_ProceedsFromIssuancePublicOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ProceedsFromIssuancePublicOffering_doc" xml:lang="en-US">The cash inflow associated with the amount received from entity's raising of capital by public offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LicenseExpendituresIncurredButNotYetPaid" xlink:to="txmd_LicenseExpendituresIncurredButNotYetPaid_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LicenseExpendituresIncurredButNotYetPaid_doc" xml:lang="en-US">Future cash outflow to pay for purchases of licenses that have occurred.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_doc" xml:lang="en-US">The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SupplierThreeConcentrationRiskMember" xlink:to="txmd_SupplierThreeConcentrationRiskMember_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SupplierThreeConcentrationRiskMember_3_lbl" xml:lang="en-US">Supplier [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross Profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:to="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PaymentsToAcquireIntellectualPropertyLicense_3_lbl" xml:lang="en-US">Payments to acquire intellectual property license</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfOtherLongTermDebt" xlink:to="us-gaap_RepaymentsOfOtherLongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfOtherLongTermDebt_2_lbl" xml:lang="en-US">Repayments of Other Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_2_lbl" xml:lang="en-US">Interest Expense, Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Outstanding Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_3_lbl" xml:lang="en-US">Unvested ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_3_lbl" xml:lang="en-US">Outstanding Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:to="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount_3_lbl" xml:lang="en-US">LesseeOperatingLeaseLiabilityImputedInterestAmount</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>txmd-20190930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.1b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Cover" xlink:href="txmd-20190930.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20190930.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:href="txmd-20190930.xsd#ConsolidatedStatementOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20190930.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1Company" xlink:href="txmd-20190930.xsd#Note1Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4Inventory" xlink:href="txmd-20190930.xsd#Note4Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:href="txmd-20190930.xsd#Note7IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9Debt" xlink:href="txmd-20190930.xsd#Note9Debt" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:href="txmd-20190930.xsd#Note10NetLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:href="txmd-20190930.xsd#Note11StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:href="txmd-20190930.xsd#Note12IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:href="txmd-20190930.xsd#Note13RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:href="txmd-20190930.xsd#Note16SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20190930.xsd#Note3SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:href="txmd-20190930.xsd#Note4InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:href="txmd-20190930.xsd#Note5OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:href="txmd-20190930.xsd#Note8OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtTables" xlink:href="txmd-20190930.xsd#Note9DebtTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:href="txmd-20190930.xsd#Note10NetLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:href="txmd-20190930.xsd#Note1CompanyDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:href="txmd-20190930.xsd#FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:href="txmd-20190930.xsd#InventoryConsistsOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentAssetsConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#FixedAssetsNetConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:href="txmd-20190930.xsd#Note6FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:href="txmd-20190930.xsd#FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:href="txmd-20190930.xsd#EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note7IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:href="txmd-20190930.xsd#OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:href="txmd-20190930.xsd#AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:href="txmd-20190930.xsd#Note9DebtDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:href="txmd-20190930.xsd#TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:href="txmd-20190930.xsd#AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:href="txmd-20190930.xsd#SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:href="txmd-20190930.xsd#Note11StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note13RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note14BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:href="txmd-20190930.xsd#SupplementalLeaseInformationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:href="txmd-20190930.xsd#FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20190930.xsd#Note15CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:href="txmd-20190930.xsd#Note16SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseRights" xlink:label="loc_txmdLicenseRights" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_txmdLicenseRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrentAbstract" xlink:label="loc_us-gaapLongTermDebtNoncurrentAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongTermDebtNoncurrentAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaapProductMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NoncashOperatingLeaseExpense" xlink:label="loc_txmdNoncashOperatingLeaseExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_txmdNoncashOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PaymentsToAcquireIntellectualPropertyLicense" xlink:label="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_txmdPaymentsToAcquireIntellectualPropertyLicense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaapProceedsFromOtherDebt" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromOtherDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfOtherLongTermDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfOtherLongTermDebt" xlink:label="loc_us-gaapRepaymentsOfOtherLongTermDebt" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfOtherLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseExpendituresIncurredButNotYetPaid" xlink:label="loc_txmdLicenseExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_txmdLicenseExpendituresIncurredButNotYetPaid" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1Company" xlink:title="00000007 - Disclosure - NOTE 1 &#8211; THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements" xlink:title="00000008 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS">
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmdDisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:label="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="loc_txmdBasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies" xlink:title="00000009 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4Inventory" xlink:title="00000010 - Disclosure - NOTE 4 &#8211; INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssets" xlink:title="00000011 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNet" xlink:title="00000012 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssets" xlink:title="00000013 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9Debt" xlink:title="00000015 - Disclosure - NOTE 9 &#8211; DEBT">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="loc_us-gaapLongTermDebtTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShare" xlink:title="00000016 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquity" xlink:title="00000017 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note12IncomeTaxes" xlink:title="00000018 - Disclosure - NOTE 12 &#8211; INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedParties" xlink:title="00000019 - Disclosure - NOTE 13 &#8211; RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrations" xlink:title="00000020 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies" xlink:title="00000021 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEvents" xlink:title="00000022 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="loc_us-gaapCostOfSalesPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCostOfSalesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaapDisaggregationOfRevenueTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDisaggregationOfRevenueTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note4InventoryTables" xlink:title="00000025 - Disclosure - NOTE 4 &#8211; INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetTables" xlink:title="00000027 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsTables" xlink:title="00000028 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ScheduleOfIntangibleAssetsTableTextBlock" xlink:label="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_txmdScheduleOfIntangibleAssetsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables" xlink:title="00000029 - Disclosure - NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtTables" xlink:title="00000030 - Disclosure - NOTE 9 &#8211; DEBT (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note10NetLossPerShareTables" xlink:title="00000031 - Disclosure - NOTE 10 &#8211; NET LOSS PER SHARE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityTables" xlink:title="00000032 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:label="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative" xlink:title="00000034 - Disclosure - NOTE 1 &#8211; THE COMPANY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfSubsidiaries" xlink:label="loc_txmdNumberOfSubsidiaries" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_txmdNumberOfSubsidiaries" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative" xlink:title="00000035 - Disclosure - NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:label="loc_txmdDisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details" xlink:title="00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfProductInformationTable" xlink:label="loc_us-gaapScheduleOfProductInformationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfProductInformationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductInformationLineItems" xlink:label="loc_us-gaapProductInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_us-gaapProductInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfProductInformationTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrescriptionVitaminsMember" xlink:label="loc_txmdPrescriptionVitaminsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdPrescriptionVitaminsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ImvexxyMember" xlink:label="loc_txmdImvexxyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_BijuvaMember" xlink:label="loc_txmdBijuvaMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseAndServiceMember" xlink:label="loc_us-gaapLicenseAndServiceMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_us-gaapLicenseAndServiceMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProductInformationLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails" xlink:title="00000037 - Disclosure - Inventory consists of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSupplies" xlink:label="loc_us-gaapInventoryRawMaterialsAndSupplies" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterialsAndSupplies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails" xlink:title="00000038 - Disclosure - Other current assets consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaidSalesAndMarketingCostsCurrent" xlink:label="loc_txmdPrepaidSalesAndMarketingCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdPrepaidSalesAndMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsCurrentNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsCurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails" xlink:title="00000039 - Disclosure - Fixed assets, net consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative" xlink:title="00000040 - Disclosure - NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details" xlink:title="00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedTrademarks" xlink:label="loc_us-gaapIndefiniteLivedTrademarks" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedTrademarks" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails" xlink:title="00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative" xlink:title="00000043 - Disclosure - NOTE 7 &#8211; INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsMember" xlink:label="loc_txmdDomesticUSPatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsMember" xlink:label="loc_txmdForeignPatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsBijuvaMember" xlink:label="loc_txmdDomesticPatentsBijuvaMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsBijuvaMember" xlink:label="loc_txmdForeignPatentsBijuvaMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticPatentsNonApprovedBijuvaMember" xlink:label="loc_txmdDomesticPatentsNonApprovedBijuvaMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticPatentsNonApprovedBijuvaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSPatentsImvexxyMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSUtilityPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSUtilityPatentsImvexxyMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSDesignPatentsImvexxyMember" xlink:label="loc_txmdDomesticUSDesignPatentsImvexxyMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignPatentsImvexxyMember" xlink:label="loc_txmdForeignPatentsImvexxyMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentsImvexxyMember" xlink:label="loc_txmdForeignUtilityPatentsImvexxyMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignDesignPatentsImvexxyMember" xlink:label="loc_txmdForeignDesignPatentsImvexxyMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignDesignPatentsImvexxyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUSPatentsTopicalCreamMember" xlink:label="loc_txmdDomesticUSPatentsTopicalCreamMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUSPatentsTopicalCreamMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdDomesticUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ForeignUtilityPatentTransdermalPatchMember" xlink:label="loc_txmdForeignUtilityPatentTransdermalPatchMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdForeignUtilityPatentTransdermalPatchMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentOperaMember" xlink:label="loc_txmdDomesticUtilityPatentOperaMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentOperaMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentDLimoneneMember" xlink:label="loc_txmdDomesticUtilityPatentDLimoneneMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentDLimoneneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DomesticUtilityPatentTx009HRMember" xlink:label="loc_txmdDomesticUtilityPatentTx009HRMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdDomesticUtilityPatentTx009HRMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreement1Member" xlink:label="loc_txmdCouncilLicenseAgreement1Member" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreement1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep1Member" xlink:label="loc_txmdCouncilLicenseAgreementStep1Member" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep2Member" xlink:label="loc_txmdCouncilLicenseAgreementStep2Member" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CouncilLicenseAgreementStep3Member" xlink:label="loc_txmdCouncilLicenseAgreementStep3Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdCouncilLicenseAgreementStep3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LicenseAgreementTheramexMember" xlink:label="loc_txmdLicenseAgreementTheramexMember" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdLicenseAgreementTheramexMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtProductOrServiceAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnoveraMember" xlink:label="loc_txmdAnnoveraMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_txmdAnnoveraMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierAxis" xlink:label="loc_txmdRoyaltyTierAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_txmdRoyaltyTierAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyTierDomain" xlink:label="loc_txmdRoyaltyTierDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdRoyaltyTierAxis" xlink:to="loc_txmdRoyaltyTierDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_StepBasedRoyaltyPaymentOneMember" xlink:label="loc_txmdStepBasedRoyaltyPaymentOneMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdRoyaltyTierDomain" xlink:to="loc_txmdStepBasedRoyaltyPaymentOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_txmdSubscriptionAgreementKnightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentUponFDAApproval" xlink:label="loc_txmdMilestonePaymentUponFDAApproval" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentUponFDAApproval" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:label="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMilestonePaymentsAfterReleaseOfFirstCommercialBatch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:label="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapFinitelivedIntangibleAssetsAcquired1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAmortizationOfDeferredCharges" xlink:label="loc_us-gaapOtherAmortizationOfDeferredCharges" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapOtherAmortizationOfDeferredCharges" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NetSalesAmountPerStepbasedRoyalty" xlink:label="loc_txmdNetSalesAmountPerStepbasedRoyalty" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdNetSalesAmountPerStepbasedRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RoyaltyPercent" xlink:label="loc_txmdRoyaltyPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRoyaltyPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:label="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:label="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdMaximumCostsAndExpensesForPostApprovalStudyToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CashUpfrontPaymentReceived" xlink:label="loc_txmdCashUpfrontPaymentReceived" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdCashUpfrontPaymentReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RegulatoryMilestoneAdditionalPayment" xlink:label="loc_txmdRegulatoryMilestoneAdditionalPayment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdRegulatoryMilestoneAdditionalPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesMilestonePaymentsInTranches" xlink:label="loc_txmdSalesMilestonePaymentsInTranches" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdSalesMilestonePaymentsInTranches" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AnnualNetSalesMilestone" xlink:label="loc_txmdAnnualNetSalesMilestone" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsLineItems" xlink:to="loc_txmdAnnualNetSalesMilestone" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails" xlink:title="00000044 - Disclosure - Other current liabilities consist of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedIntellectualLicenseFee" xlink:label="loc_txmdAccruedIntellectualLicenseFee" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedIntellectualLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedMarketingCostsCurrent" xlink:label="loc_us-gaapAccruedMarketingCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedMarketingCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedResearchAndDevelopment" xlink:label="loc_txmdAccruedResearchAndDevelopment" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AccruedRebates" xlink:label="loc_txmdAccruedRebates" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_txmdAccruedRebates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails" xlink:title="00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CreditAgreementMember" xlink:label="loc_txmdCreditAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdCreditAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note9DebtDetailsNarrative" xlink:title="00000046 - Disclosure - NOTE 9 &#8211; DEBT (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdFinancingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MidCapAgreementMember" xlink:label="loc_txmdMidCapAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdMidCapAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaapCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaapCreditFacilityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityAxis" xlink:to="loc_us-gaapCreditFacilityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="loc_us-gaapRevolvingCreditFacilityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapRevolvingCreditFacilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaapSecuredDebtMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreditFacilityDomain" xlink:to="loc_us-gaapSecuredDebtMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheAxis" xlink:label="loc_txmdDebtTrancheAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_txmdDebtTrancheAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_DebtTrancheDomain" xlink:label="loc_txmdDebtTrancheDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheAxis" xlink:to="loc_txmdDebtTrancheDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheOneMember" xlink:label="loc_txmdTrancheOneMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheOneMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoMember" xlink:label="loc_txmdTrancheTwoMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheThreeMember" xlink:label="loc_txmdTrancheThreeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_TrancheTwoThreeMember" xlink:label="loc_txmdTrancheTwoThreeMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDebtTrancheDomain" xlink:to="loc_txmdTrancheTwoThreeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaapVariableRateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapVariableRateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaapVariableRateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateAxis" xlink:to="loc_us-gaapVariableRateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaapPrimeRateMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapVariableRateDomain" xlink:to="loc_us-gaapPrimeRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FinancingAgreementMember" xlink:label="loc_txmdFinancingAgreementMember_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdFinancingAgreementMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RevenueRequirementToDrawOnTermLoan" xlink:label="loc_txmdRevenueRequirementToDrawOnTermLoan" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRevenueRequirementToDrawOnTermLoan" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentDescriptionOfVariableRateBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LiborFloorRate" xlink:label="loc_txmdLiborFloorRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdLiborFloorRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfInstallmentPayments" xlink:label="loc_txmdNumberOfInstallmentPayments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfInstallmentPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeForFirstTwoYearsFundingPercent" xlink:label="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeForFirstTwoYearsFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeThirdYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeThirdYearFundingPercent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeThirdYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFourthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFourthYearFundingPercent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFourthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeeFifthYearFundingPercent" xlink:label="loc_txmdPrepaymentFeeFifthYearFundingPercent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeeFifthYearFundingPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FacilityFeePaidPercent" xlink:label="loc_txmdFacilityFeePaidPercent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdFacilityFeePaidPercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_MinimumCashBalanceRequirementUnderCreditAgreement" xlink:label="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdMinimumCashBalanceRequirementUnderCreditAgreement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfTranchesUnderTermLoanFacility" xlink:label="loc_txmdNumberOfTranchesUnderTermLoanFacility" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdNumberOfTranchesUnderTermLoanFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentOfDebtWithNewCreditFacility" xlink:label="loc_txmdRepaymentOfDebtWithNewCreditFacility" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentOfDebtWithNewCreditFacility" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PrepaymentFeePercentage" xlink:label="loc_txmdPrepaymentFeePercentage" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdPrepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RepaymentFeePercentage" xlink:label="loc_txmdRepaymentFeePercentage" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_txmdRepaymentFeePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapGainsLossesOnExtinguishmentOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaapInterestExpenseDebt" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaapDebtInstrumentCarryingAmount" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentCarryingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="loc_us-gaapPaymentsOfFinancingCosts" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPaymentsOfFinancingCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaapDebtInstrumentUnamortizedDiscount" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentUnamortizedDiscount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_2" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpenseBorrowings" xlink:label="loc_us-gaapInterestExpenseBorrowings" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapInterestExpenseBorrowings" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details" xlink:title="00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details" xlink:title="00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails" xlink:title="00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementGoldmanSachsMember" xlink:label="loc_txmdUnderwritingAgreementGoldmanSachsMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SubscriptionAgreementKnightMember" xlink:label="loc_txmdSubscriptionAgreementKnightMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdSubscriptionAgreementKnightMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsMember" xlink:label="loc_txmdWarrantsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_OutsideConsultant2Member" xlink:label="loc_txmdOutsideConsultant2Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_Plan2019Member" xlink:label="loc_txmdPlan2019Member" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdPlan2019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaapRestrictedStockMember" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaapRestrictedStockUnitsRSUMember" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapRestrictedStockUnitsRSUMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:label="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:label="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:label="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfStockIssuedInCashlessExerciseOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PlanAwardsNumberOfNewShares" xlink:label="loc_txmdPlanAwardsNumberOfNewShares" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdPlanAwardsNumberOfNewShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative" xlink:title="00000051 - Disclosure - NOTE 13 &#8211; RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_AffiliatedEntityMember" xlink:label="loc_srtAffiliatedEntityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_srtAffiliatedEntityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative" xlink:title="00000052 - Disclosure - NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierTwoConcentrationRiskMember" xlink:label="loc_txmdSupplierTwoConcentrationRiskMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierTwoConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SupplierThreeConcentrationRiskMember" xlink:label="loc_txmdSupplierThreeConcentrationRiskMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdSupplierThreeConcentrationRiskMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ThreeCustomersConcentrationRiskMember" xlink:label="loc_txmdThreeCustomersConcentrationRiskMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdThreeCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_FourCustomersConcentrationRiskMember" xlink:label="loc_txmdFourCustomersConcentrationRiskMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdFourCustomersConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPIServicesRiskMember" xlink:label="loc_txmdCustomerConcentrationPIServicesRiskMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPIServicesRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationPillPackRiskMember" xlink:label="loc_txmdCustomerConcentrationPillPackRiskMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationPillPackRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationAmerisourceBergenRiskMember" xlink:label="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationAmerisourceBergenRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CustomerConcentrationCardinalHealthRiskMember" xlink:label="loc_txmdCustomerConcentrationCardinalHealthRiskMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationCardinalHealthRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfVendors" xlink:label="loc_txmdNumberOfVendors" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfVendors" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NumberOfCustomers" xlink:label="loc_txmdNumberOfCustomers" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_txmdNumberOfCustomers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails" xlink:title="00000053 - Disclosure - Supplemental lease information (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapRightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails" xlink:title="00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:label="loc_txmdLesseeOperatingLeaseLiabilityImputedInterestAmount" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdLesseeOperatingLeaseLiabilityImputedInterestAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000055 - Disclosure - NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_NetRentableAreaLease" xlink:label="loc_txmdNetRentableAreaLease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdNetRentableAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_RentedAreaLease" xlink:label="loc_txmdRentedAreaLease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdRentedAreaLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_AdditionalAreaOfLeaseOccupied" xlink:label="loc_txmdAdditionalAreaOfLeaseOccupied" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdAdditionalAreaOfLeaseOccupied" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaapLesseeOperatingLeaseTermOfContract" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseTermOfContract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:label="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdLesseeFinanceLeaseExistenceOfOptionToExtendNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:label="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLesseeFinanceLeaseRenewalTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:label="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdLesseeOperatingLeaseLeaseNotYetCommencedArea" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_SignificantSupplyCommitmentPercentagePayable" xlink:label="loc_txmdSignificantSupplyCommitmentPercentagePayable" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdSignificantSupplyCommitmentPercentagePayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative" xlink:title="00000056 - Disclosure - NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritingAgreementJPMorganChaseMember" xlink:label="loc_txmdUnderwritingAgreementJPMorganChaseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_txmdUnderwritingAgreementJPMorganChaseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_PeriodExercisableUnderwritersOption" xlink:label="loc_txmdPeriodExercisableUnderwritersOption" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdPeriodExercisableUnderwritersOption" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_UnderwritersOptionGrantedInPeriodShares" xlink:label="loc_txmdUnderwritersOptionGrantedInPeriodShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdUnderwritersOptionGrantedInPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20190930.xsd#txmd_ProceedsFromIssuancePublicOffering" xlink:label="loc_txmdProceedsFromIssuancePublicOffering" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_txmdProceedsFromIssuancePublicOffering" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780415920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY (Details Narrative)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSubsidiaries', window );">Number of subsidiaires</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of subsidiaires for period reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6658017568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zdbjB65BooBl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;As
of  September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Financing Agreement</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zLAtaomMsoWl">200,000,000</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">&#8212;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Credit Agreement</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zerwox7m3Tek">75,000,000</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Debt discount and financing fees</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20190930_zDle5W3cHaC">5,638,831</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20181231_z91shXXUtoF2">1,618,986</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL LONG-TERM DEBT</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--LongTermDebtNoncurrent_iI_c20190930_z5GQliQ99n25">194,361,169</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_c20181231_znb2rDrzaIvk">73,381,014</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791318336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current assets consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidSalesAndMarketingCostsCurrent', window );">Prepaid sales and marketing costs</a></td>
<td class="nump">$ 1,313,192<span></span>
</td>
<td class="nump">$ 5,148,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Deferred financing fees (Note 9)</a></td>
<td class="nump">550,757<span></span>
</td>
<td class="nump">1,898,074<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">2,542,008<span></span>
</td>
<td class="nump">790,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">6,172,303<span></span>
</td>
<td class="nump">2,997,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 10,578,260<span></span>
</td>
<td class="nump">$ 10,834,693<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidSalesAndMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It refers to the amount of prepaid sales and marketing costs incurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidSalesAndMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5865-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6787-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>txmd-10q_093019_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:txmd="http://therapeuticsmd.com/20190930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="txmd-20190930.xsd" xlink:type="simple"/>
    <context id="From2019-01-01to2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-11-04</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="AsOf2018-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-03-31</instant>
        </period>
    </context>
    <context id="From2018-04-012018-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2018-04-012018-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="AsOf2019-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-01-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-01-02</instant>
        </period>
    </context>
    <context id="AsOf2019-08-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_custom_PrescriptionVitaminsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:PrescriptionVitaminsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_custom_ImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:ImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_BijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:BijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_InternetDomainNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUSPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignPatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignPatentsBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticPatentsNonApprovedBijuvaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticPatentsNonApprovedBijuvaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUSPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUSUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUSDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignUtilityPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignDesignPatentsImvexxyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignDesignPatentsImvexxyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUSPatentsTopicalCreamMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUSPatentsTopicalCreamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_ForeignUtilityPatentTransdermalPatchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ForeignUtilityPatentTransdermalPatchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUtilityPatentOperaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentOperaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUtilityPatentDLimoneneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentDLimoneneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_DomesticUtilityPatentTx009HRMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:DomesticUtilityPatentTx009HRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentOneMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">txmd:AnnoveraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:RoyaltyTierAxis">txmd:StepBasedRoyaltyPaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreementStep3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:CouncilLicenseAgreement1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-30</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-06</instant>
        </period>
    </context>
    <context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-06</instant>
        </period>
    </context>
    <context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:LicenseAgreementTheramexMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-04</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheTwoThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-24</instant>
        </period>
    </context>
    <context id="AsOf2018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-01</instant>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-30</startDate>
            <endDate>2018-05-01</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-04-232019-04-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2019-04-23</startDate>
            <endDate>2019-04-24</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_MidCapAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:MidCapAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="txmd:DebtTrancheAxis">txmd:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_FinancingAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:FinancingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_custom_CreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementGoldmanSachsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-28</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-08-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-08-01</instant>
        </period>
    </context>
    <context id="From2018-08-052018-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2018-08-05</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:SubscriptionAgreementKnightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-05</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_WarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_WarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-09-30_custom_OutsideConsultant2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultant2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_Plan2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:Plan2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2019-09-30_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-12</startDate>
            <endDate>2018-12-13</endDate>
        </period>
    </context>
    <context id="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-29</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-07-012019-09-30_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-07-012018-09-30_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-09-30_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="AsOf2018-12-31_srt_AffiliatedEntityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierTwoConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:SupplierThreeConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_ThreeCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:ThreeCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:FourCustomersConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPIServicesRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationPillPackRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationAmerisourceBergenRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationCardinalHealthRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="From2013-06-292013-07-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <startDate>2013-06-29</startDate>
            <endDate>2013-07-01</endDate>
        </period>
    </context>
    <context id="AsOf2018-10-01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-23</startDate>
            <endDate>2019-10-24</endDate>
        </period>
    </context>
    <context id="AsOf2019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-24</instant>
        </period>
    </context>
    <context id="From2018-07-282018-08-01_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-28</startDate>
            <endDate>2018-08-01</endDate>
        </period>
    </context>
    <context id="From2019-10-232019-10-29_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000025743</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">txmd:UnderwritingAgreementJPMorganChaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-23</startDate>
            <endDate>2019-10-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="SQFT">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Tranches">
        <measure>txmd:Tranch</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2019-01-01to2019-09-30">0000025743</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2019-01-01to2019-09-30">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="From2019-01-01to2019-09-30">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2019-01-01to2019-09-30">2019</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2019-01-01to2019-09-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0036">Large Accelerated Filer</dei:EntityFilerCategory>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0079"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0112"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2019-09-30"
      id="xdx2ixbrl0123"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0124"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-07-012019-09-30"
      id="xdx2ixbrl0210"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-07-012018-09-30"
      id="xdx2ixbrl0211"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0213"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-07-012019-09-30"
      id="xdx2ixbrl0235"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2018-07-012018-09-30"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2019-01-01to2019-09-30"
      id="xdx2ixbrl0237"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0238"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0268"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0272"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0274"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0278"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0290"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0318"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0346"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0350"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0352"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0355"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0366"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0368"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0371"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0372"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0384"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0393"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0417"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0426"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2019-01-01to2019-09-30"
      id="xdx2ixbrl0461"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2019-01-01to2019-09-30"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2019-01-01to2019-09-30"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:LicenseExpendituresIncurredButNotYetPaid
      contextRef="From2018-01-012018-09-30"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      id="xdx2ixbrl0640">P13Y3M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="From2018-01-012018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      id="xdx2ixbrl0651">P10Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      id="xdx2ixbrl0654"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:AccruedIntellectualLicenseFee
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0743"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2018-12-31"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedRentCurrent
      contextRef="AsOf2019-09-30"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0881">P2Y73D</txmd:WarrantsAndRightsWeightedAverageContractualRemainingLife>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2019-01-012019-09-30_custom_WarrantsMember"
      id="xdx2ixbrl0906">P146D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2018-01-012018-12-31_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0960">P5Y343DT2H24M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl0979">P6Y18DT6H</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0987">P4Y292D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms contextRef="From2019-01-01to2019-09-30" id="xdx2ixbrl0995">P9Y21DT21H36M</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      id="xdx2ixbrl1007">P2Y146D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockUnitsRSUMember"
      id="xdx2ixbrl1015">P2Y73D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <dei:DocumentType contextRef="From2019-01-01to2019-09-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2019-01-01to2019-09-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2019-01-01to2019-09-30">2019-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2019-01-01to2019-09-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2019-01-01to2019-09-30">001-00100</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2019-01-01to2019-09-30">THERAPEUTICSMD, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2019-01-01to2019-09-30">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2019-01-01to2019-09-30">87-0233535</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2019-01-01to2019-09-30">951 Yamato Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2019-01-01to2019-09-30">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2019-01-01to2019-09-30">Boca Raton</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2019-01-01to2019-09-30">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2019-01-01to2019-09-30">33431</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2019-01-01to2019-09-30">561</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2019-01-01to2019-09-30">961-1900</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2019-01-01to2019-09-30">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2019-01-01to2019-09-30">TXMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2019-01-01to2019-09-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2019-01-01to2019-09-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2019-01-01to2019-09-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntitySmallBusiness contextRef="From2019-01-01to2019-09-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2019-01-01to2019-09-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2019-01-01to2019-09-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2019-11-04" decimals="INF" unitRef="Shares">271177076</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Cash contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">155330050</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">691699</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">596602</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">15323614</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">11063821</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10532844</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10578260</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">191764768</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">186779261</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2338346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:LicenseRights contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">39984002</txmd:LicenseRights>
    <txmd:LicenseRights contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">20000000</txmd:LicenseRights>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">4942151</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10459635</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">473009</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">639301</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">55858797</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">24731980</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">249961911</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">211983924</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">24133506</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">22743841</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">43196032</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">67329538</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">41078789</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">194361169</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">9500133</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">271190840</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">114459803</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2018-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">241277076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" decimals="0" unitRef="Shares">241277076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">240462439</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-12-31" decimals="0" unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">241277</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">240463</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">624515559</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">616559938</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-645985765</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">-519276280</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-21228929</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">249961911</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">211983924</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">8213341</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">3473535</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">18238857</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-09-30_us-gaap_ProductMember"
      decimals="0"
      unitRef="USD">11009937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">23719741</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">3473535</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">33745257</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">11009937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">1444308</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">699118</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">3455995</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">1786902</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">22275433</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">2774417</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">30289262</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">9223035</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">45126986</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">30354072</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">121378519</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">80578079</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">4077738</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">6708271</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">15359988</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">20545948</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">141959</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">73321</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">363956</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">198545</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">49346683</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">37135664</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">137102463</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">101322572</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-27071250</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">-34361247</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-106813201</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-92099537</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">703662</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">809022</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1878980</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">1457817</us-gaap:OtherNonoperatingIncome>
    <us-gaap:InterestExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">5599005</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">2053077</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">11717632</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">2584459</us-gaap:InterestExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-4895343</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">-1244055</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-19896284</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-1126642</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">-35605302</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-93226179</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">-35605302</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-93226179</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="2"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-07-012018-09-30"
      decimals="2"
      unitRef="USDPShares">-0.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2019-01-01to2019-09-30"
      decimals="2"
      unitRef="USDPShares">-0.53</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2018-01-012018-09-30"
      decimals="2"
      unitRef="USDPShares">-0.42</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="Shares">241261299</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="Shares">228107240</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="Shares">241163994</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="Shares">220466673</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">216429642</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">216430</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">516351405</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-386659120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">129908715</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">154632</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">154</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">43902</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-03-31"
      decimals="0"
      unitRef="USD">44056</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1751358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-01-012018-03-31"
      decimals="0"
      unitRef="USD">1751358</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-24401829</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-03-31"
      decimals="0"
      unitRef="USD">-24401829</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">216584274</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">216584</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">518146665</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-411060949</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-03-31" decimals="0" unitRef="USD">107302300</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">249785</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-04-012018-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">250</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1084689</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-04-012018-06-30"
      decimals="0"
      unitRef="USD">1084939</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-04-012018-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2377082</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-04-012018-06-30"
      decimals="0"
      unitRef="USD">2377082</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-04-012018-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-33219048</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-04-012018-06-30"
      decimals="0"
      unitRef="USD">-33219048</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">216834059</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">216834</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">521608436</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-444279997</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-06-30" decimals="0" unitRef="USD">77545273</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">1052300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1053</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">106265</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">107318</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">18578430</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-012018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">18578</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">89889219</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">89907797</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-07-012018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2260195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">2260195</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-35605302</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">-35605302</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">236464789</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">236465</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">613864115</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-479885299</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">134215281</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">240462439</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">240463</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">616559938</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-519276280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">97524121</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">759401</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-012019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">759</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">99348</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">100107</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">2575369</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-012019-03-31"
      decimals="0"
      unitRef="USD">-39506375</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">619234655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-558782655</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-03-31" decimals="0" unitRef="USD">60693222</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">2637264</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-04-012019-06-30"
      decimals="0"
      unitRef="USD">-55236517</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">241221840</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241222</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">621871919</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-614019172</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-06-30" decimals="0" unitRef="USD">8093969</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">55236</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">55</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">8494</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">8549</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">2635146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">2635146</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">-31966593</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="Shares">241277076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">241277</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">624515559</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-09-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-645985765</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">-21228929</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-126709485</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-93226179</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">223750</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">121423</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">140206</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">77123</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OtherNoncashExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">78864</us-gaap:OtherNoncashExpense>
    <txmd:NoncashOperatingLeaseExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">711836</txmd:NoncashOperatingLeaseExpense>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">95097</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">231475</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">7859357</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">6388635</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">15998</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">582829</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">149909</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">4354890</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">8705325</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">7265174</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">892863</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1128515</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-1233482</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1389665</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">7284493</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">3402511</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">8670986</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-114900319</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-78666841</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <txmd:PaymentsToAcquireIntellectualPropertyLicense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">20000000</txmd:PaymentsToAcquireIntellectualPropertyLicense>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1068542</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">748906</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">2089413</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">66295</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">20420</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">11485</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-3178375</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">-20826686</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromOtherDebt
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromOtherDebt>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">108656</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">1236313</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">89907797</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">75000000</us-gaap:ProceedsFromIssuanceOfOtherLongTermDebt>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">3786918</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:RepaymentsOfOtherLongTermDebt
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">81660719</us-gaap:RepaymentsOfOtherLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">111795667</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">162357192</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">-6283027</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">62863665</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">161613077</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" decimals="0" unitRef="USD">127135628</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">155330050</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-09-30" decimals="0" unitRef="USD">189999293</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaid
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">12446792</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">1759316</us-gaap:InterestPaid>
    <txmd:LicenseExpendituresIncurredButNotYetPaid
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">20000000</txmd:LicenseExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_800_eus-gaap--NatureOfOperations_zowNzJ6U04ue" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 1 &#x2013; THE COMPANY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;TherapeuticsMD, Inc., a Nevada corporation,
    or TherapeuticsMD or the Company, has &lt;span id="xdx_909_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20190930_znCImS6ahGld"&gt;three
    &lt;/span&gt;wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
    corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
    otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201c;our
    company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us.&#x201d; TherapeuticsMD&lt;sup&gt;&#xae;&lt;/sup&gt;, vitaMedMD&lt;sup&gt;&#xae;&lt;/sup&gt;, BocaGreenMD&lt;sup&gt;&#xae;&lt;/sup&gt;, IMVEXXY&lt;sup&gt;&#xae;&lt;/sup&gt;&#160;and BIJUVA&lt;sup&gt;&#xae;&lt;/sup&gt; are registered trademarks of our company and ANNOVERA&lt;sup&gt;&#x2122;&lt;/sup&gt; is a licensed trademark of our company.&lt;/p&gt;



&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Nature of Business&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We are a women&#x2019;s healthcare company focused
on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#x2019;s
healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD,
we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that
enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled,
long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD&#xae;
and BocaGreenMD&#xae; brands.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;With our SYMBODA&#x2122; technology,
we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of
bio-identical hormones through a variety of dosage forms and administration routes. Our commercialization plan allows us to
efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products. During
2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our
FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain
associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we
launched our FDA-approved product BIJUVA, our hormone therapy combination of bio-identical 17&#xdf;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus, which was approved by the FDA on October 28, 2018. In October 2019, we began a
test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal
system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was
approved by the FDA on August 10, 2018. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On
July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the
Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we
entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an
exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive
license and supply agreement, or the License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and
IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory.&lt;/p&gt;

    </us-gaap:NatureOfOperations>
    <txmd:NumberOfSubsidiaries contextRef="AsOf2019-09-30" decimals="INF" unitRef="Pure">3</txmd:NumberOfSubsidiaries>
    <txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_803_ecustom--BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_zMhcMYXC0EOc" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 2 &#x2013; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Interim Financial Statements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited interim consolidated
financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the
audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December
31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated
balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying
unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete
financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting
of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the
interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period
in the future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Recently Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;In August 2018, the Financial
Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure
requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies
some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project,
which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly
communicate the most important information to users of the financial statements. The new guidance is effective for all entities
for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to
early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating
the effect of this guidance on our disclosures.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In June 2018, the FASB issued ASU 2018-07 to
simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to
employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees
in exchange for goods or services used or consumed in an entity&#x2019;s own operations and supersedes the guidance in ASC 505-50.
The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods
within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not
been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard
did not have a material effect on our consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In February 2016, the FASB issued
ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses
on their income statements in a manner similar to current accounting. The guidance also eliminates current real
estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the
accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual
periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new
leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for
transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the
alternative transition method allowed for under ASU 2018-11 and we recorded a $&lt;span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pii_dm_c20190102_zM6IIzq6G3xf"&gt;3.8
million&lt;/span&gt;  right of use asset and a $&lt;span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pii_dm_c20190102_z89xzluQxGR2"&gt;4.1
million &lt;/span&gt; liability related to adoption of this standard. In addition, upon commencement of additional lease space
in the third quarter of 2019 (as disclosed in Note 15) we recorded an additional  $&lt;span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zFgr8m2nMBHd"&gt;7.4
million&lt;/span&gt; right of use asset and an additional $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zs16srcNqZn4"&gt;7.2
million&lt;/span&gt; liability related to our new lease space. Comparative financial information was not adjusted and will continue
to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did
not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired
leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical
expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate
lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard
resulted in increased disclosure requirements in our quarterly and annual filings.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525"&gt;Other recent accounting pronouncements
issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC
did not, and are not expected to, have a material effect on our results of operations or financial position.&lt;/p&gt;

    </txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-01-02" decimals="0" unitRef="USD">3800000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-01-02" decimals="0" unitRef="USD">4100000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-08-31" decimals="0" unitRef="USD">7400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-08-31" decimals="0" unitRef="USD">7200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zs8Vy2lmjPK4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzgriDLIUlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of September 30, 2019 (as
disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification,
or ASC, 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2019 and 2018, we had no assets
or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of indefinite-lived assets or
long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the company&#x2019;s
impairment test on an annual basis.&lt;/p&gt;

    &lt;p id="xdx_854_zo3oEjfEs0g" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zDF1c5buzsl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations due under normal
trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for
doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing
economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off
delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when
received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does
not accurately reflect bad debts, adjustments to these reserves may be required.&lt;/p&gt;

&lt;p id="xdx_85C_zz08qjZ5B6nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;







    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"/&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zUS9yHUzpj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We adopted ASC 606 on January 1, 2018 using
the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is
considered &#x201c;completed&#x201d; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance
that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of
our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are
considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary
upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control
of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to
receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue
recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be
entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with
the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription Products&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2019, our products
consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third
quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the
third quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and
retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors,
which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail
pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat
shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we
satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to
be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s
ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts,
we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We
disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or
services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction price of a contract is the
amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration
to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative
assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated
with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain
event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the
future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in
the period such changes in estimates become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable prescription
products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product
returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be
returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers.
For our newly launched products, for which the right of return exists but for which we currently do not have history of product
returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory
remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated
balance sheet.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;










&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We offer various rebate and discount programs
in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance
for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at
the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates
and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate
chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience.
Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our
customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues
at the time the revenues are recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of commercial launches for
our FDA-approved prescription products, we introduce a co-pay assistance program where eligible enrolled patients, out of
pocket cost is reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in
line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We
consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction
price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated
based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance
paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any
time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our
prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a
result, we constrain revenue recognized for our prescription products to an amount that will not result in a
significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription
products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related
to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated
co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate
any constraint each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable up-front fees
that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data or technology is delivered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Three Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Nine Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a"&gt;2,550,330&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj"&gt;3,261,459&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah"&gt;7,309,174&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc"&gt;10,797,861&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd"&gt;4,772,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl"&gt;9,904,744&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3"&gt;490,705&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g"&gt;624,987&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr"&gt;23,719,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5"&gt;3,473,535&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk"&gt;33,745,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3"&gt;11,009,937&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_8AF_zOXgLiMXZZF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


    &lt;p id="xdx_851_zZ4tGTJsR7Ka" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;



&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zY3xkSL9zzw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Cost of Sales&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;Cost of sales includes the cost of
inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. Certain
license agreements require the payment of royalties based on the sale of future products. Such royalties are recorded as a
component of cost of sales. Additionally, the&#160;amortization of license&#160;fees or milestone payments related to
licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/p&gt;

&lt;p id="xdx_85F_zyE5LzD267Nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;





    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ttCnOrRyR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options.
Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option
using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have
no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective
judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates.
The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions,
our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based
compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation
expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for
forfeitures when they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 1, 2019, we adopted ASU 2018-07
which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

    &lt;p id="xdx_85A_zHBHVAziZYij" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zH5JRMQSacq9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Expenses&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;amp;D,
expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their
clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity
expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting
expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and
investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make
payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense
nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has
been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO
expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the
completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.&lt;/p&gt;

    &lt;p id="xdx_85B_zGkKZQMLVu8b" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGdDrHDqi1a4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single management team that reports to the President of our company. We do not operate separate lines of business with respect
to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales
are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;

&lt;p id="xdx_853_zfPbqggqPpWi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzgriDLIUlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of September 30, 2019 (as
disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification,
or ASC, 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt;The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.5in; text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1in; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;unobservable inputs for the asset or liability.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At September 30, 2019 and 2018, we had no assets
or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The fair value of indefinite-lived assets or
long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the company&#x2019;s
impairment test on an annual basis.&lt;/p&gt;

    </us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zDF1c5buzsl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Trade Accounts Receivable and Allowance
for Doubtful Accounts&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Trade accounts receivable are customer obligations due under normal
trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for
doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing
economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off
delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when
received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does
not accurately reflect bad debts, adjustments to these reserves may be required.&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zUS9yHUzpj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We adopted ASC 606 on January 1, 2018 using
the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is
considered &#x201c;completed&#x201d; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance
that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of
our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are
considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary
upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control
of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to
receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue
recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be
entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with
the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Prescription Products&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of September 30, 2019, our products
consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third
quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the
third quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and
retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors,
which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail
pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat
shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we
satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to
be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#x2019;s
ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts,
we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We
disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or
services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The transaction price of a contract is the
amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration
to include in a contract&#x2019;s transaction price, we rely on our historical experience and other evidence that supports our qualitative
assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated
with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain
event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the
future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in
the period such changes in estimates become known.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We accept returns of unsalable prescription
products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product
returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be
returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers.
For our newly launched products, for which the right of return exists but for which we currently do not have history of product
returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory
remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#x2019;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated
balance sheet.&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;










&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We offer various rebate and discount programs
in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance
for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at
the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates
and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate
chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience.
Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our
customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues
at the time the revenues are recognized.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As part of commercial launches for
our FDA-approved prescription products, we introduce a co-pay assistance program where eligible enrolled patients, out of
pocket cost is reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in
line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We
consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction
price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated
based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance
paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#x2019; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any
time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our
prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a
result, we constrain revenue recognized for our prescription products to an amount that will not result in a
significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription
products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related
to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated
co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate
any constraint each reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;License Revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable up-front fees
that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data or technology is delivered.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Disaggregation of revenue&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Three Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Nine Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a"&gt;2,550,330&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj"&gt;3,261,459&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah"&gt;7,309,174&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc"&gt;10,797,861&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd"&gt;4,772,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl"&gt;9,904,744&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3"&gt;490,705&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g"&gt;624,987&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr"&gt;23,719,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5"&gt;3,473,535&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk"&gt;33,745,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3"&gt;11,009,937&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

&lt;p id="xdx_8AF_zOXgLiMXZZF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;


    </us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Three Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;Nine Months &lt;br/&gt;Ended September 30,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-size: 12pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 20%; text-align: justify"&gt;Prescription vitamins&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a"&gt;2,550,330&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj"&gt;3,261,459&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah"&gt;7,309,174&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc"&gt;10,797,861&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;IMVEXXY&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd"&gt;4,772,354&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl"&gt;9,904,744&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i"&gt;212,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;BIJUVA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3"&gt;490,705&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g"&gt;624,987&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ANNOVERA&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk"&gt;399,952&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;License revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7"&gt;15,506,400&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt"&gt;Net revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr"&gt;23,719,741&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5"&gt;3,473,535&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk"&gt;33,745,257&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3"&gt;11,009,937&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">2550330</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">3261459</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">7309174</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-09-30_custom_PrescriptionVitaminsMember"
      decimals="0"
      unitRef="USD">10797861</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">4772354</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">212076</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">9904744</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-09-30_custom_ImvexxyMember"
      decimals="0"
      unitRef="USD">212076</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">490705</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_BijuvaMember"
      decimals="0"
      unitRef="USD">624987</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">399952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">399952</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-012019-09-30_us-gaap_LicenseAndServiceMember"
      decimals="0"
      unitRef="USD">15506400</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">23719741</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">3473535</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">33745257</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">11009937</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zY3xkSL9zzw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Cost of Sales&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify"&gt;Cost of sales includes the cost of
inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. Certain
license agreements require the payment of royalties based on the sale of future products. Such royalties are recorded as a
component of cost of sales. Additionally, the&#160;amortization of license&#160;fees or milestone payments related to
licensed products are classified as components of cost of sales to the extent such payments become due in the future.&lt;/p&gt;

</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ttCnOrRyR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Share-Based Compensation&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options.
Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option
using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have
no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective
judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates.
The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions,
our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based
compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation
expense on a straight-line basis over the employee&#x2019;s requisite service period. Effective January 1, 2017, we account for
forfeitures when they occur.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 1, 2019, we adopted ASU 2018-07
which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
nonemployees in exchange for goods or services used or consumed in an entity&#x2019;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.&lt;/p&gt;

    </us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zH5JRMQSacq9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Research
and Development Expenses&#160;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Research and development, or R&amp;amp;D,
expenses include internal R&amp;amp;D activities, services of external contract research organizations, or CROs, costs of their
clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;amp;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity
expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;amp;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting
expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and
investigative drugs. We charge internal R&amp;amp;D activities and other activity expenses to operations as incurred. We make
payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense
nonrefundable advance payments for goods and services that will be used in future R&amp;amp;D activities when the activity has
been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO
expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the
completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.&lt;/p&gt;

    </us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGdDrHDqi1a4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Segment Reporting&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single management team that reports to the President of our company. We do not operate separate lines of business with respect
to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales
are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;

</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_z7F4ior80dE" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 4 &#x2013; INVENTORY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zAswskwBVkSe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49C_20190930_zM0dt3gzECm9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_499_20181231_zTdogbT3oo4d" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maINz2Fg_zjcVWlMql0t2" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Finished product&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;5,011,192&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;2,908,958&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz2Fg_zCD9rjFup0P9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,005,575&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;339,312&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz2Fg_zI2NxnPuA5f7" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Raw material&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,516,077&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,400&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_eus-gaap--InventoryNet_iTI_mtINz2Fg_z5Z9mF4uMIt9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL INVENTORY&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,532,844&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;3,267,670&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A0_zFgQLRpRYzM3" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zAswskwBVkSe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49C_20190930_zM0dt3gzECm9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_499_20181231_zTdogbT3oo4d" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maINz2Fg_zjcVWlMql0t2" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Finished product&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;5,011,192&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;2,908,958&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz2Fg_zCD9rjFup0P9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Work in process&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,005,575&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;339,312&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz2Fg_zI2NxnPuA5f7" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Raw material&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;4,516,077&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;19,400&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_eus-gaap--InventoryNet_iTI_mtINz2Fg_z5Z9mF4uMIt9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL INVENTORY&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,532,844&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;3,267,670&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5011192</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2908958</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1005575</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">339312</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">4516077</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryRawMaterialsAndSupplies contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">19400</us-gaap:InventoryRawMaterialsAndSupplies>
    <us-gaap:InventoryNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10532844</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">3267670</us-gaap:InventoryNet>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_zESUyHuAmxX4" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 5 &#x2013; OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_89D_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zgT8WEKmKcYf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current assets consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_499_20190930_z5lFsdxdiy6h" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49B_20181231_zqoOZTX38e02" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_409_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzWNe_z03udn5Zcvz5" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Prepaid sales and marketing costs&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;1,313,192&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;5,148,789&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzWNe_zKF6ZFEUcpnc" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Deferred financing fees (Note 9)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;550,757&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,898,074&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzWNe_zEu94eEnCyRd" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Prepaid insurance&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,542,008&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;790,465&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzWNe_zt6BMaq8zV2k" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Other prepaid costs&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,172,303&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,997,365&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzWNe_zIBTXHrUL8Xg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,578,260&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,834,693&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A5_zX2pXPGsf8Sa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zgT8WEKmKcYf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current assets consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_499_20190930_z5lFsdxdiy6h" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49B_20181231_zqoOZTX38e02" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_409_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzWNe_z03udn5Zcvz5" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Prepaid sales and marketing costs&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;1,313,192&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;5,148,789&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzWNe_zKF6ZFEUcpnc" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Deferred financing fees (Note 9)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;550,757&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,898,074&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzWNe_zEu94eEnCyRd" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Prepaid insurance&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,542,008&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;790,465&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzWNe_zt6BMaq8zV2k" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Other prepaid costs&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;6,172,303&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;2,997,365&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzWNe_zIBTXHrUL8Xg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,578,260&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,834,693&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1313192</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <txmd:PrepaidSalesAndMarketingCostsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">5148789</txmd:PrepaidSalesAndMarketingCostsCurrent>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">550757</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsCurrentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1898074</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:PrepaidInsurance contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2542008</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">790465</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">6172303</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2997365</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10578260</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">10834693</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zymnE1GYXyh1" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 6 &#x2013; FIXED ASSETS, NET&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcUFkzdYbJ8l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Fixed assets, net consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September&lt;/b&gt;  &lt;b&gt;30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Accounting system&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPuW8gNhfigf"&gt;301,096&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBQTwKu5NDS8"&gt;301,096&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Equipment&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKxvlZ4OsLs7"&gt;1,371,390&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zedjHDHH1z3f"&gt;490,576&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Furniture and fixtures&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRHfmaqz8eue"&gt;1,294,241&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxPPECpfGlQj"&gt;116,542&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Computer hardware&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zy9v8zzBD225"&gt;80,211&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zINZNj8PrU57"&gt;80,211&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Leasehold improvements&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwF24goIlzf6"&gt;68,788&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6bhwtAy5Nn"&gt;37,888&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930_zRv4nr0Xjkgl"&gt;3,115,726&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231_z2f4fZOthu39"&gt;1,026,313&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Accumulated depreciation&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_909_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20190930_zGl7iKfBxxva"&gt;777,380&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20181231_zBUbMCBfqcaj"&gt;553,630&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20190930_zYJbMIldt7cj"&gt;2,338,346&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20181231_z6vkyVW9hikf"&gt;472,683&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A7_zhu1GBB3i4Mc" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Depreciation expense for the three months ended
September 30, 2019 and 2018 was $&lt;span id="xdx_90B_eus-gaap--Depreciation_c20190701__20190930_zrirdn6ufr2j"&gt;90,700&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--Depreciation_c20180701__20180930_zbbsakzAFXRh"&gt;42,221&lt;/span&gt;, respectively, and $&lt;span id="xdx_902_eus-gaap--Depreciation_c20190101__20190930_zDktTGWTHR9i"&gt;223,750&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--Depreciation_c20180101__20180930_zlCmbV1Sy2A8"&gt;121,423&lt;/span&gt; for the nine months ended September
30, 2019 and 2018, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcUFkzdYbJ8l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Fixed assets, net consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September&lt;/b&gt;  &lt;b&gt;30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Accounting system&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPuW8gNhfigf"&gt;301,096&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBQTwKu5NDS8"&gt;301,096&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Equipment&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKxvlZ4OsLs7"&gt;1,371,390&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zedjHDHH1z3f"&gt;490,576&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Furniture and fixtures&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRHfmaqz8eue"&gt;1,294,241&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxPPECpfGlQj"&gt;116,542&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Computer hardware&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zy9v8zzBD225"&gt;80,211&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zINZNj8PrU57"&gt;80,211&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Leasehold improvements&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwF24goIlzf6"&gt;68,788&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6bhwtAy5Nn"&gt;37,888&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930_zRv4nr0Xjkgl"&gt;3,115,726&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231_z2f4fZOthu39"&gt;1,026,313&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Accumulated depreciation&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_909_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20190930_zGl7iKfBxxva"&gt;777,380&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20181231_zBUbMCBfqcaj"&gt;553,630&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20190930_zYJbMIldt7cj"&gt;2,338,346&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20181231_z6vkyVW9hikf"&gt;472,683&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-09-30_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      unitRef="USD">301096</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-09-30_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">1371390</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_EquipmentMember"
      decimals="0"
      unitRef="USD">490576</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-09-30_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">1294241</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">116542</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-09-30_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">80211</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2019-09-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">68788</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">37888</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">3115726</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1026313</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">777380</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">553630</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2338346</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">472683</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">90700</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">42221</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">223750</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">121423</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_809_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zUGf6R4dvZ5k" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 7 &#x2013; INTANGIBLE ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_894_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zF2pG48UUutj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The
    following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible
    assets as of  September 30, 2019 and December 31, 2018:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHT4kcSu00h4"&gt;3,138,308&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;(&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfGFHL86MePe"&gt;421,694&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zjdehtxU1VZ9"&gt;2,716,614&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxexs92WpqWl"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;13.25 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patent (pending)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zecx6GTDwx55"&gt;1,937,691&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zyr7z5nVMYtb"&gt;1,937,691&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--IndefiniteLivedTrademarks_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zrVf8dqjdmQ3"&gt;287,846&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zGkffbfhIFqd"&gt;287,846&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20190930_z0pNSTmUTR7l"&gt;5,363,845&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930_zPaKAwZSUr06"&gt;421,694&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20190930_zE2rT6V2zNge"&gt;4,942,151&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td colspan="14" style="text-align: center"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in"&gt;OPERA&lt;sup&gt;&#xae;&lt;/sup&gt; software patent&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zH8PtIeI4Yu1"&gt;31,951&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;(&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zlWYTVlSdoy7"&gt;10,484&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zhNgaqL1IuJ5"&gt;21,467&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zfomTckYUkHf"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;10.75 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Development costs of corporate website&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zPFT8hiW06a9"&gt;91,743&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zeGvdBObtG81"&gt;91,743&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_z0VUomajPbY2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z0rhyjQ4RQr8"&gt;2,234,129&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4pIuwCw1lQa"&gt;282,485&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaymSAUbGVT5"&gt;1,951,644&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zRlkL68D776a"&gt;14&lt;/span&gt; years&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zRu92iHsrlo3"&gt;1,855,279&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zlXVUgqxn2Id"&gt;1,855,279&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z4YwYthUGCE3"&gt;264,289&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zv60HoAHnCZk"&gt;264,289&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_zg4kASQUQK9c"&gt;4,477,391&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;(&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231_zYJpcxmeA1gi"&gt;384,712&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zJnQ5BGJ8R23"&gt;4,092,679&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A9_zKlXrzk73vTi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We capitalize external costs,
    consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize
    the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of
    approximately &lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcxFu8f3xYy7"&gt;20&lt;/span&gt; years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized
    patent costs at that time. Trademarks are perpetual and are not amortized. During the  nine months ended  September 30, 2019,
    we     wrote off $&lt;span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20190930_zO4zzKp2gqA7"&gt;78,864&lt;/span&gt;
    in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.&lt;/p&gt;





    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of  September 30, 2019, we had &lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zMV96WVwqBkd"&gt;26&lt;/span&gt;
    issued domestic, or U.S., patents and &lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zy5qZxrzt4Ge" title="Number of issued patents"&gt;28&lt;/span&gt;
    issued foreign patents, including: &lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_pii_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_z8qfltyCATu4"&gt;12&lt;/span&gt; domestic patents and &lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zjdDjw9dWhB6"&gt;six&lt;/span&gt; foreign patents that relate to BIJUVA as well as &lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_z4P5ToYu9xPl"&gt;three&lt;/span&gt; domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;&lt;/p&gt;


    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zTbMhinwjrg1"&gt;Five&lt;/span&gt; domestic patents (&lt;span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zcdUdW1K7ehf"&gt;four&lt;/span&gt; utility and &lt;span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zOfhXCHGy0vg"&gt;one&lt;/span&gt; design) and &lt;span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zFWiHHvOLaU4"&gt;13&lt;/span&gt; foreign patents (&lt;span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zknycpPqXsr5"&gt;three&lt;/span&gt; utility and &lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z9VjnyiAQjzc"&gt;ten&lt;/span&gt; design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;&lt;/p&gt;


    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zoHdGdPLtO7"&gt;One&lt;/span&gt; domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;&lt;/p&gt;


    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zHMvCZ8shUN6"&gt;One&lt;/span&gt; domestic utility patent and &lt;span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zNuk6TOMOVLe"&gt;five&lt;/span&gt; foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Europe, Mexico, and South Africa;&lt;/p&gt;


    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_ziuOF0i3T0Ji"&gt;One&lt;/span&gt; domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentDLimoneneMember_zwEEMWSOa8Wa"&gt;One&lt;/span&gt; domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036; and&lt;/p&gt;


    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"&gt; &#x25cf;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"&gt;&lt;span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zgILgfro8lkc"&gt;Two&lt;/span&gt; domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.&lt;/p&gt;







    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Amortization expense was $&lt;span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930_zMNDtbUkzAB6"&gt;51,259
&lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20180701__20180930_zx62xv28P7Jd"&gt;31,100&lt;/span&gt; for the three months ended September 30, 2019 and 2018, respectively, and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930_zlKbrsgfu9Hl"&gt;140,206&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20180930_zT82fUYIIuta"&gt;77,123&lt;/span&gt; for the nine
months ended September 30, 2019 and 2018, respectively. &lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAci4sN9jYqf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 10%; text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019 (3 months)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20190930_zThwUBK0S9ml"&gt;51,259&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2020&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20190930_zUjJVCXk7WT8"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2021&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20190930_zgQfK1pgKl12"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2022&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20190930_zC6w2B1yBR7j"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2023&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20190930_zTOwKhv8PJre"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A3_zrdPQqZP9AGa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with the Population Council&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On July 30, 2018, we entered into the Council License Agreement to
commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full
commercial launch in the first quarter of 2020.&lt;/p&gt;



&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Under the terms of the Council
    License Agreement, we paid the Population Council a milestone payment of $&lt;span id="xdx_900_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zdEopnBw5039"&gt;20,000,000&lt;/span&gt;
    within 30 days following approval by the FDA of the new drug application, or NDA, for ANNOVERA. The first commercial batch
    of     ANNOVERA         was     released     during the     third quarter of 2019 and we are required to pay the
    Population     Council     $&lt;span id="xdx_907_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4aqI3Gp9oY2"&gt;20,000,000&lt;/span&gt; as a result of the commercial batch release. Both milestone payments of $&lt;span id="xdx_90C_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zJisBxrnrfj8"&gt;20,000,000&lt;/span&gt;
    were recorded as  finite-lived intangible asset in the consolidated balance sheet as of September 30, 2019. We     started
    amortizing the intangible asset in  the third quarter of 2019 once ANNOVERA became commercially available for use. The cost
    is     amortized     over     the     remaining useful life over which an intangible asset will contribute directly or
    indirectly to     our cash     flows.     During     both the three and nine months ended September 30, 2019, we recorded
    $&lt;span id="xdx_908_eus-gaap--OtherAmortizationOfDeferredCharges_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zxgyFE9a4CWc"&gt;&lt;span id="xdx_902_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z1LXOHwdFNU5"&gt;15,998&lt;/span&gt;&lt;/span&gt;
    in amortization expense related to the license fee     which was recorded as a component of cost of
    sales.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The Population Council is also
eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for
marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to  $&lt;span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember__custom--RoyaltyTierAxis__custom--StepBasedRoyaltyPaymentOneMember__srt--RangeAxis__srt--MaximumMember_ztQwC0HJUrof"&gt;50,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_904_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zVFqGfPOp1V4"&gt;5&lt;/span&gt;%
of net sales; (ii) for annual net sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zRjIN2F1tYPf"&gt;50,000,000&lt;/span&gt;
and less than or equal to $&lt;span id="xdx_90B_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zp8hnq8MjsR"&gt;150,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_90F_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zzm6ms4ydZK3"&gt;10&lt;/span&gt;%
of such net sales; and (iii) for net sales greater than $&lt;span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z16mp6wmofGb"&gt;150,000,000&lt;/span&gt;,
a royalty of &lt;span id="xdx_901_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zr2gy2T8UbS9"&gt;15&lt;/span&gt;%
of such net sales. The annual royalty rate will be reduced to &lt;span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zh7ru0AV8nTi"&gt;50&lt;/span&gt;%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will
be     reduced to &lt;span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zw5UuV3ddgpg"&gt;20&lt;/span&gt;%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed  $&lt;span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zpjdnchgCzA3"&gt;20,000,000&lt;/span&gt;,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Council
License Agreement. We and the Population Council have agreed to form a joint product committee responsible for overseeing
activities under the Council License Agreement. We will be responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the
one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. The Council
License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal
contraceptive systems in development by the Population Council.&lt;/p&gt;






    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We assess our intangible assets for impairment
if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or
changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated
undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash
flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset
and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining
useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would
indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#x2019;s remaining
useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining
useful life.&lt;/p&gt;


&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Knight Therapeutics Inc.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On July 30, 2018, we entered into a license
and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us
a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and
Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either
party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified
time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement,
Knight entered into a subscription agreement with us, pursuant to which Knight purchased  &lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zuRaBA4CGKlj"&gt;3,921,568&lt;/span&gt; shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $&lt;span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_znvoxappvw2k"&gt;5.10&lt;/span&gt;, for proceeds of $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_uUSD_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zpFM1wNNrC1a"&gt;20,000,000&lt;/span&gt;, on August 6, 2018.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;License Agreement with Theramex&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#x2019;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR &lt;span id="xdx_90C_ecustom--CashUpfrontPaymentReceived_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zcXjUxf5vXja"&gt;14 &lt;/span&gt;million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the License Agreement, we provided Theramex the
regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other
applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee,
which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and
benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive
additional milestone payments comprised of (i) up to an aggregate of EUR &lt;span id="xdx_901_ecustom--RegulatoryMilestoneAdditionalPayment_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zz9bQKJRfMme"&gt;2 &lt;/span&gt;million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and
(ii) up to an aggregate of EUR &lt;span id="xdx_908_ecustom--SalesMilestonePaymentsInTranches_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_znvl9LeAbaif"&gt;27.5&lt;/span&gt;
million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR &lt;span id="xdx_904_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zrf9gehw4FDh"&gt;25 &lt;/span&gt;million
to EUR &lt;span id="xdx_906_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zlCKA6MO19Zg"&gt;100 &lt;/span&gt;million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    </us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <txmd:ScheduleOfIntangibleAssetsTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_894_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zF2pG48UUutj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The
    following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible
    assets as of  September 30, 2019 and December 31, 2018:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHT4kcSu00h4"&gt;3,138,308&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;(&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfGFHL86MePe"&gt;421,694&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zjdehtxU1VZ9"&gt;2,716,614&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxexs92WpqWl"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0640"&gt;13.25 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patent (pending)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zecx6GTDwx55"&gt;1,937,691&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zyr7z5nVMYtb"&gt;1,937,691&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--IndefiniteLivedTrademarks_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zrVf8dqjdmQ3"&gt;287,846&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zGkffbfhIFqd"&gt;287,846&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20190930_z0pNSTmUTR7l"&gt;5,363,845&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930_zPaKAwZSUr06"&gt;421,694&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20190930_zE2rT6V2zNge"&gt;4,942,151&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td colspan="14" style="text-align: center"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Gross Carrying Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net &lt;br/&gt;Amount&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted-Average &lt;br/&gt;Remaining Amortization Period (yrs.)&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"&gt;Amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in"&gt;OPERA&lt;sup&gt;&#xae;&lt;/sup&gt; software patent&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zH8PtIeI4Yu1"&gt;31,951&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;(&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zlWYTVlSdoy7"&gt;10,484&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zhNgaqL1IuJ5"&gt;21,467&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zfomTckYUkHf"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0651"&gt;10.75 years&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Development costs of corporate website&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zPFT8hiW06a9"&gt;91,743&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zeGvdBObtG81"&gt;91,743&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_z0VUomajPbY2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0654"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z0rhyjQ4RQr8"&gt;2,234,129&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4pIuwCw1lQa"&gt;282,485&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaymSAUbGVT5"&gt;1,951,644&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zRlkL68D776a"&gt;14&lt;/span&gt; years&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.25in; text-indent: -0.125in"&gt;Hormone therapy drug candidate patents (pending)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zRu92iHsrlo3"&gt;1,855,279&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zlXVUgqxn2Id"&gt;1,855,279&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Non-amortizable intangible assets:&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;Multiple trademarks&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z4YwYthUGCE3"&gt;264,289&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zv60HoAHnCZk"&gt;264,289&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_zg4kASQUQK9c"&gt;4,477,391&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;(&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231_zYJpcxmeA1gi"&gt;384,712&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zJnQ5BGJ8R23"&gt;4,092,679&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </txmd:ScheduleOfIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">3138308</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">421694</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2716614</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1937691</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2019-09-30_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1937691</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">287846</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2019-09-30_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">287846</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5363845</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">421694</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">4942151</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">10484</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember"
      decimals="0"
      unitRef="USD">21467</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_us-gaap_InternetDomainNamesMember"
      decimals="0"
      unitRef="USD">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">2234129</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">282485</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1951644</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2018-01-012018-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P14Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2018-12-31_custom_HormoneTherapyDrugCandidatePatentsMember"
      decimals="0"
      unitRef="USD">1855279</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedTrademarks
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">264289</us-gaap:IndefiniteLivedTrademarks>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="AsOf2018-12-31_custom_MultipleTrademarksForVitaminsSupplementsMember"
      decimals="0"
      unitRef="USD">264289</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4477391</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">384712</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">4092679</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2019-01-012019-09-30_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">78864</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUSPatentsMember"
      decimals="INF"
      unitRef="Pure">26</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignPatentsMember"
      decimals="INF"
      unitRef="Pure">28</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">12</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignPatentsBijuvaMember"
      decimals="INF"
      unitRef="Pure">6</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticPatentsNonApprovedBijuvaMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUSPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUSUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUSDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">13</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignUtilityPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignDesignPatentsImvexxyMember"
      decimals="INF"
      unitRef="Pure">10</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUSPatentsTopicalCreamMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_ForeignUtilityPatentTransdermalPatchMember"
      decimals="INF"
      unitRef="Pure">5</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentOperaMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentDLimoneneMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents
      contextRef="AsOf2019-09-30_custom_DomesticUtilityPatentTx009HRMember"
      decimals="INF"
      unitRef="Pure">2</txmd:NumberOfIssuedPatents>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">51259</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">31100</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">140206</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">77123</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAci4sN9jYqf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Year Ending December 31,&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Estimated Amortization&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 10%; text-align: right"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019 (3 months)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 10%; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20190930_zThwUBK0S9ml"&gt;51,259&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2020&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20190930_zUjJVCXk7WT8"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2021&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20190930_zgQfK1pgKl12"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2022&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20190930_zC6w2B1yBR7j"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2023&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20190930_zTOwKhv8PJre"&gt;205,035&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">51259</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">205035</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">205035</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">205035</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">205035</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <txmd:MilestonePaymentUponFDAApproval
      contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentUponFDAApproval>
    <txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch
      contextRef="AsOf2019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</txmd:MilestonePaymentsAfterReleaseOfFirstCommercialBatch>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-07-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">15998</us-gaap:OtherAmortizationOfDeferredCharges>
    <us-gaap:OtherAmortizationOfDeferredCharges
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember"
      decimals="0"
      unitRef="USD">15998</us-gaap:OtherAmortizationOfDeferredCharges>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member_custom_AnnoveraMember_custom_StepBasedRoyaltyPaymentOneMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep1Member"
      decimals="INF"
      unitRef="Pure">5</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">50000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member_srt_MaximumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep2Member"
      decimals="INF"
      unitRef="Pure">10</txmd:RoyaltyPercent>
    <txmd:NetSalesAmountPerStepbasedRoyalty
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member_srt_MinimumMember"
      decimals="0"
      unitRef="USD">150000000</txmd:NetSalesAmountPerStepbasedRoyalty>
    <txmd:RoyaltyPercent
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreementStep3Member"
      decimals="INF"
      unitRef="Pure">15</txmd:RoyaltyPercent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member"
      decimals="INF"
      unitRef="Pure">50</txmd:AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member"
      decimals="INF"
      unitRef="Pure">20</txmd:AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent>
    <txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid
      contextRef="From2019-01-012019-09-30_custom_CouncilLicenseAgreement1Member"
      decimals="0"
      unitRef="USD">20000000</txmd:MaximumCostsAndExpensesForPostApprovalStudyToBePaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="Shares">3921568</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="AsOf2018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-07-302018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <txmd:CashUpfrontPaymentReceived
      contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember"
      decimals="0"
      unitRef="EUR">14000000</txmd:CashUpfrontPaymentReceived>
    <txmd:RegulatoryMilestoneAdditionalPayment
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">2000000</txmd:RegulatoryMilestoneAdditionalPayment>
    <txmd:SalesMilestonePaymentsInTranches
      contextRef="AsOf2019-06-06_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">27500000</txmd:SalesMilestonePaymentsInTranches>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MinimumMember"
      decimals="0"
      unitRef="EUR">25000000</txmd:AnnualNetSalesMilestone>
    <txmd:AnnualNetSalesMilestone
      contextRef="From2019-08-042019-08-05_custom_LicenseAgreementTheramexMember_srt_MaximumMember"
      decimals="0"
      unitRef="EUR">100000000</txmd:AnnualNetSalesMilestone>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zKU8DQ7vNe2j" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 8 &#x2013; OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_89D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zHT0ZkweaNyb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current liabilities consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49E_20190930_z1xiew4yGEf9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_496_20181231_zwgr1Gv7Yx4i" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_403_eus-gaap--AccruedSalariesCurrent_iI_maOLCzFFK_zQBchktIR34g" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; width: 50%; text-align: justify; text-indent: -0.125in"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;4,536,358&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;6,854,002&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--AccruedIntellectualLicenseFee_iI_maOLCzFFK_zbTF9nuIxlf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued intellectual license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzFFK_zvwBizl1yWcj" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Allowance for coupons and returns&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;7,079,005&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;5,294,120&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_405_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzFFK_z2n8nuuRe9Mf" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued sales and marketing costs&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,560,257&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,288,028&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_eus-gaap--AccruedVacationCurrent_iI_maOLCzFFK_zp1m4PVFG1P4" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued compensated absences&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,551,042&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,178,110&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40E_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzFFK_zyS87ucdA3Q8" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Allowance for wholesale distributor fees&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,375,894&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;792,891&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzFFK_zm9mIQ4XU8Ke" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued legal and accounting expense&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;469,446&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;385,824&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_ecustom--AccruedResearchAndDevelopment_iI_maOLCzFFK_zNWXwppcCpWf" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued research and development&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,226,160&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;388,675&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzFFK_zQT2vGFHlBFg" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Operating lease liability&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,242,290&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40E_eus-gaap--AccruedRentCurrent_iI_maOLCzFFK_zINtVwuf6UUg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued rent&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;365,155&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_ecustom--AccruedRebates_iI_maOLCzFFK_zXduvJzfogJ9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued rebates&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,543,456&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;412,570&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzFFK_zD1HVBJRBcP6" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Other accrued expenses&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;612,124&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,573&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzFFK_z82CcnQ6IA11" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;43,196,032&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;18,334,948&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8AD_zWRKTMXGmG38" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zHT0ZkweaNyb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Other current liabilities consist of the following:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_49E_20190930_z1xiew4yGEf9" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" id="xdx_496_20181231_zwgr1Gv7Yx4i" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_403_eus-gaap--AccruedSalariesCurrent_iI_maOLCzFFK_zQBchktIR34g" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; width: 50%; text-align: justify; text-indent: -0.125in"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;4,536,358&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;6,854,002&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
&lt;tr id="xdx_400_ecustom--AccruedIntellectualLicenseFee_iI_maOLCzFFK_zbTF9nuIxlf6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Accrued intellectual license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;20,000,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0743"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr id="xdx_403_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzFFK_zvwBizl1yWcj" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Allowance for coupons and returns&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;7,079,005&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;5,294,120&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_405_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzFFK_z2n8nuuRe9Mf" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued sales and marketing costs&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,560,257&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,288,028&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_eus-gaap--AccruedVacationCurrent_iI_maOLCzFFK_zp1m4PVFG1P4" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued compensated absences&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,551,042&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,178,110&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40E_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzFFK_zyS87ucdA3Q8" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Allowance for wholesale distributor fees&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,375,894&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;792,891&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzFFK_zm9mIQ4XU8Ke" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued legal and accounting expense&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;469,446&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;385,824&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_ecustom--AccruedResearchAndDevelopment_iI_maOLCzFFK_zNWXwppcCpWf" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued research and development&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,226,160&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;388,675&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzFFK_zQT2vGFHlBFg" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Operating lease liability&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,242,290&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0764"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40E_eus-gaap--AccruedRentCurrent_iI_maOLCzFFK_zINtVwuf6UUg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued rent&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0766"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;365,155&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40C_ecustom--AccruedRebates_iI_maOLCzFFK_zXduvJzfogJ9" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Accrued rebates&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,543,456&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;412,570&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzFFK_zD1HVBJRBcP6" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in"&gt;Other accrued expenses&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;612,124&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;375,573&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzFFK_z82CcnQ6IA11" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;43,196,032&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;18,334,948&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">4536358</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">6854002</us-gaap:AccruedSalariesCurrent>
    <txmd:AccruedIntellectualLicenseFee contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">20000000</txmd:AccruedIntellectualLicenseFee>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">7079005</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">5294120</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1560257</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedMarketingCostsCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">2288028</us-gaap:AccruedMarketingCostsCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1551042</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1178110</us-gaap:AccruedVacationCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2375894</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">792891</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">469446</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">385824</us-gaap:AccruedProfessionalFeesCurrent>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1226160</txmd:AccruedResearchAndDevelopment>
    <txmd:AccruedResearchAndDevelopment contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">388675</txmd:AccruedResearchAndDevelopment>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1242290</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">365155</us-gaap:AccruedRentCurrent>
    <txmd:AccruedRebates contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2543456</txmd:AccruedRebates>
    <txmd:AccruedRebates contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">412570</txmd:AccruedRebates>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">612124</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">375573</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">43196032</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">18334948</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LongTermDebtTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_800_eus-gaap--LongTermDebtTextBlock_zdGgh6tvQ3Kh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 9 &#x2013; DEBT&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2019, we entered into a Financing
    Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent,
    various lenders from time to time party thereto, and certain of the Company&#x2019;s subsidiaries party thereto from time to
    time as guarantors, which provides us with a $&lt;span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zUb2QC61vNT9"&gt;300,000,000&lt;/span&gt; first lien secured term loan credit facility, or the Facility. The
    Facility provides for availability to us in three tranches: (i) $&lt;span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_z5yhTnbQyXJa"&gt;200,000,000&lt;/span&gt; was drawn upon entering into the Financing Agreement;
    (ii) $&lt;span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zXWdeo4W1wy5"&gt;50,000,000&lt;/span&gt; will be available to us upon the designation of our ANNOVERA product as a new category of birth control by
    the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $&lt;span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zqS7FM6o0EG5"&gt;50,000,000&lt;/span&gt;
    will be available to us upon our achieving $&lt;span id="xdx_901_ecustom--RevenueRequirementToDrawOnTermLoan_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zAXiKjGcRLkj"&gt;11,000,000&lt;/span&gt; in net revenues, as defined in the Financing Agreement, from our IMVEXXY,
    BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent.
    Borrowings under the Facility accrue interest at either (i) &lt;span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zICa8SIqMjFl"&gt;3-month LIBOR&lt;/span&gt; plus &lt;span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJDoA3NI2lxh"&gt;7.75&lt;/span&gt;%, subject to a LIBOR floor of &lt;span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z6OHd3kwZDy9"&gt;2.70&lt;/span&gt;% or
    (ii) the &lt;span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zJGqH9ymcwL9"&gt;prime rate&lt;/span&gt; plus &lt;span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zwZPcyTMB8Qc"&gt;6.75&lt;/span&gt;%, subject to a prime rate floor of &lt;span id="xdx_909_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zlGPWPBelbk6"&gt;5.2&lt;/span&gt;% as selected by us. Interest on amounts borrowed under
    the Facility will be payable quarterly. The outstanding principal amount of the Facility is payable in &lt;span id="xdx_900_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zqHAO5bOIhW6"&gt;four&lt;/span&gt; equal quarterly
    installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings
    under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i)
    &lt;span id="xdx_90B_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9XkKYONZ6Zk"&gt;30.0&lt;/span&gt;% for the first two years following the initial funding date of the applicable borrowing, (ii) &lt;span id="xdx_907_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zdW1hUCH8g93"&gt;5.0&lt;/span&gt;% for the third year
    following the initial funding date of the applicable borrowing, (iii) &lt;span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zYnRxXvIpj4g"&gt;3.0&lt;/span&gt;% for the fourth year following the initial funding
    date of the applicable borrowing and (iv) &lt;span id="xdx_90D_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3kQEd2XbCj3"&gt;1.0&lt;/span&gt;% for the fifth year following the initial funding date of the applicable borrowing
    but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the
    lenders, a facility fee equal to &lt;span id="xdx_909_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zwOFIdSBJqMi"&gt;2.5&lt;/span&gt;% of the initial amount borrowed and will be required to pay such a facility fee in connection
    with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an
    annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments,
    restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are
    required to (i) maintain a minimum unrestricted cash balance of $&lt;span id="xdx_904_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zHvuzfaTSxxi"&gt;50,000,000&lt;/span&gt;, which will increase to $&lt;span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_z1eMhj5FoEXa"&gt;60,000,000&lt;/span&gt; if we draw
    either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable
    to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020.
    The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary
    for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an
    event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing
    Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement.
    The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted
    liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after-acquired
    assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our
    future direct and indirect subsidiaries, subject to certain exceptions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On May 1, 2018, we entered into a Credit and
Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the
additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement
provided a secured term loan facility in an aggregate principal amount of up to $&lt;span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zliFhCtFd7j5"&gt;200,000,000&lt;/span&gt;, or the Term Loan. Under the terms
of the Credit Agreement, the Term Loan was available to be made in &lt;span id="xdx_909_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uTranches_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zp4qL7gV5o3l"&gt;three&lt;/span&gt; separate tranches, with each tranche to be made available
to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate
equal to the sum of (i) &lt;span id="xdx_901_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zQEuiyFE6Cwk"&gt;one-month LIBOR&lt;/span&gt; (subject to a LIBOR floor of &lt;span id="xdx_906_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z9QUX4BDIIMd"&gt;1.50&lt;/span&gt;%) plus (ii) &lt;span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zIzBNZt0SsFd"&gt;7.75&lt;/span&gt;% per annum.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $&lt;span id="xdx_904_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zLTRnyXdkh4g"&gt;81,661,000&lt;/span&gt;
was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of &lt;span id="xdx_90A_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424_zAQHBCcaAHGk"&gt;4&lt;/span&gt;%, a repayment fee of &lt;span id="xdx_90A_ecustom--RepaymentFeePercentage_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_ziXmQE8FbiSk"&gt;4&lt;/span&gt;% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit
Agreement, we recorded $&lt;span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zY5uklUD2Bcl"&gt;10,057,632&lt;/span&gt; in loss on extinguishment of debt in the accompanying unaudited consolidated financial statements.
Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the nine months
ending September 30, 2019 related to the Credit Agreement was $&lt;span id="xdx_901_eus-gaap--InterestExpenseDebt_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBO6TnW43oJ5"&gt;1,816,747&lt;/span&gt;. During the nine months ended September 30, 2019, and
prior to the repayment of the Credit Agreement, we amortized $&lt;span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z8w78dm3QLJk"&gt;120,146&lt;/span&gt; of deferred financing fees as interest expense in the accompanying
unaudited consolidated financial statements.&lt;/p&gt;







    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of September 30, 2019, we had
    $&lt;span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zmXXipafmeEg"&gt;200,000,000&lt;/span&gt;
    in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
    unaudited consolidated financial statements. We incurred $&lt;span id="xdx_901_eus-gaap--PaymentsOfFinancingCosts_c20190101__20190930_z11mGaBanh4a"&gt;6,652,270&lt;/span&gt;
    in deferred financing fees related to the Financing Agreement.     Deferred financing fees related to the entire Financing
    Agreement have been allocated pro rata between the funded and unfunded     portions of each tranche. Allocated deferred
    financing fees related to Tranche 1 of $&lt;span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190930_zNU5p2P7KhJ1"&gt;6,101,513&lt;/span&gt;
    have been reflected as a debt     discount and are accreted to interest expense using the effective interest method. Deferred
    financing fees associated with     unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones
    have been met. As of September 30,     2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in
    other current assets in the accompanying     consolidated financial statements. During the three and nine months ended
    September 30, 2019, we amortized $&lt;span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_c20190701__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zztLAoHxCQP5"&gt;265,949&lt;/span&gt;
    and $&lt;span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zaJ9vsMFTHGe"&gt;462,683&lt;/span&gt;,
    respectively, of deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated
    financial statements.     Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears.
    Interest expense for the three and nine months ended September 30, 2019 was $&lt;span id="xdx_900_eus-gaap--InterestExpenseBorrowings_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zvR1wRq01M3f"&gt;5,333,056&lt;/span&gt;
    and $&lt;span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zAZw34Z0j7pe"&gt;9,318,056&lt;/span&gt;,
    respectively. The overall effective interest     rate under the Financing Agreement was approximately &lt;span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_c20190930_zdXK3sHJsMQi"&gt;11&lt;/span&gt;%
    as of September 30, 2019.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span/&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zdbjB65BooBl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;As
of  September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zLAtaomMsoWl"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Credit Agreement&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zerwox7m3Tek"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Debt discount and financing fees&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20190930_zDle5W3cHaC"&gt;5,638,831&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20181231_z91shXXUtoF2"&gt;1,618,986&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LongTermDebtNoncurrent_iI_c20190930_z5GQliQ99n25"&gt;194,361,169&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_c20181231_znb2rDrzaIvk"&gt;73,381,014&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A6_zOEvQirJXnF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:LongTermDebtTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_RevolvingCreditFacilityMember"
      decimals="0"
      unitRef="USD">300000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">50000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:RevenueRequirementToDrawOnTermLoan
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_custom_TrancheThreeMember"
      decimals="0"
      unitRef="USD">11000000</txmd:RevenueRequirementToDrawOnTermLoan>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember">3-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">7.75</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0270</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember">prime rate</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:LiborFloorRate
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_us-gaap_PrimeRateMember"
      decimals="INF"
      unitRef="Pure">0.052</txmd:LiborFloorRate>
    <txmd:NumberOfInstallmentPayments
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfInstallmentPayments>
    <txmd:PrepaymentFeeForFirstTwoYearsFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.300</txmd:PrepaymentFeeForFirstTwoYearsFundingPercent>
    <txmd:PrepaymentFeeThirdYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.050</txmd:PrepaymentFeeThirdYearFundingPercent>
    <txmd:PrepaymentFeeFourthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.030</txmd:PrepaymentFeeFourthYearFundingPercent>
    <txmd:PrepaymentFeeFifthYearFundingPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.010</txmd:PrepaymentFeeFifthYearFundingPercent>
    <txmd:FacilityFeePaidPercent
      contextRef="From2019-04-232019-04-24_custom_FinancingAgreementMember"
      decimals="INF"
      unitRef="Pure">0.025</txmd:FacilityFeePaidPercent>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">50000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <txmd:MinimumCashBalanceRequirementUnderCreditAgreement
      contextRef="AsOf2019-04-24_custom_FinancingAgreementMember_custom_TrancheTwoThreeMember"
      decimals="0"
      unitRef="USD">60000000</txmd:MinimumCashBalanceRequirementUnderCreditAgreement>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <txmd:NumberOfTranchesUnderTermLoanFacility
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Tranches">3</txmd:NumberOfTranchesUnderTermLoanFacility>
    <us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="From2018-04-302018-05-01_us-gaap_SecuredDebtMember">one-month LIBOR</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
    <txmd:LiborFloorRate
      contextRef="AsOf2018-05-01_us-gaap_SecuredDebtMember"
      decimals="INF"
      unitRef="Pure">0.0150</txmd:LiborFloorRate>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="From2018-04-302018-05-01_us-gaap_RevolvingCreditFacilityMember"
      decimals="INF"
      unitRef="Pure">7.75</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <txmd:RepaymentOfDebtWithNewCreditFacility
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">81661000</txmd:RepaymentOfDebtWithNewCreditFacility>
    <txmd:PrepaymentFeePercentage
      contextRef="From2019-04-232019-04-24"
      decimals="INF"
      unitRef="Pure">0.04</txmd:PrepaymentFeePercentage>
    <txmd:RepaymentFeePercentage
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="INF"
      unitRef="Pure">4</txmd:RepaymentFeePercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="From2019-04-232019-04-24_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">-10057632</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="From2019-01-012019-09-30_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">1816747</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-09-30_custom_MidCapAgreementMember"
      decimals="0"
      unitRef="USD">120146</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">6652270</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">6101513</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-07-012019-09-30_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">265949</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2019-01-012019-09-30_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">462683</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-07-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">5333056</us-gaap:InterestExpenseBorrowings>
    <us-gaap:InterestExpenseBorrowings
      contextRef="From2019-01-012019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">9318056</us-gaap:InterestExpenseBorrowings>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="AsOf2019-09-30" decimals="INF" unitRef="Pure">11</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zdbjB65BooBl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;As
of  September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, &lt;br/&gt;2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 50%; text-align: justify"&gt;Financing Agreement&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zLAtaomMsoWl"&gt;200,000,000&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Credit Agreement&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zerwox7m3Tek"&gt;75,000,000&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Debt discount and financing fees&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20190930_zDle5W3cHaC"&gt;5,638,831&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20181231_z91shXXUtoF2"&gt;1,618,986&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left"&gt;TOTAL LONG-TERM DEBT&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--LongTermDebtNoncurrent_iI_c20190930_z5GQliQ99n25"&gt;194,361,169&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_c20181231_znb2rDrzaIvk"&gt;73,381,014&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2019-09-30_custom_FinancingAgreementMember"
      decimals="0"
      unitRef="USD">200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="AsOf2018-12-31_custom_CreditAgreementMember"
      decimals="0"
      unitRef="USD">75000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5638831</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">1618986</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">194361169</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2018-12-31" decimals="0" unitRef="USD">73381014</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zbXpKliL0H3a" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
    10 &#x2013; NET LOSS PER SHARE&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We calculate earnings per share, or EPS, in
accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted.
We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock,
outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding
plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our
Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted EPS because
their effect would have been antidilutive due to the net loss reported by us.&lt;span/&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWarCx3JZYAg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three and  Nine months ended&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 30%; text-align: justify"&gt;Stock options&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOYTmjrLe0t6"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJrVAKWWCSlc"&gt;24,849,984&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zge6deMEgupj"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrrfOQAYp4bk"&gt;24,837,349&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzo6au7jLMJl"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXMIaNe9C2D3"&gt;1,832,571&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQ6UEgPMZx3"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMQohizb05J"&gt;3,007,571&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Restricted stock awards&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4coHhgm7APk"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0fGdSduEef6"&gt;1,240,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpHXTVFnBHi7"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAcuMHRwC7M2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930_zRk9YdjIQD27"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930_z5VUxV5e6f1f"&gt;27,922,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930_zjSqvqZLtHL8"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930_zdrT0GLApXQ6"&gt;27,844,920&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A5_z8L2y6L6fDZa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWarCx3JZYAg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three and  Nine months ended&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;September 30, 2018&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 30%; text-align: justify"&gt;Stock options&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOYTmjrLe0t6"&gt;&lt;span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJrVAKWWCSlc"&gt;24,849,984&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zge6deMEgupj"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrrfOQAYp4bk"&gt;24,837,349&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: justify"&gt;Warrants&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzo6au7jLMJl"&gt;&lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXMIaNe9C2D3"&gt;1,832,571&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQ6UEgPMZx3"&gt;&lt;span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMQohizb05J"&gt;3,007,571&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: justify"&gt;Restricted stock awards&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4coHhgm7APk"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0fGdSduEef6"&gt;1,240,000&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpHXTVFnBHi7"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAcuMHRwC7M2"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt; padding-left: 0.125in"&gt;TOTAL&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930_zRk9YdjIQD27"&gt;&lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930_z5VUxV5e6f1f"&gt;27,922,555&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930_zjSqvqZLtHL8"&gt;&lt;span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930_zdrT0GLApXQ6"&gt;27,844,920&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-07-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">24849984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">24849984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-07-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">24837349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">24837349</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-07-012019-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="Shares">1832571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-07-012018-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-09-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="Shares">3007571</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-07-012019-09-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="Shares">1240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-012019-09-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="Shares">1240000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-07-012018-09-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-09-30_us-gaap_RestrictedStockMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="Shares">27922555</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="Shares">27922555</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="Shares">27844920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="Shares">27844920</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs3ZJAYk7w7i" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 11 &#x2013; STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At  September 30, 2019, we had &lt;span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20190930_zFYiirVeCzil"&gt;10,000,000&lt;/span&gt;
    shares of preferred stock, par value $&lt;span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20190930_zDt5xLPzJTLl"&gt;0.001&lt;/span&gt;
    per share, authorized for issuance, of which no shares of preferred stock were issued or outstanding.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At  September 30, 2019, we had &lt;span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20190930_ziDok71XeBAl"&gt;350,000,000 &lt;/span&gt;shares
    of Common Stock authorized for issuance, of which &lt;span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20190930_zargAC1LU7o8"&gt;&lt;span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20190930_zrNdXVze2qQ2"&gt;241,277,076&lt;/span&gt;&lt;/span&gt;
    shares of Common Stock were issued and outstanding.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances During the Three and Nine Months
Ended September 30, 2019&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the three months ended September 30,
2019, certain individuals exercised stock options to purchase &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20190701__20190930_zJUfJORn5Tx6"&gt;55,236&lt;/span&gt;  shares of Common Stock for $&lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190701__20190930_zC8RXIjxh6cf"&gt;8,549&lt;/span&gt; in cash. During the nine
months ended September 30, 2019, certain individuals exercised stock options to purchase &lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930_zbMDX7EsnWol"&gt;331,619&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20190930_zDNYOWqYezTe"&gt;108,656&lt;/span&gt; in cash. Also, during the same period, stock options to purchase &lt;span id="xdx_906_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20190930_zd9sfAbvvH05"&gt;12,097&lt;/span&gt; shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein &lt;span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20190930_zkWxwKjSwESd"&gt;11,834&lt;/span&gt; shares of Common Stock were issued.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Issuances During the Three and Nine Months
Ended September 30, 2018&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended September 30,
2018, certain individuals exercised stock options to purchase &lt;span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180701__20180930_zM3Z0XU79EDd"&gt;1,052,300&lt;/span&gt; shares of Common Stock for $&lt;span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180701__20180930_zLnvjtbWk4z8"&gt;107,318&lt;/span&gt; in cash. During the
nine months ended September 30, 2018, certain individuals exercised stock options to purchase &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20180930_zGmNdsAgIoyf"&gt;1,446,876&lt;/span&gt; shares of Common Stock
for $&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20180930_zkEy4oiUdphb"&gt;1,236,313&lt;/span&gt; in cash. Also, during the nine months ended September 30, 2018, stock options to purchase &lt;span id="xdx_908_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20180930_zvWmEtndmXkc"&gt;10,000&lt;/span&gt; shares of Common
Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein &lt;span id="xdx_90B_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20180930_zAxNw5hUUWY7"&gt;9,841&lt;/span&gt; shares of Common Stock were issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On August 1, 2018, we entered into an
underwriting agreement with Goldman Sachs &amp;amp; Co. LLC, as representative of the underwriters, relating to an underwritten
public offering of &lt;span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRAyHGwaTnOj"&gt;12,745,098&lt;/span&gt;
shares of our Common Stock at a price of $&lt;span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20180801_zR3nP3CWo06c"&gt;5.10&lt;/span&gt;
per share. We granted the underwriters an option, exercisable for a period of &lt;span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zHkRZHv9eKK9"&gt;30&lt;/span&gt; days,
to purchase up to &lt;span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zoFFUgInk1Kk"&gt;1,911,764&lt;/span&gt;
additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds from
the offering, including the exercise of the option to purchase additional shares, were approximately $&lt;span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180805__20180806_ze683lWjlzc7"&gt;69,908,000&lt;/span&gt;,
after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In
connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight
purchased $&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXEcnarx6TEi"&gt;20,000,000&lt;/span&gt;
of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock on August 6,
2018.&lt;/p&gt;






    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Warrants to Purchase Common Stock&lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of  September 30, 2019, we had
    warrants outstanding to purchase an aggregate of &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_c20190930_zhEn3S8s7EO7"&gt;1,832,571&lt;/span&gt;
    shares of Common Stock with a weighted-average contractual remaining life of approximately &lt;span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_c20190101__20190930_z9ik3ScS5mxb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;2.2
    years&lt;/span&gt;&lt;/span&gt;, and exercise prices ranging from $&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z1huLMDtVZy3"&gt;0.24&lt;/span&gt;
    to $&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zDL9culEKwC8"&gt;8.20&lt;/span&gt;
    per share, resulting in a weighted average exercise price of $&lt;span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_c20190101__20190930_z5pnRBhFW3fb"&gt;2.62&lt;/span&gt;
    per share.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to
    determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number
    of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30, 2019, we granted warrants to purchase &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zurnvHwd7nG8"&gt;75,000
    &lt;/span&gt;shares of Common Stock to outside consultants at an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvXzbPTO7jNa"&gt;5.63&lt;/span&gt;.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    &lt;span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z46SCijEdjxk"&gt;5
    years&lt;/span&gt;; volatility of &lt;span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMOS2WUC2lia"&gt;60.8&lt;/span&gt;%;
    risk free rate of &lt;span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zPEXATfZlAE5"&gt;2.52&lt;/span&gt;%;
    and dividend yield of &lt;span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ziGrNJcskqX"&gt;0&lt;/span&gt;%.
    The grant date fair value of the warrants was $&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zN5TCM3mEkf3"&gt;3.00
    &lt;/span&gt;per share. The warrants are vesting ratably over a &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zuaXz5DfZRqk"&gt;12
    month &lt;/span&gt;period and have an expiration date of February 12, 2024. During the nine months ended September 30, 2018, we
    granted warrants to purchase &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z1WM5rXAF84"&gt;175,000
    &lt;/span&gt;shares of Common Stock to outside consultants at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z5kXncaapQI9"&gt;5.16&lt;/span&gt;.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    &lt;span id="xdx_903_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmyr7B2zqr5l"&gt;5
    years&lt;/span&gt;; volatility of &lt;span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmCkIPCu4sm8"&gt;62.1&lt;/span&gt;%;
    risk free rate of &lt;span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zEwqfvsNz0ii"&gt;2.36&lt;/span&gt;%;
    and dividend yield of &lt;span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zV7xpkvTpTmg"&gt;0&lt;/span&gt;%.
    The grant date fair value of the warrants was $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zoKk1K3FCr2d"&gt;2.79
    &lt;/span&gt;per share. The warrants vest ratably over a &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zjjDzZbXZ328"&gt;12
    month &lt;/span&gt;period and have an expiration date of March 15, 2023. During the three months ended September 30, 2019 and 2018,
    we recorded $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensation_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zd2AhydHsA63"&gt;56,418
    &lt;/span&gt;and $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensation_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zeXbsmf4CiV4"&gt;150,977&lt;/span&gt;,
    respectively, and during the nine months ended September 30, 2019 and 2018, we recorded $&lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zds0ppTmdsw1"&gt;198,306
    &lt;/span&gt;and $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zR8JQpsHKJXc"&gt;407,292&lt;/span&gt;,
    respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants.
    As of September 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants
    was approximately $&lt;span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zVS1ElagjrLi"&gt;83,000&lt;/span&gt;,
    which is expected to be recognized over a weighted-average period of &lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zUiDDld9hpZ2"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0906"&gt;0.4
    years&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30,
2019, warrants to purchase  &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHLrhYc10rh"&gt;1,250,000&lt;/span&gt; shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions,
wherein  &lt;span id="xdx_903_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zGtOfVnkIIZe"&gt;471,184&lt;/span&gt; shares of Common Stock were issued. During the nine months ended September 30, 2018, &lt;span id="xdx_90E_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfuvSuSYti4d"&gt;no&lt;/span&gt; warrants were exercised.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Options to Purchase Common Stock &lt;/span&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In 2009, we adopted the 2009 Long
    Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
    consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
    providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
    consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
    units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
    as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
    on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
    exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
    September 30, 2019, there were non-qualified stock options to purchase &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z084QCI0OcH9"&gt;15,028,509&lt;/span&gt;
    shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.&lt;/p&gt;





    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt; In 2012, we adopted the 2012 Stock
    Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve
    as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
    advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights,
    restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
    in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each
    option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested
    and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date
    is generally ten years from the date the option is issued. As of September 30, 2019, there were non-qualified stock options
    to purchase &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zEdFpQOY1fQa"&gt;6,316,474&lt;/span&gt;
    shares of Common Stock outstanding and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCJZpEGc0iH7"&gt;1,040,000&lt;/span&gt;
    restricted stock awards under the 2012 Plan. Effective upon our adoption of the  2019 Plan,
    no future awards may be made under the 2012 Plan.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On June 20, 2019, we adopted the
    2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
    consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock
    appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash
    awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of
    directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
    after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if
    any. The expiration date is generally ten years from the date the option is issued. As of September 30, 2019, there were &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930_zcxt7nlgS7Gg"&gt;13,779,632&lt;/span&gt;
    shares of Common Stock available  for issuance thereunder, consisting of (i) &lt;span id="xdx_900_ecustom--PlanAwardsNumberOfNewShares_iI_c20190930_zcHVE9Tn5KH4"&gt;11,294,999&lt;/span&gt;
    new shares, (ii) &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z9InMTp5NhH9"&gt;2,395,333&lt;/span&gt;
    unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding
    &#x201c;Awards&#x201d; (as defined in the 2012 Plan), and (iii) &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z56BRzUqMncb"&gt;89,300&lt;/span&gt;
    &lt;span style="background-color: white"&gt;unallocated shares previously available for issuance under the 2009 Plan that were
    not then subject to outstanding &#x201c;Awards&#x201d; (as defined in the 2009 Plan). Any shares subject to outstanding options
    or other equity &#x201c;Awards&#x201d; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or
    otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not
    result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in
    connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those
    Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again
    be available for delivery with respect to Awards under the 2019 Plan. As of September 30, 2019, there were non-qualified
    stock options to purchase&lt;/span&gt; &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member_zzzyUoJA9mo8"&gt;3,505,001&lt;/span&gt;
    shares of Common Stock outstanding and &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyja3bnqdq9h"&gt;200,000&lt;/span&gt;
    restricted stock awards outstanding under the 2019 Plan.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. &lt;span/&gt;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBj64RxovG9h" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
assumptions used in the Black-Scholes Model for options granted during the  nine months ended  September 30, 2019 and 2018
are set forth in the table below.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: top"&gt;
            &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="3" style="border-bottom: Black 1pt solid"&gt;
                &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Nine months ended&lt;/b&gt;&lt;/p&gt;
                &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: top"&gt;
            &lt;td style="width: 38%"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 2%; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztEnj6eKOIo1" title="Risk-free interest rate"&gt;1.83&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNcE7gUfeyDl" title="Risk-free interest rate"&gt;2.54&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY6csQbSvxrk" title="Risk-free interest rate"&gt;2.78&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ7wNll52r2" title="Risk-free interest rate"&gt;2.82&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBKnAH03VqWa" title="Volatility"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW5gMV6ePm46" title="Volatility"&gt;64.49&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z349HZXWPMU4" title="Volatility"&gt;61.8&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z62HC0owMh6j" title="Volatility"&gt;63.34&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span title="Term (in years)"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z3iipLHbbVJh"&gt;5.5&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxarVQm1Gd1j"&gt;6.5&lt;/span&gt;&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHWgG5iMFhy"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zO3ML0oAWKh9"&gt;6.25&lt;/span&gt;&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6t5D207Slki" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTRX8BsOqGud" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A6_zUoD2ZARFQZd" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;





    &lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwxpXkWpakyh" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;A
    summary of activity under the 2009,  2012 and 2019 Plans and related information follows:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Underlying Stock Options&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life in Years&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 39%"&gt;Balance at December 31, 2018&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs3V32eqjqE8" style="width: 11%; text-align: right" title="Balance, beginning"&gt;20,872,824&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAxABV2Rww02" style="width: 11%; text-align: right" title="Balance, beginning"&gt;4.93&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX9qeCnIo42i" style="width: 11%; text-align: right" title="Balance, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;5.94 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EpKMBVobLh" style="width: 11%; text-align: right" title="Balance, beginning"&gt;12,239,876&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzSngjQz0iC2" title="Granted"&gt;4,419,501&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMYc3ltrTObg"&gt;3.13&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTz7PTTdeK1e" title="Exercised"&gt;343,716&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgIE1urwOXzf"&gt;0.32&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zon5Zys4OMge" title="Exercised"&gt;1,426,828&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Expired/Forfeited&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxIxwNq315De" title="Expired Forfeited"&gt;98,625&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4e5hGktTPj1"&gt;5.63&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt"&gt;Balance at  September 30, 2019&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgBuC4KYmSw7" style="border-bottom: Black 2pt double; text-align: right" title="Balance, ending"&gt;24,849,984&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmsrULLhSaKi" style="text-align: right" title="Balance, ending"&gt;4.67&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znAcD8jplAsi" style="text-align: right" title="Balance, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0979"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4EflkOoQvyh" style="text-align: right" title="Balance, ending"&gt;13,761,778&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Vested and Exercisable at  September 30, 2019&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrfkt827YW56" title="Vested and Exercisable"&gt;17,601,027&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9wcx9jAGAZe" title="Vested and Exercisable"&gt;4.85&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dt_c20190101__20190930_zNxPz67KfwP1" style="text-align: right" title="Vested and Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;4.81 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwbiAOAHChfc" title="Vested and Exercisable"&gt;9,745,527&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td&gt;Unvested at  September 30, 2019&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjo6frZNvAx2" title="Unvested"&gt;7,248,957&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhDCRxWuRz6c" title="Unvested"&gt;4.22&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_pii_dt_c20190101__20190930_zdCGHXLXTN4e" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;9.06 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCtVwMvrQmEj" title="Unvested"&gt;4,016,251&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A2_zAyFDSj1qmFh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At September 30, 2019,
our outstanding stock options had exercise prices ranging from  $&lt;span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MinimumMember_zIKC6OCqcw6a"&gt;0.19&lt;/span&gt;
to $&lt;span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MaximumMember_z8pkrFQCNi9f"&gt;8.92&lt;/span&gt;
per share. The weighted average grant date fair value per share of options granted was $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930_zaLpT0qHUF6e"&gt;1.84&lt;/span&gt;
and $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930_zj44DzaWsxx7"&gt;3.27&lt;/span&gt;
during the nine months ended September 30, 2019 and 2018, respectively. Share-based compensation expense for
options recognized in our results of operations for the three months ended September 30, 2019 and 2018 ($&lt;span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930_zAZWRMss6SD5"&gt;2,194,667&lt;/span&gt;
and $&lt;span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20180701__20180930_zmYXcgmeQJM"&gt;2,109,218&lt;/span&gt;,
respectively)  and for the nine months ended September 30, 2019 and 2018 ($&lt;span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930_zI3suye304c5"&gt;6,568,736&lt;/span&gt;
and $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20180930_znBu4p2Pse9c"&gt;5,981,343&lt;/span&gt;,
respectively) is based on vested awards. At September 30, 2019, total unrecognized estimated compensation expense related to
unvested options granted prior to that date was approximately $&lt;span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20190930_z0gpzIhwTbe8"&gt;13,468,000&lt;/span&gt; which may be adjusted for future changes in
forfeitures. This cost is expected to be recognized over a weighted-average period of &lt;span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv80CJ3wG3ff"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1007"&gt;2.4 years&lt;/span&gt;&lt;/span&gt;. No tax benefit was realized
due to a continued pattern of operating losses.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Restricted stock awards granted under our 2009,
2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock.
Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably
over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 13, 2018, we granted &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK9m5YUnOWm5"&gt;1,040,000&lt;/span&gt;
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5FyY4NUCrGh"&gt;4.06&lt;/span&gt;
per unit. On July 30, 2019, we granted &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpBzKDfdNFIh"&gt;200,000&lt;/span&gt;
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value was
$&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zunBbgO17NGj"&gt;2.18&lt;/span&gt;
per unit. During the three and nine months ended September 30, 2019, we recorded $&lt;span id="xdx_90D_eus-gaap--RestrictedStockExpense_c20190701__20190930_z6zPla3PyFB1"&gt;384,061&lt;/span&gt;
and $&lt;span id="xdx_903_eus-gaap--RestrictedStockExpense_c20190101__20190930_z3VLgpLjCcb5"&gt;1,080,738&lt;/span&gt;, respectively, in
share-based compensation expense related to restricted stock units. At September 30, 2019, total unrecognized estimated
compensation expense related to unvested restricted stock units was approximately $&lt;span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20190930_zcL9lwCGZUZi"&gt;3,505,000&lt;/span&gt;,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of &lt;span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR7fVr6H4ceb"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1015"&gt;2.2
years&lt;/span&gt;&lt;/span&gt;. At September 30, 2019, we had &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930_zPGdpZY9VZXl"&gt;1,240,000&lt;/span&gt;
restricted stock awards outstanding.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cash-Settled Stock Appreciation Rights (SARs)&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On July 1, 2018, we issued cash-settled SARs
to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30,
2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled
SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant
price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over
the grant price is paid in cash and not in Common Stock.&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;






    &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Cash settled SARs were recorded in our consolidated
balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes
valuation model. In accordance with ASC Topic 718, &#x201c;Stock Compensation,&#x201d; the fair value of each SAR award was recalculated
at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested.
At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded
liability was reversed and no cash payment was made.&lt;/p&gt;
    </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2019-09-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">241277076</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">241277076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-07-012019-09-30"
      decimals="INF"
      unitRef="Shares">55236</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">8549</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="Shares">331619</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">108656</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="Shares">12097</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="Shares">11834</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-07-012018-09-30"
      decimals="INF"
      unitRef="Shares">1052300</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">107318</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2018-01-012018-09-30"
      decimals="INF"
      unitRef="Shares">1446876</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">1236313</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise
      contextRef="From2018-01-012018-09-30"
      decimals="INF"
      unitRef="Shares">10000</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares
      contextRef="From2018-01-012018-09-30"
      decimals="INF"
      unitRef="Shares">9841</txmd:NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">12745098</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2018-08-01"
      decimals="INF"
      unitRef="USDPShares">5.10</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementGoldmanSachsMember"
      decimals="INF"
      unitRef="Shares">1911764</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2018-08-052018-08-06"
      decimals="0"
      unitRef="USD">69908000</txmd:ProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2018-08-052018-08-06_custom_SubscriptionAgreementKnightMember"
      decimals="0"
      unitRef="USD">20000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1832571</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-30_custom_WarrantsMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-30_custom_WarrantsMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="USDPShares">2.62</txmd:WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">5.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.608</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">2.52</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">3.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2019-01-012019-09-30_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Shares">175000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">5.16</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate
      contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.621</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate
      contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0.0236</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate
      contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="Pure">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member"
      decimals="INF"
      unitRef="USDPShares">2.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-012018-09-30_custom_OutsideConsultant2Member">P12M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-07-012019-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">56418</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-07-012018-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">150977</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2019-01-012019-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">198306</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2018-01-012018-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">407292</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="AsOf2019-09-30_custom_WarrantsMember"
      decimals="0"
      unitRef="USD">83000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2019-01-012019-09-30_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">1250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2019-01-012019-09-30_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">471184</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants
      contextRef="From2018-01-012018-09-30_custom_WarrantsMember"
      decimals="INF"
      unitRef="Shares">0</txmd:NumberOfStockIssuedInCashlessExerciseOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">15028509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">6316474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">13779632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <txmd:PlanAwardsNumberOfNewShares contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">11294999</txmd:PlanAwardsNumberOfNewShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-09-30_custom_NonQualified2012StockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">2395333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2019-09-30_custom_LongTermIncentiveCompensationPlan2009Member"
      decimals="INF"
      unitRef="Shares">89300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_Plan2019Member"
      decimals="INF"
      unitRef="Shares">3505001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-09-30_custom_Plan2019Member_us-gaap_RestrictedStockMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBj64RxovG9h" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span&gt;The
assumptions used in the Black-Scholes Model for options granted during the  nine months ended  September 30, 2019 and 2018
are set forth in the table below.&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: top"&gt;
            &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="3" style="border-bottom: Black 1pt solid"&gt;
                &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Nine months ended&lt;/b&gt;&lt;/p&gt;
                &lt;p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;September 30,&lt;/b&gt;&lt;/p&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="vertical-align: top"&gt;
            &lt;td style="width: 38%"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2019&lt;/b&gt;&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 2%; text-align: right"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; width: 15%; text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;2018&lt;/b&gt;&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztEnj6eKOIo1" title="Risk-free interest rate"&gt;1.83&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNcE7gUfeyDl" title="Risk-free interest rate"&gt;2.54&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY6csQbSvxrk" title="Risk-free interest rate"&gt;2.78&lt;/span&gt;-&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ7wNll52r2" title="Risk-free interest rate"&gt;2.82&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBKnAH03VqWa" title="Volatility"&gt;61.25&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW5gMV6ePm46" title="Volatility"&gt;64.49&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z349HZXWPMU4" title="Volatility"&gt;61.8&lt;/span&gt;-&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z62HC0owMh6j" title="Volatility"&gt;63.34&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span title="Term (in years)"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z3iipLHbbVJh"&gt;5.5&lt;/span&gt;&lt;/span&gt;-&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxarVQm1Gd1j"&gt;6.5&lt;/span&gt;&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHWgG5iMFhy"&gt;5.5&lt;/span&gt;-&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zO3ML0oAWKh9"&gt;6.25&lt;/span&gt;&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: top"&gt;
            &lt;td&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6t5D207Slki" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: center"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTRX8BsOqGud" title="Dividend yield"&gt;0.00&lt;/span&gt;%&lt;/span&gt;
            &lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0278</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.6125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.6449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.6334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MinimumMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember_srt_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2018-01-012018-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwxpXkWpakyh" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;A
    summary of activity under the 2009,  2012 and 2019 Plans and related information follows:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Number of Shares Underlying Stock Options&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted Average Exercise Price&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Weighted &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life in Years&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Aggregate Intrinsic Value&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 39%"&gt;Balance at December 31, 2018&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs3V32eqjqE8" style="width: 11%; text-align: right" title="Balance, beginning"&gt;20,872,824&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAxABV2Rww02" style="width: 11%; text-align: right" title="Balance, beginning"&gt;4.93&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX9qeCnIo42i" style="width: 11%; text-align: right" title="Balance, beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0960"&gt;5.94 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EpKMBVobLh" style="width: 11%; text-align: right" title="Balance, beginning"&gt;12,239,876&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in"&gt;Granted&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzSngjQz0iC2" title="Granted"&gt;4,419,501&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMYc3ltrTObg"&gt;3.13&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in"&gt;Exercised&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;(&lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTz7PTTdeK1e" title="Exercised"&gt;343,716&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgIE1urwOXzf"&gt;0.32&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zon5Zys4OMge" title="Exercised"&gt;1,426,828&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; padding-left: 0.125in"&gt;Expired/Forfeited&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxIxwNq315De" title="Expired Forfeited"&gt;98,625&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4e5hGktTPj1"&gt;5.63&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 2pt"&gt;Balance at  September 30, 2019&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgBuC4KYmSw7" style="border-bottom: Black 2pt double; text-align: right" title="Balance, ending"&gt;24,849,984&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmsrULLhSaKi" style="text-align: right" title="Balance, ending"&gt;4.67&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znAcD8jplAsi" style="text-align: right" title="Balance, ending"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0979"&gt;6.05 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4EflkOoQvyh" style="text-align: right" title="Balance, ending"&gt;13,761,778&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Vested and Exercisable at  September 30, 2019&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrfkt827YW56" title="Vested and Exercisable"&gt;17,601,027&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9wcx9jAGAZe" title="Vested and Exercisable"&gt;4.85&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dt_c20190101__20190930_zNxPz67KfwP1" style="text-align: right" title="Vested and Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0987"&gt;4.81 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwbiAOAHChfc" title="Vested and Exercisable"&gt;9,745,527&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td&gt;Unvested at  September 30, 2019&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjo6frZNvAx2" title="Unvested"&gt;7,248,957&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhDCRxWuRz6c" title="Unvested"&gt;4.22&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_pii_dt_c20190101__20190930_zdCGHXLXTN4e" style="text-align: right" title="Unvested"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;9.06 years&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCtVwMvrQmEj" title="Unvested"&gt;4,016,251&lt;/span&gt;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">20872824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2018-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">12239876</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">4419501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">3.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">343716</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">0.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">1426828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">98625</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">24849984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">4.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">13761778</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">17601027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">4.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">9745527</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">7248957</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      unitRef="USDPShares">4.22</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue
      contextRef="AsOf2019-09-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="USD">4016251</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2019-09-30_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.19</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice
      contextRef="AsOf2019-09-30_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">8.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="USDPShares">1.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-01-012018-09-30"
      decimals="INF"
      unitRef="USDPShares">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">2194667</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">2109218</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">6568736</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">5981343</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">13468000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">1040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2018-12-122018-12-13_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">4.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="Shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="From2019-07-292019-07-30_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      unitRef="USDPShares">2.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">384061</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1080738</us-gaap:RestrictedStockExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">3505000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2019-09-30" decimals="INF" unitRef="Shares">1240000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zLZMvvRx8HFf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 12 &#x2013; INCOME TAXES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the nine months ended September
30, 2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior
years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is "more likely
than not" that some component or all of the benefits of deferred tax assets will not be realized. As of September 30, 2019,
we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income
taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z9lBeo3fc59e" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 13 &#x2013; RELATED PARTIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the three months ended September 30, 2019 and 2018,  we were billed by Catalent approximately $&lt;span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z5ZbCHddDQCj"&gt;2,196,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180701__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zBOQJnvfxA5f" title="Amount billed"&gt;830,000&lt;/span&gt;, respectively,
for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.
During the nine months ended September 30, 2019 and 2018, we were billed by Catalent approximately $&lt;span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zbqgsDGIuhij"&gt;4,118,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zsGGVNSFHjZ1"&gt;2,774,000&lt;/span&gt;, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of September 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $&lt;span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z0aHDfBmz2Xi"&gt;425,000&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zCm29zDWXhca"&gt;88,000&lt;/span&gt;, respectively.&lt;/p&gt;
    </us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-07-012019-09-30_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">2196000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2018-07-012018-09-30_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">830000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2019-01-012019-09-30_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">4118000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="From2018-01-012018-09-30_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">2774000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2019-09-30_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">425000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent
      contextRef="AsOf2018-12-31_srt_AffiliatedEntityMember"
      decimals="0"
      unitRef="USD">88000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zGhipIvhCcZf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 14 &#x2013; BUSINESS CONCENTRATIONS&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We purchase our prescription
    products from several suppliers with approximately &lt;span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zJOO7dqE9r2c" title="Concentration risk"&gt;36&lt;/span&gt;%, &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z10Khkqoi0cj"&gt;28&lt;/span&gt;%,
    and &lt;span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zSAfmDABDcB2"&gt;26&lt;/span&gt;%
    of our purchases supplied by &lt;span id="xdx_901_ecustom--NumberOfVendors_dc_uPure_c20190101__20190930_zD8mSqSvTHzi" title="Number of vendors - suppliers"&gt;three&lt;/span&gt;
    vendors each, respectively, during the nine months ended September 30, 2019. Approximately &lt;span title="Number of vendors - suppliers"&gt;&lt;span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2bG5jRNZPqj"&gt;100&lt;/span&gt;&lt;/span&gt;%
    of our products were manufactured by  &lt;span id="xdx_90B_ecustom--NumberOfVendors_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zU5zOInSbSh9" title="Number of vendors - suppliers"&gt;one&lt;/span&gt;
    vendor related to each of IMVEXXY
and prenatal vitamins during the nine months ended September 30, 2018.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our prescription prenatal
    vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
    generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
    September 30, 2019, &lt;span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcbxkREYLq0h"&gt;four&lt;/span&gt;
    customers each generated more than &lt;span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeIcHfUSk864" title="Concentration risk"&gt;10&lt;/span&gt;%
    of our total prescription revenues. During the nine months ended September 30, 2018,  &lt;span id="xdx_904_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zp4ZEpTALvCh" title="Number of customers - revenue"&gt;four&lt;/span&gt;
    customers each generated more than &lt;span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUKn9O2RkR63"&gt;10&lt;/span&gt;%
    of our total prescription revenues. Prescription revenue generated from the &lt;span id="xdx_90D_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX18O6ouVBDj"&gt;four&lt;/span&gt;
    customers combined accounted for approximately &lt;span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember_zGN3tQi0UoVd"&gt;68&lt;/span&gt;%
    of our prescription revenue for the nine months ended September 30, 2019, and prescription revenue generated from the  &lt;span id="xdx_907_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znBjqGIh6T91"&gt;four&lt;/span&gt;
    customers combined accounted for approximately &lt;span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zbTlgbKrTkW5"&gt;71&lt;/span&gt;%
    of our prescription revenue for the nine months ended September 30, 2018.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the nine months ended September 30,
2019, PI Services accounted for approximately $&lt;span id="xdx_901_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zv0WckalJ6g5"&gt;1,935,000&lt;/span&gt; of our prescription revenue, Pillpack, Inc. accounted for approximately
$&lt;span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zqu4stv5lTEl"&gt;6,397,000&lt;/span&gt; of our prescription revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_90E_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zFoOtj3urO81"&gt;2,226,000&lt;/span&gt; of our prescription revenue and
Cardinal Health accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zNpuvcB7IJY5"&gt;1,863,000&lt;/span&gt; of our prescription revenue. During the nine months ended September 30,
2018, PI Services accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zsCm87i31OMl"&gt;1,559,000&lt;/span&gt; of our prescription revenue, Pillpack, Inc. accounted for approximately
$&lt;span id="xdx_908_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zZkrb1oUo9Kl"&gt;3,057,000&lt;/span&gt; of our prescription revenue, AmerisourceBergen accounted for approximately $&lt;span id="xdx_904_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zKa65h6uYBD2"&gt;1,834,000&lt;/span&gt; of our prescription revenue and
Cardinal Health accounted for approximately $&lt;span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zq0VyYCaUdhg"&gt;1,399,000&lt;/span&gt; of our prescription revenue.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    </us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_SupplierTwoConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_custom_SupplierThreeConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.26</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="Pure">3</txmd:NumberOfVendors>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfVendors
      contextRef="From2018-01-012018-09-30_us-gaap_SupplierConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">1</txmd:NumberOfVendors>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_ThreeCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.68</us-gaap:ConcentrationRiskPercentage1>
    <txmd:NumberOfCustomers
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">4</txmd:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_FourCustomersConcentrationRiskMember"
      decimals="INF"
      unitRef="Pure">0.71</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember"
      decimals="0"
      unitRef="USD">1935000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">6397000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">2226000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2019-01-012019-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">1863000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPIServicesRiskMember"
      decimals="0"
      unitRef="USD">1559000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationPillPackRiskMember"
      decimals="0"
      unitRef="USD">3057000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationAmerisourceBergenRiskMember"
      decimals="0"
      unitRef="USD">1834000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="From2018-01-012018-09-30_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationCardinalHealthRiskMember"
      decimals="0"
      unitRef="USD">1399000</us-gaap:Revenues>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zt7pYfi40Gx9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 15 &#x2013; COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We adopted ASC 842 effective January 1, 2019.
Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used
to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have
commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease
liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at
cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease
incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present
value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease
because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based
on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect
at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion
of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease
liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial
lease liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We lease administrative office space
    in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided
    for a &lt;span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dt_c20130629__20130701_zXWLNbBEhyCd"&gt;63 month&lt;/span&gt; term. On
    February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the
    same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the
    same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
    1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an
    agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum
    to such lease. This addendum is effective beginning November 1, 2016.&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes &lt;span id="xdx_908_ecustom--NetRentableAreaLease_iI_uSQFT_c20181001_z2xtmJDClHXf"&gt;56,212&lt;/span&gt; rentable square feet, or the full premises, of which lease on &lt;span id="xdx_908_ecustom--RentedAreaLease_iI_uSQFT_c20181001_zAu0BnRUfJL5"&gt;7,561&lt;/span&gt; square feet commenced in 2018 and the lease on the remaining &lt;span id="xdx_909_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSQFT_c20181001_zEIYwbIZzzqa"&gt;48,651&lt;/span&gt; square feet commenced in August 2019, or the full
premises commencement date. The lease will expire &lt;span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20190930_zxwXhiRgdfkg"&gt;11&lt;/span&gt; years after full premises commencement date, unless terminated earlier in
accordance with the terms of the lease. We have the option to extend the term of the lease for &lt;span id="xdx_906_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20190930_zxAN8GnjQKV6"&gt;two&lt;/span&gt; additional consecutive periods
of &lt;span id="xdx_90C_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20190930_zAB5OHfC6tc1"&gt;5&lt;/span&gt; years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be
exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating
costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors
to lease additional &lt;span id="xdx_906_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSQFT_c20190930_zkteCQtw3eLe"&gt;6,536&lt;/span&gt; square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.&lt;/p&gt;






&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/&gt;
    &lt;p style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_zYiFlHN7nJS1" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental lease information  &lt;br/&gt;
at September 30,
            2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;
            &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20190930_ze72r3SrGogd" style="width: 12%; text-align: right"&gt;10,459,635&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20190930_z7rpaP1P99r" style="text-align: right"&gt;1,242,290&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20190930_zOVkoE6yvSrg" style="text-align: right"&gt;9,500,133&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td&gt;Weighted average remaining term&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20190930_zKJ121cxsyt3"&gt;9&lt;/span&gt; Years&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td&gt;Weighted average discount rate&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20190930_znuDhfIpmbua" style="text-align: right"&gt;8.25&lt;/td&gt;
            &lt;td style="text-align: left"&gt;%&lt;/td&gt;
        &lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information &lt;br/&gt;for  nine months
            ended September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;
            &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_982_eus-gaap--OperatingLeasePayments_c20190101__20190930_zLWiTbrLwsS9" style="width: 12%; text-align: right"&gt;849,440&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20190930_zeOWIvNo2GZ2" style="text-align: right"&gt;11,171,471&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqAsztLw02Nd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The
    following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease
    liabilities recorded on the balance sheet:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"/&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_493_20190930_zRCcJ7ZiCOd6" style="text-align: right"/&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzviC_zvmluQVXekw4" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019 (3 months)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;314,670&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzviC_z5W1ORnPZWP4" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2020&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,566,617&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzviC_zqlbVbfakOD5" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2021&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,198,541&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzviC_zi09GQCrlCVc" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2022&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,262,302&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzviC_zVZQYJZM1UYe" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2023&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,293,859&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzviC_zqenOG7RntNe" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,363,136&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzviC_maOLLzDJI_zXyLb0F2X4eg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total undiscounted lease payments&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;15,999,125&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityImputedInterestAmount_iNI_di_msOLLzFSB_msOLLzDJI_zaePQXH7GRA2" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,256,702&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzDJI_zLzePcvvgFx9" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease payments&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,742,423&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    &lt;p id="xdx_8A9_z6oWlmWoyIbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt; During the three and nine  months
    ended September 30, 2019, operating lease expense related to our real estate leases was approximately $&lt;span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zn3CMh36la1a" title="Operating lease expense"&gt;458,000&lt;/span&gt;
    and $&lt;span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20190101__20190930_zSeePHiSmW3e"&gt;1,062,000&lt;/span&gt;, respectively, and
    variable lease expense was insignificant for the three and nine months ended September 30, 2019. Rent expense totaled $&lt;span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20180701__20180930_zzuHt0mauBd4"&gt;257,000&lt;/span&gt;
    and $&lt;span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20180101__20180930_z4rn8gJT0G6f"&gt;772,000&lt;/span&gt; during the three and
    nine months ended September 30, 2018, respectively.&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;

&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Intellectual Property Licenses &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have license agreements with third parties
that provide for minimum royalty, license, and exclusivity payments to be paid by us for access to certain technologies. In addition,
we pay royalties as a percent of revenue as described in Note 7, Intangible Assets, to these consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Purchase commitments&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have a manufacturing and supply agreement
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent &lt;span id="xdx_900_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20190930_z9J48PRHhMyl"&gt;50&lt;/span&gt;%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and the
sum of all purchases of our products from Catalent during the contract year.&#160;&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/&gt;
    </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <txmd:CapitalLeaseObligationsTerm contextRef="From2013-06-292013-07-01">P63M</txmd:CapitalLeaseObligationsTerm>
    <txmd:NetRentableAreaLease contextRef="AsOf2018-10-01" decimals="INF" unitRef="SQFT">56212</txmd:NetRentableAreaLease>
    <txmd:RentedAreaLease contextRef="AsOf2018-10-01" decimals="INF" unitRef="SQFT">7561</txmd:RentedAreaLease>
    <txmd:AdditionalAreaOfLeaseOccupied contextRef="AsOf2018-10-01" decimals="INF" unitRef="SQFT">48651</txmd:AdditionalAreaOfLeaseOccupied>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="AsOf2019-09-30">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber
      contextRef="From2019-01-01to2019-09-30"
      decimals="INF"
      unitRef="Pure">2</txmd:LesseeFinanceLeaseExistenceOfOptionToExtendNumber>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1 contextRef="AsOf2019-09-30">P5Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea contextRef="AsOf2019-09-30" decimals="INF" unitRef="SQFT">6536</txmd:LesseeOperatingLeaseLeaseNotYetCommencedArea>
    <txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_zYiFlHN7nJS1" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)"&gt;
        &lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental lease information  &lt;br/&gt;
at September 30,
            2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;Right-of-use asset&lt;/td&gt;
            &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20190930_ze72r3SrGogd" style="width: 12%; text-align: right"&gt;10,459,635&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Short-term operating lease liability (included in Other current liabilities)&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20190930_z7rpaP1P99r" style="text-align: right"&gt;1,242,290&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Long-term operating lease liability&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20190930_zOVkoE6yvSrg" style="text-align: right"&gt;9,500,133&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td&gt;Weighted average remaining term&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20190930_zKJ121cxsyt3"&gt;9&lt;/span&gt; Years&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td&gt;Weighted average discount rate&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20190930_znuDhfIpmbua" style="text-align: right"&gt;8.25&lt;/td&gt;
            &lt;td style="text-align: left"&gt;%&lt;/td&gt;
        &lt;/tr&gt;

&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="padding-bottom: 1pt; text-align: center"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
            &lt;td colspan="2"&gt;&#160;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Supplemental cash flow information &lt;br/&gt;for  nine months
            ended September 30, 2019&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities for operating lease&lt;/td&gt;
            &lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_982_eus-gaap--OperatingLeasePayments_c20190101__20190930_zLWiTbrLwsS9" style="width: 12%; text-align: right"&gt;849,440&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;Right-of-use assets obtained in exchange for lease obligation&lt;/td&gt;
            &lt;td&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;$&lt;/td&gt;
            &lt;td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20190930_zeOWIvNo2GZ2" style="text-align: right"&gt;11,171,471&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;</txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10459635</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1242290</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">9500133</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2019-09-30">P9Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2019-09-30" decimals="INF" unitRef="Pure">0.0825</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">849440</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">11171471</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqAsztLw02Nd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The
    following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease
    liabilities recorded on the balance sheet:&lt;/p&gt;
    &lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/p&gt;
    &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto"&gt;
&lt;tr style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"/&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td id="xdx_493_20190930_zRCcJ7ZiCOd6" style="text-align: right"/&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
&lt;tr style="vertical-align: bottom"&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td colspan="2"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzviC_zvmluQVXekw4" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="width: 44%; text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2019 (3 months)&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="width: 12%; text-align: right"&gt;314,670&lt;/td&gt;
            &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzviC_z5W1ORnPZWP4" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2020&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,566,617&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzviC_zqlbVbfakOD5" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2021&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;2,198,541&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzviC_zi09GQCrlCVc" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2022&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,262,302&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzviC_zVZQYJZM1UYe" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;2023&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;1,293,859&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzviC_zqenOG7RntNe" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;9,363,136&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzviC_maOLLzDJI_zXyLb0F2X4eg" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total undiscounted lease payments&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="text-align: right"&gt;15,999,125&lt;/td&gt;
            &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityImputedInterestAmount_iNI_di_msOLLzFSB_msOLLzDJI_zaePQXH7GRA2" style="background-color: white; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Less: imputed interest&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(5,256,702&lt;/td&gt;
            &lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzDJI_zLzePcvvgFx9" style="background-color: #cceeff; vertical-align: bottom"&gt;
            &lt;td style="text-align: left"&gt;
                &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Present value of lease payments&lt;/span&gt;
            &lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: left"&gt;$&lt;/td&gt;
            &lt;td style="border-bottom: Black 2pt double; text-align: right"&gt;10,742,423&lt;/td&gt;
            &lt;td style="padding-bottom: 2pt; text-align: left"&gt;&#160;&lt;/td&gt;
        &lt;/tr&gt;
    &lt;/table&gt;
    </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">314670</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1566617</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">2198541</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1262302</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">1293859</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">9363136</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">15999125</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">5256702</txmd:LesseeOperatingLeaseLiabilityImputedInterestAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2019-09-30" decimals="0" unitRef="USD">10742423</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-07-012019-09-30"
      decimals="0"
      unitRef="USD">458000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2019-01-01to2019-09-30"
      decimals="0"
      unitRef="USD">1062000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2018-07-012018-09-30"
      decimals="0"
      unitRef="USD">257000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2018-01-012018-09-30"
      decimals="0"
      unitRef="USD">772000</us-gaap:OperatingLeaseExpense>
    <txmd:SignificantSupplyCommitmentPercentagePayable contextRef="AsOf2019-09-30" decimals="INF" unitRef="Pure">0.50</txmd:SignificantSupplyCommitmentPercentagePayable>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2019-01-01to2019-09-30">&lt;p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zjWsXK4Vjrsc" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE
16 &#x2013; SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters,
relating to an underwritten public offering of &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zuTda8ha01Nc"&gt;26,000,000&lt;/span&gt; shares of our Common Stock at a public offering price of $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zdMpApxnu2Ti"&gt;2.75&lt;/span&gt; per share.
We granted the underwriters an option, exercisable for a period of &lt;span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zv1tZUXL8Mb2"&gt;30&lt;/span&gt; days, to purchase up to &lt;span id="xdx_900_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zjLEa2Iqock2"&gt;3,900,000&lt;/span&gt; additional shares of Common
Stock, which was exercised in full. The net proceeds from the offering were approximately $&lt;span id="xdx_90F_ecustom--ProceedsFromIssuancePublicOffering_dm_c20191023__20191029__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zgWWyCK7Sm62"&gt;77.0 million&lt;/span&gt;, after deducting the underwriting
discount and offering expenses payable by us. The offering closed on October 29, 2019.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 11pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;

</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">26000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="USDPShares">2.75</us-gaap:SharesIssuedPricePerShare>
    <txmd:PeriodExercisableUnderwritersOption contextRef="From2019-10-232019-10-24_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember">P30D</txmd:PeriodExercisableUnderwritersOption>
    <txmd:UnderwritersOptionGrantedInPeriodShares
      contextRef="From2018-07-282018-08-01_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="INF"
      unitRef="Shares">3900000</txmd:UnderwritersOptionGrantedInPeriodShares>
    <txmd:ProceedsFromIssuancePublicOffering
      contextRef="From2019-10-232019-10-29_us-gaap_SubsequentEventMember_custom_UnderwritingAgreementJPMorganChaseMember"
      decimals="0"
      unitRef="USD">77000000.0</txmd:ProceedsFromIssuancePublicOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780319184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">NOTE 7 &#8211; INTANGIBLE ASSETS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--GoodwillAndIntangibleAssetsDisclosureTextBlock_zUGf6R4dvZ5k" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 7 &#8211; INTANGIBLE ASSETS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_894_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zF2pG48UUutj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible
    assets as of  September 30, 2019 and December 31, 2018:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHT4kcSu00h4">3,138,308</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfGFHL86MePe">421,694</span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zjdehtxU1VZ9">2,716,614</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxexs92WpqWl"><span style="-sec-ix-hidden: xdx2ixbrl0640">13.25 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patent (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zecx6GTDwx55">1,937,691</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zyr7z5nVMYtb">1,937,691</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--IndefiniteLivedTrademarks_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zrVf8dqjdmQ3">287,846</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zGkffbfhIFqd">287,846</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20190930_z0pNSTmUTR7l">5,363,845</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930_zPaKAwZSUr06">421,694</span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_902_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20190930_zE2rT6V2zNge">4,942,151</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="14" style="text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">OPERA<sup>&#174;</sup> software patent</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zH8PtIeI4Yu1">31,951</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zlWYTVlSdoy7">10,484</span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zhNgaqL1IuJ5">21,467</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zfomTckYUkHf"><span style="-sec-ix-hidden: xdx2ixbrl0651">10.75 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Development costs of corporate website</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zPFT8hiW06a9">91,743</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zeGvdBObtG81">91,743</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_z0VUomajPbY2"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z0rhyjQ4RQr8">2,234,129</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4pIuwCw1lQa">282,485</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaymSAUbGVT5">1,951,644</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zRlkL68D776a">14</span> years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zRu92iHsrlo3">1,855,279</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zlXVUgqxn2Id">1,855,279</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z4YwYthUGCE3">264,289</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zv60HoAHnCZk">264,289</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_zg4kASQUQK9c">4,477,391</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231_zYJpcxmeA1gi">384,712</span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_903_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zJnQ5BGJ8R23">4,092,679</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A9_zKlXrzk73vTi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We capitalize external costs,
    consisting primarily of legal costs, related to securing our patents and trademarks. Once a patent is granted, we amortize
    the approved hormone therapy drug candidate patents using the straight-line method over the estimated useful life of
    approximately <span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zcxFu8f3xYy7">20</span> years, which is the life of intellectual property patents. If the patent is not granted, we write-off any capitalized
    patent costs at that time. Trademarks are perpetual and are not amortized. During the  nine months ended  September 30, 2019,
    we     wrote off $<span id="xdx_902_eus-gaap--ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_c20190101__20190930_zO4zzKp2gqA7">78,864</span>
    in costs related to trademarks and patents, including the net carrying amount of the OPERA patent.</p>





    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of  September 30, 2019, we had <span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsMember_zMV96WVwqBkd">26</span>
    issued domestic, or U.S., patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsMember_zy5qZxrzt4Ge" title="Number of issued patents">28</span>
    issued foreign patents, including: </p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_90F_ecustom--NumberOfIssuedPatents_iI_pii_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsBijuvaMember_z8qfltyCATu4">12</span> domestic patents and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsBijuvaMember_zjdDjw9dWhB6">six</span> foreign patents that relate to BIJUVA as well as <span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticPatentsNonApprovedBijuvaMember_z4P5ToYu9xPl">three</span> domestic patents that relate to estradiol and progesterone product candidates. These patents establish an important intellectual property foundation for BIJUVA and are owned by us. The domestic patents will expire in 2032. The foreign patents will expire no earlier than 2032. In addition, we have pending patent applications relating to BIJUVA in the U.S., Argentina, Australia, Brazil, Canada, China, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsImvexxyMember_zTbMhinwjrg1">Five</span> domestic patents (<span id="xdx_90C_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSUtilityPatentsImvexxyMember_zcdUdW1K7ehf">four</span> utility and <span id="xdx_90B_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSDesignPatentsImvexxyMember_zOfhXCHGy0vg">one</span> design) and <span id="xdx_900_ecustom--NumberOfIssuedPatents_iI_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignPatentsImvexxyMember_zFWiHHvOLaU4">13</span> foreign patents (<span id="xdx_909_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentsImvexxyMember_zknycpPqXsr5">three</span> utility and <span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignDesignPatentsImvexxyMember_z9VjnyiAQjzc">ten</span> design) that relate to IMVEXXY. These patents establish an important intellectual property foundation for IMVEXXY and are owned by us. The domestic patents will expire in 2032 or 2033. The foreign utility patents will expire no earlier than 2033. The foreign design patents provide protection expiring no earlier than 2025. In certain jurisdictions, the foreign design patents provide protection through at least 2037. In addition, we have pending patent applications related to IMVEXXY in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_90E_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUSPatentsTopicalCreamMember_zoHdGdPLtO7">One</span> domestic utility patent that relates to our topical-cream candidates, which is owned by us. The domestic patent will expire in 2035. We have pending patent applications with respect to our topical-cream candidates in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_903_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTransdermalPatchMember_zHMvCZ8shUN6">One</span> domestic utility patent and <span id="xdx_906_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ForeignUtilityPatentTransdermalPatchMember_zNuk6TOMOVLe">five</span> foreign patents that relate to our transdermal-patch candidates, which are owned by us. The domestic utility patent will expire in 2032. The foreign patents will expire no earlier than 2033. We have pending patent applications with respect to our transdermal-patch candidates in the U.S., Brazil, Canada, Europe, Mexico, and South Africa;</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_905_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentOperaMember_ziuOF0i3T0Ji">One</span> domestic utility patent that relates to our OPERA information-technology platform, which is owned by us and will expire in 2031;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_901_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentDLimoneneMember_zwEEMWSOa8Wa">One</span> domestic utility patent that relates to a product candidate containing d-limonene, which is owned by us and will expire in 2036; and</p>


    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in"> &#9679;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: -11pt; margin-bottom: 0pt; margin-left: 0.5in; text-align: justify"><span id="xdx_908_ecustom--NumberOfIssuedPatents_iI_dc_uPure_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--DomesticUtilityPatentTx009HRMember_zgILgfro8lkc">Two</span> domestic utility patents that relate to TX-009HR, a progesterone and estradiol product candidate, which are owned by us and will expire in 2037. We have pending patent applications with respect to TX-009HR in the U.S., Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, New Zealand, Russia, South Africa, and South Korea.</p>







    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Amortization expense was $<span id="xdx_90F_eus-gaap--AmortizationOfIntangibleAssets_c20190701__20190930_zMNDtbUkzAB6">51,259
</span>and $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20180701__20180930_zx62xv28P7Jd">31,100</span> for the three months ended September 30, 2019 and 2018, respectively, and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20190101__20190930_zlKbrsgfu9Hl">140,206</span> and $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_c20180101__20180930_zT82fUYIIuta">77,123</span> for the nine
months ended September 30, 2019 and 2018, respectively. </p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAci4sN9jYqf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20190930_zThwUBK0S9ml">51,259</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2020</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20190930_zUjJVCXk7WT8">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2021</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20190930_zgQfK1pgKl12">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2022</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20190930_zC6w2B1yBR7j">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2023</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20190930_zTOwKhv8PJre">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A3_zrdPQqZP9AGa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with the Population Council</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 30, 2018, we entered into the Council License Agreement to
commercialize ANNOVERA in the U.S. ANNOVERA became commercially available in the third quarter of 2019 and we expect the full
commercial launch in the first quarter of 2020.</p>



<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Under the terms of the Council
    License Agreement, we paid the Population Council a milestone payment of $<span id="xdx_900_ecustom--MilestonePaymentUponFDAApproval_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zdEopnBw5039">20,000,000</span>
    within 30 days following approval by the FDA of the new drug application, or NDA, for ANNOVERA. The first commercial batch
    of     ANNOVERA         was     released     during the     third quarter of 2019 and we are required to pay the
    Population     Council     $<span id="xdx_907_ecustom--MilestonePaymentsAfterReleaseOfFirstCommercialBatch_iI_c20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z4aqI3Gp9oY2">20,000,000</span> as a result of the commercial batch release. Both milestone payments of $<span id="xdx_90C_eus-gaap--FinitelivedIntangibleAssetsAcquired1_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zJisBxrnrfj8">20,000,000</span>
    were recorded as  finite-lived intangible asset in the consolidated balance sheet as of September 30, 2019. We     started
    amortizing the intangible asset in  the third quarter of 2019 once ANNOVERA became commercially available for use. The cost
    is     amortized     over     the     remaining useful life over which an intangible asset will contribute directly or
    indirectly to     our cash     flows.     During     both the three and nine months ended September 30, 2019, we recorded
    $<span id="xdx_908_eus-gaap--OtherAmortizationOfDeferredCharges_c20190701__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_zxgyFE9a4CWc"><span id="xdx_902_eus-gaap--OtherAmortizationOfDeferredCharges_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember_z1LXOHwdFNU5">15,998</span></span>
    in amortization expense related to the license fee     which was recorded as a component of cost of
    sales.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The Population Council is also
eligible to receive milestone payments and royalties from commercial sales of ANNOVERA. We will assume responsibility for
marketing expenses related to the commercialization of ANNOVERA. In addition, we are required to pay the Population Council,
on a quarterly basis, step-based royalty payments based on annual net sales of ANNOVERA in the U.S. by the Company and its
affiliates and permitted licensees as follows: (i) if annual net sales are less than or equal to  $<span id="xdx_905_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member__srt--ProductOrServiceAxis__custom--AnnoveraMember__custom--RoyaltyTierAxis__custom--StepBasedRoyaltyPaymentOneMember__srt--RangeAxis__srt--MaximumMember_ztQwC0HJUrof">50,000,000</span>,
a royalty of <span id="xdx_904_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep1Member_zVFqGfPOp1V4">5</span>%
of net sales; (ii) for annual net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MinimumMember_zRjIN2F1tYPf">50,000,000</span>
and less than or equal to $<span id="xdx_90B_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member__srt--RangeAxis__srt--MaximumMember_zp8hnq8MjsR">150,000,000</span>,
a royalty of <span id="xdx_90F_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep2Member_zzm6ms4ydZK3">10</span>%
of such net sales; and (iii) for net sales greater than $<span id="xdx_90F_ecustom--NetSalesAmountPerStepbasedRoyalty_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member__srt--RangeAxis__srt--MinimumMember_z16mp6wmofGb">150,000,000</span>,
a royalty of <span id="xdx_901_ecustom--RoyaltyPercent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreementStep3Member_zr2gy2T8UbS9">15</span>%
of such net sales. The annual royalty rate will be reduced to <span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zh7ru0AV8nTi">50</span>%
of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic
equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S., and thereafter will
be     reduced to <span id="xdx_90C_ecustom--AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zw5UuV3ddgpg">20</span>%
of the initial rate. The Population Council has agreed to perform and pay the costs and expenses associated with four
post-approval studies required by the FDA for ANNOVERA and we have agreed to perform and pay the costs and expenses
associated with a post approval study required by the FDA to measure risk for venous thromboembolism, provided that if the
costs and expenses associated with such post-approval study exceed  $<span id="xdx_906_ecustom--MaximumCostsAndExpensesForPostApprovalStudyToBePaid_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--CouncilLicenseAgreement1Member_zpjdnchgCzA3">20,000,000</span>,
half of such excess will be offset against royalties or other payments owed by us to the Population Council under the Council
License Agreement. We and the Population Council have agreed to form a joint product committee responsible for overseeing
activities under the Council License Agreement. We will be responsible for all aspects of promotion, product
positioning, pricing, education programs, publications, sales messages and any additional desired clinical studies for the
one-year vaginal contraceptive system, subject to oversight and decisions made by the joint product committee. The Council
License Agreement includes exclusive rights for us to negotiate co-development of two other investigational vaginal
contraceptive systems in development by the Population Council.</p>






    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We assess our intangible assets for impairment
if indicators are present or changes in circumstance suggest that impairment may exist. If impairment indicators are present or
changes in circumstance suggest that impairment may exist, we perform a recoverability test by comparing the sum of the estimated
undiscounted cash flows of each intangible asset to its carrying value on the consolidated balance sheet. If the undiscounted cash
flows used in the recoverability test are less than the carrying value, we would determine the fair value of the intangible asset
and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. We also evaluate the remaining
useful life of intangible assets subject to amortization on a periodic basis to determine whether events and circumstances would
indicate impairment or warrant a revision to the remaining useful life. If the estimate of an intangible asset&#8217;s remaining
useful life is changed, we will amortize the remaining carrying value of the intangible asset prospectively over the revised remaining
useful life.</p>


<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with Knight Therapeutics Inc.</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 30, 2018, we entered into a license
and supply agreement, or the Knight License Agreement, with Knight pursuant to which we granted Knight an exclusive license to
commercialize IMVEXXY and BIJUVA in Canada and Israel. Pursuant to the terms of the Knight License Agreement, Knight will pay us
a milestone fee upon first regulatory approval in Canada of each of IMVEXXY and BIJUVA, sales milestone fees based upon certain
aggregate annual sales in Canada and Israel of each of IMVEXXY and BIJUVA and royalties based on aggregate annual sales of each
of IMVEXXY and BIJUVA in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and
Israel related to IMVEXXY and BIJUVA. We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY and BIJUVA in Canada and Israel
within certain specified time periods. We also may terminate the Knight License Agreement if Knight challenges our patents. Either
party may terminate the Knight License Agreement for any material breach by the other party that is not cured within certain specified
time periods or if the other party files for bankruptcy or other related matters. In connection with the Knight License Agreement,
Knight entered into a subscription agreement with us, pursuant to which Knight purchased  <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_uShares_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zuRaBA4CGKlj">3,921,568</span> shares of our Common Stock concurrent with the closing of the underwritten public offering of Common Stock at a price of $<span id="xdx_900_eus-gaap--SaleOfStockPricePerShare_iI_c20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_znvoxappvw2k">5.10</span>, for proceeds of $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_uUSD_c20180730__20180806__us-gaap--SubsidiarySaleOfStockAxis__custom--SubscriptionAgreementKnightMember_zpFM1wNNrC1a">20,000,000</span>, on August 6, 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License Agreement with Theramex</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On June 6, 2019, we entered into an
exclusive license and supply agreement, or the License Agreement, with Theramex, a leading, global specialty pharmaceutical
company dedicated to women&#8217;s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and
Israel, or the Territory. Under the terms of the License Agreement, Theramex paid us EUR <span id="xdx_90C_ecustom--CashUpfrontPaymentReceived_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember_zcXjUxf5vXja">14 </span>million
in cash as an upfront fee on August 5, 2019. Within thirty days of signing the License Agreement, we provided Theramex the
regulatory materials and clinical data that were necessary for Theramex to obtain marketing authorizations and other
applicable regulatory approvals for commercializing BIJUVA and IMVEXXY. We recognized the revenue related to the upfront fee,
which was a non-refundable payment, during the third quarter of 2019, at a point in time when Theramex was able to use and
benefit from the license which was when the knowledge transfer of regulatory documents occurred. We are eligible to receive
additional milestone payments comprised of (i) up to an aggregate of EUR <span id="xdx_901_ecustom--RegulatoryMilestoneAdditionalPayment_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zz9bQKJRfMme">2 </span>million
in regulatory milestone payments based on regulatory approvals for BIJUVA and IMVEXXY in certain specified markets and
(ii) up to an aggregate of EUR <span id="xdx_908_ecustom--SalesMilestonePaymentsInTranches_iI_pin6_uEUR_c20190606__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_znvl9LeAbaif">27.5</span>
million in sales milestone payments to be paid in escalating tranches based on Theramex first attaining certain
aggregate annual net sales milestones of BIJUVA and IMVEXXY in the Territory ranging from EUR <span id="xdx_904_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MinimumMember_zrf9gehw4FDh">25 </span>million
to EUR <span id="xdx_906_ecustom--AnnualNetSalesMilestone_pin6_uEUR_c20190804__20190805__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementTheramexMember__srt--RangeAxis__srt--MaximumMember_zlCKA6MO19Zg">100 </span>million.
We are also entitled to receive quarterly royalty payments on net sales of BIJUVA and IMVEXXY in the Territory. Theramex will
be responsible for all regulatory and commercial activities for BIJUVA and IMVEXXY in the Territory. Theramex may sublicense
its rights to commercialize BIJUVA and IMVEXXY in the Territory, except for certain specified markets. We may terminate the
License Agreement if Theramex does not submit all regulatory applications, submissions and/or registrations required for
regulatory approval to use and commercialize BIJUVA and IMVEXXY within certain specified time periods. We also may terminate
the License Agreement if Theramex challenges our patents. Either party may terminate the License Agreement for any material
breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy
or other related matters.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784317520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_807_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zs3ZJAYk7w7i" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Preferred Stock</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At  September 30, 2019, we had <span id="xdx_908_eus-gaap--PreferredStockSharesAuthorized_iI_c20190930_zFYiirVeCzil">10,000,000</span>
    shares of preferred stock, par value $<span id="xdx_900_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_pii_c20190930_zDt5xLPzJTLl">0.001</span>
    per share, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Common Stock</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At  September 30, 2019, we had <span id="xdx_90C_eus-gaap--CommonStockSharesAuthorized_iI_c20190930_ziDok71XeBAl">350,000,000 </span>shares
    of Common Stock authorized for issuance, of which <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20190930_zargAC1LU7o8"><span id="xdx_902_eus-gaap--CommonStockSharesOutstanding_iI_c20190930_zrNdXVze2qQ2">241,277,076</span></span>
    shares of Common Stock were issued and outstanding.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During the Three and Nine Months
Ended September 30, 2019</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the three months ended September 30,
2019, certain individuals exercised stock options to purchase <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20190701__20190930_zJUfJORn5Tx6">55,236</span>  shares of Common Stock for $<span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190701__20190930_zC8RXIjxh6cf">8,549</span> in cash. During the nine
months ended September 30, 2019, certain individuals exercised stock options to purchase <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930_zbMDX7EsnWol">331,619</span> shares of Common Stock for $<span id="xdx_906_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20190101__20190930_zDNYOWqYezTe">108,656</span> in cash. Also, during the same period, stock options to purchase <span id="xdx_906_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20190101__20190930_zd9sfAbvvH05">12,097</span> shares of Common Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_901_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20190101__20190930_zkWxwKjSwESd">11,834</span> shares of Common Stock were issued.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><span style="text-decoration: underline">Issuances During the Three and Nine Months
Ended September 30, 2018</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the three months ended September 30,
2018, certain individuals exercised stock options to purchase <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180701__20180930_zM3Z0XU79EDd">1,052,300</span> shares of Common Stock for $<span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180701__20180930_zLnvjtbWk4z8">107,318</span> in cash. During the
nine months ended September 30, 2018, certain individuals exercised stock options to purchase <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20180101__20180930_zGmNdsAgIoyf">1,446,876</span> shares of Common Stock
for $<span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20180101__20180930_zkEy4oiUdphb">1,236,313</span> in cash. Also, during the nine months ended September 30, 2018, stock options to purchase <span id="xdx_908_ecustom--NumberOfStockOptionsExercisedInCashlessExercise_c20180101__20180930_zvWmEtndmXkc">10,000</span> shares of Common
Stock were exercised pursuant to the options&#8217; cashless exercise provisions, wherein <span id="xdx_90B_ecustom--NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares_c20180101__20180930_zAxNw5hUUWY7">9,841</span> shares of Common Stock were issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On August 1, 2018, we entered into an
underwriting agreement with Goldman Sachs &amp; Co. LLC, as representative of the underwriters, relating to an underwritten
public offering of <span id="xdx_902_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zRAyHGwaTnOj">12,745,098</span>
shares of our Common Stock at a price of $<span id="xdx_904_eus-gaap--SharesIssuedPricePerShare_iI_c20180801_zR3nP3CWo06c">5.10</span>
per share. We granted the underwriters an option, exercisable for a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zHkRZHv9eKK9">30</span> days,
to purchase up to <span id="xdx_904_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementGoldmanSachsMember_zoFFUgInk1Kk">1,911,764</span>
additional shares of Common Stock. On August 2, 2018, the underwriters exercised the option in full. The net proceeds from
the offering, including the exercise of the option to purchase additional shares, were approximately $<span id="xdx_90D_ecustom--ProceedsFromIssuancePublicOffering_c20180805__20180806_ze683lWjlzc7">69,908,000</span>,
after deducting the underwriting discount and offering expenses payable by us. The offering closed on August 6, 2018. In
connection with the Knight License Agreement, Knight entered into a subscription agreement with us, pursuant to which Knight
purchased $<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20180805__20180806__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementKnightMember_zXEcnarx6TEi">20,000,000</span>
of shares of our Common Stock concurrently with the closing of the underwritten public offering of Common Stock on August 6,
2018.</p>






    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Warrants to Purchase Common Stock</span></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of  September 30, 2019, we had
    warrants outstanding to purchase an aggregate of <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstanding_iI_c20190930_zhEn3S8s7EO7">1,832,571</span>
    shares of Common Stock with a weighted-average contractual remaining life of approximately <span id="xdx_90B_ecustom--WarrantsAndRightsWeightedAverageContractualRemainingLife_c20190101__20190930_z9ik3ScS5mxb"><span style="-sec-ix-hidden: xdx2ixbrl0881">2.2
    years</span></span>, and exercise prices ranging from $<span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MinimumMember_z1huLMDtVZy3">0.24</span>
    to $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember__srt--RangeAxis__srt--MaximumMember_zDL9culEKwC8">8.20</span>
    per share, resulting in a weighted average exercise price of $<span id="xdx_90F_ecustom--WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice_c20190101__20190930_z5pnRBhFW3fb">2.62</span>
    per share.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to
    determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number
    of assumptions, including volatility of the stock price, the risk-free interest rate, dividend rate and the term of the warrant.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30, 2019, we granted warrants to purchase <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zurnvHwd7nG8">75,000
    </span>shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zvXzbPTO7jNa">5.63</span>.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    <span id="xdx_90C_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z46SCijEdjxk">5
    years</span>; volatility of <span id="xdx_900_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zMOS2WUC2lia">60.8</span>%;
    risk free rate of <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zPEXATfZlAE5">2.52</span>%;
    and dividend yield of <span id="xdx_902_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_ziGrNJcskqX">0</span>%.
    The grant date fair value of the warrants was $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zN5TCM3mEkf3">3.00
    </span>per share. The warrants are vesting ratably over a <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zuaXz5DfZRqk">12
    month </span>period and have an expiration date of February 12, 2024. During the nine months ended September 30, 2018, we
    granted warrants to purchase <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z1WM5rXAF84">175,000
    </span>shares of Common Stock to outside consultants at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_z5kXncaapQI9">5.16</span>.
    The fair value for these warrants was determined by using the Black-Scholes Model on the date of the grant using a term of
    <span id="xdx_903_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_dt_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmyr7B2zqr5l">5
    years</span>; volatility of <span id="xdx_906_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zmCkIPCu4sm8">62.1</span>%;
    risk free rate of <span id="xdx_905_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zEwqfvsNz0ii">2.36</span>%;
    and dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_dp_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zV7xpkvTpTmg">0</span>%.
    The grant date fair value of the warrants was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zoKk1K3FCr2d">2.79
    </span>per share. The warrants vest ratably over a <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--OutsideConsultant2Member_zjjDzZbXZ328">12
    month </span>period and have an expiration date of March 15, 2023. During the three months ended September 30, 2019 and 2018,
    we recorded $<span id="xdx_900_eus-gaap--ShareBasedCompensation_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zd2AhydHsA63">56,418
    </span>and $<span id="xdx_901_eus-gaap--ShareBasedCompensation_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zeXbsmf4CiV4">150,977</span>,
    respectively, and during the nine months ended September 30, 2019 and 2018, we recorded $<span id="xdx_90E_eus-gaap--ShareBasedCompensation_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zds0ppTmdsw1">198,306
    </span>and $<span id="xdx_90F_eus-gaap--ShareBasedCompensation_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zR8JQpsHKJXc">407,292</span>,
    respectively, as share based compensation expense in the accompanying consolidated financial statements related to warrants.
    As of September 30, 2019, total unrecognized estimated compensation expense related to the unvested portion of these warrants
    was approximately $<span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_c20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zVS1ElagjrLi">83,000</span>,
    which is expected to be recognized over a weighted-average period of <span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zUiDDld9hpZ2"><span style="-sec-ix-hidden: xdx2ixbrl0906">0.4
    years</span></span>.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30,
2019, warrants to purchase  <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zHLrhYc10rh">1,250,000</span> shares of Common Stock were exercised pursuant to the warrants&#8217; cashless exercise provisions,
wherein  <span id="xdx_903_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zGtOfVnkIIZe">471,184</span> shares of Common Stock were issued. During the nine months ended September 30, 2018, <span id="xdx_90E_ecustom--NumberOfStockIssuedInCashlessExerciseOfWarrants_do_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantsMember_zfuvSuSYti4d">no</span> warrants were exercised.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Options to Purchase Common Stock </span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2009, we adopted the 2009 Long
    Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and
    consultants of our company who are able to contribute towards the creation of or who have created stockholder value by
    providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan
    consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance
    units, and other stock or cash awards as described in the 2009 Plan. Generally, the options vest annually over four years or
    as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or
    on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable
    exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. As of
    September 30, 2019, there were non-qualified stock options to purchase <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z084QCI0OcH9">15,028,509</span>
    shares of Common Stock outstanding under the 2009 Plan. Effective upon our adoption of the
TherapeuticsMD, Inc. 2019 Stock Incentive Plan, or the 2019 Plan, on June 20, 2019, no future awards may be made under the 2009
Plan.</p>





    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"> In 2012, we adopted the 2012 Stock
    Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve
    as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and
    advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights,
    restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described
    in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each
    option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested
    and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date
    is generally ten years from the date the option is issued. As of September 30, 2019, there were non-qualified stock options
    to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_zEdFpQOY1fQa">6,316,474</span>
    shares of Common Stock outstanding and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zCJZpEGc0iH7">1,040,000</span>
    restricted stock awards under the 2012 Plan. Effective upon our adoption of the  2019 Plan,
    no future awards may be made under the 2012 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On June 20, 2019, we adopted the
    2019 Plan to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain
    consultants and advisors of our company. The Awards available under the 2019 Plan consist of stock options, stock
    appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash
    awards as described in the 2019 Plan. Generally, the options vest annually over four years or as determined by our board of
    directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis
    after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if
    any. The expiration date is generally ten years from the date the option is issued. As of September 30, 2019, there were <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930_zcxt7nlgS7Gg">13,779,632</span>
    shares of Common Stock available  for issuance thereunder, consisting of (i) <span id="xdx_900_ecustom--PlanAwardsNumberOfNewShares_iI_c20190930_zcHVE9Tn5KH4">11,294,999</span>
    new shares, (ii) <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--NonQualified2012StockIncentivePlanMember_z9InMTp5NhH9">2,395,333</span>
    unallocated shares previously available for issuance under the 2012 Plan that were not then subject to outstanding
    &#8220;Awards&#8221; (as defined in the 2012 Plan), and (iii) <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_c20190930__us-gaap--PlanNameAxis__custom--LongTermIncentiveCompensationPlan2009Member_z56BRzUqMncb">89,300</span>
    <span style="background-color: white">unallocated shares previously available for issuance under the 2009 Plan that were
    not then subject to outstanding &#8220;Awards&#8221; (as defined in the 2009 Plan). Any shares subject to outstanding options
    or other equity &#8220;Awards&#8221; under the 2019 Plan, the 2012 Plan and the 2009 Plan that are forfeited, expire or
    otherwise terminate without issuance of the underlying shares, or if any such Award is settled for cash or otherwise does not
    result in the issuance of all or a portion of the shares subject to such Award (other than shares tendered or withheld in
    connection with the exercise of an Award or the satisfaction of withholding tax liabilities), the shares to which those
    Awards were subject, shall, to the extent of such forfeiture, expiration, termination, cash settlement or non-issuance, again
    be available for delivery with respect to Awards under the 2019 Plan. As of September 30, 2019, there were non-qualified
    stock options to purchase</span> <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member_zzzyUoJA9mo8">3,505,001</span>
    shares of Common Stock outstanding and <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930__us-gaap--PlanNameAxis__custom--Plan2019Member__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zyja3bnqdq9h">200,000</span>
    restricted stock awards outstanding under the 2019 Plan.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. <span/></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBj64RxovG9h" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The
assumptions used in the Black-Scholes Model for options granted during the  nine months ended  September 30, 2019 and 2018
are set forth in the table below.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: top">
            <td><b>&#160;</b></td>
            <td colspan="3" style="border-bottom: Black 1pt solid">
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>Nine months ended</b></p>
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></p>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="width: 38%"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span>
            </td>
            <td style="width: 2%; text-align: right"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztEnj6eKOIo1" title="Risk-free interest rate">1.83</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNcE7gUfeyDl" title="Risk-free interest rate">2.54</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY6csQbSvxrk" title="Risk-free interest rate">2.78</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ7wNll52r2" title="Risk-free interest rate">2.82</span>%</span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Volatility</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBKnAH03VqWa" title="Volatility">61.25</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW5gMV6ePm46" title="Volatility">64.49</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z349HZXWPMU4" title="Volatility">61.8</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z62HC0owMh6j" title="Volatility">63.34</span>%</span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Term (in years)</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span title="Term (in years)"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z3iipLHbbVJh">5.5</span></span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxarVQm1Gd1j">6.5</span></span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHWgG5iMFhy">5.5</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zO3ML0oAWKh9">6.25</span></span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Dividend yield</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6t5D207Slki" title="Dividend yield">0.00</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTRX8BsOqGud" title="Dividend yield">0.00</span>%</span>
            </td>
        </tr>
    </table>
    <p id="xdx_8A6_zUoD2ZARFQZd" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>





    <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwxpXkWpakyh" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">A
    summary of activity under the 2009,  2012 and 2019 Plans and related information follows:</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Underlying Stock Options</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Life in Years</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 39%">Balance at December 31, 2018</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs3V32eqjqE8" style="width: 11%; text-align: right" title="Balance, beginning">20,872,824</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAxABV2Rww02" style="width: 11%; text-align: right" title="Balance, beginning">4.93</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX9qeCnIo42i" style="width: 11%; text-align: right" title="Balance, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0960">5.94 years</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EpKMBVobLh" style="width: 11%; text-align: right" title="Balance, beginning">12,239,876</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in">Granted</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzSngjQz0iC2" title="Granted">4,419,501</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMYc3ltrTObg">3.13</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in">Exercised</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTz7PTTdeK1e" title="Exercised">343,716</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgIE1urwOXzf">0.32</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zon5Zys4OMge" title="Exercised">1,426,828</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in">Expired/Forfeited</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxIxwNq315De" title="Expired Forfeited">98,625</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4e5hGktTPj1">5.63</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt">Balance at  September 30, 2019</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgBuC4KYmSw7" style="border-bottom: Black 2pt double; text-align: right" title="Balance, ending">24,849,984</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmsrULLhSaKi" style="text-align: right" title="Balance, ending">4.67</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znAcD8jplAsi" style="text-align: right" title="Balance, ending"><span style="-sec-ix-hidden: xdx2ixbrl0979">6.05 years</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4EflkOoQvyh" style="text-align: right" title="Balance, ending">13,761,778</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Vested and Exercisable at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrfkt827YW56" title="Vested and Exercisable">17,601,027</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9wcx9jAGAZe" title="Vested and Exercisable">4.85</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dt_c20190101__20190930_zNxPz67KfwP1" style="text-align: right" title="Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0987">4.81 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwbiAOAHChfc" title="Vested and Exercisable">9,745,527</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Unvested at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjo6frZNvAx2" title="Unvested">7,248,957</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhDCRxWuRz6c" title="Unvested">4.22</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_pii_dt_c20190101__20190930_zdCGHXLXTN4e" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl0995">9.06 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCtVwMvrQmEj" title="Unvested">4,016,251</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A2_zAyFDSj1qmFh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2019,
our outstanding stock options had exercise prices ranging from  $<span id="xdx_90B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MinimumMember_zIKC6OCqcw6a">0.19</span>
to $<span id="xdx_90C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice_iI_c20190930__srt--RangeAxis__srt--MaximumMember_z8pkrFQCNi9f">8.92</span>
per share. The weighted average grant date fair value per share of options granted was $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190101__20190930_zaLpT0qHUF6e">1.84</span>
and $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20180101__20180930_zj44DzaWsxx7">3.27</span>
during the nine months ended September 30, 2019 and 2018, respectively. Share-based compensation expense for
options recognized in our results of operations for the three months ended September 30, 2019 and 2018 ($<span id="xdx_900_eus-gaap--AllocatedShareBasedCompensationExpense_c20190701__20190930_zAZWRMss6SD5">2,194,667</span>
and $<span id="xdx_90B_eus-gaap--AllocatedShareBasedCompensationExpense_c20180701__20180930_zmYXcgmeQJM">2,109,218</span>,
respectively)  and for the nine months ended September 30, 2019 and 2018 ($<span id="xdx_901_eus-gaap--AllocatedShareBasedCompensationExpense_c20190101__20190930_zI3suye304c5">6,568,736</span>
and $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_c20180101__20180930_znBu4p2Pse9c">5,981,343</span>,
respectively) is based on vested awards. At September 30, 2019, total unrecognized estimated compensation expense related to
unvested options granted prior to that date was approximately $<span id="xdx_908_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20190930_z0gpzIhwTbe8">13,468,000</span> which may be adjusted for future changes in
forfeitures. This cost is expected to be recognized over a weighted-average period of <span id="xdx_90D_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zv80CJ3wG3ff"><span style="-sec-ix-hidden: xdx2ixbrl1007">2.4 years</span></span>. No tax benefit was realized
due to a continued pattern of operating losses.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Restricted Stock Awards</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Restricted stock awards granted under our 2009,
2012 and 2019 Plans entitle the holder to receive, at the end of vesting period, a specified number of shares of our Common Stock.
Share-based compensation expense is measured by the market value of our Common Stock on the day of the grant. The shares vest ratably
over the period specified in the grant. There is no partial vesting and any unvested portion is forfeited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 13, 2018, we granted <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zK9m5YUnOWm5">1,040,000</span>
restricted stock units to certain executive employees which will vest at the end of the third year. The grant date fair
value was $<span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20181212__20181213__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z5FyY4NUCrGh">4.06</span>
per unit. On July 30, 2019, we granted <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zpBzKDfdNFIh">200,000</span>
restricted stock units to certain executive employees which will vest on January 31, 2022. The grant date fair value was
$<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20190729__20190730__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zunBbgO17NGj">2.18</span>
per unit. During the three and nine months ended September 30, 2019, we recorded $<span id="xdx_90D_eus-gaap--RestrictedStockExpense_c20190701__20190930_z6zPla3PyFB1">384,061</span>
and $<span id="xdx_903_eus-gaap--RestrictedStockExpense_c20190101__20190930_z3VLgpLjCcb5">1,080,738</span>, respectively, in
share-based compensation expense related to restricted stock units. At September 30, 2019, total unrecognized estimated
compensation expense related to unvested restricted stock units was approximately $<span id="xdx_90F_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_c20190930_zcL9lwCGZUZi">3,505,000</span>,
which may be adjusted for future changes in forfeitures. This cost is expected to be recognized over a weighted-average
period of <span id="xdx_907_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zR7fVr6H4ceb"><span style="-sec-ix-hidden: xdx2ixbrl1015">2.2
years</span></span>. At September 30, 2019, we had <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20190930_zPGdpZY9VZXl">1,240,000</span>
restricted stock awards outstanding.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Cash-Settled Stock Appreciation Rights (SARs)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On July 1, 2018, we issued cash-settled SARs
to certain consultants and employees. The SARs plan year began on July 1, 2018 and ended on or immediately following June 30,
2019. SARs were granted with a grant price equal to the market value of a share of our Common Stock on the date of grant. Cash-settled
SARs provided for the cash payment of the excess of the fair market value of our Common Stock on June 30, 2019 over the grant
price. Cash-settled SARs have no effect on dilutive shares or shares outstanding as any appreciation of our Common Stock over
the grant price is paid in cash and not in Common Stock.&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>






    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Cash settled SARs were recorded in our consolidated
balance sheets as a liability until the date of exercise. The fair value of each SAR award was estimated using the Black-Scholes
valuation model. In accordance with ASC Topic 718, &#8220;Stock Compensation,&#8221; the fair value of each SAR award was recalculated
at the end of each reporting period and the liability and expense adjusted based on the new fair value and the percent vested.
At June 30, 2019, the fair market value of our Common Stock was lower than the grant price of SARs and, as a result, the recorded
liability was reversed and no cash payment was made.</p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775301600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES (Details Narrative) - Affiliated Entity [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Amount billed</a></td>
<td class="nump">$ 2,196,000<span></span>
</td>
<td class="nump">$ 830,000<span></span>
</td>
<td class="nump">$ 4,118,000<span></span>
</td>
<td class="nump">$ 2,774,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts Payable, Related Parties, Current</a></td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776317456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2013</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetRentableAreaLease', window );">Net rentable area</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RentedAreaLease', window );">Rented area lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalAreaOfLeaseOccupied', window );">[custom:AdditionalAreaOfLeaseOccupied-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber', window );">Number of options to extend lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Lessee, Finance Lease, Renewal Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea', window );">Lease not yet commenced (area)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 458,000<span></span>
</td>
<td class="nump">$ 257,000<span></span>
</td>
<td class="nump">$ 1,062,000<span></span>
</td>
<td class="nump">$ 772,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SignificantSupplyCommitmentPercentagePayable', window );">[custom:SignificantSupplyCommitmentPercentagePayable-0]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalAreaOfLeaseOccupied">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional rented area occupied under the lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalAreaOfLeaseOccupied</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options to extend lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future rented area to be occupied for administrative office space as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetRentableAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net rentable area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetRentableAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RentedAreaLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rented area as defined in lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RentedAreaLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SignificantSupplyCommitmentPercentagePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SignificantSupplyCommitmentPercentagePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775752560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other current liabilities consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">$ 4,536,358<span></span>
</td>
<td class="nump">$ 6,854,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedIntellectualLicenseFee', window );">Accrued intellectual license fee</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">7,079,005<span></span>
</td>
<td class="nump">5,294,120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedMarketingCostsCurrent', window );">Accrued sales and marketing costs</a></td>
<td class="nump">1,560,257<span></span>
</td>
<td class="nump">2,288,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">1,551,042<span></span>
</td>
<td class="nump">1,178,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">2,375,894<span></span>
</td>
<td class="nump">792,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">469,446<span></span>
</td>
<td class="nump">385,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedResearchAndDevelopment', window );">Accrued research and development</a></td>
<td class="nump">1,226,160<span></span>
</td>
<td class="nump">388,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,242,290<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">365,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">2,543,456<span></span>
</td>
<td class="nump">412,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">612,124<span></span>
</td>
<td class="nump">375,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 43,196,032<span></span>
</td>
<td class="nump">$ 18,334,948<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedIntellectualLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid for intellectual license fee, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedIntellectualLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedMarketingCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedMarketingCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795380384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 90,700<span></span>
</td>
<td class="nump">$ 42,221<span></span>
</td>
<td class="nump">$ 223,750<span></span>
</td>
<td class="nump">$ 121,423<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774827056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details) - Share-based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate</a></td>
<td class="nump">1.83%<span></span>
</td>
<td class="nump">2.78%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate</a></td>
<td class="nump">2.54%<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility</a></td>
<td class="nump">61.25%<span></span>
</td>
<td class="nump">61.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility</a></td>
<td class="nump">64.49%<span></span>
</td>
<td class="nump">63.34%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6592224288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8 &#8211; OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other current liabilities consist of the following:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zHT0ZkweaNyb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current liabilities consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49E_20190930_z1xiew4yGEf9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_496_20181231_zwgr1Gv7Yx4i" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_403_eus-gaap--AccruedSalariesCurrent_iI_maOLCzFFK_zQBchktIR34g" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; width: 50%; text-align: justify; text-indent: -0.125in">Accrued payroll, bonuses and commission costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">4,536,358</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">6,854,002</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
<tr id="xdx_400_ecustom--AccruedIntellectualLicenseFee_iI_maOLCzFFK_zbTF9nuIxlf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued intellectual license fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzFFK_zvwBizl1yWcj" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for coupons and returns</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">7,079,005</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">5,294,120</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzFFK_z2n8nuuRe9Mf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued sales and marketing costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,560,257</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,288,028</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--AccruedVacationCurrent_iI_maOLCzFFK_zp1m4PVFG1P4" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued compensated absences</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,551,042</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,178,110</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzFFK_zyS87ucdA3Q8" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for wholesale distributor fees</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,375,894</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">792,891</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzFFK_zm9mIQ4XU8Ke" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued legal and accounting expense</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">469,446</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">385,824</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopment_iI_maOLCzFFK_zNWXwppcCpWf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued research and development</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,226,160</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">388,675</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzFFK_zQT2vGFHlBFg" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,242,290</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_eus-gaap--AccruedRentCurrent_iI_maOLCzFFK_zINtVwuf6UUg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rent</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">365,155</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedRebates_iI_maOLCzFFK_zXduvJzfogJ9" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rebates</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,543,456</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">412,570</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzFFK_zD1HVBJRBcP6" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Other accrued expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">612,124</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">375,573</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzFFK_z82CcnQ6IA11" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">43,196,032</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">18,334,948</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784214032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zt7pYfi40Gx9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC 842 effective January 1, 2019.
Substantially all our operating lease right-of-use assets and operating lease liabilities represent leases for office space used
to conduct our business. Upon adoption, we have recognized a right-of-use asset and a lease liability for all leases that have
commenced as of January 1, 2019. The right-of-use assets represent the right to use the leased asset for the lease term. The lease
liabilities represent the present value of the lease payments under the lease. The right-of-use asset is initially measured at
cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, less any lease
incentives received. All right-of-use assets are reviewed for impairment. The lease liability is initially measured at the present
value of the lease payments, discounted using our secured incremental borrowing rate for the same term as the underlying lease
because the rates are not implicit in the leases. Some of our leases contain variable lease payments, including payments based
on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect
at lease commencement. Additional payments based on the change in an index or rate, or payments based on a change in our portion
of the operating expenses are recorded as a period expense when incurred. Lease modifications result in remeasurement of the lease
liability. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial
lease liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We lease administrative office space
    in Boca Raton, Florida pursuant to a non-cancelable operating lease that commenced on July 1, 2013 and originally provided
    for a <span id="xdx_900_ecustom--CapitalLeaseObligationsTerm_dt_c20130629__20130701_zXWLNbBEhyCd">63 month</span> term. On
    February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the
    same location, pursuant to an addendum to such lease. In addition, on April 26, 2016, we entered into an agreement with the
    same lessors to lease additional administrative office space in the same location. This agreement was effective beginning May
    1, 2016 and extended the original expiration of the lease term to October 31, 2021. On October 4, 2016, we entered into an
    agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum
    to such lease. This addendum is effective beginning November 1, 2016.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In October 2018, we entered into a lease for new corporate offices in Boca Raton, Florida. The lease includes <span id="xdx_908_ecustom--NetRentableAreaLease_iI_uSQFT_c20181001_z2xtmJDClHXf">56,212</span> rentable square feet, or the full premises, of which lease on <span id="xdx_908_ecustom--RentedAreaLease_iI_uSQFT_c20181001_zAu0BnRUfJL5">7,561</span> square feet commenced in 2018 and the lease on the remaining <span id="xdx_909_ecustom--AdditionalAreaOfLeaseOccupied_iI_uSQFT_c20181001_zEIYwbIZzzqa">48,651</span> square feet commenced in August 2019, or the full
premises commencement date. The lease will expire <span id="xdx_90B_eus-gaap--LesseeOperatingLeaseTermOfContract_iI_dtY_c20190930_zxwXhiRgdfkg">11</span> years after full premises commencement date, unless terminated earlier in
accordance with the terms of the lease. We have the option to extend the term of the lease for <span id="xdx_906_ecustom--LesseeFinanceLeaseExistenceOfOptionToExtendNumber_dc_uPure_c20190101__20190930_zxAN8GnjQKV6">two</span> additional consecutive periods
of <span id="xdx_90C_eus-gaap--LesseeFinanceLeaseRenewalTerm1_iI_dtY_c20190930_zAB5OHfC6tc1">5</span> years. The extension option is not included in the determination of the lease term as it is not reasonably certain to be
exercised. The term of the lease includes escalating rent and free rent periods. We are also responsible for certain other operating
costs under the lease, including electricity and utility expenses. In June 2019, we entered into an agreement with the same lessors
to lease additional <span id="xdx_906_ecustom--LesseeOperatingLeaseLeaseNotYetCommencedArea_iI_uSQFT_c20190930_zkteCQtw3eLe">6,536</span> square feet of administrative office space in the same location, pursuant to an addendum to such lease, which is expected to commence as soon as the fourth quarter of 2019.</p>






<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"/>
    <p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_zYiFlHN7nJS1" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
        <tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information  <br/>
at September 30,
            2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Right-of-use asset</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20190930_ze72r3SrGogd" style="width: 12%; text-align: right">10,459,635</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Short-term operating lease liability (included in Other current liabilities)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20190930_z7rpaP1P99r" style="text-align: right">1,242,290</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">Long-term operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20190930_zOVkoE6yvSrg" style="text-align: right">9,500,133</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td>Weighted average remaining term</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20190930_zKJ121cxsyt3">9</span> Years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Weighted average discount rate</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20190930_znuDhfIpmbua" style="text-align: right">8.25</td>
            <td style="text-align: left">%</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental cash flow information <br/>for  nine months
            ended September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_982_eus-gaap--OperatingLeasePayments_c20190101__20190930_zLWiTbrLwsS9" style="width: 12%; text-align: right">849,440</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20190930_zeOWIvNo2GZ2" style="text-align: right">11,171,471</td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqAsztLw02Nd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease
    liabilities recorded on the balance sheet:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left"/>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_493_20190930_zRCcJ7ZiCOd6" style="text-align: right"/>
            <td style="text-align: left">&#160;</td>
        </tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: left"><b>Years Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzviC_zvmluQVXekw4" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 2%; text-align: left">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">314,670</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzviC_z5W1ORnPZWP4" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2020</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,566,617</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzviC_zqlbVbfakOD5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2021</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,198,541</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzviC_zi09GQCrlCVc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2022</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,262,302</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzviC_zVZQYJZM1UYe" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2023</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,293,859</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzviC_zqenOG7RntNe" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">9,363,136</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzviC_maOLLzDJI_zXyLb0F2X4eg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span>
            </td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15,999,125</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityImputedInterestAmount_iNI_di_msOLLzFSB_msOLLzDJI_zaePQXH7GRA2" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(5,256,702</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzDJI_zLzePcvvgFx9" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span>
            </td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,742,423</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A9_z6oWlmWoyIbb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"> During the three and nine  months
    ended September 30, 2019, operating lease expense related to our real estate leases was approximately $<span id="xdx_90A_eus-gaap--OperatingLeaseExpense_c20190701__20190930_zn3CMh36la1a" title="Operating lease expense">458,000</span>
    and $<span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20190101__20190930_zSeePHiSmW3e">1,062,000</span>, respectively, and
    variable lease expense was insignificant for the three and nine months ended September 30, 2019. Rent expense totaled $<span id="xdx_901_eus-gaap--OperatingLeaseExpense_c20180701__20180930_zzuHt0mauBd4">257,000</span>
    and $<span id="xdx_90F_eus-gaap--OperatingLeaseExpense_c20180101__20180930_z4rn8gJT0G6f">772,000</span> during the three and
    nine months ended September 30, 2018, respectively.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Intellectual Property Licenses </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have license agreements with third parties
that provide for minimum royalty, license, and exclusivity payments to be paid by us for access to certain technologies. In addition,
we pay royalties as a percent of revenue as described in Note 7, Intangible Assets, to these consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Purchase commitments</span></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have a manufacturing and supply agreement
whereby we are required to purchase from Catalent a minimum number of softgels during the first contract year and a higher number
of softgels after the first contract year. If the minimum order quantities of specific products are not met, we are required to
pay Catalent <span id="xdx_900_ecustom--SignificantSupplyCommitmentPercentagePayable_iI_dp_c20190930_z9J48PRHhMyl">50</span>%
of the difference between the total amount we would have paid to Catalent if the minimum requirement had been fulfilled and the
sum of all purchases of our products from Catalent during the contract year.&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780342608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory consists of the following:</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zAswskwBVkSe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49C_20190930_zM0dt3gzECm9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20181231_zTdogbT3oo4d" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maINz2Fg_zjcVWlMql0t2" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Finished product</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">5,011,192</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">2,908,958</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz2Fg_zCD9rjFup0P9" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Work in process</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,005,575</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">339,312</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz2Fg_zI2NxnPuA5f7" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Raw material</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">4,516,077</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">19,400</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_mtINz2Fg_z5Z9mF4uMIt9" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,532,844</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">3,267,670</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795899696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (126,709,485)<span></span>
</td>
<td class="num">$ (93,226,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in&#160;operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">223,750<span></span>
</td>
<td class="nump">121,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">140,206<span></span>
</td>
<td class="nump">77,123<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Write off of patent and trademark cost</a></td>
<td class="nump">78,864<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NoncashOperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">711,836<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">95,097<span></span>
</td>
<td class="nump">231,475<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">7,859,357<span></span>
</td>
<td class="nump">6,388,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of intellectual property license fee</a></td>
<td class="nump">15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing fees</a></td>
<td class="nump">582,829<span></span>
</td>
<td class="nump">149,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,354,890)<span></span>
</td>
<td class="num">(8,705,325)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(7,265,174)<span></span>
</td>
<td class="num">(892,863)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(1,128,515)<span></span>
</td>
<td class="nump">1,233,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,389,665<span></span>
</td>
<td class="nump">7,284,493<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">3,402,511<span></span>
</td>
<td class="nump">8,670,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(114,900,319)<span></span>
</td>
<td class="num">(78,666,841)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PaymentsToAcquireIntellectualPropertyLicense', window );">Payment for intellectual property license</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(20,000,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(1,068,542)<span></span>
</td>
<td class="num">(748,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(2,089,413)<span></span>
</td>
<td class="num">(66,295)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Payment of security deposit</a></td>
<td class="num">(20,420)<span></span>
</td>
<td class="num">(11,485)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(3,178,375)<span></span>
</td>
<td class="num">(20,826,686)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherDebt', window );">Proceeds from Financing Agreement</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options and warrants</a></td>
<td class="nump">108,656<span></span>
</td>
<td class="nump">1,236,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt', window );">Proceeds from Credit Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="num">(6,652,270)<span></span>
</td>
<td class="num">(3,786,918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfOtherLongTermDebt', window );">Repayment of Credit Agreement</a></td>
<td class="num">(81,660,719)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">111,795,667<span></span>
</td>
<td class="nump">162,357,192<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">(Decrease) increase in cash</a></td>
<td class="num">(6,283,027)<span></span>
</td>
<td class="nump">62,863,665<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, beginning of period</a></td>
<td class="nump">161,613,077<span></span>
</td>
<td class="nump">127,135,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, end of period</a></td>
<td class="nump">155,330,050<span></span>
</td>
<td class="nump">189,999,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">12,446,792<span></span>
</td>
<td class="nump">1,759,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseExpendituresIncurredButNotYetPaid', window );">Amount accrued for intellectual property license</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of licenses that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PaymentsToAcquireIntellectualPropertyLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outlow for payments to acquir intellectual property license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PaymentsToAcquireIntellectualPropertyLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794820256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 155,330,050<span></span>
</td>
<td class="nump">$ 161,613,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts&#160;of $691,699 and $596,602, respectively</a></td>
<td class="nump">15,323,614<span></span>
</td>
<td class="nump">11,063,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,532,844<span></span>
</td>
<td class="nump">3,267,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">10,578,260<span></span>
</td>
<td class="nump">10,834,693<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">191,764,768<span></span>
</td>
<td class="nump">186,779,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">2,338,346<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LicenseRights', window );">License rights, net</a></td>
<td class="nump">39,984,002<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">4,942,151<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">10,459,635<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">473,009<span></span>
</td>
<td class="nump">639,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">55,858,797<span></span>
</td>
<td class="nump">24,731,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">249,961,911<span></span>
</td>
<td class="nump">211,983,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">24,133,506<span></span>
</td>
<td class="nump">22,743,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">43,196,032<span></span>
</td>
<td class="nump">18,334,948<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">67,329,538<span></span>
</td>
<td class="nump">41,078,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">194,361,169<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">9,500,133<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">271,190,840<span></span>
</td>
<td class="nump">114,459,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 shares authorized: 241,277,076 and 240,462,439 issued and outstanding, respectively</a></td>
<td class="nump">241,277<span></span>
</td>
<td class="nump">240,463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">624,515,559<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(645,985,765)<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; (deficit) equity</a></td>
<td class="num">(21,228,929)<span></span>
</td>
<td class="nump">97,524,121<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 249,961,911<span></span>
</td>
<td class="nump">$ 211,983,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LicenseRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of license rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LicenseRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774721472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="nump">55,236<span></span>
</td>
<td class="nump">1,052,300<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
<td class="nump">1,446,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 292 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms', window );">Unvested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 21 days 21 hours 36 minutes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 18 days 6 hours<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 343 days 2 hours 24 minutes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,419,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,426,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance, ending</a></td>
<td class="nump">24,849,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,849,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance, ending</a></td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Balance, ending</a></td>
<td class="nump">$ 13,761,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,761,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,239,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Exercisable</a></td>
<td class="nump">17,601,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,601,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and Exercisable</a></td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and Exercisable</a></td>
<td class="nump">$ 9,745,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,745,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested</a></td>
<td class="nump">7,248,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,248,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice', window );">Unvested</a></td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 4,016,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,016,251<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire unvested shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>229</ContextCount>
  <ElementCount>379</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>81</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENT OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - NOTE 1 ??? THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1Company</Role>
      <ShortName>NOTE 1 ??? THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</Role>
      <ShortName>NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - NOTE 4 ??? INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4Inventory</Role>
      <ShortName>NOTE 4 ??? INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNet</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssets</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - NOTE 8 ??? OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</Role>
      <ShortName>NOTE 8 ??? OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTE 9 ??? DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9Debt</Role>
      <ShortName>NOTE 9 ??? DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShare</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquity</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - NOTE 12 ??? INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note12IncomeTaxes</Role>
      <ShortName>NOTE 12 ??? INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - NOTE 13 ??? RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedParties</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - NOTE 14 ??? BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14BusinessConcentrations</Role>
      <ShortName>NOTE 14 ??? BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEvents</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>NOTE 3 ??? SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - NOTE 4 ??? INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note4InventoryTables</Role>
      <ShortName>NOTE 4 ??? INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note4Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables</Role>
      <ShortName>NOTE 5 ??? OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note5OtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsTables</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - NOTE 8 ??? OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables</Role>
      <ShortName>NOTE 8 ??? OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - NOTE 9 ??? DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtTables</Role>
      <ShortName>NOTE 9 ??? DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9Debt</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - NOTE 10 ??? NET LOSS PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note10NetLossPerShareTables</Role>
      <ShortName>NOTE 10 ??? NET LOSS PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note10NetLossPerShare</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - NOTE 1 ??? THE COMPANY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative</Role>
      <ShortName>NOTE 1 ??? THE COMPANY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note1Company</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative</Role>
      <ShortName>NOTE 2 ??? BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details</Role>
      <ShortName>The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Inventory consists of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails</Role>
      <ShortName>Inventory consists of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Other current assets consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails</Role>
      <ShortName>Other current assets consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Fixed assets, net consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails</Role>
      <ShortName>Fixed assets, net consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative</Role>
      <ShortName>NOTE 6 ??? FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note6FixedAssetsNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details</Role>
      <ShortName>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails</Role>
      <ShortName>Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - NOTE 7 ??? INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative</Role>
      <ShortName>NOTE 7 ??? INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note7IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Other current liabilities consist of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails</Role>
      <ShortName>Other current liabilities consist of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails</Role>
      <ShortName>As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - NOTE 9 ??? DEBT (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note9DebtDetailsNarrative</Role>
      <ShortName>NOTE 9 ??? DEBT (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note9DebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details</Role>
      <ShortName>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details</Role>
      <ShortName>The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails</Role>
      <ShortName>A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative</Role>
      <ShortName>NOTE 11 ??? STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note11StockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - NOTE 13 ??? RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative</Role>
      <ShortName>NOTE 13 ??? RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note13RelatedParties</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - NOTE 14 ??? BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>NOTE 14 ??? BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note14BusinessConcentrations</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Supplemental lease information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails</Role>
      <ShortName>Supplemental lease information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails</Role>
      <ShortName>The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>NOTE 15 ??? COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-10q_093019.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative</Role>
      <ShortName>NOTE 16 ??? SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Note16SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="txmd-10q_093019.htm">txmd-10q_093019.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>txmd-20190930.xsd</File>
    <File>txmd-20190930_cal.xml</File>
    <File>txmd-20190930_def.xml</File>
    <File>txmd-20190930_lab.xml</File>
    <File>txmd-20190930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780916768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</a></td>
<td class="nump">$ 5,638,831<span></span>
</td>
<td class="nump">$ 1,618,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term Debt, Excluding Current Maturities</a></td>
<td class="nump">194,361,169<span></span>
</td>
<td class="nump">73,381,014<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember', window );">Credit Agreement Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794931040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="nump">$ 421,694<span></span>
</td>
<td class="nump">$ 384,712<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="nump">5,363,845<span></span>
</td>
<td class="nump">4,477,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="nump">4,942,151<span></span>
</td>
<td class="nump">4,092,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone Therapy Drug Candidate Patents - (Pending) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">1,937,691<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">1,937,691<span></span>
</td>
<td class="nump">1,855,279<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple Trademarks [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedTrademarks', window );">Indefinite-Lived Trademarks</a></td>
<td class="nump">287,846<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">287,846<span></span>
</td>
<td class="nump">264,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">3,138,308<span></span>
</td>
<td class="nump">2,234,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="nump">421,694<span></span>
</td>
<td class="nump">282,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="nump">$ 2,716,614<span></span>
</td>
<td class="nump">$ 1,951,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">13 years 3 months<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Computer Software, Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,951<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived Intangible Assets, Remaining Amortization Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Internet Domain Names [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedTrademarks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedTrademarks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784197392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 &#8211; BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p id="xdx_807_eus-gaap--ConcentrationRiskDisclosureTextBlock_zGhipIvhCcZf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 14 &#8211; BUSINESS CONCENTRATIONS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We purchase our prescription
    products from several suppliers with approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zJOO7dqE9r2c" title="Concentration risk">36</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierTwoConcentrationRiskMember_z10Khkqoi0cj">28</span>%,
    and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_dp_c20190101__20190930__us-gaap--ConcentrationRiskByTypeAxis__custom--SupplierThreeConcentrationRiskMember_zSAfmDABDcB2">26</span>%
    of our purchases supplied by <span id="xdx_901_ecustom--NumberOfVendors_dc_uPure_c20190101__20190930_zD8mSqSvTHzi" title="Number of vendors - suppliers">three</span>
    vendors each, respectively, during the nine months ended September 30, 2019. Approximately <span title="Number of vendors - suppliers"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_dp_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_z2bG5jRNZPqj">100</span></span>%
    of our products were manufactured by  <span id="xdx_90B_ecustom--NumberOfVendors_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember_zU5zOInSbSh9" title="Number of vendors - suppliers">one</span>
    vendor related to each of IMVEXXY
and prenatal vitamins during the nine months ended September 30, 2018.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our prescription prenatal
    vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that
    generally sell products to retail pharmacies, hospitals, and other institutional customers. During the nine months ended
    September 30, 2019, <span id="xdx_906_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zcbxkREYLq0h">four</span>
    customers each generated more than <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeIcHfUSk864" title="Concentration risk">10</span>%
    of our total prescription revenues. During the nine months ended September 30, 2018,  <span id="xdx_904_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zp4ZEpTALvCh" title="Number of customers - revenue">four</span>
    customers each generated more than <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUKn9O2RkR63">10</span>%
    of our total prescription revenues. Prescription revenue generated from the <span id="xdx_90D_ecustom--NumberOfCustomers_dc_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zX18O6ouVBDj">four</span>
    customers combined accounted for approximately <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--ThreeCustomersConcentrationRiskMember_zGN3tQi0UoVd">68</span>%
    of our prescription revenue for the nine months ended September 30, 2019, and prescription revenue generated from the  <span id="xdx_907_ecustom--NumberOfCustomers_dc_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_znBjqGIh6T91">four</span>
    customers combined accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_dp_uPure_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--FourCustomersConcentrationRiskMember_zbTlgbKrTkW5">71</span>%
    of our prescription revenue for the nine months ended September 30, 2018.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the nine months ended September 30,
2019, PI Services accounted for approximately $<span id="xdx_901_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zv0WckalJ6g5">1,935,000</span> of our prescription revenue, Pillpack, Inc. accounted for approximately
$<span id="xdx_902_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zqu4stv5lTEl">6,397,000</span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_90E_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zFoOtj3urO81">2,226,000</span> of our prescription revenue and
Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20190101__20190930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zNpuvcB7IJY5">1,863,000</span> of our prescription revenue. During the nine months ended September 30,
2018, PI Services accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPIServicesRiskMember_zsCm87i31OMl">1,559,000</span> of our prescription revenue, Pillpack, Inc. accounted for approximately
$<span id="xdx_908_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationPillPackRiskMember_zZkrb1oUo9Kl">3,057,000</span> of our prescription revenue, AmerisourceBergen accounted for approximately $<span id="xdx_904_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationAmerisourceBergenRiskMember_zKa65h6uYBD2">1,834,000</span> of our prescription revenue and
Cardinal Health accounted for approximately $<span id="xdx_907_eus-gaap--Revenues_c20180101__20180930__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__custom--CustomerConcentrationCardinalHealthRiskMember_zq0VyYCaUdhg">1,399,000</span> of our prescription revenue.</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784222944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Three Months <br/>Ended September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Nine Months <br/>Ended September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a">2,550,330</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj">3,261,459</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah">7,309,174</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc">10,797,861</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd">4,772,354</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8">212,076</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl">9,904,744</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i">212,076</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3">490,705</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g">624,987</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr">23,719,741</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5">3,473,535</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk">33,745,257</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3">11,009,937</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784208624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock', window );">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018:</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfIntangibleAssetsTableTextBlock_zF2pG48UUutj" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible
    assets as of  September 30, 2019 and December 31, 2018:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zHT4kcSu00h4">3,138,308</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zfGFHL86MePe">421,694</span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zjdehtxU1VZ9">2,716,614</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20190101__20190930__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zxexs92WpqWl"><span style="-sec-ix-hidden: xdx2ixbrl0640">13.25 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patent (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zecx6GTDwx55">1,937,691</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zyr7z5nVMYtb">1,937,691</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--IndefiniteLivedTrademarks_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zrVf8dqjdmQ3">287,846</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20190930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zGkffbfhIFqd">287,846</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20190930_z0pNSTmUTR7l">5,363,845</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20190930_zPaKAwZSUr06">421,694</span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_902_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20190930_zE2rT6V2zNge">4,942,151</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="14" style="text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Gross Carrying Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Accumulated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Net <br/>Amount</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted-Average <br/>Remaining Amortization Period (yrs.)</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in">Amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; width: 30%; text-align: left; text-indent: -0.125in">OPERA<sup>&#174;</sup> software patent</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zH8PtIeI4Yu1">31,951</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">(<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zlWYTVlSdoy7">10,484</span></td>
            <td style="width: 1%; text-align: left">)</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zhNgaqL1IuJ5">21,467</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_pii_dt_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--ComputerSoftwareIntangibleAssetMember_zfomTckYUkHf"><span style="-sec-ix-hidden: xdx2ixbrl0651">10.75 years</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Development costs of corporate website</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zPFT8hiW06a9">91,743</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_zeGvdBObtG81">91,743</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--InternetDomainNamesMember_z0VUomajPbY2"><span style="-sec-ix-hidden: xdx2ixbrl0654">&#8212;</span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Approved hormone therapy drug candidate patents</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z0rhyjQ4RQr8">2,234,129</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_z4pIuwCw1lQa">282,485</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zaymSAUbGVT5">1,951,644</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_dtY_c20180101__20181231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--ApprovedHormoneTherapyDrugCandidatePatentsMember_zRlkL68D776a">14</span> years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.25in; text-indent: -0.125in">Hormone therapy drug candidate patents (pending)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zRu92iHsrlo3">1,855,279</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetsNet_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--HormoneTherapyDrugCandidatePatentsMember_zlXVUgqxn2Id">1,855,279</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">n/a</span>
            </td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Non-amortizable intangible assets:</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">Multiple trademarks</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_904_eus-gaap--IndefiniteLivedTrademarks_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_z4YwYthUGCE3">264,289</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">&#8212;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--IndefiniteLivedIntangibleAssetsExcludingGoodwill_iI_c20181231__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--MultipleTrademarksForVitaminsSupplementsMember_zv60HoAHnCZk">264,289</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">indefinite</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.375in; text-indent: -0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--IntangibleAssetsGrossExcludingGoodwill_iI_c20181231_zg4kASQUQK9c">4,477,391</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">(<span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20181231_zYJpcxmeA1gi">384,712</span></td>
            <td style="padding-bottom: 2pt; text-align: left">)</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_903_eus-gaap--IntangibleAssetsNetExcludingGoodwill_iI_c20181231_zJnQ5BGJ8R23">4,092,679</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_zAci4sN9jYqf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 25%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Year Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Estimated Amortization</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 10%; text-align: right">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 10%; text-align: right"><span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_c20190930_zThwUBK0S9ml">51,259</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2020</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_iI_c20190930_zUjJVCXk7WT8">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2021</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_c20190930_zgQfK1pgKl12">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2022</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_c20190930_zC6w2B1yBR7j">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2023</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90F_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_iI_c20190930_zTOwKhv8PJre">205,035</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of intangible assets, which may be broken down by major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784195216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 1 &#8211; THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NOTE 1 &#8211; THE COMPANY</a></td>
<td class="text"><p id="xdx_800_eus-gaap--NatureOfOperations_zowNzJ6U04ue" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 1 &#8211; THE COMPANY</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">TherapeuticsMD, Inc., a Nevada corporation,
    or TherapeuticsMD or the Company, has <span id="xdx_909_ecustom--NumberOfSubsidiaries_iI_dc_uPure_c20190930_znCImS6ahGld">three
    </span>wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada
    corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context
    otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#8220;our
    company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us.&#8221; TherapeuticsMD<sup>&#174;</sup>, vitaMedMD<sup>&#174;</sup>, BocaGreenMD<sup>&#174;</sup>, IMVEXXY<sup>&#174;</sup>&#160;and BIJUVA<sup>&#174;</sup> are registered trademarks of our company and ANNOVERA<sup>&#8482;</sup> is a licensed trademark of our company.</p>



<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Nature of Business</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We are a women&#8217;s healthcare company focused
on creating and commercializing innovative products to support the lifespan of women and championing awareness of women&#8217;s
healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD,
we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that
enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled,
long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD&#174;
and BocaGreenMD&#174; brands.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">With our SYMBODA&#8482; technology,
we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of
bio-identical hormones through a variety of dosage forms and administration routes. Our commercialization plan allows us to
efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products. During
2018, the U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately
focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our
FDA-approved product, IMVEXXY (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain
associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we
launched our FDA-approved product BIJUVA, our hormone therapy combination of bio-identical 17&#223;-estradiol and
bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or
VMS, due to menopause in women with a uterus, which was approved by the FDA on October 28, 2018. In October 2019, we began a
test and learn market introduction for our FDA-approved product ANNOVERA (segesterone acetate and ethinyl estradiol vaginal
system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive option for women, which was
approved by the FDA on August 10, 2018. We expect the full commercial launch of ANNOVERA in the first quarter of 2020. On
July 30, 2018, we entered into an exclusive license agreement, or the Population Council License Agreement, with the
Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. In addition, on July 30, 2018, we
entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an
exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. On June 6, 2019, we entered into an exclusive
license and supply agreement, or the License Agreement, with Theramex HQ UK Limited, or Theramex, to commercialize BIJUVA and
IMVEXXY outside of the U.S., excluding Canada and Israel, or the Territory.</p>

    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6662723616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">allowance for doubtful accounts</a></td>
<td class="nump">$ 691,699<span></span>
</td>
<td class="nump">$ 596,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775952544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed assets, net consist of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 3,115,726<span></span>
</td>
<td class="nump">$ 1,026,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</a></td>
<td class="nump">777,380<span></span>
</td>
<td class="nump">553,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">2,338,346<span></span>
</td>
<td class="nump">472,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software and Software Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">301,096<span></span>
</td>
<td class="nump">301,096<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,371,390<span></span>
</td>
<td class="nump">490,576<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">1,294,241<span></span>
</td>
<td class="nump">116,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">80,211<span></span>
</td>
<td class="nump">80,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, Plant and Equipment, Gross</a></td>
<td class="nump">$ 68,788<span></span>
</td>
<td class="nump">$ 37,888<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794552928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract', window );"><strong>Note 2 Basis Of Presentation And Recently Issued Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 10,459,635<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">$ 10,742,423<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784213232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</a></td>
<td class="text"><p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWarCx3JZYAg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three and  Nine months ended</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 30%; text-align: justify">Stock options</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOYTmjrLe0t6"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJrVAKWWCSlc">24,849,984</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zge6deMEgupj"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrrfOQAYp4bk">24,837,349</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Warrants</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzo6au7jLMJl"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXMIaNe9C2D3">1,832,571</span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQ6UEgPMZx3"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMQohizb05J">3,007,571</span></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Restricted stock awards</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4coHhgm7APk"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0fGdSduEef6">1,240,000</span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpHXTVFnBHi7"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAcuMHRwC7M2">&#8212;</span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930_zRk9YdjIQD27"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930_z5VUxV5e6f1f">27,922,555</span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930_zjSqvqZLtHL8"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930_zdrT0GLApXQ6">27,844,920</span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784298656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">NOTE 6 &#8211; FIXED ASSETS, NET</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zymnE1GYXyh1" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 6 &#8211; FIXED ASSETS, NET</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcUFkzdYbJ8l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Fixed assets, net consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September</b>  <b>30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Accounting system</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPuW8gNhfigf">301,096</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBQTwKu5NDS8">301,096</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Equipment</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKxvlZ4OsLs7">1,371,390</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zedjHDHH1z3f">490,576</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Furniture and fixtures</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRHfmaqz8eue">1,294,241</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxPPECpfGlQj">116,542</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Computer hardware</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zy9v8zzBD225">80,211</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zINZNj8PrU57">80,211</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Leasehold improvements</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwF24goIlzf6">68,788</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6bhwtAy5Nn">37,888</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930_zRv4nr0Xjkgl">3,115,726</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231_z2f4fZOthu39">1,026,313</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Accumulated depreciation</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20190930_zGl7iKfBxxva">777,380</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20181231_zBUbMCBfqcaj">553,630</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20190930_zYJbMIldt7cj">2,338,346</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20181231_z6vkyVW9hikf">472,683</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A7_zhu1GBB3i4Mc" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Depreciation expense for the three months ended
September 30, 2019 and 2018 was $<span id="xdx_90B_eus-gaap--Depreciation_c20190701__20190930_zrirdn6ufr2j">90,700</span> and $<span id="xdx_90E_eus-gaap--Depreciation_c20180701__20180930_zbbsakzAFXRh">42,221</span>, respectively, and $<span id="xdx_902_eus-gaap--Depreciation_c20190101__20190930_zDktTGWTHR9i">223,750</span> and $<span id="xdx_900_eus-gaap--Depreciation_c20180101__20180930_zlCmbV1Sy2A8">121,423</span> for the nine months ended September
30, 2019 and 2018, respectively.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784240000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 10 &#8211; NET LOSS PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NOTE 10 &#8211; NET LOSS PER SHARE</a></td>
<td class="text"><p id="xdx_808_eus-gaap--EarningsPerShareTextBlock_zbXpKliL0H3a" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
    10 &#8211; NET LOSS PER SHARE</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We calculate earnings per share, or EPS, in
accordance with ASC 260, Earnings Per Share, which requires the computation and disclosure of two EPS amounts: basic and diluted.
We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock,
outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding
plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our
Common Stock consist of options, warrants and restricted stock awards and were excluded from the calculation of diluted EPS because
their effect would have been antidilutive due to the net loss reported by us.<span/></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>&#160;</span></p>

<p id="xdx_894_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zWarCx3JZYAg" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="6" style="border-bottom: Black 1pt solid; text-align: center"><b>Three and  Nine months ended</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, 2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 30%; text-align: justify">Stock options</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOYTmjrLe0t6"><span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zJrVAKWWCSlc">24,849,984</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zge6deMEgupj"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrrfOQAYp4bk">24,837,349</span></span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Warrants</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zzo6au7jLMJl"><span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zXMIaNe9C2D3">1,832,571</span></span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zlQ6UEgPMZx3"><span id="xdx_909_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zMQohizb05J">3,007,571</span></span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Restricted stock awards</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_903_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z4coHhgm7APk"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z0fGdSduEef6">1,240,000</span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180701__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zpHXTVFnBHi7"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d0_uShares_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zAcuMHRwC7M2">&#8212;</span></span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in">TOTAL</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190701__20190930_zRk9YdjIQD27"><span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20190101__20190930_z5VUxV5e6f1f">27,922,555</span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_90A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180101__20180930_zjSqvqZLtHL8"><span id="xdx_905_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_uShares_c20180701__20180930_zdrT0GLApXQ6">27,844,920</span></span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A5_z8L2y6L6fDZa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6802449712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Dec. 13, 2018</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Aug. 01, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common Stock, Shares, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,236<span></span>
</td>
<td class="nump">1,052,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
<td class="nump">1,446,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Stock Issued During Period, Value, Stock Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,549<span></span>
</td>
<td class="nump">$ 107,318<span></span>
</td>
<td class="nump">$ 1,084,939<span></span>
</td>
<td class="nump">$ 44,056<span></span>
</td>
<td class="nump">$ 108,656<span></span>
</td>
<td class="nump">$ 1,236,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,097<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares', window );">Number of common stock issued during period for stock options exercised in cashless exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,834<span></span>
</td>
<td class="nump">9,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,832,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife', window );">Weighted-average contractual remaining life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 73 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice', window );">Weighted average exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,859,357<span></span>
</td>
<td class="nump">$ 6,388,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,779,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,779,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PlanAwardsNumberOfNewShares', window );">Plan Awards Number of New Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,294,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.84<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,194,667<span></span>
</td>
<td class="nump">2,109,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,568,736<span></span>
</td>
<td class="nump">$ 5,981,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,468,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted Stock or Unit Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,080,738<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,505,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,849,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,849,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,872,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.18<span></span>
</td>
<td class="nump">$ 4.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 73 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,028,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,028,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,316,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,395,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,505,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,505,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_Plan2019Member', window );">Plan 2019 [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice', window );">Range - exercise price of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Payment Arrangement, Noncash Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,418<span></span>
</td>
<td class="nump">$ 150,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198,306<span></span>
</td>
<td class="nump">$ 407,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">146 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants', window );">[custom:NumberOfStockIssuedInCashlessExerciseOfWarrants]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">471,184<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember', window );">Warrants Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member', window );">Outside Consultants Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="nump">175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.80%<span></span>
</td>
<td class="nump">62.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252.00%<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="nump">$ 2.79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember', window );">Underwriting Agreement Goldman Sachs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,745,098<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">[custom:PeriodExercisableUnderwritersOption]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">[custom:UnderwritersOptionGrantedInPeriodShares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,911,764<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember', window );">Subscription Agreement Knight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to stock options exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock issued attributable to warrants exercised in cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodExercisableUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period the option is exercisable per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodExercisableUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PlanAwardsNumberOfNewShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new shares authorized for stock awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PlanAwardsNumberOfNewShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital by public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnderwritersOptionGrantedInPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares available to be purchased per underwriter's option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnderwritersOptionGrantedInPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item provides the weighted-average contractual remaining life of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which warrant holders can acquire the shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_Plan2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_Plan2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_WarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementGoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_SubscriptionAgreementKnightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774301424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2019 (3 months)</a></td>
<td class="nump">$ 314,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">1,566,617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">2,198,541<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">1,262,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">1,293,859<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">9,363,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">15,999,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,256,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease payments</a></td>
<td class="nump">$ 10,742,423<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of computed imputed interest for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776023760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">27,922,555<span></span>
</td>
<td class="nump">27,844,920<span></span>
</td>
<td class="nump">27,922,555<span></span>
</td>
<td class="nump">27,844,920<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
<td class="nump">1,832,571<span></span>
</td>
<td class="nump">3,007,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">24,849,984<span></span>
</td>
<td class="nump">24,837,349<span></span>
</td>
<td class="nump">24,849,984<span></span>
</td>
<td class="nump">24,837,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,240,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,240,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6799850064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 7 &#8211; INTANGIBLE ASSETS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Aug. 06, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 06, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,259<span></span>
</td>
<td class="nump">$ 31,100<span></span>
</td>
<td class="nump">140,206<span></span>
</td>
<td class="nump">$ 77,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of Other Deferred Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,907,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember', window );">Subscription Agreement Knight [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,921,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent', window );">Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid', window );">maximum costs and expenses for post approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member] | ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentUponFDAApproval', window );">Milestone payment upon FDA Approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch', window );">Milestone payments (payment after release of first commercial batch)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAmortizationOfDeferredCharges', window );">Amortization of Other Deferred Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member', window );">Council License Agreement [Member] | ANNOVERA [Member] | Step-based Royalty Payment One [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member', window );">CouncilLicenseAgreementStep1Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">CouncilLicenseAgreementStep2Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1000.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">CouncilLicenseAgreementStep2Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member', window );">CouncilLicenseAgreementStep2Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">CouncilLicenseAgreementStep3Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RoyaltyPercent', window );">Royalty (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1500.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member', window );">CouncilLicenseAgreementStep3Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NetSalesAmountPerStepbasedRoyalty', window );">Net sales amount per step-based royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CashUpfrontPaymentReceived', window );">Cash upfront payment received | &#8364;</a></td>
<td class="nump">&#8364; 14,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex Member | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RegulatoryMilestoneAdditionalPayment', window );">Regulatory milestone payments | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesMilestonePaymentsInTranches', window );">Sales milestone payment | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 27,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember', window );">License Agreement Theramex Member | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AnnualNetSalesMilestone', window );">Sales milestone | &#8364;</a></td>
<td class="nump">&#8364; 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember', window );">Domestic US Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember', window );">Foreign Patents Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember', window );">Domestic Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember', window );">Foreign Patents BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember', window );">Domestic Patents NonApproved BIJUVA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember', window );">Domestic US Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember', window );">Domestic US Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember', window );">Domestic US Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember', window );">Foreign Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember', window );">Foreign Utility Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember', window );">Foreign Design Patents IMVEXXY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember', window );">Domestic US Patents Topical Cream</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember', window );">Domestic Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember', window );">Foreign Utility Patent Transdermal Patch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember', window );">Domestic Utility Patent Opera</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentDLimoneneMember', window );">Domestic Utility Patent DLimonene</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember', window );">Domestic Utility Patent TX009HR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualNetSalesMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual net sale milestones in the Territory per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualNetSalesMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CashUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CashUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments upon FDA approval.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payments payable after release of first commercial batch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NetSalesAmountPerStepbasedRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net sales amount as defined in license agreement for step-based royalty payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NetSalesAmountPerStepbasedRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RegulatoryMilestoneAdditionalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RegulatoryMilestoneAdditionalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percent of the net sales to be paid as royalty per license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesMilestonePaymentsInTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales milestone payments per licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesMilestonePaymentsInTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of other deferred costs recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=txmd_SubscriptionAgreementKnightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreement1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RoyaltyTierAxis=txmd_StepBasedRoyaltyPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_CouncilLicenseAgreementStep3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_LicenseAgreementTheramexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticPatentsNonApprovedBijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignDesignPatentsImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUSPatentsTopicalCreamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ForeignUtilityPatentTransdermalPatchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentOperaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentDLimoneneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentDLimoneneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_DomesticUtilityPatentTx009HRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>48
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MP^\J;+TV>_./C2^"70N__D7W!5!+ P04    "  I@FA/F5R<(Q &  "<)P
M$P   'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03
M<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS
M[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#
MW(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S
M^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4
MPL3 :F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:
MX./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;
M:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ
M$A6UY4#3( !8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&
M<IV0!0X -\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD
M,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z
M'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S
M(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(
MWXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU
M+,76>)7 \:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/
M:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:
MK<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1
MDEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*
MY \FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_
MT=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=R
MS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;
M)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R
M2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZ
MG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCR
MHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)2
M56 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYE
ML<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_
M13.V$I<8O./FQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7G
MFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5
M' 86%S+D4.Z2D 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2
M)1(4BK ,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%
MV^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODR
MWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\
MU*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHS
MU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!
M4$L#!!0    ( "F":$_[K444.@,  )T/   8    >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL?5?A;ILP&'P5Q ,4;$-(JB12DVG:I$VJ.JW[31,G006<@9-T
M;S]C*&7^SOM3L+G[SN:XU-_RIIK7]B2E#MZJLFY7X4GK\WT4M;N3K/+V3IUE
M;9X<5%/EV@R;8]2>&YGO+:DJ(Q['LZC*BSI<+^W<8[->JHLNBUH^-D%[J:J\
M^;.1I;JM0A:^3SP5QY/N)J+U\IP?Y0^I?YX?&S.*QBK[HI)U6Z@Z:.1A%3ZP
M^ZT0'<$BG@MY:R?W0;>5%Z5>N\'7_2J,NQ7)4NYT5R(WEZO<RK+L*IEU_!Z*
MAJ-F1YS>OU?_;#=O-O.2MW*KRE_%7I]6X3P,]O*07TK]I&Y?Y+"A- R&W7^3
M5UD:>+<2H[%396O_!KM+JU4U5#%+J?*W_EK4]GKKGR3)0,,$/A#X!X']ER &
M@A@)S"I$_<KL5C_E.E\O&W4+FMZM<]Y]%.Q>F)>YZR;MN[//S&Y;,WM=Q\OH
MVI49$)L>P2<(-B(B4WL4X$A@PPF=_RNPI0B!!03<@;!T,:$GF)Y >F+IR82>
M.B^ (F98((4"*:%GC@!%S+' # K,"'WA"% $B[%"!A4RRF>.!(5X]C"'"G.J
MX'PF&P#Q?"<+*+&@_,21 ) 42[ 8IRFF%69NG@ F\ZAX,LMHA;FK C +CPH,
M[@/CI (GOPT X_EU8#B]3- *KO,(X[&>X9 SFF'NFH\P/O=QTAD-,B?N XS/
M?1QW1M/,B?L XW,?1Y[10 OB/L#XW,>Q9S34@K@/,#[W<?(9S;4@[@.,QWV.
ML\]IKH7K/L)XW.<X^YSF6KCN(XS'?8ZSSVFN$]=]A/&=#'#V.<UUXKJ/,![W
M.<X^I[E.7/<1QN<^SCZGN4Z(^P#C<Q]GG]-<)\1]@/&YC[//::Y3XC[ ^-S'
MV><TUREQ'V!\*CC[G.8Z%:X*P'C.D )G7]!<I^XQ$F \1R2!HR]HK%/W$P,8
MGPA.OJ"I3MWS*L#X1#Q'=AKJU/F,MP,FM9AZ^$?)6);%F7O\CB;-3B6;H^T+
MVV"G+K5M2B>S8^_YP&VS] 'O&]?O>7,LZC9X4=JT7+8Q.BBEI5E1?&?6<C*]
M\C@HY4%WMYFY;_J&L1]H=1Z:X6CLR-=_ 5!+ P04    "  I@FA/4Y7LCB@$
M   O$@  &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V8;8_B-A#'OPK*
M^[O8X^<5('6IJE9JI=55U[[.+F9!EQ":9)?KMZ\3L@AFQJ>"1![XC_VW/?[9
MR?+<=M_Z?8S#XGM3'_M5L1^&TT-9]B_[V%3]Y_84C^F?7=LUU9 NN]>R/W6Q
MVDY!35V"$+9LJL.Q6"^G>T_=>MF^#?7A&)^Z1?_6-%7W[V.LV_.JD,7'C2^'
MU_TPWBC7RU/U&O^,P]?34Y>NRFLIVT,3C_VA/2ZZN%L5/\F'C1)CP*3XZQ#/
M_<WY8FS*<]M^&R]^VZX*,3J*=7P9QB*J='B/FUC78TG)QS]SH<6USC'P]ORC
M]%^FQJ?&/%=]W+3UWX?ML%\5OEALXZYZJX<O[?G7.#?(%(NY];_']U@G^>@D
MU?'2UOWTNWAYZX>VF4M)5IKJ^^5X.$['\US^1Q@? ', 7 .D_F& F@,4"B@O
MSJ:F_EP-U7K9M>=%=QFM4S4FA7Q0J3-?QIM3WTW_I=;VZ>[[VH1E^3Z6,TL>
M+Q*XD<"]8D,55EPE9:K_:@)8$S#%J]MXR<<K-EY-\?HV'EE\O$CL)#E.$FF,
M4D(8@1K#*&WZ*N$<[TFSGC3UI)"GB\3<>5*@K-3($B.4PBH/F5XRK"-#':&*
M'@VM2"1+7F-'5*C .NLRPVY90Y8:,LB0Y0PY#Q:/&B?T2MN@>$>.=>2H(XL<
M.5I1D,YJ9SVRQ"B]=2Y +KD]Z\E33PYY\J0F4&IL/7)$==J!]9DN"JR=0.>J
MY^.EX(DC:(,(<@3-KQ"\%H*@ARK3&C9],JXR')3$E1/8E:3]%S1(([$I1BC2
MN+N0\<1C40+U)+$G8!)?FV"5P::8TB#CA\>LI)QUF&FSYC['$F8#=D-U5@4E
M,E-#\I"5E+(.,TU2>AKCC7?!84]4"<F\##Z72SQH)26MPV"3E*"@0[ ))B2;
M&*E,IE0 G?'%\U9:,G>=S93 \U%20#H,(TFY!UHJ903&$:<$IY77N2S@"2DI
M(IW'KACVI9&U0A&B4*7T2J69GN,<#TH9J"O"N4!G@5,0C,*+":/44CCO?(8I
MP-,7!,F!7'8#3TJ@I/282D !*(-..QN)4;]AI"XM7E+(3')#9@])\>;Q)A H
M+(,1(B4G-O7_60D\*X&RTF-6 F4@N#2S15KHL"$JE5(GSGN16;V!)R9H.OZY
MCN;I!I1N'M.-T3@\SWZLN7?"\PSH!M+C[1K0C6&B$6!J;5B=T#;7NSP?@?+1
M8SX"I9X%;=+C"'[RVG!2:9,NJ R+@"<D4$)Z3$B@W/MDQPPS#F_+-YS6R #.
M0I8F/"6!4M)C2@)EWR>0 #X Z3$J#<Z,(YY[H.0QJ>@F->#MX*RQ=RG#+^&<
M-+.$ES=/[N.KE#^J[O5P[!?/[3"TS?2HOFO;(:9BQ>?4SGVLMM>+.NZ&\=2E
M\^[R"N-R,;2G^?5,>7U'M/X/4$L#!!0    ( "F":$^95L[O6P(  $P(   8
M    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULC9;;CML@%$5_Q?('#.!K'#F6
MFE15*[52-%7;9Y*0V!IL7"#)].\+V&/9F%SR$'/9^YQU"(;D5\;?1$F(]-YK
MVHB57TK9+@$0^Y+46+RPEC1JYLAXC:7J\A,0+2?X8$PU!0&$":AQU?A%;L:V
MO,C96=*J(5ONB7-=8_YO32B[KGSD?PR\5J=2Z@%0Y"T^D9]$_FJW7/7 $.50
MU:01%6L\3HXK_Q-:;I Q&,7OBES%J.WI4G:,O>G.M\/*AYJ(4+*7.@16CPO9
M$$IU),7QMP_J#SFU<=S^B/[%%*^*V6%!-HS^J0ZR7/D+WSN0(SY3^<JN7TE?
M4.Q[??7?R850)=<D*L>>46&^O?U92%;W411*C=^[9]68Y[6;B:/>YC8$O2$8
M#.B^(>P-H64 '9DI]3.6N,@YNWJ\^[5:K#<%6H9J,?=ZT*R=F5/5"C5Z*3*4
M@XN.TTO6G20828*I8C-7)'"0 )5_@ B<$('QAV.(P.T/G?[0^*.Q/[2*Z"2)
MD30=8H:2++,JF<OB+$G@#9K(21/-:2*+II.DHS3P!4)KX3>/5!.6V,D2SUEB
MBZ63Q*,L"'8?"^<)X80H<1(E<Z+$(DIFB6R4>XH)0^ID2.<,J<60/F2XIY@P
M+)P,BSG#PF)8/+5+'JDF+)F3)9NS6"_&.IM5&\;N;?*,<L*$H/MD@C,J9"=;
M]Z)QMB!"09K"-+$/*9<41DD0A=D-L!M')G* S0Y-]#R82^H& Z-C7=^S/S _
M58WP=DRJ&\*<XT?&)%%AX8L*6*JK?>A0<I2ZF:HV[^ZWKB-9V]_=8/@#4?P'
M4$L#!!0    ( "F":$\NL2VA^@0  &P6   8    >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&ULC9C;;N,V$(9?Q?!]UISA.7 ,Q(>B!5H@V*+MM6(SL;&RY4I*
MO'W[4H?UVL.1DQO;DC\.^9/4S"].3T7YK=J&4(^^[_-#]3#>UO7Q?C*IUMNP
MSZHOQ3$<XC\O1;G/ZGA9ODZJ8QFR3=MHGT]0"#/99[O#>#9M[SV5LVGQ5N>[
M0W@J1]7;?I^5_\U#7IP>QC#^<>/K[G5;-S<FL^DQ>PU_AOJOXU,9KR;G*)O=
M/ARJ77$8E>'E8?P(]RO438.6^'L73M7%[U$CY;DHOC47OVT>QJ(94<C#NFY"
M9/'K/2Q"GC>1XCC^[8..SWTV#2]__XC^2RL^BGG.JK H\G]VFWK[,';CT2:\
M9&]Y_;4X_1IZ07H\ZM7_'MY#'O%F)+&/=9%7[>=H_5;5Q;Z/$H>RS[YWW[M#
M^WWJ_K'8-^,;8-\ SPU WVP@^P;R9P-ULX'J&ZC/]J#[!IKT,.FTMY.YS.IL
M-BV+TZCL]L,Q:[8=W.NX7.OF9KLZ[7]Q/JMX]WT& J>3]R90S\P[!J\8><TL
M&>9,3.((SL- ;AAS3)J302Q2 H0B@_@PRNIVE*N!2G:^9!M 70709+XZQK3,
MH1N&M."M J(I!:6R4DL2<,EPTBJ-VA)Y*0@@A/?2\AH5JU$Q&@W1V#'ZLB>E
ME!2.2$PYXST P98I)I76WI.96#'=6F?\Q9:]TJ=9?9K11V9RKI..$-%J)<G&
M7S"@M4H!";A,.2G0>31TBZ:@1Y3B8E-<232L1-,&D5<2'1_ L@$L,T>>S)%-
M1JHTH/&.;)9%"C9ZE+!$^S(% 4%:IX'TO4I))[1UPGI>I6-5NE0E"*+2I2J%
MM5;2G9YRQ@J'ECSTRY2#^,1[[TC 50JBT$I[-;"0GI7H&8ED2'///,S@-9GS
M18I9*9'J2REII-=D3ZR8/KV+\GAM(/CJ)1AU2?D2Z0IZJ8QQ]%EFR)BXI3:&
M5AJ&C/LTEDYE2- 5APJ0&+/W0-:"@5(-C%A)Q4+2VQU:80&UH&H95"II !5-
M7AP::X*+,@10O0SK,18A/52%@/4$CX",7D7UIA#-*HM/,,N>(0IC2C&2)NC;
MX:Z5\28"&!<!U$7TT-7C)J2A]6+!<$[$BI@H3#EPUGDGJ#X&5#&WPM#R\2X"
M&!L!U$9 6M#OFKHOJ*E:<&3,AS+F8BJ4(0$L<$O)!=5.*3U01H!W%,!8"NH
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M+W7ST\;?97?^V5W4Q;$_VYV<#YAG_P-02P,$%     @ *8)H3_F%#VZG!P
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MT=MF7+/1<=A-+XC-S[CX"U!+ P04    "  I@FA/_=785;4!  #2 P  &
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M\?BRL?^U,1XPE>0*1ZC%#[88"FH?CI_P;*<QFPQO^OD'L>4;%W\!4$L#!!0
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M_C>(#KR4PXT?H<Y_L-50T+AP?._/9AZSV7 X+#^(K=^X_ U02P,$%     @
M*8)H3^!T)%VU 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&UL
M?5-A;]L@$/TKB!]08I(V561;:EI5G;1)4:MMGXE]ME'!N(#C[M_WP*[G;=:^
M '?<>_?N.-+!V%?7 'CRKE7K,MIXWQT8<T4#6K@KTT&+-Y6Q6G@T;<U<9T&4
M$:05XYO-#=-"MC1/H^]D\]3T7LD63I:X7FMA?QU!F2&C"?UT/,NZ\<'!\K03
M-;R _]Z=+%IL9BFEAM9)TQ(+54;ODL-Q%^)CP \)@UN<2:CD;,QK,+Z4&=T$
M0:"@\(%!X':!>U J$*&,MXF3SBD#<'G^9'^,M6,M9^'@WJB?LO1-1F\I*:$2
MO?+/9GB"J9YK2J;BO\(%%(8')9BC,,K%E12]\T9/+"A%B_=QEVW<A_&&[R?8
M.H!/ #X#;F,>-B:*RA^$%WEJS4#LV/M.A"=.#AQ[4P1G;$6\0_$.O9><)]<I
MNP2B*>8XQO!%3#)',&2?4_"U%$?^#YROP[>K"K<1OOU#X<TZP6Z58!<)=O\M
M<2UF_U<2MNBI!EO':7*D,'T;)WGAG0?VCL<W^1T^3OLW86O9.G(V'E\V]K\R
MQ@-*V5SA"#7XP69#0>7#<8]G.X[9:'C333^(S=\X_P!02P,$%     @ *8)H
M3S;[O=:U 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,38N>&UL?5-A
M;]L@$/TKB!]08I)V661;:CI-F[1)4:>UGXE]ME'!N(#C[M_OP*YK;6Z_ '?<
M>^_N.-+!V"?7 'CRHE7K,MIXWQT8<T4#6K@KTT&+-Y6Q6G@T;<U<9T&4$:05
MXYO-#=-"MC1/H^]D\]3T7LD63I:X7FMA_QQ!F2&C"7UUW,NZ\<'!\K03-?P"
M_[L[6;38S%)*#:V3IB46JHS>)H?C+L3'@ <)@UN<2:CD;,Q3,+Z7&=V$A$!!
MX0.#P.T"=Z!4(,(TGB=..DL&X/+\ROXUUHZUG(6#.Z,>9>F;C.XI*:$2O?+W
M9O@&4SW7E$S%_X +* P/F:!&892+*REZYXV>6# 5+5[&7;9Q'\:;[?4$6P?P
M"<!GP#[JL%$H9OY%>)&GU@S$CKWO1'CBY,"Q-T5PQE;$.TS>H?>2\V2?LDL@
MFF*.8PQ?Q"1S!$/V68*O21SY?W"^#M^N9KB-\.U2G;^COULEV$6"W8<EKL5\
M_D>$+7JJP=9QFAPI3-_&25YXYX&]Y?%-WL+':?\I;"U;1\[&X\O&_E?&>,!4
M-E<X0@U^L-E04/EP_(1G.X[9:'C333^(S=\X_PM02P,$%     @ *8)H3VJ*
M/Y^S 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL?5-A;]P@
M#/TKB!]0$NZV5:<D4J_3M$JK=.JT[3.7. DJQ"F02_OO!R3-LBWM%\#&[_G9
MF&Q$\VA; $>>M>IL3EOG^@-CMFQ!"WN%/73^ID:CA?.F:9CM#8@J@K1B/$D^
M,BUD1XLL^DZFR'!P2G9P,L0.6@OS<@2%8TY3^NIXD$WK@H,562\:^ [N1W\R
MWF(+2R4U=%9B1PS4.;U)#\=]B(\!/R6,=G4FH9(SXF,P[JJ<)D$0*"A=8!!^
MN\ M*!6(O(RGF9,N*0-P?7YE_Q)K][6<A85;5+]DY=J<7E-202T&Y1YP_ IS
M/1\HF8O_!A=0/CPH\3E*5#:NI!RL0SVS>"E:/$^[[.(^3C>[=(9M _@,X O@
M.N9A4Z*H_+-PHL@,CL1,O>]%>.+TP'UORN",K8AW7KSUWDO!>9*Q2R":8XY3
M#%_%I$L$\^Q+"KZ5XLC_@_-M^&Y3X2["=W\I?"/_?I-@'PGV[Y:X%?.O2K;J
MJ0;3Q&FRI,2ABY.\\BX#>\/CF_P)GZ;]7IA&=I:<T?F7C?VO$1UX*<F5'Z'6
M?[#%4%"[</SDSV8:L\EPV,\_B"W?N/@-4$L#!!0    ( "F":$]/IUX/M $
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M";4/QT]XMM.8388W_?R#V/*-B]]02P,$%     @ *8)H3T1#?L&U 0  T@,
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M[\+9CF,V&AZ[Z0>Q^1L7OP%02P,$%     @ *8)H3[SZ$'^T 0  T@,  !D
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MG&_#DTV%280G?RE,M@G238(T$J0?EK@5D_Z3A*UZJL$T<9HL*7'HXB2OO,O
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MQN/-QOE7QGC 4C9WN$(-/K#945#Y8'Y$VXYK-CK>=-,+8O,SSO\ 4$L#!!0
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M.O^RL?\5H@.?2G+C1ZCQ'VPV%%0N'/?^;,8Q&PV'W?2#V/R-\S]02P,$%
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MMY\R=@U",^8T8?@*LUL0S*LO(?A6B!/_C\ZWZ?O-#/>1OE_3DW1;(-T42*-
MNA:X2SZ4N(7Y6"1;]52#:>(T65+BT,5)7GF7@7W@\4W^P:=I_R9,(SM++NC\
MR\;^UX@.?"K)C1^AUG^PQ5!0NW \^+.9QFPR'/;S#V++-R[^ E!+ P04
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M^U\C.O"I)%=^A%K_P19#0NW"\<:?S31FD^&PGW\06[YQ\0]02P,$%     @
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M\S<;YU\C.O"E[.[\"K7^@2V.@MH%\]';9EJSR7'8SR^(+<^X^ M02P,$%
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M'GE3T-O<;B'ZA-7^M@/Q%*OQT&H.&'"[@0<7(\)G8R7Y&QD<=C(,T B%OT]
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M[_1.F98;$AWCQ)FT_\'I)A7O9B\:I2.O4]OVMAVG%8QG,[]!/!O$BT&4_-<
MS0;(,0 3F4WU,U&D*@4? S$=UD#,G8@>D=[,DYFT>V?7=+92S]XK!/,2W(VC
M6;.?-/%*$[]7U%M%!A<)T  +1>REB*T]6D> B=\!\CI UD'R+HW"26/29%;3
M6TV$]*]PD]GJTBC)<5[X@1(O4+(%BJ #-&G2=: 4XA0[/%M9E!<YQ!]L4.KE
M23T\D<.3;@+%::(+@G,?ZJT.%S#)4C]/YN7)/#S.0>RS39PLPC&"R.'9ZN*B
MP.@C(.P%PAX@)] >;V\03'$>9\[)UCYACI*L0 X26+U34S=_$'%M>QD<N=)/
MWC[,"^>*:J?P06?8Z%*]#!B]*-/%NB^F@C4-%!_F6@R6#T+U#U!+ P04
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MX<0>QS^>OJM1=#I_70DP_",ZPWL"%Z S@E:.=P4NY\\AQ\1S@+R)]E$D(C9
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MJO2PI#2!,\3%.0.U*G4VY(RX$&<9U6K_*B,V,J=>?5=-SO;1L*0T!V=6)R_
M]>]A_E'43^M=L[BKVK;:#F^\/5956W;VV*?.T'-9/!P_;,K'MO^U/RC4A]<?
M#Q_::G]^>+=S=7S!].(_4$L#!!0    ( "F":$]1-579[@(  *@*   9
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M29EAJL=B:&[#1/%N;-QH^O<H_@!02P,$%     @ *8)H3V_\IM<6!0  K1T
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M0B#,G8S,0"$S@"!SA$"8N2/D%I,$ 2PD!86D#PBYQ20!=H1 F! 6DH%",H#
M_300QOU'WL=<"9F#0N8 P9V?# ?PJ0\>/S#X3N' @(J96SD@4.KDXQ^@:S%@
MB5GA$*#([E# )03_1PW!<!'!MZ<?2 D$<@\-!,+NJ4&3&E]3<;3M4'H%/S7*
M5-.)=6RYJ]#T",>^-JW8]HZ_-'T?_TK$L6JDM^-*=R#;)PZ<*ZHU!D^ZQ)3Z
MZC N&#TH,TWU7/3]LU\HW@YW S1>4/(_4$L#!!0    ( "F":$_W2YUSX0,
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M?&8$^M#+IQE>MC:&^W@N%)UVVMG3@3T3$Y/!4 >L<\!&=3,2B7M,T&&*'A,
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M9=E(%;^_4-4]R61_>\CDH6EO0W5?]8<*_4-3GO6!B7<[M=G\#U!+ P04
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M(@PZ0H2(2] T0PU-4</#B1,%!*).<DWHI'@GWFH&&IK(&BV#0\U 0Y\!#<U
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M$/E+[U([:C6;1@,]#>T4GO;>A0 LQ 9&YG ;8#M64.+C(1A:!3,.V$T5 >[
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M4@F=)_FD&W?2@V]WD8J#JD\7^KQLIK_F0LFBG6R];KQ>_P=02P,$%     @
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M2VF$-4T?['0<[;TY=FJQ-ZZ9V[;J+X^^8V0W7(S)>#NO_P)02P,$%     @
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MC<IEU#]KEO]##>-\<NYA(,[$C]."V/ENHQE"R#_8QCA"TQ%N"> P8F0$? "
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M@R%5%/@01J#"9>WFF9G;\CQC9TG+FFRY(\Y5A?F?1T)9NW8]]V/BI3P54D^
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MJ+?! 3.]."M+U(GI^L[WD?_<QV1/7Y\])>42UJ[#7\B<>)7%EG=LNH4WW7=
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M52<JV<<JW'TL-A@0@/O#H,H%W")USIRYAPF#X''3?%R%RH/CQ4UJ7=\D$6/
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M0O!YB=G5."4;N8L6;]#Q5 *D1R_.8Q;I+'T SIPAU=_6CR4X!#%R1Y1?@FN
M ]#%68=,YUO/MAV(C\D7Y,DIJ2THC2T-"AXP;+FD1; 4X/ ;)"889(.RM42,
M(&%9(--CP-,USVD9A(BT_+,UZDD)P>;GL[./L36<X#+=RK*<TVP CJ0;6;B#
M<+DM62X@Y41/\D]T#&>@K2Z &_>Z.-E-^J#,Y/;TSQVZG262&U2Y*XQMQR'W
MI#?I$AQ(XL;IF.\![+) Y+27 R.=A09Z>_1PN,3PMI(E H00 0C7L$JW:>N]
M_ =A0)G>H^V*5I@X]T5,KV9D2S6P\AS7C)%*&!7**J7W+"KX$<6." :@*BJ"
M,*MF>?(@#"8'5*ZJ!#1*XL?W25:Z]2B0@.+N5K ZN:=&]\,6NXKD+N1]RXXE
M@/H*'BN"7N?) $&S?$DY)5^($_F#)RQ5$1W /T$-8S-\.*-1P6J'-H'.RSD
MJ1DLUCDUTM)JX[UW:XTB;PJ*:Q Z\N[L]DVL?M'6YS]M\'SIA;/;3TP?3GL#
MH3N@O[,Z644+4-! OT)SQF)55+ 3(WC':T6 T'FP>VV=)OB,^PUQ!)65+5%T
M>14.8S<':</^0L8AGB&U4Z+9IX[YH*ID]_""J3#0R2TJ\A?%:(Y 4$U7":AF
MI]&$9[?GT;3?17()9(SP*(-?YF6!-BM_\'L47YZ*\C>4Z_\*J!\;!E22K6FH
M;$W".4V2WM]S *U:^-Q E>*Z,*&B_7[-Q1Y)RG<>;(VOS0(U(%#U49;:H0%N
MRU.O,? /U@*\"^5,'W@P%ZAJ9:6WY3!Y0+ _[#*FY2#-V/TTSM/0X7,R&MZ&
MRK.F)_>H1E@>U!NQ!$J'Z!-RO9U(M@DXB '^F$",<YYQCZN!YT&P1-*$!AZ$
M I 5T)NB-*,[2"< 3\.IJ<D0D9P4-?QMH[Y$ :5%=7R*L&M?PR4Q(DMH.PR3
M(JJ3B=BX\V:XP@(MZ J6*+S3%_L)R./>O48LU9MZ^XDO8G>"NZO@)%>X'N4N
M<HL1?)47E"1^%784@TH+;Q7[-"4\ BG[@<XCVSK.^+*QC!U()'R]ER"+I^R0
M:D$8T#W1$DGS5 NX><3+X:9->M/("5SMDZHR5-N(X4E9;,(5<V K+IU#^BIV
MYA'[RZO=FL6*1/'&&OY!R%3_I[K30,^!6Y$N62;T$#^G58^ZH]-1MV/N@M_J
MET*HF;5Z6[)&JR")4O'\N1LR90-Z[7J8X'J$0W8P'%"O 5YU_Y;$ G#V72!(
MPI'9UD"T[+"P!]3*D,#'>!K#1K?$+R5 U0*:UU 1Y,;=,=\=_(KH+ZS+74FX
M" GL EAZSZ,,A)VZ#[U1^I)99B3Z\*(2D!!P)^A\D!N8BVGT&?F%KN&[=%[2
M]##WN'$5C5S%\2FF.[U'-R(ANW^_+2\#P;9*4QN]42Z9#E-( T46P^# ( ,9
MO4*@KU)Z 2[HW_WP96-?D7A>[SS(Q >B48ZAMT"Y5B"#H%*M&5/V9O/5M(LE
M%X7/UN4%4*Q6)J4)3M71Y-/(.LE'4W9).RY*D7OM',J;Z=O%*@'=QJ;E+C!0
M! Y+3]G4:1":WD^W^XTZ3TH\4>?Q7=DC\.@Z6A9?>!%I'W1MS.^[B2&C$@X5
MFL4M+I&X(:('$$DC&&'73\/72'^OI_@61R=W(!,OHNFP_^JGZ X3)1&E+UG6
ML"3_ 3=O-YKD+(LZ4Z)QS@.&?J%>=3U'M=MN**M3W7E+-&H&5]B[%&T7&%1]
M\1C0 :\ ;CD+T-X*UBE ;LE^&G&&LZ_+@P#'.:1RF]!Q%OT0#3I3 _B^PD&&
MG9[]/.D,O<]]^YDSU]A5$VJCOJQM!/YJ5,5C._%()H#8II-RD"4<1/4;WH)%
M*N9@T51S0 /0?;8[BHB*SM$?"M=A&7UDI!0Y/%%#A"C\2M4DBT(T$3;A$BN,
MGZ%WJII0G(CE;229*>W;2%92NV%L8(U+MY\^?#B[^0M%O%_^?'7Y[O+\[.HN
ML"1=O[\\;PEV\949(+X+1,6#@03MF9'?O9;H'>H?G#H4!#5<D@6 +PKZ#'VC
M@?M%E%8T4ZQ)]3/D8<:8CZ0MA3:II4S&-K(CB,Q:!1F,3+D625F2UIUP2,C1
MB4Q](D:0QESH%_B:K1,Q:V6!/C9/%^2B$:F_>@35@%>UQG")C!VOU8Z,<A8F
M8J<S'"&1HSD6[0SO49F*>AK3YGS4WH2/&:!@N7C<M^\8[WL(&;%6W:(UB,U5
M$ID9G2254:60!#HRLLY>Q>&>_=TFXL(4WY!Z_]@O1 2!IO2/G[V%PDI!QD2$
MA6M6H=W2B&,<U$,Z /CZM^B$P=!_1;1QP7GMZAIN#_?C:(:$_&HK2KO<^LM&
MPNR92>9D1!;? X7!G*YHRC8P(_@P7S)G(M:J[)\38UZX\!N0SV)4?6/_ZGSP
M5/>.T;/>Y6RU@>'_MBNVY$XCB9ML?D3=&=C,8YUG4B!1!-&)KV7<?FTP$@'D
M#%I?;)F.E,C-3G5BA&XQ1UI"1Z766AK-'VP?JZK(0L9JSR/9OS0T07 (6%!9
MS&UE$%KI;HX\?)N1)=.ZV0BE&^JUP[77Y.9@  P L-YJ92.'%TT!.BUWA-)Z
MU2WWF" G$0":&@ )2$_IM^ @7V'_(0RF)6P#:>YT189I>UP<)!-\"6@L!J$E
M3P!:W6D=T=G.4:&>BDB:;UM!([=N\$K< 'D:>@$T(L)&4H'R# OG$ =T')/T
MHZJ3;@_#E",;>WMCB2^;B#51E^P<;S7LV#[.;[>0;K$75%L0WH'N /=_$*Z,
MKG,FFVP<-10H39C#EH8R_9*!.MTV*(M*BX+B!CDF6Y\B,L4AE0L4+)&,/:3S
M9/$;_Z;RG@;(:/:Q:<126P]-)<1TMQ',H'61;=:&Y'NK@Q=!.=H6)=U]720J
MH\X&Q1).^E4LQ!CH7JQ!,,(HE4SL">B]9O-*RD'D[?!]2%')*M'J!7N:=:-E
MLN?K@[%'^=]V:;[8TVA/&J%N["];?]TP5H)7E*GW\=1LQU^07 !$$94$[FH4
MHJPRWQQ=W!L/'""Z 0>N&!16X5IDY6*W1K NV/FAR*-(05HE_O,E1=<8E?"P
MT@&>3;&K@!3A9K<IY13!.::YX8W2A63=WX7$$ITYOE^X( 4;U+Y2B/82B[T
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M[U\T2-OJJ7C%\V.:8$Q/)[!U#,0(J[)VK82!I&"R1Q K['V5.OVVAG4M?3@
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MO8^/0Q,Z7)A$JK_?'YB-&5IINQ(MO38/:<[=)'&8TM826"5/M7*Q66YCT+2
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M\+[Y='MY=7%[&YU?7YU?7-W=G-U=7E\UT3NK?F.V\RGH-/-=K/G9V:E;O)I
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M:>?T5)6BA6<;7K3/'C<)CT"O;Y&C7(QL["DU>G</@0USUV3/;/4/=^[1T/!
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M3!QN\6(>_3'2O]1T*"4%F+[33\;*-W&8EUK[DXJ^/J;)TL]7Y7)15'0EUFP
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M%-QA<6T(_F?T^&0**]SL.^+/:;KYQ_\ 4$L#!!0    ( "F":$^)[ #[50(
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MF)A\'!/R.9)Q0+SKL^*8A=R6+70HA%3#P]WJE=Z]NYB%W)8MY(N:P56RX0L
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M;LQ?2=ZL76SGL^%O&[>?4$L! A0#%     @ *8)H3Q\CSP/     $P(   L
M             ( !     %]R96QS+RYR96QS4$L! A0#%     @ *8)H3R?H
MAPZ"    L0   !               ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q0
M2P$"% ,4    "  I@FA/T !_FNX    K @  $0              @ &9 0
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  I@FA/F5R<(Q &  "<)P
M$P              @ &V @  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "F":$_[K444.@,  )T/   8              "  ?<(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  I@FA/4Y7LCB@$   O$@
M&               @ %G#   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ *8)H3YE6SN]; @  3 @  !@              ( !Q1   'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "F":$\NL2VA^@0
M &P6   8              "  583  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  I@FA/^84/;J<'   $+   &               @ &&
M&   >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ *8)H3U3F
M#;0>!0  R!<  !@              ( !8R   'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( "F":$^%P.OUL $  -(#   8
M  "  ;<E  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  I
M@FA/_=785;4!  #2 P  &               @ &=)P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ *8)H3S"^,?6U 0  T@,  !@
M         ( !B"D  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( "F":$_-$;4NLP$  -(#   9              "  7,K  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ *8)H3P7M'[.U 0  T@,
M !D              ( !72T  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  I@FA/WV7F"K4!  #2 P  &0              @ %)+P
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "F":$_[*5V9
MM0$  -(#   9              "  34Q  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ *8)H3\!HB:FT 0  T@,  !D
M ( !(3,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  I
M@FA/X'0D7;4!  #2 P  &0              @ $,-0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "F":$\V^[W6M0$  -(#   9
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M970R,"YX;6Q02P$"% ,4    "  I@FA/%>>ED;0!  #2 P  &0
M    @ &00   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M "F":$_*-A>XM0$  -(#   9              "  7M"  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ *8)H3Y1='*T* @  - 8  !D
M             ( !9T0  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  I@FA/?7/"7[0!  #2 P  &0              @ &H1@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "F":$^=NS#<MP$
M -(#   9              "  9-(  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ *8)H3T/49#6W 0  T@,  !D              ( !
M@4H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  I@FA/
MR#6)U+8!  #2 P  &0              @ %O3   >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( "F":$\9,8HWP@$  #<$   9
M      "  5Q.  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ *8)H3[WT9F:V 0  T@,  !D              ( !55   'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  I@FA/V(4SI+,!  #2 P
M&0              @ %"4@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( "F":$^=C13RM $  -(#   9              "  2Q4  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ *8)H3TB1(7G
M 0  -P0  !D              ( !%U8  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  I@FA/XWGH4,(!   W!   &0
M@ $.6   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "F"
M:$\A*:3BF0$  %8#   9              "  0=:  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ *8)H3VN]><'\ 0  B 4  !D
M         ( !UUL  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  I@FA/7_TIC08#  #@"P  &0              @ $*7@  >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "F":$^AD"<J#0(  (D%
M   9              "  4=A  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ *8)H3V2EG&(J @  ' 8  !D              ( !BV,
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  I@FA/B*CN
M5:\"  !I"@  &0              @ 'L90  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( "F":$^YG) ^%@(  )D%   9
M  "  =)H  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M*8)H3Q=AO5-Z P  J \  !D              ( !'VL  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  I@FA/&@!*K]H!  #\!   &0
M            @ '0;@  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( "F":$]8!@:L?P8  &PJ   9              "  >%P  !X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ *8)H3U$U5=GN @
MJ H  !D              ( !EW<  'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  I@FA/H, ?(QP"  !)!@  &0              @ &\
M>@  >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "F":$]O
M_*;7%@4  *T=   9              "  0]]  !X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ *8)H3R<.BSB@ @  U0D  !D
M     ( !7((  'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F":$^YMDE900,  &H/   9              "
M 7J6  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ *8)H
M3].9-)EU @    @  !D              ( !\ID  'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    "  I@FA/<Y&H<&,"  "I!P  &0
M        @ &>G   >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( "F":$^+X*VBEP(  *T)   9              "  3B?  !X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ *8)H3QR_.515 @  W <
M !D              ( !!J(  'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    "  I@FA/>MS;.'U\  "?P@$ %               @ &2I
M>&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4    "  I@FA/B>P ^U4"  !^
M"P  #0              @ %!(0$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M "F":$\FJ6>:604  )4E   /              "  <$C 0!X;"]W;W)K8F]O
M:RYX;6Q02P$"% ,4    "  I@FA/90V\O_T!   -(@  &@
M@ %'*0$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  I
M@FA/5=WD$-D!  "^(0  $P              @ %\*P$ 6T-O;G1E;G1?5'EP
=97-=+GAM;%!+!08     00!! +D1  "&+0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6788307008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">$ 516,351,405<span></span>
</td>
<td class="num">$ (386,659,120)<span></span>
</td>
<td class="nump">$ 129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">43,902<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">44,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">154,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,751,358<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,751,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(24,401,829)<span></span>
</td>
<td class="num">(24,401,829)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2018</a></td>
<td class="nump">216,584,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2018</a></td>
<td class="nump">$ 216,584<span></span>
</td>
<td class="nump">518,146,665<span></span>
</td>
<td class="num">(411,060,949)<span></span>
</td>
<td class="nump">107,302,300<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2017</a></td>
<td class="nump">$ 216,430<span></span>
</td>
<td class="nump">516,351,405<span></span>
</td>
<td class="num">(386,659,120)<span></span>
</td>
<td class="nump">129,908,715<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2017</a></td>
<td class="nump">216,429,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,236,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,446,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (93,226,179)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2018</a></td>
<td class="nump">236,464,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2018</a></td>
<td class="nump">$ 236,465<span></span>
</td>
<td class="nump">613,864,115<span></span>
</td>
<td class="num">(479,885,299)<span></span>
</td>
<td class="nump">134,215,281<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2018</a></td>
<td class="nump">$ 216,584<span></span>
</td>
<td class="nump">518,146,665<span></span>
</td>
<td class="num">(411,060,949)<span></span>
</td>
<td class="nump">107,302,300<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2018</a></td>
<td class="nump">216,584,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">1,084,689<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,084,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">249,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,377,082<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,377,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33,219,048)<span></span>
</td>
<td class="num">(33,219,048)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2018</a></td>
<td class="nump">216,834,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2018</a></td>
<td class="nump">$ 216,834<span></span>
</td>
<td class="nump">521,608,436<span></span>
</td>
<td class="num">(444,279,997)<span></span>
</td>
<td class="nump">77,545,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 1,053<span></span>
</td>
<td class="nump">106,265<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 107,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">1,052,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,260,195<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,260,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(35,605,302)<span></span>
</td>
<td class="num">(35,605,302)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2018</a></td>
<td class="nump">236,464,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offering, net</a></td>
<td class="nump">$ 18,578<span></span>
</td>
<td class="nump">89,889,219<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">89,907,797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">18,578,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2018</a></td>
<td class="nump">$ 236,465<span></span>
</td>
<td class="nump">613,864,115<span></span>
</td>
<td class="num">(479,885,299)<span></span>
</td>
<td class="nump">134,215,281<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,575,369<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,575,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
<td class="num">(39,506,375)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued for exercise of options and warrants, net</a></td>
<td class="nump">$ 759<span></span>
</td>
<td class="nump">99,348<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other</a></td>
<td class="nump">759,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2018</a></td>
<td class="nump">$ 240,463<span></span>
</td>
<td class="nump">616,559,938<span></span>
</td>
<td class="num">(519,276,280)<span></span>
</td>
<td class="nump">$ 97,524,121<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Dec. 31, 2018</a></td>
<td class="nump">240,462,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,462,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,656<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (126,709,485)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 241,277<span></span>
</td>
<td class="nump">624,515,559<span></span>
</td>
<td class="num">(645,985,765)<span></span>
</td>
<td class="num">$ (21,228,929)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">619,234,655<span></span>
</td>
<td class="num">(558,782,655)<span></span>
</td>
<td class="nump">60,693,222<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Beginning Balance at Mar. 31, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,637,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
<td class="num">(55,236,517)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Jun. 30, 2019</a></td>
<td class="nump">241,221,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2019</a></td>
<td class="nump">$ 241,222<span></span>
</td>
<td class="nump">621,871,919<span></span>
</td>
<td class="num">(614,019,172)<span></span>
</td>
<td class="nump">8,093,969<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options, net</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">8,494<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="nump">55,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,635,146<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,635,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(31,966,593)<span></span>
</td>
<td class="num">$ (31,966,593)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding, Ending Balance at Sep. 30, 2019</a></td>
<td class="nump">241,277,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">241,277,076<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Sep. 30, 2019</a></td>
<td class="nump">$ 241,277<span></span>
</td>
<td class="nump">$ 624,515,559<span></span>
</td>
<td class="num">$ (645,985,765)<span></span>
</td>
<td class="num">$ (21,228,929)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6791460096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Nov. 04, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-00100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">THERAPEUTICSMD, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0233535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">951 Yamato Road<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boca Raton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">961-1900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TXMD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,177,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784195216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SignificantAccountingPoliciesTextBlock_zs8Vy2lmjPK4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzgriDLIUlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Fair Value of Financial Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of September 30, 2019 (as
disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification,
or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 1in; text-align: justify"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unadjusted quoted prices in active markets for identical assets or liabilities;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unobservable inputs for the asset or liability.</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2019 and 2018, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets or
long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the company&#8217;s
impairment test on an annual basis.</p>

    <p id="xdx_854_zo3oEjfEs0g" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zDF1c5buzsl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations due under normal
trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for
doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing
economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off
delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when
received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does
not accurately reflect bad debts, adjustments to these reserves may be required.</p>

<p id="xdx_85C_zz08qjZ5B6nb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>







    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline"/></p>

<p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zUS9yHUzpj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Revenue Recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC 606 on January 1, 2018 using
the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is
considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance
that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of
our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are
considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary
upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control
of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to
receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue
recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be
entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with
the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, our products
consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third
quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the
third quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and
retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors,
which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail
pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat
shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we
satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to
be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s
ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts,
we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We
disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or
services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transaction price of a contract is the
amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration
to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative
assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated
with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain
event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the
future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in
the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable prescription
products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product
returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be
returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers.
For our newly launched products, for which the right of return exists but for which we currently do not have history of product
returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory
remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated
balance sheet.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>










<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We offer various rebate and discount programs
in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance
for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at
the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates
and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate
chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience.
Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our
customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues
at the time the revenues are recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of commercial launches for
our FDA-approved prescription products, we introduce a co-pay assistance program where eligible enrolled patients, out of
pocket cost is reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in
line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We
consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction
price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated
based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance
paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any
time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our
prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a
result, we constrain revenue recognized for our prescription products to an amount that will not result in a
significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription
products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related
to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated
co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate
any constraint each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable up-front fees
that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data or technology is delivered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Three Months <br/>Ended September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Nine Months <br/>Ended September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a">2,550,330</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj">3,261,459</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah">7,309,174</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc">10,797,861</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd">4,772,354</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8">212,076</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl">9,904,744</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i">212,076</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3">490,705</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g">624,987</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr">23,719,741</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5">3,473,535</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk">33,745,257</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3">11,009,937</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_8AF_zOXgLiMXZZF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


    <p id="xdx_851_zZ4tGTJsR7Ka" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>



<p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zY3xkSL9zzw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Cost of Sales&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Cost of sales includes the cost of
inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. Certain
license agreements require the payment of royalties based on the sale of future products. Such royalties are recorded as a
component of cost of sales. Additionally, the&#160;amortization of license&#160;fees or milestone payments related to
licensed products are classified as components of cost of sales to the extent such payments become due in the future.</p>

<p id="xdx_85F_zyE5LzD267Nd" style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/>





    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ttCnOrRyR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Share-Based Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options.
Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option
using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have
no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective
judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates.
The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions,
our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based
compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation
expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for
forfeitures when they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, we adopted ASU 2018-07
which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

    <p id="xdx_85A_zHBHVAziZYij" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"/>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zH5JRMQSacq9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&amp;D,
expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their
clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity
expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting
expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and
investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make
payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense
nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has
been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO
expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the
completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.</p>

    <p id="xdx_85B_zGkKZQMLVu8b" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGdDrHDqi1a4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Segment Reporting</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single management team that reports to the President of our company. We do not operate separate lines of business with respect
to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales
are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>

<p id="xdx_853_zfPbqggqPpWi" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780348784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">NOTE 16 &#8211; SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_809_eus-gaap--SubsequentEventsTextBlock_zjWsXK4Vjrsc" style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE
16 &#8211; SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
October 24, 2019, we entered into an underwriting agreement with J.P. Morgan Securities LLC, as representative of the underwriters,
relating to an underwritten public offering of <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zuTda8ha01Nc">26,000,000</span> shares of our Common Stock at a public offering price of $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_c20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zdMpApxnu2Ti">2.75</span> per share.
We granted the underwriters an option, exercisable for a period of <span id="xdx_907_ecustom--PeriodExercisableUnderwritersOption_dtD_c20191023__20191024__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zv1tZUXL8Mb2">30</span> days, to purchase up to <span id="xdx_900_ecustom--UnderwritersOptionGrantedInPeriodShares_c20180728__20180801__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zjLEa2Iqock2">3,900,000</span> additional shares of Common
Stock, which was exercised in full. The net proceeds from the offering were approximately $<span id="xdx_90F_ecustom--ProceedsFromIssuancePublicOffering_dm_c20191023__20191029__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--TypeOfArrangementAxis__custom--UnderwritingAgreementJPMorganChaseMember_zgWWyCK7Sm62">77.0 million</span>, after deducting the underwriting
discount and offering expenses payable by us. The offering closed on October 29, 2019.</span></p>

<p style="font: 11pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784259472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Other current assets consist of the following:</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zgT8WEKmKcYf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current assets consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20190930_z5lFsdxdiy6h" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49B_20181231_zqoOZTX38e02" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzWNe_z03udn5Zcvz5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Prepaid sales and marketing costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">1,313,192</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">5,148,789</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzWNe_zKF6ZFEUcpnc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Deferred financing fees (Note 9)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">550,757</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,898,074</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzWNe_zEu94eEnCyRd" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Prepaid insurance</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,542,008</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">790,465</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzWNe_zt6BMaq8zV2k" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other prepaid costs</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">6,172,303</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">2,997,365</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzWNe_zIBTXHrUL8Xg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,578,260</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,834,693</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775847264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 12 &#8211; INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">NOTE 12 &#8211; INCOME TAXES</a></td>
<td class="text"><p id="xdx_80B_eus-gaap--IncomeTaxDisclosureTextBlock_zLZMvvRx8HFf" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 12 &#8211; INCOME TAXES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets and liabilities
are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured
using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay
any significant federal or state income tax for 2019 as a result of (i) the losses recorded during the nine months ended September
30, 2019, (ii) additional losses expected for the remainder of 2019, and/or (iii) net operating loss carry forwards from prior
years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is "more likely
than not" that some component or all of the benefits of deferred tax assets will not be realized. As of September 30, 2019,
we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income
taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780336752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 4 &#8211; INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">NOTE 4 &#8211; INVENTORY</a></td>
<td class="text"><p id="xdx_80D_eus-gaap--InventoryDisclosureTextBlock_z7F4ior80dE" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 4 &#8211; INVENTORY</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_89F_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zAswskwBVkSe" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49C_20190930_zM0dt3gzECm9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20181231_zTdogbT3oo4d" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_40F_eus-gaap--InventoryFinishedGoods_iI_maINz2Fg_zjcVWlMql0t2" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Finished product</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">5,011,192</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">2,908,958</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--InventoryWorkInProcess_iI_maINz2Fg_zCD9rjFup0P9" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Work in process</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,005,575</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">339,312</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--InventoryRawMaterialsAndSupplies_iI_maINz2Fg_zI2NxnPuA5f7" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Raw material</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">4,516,077</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">19,400</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--InventoryNet_iTI_mtINz2Fg_z5Z9mF4uMIt9" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL INVENTORY</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,532,844</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">3,267,670</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A0_zFgQLRpRYzM3" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784228336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 8 &#8211; OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zKU8DQ7vNe2j" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 8 &#8211; OTHER CURRENT LIABILITIES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_89D_eus-gaap--OtherCurrentLiabilitiesTableTextBlock_zHT0ZkweaNyb" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current liabilities consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49E_20190930_z1xiew4yGEf9" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_496_20181231_zwgr1Gv7Yx4i" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_403_eus-gaap--AccruedSalariesCurrent_iI_maOLCzFFK_zQBchktIR34g" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; width: 50%; text-align: justify; text-indent: -0.125in">Accrued payroll, bonuses and commission costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">4,536,358</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">6,854,002</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
<tr id="xdx_400_ecustom--AccruedIntellectualLicenseFee_iI_maOLCzFFK_zbTF9nuIxlf6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Accrued intellectual license fee</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0743">&#8212;</span>&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr id="xdx_403_ecustom--SalesDiscountsReturnsAndAllowancesGoods1_iI_maOLCzFFK_zvwBizl1yWcj" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for coupons and returns</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">7,079,005</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">5,294,120</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--AccruedMarketingCostsCurrent_iI_maOLCzFFK_z2n8nuuRe9Mf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued sales and marketing costs</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,560,257</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,288,028</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_eus-gaap--AccruedVacationCurrent_iI_maOLCzFFK_zp1m4PVFG1P4" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued compensated absences</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,551,042</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,178,110</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_ecustom--AllowanceForWholesaleDistributorFeesCurrent_iI_maOLCzFFK_zyS87ucdA3Q8" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Allowance for wholesale distributor fees</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,375,894</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">792,891</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--AccruedProfessionalFeesCurrent_iI_maOLCzFFK_zm9mIQ4XU8Ke" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued legal and accounting expense</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">469,446</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">385,824</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedResearchAndDevelopment_iI_maOLCzFFK_zNWXwppcCpWf" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued research and development</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,226,160</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">388,675</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_iI_maOLCzFFK_zQT2vGFHlBFg" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,242,290</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40E_eus-gaap--AccruedRentCurrent_iI_maOLCzFFK_zINtVwuf6UUg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rent</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">365,155</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40C_ecustom--AccruedRebates_iI_maOLCzFFK_zXduvJzfogJ9" style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Accrued rebates</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,543,456</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">412,570</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40D_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzFFK_zD1HVBJRBcP6" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in; text-align: justify; text-indent: -0.125in">Other accrued expenses</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">612,124</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">375,573</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzFFK_z82CcnQ6IA11" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; text-indent: -0.125in">TOTAL OTHER CURRENT LIABILITIES</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">43,196,032</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">18,334,948</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8AD_zWRKTMXGmG38" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6776040368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory consists of the following: (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 5,011,192<span></span>
</td>
<td class="nump">$ 2,908,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,005,575<span></span>
</td>
<td class="nump">339,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSupplies', window );">Raw material</a></td>
<td class="nump">4,516,077<span></span>
</td>
<td class="nump">19,400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 10,532,844<span></span>
</td>
<td class="nump">$ 3,267,670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSupplies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4),(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSupplies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794905456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 15 &#8211; COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" id="xdx_88C_ecustom--ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock_zYiFlHN7nJS1" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto" summary="xdx: Disclosure - Supplemental lease information (Details)">
        <tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental lease information  <br/>
at September 30,
            2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Right-of-use asset</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20190930_ze72r3SrGogd" style="width: 12%; text-align: right">10,459,635</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Short-term operating lease liability (included in Other current liabilities)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98D_eus-gaap--OperatingLeaseLiabilityCurrent_iI_c20190930_z7rpaP1P99r" style="text-align: right">1,242,290</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">Long-term operating lease liability</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_984_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_c20190930_zOVkoE6yvSrg" style="text-align: right">9,500,133</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td>Weighted average remaining term</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_904_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20190930_zKJ121cxsyt3">9</span> Years</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Weighted average discount rate</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_pii_dp_c20190930_znuDhfIpmbua" style="text-align: right">8.25</td>
            <td style="text-align: left">%</td>
        </tr>

<tr style="vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: center">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td colspan="2">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: center"><b>Supplemental cash flow information <br/>for  nine months
            ended September 30, 2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td>
            <td style="width: 2%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_982_eus-gaap--OperatingLeasePayments_c20190101__20190930_zLWiTbrLwsS9" style="width: 12%; text-align: right">849,440</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">Right-of-use assets obtained in exchange for lease obligation</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_989_eus-gaap--RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c20190101__20190930_zeOWIvNo2GZ2" style="text-align: right">11,171,471</td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet:</a></td>
<td class="text"><p id="xdx_898_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zqAsztLw02Nd" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The
    following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease
    liabilities recorded on the balance sheet:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 60%; border-collapse: collapse; margin-left: auto; margin-right: auto">
<tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: left"/>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_493_20190930_zRCcJ7ZiCOd6" style="text-align: right"/>
            <td style="text-align: left">&#160;</td>
        </tr>
<tr style="vertical-align: bottom">
            <td style="border-bottom: Black 1pt solid; text-align: left"><b>Years Ending December 31,</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maLOLLPzviC_zvmluQVXekw4" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 44%; text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">2019 (3 months)</span>
            </td>
            <td style="width: 2%; text-align: left">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">314,670</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maLOLLPzviC_z5W1ORnPZWP4" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2020</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,566,617</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maLOLLPzviC_zqlbVbfakOD5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2021</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,198,541</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_405_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFour_iI_maLOLLPzviC_zi09GQCrlCVc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">2022</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,262,302</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearFive_iI_maLOLLPzviC_zVZQYJZM1UYe" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">2023</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,293,859</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_iI_maLOLLPzviC_zqenOG7RntNe" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">9,363,136</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPzviC_maOLLzDJI_zXyLb0F2X4eg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Total undiscounted lease payments</span>
            </td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">15,999,125</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_404_ecustom--LesseeOperatingLeaseLiabilityImputedInterestAmount_iNI_di_msOLLzFSB_msOLLzDJI_zaePQXH7GRA2" style="background-color: white; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Less: imputed interest</span>
            </td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(5,256,702</td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iTI_mtOLLzDJI_zLzePcvvgFx9" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: left">
                <span style="font: 10pt Times New Roman, Times, Serif">Present value of lease payments</span>
            </td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,742,423</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of supplementary lease and cash flow information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6773433456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 14 &#8211; BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfVendors', window );">Number of vendors - suppliers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">36.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfVendors', window );">Number of vendors - suppliers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember', window );">Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember', window );">Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfCustomers', window );">Number of customers - revenue</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember', window );">Three Customers Concentration Risk Member | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember', window );">Four Customers Concentration Risk Member | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember', window );">Customer Concentration P I Services Risk [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,935,000<span></span>
</td>
<td class="nump">$ 1,559,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember', window );">PillPack - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">6,397,000<span></span>
</td>
<td class="nump">3,057,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember', window );">AmerisourceBergen - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,226,000<span></span>
</td>
<td class="nump">1,834,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember', window );">Cardinal Health - Major Customer | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 1,863,000<span></span>
</td>
<td class="nump">$ 1,399,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfVendors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of vendors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfVendors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierTwoConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_SupplierThreeConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_ThreeCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_FourCustomersConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPIServicesRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationPillPackRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationAmerisourceBergenRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationCardinalHealthRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6773944176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTE 16 &#8211; SUBSEQUENT EVENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Oct. 29, 2019</div></th>
<th class="th"><div>Oct. 24, 2019</div></th>
<th class="th"><div>Aug. 06, 2018</div></th>
<th class="th"><div>Aug. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember', window );">Underwriting Agreement JP Morgan Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_UnderwritersOptionGrantedInPeriodShares', window );">[custom:UnderwritersOptionGrantedInPeriodShares]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriting Agreement JP Morgan Chase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PeriodExercisableUnderwritersOption', window );">[custom:PeriodExercisableUnderwritersOption]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ProceedsFromIssuancePublicOffering', window );">Proceeds from issuance public offering</a></td>
<td class="nump">$ 77,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PeriodExercisableUnderwritersOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period the option is exercisable per agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PeriodExercisableUnderwritersOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital by public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_UnderwritersOptionGrantedInPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares available to be purchased per underwriter's option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_UnderwritersOptionGrantedInPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_UnderwritingAgreementJPMorganChaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001387131-19-008469-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-19-008469-xbrl.zip
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M$GM"Z\T&G[Y8-;Q<'^_?8K6_-O?37.WZ*MOHI(0",/0'X^&<<TJ2P41=-0.
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MNV[$&(,,A4JFP3E&HO*80W9AP.VU\(7X,MMDF^K6I1$7QRCP5>5H5/0PIQ'
M=O AN\3V4W6C5^+5,W ;O: UAZQM6EQ/0J!!)!)$,].17::-,#?- B]D4Z:N
M6,+ZJET1WM$9"XK3%3SX0DTJ"<<M,1BH \[[@[ZFS<798\Y<.,YCV+Y@&4P2
ML _$21,Z8_R9UT^CL)8SO":. \/ VA-H37!T.U6A7-E%<R>IA[^WT?CG!AYN
MCL#X172I9\WH$*VST;'#RV*IN[_;R<6:='W4<[2-")D*Y%0IF%K2LE ZEC\O
M$C-0<L-0CWK2:3C.J^FS(OL31UU1?))GCK6C*SQ6=EZYSUD=ZBO]ZGF^R0A!
M-DUN0R"S00D &[E&VTZ ?/+[M<WR@[S&74=:WNF<#\$RW:1/:S\)7P-*LK%'
MM&5.OM';L\QY29@U_' .WR,I&O46RI4]'ZD/1DL<Q#S3Q2P+]:N0>C/LC;HI
M7G$24Y8 !A-;FC/\N=TNW8Z!QB?A&-XD<@"R+H$;LO6"4X/O=,4/.4O5$A4H
M]!03,9L)S+NY'XD9V9P.'C82<$B=AMGX%G@ M67B]+Q%JE3(NAO"35+PG%#S
MX'E.,U"K$ZCG9.E,)<W)6D(WH=1JV[MC/1.V*J$[54P"O%+,2.$Y -Y:SBLR
MW?Y6RJDDI(T9!P8''[SLHB5+TRC3,SP\MZ\^%YP>K1MALA0K%MH_Z4"35CEY
MWE$,QW#!T;85K^-4U;?;G8]4)U^=07FYSJ X&927ZPS*(\F@W'5LT75K0>U@
M(@7\RL24E;4=D(C>0%>,AF[M0Q/[ ]_J$RJL)"O$,,RFZ!50^]\I4=@C-YQV
M06"^J-XD8I O?I2J<YA5"L1-A*%^'@N9'-S8\<_J:0/7960]K$]<LK.U!>XY
MQ4@^+^EO\+!-_OOJ$QDF2H4(DPBI98A%J_2%$G7G^2-5O#]VX.K9[2I!,/*2
MEUBSPS40!VBW$1&)J8GS?4/3"%OU;(-(S>M;Y0;89=O;^!%KC@J%_,P>$K>C
M3U=P$9BV,-EIM*[@*H27(;KA4'3;78.5-XW=S<R]M27O@,WD"+]3#USW3%<Y
M&SD0W[N>4N.D0%J:"'<VW0X^**H&6Y6+L[A'>1,[^,;HD5^R2BFX$:V.S(F+
MC9Z%#@>9KIT)M7E@VY^M7B+5QU6.2&J-YT*].YT%3;0[X/8>Q6P=*",>I]]/
MXZ;+@ZZ.?4.3V7'*)F0FR<,7,YIR+0XZC& ^&HKHEB.)94L#7-7^?1VTOG=U
M=:N*',2?USD9W3(<7$AL3SOYE&:7X-J<J\(*/&T[<R'N?\KT9PD?EM=M^]@T
MBK%<KQ09UOGH8)]CA"+[<V,#>&3D(.K993UB '),?3/$&T.7O6W$\G@69*YL
M1T1@39HU&-%M;58O9M./Q]2J1MN!OFEY:)'A^+$HCY$9%!@.#9<[310-@V>*
M$K"2-@BGH!_"/&J[K:G()Z1%I'!H.-\3XK0L\"%5H8I5S<W,O;E&&31'R0%C
MR\9IT;\K4>'V'32S)K<ULQ6*K.4689QKJ(7_'F8FM5&)6@GT;-(+..*#YI]*
M6Z< P_$I@@[C/"+4[I([&X$JA-\4,T?.*&J<,1=^^SC:4.-S77M=>S!%"PBT
M6^4YE6UG$XL0S2K>+J"E.2(D=B$FE^5PQ_LU8M+XQ/.<C@J)EY=+;N^$43"$
MBE,D"IWTA!(FG(&WX'@X'*OY6#!#3=''N0)OK,<=JA%0P^NGX>2<I0G >$]M
MI;@92*2P:H\SSVW+^!&_0#-9%:7=]Y<S9FP5#6*! 685D$D<T:!H"I'YP&'D
M!O:90\GS\%/KBH#3&;%Q X8(5JCCB4:_P8A/25W3025SAQQCM,ALZS)\28QP
M\;=SB6<></XC5DY58I6#H-G8E8R@19W%3BR-Q^&Y-#UY?_@S1BS1)%S TT@(
MZ%>2=VI?7525!?=OATNKPLN"6?@! _?-^NC70GL KF'[K2[M,H6FNY9^X:8Z
MU8^W4+E:\(MNAH7 )]E"-P#;RZH4)K47#-/)-H?HG-E?6Q3W;E%\;2,!XP 9
M[@F,+;HK?Q"GB@T,%ZH/&B>5L&W$">A%AO*/R; (_(@T,GO+:7MI!;P!_1,M
MK/<+[R,-1&='@>DL]'EDXMSDO7->UY=9L_= 984I'2$T;&'X2.'%X,N-5T\E
M1RW[4I":.( 6J";= 1\61;GB6(=DD7791 GZ+>W5:+'Y*X-G8@6%Z-4$S!W6
M(],8CUN<0'-$Q]QX7J.#T&]$A!3G)[C  %ZBA[G$B%J%T?"P11Y8?:7.!8/4
M:8_4N[/3]B]&R@_#(T*^*QX;&7%X.'/:[> #G18T5K_-R2&6+ @G2GV*/S-]
M3.5!$[>"SL-*8W#H/QZED:4!_&B:4_3=,+,?&625/=$>U";^BHCWS^N(MQ/Q
M_OFO%/%^X#2"SQ]:G3LR6GT<[7WHG\+HCT?[@Y$NW=?\?(?]LS/X]*&]V ,T
M=Y[?NH!?D_'!4I)%,[*Y ;9UCK*:P>T$.ZNQ=#&AO 8; 0;UAC%)E=,Q;DE0
MZ*MMAP*037@XU!,NR+;HXL*WD_BF+<_.TH2<"OX!DX'-,1,.!_F:5.?^)?"V
MD.'W%5L^)&Y>>?$GI1;&J3/]AR7PS68..E<(!IW$"Y*O5(DT&BX="[%W?Y>$
MX*;-'"1I3U>E=SL>/@X$;3['7 .SKZ&["W_XN,XY3,JL8$XH76_-;S#)A I(
MZDW5%(U @5A0!H4]!]X'C"Y#@><NT;5MAQ+O])32&$@NT]6XU@<E/ ]2WF^;
M8:MIW#4\_N'#X_N%DRRK([%!8C;ZFQZTE@\O'UD[YJZ$/42+;4U0(2:47JMI
M 4>W25GGDDY- @YPP%1S92KMATL&$-UK_!D?D3@3P887LFL!%@I0V=P0O5,I
M7RSI%L4FMY4GZ ,'3)7E*. 0 G'%(%R G^S4F!H[@+:"6VNZA@_\(*]QUUC:
MDZN95,+ EXD&FA;9-N!7.@_A)/<HM.,(5]__RJ]DGH4EIHDH7KY@&$RN_B#,
M)7-:>J/8#@8HO_QC"M/4;JZ9C&*.!67I-!;8I+\5_#;$%-CS'D3I#/.;T(5.
MA@GX.UB6>%&[J9L$<+DN&^4E;GR<7Y9J:NI#H-0-W#YMZWGLAP)?:SL&5,NL
MO0"$YRQH>0ZO 89,.7CHPY*^/;OV6B'\& 6^(>V?))Z4ICZ^-&RK4K/2W#7U
M#<E%K'[<VKN-_Z7.V$I>E?S>NB:2;1UJ[K)XL<#-I4FC>U:/Y:;HQY!ARVY
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MN89I'G*JG?9\/9Q^]F$0'+\]&+[OGPV/CX+C=_#\#_W183\X.PY&@Y.#_MX
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MJLLN.%UNKT0J8C(#ZL5X"&)P6&H,EMM&*[V[<,91$6K"AL5UBA+V$%U7[^W
MK4QK]>.4V\> 2M'R''V-5VH_K6//F82*"/J)G;E4"9:15\B);=MA7,)DDTV$
M/8\1B3ZNX)1."XP&$LR'BP"MHL*\<2RM7&UI@6,-^5TL$6%2*#8(]=K!\SG
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MTSCE"B<=5Z[U&0J(^A .)D+RF,.$,2\UZ%P@D4WJJE<N'32,70>*'0JH4A/
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M-V@9GB.J.Z5,!!Q.YPRH,*:&I05)8E"(=(#W6JZ)*6KA\^N>8TMC<O2=T\V
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M2I77CLNT:M+UJ=$:R#"?0>'9HM"TUJL0QU2K22]BP@W\(K:\U0FANB6]&D]
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M7 8I304E"!X88IIT^2$+O>UM;1K0MQJ/& ,@K-R_.<(YF:DY =W0S,D*:;V
MT01IP)FY<#9F<,JO1@.1'>S8:RF'6XA:A\B6PDI"CEZGSR]_4. ^1W*F6&:
M:#?)ZNH$ YJ('')!F&!<M%;_85V?QW2%@G %,R!8TK3CN0">=C530NJR1X[2
MDH9T&+@-?7Y9J&3J:Q9GO#WACRXPNS0EZD,N9LDD<!Z.X9_8[1MC/F#/8M#+
MEA6R%?J%;^*!X%A,=$^U5D&Y>NUL61@&K UV8*W"6DW6NQSQKV.GO&/GUR=C
M^"3'3X='9X.#@\'>V<?^07 R.CX9C,Y^I^_7:W+OQ\K.]LZ-CA7GOV>./C>5
M:9:ZU&2=J>M/+$82NOS$@$M[-&V2#]8L)H);G(=L? DF^P([+JM%0>PXDL-#
MQYH@)+F*I)LQZ0XNH".F70=1RC9>$\6]#5,&ZA;NF1"^R&TE8#KNV"A_3S/)
MMB+"XX('AK2X,BZMT7A4/0<2Y*'C-1:GA5U0)A+M1?@]'6=N>7X+XTY;U,:"
M<75HO_452,T[Q[=5_SHK*0@ ES+>F-^K[QL(C2##TUH:(_H</MO!L9D:.W(:
M N7Z7*; M0)?Y>Y-LB3+?PG&&+NX8]6Q^Q6NWED>IL44JV[(U7MGR!\D+\5
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M7U?^(TJ&.9.O5PT]1S<TU^5*;?%UFH*DL:8JS&4(P,&R*I8<(5(B4B6>R7I
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MQ]V?:MQ=X^Y_16G=,Z^T[NA7^'23X0/NTE?9PVIXSIX3/X/N&S#B7J7B$O@
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MFILOY,3+8M/=ECO2Q\!IX &PMJ4-<WL>%S$ZJG'!^=\[S+>IJ#8\;TU ;XU
ML$G61W$.CFV8328V#U$)OC9E./:W*,AJ9$=XZD<I/D$! BEXMOMP;W?-B+;$
M[M[:I*_C7W[?7?_RUCRROTQ2UE.3O;P_S*(9_#$N)PG\_?]02P,$%     @
M*8)H3R_E@?[?K0  FUH%  H   !E>#$P+3(N:'1M[+UY<QM7DB_ZOR+T'>JY
M9SK(#D@6)5M>Y'$$1$(V>RA20U+V^-VX\:( ')!E%:K0M9!"?_J7ZUFJ"N J
MF:3JWIBV2 )59\F3)Y=?_O*G7X_?[OW\^-%/OXZ&._#?"/_?3\>[QWNCGW_Z
MFO\+?_U:_OS3ZX.=/Z*CXS_V1O_UU2S/JA^CK6>+*CI.YJ:,]LUY=)C/XVS
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M7.(0W>%S\N7YGJ@''3SPG2DPXQ2?//1#\G_^\8]__-__',"%JD)+"@(/Q:J
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MKUV?$PIJ8N09\%KX/Y!6=9,4A/C,4!R#GBL0NJ?.-X/7HA+UNE.L;%8TP_N
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MJZ.D OU LAM?5&#P]=T)# :^U$K%.K#=S]G8E@O#_OWKCGN##)G$U8YBYY(
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M=L>47:S3%JT%>L(3AM8(W)MPN?-9B^P][,LE@<)&J1H7R[.3,1%< _&M2[,
MBMEI+R8E8O=8\4K!U37)*CLZLJR!AA/,O.)I7+JHK2L,VH!\?P)\(F]<$/=M
MS)+:E6B)+#4+$T>& 81E/1>\\$0:4REZ'__B'6O6"A/>?"-L3F+8E[G?C+/1
M$W0<U.\1V(J::*&'T8BB*K4H/;1>G!0Q^O5E36%K\!YLBWKP2$Q:*DE:68^?
MS W1!(\IV5[%U#VLH_.;R$S#ZY2P)B%&<M4<4DM)[5T6R4*A.PO$4%8UNON,
M'J"-%HV(RR:>X$75T83XM/$D>*V,FYD/[16+7C]I2=^M#7;@<AK,X*%;WKX
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MYEN6TE]=&+_6AX2:[]AT0(2+2)0]9^Q21:Q">(;8 X?Q90'UB44]IF=2_M-
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M" 2C&2&R=K8L)4;U73"TP641>&9I/N%PIO:WM.^3!;0"'-SC52N3-;-1XZ;
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MJ"3:MFEQ]YC>L>ERT>(2>["7*1&$/R "-[T.M.V7F>P5MY#R/,M/;<5C4IB
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MB#!53O4+P-?:$KCTS&4XAMHOKK\B%"IEHQ?.>,*N??!=>WUJC7M6#UT($RR
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M._^]SG 8_?&I,^CT/[1,H9]#FH(Y7T/!XE"-UTU$B0E!.HG__<WK;_06FLU
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MQ'V#@GU4DD9+^_]:.MYJ!Z*_RW\&,?\@8AZ[4QU0B.$R*951O-$?67[Z+-3
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MW[*L.G'5Q??;]IL)OVV_Q-C<^ M02P,$%     @ *8)H3ST0A9J'!0  BQ@
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M)T:E<EU.4X7V@FNRO'V_(M_:5;>_SVY*(/+'A/S7!?DCQ+]02P,$%     @
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M'PZ%PRRE'C)F/.. ;VY&3]>,9AR^"]_/%"AFOME)5D4XSU>'<U$Y<'4[?;?
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MW=JETI*-$REXW1C6]6QS^KV#!WF@$FK/L,O-SJMVCJ!R>@/NXD$.JFB@&ND
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M-"7@+!T6HUF> L3"XOA*B$B<*/)XD4^GABA/5^63V?T<@Z8..T ?5T#/7"Q
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M[!E@NM8_9XZ]0TK15$'UZ'__;?WSFI'Y3@^KIH?7C[#?ZLQC#59%7TW>O_
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M-$*)A:V(@$/<KF:+56%;<5[#IURCS1;5!EB0"%@2:-A5]H''[>[V%@9\5:+
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M]^%+08S"K;;3@0M'55#I *4"!67L#HM=B[R_871)2T@$,D_&8BWHPD4 %XE
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M:>BX=^B8O04IA1$QPI5F]FDMLT_>57J+01V4@,-%Q#E:R1-BB:L-3K(L;/$
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MC8]J9O'PV*AUVAN48]F-R[%L1BU7RVJE-#V6>5DB6T)5_-XS?6/1CNV\582
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MPVR!< C8WR]P;D^Z6!;W.LM#N6:H$_RB8X7Y.(HK_(@NU6@\E\+_67B44_3
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MLTE1@J491PN7TF3'D-G</:"L55WI.6[?L3%V ^)O,%)T-^B"=6#KI@ZWH#*
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M[GBX%6LG+T>;E9Q:J#PSA?.-*"WYS2HMSZ<_;=1OU*Y;1S=7Z_1AO1BM41A
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MP%2ZJ@P-,6V;S\_&$=W:T[(AE<"C:=_PI =O16K:P='M2M_P>XZNP%(N?6O
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MY&.%GX)E9'H]!8^\/W!<.!\_Q;_6P1 _ZU0+FPTIASN^G*$-UU]KI 3L+=.
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M,5"%_2>]!AC'";H]S"^P#,WS$=;R<RT;%K462'^&9?-NTFS<I#EX'2;-E3/
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M54H=O APE(Q!_4?YL7J3YRH[.AC\L7=,M@5*LP^F]Z]N;\%?-'&M8C:8YIF
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MYSR!A;&;ZXYR5Y7K5F-VO&M-G)=?GO/FZ#1QSF/>2Z[3B!-QL;L%F9DMM/S
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MUC'AN@I;@('40Z>TY+OGL61T0WH&5D\#JV'QO4G[F0)L.D\M"@NTII?5*%J
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M+.U<\.NJ3I] WCL-RK>4H4VC\AE:;(HCVD0-!+$[GD=D 2F;0)V,C]F3,*8
M]BC^5QELU T9\ZA9:.L/N:QQMC0:$S"E,%8$@!87GB45;2SP):' %W-!#3$Q
M QYR-9)_.K=M' Z_!6P:3^*03J8(3DYU5$IHI&:"K3%DW\V"!)"O?Q/YF41<
M2L>ZPXTM4]G<TJ18D@?9FXNS4,WC0(]'S.TK=UG,\$)@BR,B9,AMCV*:KHQ
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M0NZ^/SY3ZS>Q"DAV M,T;#EYM!TWRN/DHVKTGG/I+&<IHVRA,LFKYKT%0Q6
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M.P_?*E5K6T9*[K!0_"48/Z;(7W!$ORYG*]&#H%>ZM=+;4*M8ZQV$F$E:Q3(
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MM__\Y[]<Y_7[__GCSS/7.?OX\=.?;[^<\8&#9JY@J4'6D-KB36;.,)E>PAK
ML<7=+@>3>&%M)[=H(C"52H^9L>(#,_VS++;IAVQYT 6^^9F"3^8!E0-O8K@S
MK<MPQFS3U=- 2X7#)*F%C1LU>0):&5_P_ NH4K@TZ%3E-GF;YL!MGG*P7PLN
MKC#/$S#)J%M\[.63W _Z,[XS]-$/;+I$@.5)1L>I@*;C-_$N@2F@S8S2U/?"
M[&J ?1&S)Z&MC>*==BE+8)A3A9'&\Y)OMM#O1>L'\BJ"1?1!==4+-_$1 HK0
M0KF*]*S"N ?23WF.HMLR?ZR!)"0C^V#5CJ&OUQY<3RJLR5;",!B(N%(J" T6
MZ^9"<]R+P$;43Q2B7O7G9RUF;T0AP6G!KW 17<3E:E-A ,L)HY6]86XD*=&,
M7Z.B-V$,:A7L2)JVHA5@O88'+@%9;$TG;(IH<,5$LXE/[?XLM9^CR^P*[L,X
MS?(R,Z?EX[3#'I K%#8MJ7/V)J92Q->P%7#'@U#Q0<X-K(L#1,;(AQEBZ6R)
M4WD+@<KTBHRF<#AU+^3>1F.#;X,YT@<TVH"W=)1'_O,*1/AH];@0G>,E>$/0
M8=%BO2P4> K5/I8>2M: ^I M[*A!K-4<@$JN91_]F<6?-,A;4K<*UMJX#YN/
M,49T7US"B).(>S7-0$0:N<3'$S._I@E- &XW+]*\^*7C'<#/ ](!Y.]6-2^X
MTF'/XY/J@(&.$+);&%[PN7SZM2\[-\U@&:V^F9M_*\W KU=)/+T$73VKH;KQ
M@<&#K"V(&[^H0$]+RC:L5_%/7^DF]*=@/J0?WNA?87'-.[+J6A.'BP\-L]@I
MO.R\CP8-4 =@9JZ]H0>O)1-Q]KDB#[!DNP+:^T-;#50*!'[OYBI&;2:^09<*
MFJ_!,/ 2TKO S/,^^$/\&H/@G#=@;MZ@3%7FJ-EQTF]R??S)+_[LO(X'WJ]P
M:47+>@POZ6=YSV(;Y_BISWP]L5$ JWX-YS0UK;T+X1!5-*?>W](-;._:_;TJ
MBT,6.>5[* '+!=4&E/_X[Q39%H6(Y]21GY6UK%?_;^ET@L,\[J)G&_[=W=^S
M%K;\LQ*0%;^PN+1^T!YS^ N%"T2-E$=.NB=M^=6H__M[(/ R-OGXJH6[!,0W
MW=/5]SO*0VUST 6H?HE'M%U$^K.#Q3J'XKE<,M?DQ=3.HMJ335</EUI4LM[V
ML1;ZB:EO?I!8N99T:I.TX5S$(5[$>$] +T K(8O:7:$G)&<DI4BY=/]M!LWN
M1G+-P%RC.Q6U(!:@OL-+Z3JR7CB?%Q^<=#;NQW@QHQ^+=A5]!'MF#$7VC:CO
MD@)' HILX!MOYDK"GU+'\!UT,J MI%S54UCO-.-++2OO"%A[7E(*<J;*>YLH
MMP1=W=;CM!/PH9AF'%.GZTYCP_D+C+[8&AE[XU/27$&%F(3>S*RZ:#;*&V)_
M!SYM?0A>SB\7SA8JHZXDC,'D%CXB_G7L29\3"A&O/[3?%.\A_'053&A!\2CL
M[T&W8Z6UX)<G&$)(Z"'H^C1U^C-7$A5SXWA04;L(AW!RCSB$_VC2_\LA$:J+
M@%>7^*H:RDKI*;<!!)PL  1,[B6:K]9B:4#]\>.=GZ[QZ/@W6Q[P_(NM7<^Y
M ?,X,AY6R^R7.PUVWV J#EST"VG/B6WUX-^"*(JO.=W!F.(QY:?B;4!V:##R
M:2'0/X<?YH:NO/$$UH$:1H51^2#F]RT@3+^K,T/1Q^;2C38!:P2="C/\-_1J
MDHJG_PHV\%40#OM!@O(K GL+ODJ_'\*WX@EZ_5A,ZO]L.&=92:&^H?GI(]T!
M?(.R/2)_FE!<;A* H>8:DY.\UEF@&M8NP]#WT*N"DG*A]TQL/9 G4\M?X4=T
M :%'ER+)7C)DAPC.#WF6</8:SB>X4LRK"5>E0NL23'*T'(<EW]ODRDO&WH &
MRVJ17DSQ]QR*#S7TAZX38KU>CX%^DGZ)3OEKG^XW4G:,/5TRC_O0HZ'XN2X1
M:T!IOI82CS.+B9ZD8HX#[3#!_31?ZV1S>X'>R1]^V%OHP0ZW!/;W]R[^]>'U
MIS=G2M72% 4SG34MVV[>H;[-)N&=N;\W]$/8!0FI,/T@/@RPC_2T-(8[F6QK
MD$-(;^.S)V08IQZ73AN+&C[$)&)RQ>*.@%<RC(Q^JO+O4B!S?\\+J:K2E#LT
M A&!^Q:TWM"7XJVTX9+XAG2NO$]8_-X(GE6MEKP\['T:<*/*.T6V!LU#0[%1
M,>,);M8_&A<8#8EYK[]!!_=9;F!D6KQ[<^9*>^QOPP^A-QSDGT?60J3B<K;E
M04<:/^\/8VB3<=FVY&9?&/9HKN<+7;21GW\KOQMT7XC?XG^F\ T>WPTL=^A-
MT?O(W8)A'!9]=MK4<PY\'/,PB.%4>["_8:1PL$%(IB\-?1'>-:KZXS@>(@+!
MA]-VF.(*PL:=P4V"7L[ V]\[4,U,R,.<IO$@( P+N5]3_SO:=Q*,GKU$;1;L
MC0D<4VS\>AI>"Y&!:L8#Z3:Y$O\$!BR&4W+J6I<"3,#9) G"_3V=/[AT!G3\
MHRKDP?>)]H/F3TSK^#__H]WN_'QH9HY(=_)/P6<NX0$_P79Q(AR\WD(?QX$W
M$U,R8)0CG>)?Z\[UM9?&XSA#]9ZG+67=_\\/%^6IP0_SY4Z3[SEP6I-I:F<>
MZ'F1*"+,50[/?<)H&YID_4<URWT?<RYAT<4/EOGBU(;[-(F4*TRB'@'>4[3S
M43108@NR)])":4^I-N<KUTS'J@Y27\\N2)B!GZE@BP\6<#0C4KC"MDYG\,+X
MI6OQ7U!$)T)1A!=GZ*49JR 55RNE80SAUCP<P35&&:/H1B<:F-PEF;MW)9W+
M* $+IGY_3^;^;'H)-PK<26KJ__(E5*[-9DL<J!F$N=33H_ 7-$CQ!N #6(@&
MA+7("\,"A3*CF'&K^'<J^'TTD.IS/!%WLW,>3[&TGJ(X<L[,PSKN4GY<W('[
M>W,;=,OROCA,DN8YA%!<,<)"2K$9%9[=(G,+]_GO$;D:;(53W)?07?[1Y2B5
MP ME;4V&G[10.9WHIJB,S5KQ"1SBN1>AVQ7_^#Y-/#^4%02Y<K0@8[IB_31%
M#1R9TEK.6S@:_=C_[OSV#^>/O\-CY$"FU]1/%6LDW:=.RZA,[)_<,[1L+G>3
M@FJE<>JN??434./C9+:5*J+2G1!;R7EA<)D*O>P/S4:SV3+YHWI*[ QC%VPP
M=D'IVI(?O73H_=OY-8S[("$N? (3?I"P]XB B/((YRC+3Q0MD"_P[ZZEXK-?
M4 =%_OGA34.)^+]\ UNX\?N@%G&YS-JV_LW-32.SSMEXV( Y43QI%O@-E=-X
MFNHK07V-T975@-.8$1FZ8S1"C(="WS!,3!%L FJR"IQ[>!C#_T%O'+GB@@PM
M)?2;U<,/;8QK[?1GYT_<4O!M\>^LP<%6)O7;/!?;Z4(7&Z9NL6OL?AQL#^U<
M4Q&<+?65P<7WP2O<ZUX4H:I Y]?+M!*+Q%9:P\(_=@__\S].>T<_LV$)AU/]
M)QBYC*U:DTWDW,DDFF/S?,V-"*6>4IRL@6CJ$RYX#'8X*N@YU1H'3Y:7=-$R
M:A109SMO75$13ZV=I(U&-7_6)M$9&F#9P&L6_!4M/5"#*+W$R: O/BYMZHTG
MH3\/OD6W[&_GGPG58V$:1)FEW&]/H$1&O\??"_O67FVVQ@)M0/"X%(ZD._<]
M8RM'%D=LJZ/,CXL AXEGJN@,^0A_PP.A084WPH[(C'+&>^%_]P?33/DM9$3H
M'N*Q?O-G%@)> WO,8RHH_I-S$+R4:<36^DGLV9XRQ04J<B !NQ!L$G0TA8SD
MQ56T'I]X,UJ-@P":%;!EWO=-3B\8MH]'5HX7 ::42]G"WCDC'XN>YX6)!WK:
M):P&KS9\"+XT](DE6GQ<0W\2QC,U.9Q'SK!G_!O*EI"7\2"X?FE["14L+L%M
MDL-+'N"J^-]I#[K*3O)P= 3K):P?_' UA>.$7BAHB< 98W_(@QJ-O  G)I=>
M9;DLAU[F<386:FNN\D'"NEP&7-8<^S- @(GX,B<,#WMI!R+RL-##%+D730!?
M46T2>)M.&2X(#,;W]'E(>?.H1(D!#_*G)RZQ7OQR;O;H&6WI!QT29_RROE>9
M[%M,!BXG_Q8R>RDI7FJ+ZWS@RCQME>E,4OJA!LP5'&IVK75R^ZY57D_YNO=V
MCY<-X?3H^'25,6Q$MU_'X@^JKY%1[@K*>G32:  QB(*Q][\8:63I,\/X)8:E
M+,>0:V=.Z4O\]?M/A^]__?C^ZUL5CT&3+J*[X!HT-H)>(8CU$/^._L'+("7_
MCP*!Z[@9>3/EY49^*;@0"/V+E %9VVY^1@=W=V0?OMM_^?M[=!=SXH!85'3X
M!#-=5*H(9*^C>^B+"2(V8E+?_^9,(ZR/E00#3G661S7%4>*C.XGH::R&#<2:
M4R05P(QZABZ:F6\XK75N<*Q)YT&K@9-!1T3T1((I2.+$[O#N;MTM/L*"G=_?
MJRJWA&Z4P15G5U8?33I+O@V]A,\YE,);-*?$:V& "/U963R$9.EQ=B4><DL^
MP'@)2U.L)R&M4ZP!>J64 Z$6ST> V-"I&FIV$]LC2(/OS@>R>A"RCG[=-_.&
MP71KP_^=<KH2&&#&[J7PJDG_,2F((PS.,MIRSF=T%JS-[@\J!K28"]T1J=9.
M0NTDU+9*J-=@P$=\Z<.]SMX?E_D()/""Y2V4KP49[3R=BJBN=LYIT2XY2C]D
M_!%6,?"AIQRQ5\F2-U<(DL(@/\5C$4:$(5-M=V2$MO;2F"%^F''5</["#$E/
MAZ "%1]"Q^]0\O2DET%*L'^0!($D(V(Y#!W&9QI@\2GO[['[A248QY(Q1&55
M%$.H @9@S3P83*:=ENK-)-JKF H=,%3LU#Y)4<#^-YS/28!2"EY4"(^6DI8\
M-[Z57CH,&)R.WQC'E.T ??RATU,TM388PIAP#><B0[0Y"+CB1Q![4/P*C2"%
MP6992)G[2S]0\NW9"7F6*EIL>7_OAUZS1M/HH%W8^DXZ[Z3S%DMGY8UEWS4!
M34#;\=AC3QG0*#C3C#66"9) 7L?A=,RGCN,B.I4<&1ZF*5.(BA\=/<IV$I56
MBXCM [JS!-6D"S,Q,=7E%$5TSDN#6*RQQJ8BGBLU-J0 K"A724@Z\)-C"I-Q
MG ]U3I4.G6L8;X54 >@X][G0/3MY7-H<.L[(%Q48M5V)52A7TE4P>42+=/T.
M[M<)90WFXBQG0X;+[7S=.ZFY)5+3,DH5U1>%13$H.@P2%#FI3VP?[/S"!\J8
M=Q-8Y4 J*<(J76,,LBI LKL(@YSZ0 V\\<1#4WHDH6:%MV=:Q<L@\T(7-+GH
M< +BAJQ6D$OC6*O4_PM](0#VD"8W5>%*D;)(_(=$=1Z%CL=(9Z%R,CG'555K
MH6^C!B7R&VUJS!:]C!/AY- !;#4BY(^Y5)@NF:^1"7=ZPL5#+U/SBFN/X\,*
M:6R9Z-QS6#TBM3)$V&,_TT%/Y#SA^T"]A-JWU$7CBI64W,HXWODAXV*$6&*E
M"\/$*L"+C8Z\,>CJ7L) ?SU]S"0A3:@(JF27IG88ON&<S?5^Y-GB6SWWJ-GD
M3R!>)F76#3W^G#Y,^ 8=:2&%.:,*R!GE*DC/-N3.6@"%ZS1W4#B"PG6:VPN%
M^RSG1"L8KG.6<Q&POG$EA14_L\-@%V7?:1[;HGG\9?$@6PXIKW0*/'T*Q&UF
MC")*,I:,T$D0QO3O23R5&/C"Y%"37$L*0YZ\BLD,T S2'3,0H3RDC.! 0G A
MK 7*(5^A4) =F$O^6F'@]H?Q<U=^.#$N*6;!Q#2&PWAT.(D'W\B@385&3(W'
M^"43_])+R.3[LY *H3-B+F,&TUEZA.ZO[ET>0,4W;V3,2(-$-:!$%1.IJPB<
MMG]4&A;7E54]1=5'5I ]B!+ZU7J(=PV=3O76R<__) DPCX3PKJ!L3N* \;(4
M!>'L8])#115&^"RB[+%HAI4':J^*+'F%D=TZ7:3WD/X\+(ZZYW;@ULXY@VFH
MX@8>%C6<8%BM&JG"N9FE(6V((K0>=)K"*'Y <.+NTMQ=FEMR:9ZE5'9[D001
M\QR$TL!7M(K75+PO)UO:(%@RR5L+3'I]#N;]ES:*4W]_+_\TQ9I+Y;VZ5'2,
M#3;ZMD;XEP Y1,K #EBLX)%/IS6R2R+4#*55$2VY30-E@O.0\X544^73]3C,
ME!E$KBX23_W4G-.J=:;T0!.?8GT6\%NB,!@G&DR1PUHDO%!G6!./914T;-IS
MKF;])%!L 8285DM#Q"!465$CI>FI_3V;\\.'RU]2I#$N-\."641I-31ES'/K
M'CM(=*(RRS1F>QH%1*X)5Y$& X0SX[Y!/H1\/_C;N7VD8-IZG]S0;D"<,TTH
M\?C%W#NDZ.*?;S2!E;CI1XS3LG85I;JJKN24I+]#VV<#+@/&M6&@(P=_/_N0
MOF0:B4N- <G#)PWTL2+7CQ@2$#_^DS.=($,X[(07O[P.XL/WEU&0^;K>2I!R
M.%64,)TV(%X.Y:Y)9_ E!F+F*+"0&CR[\06+PH2^<@TKDDZ:N#3FB5;UR_;W
M*M)456(V,XM;VI47TKKQ3H4>^[ SXC$3WD#GT2E%W/NJ&L@ST />1Z/$0WXR
MXI/9Z0$[/6!+]("__!QD%0PKA?NNSK<ID&NI=X=6\I9VSOY5%, H9HM9,142
MM@2D[4^#L&:G^@BYMR,*J1V1M(Q+$'PC+AKAA?Q%[13 _\ [B-S9VO],I!JB
MC"B<+8C,\#"#U>%GE42T+U!L#,?=R-T:@SB,DY^</I80?/$+7?HT.0SP50EQ
M.3B'*"$4G&UA5=;J.X#ZQU>P"<#@N-&9@?=H-2F22IZCYMND>UDH/Z.&D:8V
M&J';W@"/6:72?1";'/4I&)23Q"&I,9XSI+H&,2<T"%,3JS5,)2GA$)74IEWP
M)JW-LY$IA<>AD_QDHZ(:YE;>2E^8!#M.9KL;:7<C;<F-=)9:K!.4C6LA_ZRT
MW%(J+DJ&(!,@C>+A][!P0G9H7NQC(%$)V#2;#@E'Z",+"6G!Q+N;?B,.^F@(
MM@Z1]V. =.!3O2=J3^6GPR\5M%/D7Z-2+IB)?DAIR';:>7P);TPC+,N1,BN2
MIVBT\"<V13FU/V68CY=^$W^DXKHU'+VEEFU>/'J;[4RN825^Q8IY(&HAF+?(
M+Q2WJWC6M:M/Z$H]5@:*SF)E7F9=M4^8GY!,B\O&@-$<B/%M\\(ISA&8_ZMX
MB-<'UW+VA%#8&('&]^\IG215U>;ZZ"G@>C@%XB35%YY8RH[)[1,['9@F0CBM
M:6])&0M3THLSYLA2XVFP4*=F]VKB4-%+-(E2.NV;G4MD?&R;D[KBBU48<$DD
M'W&Y5=)I$P/0K5T F@/0K>T-0/^M_XMPYF\O%4N1)-"2'\K5* Z6@QQ78HX<
M\:7B0(3^M)SQY2O0?> ?E31].2\FJ.PEC7T>@^/\SU=P,TI_[DC)Z/SYX<(Y
M8&(OZ/JW*+Y![A?H:>:,0B^]8B*J43C%?WU9F[R1+P5]JU6-1R9=QUU3.'<@
MEOVQ)JP8@[7!'E;MO<&^X<,6(:P8-A&BE<3+A;*;JZ(17[5G<4+W8[PLW^G2
MO6.?9'1J;DR2X3><O<G6:9]S&7!G,@LKT_G3LAU\?'/VD@ECT=HAYCJIR",+
MTVST9+=H3A,9NG6M*M1P9485-87%^S#=#&=21ZCUE<<P9?][0.208M$JJ-YG
MHK'L.%_>?O[][<?W%[]Q42-J5A&,FM)B.;(B5>T)^J=KVT*7CMQ"56#+WK1O
M7T]70_9SU0NLNIPY.B0!-I-*0C4:$'-<*,4D=7QSF@X!$G&=N("QJ)](_%*Q
M,J!-C*2ZF:@/,K>&7-2UP-:Z@W.:LU0I; 5S:YB-3J&P<R5F: /] 3J9\\[W
MG3-L'Z0<TLM1F#UU-0@1C@UL\>PJY6)/ Q]:L+JXE7Q'=EA>#DDLM+E.2\H?
M*T&C*HA*("4VOJM;D/5L,$6/\OY7,/2PQT]!7BWD+%% *6&PC*M',US?/U-/
M/6*>1>0[Q BFW9,\%UNY]3_1Y <9"V;T_:$!2115,'FXG3^]?O7KOSZ*+S%U
MK0ADB%(![Q9))634LX>)"H8GS.6B >2X$ULKL;:?@C/;3"3*(+2748*)JR"U
MR'S3?N-1CM1ZA)JNN%MY.[,EM3A.'2BAP(B:G'6HC%O;"<U1V)+/6F)Y5DS5
M3[@7*6.);ZA( DX6%=N1ZYC(:S%AAJM0ZK"IRDTW3!&B LRAH*ADB@APT6>Q
M*EP9?.=;0!+2^V$\^+:5^W\.(FY_KRXD3NTJ=2^8&\&]-4Q.=\+@Y=:/BJL"
MB"G2^/RQ.#DI .+DKE@=#T?)M<ZBW-K]O5LGUXK4GI];6Y' 6Y$ NZ3]VZ;6
M.O,S:ZV&8:?,87G1F;7+@'W719S,J=M:$=BGL0!U@7T/>( ?2VK8/D3F[)9J
MOR#/RY%-E6C/A3ZTZF.4)0'26-DLU11;$O!45%O[>]5<6U32QE@[6CC!/ZFT
MA@+?+F F2I4QPO)AF$]'PJ-!&3]EAA-_3+>>4&&#*87N $:L\D6BJX'C]H??
M,7%?R6 N=X,V84CV.1QU+"R?49% Q1P"&Q-/A3H O\4W.*%NL9!S>9K5&-5D
MHQL=Y"#7+8YU"5$ETSTL?6!6A.NH@%0V_*9:+,O8L99@BJ7H8.?PI0%[(B2G
MB'+PXAY!8X'IM%<AG#%CYN^.J(A"'<*9#Q?U"6><(M_,_EX=PADE;<]"E%HP
M,LWH0G'<=(R0,,0Y(4;N4O<;N\9[HY*71EU JQ'3V,.E8A(V+\T6*_-_J=UH
M![W49E;.#AUZ*<:Y.!BF2NR,T"7D)[EZ7_ 4U;D7D^WP.LB2&-.]5>$N%7O!
MG7,5WSCX/U6L@8(=/N$=-969\B92:4S38NIG&MS^[ZDGI7BIW@C5R4Q3VHA+
M0T!6GTF'\J5<7.BKQ(U<&,4$>,PD!6QWJ$G:%,KZ3GL7)N$P27NKPR2Z<O#V
M!DI4,1H2]575:!:6VUE40*=<><4NBJ.F=G_/+ICDW+U>4HT*28XID$3%T.95
M2-*5.*1(I%4V$F7C=,*)QT27-/.]I$;Q*E- B2=\*R]"704))V(0PIW!Y>*M
MJ< 9LG14$P+"&$<VLPO9?SQ_JZCBQ3]&FA=.N'C)%:9*[U2\L4QQ&/*^?R8Z
MJW,A>5%ABL\>U7?^ZB=CYPN".:1X(+KHH>G6Z4G7-57N3:2,T&M>-K@Z_,O[
MCN[/,R2K,M6?<'2PG0^QDPXBY@[3*V]B(/NRP?+[F4)SYW]:AT-M*+Q3$6ZG
MG>!P$/&T^%@7#+V\KJD47G&:L&Q#Z_0PHL*G5CP.)BB06JR$.M'#^TA3 8]4
ME%O'%7E[X5:?4/KY[=L&_(\F(3+G0*@78"Y MC !6<2L!:R ZNJ17EB8)5,M
M\:)Z;%4;B-> @V9JU$&DFLC+&AR[KJ73#R*MCL 8.92)CG 5UD0[9$(T04PY
M@:\YE^%T$ \P(6 0!T.,&/FH_GI982Q$'RUP1TF$A-DT7E\%:R+5I]<RGEH$
M\5#&P"")B1L($9RZ=J;"NM(&,=Z9]I%[?-IU!K-!R&$%L)WB%.3@=HL=*9[$
MA5%$U4S\L2V.*4#L7&%"3#C*%9['3$J8*:^J. :VA(&^,/CF2T#>7ET.KG\Z
MQXQ^U1>]KU2 <^@%R!2>+U:*"<1$7ZPQVF;+\%X"H3#"Z'"[!2W,4JZ:[KO6
M8'B$J?GTB$J\P\5%;[B<N=6?634J/!&>Z&+V_:%X,S$6Y!P$#;_!<<EAXMUX
MX:L4/013]#FIAU^J%*RQCW*+:GU=T0DYU'-//C83)VZW7AT?T@""Z!5,N9N[
M2=F?B8*WHS;M 9Y4%*,O+?DJIDPJDZG$J.9F)TQY2>! 8WC6<#>\?2M]A]L)
M-MY0M>B0JP [T&LZ0OG^"KKKJ!=;'?I/Q0;/8DZB'&9WP8'%$ WM/7$9Y#[
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MSR+!JKQTU5QDPU^L1V54>MI:]K01!8]J&\:"S'/__>+H1=5WE"^DX%YYC5R
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M*TBVD>_G*JKM[R$94.*/D"D.5TY(%/&LS>@/,) IE5@%<0 ;R_]N,2<RWZW
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MBO%^?P_):-,KC]TZYW QPLFZP$"\B^6L@P%[;H)P"B?5)6;"@Q^:C5;G)?U
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MI'@?X;<.X,D;#_9-\I+D';GT^>[T$HQ^"'8+M1QH;4C#(P=/L-(849!Z@ZO
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MMU.'^22)!(/\O8_"W?)DJ0M&T=O@O71@:;GPQ-NQGU"NT'M\-(6;)OV&M_S
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M ,P<2M=7_7@XDVUQE8U#^-?_#U!+ P04    "  I@FA/)=3A8+06   7V0
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MMLCU!3B$$;AH@:'*-2CQYB*4Y+SUXN#:Q?.B*SV^S"I4=[UBCF2@A@.V]J[
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MDP=BP+S E*E[(_!+L1Y;31,[>V)=K4#86'%'NY1 )@E3GBO=WUJ J5@%S9^
M2P-,#[5#KD9@#48,[VCC^$7?'I[LATHH#;YV.N9K]:'0X*.]5\)=;I4.!36<
M?6(.'N'%#Q+";$S@_@7/^><8235S?_Y /N(Q-8_C-5WSI;]4O@TX.V$B0WTK
M&HHB0S_V?&LS<=LL&28_K&E3$R3H?-^N9A!Z>:'9Q_",W[$8KY:BJ;!&;(Y?
M2''%)E[5#,M2WQ#!+=X*1FPMJ]$VU/%5:U=NZ>XYX>Z8V"6K0-=0A($QBI;I
M&$+:5A55-W;5-DP3.+*2><4P^7;%MKAV$#75\5)BN R_%BA'S/.%^EPT?J3_
M'CF0GUS7DJV48E:C;RKDF%58!+ZJKZ(#)H $,>+4!\," LM&V_LU:2SP0$='
M3#(JS(6Z\N6.V>XJ:5]W$34>W!1<'9E#$Y4VE7V\@"4T[LF,2*ZXP1F1!*_I
MC$A11>T9D?#N[!%3+XW4)G'W4M#[H8/[P_HNW29TJE V=O7J\RG8)]MU!<8
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M6PY%/@AW/F4BN>X,.C*. (/ON@6GI4'JA7R,WB=()3\E+1W_HNP:\.>X-[,
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M$C$"@?51LZ<6V02QZ+_!BL7BQ*%44F\MW*GQ2XF#09,Q4_FE1<U6*"_W7,(
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M85> DQIO8##?L=JU#DOG6+[Z6+ZZ-5B9;(T87[X:V,D2 L1&1K;1[-SX<M0
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M L2R6J, D;!6#<O[V)]*OV !@-JE-]*LHOETZ3ZZ#J+GT";6K_3'_E3:!0L
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M K7PNUHU6,Y7D.#B#C_BM,(WV' M3"[KU-'2P>VY5S)!,*S2H9-$D:%B7?[
MFB)619FMQ[KO1BVG%LRN"CT#IE<!PS0[G(+YJK4\N.]\3*_?7XSPQ"P5W=U[
M'E.1[3UH&RWO[!H-5;@GS>Y&M\HRGAWT0-45^0R[D,Q.SV&V7OMJ=/+TFI5@
M,&P$4C$W;Y5[Y)?4[-Y.YSA_C$,R]&M)-D+9W9W*L17:WK.TU83!N;%P+8?.
M6S1%31E.QE%Y/>(DN0W"+[OP3Z+JF7W*RABX)^A!9IX*K' .HQ9$I^AC\(]L
M:_Q<\FM"?HCY)SG#^0H;1M/Q9?AEG$7U]-33% "8@V;4PK;F4,,K*\^#/(K3
M(/D)!TGYL ,EU07XY:.I8GHRJK0!,]$ 61B+:W'$Y?=.POUE1,&_5J22EX\T
M)+Y^?UTI[3H;B@;R,!>*1-0[R>SPR5)9<&G$Q"'NIO?J8]A#E\IZ9))NOUPB
M")5%ABVH 8=\W$3]T^U'4KL@/7\("DWP0'M=OW=1-=717T:5*'HGU2YH+:^C
M_ND6\1(0*V(?)JMH;%:!P^]6V>/W$8ZYN2)_&%HI\M/?S[-'G$_N"S*FA^6@
MZI+G+HBEA$7)(SST3A 5(G$7\I&E0Z^E]C)"C6[NBRRLUO7(*JE'_[&KQI:!
M:MJZ^PQ$4TL "9D':A'FCWAI9C+E2R,*X2H)5I)*#)Z[:F@IK*:E>P]!-+4,
MD61RS640%?+;V!>XS>RFJTU/S'G32T *#.C(P"*""$S-AXZL5U-_AU=Q44_9
MYV50,M]#8]@4\JX' RWLX>@@%09!'1N$RO&CJX1:+:]LFJ1I%21W>)/E.A+U
MQ5QS1P9R2)FN#"BF2( I"<)E$1?VRHN_5$%>XCQY,5)#D'3-#@74(4$&8J X
M(L>FI$DK#H$I[/Y>S,X-F*@BBCJ?DBC "M.3@1PHMBC J:<MK3P$OLP?<)+0
M4!E!:C8N,F'7G%$#'K)&E 3%&R4\)7.8!JI5H)&'K>]>$"?*LLH=>9\4$F#K
M6-0*@R72$*$EE_CB/-7SRJ=;G,=91%SQW,0D0=(UAQ10A^P9B('BC1R;DC%<
M'#%Y*%2Y3",KHK1R?F@R@"DG22T$D")]9":"$&G_]+B*BS!(.*(K\MOPB(%!
MUC5-E'"'5!$$0=%%A4Y)&:[0,(>I *#-+SC([4C3D?1#&0&JG#"M&$"Z#+&9
MR$+E/5+EO,KS'G;U&*06=;;1:P#;[ODJY$#0Q0!./)7.Q'MT\3HF7;)H-U=Q
M@F\JR>$3N8@KAJC -<P8/@?!" 6H(1.X&*)RB MZ;/]FMR$M:5Q<9:6&8FYY
M( ?9YT)?!A ?I, 4G-C*LC#%'GEQCNF)WV2:1OCYS_A%63M!SBTS%##[U!@(
M >*&')F"'+4P8M*(B'ND!\VR'.0O\S@T#!ZBH%N"J(#V&3*4 D01!30%1VII
M-)^>^Q];%L'S-"*DC9=QR+:S#5Q1RKNEC %VGSD*84 $TB-4\(@HH;Z6?SI-
MTS#+-UGG.,5Y5A&3^'*>16K/Q:#EEEI65>@33*L"B&8V.!5DZZF>\#,O-.E<
M70"B)7CDW22*R.<JZO]<QRE^J_P*4EFW'-/ [3-+(@B(3VIT"A;5DB?-'Q#5
M0;,4%G7>C:CP.__4>6=+G7>@J?-N%^HLGC)0U'D_HL+O_5/GO2UUWH.FSON=
MJ$.#Z_@GSSGYXRQ?9$^RH^%*22_$$:%*:;,5@T<: 9N),E2!^CE4Q3]9F-LU
MRV_S[#%.0[5#K1+W0AL%:"EW!K+P""0':&)1ZRXW>OZI5#ONQ@[3B/FQ.'V0
M<G/#9>!1I0_,:&BXM']BW&9%&23_;[S13MGEPEY((@4LI4I/$AYA9/!,M.$Z
MB"CYFX+7U*4;(](+;H/G[JXJ2V!MKRIW'H*@@@R1>%69K[9P(3^-3?F:XT!A
M'?J/G36U!%3;TIUG,!I:!"2T,^OC1,9?I[[.Z'FLARQ5'ST015RUMPI<T^;#
MYR#:70%JV/9,##$YK^OYSR5."[E![SQS-N(/X;0#?/, 1!L/T0C#=_/<2YO^
MG,<E>?]YMEY7:;UG)#NIJ)!SU=9:F$V[2X5 <$"';,B'6A;UA;V08YXE<<@B
MX7PDD]4\#F1UDPFYHH4:8,,)40($(92PA)A7K2!J)+U0X3:GR;37F#0'NZ:(
M:9BDV7(I]0)TPJZH80;<4$0M"8(J1GA"0-L<GX8=#<15$-.!0)YI450X'T4A
MB8HG(BG!*^@DR$,DE0JDD5I<T3_#YCBLR+CY\O;=_2(N$]DT5!1Q-DHIP+5C
MU. Y"(8H0 GY*.@SE"W1VW??W'^+&BTO)+C)%GD0D:%R_K*^SQ)%/"VIE"LJ
M:" V;)"(@""$&M>0$S<9JD41E_47;ZL'65*IP7-7-)#":@C0>PBBZ66(!$/0
M:W&O@\#E<_A H&'%U0BYF.O!0 9R."!T94 000-,F+C4HJB1]7<U8CN4K<S.
MP<J;<[ R. <KB,[!RM8Y6'EV#IJ7\T GQ%+-[I-X%2@",&JE75-# WG($HDH
M*,*H\2GM1ZN"MCI^8G>R &[3=)GE:X;BBOQ!4E>%G+/HG3J8;?A.F1 (INB0
M"0$\>4B]CC"BTG[8445QB2,.Z2I.@S2,@Z0-!"E;4S>K...,)?B6/@9Y&$RR
M RF0BJLU\1I;Q6U03S^+\?R8Q\\X2?Z<9D_I' =%EN*(K\#(]IWT\F[/Y1A@
M]X_F*(1!D,H&H>* #E4Z_4*U4*-6KY]YY-/G+*G2,LC9_?=<9J44<F[YHX#9
MY\U "!!?Y,@4/&F%$9?V>9V<1[]H73!J J6!;/3BCB^7:T$/[IA+90$Q1PM0
M=>.\CEFR]9RYEM=+H"6FF33B1WP1E$&-4%EKE;CK:Y\ZT,/[GC)90$32 E3>
M\&QU:,";H&&6Y\ W^3EQQ%:9YJ3Z0,I]^!L!HA@!IQ4!1!(9+DT<G!PULAX9
M,5\'27)6%7&*"_70-)!RRP@IQ#XC>B* &"'#I6 $$T6-K$=&7*YQOB+#WH]Y
M]E0^U%%IE3542+MEB!9RGRE244",T>%3,*=105RG"23LDT+/V\#J/)ZDNKX2
M4<?D48(=,$>0@T0;%3B!,PD.Z?K,35:B188^%1B5#QBQ8[01^;T3$9^7XS<'
M2QC2"QK<<T^C()<122?L/!^+$K"0E460!$$G(SQUAI96 S4J7K@S(WS.NS,^
M!F5:XK7RWH59Q16/;,$W;#+)@^"4)<@ALYA:?QK.%!'5]!^9J1OJ7^T ]H0<
M^\T2@ .WN2,!@BE*6"JGN9LYP6=DP.H^B<.K) O4JS(]&<?Q $5X@U" 6P%
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M4?^'CB2/L3G<5+A\#I.*1GXD?V WF.Z(:;A<+K%RZ=(U")?=R,\'[B4><(H
M5G?V4O>A2?BF4?V69L%F?Z)[$M1*? 5&X!!?_HBZZ-Y[',BTAGNHD+"+0:1.
MT'V;V)#&T#(FN?K788&/]):FC#![J9"<!YA>%K!A@,M3+24FW[*D6:.4YRFZ
M(FY/JXC@^B=3ML_!K'!)0(EW/+D(VA"9 QU*KH^HLC!M9$99D?>109[><XG.
MJO(F*W_!LD8?J>OL,/+8ZK0'D6T5O?-G%[22(" 5O;)9WU(ZD@/(LWP5I'7H
MDO,L+;(DCMA?B*F])5^ 6-9^))0@::.BFPZ,[*ELI_&5]ODY>B&8]E&P]WYR
MB-H(-Z [99^@7NELE[9;/AW1VS>@[2O 1>B_":@]F2WK&V.D4JKE(8F@TT4Y
M)=#>XIL@!8::2FC".MIL<8G>HG__[7^]>_OVCVCQTR4ZGWV\G=S\<B"OX"(N
MPB0K"#HREN!W9T$1%[-EE\[,O26#0YF\\%PS]75LFJDFSU+RQU!K> _W&F>^
MQ@$_4NN6'. =WNE_X(J),89+C-XA]@8T6_:-,GD):M[2)$W:O@?U7W2@SO::
MNB_P<WF6B"=L]EFPLPZUUP_1=J&]E JCT^RS*M(QYET[QIQ-YM,YFEVAV[O+
M^>7-8K*8SF[0Y.8"W5V>D[]?_X*F\_FGRPLT.3^??;IA5VAO[V8WY,_GEQ^)
M!)!CMYWO09RST")MD$;!:<1*(_!>O$JEM'?J6D-41'AAAKC6 .<MS^-5&B_C
MD%Y=$^JGLLYCE9V&AAY5H5ZH:"M-,'0<!5=J+=^WUG+^Z>/'R=TOU%[.IS_>
M3*^FYY.;1<\TSJZGYV#N(K31X[9NF#&2JD;#[6*O$7I_[5<I#H:)9HS*Z']H
MJP+.-$JJ93*(>A7/--,:/YT\9*)9&;K?M8:.ADNY6<SN7KWPL*_4='6\=7I@
MLPXD'/\3TX4]NF="G&,>I)W=#[>V=:\NU6T"O+U\@G[.O%<5"8;N^ZF'F)FO
M/O7+BCU!G8)/4%WT"5O^Y0$R>?&0#;48\=-DI[4:SI-,Z*$+V27DXF!8:\8H
MM='_V=KHV>*GRSMT_NGN[I+ZH//Y)92YN#+2A\$@6^@YOH=C5XW!#1R]$A@"
MVB*5W+IA>L0*4DUF EM=<$9/64M[;W5<$2 8:NG-CM&'S]N1WN[O6TMZ-?TK
M7>!D%O0$W5PN8%#WQRR+GN(D(74<AO6R]G%'EN&2O#M5KY<?;TP!8.B["^HA
M?YLRF.W=EG($/JA5[4T&>6PAX%BM-<KC2C@N7EL9YC]TEB$6DYL?IV?7E[#\
M6QZ)OB!591' @\2TV:35<'RSUP1]<+E7)0Z&>&:,DKN]3(.9ST8'G*D<I$>H
M8\UW@M(W"QN=G[8]K9Y9FDSIOE_B8>=TSQ](LMNZIS> Z3$'J9;4E/^78K7B
M>CHYFUX#BMI%+V2/6#B6"[M=#]8![B_SRB3!D%$+3UR4O2\AN[?=^_TFTZN0
M=4DB+=PNAZ2"8"BD0R<U2Q]:LW1Q>::=[1_PXU\&.;T$2*_<LE35NCZLDG5\
M9<XBS9,1Z;!!&@5$-!!3 =>KAW4R]6R-O,O>;82M8QB\7FY"*#]-_Z;MZC>7
MQ.^8S>?HEC@B\Y\F=Y= V/5K%9<O!I=C*.241U* /?+T). P1@9+L#],")S-
M89'Z'K(DPGG!(=(#[O9K9"/TG1X['%NMWLE#6V4P#!R+6&[#ME>"YHO9^9]_
MFEU?7-[-V6]_^".Z_,NGZ0+(09UI&F9KO B>1QPXU&@XSH5@@CY(@Z 2!\,^
M,T;QP"'50$0%\BQ+4B_SB4.=BF>>&4X<JN4A,\W.M+WKK/6?SSY>HL7DKU#6
MA.YP0@/\W09Y^;+(@[2@@<RRU+36;U9S&V#1KA+]&(MZ'3"TLP0JAEAD:HCI
MH:XB.%.GJJ&]Y1M5 @1F6MK%$>K@^3K6:FYOI-Q=7D\6EQ?H=G('9S']+BZ^
MT#V$3X0#>1G$J44J%X..4V+:P.]14:< AWP6* 5+2778-FE/"YR9/*>MFI8\
MO (%;6\?[52=QN8;49E>\#4+/3!L' %6;@.WEU7./LVG-Y?S.3J?W= [RW?L
M$C,06TCS+L0E#V"01J36]/HA3L/>EJK!-HXLPRU7=ZA>G[0C"@#$WO&HA2"
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M_O1KHZ8T]$2*0TUY)Z@M$35%TI#W,.Q->Y>!'KXBL[&()E95F1J5L-N ]CK
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M5C7&\BK+?WX@M:%,)K:WS./[BA1"AG1=$O-1ZNY<KO&5VCI@]KK>2;8C8/V
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M>8ZCN+P*0K;\6-^5.\OR/'NB)QB"#7DB1#?9K0B7-FR7RO58.D(?C'7: ;1
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MP=.=/]**W8IGP'P^,BX"0GX6J>)-7T7!B?162W[2C -$*-?\=L @(8$GK$C
M  .-#! :2&Q3]/V3NS*!&?MIZW$F1Z-Q-* M3/&0$>IRNM#U'1-(8H8A@V\/
M?$VSG4CC-RO+_58>X<=CY%]WC.D:8D_T/7W/MONMSZ1CE4W(3T:OLG,^$:6K
MM&0V!+ P8$QETRD<(( D@%! 8 $+#.]N.!Q /&936PQ%"2A,E^#AV&2Q\WPH
M-EP,IF(?T\<[2[]4+P^K](A^K@%!C6C:CJXN@@U(*#IRT80BN;%K? ;_OM,.
M;6%)P.0G57! XP$!:/J^W9[W^>R%7:;_MM1Q-(\UY<O.>J(>^B 2_.(&D1I>
M[HN'85F>:2"ZA'#DM(HX9X.0$.6NH Y/JD)\GD[__MAOHL?N2^QXNBCP#86/
MK4UF7!C4VDFDVI^S<5BX//YOL($%#G-R1HWC3V.&PZ'YW"[?*.TR/;NMDJ,Y
M<-QPYZ][P")^R!ZQTLY]PIJ?6"!!XUVFT_GJR5Z*FKK_GEP1;NX[];8*$WX]
M*;^=U#-74_?$X37NZD8-+Y%UC 6F3V;F6+]((:I3(^CG;\H;_\)9*"^AR/!H
MR$[:""$@L2Y""!D)&"F)CNMX)'<3)V#KK.5\^[JO9$9\W+23R>Z=CN)X$50:
M_!\@]QO[&%$>:]N?%OPW_EE_XC]P)L"__ ]02P,$%     @ *8)H3]7O5Z9A
M3   O[X$ !4   !T>&UD+3(P,3DP.3,P7W!R92YX;6SM?6USXS:VYO>MVO_
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M0YGKS,.X!PVU$#,Q'O91IIEU!2 *I;(SCV G5!Y!TI6RNO1V);$6D7%HFYX
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M2?;JF]>C)1M63EG#.;M:Y;>Z4Q5"8U4W/:<O7^+QO&PNF\[)T).&KWGJQB*
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M1[]OZL!RC%O,&8MOY6\P^5';S3:8^7?>MI?MQ+$&V%TL$IH&EV6U*19S#&-
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M;U6.@B@U2 =9'$#HD4I 6;%Y!PF I%LR],<VB""4&A/7,C2I,3>L%0IHCVD
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MMZ?F7[4YBT,;S6E?/KK:+.5GF^PQH%[D%[G V2M!Y*?UCFV:9O[K++XD>X/
M%[201C79G"!"OEMJCIL=BVMV:I&[Q_*1+F^34[)Z1'B$GMF?9$>=0'F;4TRH
M5MEZ&%G"Z_9,ZHX,)(BN):F^H%//BH3-N2>4W"EPL(0M?@O[[(89:MX)J^(V
MIZ-HV ?Y"%FXV>V[>'G_2! AV[K<L39!'J)(".91F8#-R2FDTZ4:A:XVMFA!
MGT2/D]>-?[/G^P$%C";"8*J(MKL@49LS4<AWP1K(=$0.<WG4_,[#B(91>$ON
MP,<"*)1B-J>>D)("1:33O>7:&;710[HGY)2V.:L$8"\GM)^#NIDGD9C[MWB[
M]29P'VCBBP#A?ASA *?C>?YV*YDLI:^W?E=]'8E5NWYWU0FW%3M>7K,3S]D[
MK?-U_78\ODKZ"0U9I!NQGN<EA$*L?A1)*F0R+H J@^A(X":4TYP-23R H+SA
MF"H )]73?ZGA78UX^4?)*('"$'DIT;.XK7K-?7B2C1)R&=/!3!K( ZSI?@%
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M.,LI5BZC/31*:C+\!@ETFH<-@DK$[."[YWEQ%J7XSGVE _WNKJ6?)10WR9D
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MT/]Z(.L,\LO_!U!+ 0(4 Q0    ( "F":$]#>X]'O)@  /&.!0 *
M      "  0    !E>#$P+3$N:'1M4$L! A0#%     @ *8)H3R_E@?[?K0
MFUH%  H              ( !Y)@  &5X,3 M,BYH=&U02P$"% ,4    "  I
M@FA/OCO3!0((   T,0  "@              @ 'K1@$ 97@S,2TQ+FAT;5!+
M 0(4 Q0    ( "F":$^H5\.1[ <  /\O   *              "  15/ 0!E
M>#,Q+3(N:'1M4$L! A0#%     @ *8)H3VX*!"56!0  S1@   H
M     ( !*5<! &5X,S(M,2YH=&U02P$"% ,4    "  I@FA//1"%FH<%  "+
M&   "@              @ &G7 $ 97@S,BTR+FAT;5!+ 0(4 Q0    ( "F"
M:$_+Y6AQT)(! />(#@ 3              "  59B 0!T>&UD+3$P<5\P.3,P
M,3DN:'1M4$L! A0#%     @ *8)H3R74X6"T%@  %]D  !$
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L '1X;60M,C Q.3 Y,S!?<')E+GAM;%!+!08     #  , -P"   7' 0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "txmd-10q_093019.htm": {
   "axisCustom": 2,
   "axisStandard": 18,
   "contextCount": 229,
   "dts": {
    "calculationLink": {
     "local": [
      "txmd-20190930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "txmd-20190930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "txmd-10q_093019.htm"
     ]
    },
    "labelLink": {
     "local": [
      "txmd-20190930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "txmd-20190930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "txmd-20190930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd"
     ]
    }
   },
   "elementCount": 513,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 57,
    "http://therapeuticsmd.com/20190930": 6,
    "http://xbrl.sec.gov/dei/2019-01-31": 6,
    "total": 69
   },
   "keyCustom": 62,
   "keyStandard": 317,
   "memberCustom": 53,
   "memberStandard": 26,
   "nsprefix": "txmd",
   "nsuri": "http://therapeuticsmd.com/20190930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://therapeuticsmd.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - NOTE 4 \u2013 INVENTORY",
     "role": "http://therapeuticsmd.com/role/Note4Inventory",
     "shortName": "NOTE 4 \u2013 INVENTORY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssets",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNet",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssets",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - NOTE 8 \u2013 OTHER CURRENT LIABILITIES",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities",
     "shortName": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - NOTE 9 \u2013 DEBT",
     "role": "http://therapeuticsmd.com/role/Note9Debt",
     "shortName": "NOTE 9 \u2013 DEBT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShare",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquity",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - NOTE 12 \u2013 INCOME TAXES",
     "role": "http://therapeuticsmd.com/role/Note12IncomeTaxes",
     "shortName": "NOTE 12 \u2013 INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - NOTE 13 \u2013 RELATED PARTIES",
     "role": "http://therapeuticsmd.com/role/Note13RelatedParties",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEETS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - NOTE 14 \u2013 BUSINESS CONCENTRATIONS",
     "role": "http://therapeuticsmd.com/role/Note14BusinessConcentrations",
     "shortName": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEvents",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueOfFinancialInstrumentsPolicy",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - NOTE 4 \u2013 INVENTORY (Tables)",
     "role": "http://therapeuticsmd.com/role/Note4InventoryTables",
     "shortName": "NOTE 4 \u2013 INVENTORY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables",
     "shortName": "NOTE 5 \u2013 OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS (Tables)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsTables",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - NOTE 8 \u2013 OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables",
     "shortName": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - NOTE 9 \u2013 DEBT (Tables)",
     "role": "http://therapeuticsmd.com/role/Note9DebtTables",
     "shortName": "NOTE 9 \u2013 DEBT (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "role": "http://therapeuticsmd.com/role/Note10NetLossPerShareTables",
     "shortName": "NOTE 10 \u2013 NET LOSS PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityTables",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative",
     "shortName": "NOTE 1 \u2013 THE COMPANY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
     "shortName": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details",
     "shortName": "The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueRecognitionPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30_custom_PrescriptionVitaminsMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Inventory consists of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails",
     "shortName": "Inventory consists of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoods",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Other current assets consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails",
     "shortName": "Other current assets consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaidSalesAndMarketingCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Fixed assets, net consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails",
     "shortName": "Fixed assets, net consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
     "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative",
     "shortName": "NOTE 6 \u2013 FIXED ASSETS, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
     "shortName": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)",
     "role": "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails",
     "shortName": "Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - NOTE 7 \u2013 INTANGIBLE ASSETS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative",
     "shortName": "NOTE 7 \u2013 INTANGIBLE ASSETS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Other current liabilities consist of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
     "shortName": "Other current liabilities consist of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure -  As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)",
     "role": "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
     "shortName": "As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-04-232019-04-24",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaymentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - NOTE 9 \u2013 DEBT (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative",
     "shortName": "NOTE 9 \u2013 DEBT (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-04-232019-04-24",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:PrepaymentFeePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)",
     "role": "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details",
     "shortName": "The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)",
     "role": "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
     "shortName": "The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)",
     "role": "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
     "shortName": "A summary of activity under the 2009, 2012 and 2019 Plans and related information follows: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-012019-09-30_us-gaap_EmployeeStockOptionMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2017-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2018-01-012018-03-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
     "shortName": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "INF",
      "lang": null,
      "name": "txmd:NumberOfStockOptionsExercisedInCashlessExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative",
     "shortName": "NOTE 13 \u2013 RELATED PARTIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-07-012019-09-30_srt_AffiliatedEntityMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - NOTE 14 \u2013 BUSINESS CONCENTRATIONS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative",
     "shortName": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:ConcentrationRiskDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "txmd:NumberOfVendors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000053 - Disclosure - Supplemental lease information (Details)",
     "role": "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails",
     "shortName": "Supplemental lease information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "txmd:ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000054 - Disclosure - The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "role": "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
     "shortName": "The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet: (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2013-06-292013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000055 - Disclosure - NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2013-06-292013-07-01",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:CapitalLeaseObligationsTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "AsOf2018-08-01",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssuedPricePerShare",
      "reportCount": 1,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000056 - Disclosure - NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
     "shortName": "NOTE 16 \u2013 SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2018-07-282018-08-01_custom_UnderwritingAgreementJPMorganChaseMember",
      "decimals": "INF",
      "lang": null,
      "name": "txmd:UnderwritersOptionGrantedInPeriodShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OtherNoncashExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - NOTE 1 \u2013 THE COMPANY",
     "role": "http://therapeuticsmd.com/role/Note1Company",
     "shortName": "NOTE 1 \u2013 THE COMPANY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "role": "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements",
     "shortName": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "txmd:BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies",
     "shortName": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "txmd-10q_093019.htm",
      "contextRef": "From2019-01-01to2019-09-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 81,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The start date of the period covered in the document, in CCYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r177",
      "r243",
      "r244",
      "r287"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r112",
      "r172",
      "r174",
      "r282",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AccruedIntellectualLicenseFee": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid for intellectual license fee, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued intellectual license fee"
       }
      }
     },
     "localname": "AccruedIntellectualLicenseFee",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedRebates": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable forrebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AccruedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for research and development. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopment",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AdditionalAreaOfLeaseOccupied": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional rented area occupied under the lease.",
        "label": "[custom:AdditionalAreaOfLeaseOccupied-0]"
       }
      }
     },
     "localname": "AdditionalAreaOfLeaseOccupied",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_AllowanceForWholesaleDistributorFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Allowance for wholesale distributor fees"
       }
      }
     },
     "localname": "AllowanceForWholesaleDistributorFeesCurrent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnoveraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The drug name.",
        "label": "ANNOVERA [Member]"
       }
      }
     },
     "localname": "AnnoveraMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_AnnualNetSalesMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Annual net sale milestones in the Territory per license agreement.",
        "label": "Sales milestone"
       }
      }
     },
     "localname": "AnnualNetSalesMilestone",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of initial rate six-months after the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate after the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateAfterSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reduction in royalty rate of the initial rate during the six-month period beginning on the date of the first arms-length commercial sale of a generic equivalent of the one-year vaginal contraceptive system that is launched by a third party in the U.S.",
        "label": "Annual royalty rate reduction of initial rate during the six-month period from commercial sale of a generic equivalent"
       }
      }
     },
     "localname": "AnnualRoyaltyRateReductionOfInitialRateDuringSixmonthPeriodFromCommercialSaleOfGenericEquivalent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Approved Hormone Therapy Drug Candidate Patents [Member]"
       }
      }
     },
     "localname": "ApprovedHormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "NOTE 2 \u2013 BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_BijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BIJUVA [Member]",
        "label": "BIJUVA [Member]"
       }
      }
     },
     "localname": "BijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CapitalLeaseObligationsTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total term (in months) of the company's outstanding lease obligation.",
        "label": "Non-cancelable operating lease term"
       }
      }
     },
     "localname": "CapitalLeaseObligationsTerm",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_CashUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from license agreement.",
        "label": "Cash upfront payment received"
       }
      }
     },
     "localname": "CashUpfrontPaymentReceived",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_CouncilLicenseAgreement1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "Council License Agreement [Member]"
       }
      }
     },
     "localname": "CouncilLicenseAgreement1Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep1Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "CouncilLicenseAgreementStep1Member"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep1Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "CouncilLicenseAgreementStep2Member"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep2Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CouncilLicenseAgreementStep3Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about agreement.",
        "label": "CouncilLicenseAgreementStep3Member"
       }
      }
     },
     "localname": "CouncilLicenseAgreementStep3Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CreditAgreementMember",
        "label": "Credit Agreement Member"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationAmerisourceBergenRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Custome rConcentration AmerisourceBergen Risk Member",
        "label": "AmerisourceBergen - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationAmerisourceBergenRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationCardinalHealthRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Customer Concentration Cardinal Health Risk Member",
        "label": "Cardinal Health - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationCardinalHealthRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPIServicesRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "PI Services",
        "label": "Customer Concentration P I Services Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationPIServicesRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_CustomerConcentrationPillPackRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Major customers in concentration of sales.",
        "label": "PillPack - Major Customer"
       }
      }
     },
     "localname": "CustomerConcentrationPillPackRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DebtTrancheAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portions of the Credit and Security Agreement to draw funds.",
        "label": "Debt Tranche [Axis]"
       }
      }
     },
     "localname": "DebtTrancheAxis",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_DebtTrancheDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "DebtTrancheDomain"
       }
      }
     },
     "localname": "DebtTrancheDomain",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Note 2 Basis Of Presentation And Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "xbrltype": "stringItemType"
    },
    "txmd_DomesticPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents Bijuva",
        "label": "Domestic Patents BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticPatentsNonApprovedBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Patents NonApproved Bijuva",
        "label": "Domestic Patents NonApproved BIJUVA"
       }
      }
     },
     "localname": "DomesticPatentsNonApprovedBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Design Patents IMVEXXY",
        "label": "Domestic US Design Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents IMVEXXY",
        "label": "Domestic US Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents",
        "label": "Domestic US Patents"
       }
      }
     },
     "localname": "DomesticUSPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSPatentsTopicalCreamMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Patents Topical Cream",
        "label": "Domestic US Patents Topical Cream"
       }
      }
     },
     "localname": "DomesticUSPatentsTopicalCreamMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUSUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic US Utility Patents IMVEXXY",
        "label": "Domestic US Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "DomesticUSUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentDLimoneneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent DLimonene",
        "label": "Domestic Utility Patent DLimonene"
       }
      }
     },
     "localname": "DomesticUtilityPatentDLimoneneMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentOperaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Opera",
        "label": "Domestic Utility Patent Opera"
       }
      }
     },
     "localname": "DomesticUtilityPatentOperaMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent Transdermal Patch",
        "label": "Domestic Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "DomesticUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_DomesticUtilityPatentTx009HRMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Utility Patent TX009HR",
        "label": "Domestic Utility Patent TX009HR"
       }
      }
     },
     "localname": "DomesticUtilityPatentTx009HRMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FacilityFeePaidPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.",
        "label": "Facility fee paid (percent)"
       }
      }
     },
     "localname": "FacilityFeePaidPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_FinancingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of financing agreement.",
        "label": "Financing Agreement [Member]"
       }
      }
     },
     "localname": "FinancingAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignDesignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Design Patents IMVEXXY",
        "label": "Foreign Design Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignDesignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsBijuvaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents BIJUVA",
        "label": "Foreign Patents BIJUVA"
       }
      }
     },
     "localname": "ForeignPatentsBijuvaMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents IMVEXXY",
        "label": "Foreign Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Patents Member",
        "label": "Foreign Patents Member"
       }
      }
     },
     "localname": "ForeignPatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentTransdermalPatchMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patent Transdermal Patch",
        "label": "Foreign Utility Patent Transdermal Patch"
       }
      }
     },
     "localname": "ForeignUtilityPatentTransdermalPatchMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ForeignUtilityPatentsImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign Utility Patents IMVEXXY",
        "label": "Foreign Utility Patents IMVEXXY"
       }
      }
     },
     "localname": "ForeignUtilityPatentsImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_FourCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Four Customers Concentration Risk Member",
        "label": "Four Customers Concentration Risk Member"
       }
      }
     },
     "localname": "FourCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_HormoneTherapyDrugCandidatePatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hormone Therapy Drug Candidate Patents Member.",
        "label": "Hormone Therapy Drug Candidate Patents - (Pending) [Member]"
       }
      }
     },
     "localname": "HormoneTherapyDrugCandidatePatentsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ImvexxyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about ImvexxyTm.",
        "label": "Imvexxy"
       }
      }
     },
     "localname": "ImvexxyMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LesseeFinanceLeaseExistenceOfOptionToExtendNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options to extend lease.",
        "label": "Number of options to extend lease"
       }
      }
     },
     "localname": "LesseeFinanceLeaseExistenceOfOptionToExtendNumber",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_LesseeOperatingLeaseLeaseNotYetCommencedArea": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future rented area to be occupied for administrative office space as defined in lease.",
        "label": "Lease not yet commenced (area)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedArea",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_LesseeOperatingLeaseLiabilityImputedInterestAmount": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of computed imputed interest for operating lease liability.",
        "label": "LesseeOperatingLeaseLiabilityImputedInterestAmount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestAmount",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LiborFloorRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents libor floor rate.",
        "label": "LIBOR floor rate"
       }
      }
     },
     "localname": "LiborFloorRate",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_LicenseAgreementTheramexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "License Agreement Theramex Member",
        "label": "License Agreement Theramex Member"
       }
      }
     },
     "localname": "LicenseAgreementTheramexMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_LicenseExpendituresIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of licenses that have occurred.",
        "label": "Amount accrued for intellectual property license"
       }
      }
     },
     "localname": "LicenseExpendituresIncurredButNotYetPaid",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LicenseRights": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of license rights.",
        "label": "License rights, net"
       }
      }
     },
     "localname": "LicenseRights",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_LongTermIncentiveCompensationPlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long Term Incentive Compensation Plan 2009 Member.",
        "label": "2009 Long Term Incentive Compensation Plan [Member]"
       }
      }
     },
     "localname": "LongTermIncentiveCompensationPlan2009Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MaximumCostsAndExpensesForPostApprovalStudyToBePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum amount of costs and expenses associated with a post approval study required by the FDA to measure risk for venous thromboembolism to be paid by the Company before any such excess will be offset against royalties or other payments owed by us to the Population Council under the Council License Agreement.",
        "label": "maximum costs and expenses for post approval"
       }
      }
     },
     "localname": "MaximumCostsAndExpensesForPostApprovalStudyToBePaid",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MidCapAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents member of Mid Cap agreement.",
        "label": "Credit Agreement [Member]"
       }
      }
     },
     "localname": "MidCapAgreementMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_MilestonePaymentUponFDAApproval": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments upon FDA approval.",
        "label": "Milestone payment upon FDA Approval"
       }
      }
     },
     "localname": "MilestonePaymentUponFDAApproval",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MilestonePaymentsAfterReleaseOfFirstCommercialBatch": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of milestone payments payable after release of first commercial batch.",
        "label": "Milestone payments (payment after release of first commercial batch)"
       }
      }
     },
     "localname": "MilestonePaymentsAfterReleaseOfFirstCommercialBatch",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MinimumCashBalanceRequirementUnderCreditAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.",
        "label": "Minimum cash balance requirement under credit agreement"
       }
      }
     },
     "localname": "MinimumCashBalanceRequirementUnderCreditAgreement",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_MultipleTrademarksForVitaminsSupplementsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multiple Trademarks For Vitamins Supplements Member.",
        "label": "Multiple Trademarks [Member]"
       }
      }
     },
     "localname": "MultipleTrademarksForVitaminsSupplementsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NetRentableAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net rentable area as defined in lease.",
        "label": "Net rentable area"
       }
      }
     },
     "localname": "NetRentableAreaLease",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_NetSalesAmountPerStepbasedRoyalty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net sales amount as defined in license agreement for step-based royalty payments.",
        "label": "Net sales amount per step-based royalty"
       }
      }
     },
     "localname": "NetSalesAmountPerStepbasedRoyalty",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NonQualified2012StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non Qualified 2012 Stock Incentive Plan Member.",
        "label": "2012 Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "NonQualified2012StockIncentivePlanMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to operating lease costs.",
        "label": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to stock options exercised in cashless transaction.",
        "label": "Number of common stock issued during period for stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfCustomers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of customers.",
        "label": "Number of customers - revenue"
       }
      }
     },
     "localname": "NumberOfCustomers",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfInstallmentPayments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of principal installment payments under credit and security agreement.",
        "label": "Number of quarterly principal installment payments"
       }
      }
     },
     "localname": "NumberOfInstallmentPayments",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfIssuedPatents": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of issued patents.",
        "label": "Number of issued patents"
       }
      }
     },
     "localname": "NumberOfIssuedPatents",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfStockIssuedInCashlessExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock issued attributable to warrants exercised in cashless transaction.",
        "label": "[custom:NumberOfStockIssuedInCashlessExerciseOfWarrants]"
       }
      }
     },
     "localname": "NumberOfStockIssuedInCashlessExerciseOfWarrants",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfStockOptionsExercisedInCashlessExercise": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options exercised in the cashless transaction.",
        "label": "Number of stock options exercised in cashless exercise (in shares)"
       }
      }
     },
     "localname": "NumberOfStockOptionsExercisedInCashlessExercise",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_NumberOfSubsidiaries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of subsidiaires for period reported.",
        "label": "Number of subsidiaires"
       }
      }
     },
     "localname": "NumberOfSubsidiaries",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1CompanyDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfTranchesUnderTermLoanFacility": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of seperate tranches under terms of the Credit Agreement.",
        "label": "[custom:NumberOfTranchesUnderTermLoanFacility-0]"
       }
      }
     },
     "localname": "NumberOfTranchesUnderTermLoanFacility",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_NumberOfVendors": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of vendors.",
        "label": "Number of vendors - suppliers"
       }
      }
     },
     "localname": "NumberOfVendors",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "integerItemType"
    },
    "txmd_OutsideConsultant2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A person who provides consutling services to the Company.",
        "label": "Outside Consultants Warrants [Member]"
       }
      }
     },
     "localname": "OutsideConsultant2Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PaymentsToAcquireIntellectualPropertyLicense": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outlow for payments to acquir intellectual property license.",
        "label": "Payments to acquire intellectual property license",
        "negatedLabel": "Payment for intellectual property license"
       }
      }
     },
     "localname": "PaymentsToAcquireIntellectualPropertyLicense",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PeriodExercisableUnderwritersOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The period the option is exercisable per agreement.",
        "label": "[custom:PeriodExercisableUnderwritersOption]"
       }
      }
     },
     "localname": "PeriodExercisableUnderwritersOption",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_Plan2019Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "New 2019 Plan.",
        "label": "Plan 2019 [Member]"
       }
      }
     },
     "localname": "Plan2019Member",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_PlanAwardsNumberOfNewShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new shares authorized for stock awards.",
        "label": "Plan Awards Number of New Shares"
       }
      }
     },
     "localname": "PlanAwardsNumberOfNewShares",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_PrepaidSalesAndMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It refers to the amount of prepaid sales and marketing costs incurred.",
        "label": "Prepaid sales and marketing costs"
       }
      }
     },
     "localname": "PrepaidSalesAndMarketingCostsCurrent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_PrepaymentFeeFifthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fifth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFifthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeForFirstTwoYearsFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee for first two years funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeForFirstTwoYearsFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeFourthYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee fourth year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeFourthYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "Prepayment fee percentage"
       }
      }
     },
     "localname": "PrepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrepaymentFeeThirdYearFundingPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.",
        "label": "Prepayment fee third year funding (percent)"
       }
      }
     },
     "localname": "PrepaymentFeeThirdYearFundingPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_PrescriptionVitaminsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about Prescription Vitamins.",
        "label": "Prescription Vitamins [Member]"
       }
      }
     },
     "localname": "PrescriptionVitaminsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital by public offering.",
        "label": "Proceeds from issuance public offering"
       }
      }
     },
     "localname": "ProceedsFromIssuancePublicOffering",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RegulatoryMilestoneAdditionalPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of regulatory milestone payments based on regulatory approvals for each of BIJUVA and IMVEXXY in certain specified markets.",
        "label": "Regulatory milestone payments"
       }
      }
     },
     "localname": "RegulatoryMilestoneAdditionalPayment",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RentedAreaLease": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rented area as defined in lease.",
        "label": "Rented area lease"
       }
      }
     },
     "localname": "RentedAreaLease",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "areaItemType"
    },
    "txmd_RepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The repayment fee, expressed as a percentage of the tranche funding being repaid,",
        "label": "[custom:RepaymentFeePercentage]"
       }
      }
     },
     "localname": "RepaymentFeePercentage",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RepaymentOfDebtWithNewCreditFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.",
        "label": "Repayment of debt with new credit facility"
       }
      }
     },
     "localname": "RepaymentOfDebtWithNewCreditFacility",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RevenueRequirementToDrawOnTermLoan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.",
        "label": "Revenue requirement to draw on term loan tranche"
       }
      }
     },
     "localname": "RevenueRequirementToDrawOnTermLoan",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_RoyaltyPercent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percent of the net sales to be paid as royalty per license agreement.",
        "label": "Royalty (percent)"
       }
      }
     },
     "localname": "RoyaltyPercent",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_RoyaltyTierAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Tier of step-based royalty payment.",
        "label": "Royalty Tier [Axis]"
       }
      }
     },
     "localname": "RoyaltyTierAxis",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "txmd_RoyaltyTierDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Royalty Tier Domain"
       }
      }
     },
     "localname": "RoyaltyTierDomain",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SalesDiscountsReturnsAndAllowancesGoods1": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.",
        "label": "Allowance for coupons and returns"
       }
      }
     },
     "localname": "SalesDiscountsReturnsAndAllowancesGoods1",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SalesMilestonePaymentsInTranches": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sales milestone payments per licensing agreement.",
        "label": "Sales milestone payment"
       }
      }
     },
     "localname": "SalesMilestonePaymentsInTranches",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_ScheduleOfIntangibleAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of intangible assets, which may be broken down by major class.",
        "label": "The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of September 30, 2019 and December 31, 2018:"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of supplementary lease and cash flow information.",
        "label": "Supplemental lease information"
       }
      }
     },
     "localname": "ScheduleOfSupplementalLeaseInformationAndCashFlowInformationTableTextBlock",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format,",
        "label": "Unvested ending",
        "verboseLabel": "Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise price as of the balance sheet date at which grantees can acquire the shares for options outstanding.",
        "label": "Range - exercise price of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire unvested shares reserved for issuance.",
        "label": "Outstanding Weighted Average Exercise Price",
        "verboseLabel": "Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options unvested.",
        "label": "Outstanding Aggregate Intrinsic Value",
        "verboseLabel": "Unvested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "txmd_SignificantSupplyCommitmentPercentagePayable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percent of the difference between the total amount we would have paid to supplier if the minimum requirement had been fulfilled and the sum of all purchases of our products from supplier during the contract year, required to be paid to supplier.",
        "label": "[custom:SignificantSupplyCommitmentPercentagePayable-0]"
       }
      }
     },
     "localname": "SignificantSupplyCommitmentPercentagePayable",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "txmd_StepBasedRoyaltyPaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The step-based royalty payment information.",
        "label": "Step-based Royalty Payment One [Member]"
       }
      }
     },
     "localname": "StepBasedRoyaltyPaymentOneMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SubscriptionAgreementKnightMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subscription Agreement",
        "label": "Subscription Agreement Knight [Member]"
       }
      }
     },
     "localname": "SubscriptionAgreementKnightMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierThreeConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Three Concentration Risk Member",
        "label": "Supplier [Default Label]",
        "verboseLabel": "Supplier"
       }
      }
     },
     "localname": "SupplierThreeConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_SupplierTwoConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplier Two Concentration Risk Member",
        "label": "Supplier"
       }
      }
     },
     "localname": "SupplierTwoConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_ThreeCustomersConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Three Customers Concentration Risk Member",
        "label": "Three Customers Concentration Risk Member"
       }
      }
     },
     "localname": "ThreeCustomersConcentrationRiskMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche of the Credit Facility Agreement to draw funds.",
        "label": "Tranche 1 [Member]"
       }
      }
     },
     "localname": "TrancheOneMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Three as defined in financing agreement.",
        "label": "Tranche Three [Member]"
       }
      }
     },
     "localname": "TrancheThreeMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two as defined in financing agreement.",
        "label": "Tranche Two [Member]"
       }
      }
     },
     "localname": "TrancheTwoMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_TrancheTwoThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tranche Two Three Member",
        "label": "Tranche Two Three Member"
       }
      }
     },
     "localname": "TrancheTwoThreeMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritersOptionGrantedInPeriodShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares available to be purchased per underwriter's option.",
        "label": "[custom:UnderwritersOptionGrantedInPeriodShares]"
       }
      }
     },
     "localname": "UnderwritersOptionGrantedInPeriodShares",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "txmd_UnderwritingAgreementGoldmanSachsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriter Agrrement GoldmanSachs",
        "label": "Underwriting Agreement Goldman Sachs [Member]"
       }
      }
     },
     "localname": "UnderwritingAgreementGoldmanSachsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_UnderwritingAgreementJPMorganChaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Underwriting Agreement JP Morgan Chase Member",
        "label": "Underwriting Agreement JP Morgan Chase"
       }
      }
     },
     "localname": "UnderwritingAgreementJPMorganChaseMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item provides the weighted-average contractual remaining life of warrants.",
        "label": "Weighted-average contractual remaining life"
       }
      }
     },
     "localname": "WarrantsAndRightsWeightedAverageContractualRemainingLife",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "txmd_WarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrants Member",
        "label": "Warrants Member"
       }
      }
     },
     "localname": "WarrantsMember",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "txmd_WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which warrant holders can acquire the shares reserved for issuance.",
        "label": "Weighted average exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "WarrantsOutstandingOtherThanOptionsWeightedAverageExercisePrice",
     "nsuri": "http://therapeuticsmd.com/20190930",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "NOTE 8 \u2013 OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableRelatedPartiesCurrent": {
     "auth_ref": [
      "r38",
      "r92",
      "r243",
      "r244",
      "r245"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Related Parties, Current"
       }
      }
     },
     "localname": "AccountsPayableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r1",
      "r23",
      "r113",
      "r114",
      "r173"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net of allowance for doubtful accounts\u00a0of $691,699 and $596,602, respectively"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedMarketingCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services.   Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued sales and marketing costs"
       }
      }
     },
     "localname": "AccruedMarketingCostsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued legal and accounting expense"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued rent"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued payroll, bonuses and commission costs"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r8",
      "r41",
      "r176"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued compensated absences"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r149"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r178",
      "r180",
      "r213",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in\u00a0operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r180",
      "r207",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r119",
      "r123",
      "r124",
      "r126"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r60",
      "r77",
      "r230"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of deferred financing fees",
        "negatedLabel": "Amortization of Debt Issuance Costs",
        "verboseLabel": "Amortization of Debt Issuance Costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r77",
      "r133",
      "r141"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of intangible assets",
        "verboseLabel": "Amortization of Intangible Assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r110",
      "r265",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r6",
      "r52"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total other assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r181",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r34",
      "r285",
      "r286"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r74",
      "r79",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, end of period",
        "periodStartLabel": "Cash, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r74",
      "r226"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "(Decrease) increase in cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r91",
      "r169",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r86",
      "r169",
      "r179"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r45",
      "r153",
      "r268",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies - See Note 15"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r152",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "NOTE 15 \u2013 COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock - par value $0.001; 350,000,000 shares authorized: 241,277,076 and 240,462,439 issued and outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r134",
      "r139",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r223",
      "r224",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r102",
      "r103",
      "r223",
      "r224",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.",
        "label": "NOTE 14 \u2013 BUSINESS CONCENTRATIONS"
       }
      }
     },
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r102",
      "r103",
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r100",
      "r102",
      "r103",
      "r104",
      "r223",
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r102",
      "r103",
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r20",
      "r156",
      "r266",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentDescriptionOfVariableRateBasis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.",
        "label": "Debt Instrument, Description of Variable Rate Basis"
       }
      }
     },
     "localname": "DebtInstrumentDescriptionOfVariableRateBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r43",
      "r158",
      "r229"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r44",
      "r88",
      "r164",
      "r165",
      "r166",
      "r167",
      "r228",
      "r229",
      "r231",
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r228",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r157",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r51",
      "r230"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Deferred financing fees (Note 9)"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r77",
      "r147"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation of fixed assets",
        "verboseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r77",
      "r147"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Loss per share, basic and diluted:",
        "verboseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "NOTE 10 \u2013 NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r208"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r82",
      "r221",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r142"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/EstimatedAmortizationExpenseForNextFiveYearsForPatentCostsCurrentlyBeingAmortizedIsAsFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r134",
      "r137",
      "r140",
      "r144",
      "r251"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r140",
      "r251"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r77",
      "r160",
      "r161"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r146"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "NOTE 7 \u2013 INTANGIBLE ASSETS"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r77",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r94",
      "r264",
      "r269",
      "r281"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "NOTE 12 \u2013 INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note12IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r109",
      "r216"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentAssets": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current assets classified as other.",
        "label": "Increase (Decrease) in Other Current Assets",
        "negatedLabel": "Other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in current liabilities classified as other.",
        "label": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRestrictedCash": {
     "auth_ref": [
      "r67",
      "r69"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.",
        "label": "Increase (Decrease) in Restricted Cash",
        "negatedLabel": "Payment of security deposit"
       }
      }
     },
     "localname": "IncreaseDecreaseInRestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r136",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r136",
      "r143"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IndefiniteLivedTrademarks": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (original costs adjusted for previously recognized amortization and impairment) as of the balance sheet date for the rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style for a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Trademarks"
       }
      }
     },
     "localname": "IndefiniteLivedTrademarks",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r132",
      "r138"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net",
        "verboseLabel": "Intangible Assets, Net (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r55",
      "r108",
      "r227",
      "r230",
      "r272"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseBorrowings": {
     "auth_ref": [
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate amount of interest expense on all borrowings.",
        "label": "Interest Expense, Borrowings"
       }
      }
     },
     "localname": "InterestExpenseBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r66",
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "Interest Expense, Debt",
        "negatedLabel": "Interest Expense, Debt"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternetDomainNamesMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "String of typographic characters used to describe the location of a specific individual, business, computer, or piece of information online. Formally known as the Uniform Resource Locator or URL, it is often considered to be the address of a certain World Wide Web site.",
        "label": "Internet Domain Names [Member]"
       }
      }
     },
     "localname": "InternetDomainNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r129"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "NOTE 4 \u2013 INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished product"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r0",
      "r50",
      "r128"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory",
        "totalLabel": "TOTAL INVENTORY"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSupplies": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed.",
        "label": "Raw material"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSupplies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/InventoryConsistsOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "The following table reconciles the undiscounted cash flows for all operating leases at September 30, 2019 to the operating lease liabilities recorded on the balance sheet:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.",
        "label": "2019 (3 months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r267",
      "r277"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt",
        "verboseLabel": "Long-term Debt, Excluding Current Maturities"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-Term Liabilities:"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "NOTE 9 \u2013 DEBT"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r44",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AsOfSeptember302019AndDecember312018CarryingValueOfDebtConsistedOfFollowingDetails",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r99",
      "r105"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "NOTE 1 \u2013 THE COMPANY"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note1Company"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r74",
      "r75",
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r53",
      "r54",
      "r58",
      "r78",
      "r97",
      "r270",
      "r280"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other expense"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note15CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableReconcilesUndiscountedCashFlowsForAllOperatingLeasesAtSeptember302019ToOperatingLeaseLiabilitiesRecordedOnBalanceSheetDetails",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability",
        "verboseLabel": "Operating Lease, Liability, Noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r235",
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset",
        "verboseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/Note2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsDetailsNarrative",
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r240",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r239",
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAmortizationOfDeferredCharges": {
     "auth_ref": [
      "r63",
      "r77"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization of other deferred costs recognized in the income statement.",
        "label": "Amortization of intellectual property license fee",
        "verboseLabel": "Amortization of Other Deferred Charges"
       }
      }
     },
     "localname": "OtherAmortizationOfDeferredCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Assets:"
       }
      }
     },
     "localname": "OtherAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "NOTE 5 \u2013 OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other current liabilities consist of the following:"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note8OtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r41"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other current liabilities",
        "totalLabel": "TOTAL OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentLiabilitiesConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Write off of patent and trademark cost"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncome": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income related to nonoperating activities, classified as other.",
        "label": "Miscellaneous income"
       }
      }
     },
     "localname": "OtherNonoperatingIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r2",
      "r5"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid costs"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "Payments of Financing Costs",
        "negatedLabel": "Payment of deferred financing fees"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Patent costs"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of fixed assets"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r181",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r32",
      "r33"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Other current assets",
        "totalLabel": "TOTAL OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r3",
      "r5",
      "r130",
      "r131"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/OtherCurrentAssetsConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from sale of common stock, net of costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.",
        "label": "Proceeds from Credit Agreement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r71",
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherDebt": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from debt classified as other.",
        "label": "Proceeds from Financing Agreement"
       }
      }
     },
     "localname": "ProceedsFromOtherDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r70",
      "r210"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from exercise of options and warrants"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "NOTE 6 \u2013 FIXED ASSETS, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r148"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r15",
      "r16",
      "r150",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Fixed assets, net",
        "verboseLabel": "Property, Plant and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r15",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Fixed assets, net consist of the following:"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note6FixedAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r15",
      "r148"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r59",
      "r125"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests."
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Amount billed"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r177",
      "r243",
      "r244",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "NOTE 13 \u2013 RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfOtherLongTermDebt": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.",
        "label": "Repayments of Other Long-term Debt",
        "negatedLabel": "Repayment of Credit Agreement"
       }
      }
     },
     "localname": "RepaymentsOfOtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r215",
      "r288"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r82",
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockExpense": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for award of restricted stock or unit under share-based payment arrangement.",
        "label": "Restricted Stock or Unit Expense"
       }
      }
     },
     "localname": "RestrictedStockExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r168",
      "r276"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenue, net",
        "verboseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r56",
      "r106",
      "r107",
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r238",
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "localname": "RisksAndUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "The table below presents potentially dilutive securities that could affect our calculation of diluted net loss per share allocable to common stockholders for the periods presented."
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note10NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "As of September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r134",
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableSetsForthGrossCarryingAmountAccumulatedAmortizationAndNetCarryingAmountOfOurIntangibleAssetsAsOfSeptember302019AndDecember312018Details",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r11",
      "r29",
      "r30",
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory consists of the following:"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note4InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Other current assets consist of the following:"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note5OtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FollowingTableProvidesInformationAboutDisaggregatedRevenueByProductMixForThreeAndNineMonthsEndedSeptember302019And2018Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r87",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note13RelatedPartiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r181",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r186",
      "r196",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below."
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows:"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.",
        "label": "Secured Debt [Member]"
       }
      }
     },
     "localname": "SecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64",
      "r127"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Sales, general, and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "verboseLabel": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r187",
      "r189"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Expired Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r188",
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance, ending",
        "periodStartLabel": "Balance, beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "verboseLabel": "Vested and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r179",
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails",
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r82",
      "r181",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Term"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.",
        "label": "Share-based Goods and Nonemployee Services Transaction, Valuation Method, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r202",
      "r211"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/AssumptionsUsedInBlack-scholesModelForOptionsGrantedDuringNineMonthsEndedSeptember302019And2018AreSetForthInTableBelow.Details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r209"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Vested and Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Vested and Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Unvested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Balance, ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "NOTE 3 \u2013 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/FixedAssetsNetConsistOfFollowingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r46",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r163",
      "r168"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r163",
      "r168",
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/SummaryOfActivityUnder20092012And2019PlansAndRelatedInformationFollowsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r163",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Shares issued in offering, net",
        "verboseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Shares issued for exercise of options and warrants, net"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r46",
      "r163",
      "r168"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Shares issued for exercise of options, net",
        "verboseLabel": "Stock Issued During Period, Value, Stock Options Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity",
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r121"
     ],
     "calculation": {
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 (deficit) equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets",
      "http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "NOTE 11 \u2013 STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "NOTE 16 \u2013 SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note16SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplierConcentrationRiskMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.",
        "label": "Supplier Concentration Risk [Member]"
       }
      }
     },
     "localname": "SupplierConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note14BusinessConcentrationsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r118",
      "r120",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Trade Accounts Receivable and Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note3SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative",
      "http://therapeuticsmd.com/role/Note16SubsequentEventsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note7IntangibleAssetsDetailsNarrative",
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note9DebtDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/TableBelowPresentsPotentiallyDilutiveSecuritiesThatCouldAffectOurCalculationOfDilutedNetLossPerShareAllocableToCommonStockholdersForPeriodsPresented.Details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/Note11StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted average number of common shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://therapeuticsmd.com/role/ConsolidatedStatementOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e4975-111524"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=SL6953423-111524"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5212-111524"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5093-111524"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5865-108316"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6036836-161870"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13279-108611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.7,8)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r289": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r291": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r292": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r293": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r294": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r295": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r296": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r297": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r298": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r299": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r301": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r302": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r303": {
   "Name": "Forms 20-F, 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220 and 240",
   "Subsection": "f"
  },
  "r304": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r305": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r306": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r307": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4),(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i)(4))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784208624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 5 &#8211; OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">NOTE 5 &#8211; OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_800_eus-gaap--OtherCurrentAssetsTextBlock_zESUyHuAmxX4" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 5 &#8211; OTHER CURRENT ASSETS</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p id="xdx_89D_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_zgT8WEKmKcYf" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Other current assets consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_499_20190930_z5lFsdxdiy6h" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" id="xdx_49B_20181231_zqoOZTX38e02" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr id="xdx_409_ecustom--PrepaidSalesAndMarketingCostsCurrent_iI_maPEAOAzWNe_z03udn5Zcvz5" style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Prepaid sales and marketing costs</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">1,313,192</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">5,148,789</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_407_eus-gaap--DeferredFinanceCostsCurrentNet_iI_maPEAOAzWNe_zKF6ZFEUcpnc" style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Deferred financing fees (Note 9)</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">550,757</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">1,898,074</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_40F_eus-gaap--PrepaidInsurance_iI_maPEAOAzWNe_zEu94eEnCyRd" style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Prepaid insurance</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">2,542,008</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">790,465</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_406_eus-gaap--OtherPrepaidExpenseCurrent_iI_maPEAOAzWNe_zt6BMaq8zV2k" style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Other prepaid costs</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">6,172,303</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">2,997,365</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr id="xdx_400_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_mtPEAOAzWNe_zIBTXHrUL8Xg" style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL OTHER CURRENT ASSETS</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,578,260</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right">10,834,693</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A5_zX2pXPGsf8Sa" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780319904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">NOTE 9 &#8211; DEBT</a></td>
<td class="text"><p id="xdx_800_eus-gaap--LongTermDebtTextBlock_zdGgh6tvQ3Kh" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 9 &#8211; DEBT</span></b></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2019, we entered into a Financing
    Agreement, or the Financing Agreement, with TPG Specialty Lending, Inc., as administrative agent, or the Administrative Agent,
    various lenders from time to time party thereto, and certain of the Company&#8217;s subsidiaries party thereto from time to
    time as guarantors, which provides us with a $<span id="xdx_90D_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zUb2QC61vNT9">300,000,000</span> first lien secured term loan credit facility, or the Facility. The
    Facility provides for availability to us in three tranches: (i) $<span id="xdx_902_eus-gaap--ProceedsFromLinesOfCredit_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheOneMember_z5yhTnbQyXJa">200,000,000</span> was drawn upon entering into the Financing Agreement;
    (ii) $<span id="xdx_909_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoMember_zXWdeo4W1wy5">50,000,000</span> will be available to us upon the designation of our ANNOVERA product as a new category of birth control by
    the FDA on or prior to December 31, 2019 and satisfaction (or waiver) of other customary conditions precedent; and (iii) $<span id="xdx_901_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zqS7FM6o0EG5">50,000,000</span>
    will be available to us upon our achieving $<span id="xdx_901_ecustom--RevenueRequirementToDrawOnTermLoan_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheThreeMember_zAXiKjGcRLkj">11,000,000</span> in net revenues, as defined in the Financing Agreement, from our IMVEXXY,
    BIJUVA and ANNOVERA products for the fourth quarter of 2019 and satisfaction (or waiver) of other customary conditions precedent.
    Borrowings under the Facility accrue interest at either (i) <span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zICa8SIqMjFl">3-month LIBOR</span> plus <span id="xdx_902_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zJDoA3NI2lxh">7.75</span>%, subject to a LIBOR floor of <span id="xdx_905_ecustom--LiborFloorRate_iI_dp_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z6OHd3kwZDy9">2.70</span>% or
    (ii) the <span id="xdx_90E_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zJGqH9ymcwL9">prime rate</span> plus <span id="xdx_90C_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zwZPcyTMB8Qc">6.75</span>%, subject to a prime rate floor of <span id="xdx_909_ecustom--LiborFloorRate_iI_pii_dp_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zlGPWPBelbk6">5.2</span>% as selected by us. Interest on amounts borrowed under
    the Facility will be payable quarterly. The outstanding principal amount of the Facility is payable in <span id="xdx_900_ecustom--NumberOfInstallmentPayments_iI_dc_uPure_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zqHAO5bOIhW6">four</span> equal quarterly
    installments beginning on June 30, 2023, with the Facility maturing on March 31, 2024. We have the right to prepay borrowings
    under the Facility in whole or in part at any time, subject to a prepayment fee on the principal amount being prepaid of (i)
    <span id="xdx_90B_ecustom--PrepaymentFeeForFirstTwoYearsFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z9XkKYONZ6Zk">30.0</span>% for the first two years following the initial funding date of the applicable borrowing, (ii) <span id="xdx_907_ecustom--PrepaymentFeeThirdYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zdW1hUCH8g93">5.0</span>% for the third year
    following the initial funding date of the applicable borrowing, (iii) <span id="xdx_908_ecustom--PrepaymentFeeFourthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zYnRxXvIpj4g">3.0</span>% for the fourth year following the initial funding
    date of the applicable borrowing and (iv) <span id="xdx_90D_ecustom--PrepaymentFeeFifthYearFundingPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_z3kQEd2XbCj3">1.0</span>% for the fifth year following the initial funding date of the applicable borrowing
    but prior to March 31, 2024. In connection with the initial borrowing under the Facility, we paid, for the benefit of the
    lenders, a facility fee equal to <span id="xdx_909_ecustom--FacilityFeePaidPercent_dp_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zwOFIdSBJqMi">2.5</span>% of the initial amount borrowed and will be required to pay such a facility fee in connection
    with any subsequent borrowings under the Facility. We are also required to pay the Administrative Agent and the lenders an
    annual administrative fee in addition to other fees and expenses. The Financing Agreement contains customary mandatory prepayments,
    restrictions and covenants applicable to us that are customary for financings of this type. Among other requirements, we are
    required to (i) maintain a minimum unrestricted cash balance of $<span id="xdx_904_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember_zHvuzfaTSxxi">50,000,000</span>, which will increase to $<span id="xdx_905_ecustom--MinimumCashBalanceRequirementUnderCreditAgreement_iI_c20190424__us-gaap--TypeOfArrangementAxis__custom--FinancingAgreementMember__custom--DebtTrancheAxis__custom--TrancheTwoThreeMember_z1eMhj5FoEXa">60,000,000</span> if we draw
    either the second or third tranche of the Facility, and (ii) achieve certain minimum consolidated net revenue amounts attributable
    to commercial sales of our IMVEXXY, BIJUVA and ANNOVERA products beginning with the fiscal quarter ending December 31, 2020.
    The Financing Agreement also includes other representations, warranties, indemnities and events of default that are customary
    for financings of this type, including an event of default relating to a change of control of the Company. Upon or after an
    event of default, the Administrative Agent and the lenders may declare all or a portion of our obligations under the Financing
    Agreement to be immediately due and payable and exercise other rights and remedies provided for under the Financing Agreement.
    The obligations of our company and its subsidiaries under the Financing Agreement are secured, subject to customary permitted
    liens and other agreed upon exceptions, by a first priority perfected security interest in all existing and after-acquired
    assets of our company and its subsidiaries. The obligations under the Financing Agreement will be guaranteed by each of our
    future direct and indirect subsidiaries, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On May 1, 2018, we entered into a Credit and
Security Agreement, or the Credit Agreement, with MidCap Financial Trust, or MidCap, as agent, or Agent, and as lender, and the
additional lenders party thereto from time to time (together with MidCap as a lender, the Lenders), as amended. The Credit Agreement
provided a secured term loan facility in an aggregate principal amount of up to $<span id="xdx_900_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zliFhCtFd7j5">200,000,000</span>, or the Term Loan. Under the terms
of the Credit Agreement, the Term Loan was available to be made in <span id="xdx_909_ecustom--NumberOfTranchesUnderTermLoanFacility_iI_dc_uTranches_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zp4qL7gV5o3l">three</span> separate tranches, with each tranche to be made available
to us, at our option, upon our achievement of certain milestones. Amounts borrowed under the Term Loan bore interest at a rate
equal to the sum of (i) <span id="xdx_901_eus-gaap--DebtInstrumentDescriptionOfVariableRateBasis_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_zQEuiyFE6Cwk">one-month LIBOR</span> (subject to a LIBOR floor of <span id="xdx_906_ecustom--LiborFloorRate_iI_dp_c20180501__us-gaap--CreditFacilityAxis__us-gaap--SecuredDebtMember_z9QUX4BDIIMd">1.50</span>%) plus (ii) <span id="xdx_901_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_c20180430__20180501__us-gaap--CreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zIzBNZt0SsFd">7.75</span>% per annum.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 24, 2019, we terminated the Credit
Agreement. A portion of the initial tranche of borrowing under the Financing Agreement in the amount of approximately $<span id="xdx_904_ecustom--RepaymentOfDebtWithNewCreditFacility_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zLTRnyXdkh4g">81,661,000</span>
was used to repay all amounts outstanding under the Credit Agreement, which included a prepayment fee of <span id="xdx_90A_ecustom--PrepaymentFeePercentage_dp_c20190423__20190424_zAQHBCcaAHGk">4</span>%, a repayment fee of <span id="xdx_90A_ecustom--RepaymentFeePercentage_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_ziXmQE8FbiSk">4</span>% and other fees and expenses payable to the lenders under the Credit Agreement. As a result of the termination of the Credit
Agreement, we recorded $<span id="xdx_904_eus-gaap--GainsLossesOnExtinguishmentOfDebt_iN_di_c20190423__20190424__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zY5uklUD2Bcl">10,057,632</span> in loss on extinguishment of debt in the accompanying unaudited consolidated financial statements.
Interest on amounts borrowed under the Term Loan was due and payable monthly in arrears. Interest expense for the nine months
ending September 30, 2019 related to the Credit Agreement was $<span id="xdx_901_eus-gaap--InterestExpenseDebt_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_zBO6TnW43oJ5">1,816,747</span>. During the nine months ended September 30, 2019, and
prior to the repayment of the Credit Agreement, we amortized $<span id="xdx_907_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__us-gaap--TypeOfArrangementAxis__custom--MidCapAgreementMember_z8w78dm3QLJk">120,146</span> of deferred financing fees as interest expense in the accompanying
unaudited consolidated financial statements.</p>







    <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of September 30, 2019, we had
    $<span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zmXXipafmeEg">200,000,000</span>
    in borrowings outstanding under the Financing Agreement, which are classified as long-term debt in the accompanying
    unaudited consolidated financial statements. We incurred $<span id="xdx_901_eus-gaap--PaymentsOfFinancingCosts_c20190101__20190930_z11mGaBanh4a">6,652,270</span>
    in deferred financing fees related to the Financing Agreement.     Deferred financing fees related to the entire Financing
    Agreement have been allocated pro rata between the funded and unfunded     portions of each tranche. Allocated deferred
    financing fees related to Tranche 1 of $<span id="xdx_900_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20190930_zNU5p2P7KhJ1">6,101,513</span>
    have been reflected as a debt     discount and are accreted to interest expense using the effective interest method. Deferred
    financing fees associated with     unfunded tranches were deferred as assets until the Tranche 2 and Tranche 3 milestones
    have been met. As of September 30,     2019, deferred financing fees related to Tranche 2 and Tranche 3 were included in
    other current assets in the accompanying     consolidated financial statements. During the three and nine months ended
    September 30, 2019, we amortized $<span id="xdx_900_eus-gaap--AmortizationOfFinancingCosts_c20190701__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zztLAoHxCQP5">265,949</span>
    and $<span id="xdx_903_eus-gaap--AmortizationOfFinancingCosts_c20190101__20190930__custom--DebtTrancheAxis__custom--TrancheOneMember_zaJ9vsMFTHGe">462,683</span>,
    respectively, of deferred financing fees related to Tranche 1 as interest expense in the accompanying unaudited consolidated
    financial statements.     Interest on amounts borrowed under the Financing Agreement is due and payable quarterly in arrears.
    Interest expense for the three and nine months ended September 30, 2019 was $<span id="xdx_900_eus-gaap--InterestExpenseBorrowings_c20190701__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zvR1wRq01M3f">5,333,056</span>
    and $<span id="xdx_90F_eus-gaap--InterestExpenseBorrowings_c20190101__20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zAZw34Z0j7pe">9,318,056</span>,
    respectively. The overall effective interest     rate under the Financing Agreement was approximately <span id="xdx_90E_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_c20190930_zdXK3sHJsMQi">11</span>%
    as of September 30, 2019.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span/></p>

<p id="xdx_893_eus-gaap--ScheduleOfDebtTableTextBlock_zdbjB65BooBl" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;As
of  September 30, 2019 and December 31, 2018, the carrying value of debt consisted of the following:</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September 30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Financing Agreement</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_90A_eus-gaap--DebtInstrumentCarryingAmount_iI_c20190930__us-gaap--LongtermDebtTypeAxis__custom--FinancingAgreementMember_zLAtaomMsoWl">200,000,000</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right">&#8212;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Credit Agreement</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#8212;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_900_eus-gaap--DebtInstrumentCarryingAmount_iI_c20181231__us-gaap--LongtermDebtTypeAxis__custom--CreditAgreementMember_zerwox7m3Tek">75,000,000</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Debt discount and financing fees</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20190930_zDle5W3cHaC">5,638,831</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_905_eus-gaap--DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_iI_c20181231_z91shXXUtoF2">1,618,986</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL LONG-TERM DEBT</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--LongTermDebtNoncurrent_iI_c20190930_z5GQliQ99n25">194,361,169</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_904_eus-gaap--LongTermDebtNoncurrent_iI_c20181231_znb2rDrzaIvk">73,381,014</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <p id="xdx_8A6_zOEvQirJXnF6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780316688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 13 &#8211; RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">NOTE 13 &#8211; RELATED PARTIES</a></td>
<td class="text"><p id="xdx_801_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z9lBeo3fc59e" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 13 &#8211; RELATED PARTIES</span></b></p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In July 2015, J. Martin Carroll, a director
of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with
Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by
independent directors of our Company, or a committee consisting of independent directors of our company, since July 2015. During
the three months ended September 30, 2019 and 2018,  we were billed by Catalent approximately $<span id="xdx_906_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190701__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z5ZbCHddDQCj">2,196,000</span> and $<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180701__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zBOQJnvfxA5f" title="Amount billed">830,000</span>, respectively,
for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing.
During the nine months ended September 30, 2019 and 2018, we were billed by Catalent approximately $<span id="xdx_901_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20190101__20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zbqgsDGIuhij">4,118,000</span> and $<span id="xdx_904_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20180101__20180930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zsGGVNSFHjZ1">2,774,000</span>, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of September 30, 2019 and December 31, 2018, there were amounts due to Catalent of approximately $<span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20190930__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_z0aHDfBmz2Xi">425,000</span> and $<span id="xdx_906_eus-gaap--AccountsPayableRelatedPartiesCurrent_iI_c20181231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__srt--AffiliatedEntityMember_zCm29zDWXhca">88,000</span>, respectively.</p>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795027952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>The following table provides information about disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018: (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">$ 23,719,741<span></span>
</td>
<td class="nump">$ 3,473,535<span></span>
</td>
<td class="nump">$ 33,745,257<span></span>
</td>
<td class="nump">$ 11,009,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember', window );">Prescription Vitamins [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">2,550,330<span></span>
</td>
<td class="nump">3,261,459<span></span>
</td>
<td class="nump">7,309,174<span></span>
</td>
<td class="nump">10,797,861<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember', window );">Imvexxy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">4,772,354<span></span>
</td>
<td class="nump">212,076<span></span>
</td>
<td class="nump">9,904,744<span></span>
</td>
<td class="nump">$ 212,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_BijuvaMember', window );">BIJUVA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">490,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember', window );">ANNOVERA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">399,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue from Contract with Customer, Excluding Assessed Tax</a></td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_PrescriptionVitaminsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_ImvexxyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_ImvexxyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_BijuvaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_BijuvaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=txmd_AnnoveraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=txmd_AnnoveraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6591695840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 11 &#8211; STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">The assumptions used in the Black-Scholes Model for options granted during the nine months ended September 30, 2019 and 2018 are set forth in the table below.</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zBj64RxovG9h" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span>The
assumptions used in the Black-Scholes Model for options granted during the  nine months ended  September 30, 2019 and 2018
are set forth in the table below.</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 70%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: top">
            <td><b>&#160;</b></td>
            <td colspan="3" style="border-bottom: Black 1pt solid">
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>Nine months ended</b></p>
                <p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif"><b>September 30,</b></p>
            </td>
        </tr>
        <tr style="vertical-align: top">
            <td style="width: 38%"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2019</b></span>
            </td>
            <td style="width: 2%; text-align: right"><b>&#160;</b></td>
            <td style="border-bottom: Black 1pt solid; width: 15%; text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><b>2018</b></span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_ztEnj6eKOIo1" title="Risk-free interest rate">1.83</span>-<span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zNcE7gUfeyDl" title="Risk-free interest rate">2.54</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zY6csQbSvxrk" title="Risk-free interest rate">2.78</span>-<span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zdQ7wNll52r2" title="Risk-free interest rate">2.82</span>%</span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Volatility</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zBKnAH03VqWa" title="Volatility">61.25</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zW5gMV6ePm46" title="Volatility">64.49</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z349HZXWPMU4" title="Volatility">61.8</span>-<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pp4i_dp_uPure_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z62HC0owMh6j" title="Volatility">63.34</span>%</span>
            </td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Term (in years)</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span title="Term (in years)"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_z3iipLHbbVJh">5.5</span></span>-<span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zxarVQm1Gd1j">6.5</span></span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MinimumMember_zHWgG5iMFhy">5.5</span>-<span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__srt--RangeAxis__srt--MaximumMember_zO3ML0oAWKh9">6.25</span></span>
            </td>
        </tr>
        <tr style="background-color: white; vertical-align: top">
            <td>
                <span style="font: 10pt Times New Roman, Times, Serif">Dividend yield</span>
            </td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6t5D207Slki" title="Dividend yield">0.00</span>%</span>
            </td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: center">
                <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pp4i_dp_c20180101__20180930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTRX8BsOqGud" title="Dividend yield">0.00</span>%</span>
            </td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">A summary of activity under the 2009, 2012 and 2019 Plans and related information follows:</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zwxpXkWpakyh" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">A
    summary of activity under the 2009,  2012 and 2019 Plans and related information follows:</p>
    <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Number of Shares Underlying Stock Options</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted Average Exercise Price</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Weighted <br/>Average <br/>Remaining <br/>Contractual <br/>Life in Years</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>Aggregate Intrinsic Value</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 39%">Balance at December 31, 2018</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs3V32eqjqE8" style="width: 11%; text-align: right" title="Balance, beginning">20,872,824</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zAxABV2Rww02" style="width: 11%; text-align: right" title="Balance, beginning">4.93</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td id="xdx_986_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20180101__20181231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zX9qeCnIo42i" style="width: 11%; text-align: right" title="Balance, beginning"><span style="-sec-ix-hidden: xdx2ixbrl0960">5.94 years</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1EpKMBVobLh" style="width: 11%; text-align: right" title="Balance, beginning">12,239,876</td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in">Granted</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zzSngjQz0iC2" title="Granted">4,419,501</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zMYc3ltrTObg">3.13</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-left: 0.125in">Exercised</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">(<span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zTz7PTTdeK1e" title="Exercised">343,716</span></td>
            <td style="text-align: left">)</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgIE1urwOXzf">0.32</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zon5Zys4OMge" title="Exercised">1,426,828</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 1pt; padding-left: 0.125in">Expired/Forfeited</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zxIxwNq315De" title="Expired Forfeited">98,625</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4e5hGktTPj1">5.63</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right">&#160;</td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 2pt">Balance at  September 30, 2019</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">&#160;</td>
            <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zgBuC4KYmSw7" style="border-bottom: Black 2pt double; text-align: right" title="Balance, ending">24,849,984</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pp2i_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zmsrULLhSaKi" style="text-align: right" title="Balance, ending">4.67</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_pii_dt_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_znAcD8jplAsi" style="text-align: right" title="Balance, ending"><span style="-sec-ix-hidden: xdx2ixbrl0979">6.05 years</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="text-align: left">$</td>
            <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20190101__20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z4EflkOoQvyh" style="text-align: right" title="Balance, ending">13,761,778</td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-left: 0.125in; text-indent: -0.125in">Vested and Exercisable at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zrfkt827YW56" title="Vested and Exercisable">17,601,027</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z9wcx9jAGAZe" title="Vested and Exercisable">4.85</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_98C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_pii_dt_c20190101__20190930_zNxPz67KfwP1" style="text-align: right" title="Vested and Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl0987">4.81 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zwbiAOAHChfc" title="Vested and Exercisable">9,745,527</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td>Unvested at  September 30, 2019</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zjo6frZNvAx2" title="Unvested">7,248,957</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestOutstandingWeightedAverageExercisePrice_iI_pp2i_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zhDCRxWuRz6c" title="Unvested">4.22</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsUnvestedWeightedAverageRemainingContractualTerms_pii_dt_c20190101__20190930_zdCGHXLXTN4e" style="text-align: right" title="Unvested"><span style="-sec-ix-hidden: xdx2ixbrl0995">9.06 years</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">$</td>
            <td style="text-align: right"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingAggregateIntrinsicValue_iI_c20190930__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zCtVwMvrQmEj" title="Unvested">4,016,251</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780358176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplemental lease information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Jan. 02, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 10,459,635<span></span>
</td>
<td class="nump">$ 7,400,000<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="nump">1,242,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating Lease, Liability, Noncurrent</a></td>
<td class="nump">$ 9,500,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating Lease, Weighted Average Remaining Lease Term</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating Lease, Weighted Average Discount Rate, Percent</a></td>
<td class="nump">8.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 849,440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</a></td>
<td class="nump">$ 11,171,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6794480384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 9 &#8211; DEBT (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 24, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 01, 2018 </div>
<div>USD ($) </div>
<div>Tranch</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeePercentage', window );">Prepayment fee percentage</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 10,057,632<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(582,829)<span></span>
</td>
<td class="num">(149,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of Financing Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,652,270<span></span>
</td>
<td class="nump">3,786,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,101,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,101,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 582,829<span></span>
</td>
<td class="nump">$ 149,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term Debt, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseBorrowings', window );">Interest Expense, Borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,318,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember', window );">Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(265,949)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(462,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">775.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember', window );">Secured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfTranchesUnderTermLoanFacility', window );">[custom:NumberOfTranchesUnderTermLoanFacility-0] | Tranch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">3-month LIBOR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">775.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfInstallmentPayments', window );">Number of quarterly principal installment payments</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent', window );">Prepayment fee for first two years funding (percent)</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeThirdYearFundingPercent', window );">Prepayment fee third year funding (percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFourthYearFundingPercent', window );">Prepayment fee fourth year funding (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaymentFeeFifthYearFundingPercent', window );">Prepayment fee fifth year funding (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_FacilityFeePaidPercent', window );">Facility fee paid (percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Prime Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">prime rate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_LiborFloorRate', window );">LIBOR floor rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from Lines of Credit</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Three [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RevenueRequirementToDrawOnTermLoan', window );">Revenue requirement to draw on term loan tranche</a></td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Tranche Two Three Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement', window );">Minimum cash balance requirement under credit agreement</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember', window );">Financing Agreement [Member] | Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of Credit Facility, Maximum Borrowing Capacity</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember', window );">Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentOfDebtWithNewCreditFacility', window );">Repayment of debt with new credit facility</a></td>
<td class="nump">$ 81,661,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_RepaymentFeePercentage', window );">[custom:RepaymentFeePercentage]</a></td>
<td class="nump">400.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="nump">$ 10,057,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,816,747)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,146)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_FacilityFeePaidPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The facility fee expressed as a percentage paid or payable to the Agent for the benefit of lenders, under the terms of Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_FacilityFeePaidPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_LiborFloorRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents libor floor rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_LiborFloorRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_MinimumCashBalanceRequirementUnderCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum cash balance the Borrower must maintain under the credit and secuirty agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_MinimumCashBalanceRequirementUnderCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of principal installment payments under credit and security agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfTranchesUnderTermLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of seperate tranches under terms of the Credit Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfTranchesUnderTermLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFifthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fifth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFifthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeForFirstTwoYearsFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for first two years following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeForFirstTwoYearsFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeFourthYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for fourth year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeFourthYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaymentFeeThirdYearFundingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The prepayment fee expressed as a percentage of the funding being repaid for third year following the initial funding date of the applicable borrowing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaymentFeeThirdYearFundingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The repayment fee, expressed as a percentage of the tranche funding being repaid,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RepaymentOfDebtWithNewCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the repayment of debt including all fees by borrowing funds from a new credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RepaymentOfDebtWithNewCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_RevenueRequirementToDrawOnTermLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consolidated net revenue attributable to commercial sales of TX-001HR and TX-004HR during the twelve-month period ending immediately prior to the funding of Tranche 3.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_RevenueRequirementToDrawOnTermLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of interest expense on all borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.7,8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_FinancingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DebtTrancheAxis=txmd_TrancheTwoThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DebtTrancheAxis=txmd_TrancheTwoThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=txmd_MidCapAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6775387632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Estimated amortization expense for the next five years for the patent costs currently being amortized is as follows: (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</a></td>
<td class="nump">$ 51,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Two</a></td>
<td class="nump">205,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Three</a></td>
<td class="nump">205,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Four</a></td>
<td class="nump">205,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Finite-Lived Intangible Assets, Amortization Expense, Year Five</a></td>
<td class="nump">$ 205,035<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6780319904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract', window );"><strong>Note 2 Basis Of Presentation And Recently Issued Accounting Pronouncements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock', window );">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text"><p id="xdx_803_ecustom--BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock_zMhcMYXC0EOc" style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><span style="text-decoration: underline">NOTE 2 &#8211; BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS</span></b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Interim Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited interim consolidated
financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the
audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December
31, 2018, as filed with the Securities and Exchange Commission, or the SEC, from which we derived the accompanying consolidated
balance sheet as of December 31, 2018. The accompanying unaudited interim consolidated financial statements have been prepared
in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial information
and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying
unaudited interim consolidated financial statements do not include all of the information and notes required by GAAP for complete
financial statements. The accompanying unaudited interim consolidated financial statements reflect all adjustments, consisting
of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the
interim periods presented. Interim results are not necessarily indicative of results for a full year or any other interim period
in the future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Recently Issued Accounting Pronouncements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">In August 2018, the Financial
Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, 2018-13 which eliminates certain disclosure
requirements for fair value measurements for all entities, requires public entities to disclose certain new information and modifies
some disclosure requirements. The FASB developed the amendments to ASC 820 as part of its broader disclosure framework project,
which aims to improve the effectiveness of disclosures in the notes to financial statements by focusing on requirements that clearly
communicate the most important information to users of the financial statements. The new guidance is effective for all entities
for fiscal years beginning after December 15, 2019 and for interim periods within those fiscal years. An entity is permitted to
early adopt either the entire standard or only the provisions that eliminate or modify requirements. We are currently evaluating
the effect of this guidance on our disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In June 2018, the FASB issued ASU 2018-07 to
simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to
employees, with certain exceptions. The new guidance expands the scope of ASC 718 to include share-based payments granted to nonemployees
in exchange for goods or services used or consumed in an entity&#8217;s own operations and supersedes the guidance in ASC 505-50.
The guidance is effective for public business entities in annual periods beginning after December 15, 2018, and interim periods
within those annual periods. Early adoption is permitted, including in an interim period for which financial statements have not
been issued, but not before an entity adopts ASC 606. We adopted this standard on January 1, 2019 and the adoption of this standard
did not have a material effect on our consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued
ASU 2016-02, Leases. This guidance requires lessees to record most leases on their balance sheets while recognizing expenses
on their income statements in a manner similar to current accounting. The guidance also eliminates current real
estate-specific provisions for all entities. For lessors, the guidance modifies the classification criteria and the
accounting for sales-type and direct financing leases. The standard was effective for public business entities for annual
periods beginning after December 15, 2018, and interim periods within those years. In July 2018, the FASB amended the new
leases standard and issued ASU 2018-11, Leases, (Topic 842): Targeted Improvements to give entities another option for
transition and to provide lessors with a practical expedient. We adopted ASU 2016-02 on January 1, 2019 utilizing the
alternative transition method allowed for under ASU 2018-11 and we recorded a $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pii_dm_c20190102_zM6IIzq6G3xf">3.8
million</span>  right of use asset and a $<span id="xdx_903_eus-gaap--OperatingLeaseLiability_iI_pii_dm_c20190102_z89xzluQxGR2">4.1
million </span> liability related to adoption of this standard. In addition, upon commencement of additional lease space
in the third quarter of 2019 (as disclosed in Note 15) we recorded an additional  $<span id="xdx_909_eus-gaap--OperatingLeaseRightOfUseAsset_iI_dm_c20190831_zFgr8m2nMBHd">7.4
million</span> right of use asset and an additional $<span id="xdx_90A_eus-gaap--OperatingLeaseLiability_iI_dm_c20190831_zs16srcNqZn4">7.2
million</span> liability related to our new lease space. Comparative financial information was not adjusted and will continue
to be reported under ASC 840. We also elected the transition relief package of practical expedients and as a result we did
not assess (1) whether existing or expired contracts contain leases, (2) lease classification for any existing or expired
leases, and (3) whether lease origination costs qualified as initial direct costs. We elected the short-term lease practical
expedient by establishing an accounting policy to exclude leases with a term of 12 months or less. We elected not to separate
lease components from non-lease components for our specified asset classes. Additionally, the adoption of the new standard
resulted in increased disclosure requirements in our quarterly and annual filings.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: #252525">Other recent accounting pronouncements
issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants and the SEC
did not, and are not expected to, have a material effect on our results of operations or financial position.</p>

    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the basis of accounting and adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DisclosureNote2BasisOfPresentationAndRecentlyIssuedAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6795273776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 23,719,741<span></span>
</td>
<td class="nump">$ 3,473,535<span></span>
</td>
<td class="nump">$ 33,745,257<span></span>
</td>
<td class="nump">$ 11,009,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">1,444,308<span></span>
</td>
<td class="nump">699,118<span></span>
</td>
<td class="nump">3,455,995<span></span>
</td>
<td class="nump">1,786,902<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">22,275,433<span></span>
</td>
<td class="nump">2,774,417<span></span>
</td>
<td class="nump">30,289,262<span></span>
</td>
<td class="nump">9,223,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">45,126,986<span></span>
</td>
<td class="nump">30,354,072<span></span>
</td>
<td class="nump">121,378,519<span></span>
</td>
<td class="nump">80,578,079<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,077,738<span></span>
</td>
<td class="nump">6,708,271<span></span>
</td>
<td class="nump">15,359,988<span></span>
</td>
<td class="nump">20,545,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">141,959<span></span>
</td>
<td class="nump">73,321<span></span>
</td>
<td class="nump">363,956<span></span>
</td>
<td class="nump">198,545<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">49,346,683<span></span>
</td>
<td class="nump">37,135,664<span></span>
</td>
<td class="nump">137,102,463<span></span>
</td>
<td class="nump">101,322,572<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(27,071,250)<span></span>
</td>
<td class="num">(34,361,247)<span></span>
</td>
<td class="num">(106,813,201)<span></span>
</td>
<td class="num">(92,099,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,057,632)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income</a></td>
<td class="nump">703,662<span></span>
</td>
<td class="nump">809,022<span></span>
</td>
<td class="nump">1,878,980<span></span>
</td>
<td class="nump">1,457,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(5,599,005)<span></span>
</td>
<td class="num">(2,053,077)<span></span>
</td>
<td class="num">(11,717,632)<span></span>
</td>
<td class="num">(2,584,459)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(4,895,343)<span></span>
</td>
<td class="num">(1,244,055)<span></span>
</td>
<td class="num">(19,896,284)<span></span>
</td>
<td class="num">(1,126,642)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(31,966,593)<span></span>
</td>
<td class="num">(35,605,302)<span></span>
</td>
<td class="num">(126,709,485)<span></span>
</td>
<td class="num">(93,226,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (31,966,593)<span></span>
</td>
<td class="num">$ (35,605,302)<span></span>
</td>
<td class="num">$ (126,709,485)<span></span>
</td>
<td class="num">$ (93,226,179)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.53)<span></span>
</td>
<td class="num">$ (0.42)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">241,261,299<span></span>
</td>
<td class="nump">228,107,240<span></span>
</td>
<td class="nump">241,163,994<span></span>
</td>
<td class="nump">220,466,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 8,213,341<span></span>
</td>
<td class="nump">$ 3,473,535<span></span>
</td>
<td class="nump">$ 18,238,857<span></span>
</td>
<td class="nump">$ 11,009,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and Service [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue, net</a></td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 15,506,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6774977200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 3 &#8211; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zzgriDLIUlJ2" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration: underline">Fair Value of Financial Instruments</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our financial instruments consist primarily
of cash, accounts receivable, accounts payable, accrued expenses and long-term debt. The carrying amount of cash, accounts receivable,
accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which
are considered Level 1 assets under the fair value hierarchy. The carrying amount for long-term debt as of September 30, 2019 (as
disclosed in Note 9), approximates fair value based on market activity for other debt instruments with similar characteristics
and comparable risk (Level 2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We categorize our assets and liabilities that
are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification,
or ASC, 820, <i>Fair Value Measurements. </i>The fair value hierarchy gives the highest priority to quoted prices in active markets
for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded
in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"/>

<table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 0.5in; text-align: justify">&#160;</td>
    <td style="width: 1in; text-align: justify"><span style="font-size: 10pt"><b>Level 1</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unadjusted quoted prices in active markets for identical assets or liabilities;</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 2</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Level 3</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">unobservable inputs for the asset or liability.</span></td></tr>
</table>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At September 30, 2019 and 2018, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of indefinite-lived assets or
long-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with the company&#8217;s
impairment test on an annual basis.</p>

    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p id="xdx_840_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zDF1c5buzsl6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Trade Accounts Receivable and Allowance
for Doubtful Accounts</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trade accounts receivable are customer obligations due under normal
trade terms. We review accounts receivable for uncollectible accounts and credit card chargebacks and provide an allowance for
doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing
economic conditions. We evaluate trade accounts receivable aged more than 90 days for delinquency. We write off
delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of
collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when
received as an increase in the allowance for doubtful accounts. To the extent data we use to calculate these estimates does
not accurately reflect bad debts, adjustments to these reserves may be required.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zUS9yHUzpj41" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="text-decoration: underline">Revenue Recognition</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We adopted ASC 606 on January 1, 2018 using
the modified retrospective method for all contracts not completed as of the date of adoption. ASC 606 states that a contract is
considered &#8220;completed&#8221; if all (or substantially all) of the revenue was recognized in accordance with revenue guidance
that was in effect before the date of initial application. Because all (or substantially all) of the revenue related to sales of
our products has been recognized under ASC 605 prior to the date of initial application of the new standard, the contracts are
considered completed under ASC 606. Based on our evaluation of ASC 606, we concluded that a cumulative adjustment was not necessary
upon implementation of ASC 606 on January 1, 2018. In accordance with ASC 606, revenue is recognized when a customer obtains control
of promised goods or services. The amount of revenue recognized reflects the consideration to which we expect to be entitled to
receive in exchange for these goods or services. The provisions of ASC 606 include a five-step process by which we determine revenue
recognition, depicting the transfer of goods or services to customers in amounts reflecting the payment to which we expect to be
entitled in exchange for those goods or services. ASC 606 requires us to apply the following steps: (1) identify the contract with
the customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction
price to the performance obligations in the contract; and (5) recognize revenue when, or as, we satisfy the performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Prescription Products</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of September 30, 2019, our products
consisted primarily of prescription vitamins and our FDA-approved products: IMVEXXY, which we began selling during the third
quarter of 2018, BIJUVA, which we began selling in the second quarter of 2019, and ANNOVERA, which we began selling in the
third quarter of 2019. We sell our name brand and generic prescription products primarily through wholesale distributors and
retail pharmacies. We have one performance obligation related to prescription products sold through wholesale distributors,
which is to transfer promised goods to a customer, and two performance obligations related to products sold through retail
pharmacies, which are to: (1) transfer promised goods and (2) provide customer service for an immaterial fee. We treat
shipping as a fulfillment activity rather than as a separate obligation. We recognize prescription revenue only when we
satisfy performance obligations by transferring a promised good or service to a customer. A good or service is considered to
be transferred when the customer receives the goods or service or obtains control. Control refers to the customer&#8217;s
ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. Based on our contracts,
we invoice customers once our performance obligations have been satisfied, at which point payment is unconditional. We
disclose receivables from contracts with customers separately in the statement of financial position. Payment for goods or
services sold by us is typically due between 30 and 60 days after an invoice is sent to the customer.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The transaction price of a contract is the
amount of consideration which we expect to be entitled to in exchange for transferring promised goods or services to a customer.
Prescription products are sold at fixed wholesale acquisition cost, or WAC, determined based on our list price. However, the total
transaction price is variable as it is calculated net of estimated product returns, chargebacks, rebates, coupons, discounts and
wholesaler fees. These estimates are based on the amounts earned or to be claimed on the related sales and are classified as reductions
of accounts receivable (if the amount is payable to the customer) or a current liability (if the amount is payable to a party other
than a customer). In order to determine the transaction price, we estimate the amount of variable consideration at the outset of
the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative
to the contract or each variable consideration. The estimated amount of variable consideration is included in the transaction price
only to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved. In determining amounts of variable consideration
to include in a contract&#8217;s transaction price, we rely on our historical experience and other evidence that supports our qualitative
assessment of whether revenue would be subject to a significant reversal. We consider all the facts and circumstances associated
with both the risk of a revenue reversal arising from an uncertain future event and the magnitude of the reversal if that uncertain
event were to occur. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the
future vary from our original estimates, we will adjust these estimates, which would affect net product revenue and earnings in
the period such changes in estimates become known.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We accept returns of unsalable prescription
products sold through wholesale distributors within a return period of six months prior to and up to 12 months following product
expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. We do not allow product
returns for prescription products that have been dispensed to a patient. We estimate the amount of our product sales that may be
returned by our customers and record this estimate as a reduction of revenue in the period the related product revenue is recognized.
Where historical rates of return exist, we use history as a basis to establish a returns reserve for products shipped to wholesalers.
For our newly launched products, for which the right of return exists but for which we currently do not have history of product
returns, we estimate returns based on available industry data, our own sales information and our visibility into the inventory
remaining in the distribution channel. At the end of each reporting period, we may decide to constrain revenue for product returns
based on information from various sources, including channel inventory levels and dating and sell-through data, the expiration
dates of products currently being shipped, price changes of competitive products and any introductions of generic products. We
recognize the amount of expected returns as a refund liability, representing the obligation to return the customer&#8217;s consideration.
Since our returns primarily consist of expired and short dated products that will not be resold, we do not record a return asset
for the right to recover the goods returned by the customer at the time of the initial sale (when recognition of revenue is deferred
due to the anticipated return). Return estimates are recorded in the accrued expenses and other current liabilities on the consolidated
balance sheet.</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>










<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We offer various rebate and discount programs
in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. We estimate the allowance
for consumer rebates and coupons that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis. Estimates relating to these rebates and coupons are deducted from gross product revenues at
the time the revenues are recognized. We record distributor fees based on amounts stated in contracts. Rebate and coupon estimates
and distributor fees are recorded in accrued expenses and other current liabilities on the consolidated balance sheet. We estimate
chargebacks based on number of units sold during the period taking into account prices stated in contracts and our historical experience.
Estimates related to distributors fees, rebates, coupons and returns are disclosed in Note 8. We provide invoice discounts to our
customers for prompt payment. Estimates relating to invoice discounts and chargebacks are deducted from gross product revenues
at the time the revenues are recognized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As part of commercial launches for
our FDA-approved prescription products, we introduce a co-pay assistance program where eligible enrolled patients, out of
pocket cost is reduced to a more affordable price. This allows patients to access the product at a reasonable cost and is in
line with our responsible pricing approach. We reimburse pharmacies for this discount through third-party vendors. We
consider certain payments as consideration paid to the customer and reflect such payments as a reduction of the transaction
price as we do not receive a distinct good or service related to these payments. The variable consideration is estimated
based on contract prices, the estimated percentage of patients that will utilize the copay assistance, the average assistance
paid, the estimated levels of inventory in the distribution channel and the current level of prescriptions covered by
patients&#8217; insurance. Payers may change coverage levels for our prescription products positively or negatively, at any
time up to the time that we have formally contracted coverage with the payer. As such, the net transaction price of our
prescription products is susceptible to such changes in coverage levels, which are outside the influence of the Company. As a
result, we constrain revenue recognized for our prescription products to an amount that will not result in a
significant revenue reversal in future periods. Our ability to estimate the net transaction price for our prescription
products is constrained by our estimates of the amount to be paid for the co-pay assistance program which is directly related
to the level of prescriptions paid for by insurance. As such, we record an accrual to reduce gross sales for the estimated
co-pay and other patient assistance based on currently available third-party data and our internal analyses. We re-evaluate
any constraint each reporting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">License Revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">License arrangements may consist of non-refundable
upfront license fees, exclusive licensed rights to patented or patent pending technology, and various performance or sales milestones
and future product royalty payments. Some of these arrangements are multiple element arrangements. Non-refundable up-front fees
that are not contingent on any future performance by us, and do not require continuing involvement on our part, are recognized
as revenue when the license term commences and the licensed data or technology is delivered.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><i><span style="text-decoration: underline">Disaggregation of revenue</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zc7wUNdphLJ3" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table provides information about
disaggregated revenue by product mix for the three and nine months ended September 30, 2019 and 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif; margin: auto">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Three Months <br/>Ended September 30,</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="7" style="text-align: center; border-bottom: Black 1pt solid"><b>Nine Months <br/>Ended September 30,</b></td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify"><b>&#160;</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2019</b></td><td style="padding-bottom: 1pt"><b>&#160;</b></td>
    <td colspan="3" style="text-align: center; border-bottom: Black 1pt solid"><b>2018</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; text-align: justify">Prescription vitamins</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zi7vjdWCKZ5a">2,550,330</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_ztP4O6zNXGpj">3,261,459</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zywitYmYzPah">7,309,174</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--PrescriptionVitaminsMember_zzGAi5FIeAfc">10,797,861</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">IMVEXXY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zXvY5CYTeDjd">4,772,354</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_zsKWjsUpNgO8">212,076</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z60YG81aVQDl">9,904,744</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930__srt--ProductOrServiceAxis__custom--ImvexxyMember_z5icoUBBEC3i">212,076</span></td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">BIJUVA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zqURMMfIVKk3">490,705</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--BijuvaMember_zrLsZbJgsU7g">624,987</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ANNOVERA</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_z7z6pDlYA6tk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__custom--AnnoveraMember_zayEt2LJn4lk">399,952</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1pt">License revenue</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_zUHjX2qGYS1h">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930__srt--ProductOrServiceAxis__us-gaap--LicenseAndServiceMember_z9nooBw4tBd7">15,506,400</span></td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#8212;&#160;&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 16.5pt">Net revenue</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190701__20190930_zPg3RrOkJGr">23,719,741</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180701__20180930_zvrxB29Crfq5">3,473,535</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_901_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20190101__20190930_zlg1HFI22BVk">33,745,257</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20180101__20180930_zSl9J6Z7y4M3">11,009,937</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"/>

<p id="xdx_8AF_zOXgLiMXZZF4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text"><p id="xdx_84F_eus-gaap--CostOfSalesPolicyTextBlock_zY3xkSL9zzw3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Cost of Sales&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify">Cost of sales includes the cost of
inventory, manufacturing, manufacturing overhead and supply chain costs, and product shipping and handling costs. Certain
license agreements require the payment of royalties based on the sale of future products. Such royalties are recorded as a
component of cost of sales. Additionally, the&#160;amortization of license&#160;fees or milestone payments related to
licensed products are classified as components of cost of sales to the extent such payments become due in the future.</p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ShareBasedCompensationOptionAndIncentivePlansPolicy_z3ttCnOrRyR8" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="text-decoration: underline">Share-Based Compensation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We measure the compensation costs of share-based
compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period
during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock,
restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. We amortize such
compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing
model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718, Compensation-Stock Compensation, to value options.
Option valuation models require the input of assumptions, including the expected life of the stock-based awards, the estimated
stock price volatility, the risk-free interest rate, and the expected dividend yield. The risk-free interest rate assumption is
based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the
instrument. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during
the term of the award. On January 1, 2017, we began using our own stock price in our volatility calculation along with the other
peer entities whose stock prices were publicly available that were similar to our company and in 2019 we started using only our
own stock price in the volatility calculation. Our calculation of estimated volatility is based on historical stock prices over
a period equal to the expected term of the awards. The average expected life is based on the contractual terms of the stock option
using the simplified method. We utilize a dividend yield of zero based on the fact that we have never paid cash dividends and have
no current intention to pay cash dividends. Calculating share-based compensation expense requires the input of highly subjective
judgment and assumptions, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates.
The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve
inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions,
our share-based compensation expense could be materially different in the future. We recognize the compensation expense for share-based
compensation granted based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation
expense on a straight-line basis over the employee&#8217;s requisite service period. Effective January 1, 2017, we account for
forfeitures when they occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 1, 2019, we adopted ASU 2018-07
which simplified the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments
to employees, with certain exceptions. The new guidance expanded the scope of ASC 718 to include share-based payments granted to
nonemployees in exchange for goods or services used or consumed in an entity&#8217;s own operations and superseded the guidance
in ASC 505-50. Prior to January 1, 2019, equity instruments issued to non-employees were recorded on a fair value basis, as required
by ASC 505, Equity - Based Payments to Non-Employees.</p>

    <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p id="xdx_840_eus-gaap--ResearchAndDevelopmentExpensePolicy_zH5JRMQSacq9" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Research
and Development Expenses&#160;</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development, or R&amp;D,
expenses include internal R&amp;D activities, services of external contract research organizations, or CROs, costs of their
clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity
expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory
consulting and other costs. The activities undertaken by our regulatory consultants that were classified as R&amp;D expenses
include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. These consulting
expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and
investigative drugs. We charge internal R&amp;D activities and other activity expenses to operations as incurred. We make
payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense
nonrefundable advance payments for goods and services that will be used in future R&amp;D activities when the activity has
been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO
expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the
completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies
progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become
known.</p>

    <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p id="xdx_848_eus-gaap--SegmentReportingPolicyPolicyTextBlock_zGdDrHDqi1a4" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Segment Reporting</span></p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business,
which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by
a single management team that reports to the President of our company. We do not operate separate lines of business with respect
to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales
are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5212-111524<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5093-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6784249824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTE 6 &#8211; FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Fixed assets, net consist of the following:</a></td>
<td class="text"><p id="xdx_890_eus-gaap--PropertyPlantAndEquipmentTextBlock_zcUFkzdYbJ8l" style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Fixed assets, net consist of the following:</p>
    <p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
    <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: auto; margin-right: auto">
        <tr style="vertical-align: bottom">
            <td style="text-align: justify"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>September</b>  <b>30, <br/>2019</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
            <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"><b>December 31, <br/>2018</b></td>
            <td style="padding-bottom: 1pt"><b>&#160;</b></td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="width: 50%; text-align: justify">Accounting system</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zPuW8gNhfigf">301,096</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
            <td style="width: 1%">&#160;</td>
            <td style="width: 1%; text-align: left">$</td>
            <td style="width: 12%; text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--SoftwareAndSoftwareDevelopmentCostsMember_zBQTwKu5NDS8">301,096</span></td>
            <td style="width: 1%; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Equipment</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_902_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zKxvlZ4OsLs7">1,371,390</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zedjHDHH1z3f">490,576</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="text-align: justify">Furniture and fixtures</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zRHfmaqz8eue">1,294,241</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zxPPECpfGlQj">116,542</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">Computer hardware</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zy9v8zzBD225">80,211</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_90E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zINZNj8PrU57">80,211</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Leasehold improvements</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zwF24goIlzf6">68,788</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z6bhwtAy5Nn">37,888</span></td>
            <td style="padding-bottom: 1pt; text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="text-align: justify">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20190930_zRv4nr0Xjkgl">3,115,726</span></td>
            <td style="text-align: left">&#160;</td>
            <td>&#160;</td>
            <td style="text-align: left">&#160;</td>
            <td style="text-align: right"><span id="xdx_906_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20181231_z2f4fZOthu39">1,026,313</span></td>
            <td style="text-align: left">&#160;</td>
        </tr>
        <tr style="background-color: #cceeff; vertical-align: bottom">
            <td style="padding-bottom: 1pt; text-align: justify">Accumulated depreciation</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_909_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20190930_zGl7iKfBxxva">777,380</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
            <td style="padding-bottom: 1pt">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td>
            <td style="border-bottom: Black 1pt solid; text-align: right">(<span id="xdx_90A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iI_c20181231_zBUbMCBfqcaj">553,630</span></td>
            <td style="padding-bottom: 1pt; text-align: left">)</td>
        </tr>
        <tr style="background-color: white; vertical-align: bottom">
            <td style="padding-bottom: 2pt; padding-left: 0.125in; text-align: left">TOTAL FIXED ASSETS, NET</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20190930_zYJbMIldt7cj">2,338,346</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
            <td style="padding-bottom: 2pt">&#160;</td>
            <td style="border-bottom: Black 2pt double; text-align: left">$</td>
            <td style="border-bottom: Black 2pt double; text-align: right"><span id="xdx_908_eus-gaap--PropertyPlantAndEquipmentNet_iI_c20181231_z6vkyVW9hikf">472,683</span></td>
            <td style="padding-bottom: 2pt; text-align: left">&#160;</td>
        </tr>
    </table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
